FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Bachhuber, M Patel, S Kim, C O'Brien, B Shunk, RL AF Bachhuber, Melissa Patel, Shalini Kim, Candace O'Brien, Bridget Shunk, Rebecca L. TI AN INTERPROFESSIONAL CARE TRANSITIONS CURRICULUM FOR AMBULATORY INTERNAL MEDICINE RESIDENTS AND NURSE PRACTITIONER STUDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Bachhuber, Melissa; Patel, Shalini; Kim, Candace; O'Brien, Bridget; Shunk, Rebecca L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Bachhuber, Melissa; Patel, Shalini; O'Brien, Bridget; Shunk, Rebecca L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S507 EP S507 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203086 ER PT J AU Bachhuber, M Broering, J Welles, C Wallhagen, M AF Bachhuber, Melissa Broering, Jeanette Welles, Christine Wallhagen, Margaret TI TRANSFORMING CARE TRANSITIONS: IMPLEMENTING PROJECT RED AT A VETERANS AFFAIRS MEDICAL CENTER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Bachhuber, Melissa; Broering, Jeanette] San Francisco VA Med Ctr, San Francisco, CA USA. [Bachhuber, Melissa; Broering, Jeanette; Wallhagen, Margaret] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Welles, Christine] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S499 EP S499 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203067 ER PT J AU Barahimi, M Beste, L AF Barahimi, Mitra Beste, Lauren TI TOO MUCH OF "A" GOOD THING SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Barahimi, Mitra; Beste, Lauren] Univ Washington, Seattle, WA 98195 USA. [Beste, Lauren] VA Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S457 EP S458 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996202411 ER PT J AU Bergman, AA Frankel, RM Hamilton, AB Yano, EM AF Bergman, Alicia A. Frankel, Richard M. Hamilton, Alison B. Yano, Elizabeth M. TI WOMEN VETERANS' EXPERIENCES AND PREFERENCES WITH VA PRIMARY CARE: A QUALITATIVE STUDY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Bergman, Alicia A.; Hamilton, Alison B.; Yano, Elizabeth M.] Greater Los Angeles VA Healthcare Syst, North Hills, CA USA. [Frankel, Richard M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S259 EP S260 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201238 ER PT J AU Bharmal, N Clarke, R Di Capua, P Gupta, I Doyle, B Ali, A Malim, A Mittman, BS AF Bharmal, Nazleen Clarke, Robin Di Capua, Paul Gupta, Indu Doyle, Brian Ali, Aliza Malim, Asad Mittman, Brian S. TI DEVELOPMENT AND APPLICATION OF A CLASSIFICATION SCHEME FOR CARE COORDINATION ACTIVITIES IN AN ACADEMIC PRIMARY CARE SYSTEM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Bharmal, Nazleen; Clarke, Robin; Di Capua, Paul; Gupta, Indu; Doyle, Brian] Univ Calif Los Angeles, Los Angeles, CA USA. [Ali, Aliza] Lake Erie Coll Osteopath Med, Bradenton, FL USA. [Malim, Asad] Charles R Drew Univ Med & Sci, Coll Sci & Hlth, Los Angeles, CA 90059 USA. [Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mittman, Brian S.] Kaiser Permanente So Calif, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S67 EP S67 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200165 ER PT J AU Bharmal, N Mittman, BS Shah, R Sarkisian, C AF Bharmal, Nazleen Mittman, Brian S. Shah, Raina Sarkisian, Catherine TI CULTURAL TAILORING OF STROKE RISK FACTOR REDUCTION AND WALKING PROMOTION COMMUNITY INTERVENTION FOR SOUTH ASIAN OLDER ADULT IMMIGRANTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Bharmal, Nazleen; Sarkisian, Catherine] Univ Calif Los Angeles, Los Angeles, CA USA. [Mittman, Brian S.; Sarkisian, Catherine] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shah, Raina] Univ Calif Irvine, Irvine, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S60 EP S61 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200148 ER PT J AU Brandenburg, S Brandenburg, C Anderson, M AF Brandenburg, Suzanne Brandenburg, Cynthia Anderson, Mel TI ADAPTING TO A MILLENNIAL LEARNING ENVIRONMENT: AN INTERNAL MEDICINE RESIDENCY CURRICULAR IMPROVEMENT PROJECT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Brandenburg, Suzanne; Anderson, Mel] Univ Colorado, Aurora, CO USA. [Brandenburg, Cynthia] Champlain Coll, Burlington, VT USA. [Anderson, Mel] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S505 EP S505 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203081 ER PT J AU Burke, R Jones, J Bekelman, D AF Burke, Robert Jones, Jacqueline Bekelman, David TI ROLES DESIRED BY CAREGIVERS OF PATIENTS WITH HEART FAILURE: IMPLICATIONS FOR CLINICIANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Burke, Robert; Bekelman, David] Denver VA Med Ctr, Denver, CO USA. [Burke, Robert; Jones, Jacqueline; Bekelman, David] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S204 EP S205 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201114 ER PT J AU Burke, R Jones, CD Levy, C Ginde, A AF Burke, Robert Jones, Christine D. Levy, Cari Ginde, Add TI RESIDENTIAL CARE FACILITIES' ABILITY TO COMMUNICATE WITH HOSPITALS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Burke, Robert] Denver VA Med Ctr, Denver, CO USA. [Burke, Robert; Jones, Christine D.; Levy, Cari; Ginde, Add] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S201 EP S202 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201106 ER PT J AU Cascino, T Mckee, K Kohlwes, J AF Cascino, Thomas Mckee, Kanako Kohlwes, Jeff TI ONE OF THESE THINGS IS NOT LIKE THE OTHER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Cascino, Thomas] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mckee, Kanako; Kohlwes, Jeff] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S400 EP S401 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996202251 ER PT J AU Cordasco, KM Zuchowski, J Hamilton, AB Knapp, H Saavedra, JO Washington, DL AF Cordasco, Kristina M. Zuchowski, Jessica Hamilton, Alison B. Knapp, Herschel Saavedra, Joann O. Washington, Donna L. TI VHA'S COMPREHENSIVE WOMEN'S HEALTH SCAN-ECHO PROGRAM: LESSONS LEARNED SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Cordasco, Kristina M.; Zuchowski, Jessica; Hamilton, Alison B.; Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, North Hills, CA USA. [Knapp, Herschel; Saavedra, Joann O.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cordasco, Kristina M.; Hamilton, Alison B.; Washington, Donna L.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S542 EP S542 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203171 ER PT J AU Eastman, A Chapman, E Jensen, L Bottoms, HI Thompson, M Vogelman, B Kind, AJ AF Eastman, Alexis Chapman, Elizabeth Jensen, Laury Bottoms, Holly I. Thompson, Mary Vogelman, Bennett Kind, Amy J. TI ASSESSING THE IMPACT OF A RESIDENT COORDINATED TRANSITIONAL CARE ROTATION ON RESIDENT ALTITUDES TOWARDS PATIENT TRANSITIONS AND HEALTH MANAGEMENT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Eastman, Alexis; Chapman, Elizabeth; Vogelman, Bennett] Univ WI Hosp & Clin, Madison, WI USA. [Chapman, Elizabeth; Thompson, Mary; Vogelman, Bennett; Kind, Amy J.] Univ Wisconsin, Madison, WI USA. [Jensen, Laury; Kind, Amy J.] Madison VA Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Bottoms, Holly I.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S29 EP S29 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200072 ER PT J AU Englander, H Michaels, L Chan, B Kansagara, D AF Englander, Honora Michaels, LeAnn Chan, Benjamin Kansagara, Devan TI THE CARE TRANSITIONS INNOVATION (C-TRAIN) FOR SOCIOECO-NOMICALLY DISADVANTAGED ADULTS, RESULTS OF A CLUSTERED RANDOMIZED CONTROLLED TRIAL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Englander, Honora; Kansagara, Devan] Oregon Hlth & Sci Univ, Portand, OR USA. [Michaels, LeAnn; Chan, Benjamin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kansagara, Devan] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S221 EP S221 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201154 ER PT J AU Flickinger, TE Saha, S Roter, DL Korthuis, PT Sharp, VL Cohn, JA Moore, RD Beach, MC AF Flickinger, Tabor E. Saha, Somnath Roter, Debra L. Korthuis, Philip T. Sharp, Victoria L. Cohn, Jonathan A. Moore, Richard D. Beach, Mary Catherine TI IS HEALTHCARE PROVIDERS' RESPECT FOR PATIENTS ASSOCIATED WITH COMMUNICATION BEHAVIORS IN CLINICAL ENCOUNTERS? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Flickinger, Tabor E.] Univ Virginia, Charlottesville, VA USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Saha, Somnath; Korthuis, Philip T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Roter, Debra L.; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA. [Sharp, Victoria L.] St Lukes Roosevelt, New York, NY USA. [Cohn, Jonathan A.] Wayne State Univ, Detroit, MI USA. RI Roter, Debra/N-8830-2014 NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S133 EP S133 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200316 ER PT J AU Gopalan, A McDottough, KH Kellom, K Schapira, MM AF Gopalan, Anjali McDottough, Kevin H. Kellom, Katherine Schapira, Marilyn M. TI USING PATIENT FEEDBACK TO EXPLORE AND IMPROVE DIABETES CONTROL COMMUNICATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Gopalan, Anjali; Schapira, Marilyn M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gopalan, Anjali; Kellom, Katherine; Schapira, Marilyn M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [McDottough, Kevin H.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S246 EP S247 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201212 ER PT J AU Gopalan, A Lorincz, I Wirtalla, C Long, JA Marcus, SC AF Gopalan, Anjali Lorincz, Ilona Wirtalla, Christopher Long, Judith A. Marcus, Steven C. TI AWARENESS OF PREDIABETES AND ENGAGEMENT IN DIABETES RISK-REDUCING BEHAVIORS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Gopalan, Anjali; Long, Judith A.; Marcus, Steven C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gopalan, Anjali; Lorincz, Ilona; Wirtalla, Christopher; Long, Judith A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S37 EP S37 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200094 ER PT J AU Grande, D Mitra, N Wan, F Shah, A Asch, DA AF Grande, David Mitra, Nandita Wan, Fei Shah, Anand Asch, David A. TI PATIENT PREFERENCES FOR CONSENT FOR SECONDARY USES OF ELECTRONIC HEALTH INFORMATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Grande, David; Mitra, Nandita; Wan, Fei; Asch, David A.] Univ Penn, Philadelphia, PA 19104 USA. [Shah, Anand] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Shah, Anand] PCCI, Dallas, TX USA. [Asch, David A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S167 EP S167 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201031 ER PT J AU Greene, M Ritchie, C Martin, J Madamba, JA Mattes, M Miao, YH Deeks, S Valcour, V AF Greene, Meredith Ritchie, Christine Martin, Jeff Madamba, Joy A. Mattes, Monica Miao, Yinghui Deeks, Steven Valcour, Victor TI AGING WITH HIV: SYMPTOM BURDEN AND IMPACT ON QUALITY OF LIFE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Greene, Meredith; Ritchie, Christine; Martin, Jeff; Madamba, Joy A.; Deeks, Steven; Valcour, Victor] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Greene, Meredith; Miao, Yinghui] San Francisco VA Med Ctr, San Francisco, CA USA. [Mattes, Monica] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S18 EP S18 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200046 ER PT J AU Griffith, MF Donaldson, D Young, EA Burke, R AF Griffith, Matthew F. Donaldson, Darcy Young, Eric A. Burke, Robert TI A NOVEL APPROACH TO INTERPROFESSIONAL EDUCATION (IPE) FOR RESTDENTS ON AN INPATIENT MEDICAL SERVICE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Griffith, Matthew F.; Young, Eric A.; Burke, Robert] Univ Colorado, Aurora, CO USA. [Donaldson, Darcy; Young, Eric A.; Burke, Robert] Denver Vet Affairs Hosp, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S502 EP S503 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203075 ER PT J AU Griffiths, C Moote, M Becker, C Wietzke, J Brant, AN Nielsen, D Bernstein, SJ Flanders, SA AF Griffiths, Claire Moote, Marc Becker, Carol Wietzke, Julie Brant, Amy N. Nielsen, Daniel Bernstein, Steven J. Flanders, Scott A. TI HOW WELL DOES MEDICARE'S VTE-1 CORE MEASURE CAPTURE HOSPITAL PERFORMANCE FOR VENOUS THROIVIBOEMBOLISM PROPHYLAXIS? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Griffiths, Claire; Moote, Marc; Becker, Carol; Wietzke, Julie; Brant, Amy N.; Nielsen, Daniel; Bernstein, Steven J.; Flanders, Scott A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Bernstein, Steven J.] US Dept Vet Affairs, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S113 EP S113 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200270 ER PT J AU Hanson, JT AF Hanson, Joshua T. TI A DEADLY SORE THROAT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Hanson, Joshua T.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Hanson, Joshua T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S274 EP S275 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201278 ER PT J AU Helfrich, C Simonetti, J Reid, R Joos, S Wakefield, BJ Randall, IA Schectman, G Stark, R Fihn, SD Harvey, HB Nelson, KM AF Helfrich, Christian Simonetti, Joseph Reid, Robert Joos, Sandra Wakefield, Bonnie J. Randall, Ian A. Schectman, Gordon Stark, Richard Fihn, Stephan D. Harvey, Henry B. Nelson, Karin M. TI ELEMENTS OF TEAM-BASED CARE IN A PATIENT-CENTERED MEDICAL HOME ARE ASSOCIATED WITH LOWER BURNOUT AMONG VA PRIMARY CARE EMPLOYEES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Helfrich, Christian; Simonetti, Joseph; Randall, Ian A.; Fihn, Stephan D.; Harvey, Henry B.; Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fihn, Stephan D.] Vet Hlth Adm, Seattle, WA USA. [Joos, Sandra] Dept Vet Affairs, Portland, OR USA. [Wakefield, Bonnie J.] Dept Vet Affairs, Iowa City, IA USA. [Schectman, Gordon; Stark, Richard] Vet Hlth Adm, Washington, DC USA. [Reid, Robert] Grp Hlth, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S84 EP S85 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200204 ER PT J AU Hostetler, RL Markowitz, JS AF Hostetler, Rebecca L. Markowitz, Jeremy S. TI A TIGHT SQUEEZE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Hostetler, Rebecca L.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Markowitz, Jeremy S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S289 EP S289 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201317 ER PT J AU Hsu, A Nakagawa, S Walter, L Van den Eeden, SK Brown, JS Thom, D Lee, S Huang, AJ AF Hsu, Amy Nakagawa, Sanae Walter, Louise Van den Eeden, Stephen K. Brown, Jeanette S. Thom, David Lee, Sei Huang, Alison J. TI LOOKING BEYOND THE PROSTATE: DETERMINANTS AND IMPACT OF NOCTURIA IN MIDDLE-AGED AND OLDER WOMEN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Hsu, Amy; Walter, Louise; Lee, Sei] San Francisco VA Med Ctr, San Francisco, CA USA. [Nakagawa, Sanae; Brown, Jeanette S.; Thom, David; Huang, Alison J.] Univ Calif San Francisco, San, CA USA. [Van den Eeden, Stephen K.] Kaiser Permanente Div Res, San, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S141 EP S141 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200333 ER PT J AU Johnson, K Simon, N Wicks, M Schaad, D Barr, KP O'Connor, K AF Johnson, Kay Simon, Nancy Wicks, Mark Schaad, Doug Barr, Karen P. O'Connor, Kim TI SLEEP HABITS, QUALITY OF LIFE AND SATISFACTION WITH ACADEMIC SUCCESS IN SECOND YEAR MEDICAL STUDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Johnson, Kay; Simon, Nancy; Wicks, Mark; Schaad, Doug; Barr, Karen P.; O'Connor, Kim] Univ Washington, Sch Med, Seattle, WA USA. [Johnson, Kay] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S209 EP S209 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201125 ER PT J AU Kangovi, S Kellom, K Sha, C Johnson, S Chanton, C Carter, T Long, JA Grande, D AF Kangovi, Shreya Kellom, Katherine Sha, Christopher Johnson, Sarah Chanton, Casey Carter, Tamala Long, Judith A. Grande, David TI PATIENT AND PROVIDER PERCEPTIONS OF THE PATIENT CENTERED MEDICAL HOME: AGREEMENT AND TENSIONS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Kangovi, Shreya; Carter, Tamala; Long, Judith A.; Grande, David] Univ Penn, Perelman Sch Med, Phialdelphia, PA USA. [Kangovi, Shreya; Chanton, Casey] Univ Penn Hlth Syst, Philadelphia, PA USA. [Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kellom, Katherine; Carter, Tamala; Grande, David] Univ Penn, Philadelphia, PA 19104 USA. [Sha, Christopher] Univ San Francisco, San Francisco, CA 94117 USA. [Johnson, Sarah] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S165 EP S165 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201027 ER PT J AU Kansagara, D McCiain, M Englander, H Peters, D Morris, CD AF Kansagara, Devan McCiain, Molly Englander, Honora Peters, Dawn Morris, Cynthia D. TI PATIENT ACTIVATION MEASURE AND CARE TRANSITIONS AMONG SOCIOECONOMICALLY VULNERABLE ADULTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Kansagara, Devan; McCiain, Molly; Englander, Honora; Peters, Dawn; Morris, Cynthia D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kansagara, Devan] Portland VA Med Ctr, Portland, OR USA. [McCiain, Molly] Univ New Mexico, Albuqurque, NM USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S165 EP S165 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201026 ER PT J AU Kertesz, S Holmes, S White, B Pollio, DE Austin, EL Schumacher, JE Lukas, CV AF Kertesz, Stefan Holmes, Sally White, Bert Pollio, David E. Austin, Erika L. Schumacher, Joseph E. Lukas, Carol VanDeusen TI MAKING HOUSING FIRST HAPPEN: ORGANIZATIONAL ACTIONS THAT AFFECT SUCCESS AMONG VA MEDICAL CENTERS IN ENDING HOMELESSNESS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Kertesz, Stefan; Austin, Erika L.] Birmingham VA Med Ctr, Birmingham, AL USA. [Kertesz, Stefan; Pollio, David E.; Austin, Erika L.; Schumacher, Joseph E.] Univ Alabama Birmingham, Birmingham, AL USA. [Holmes, Sally; White, Bert; Lukas, Carol VanDeusen] Boston VA Med Ctr, Boston, MA USA. [Holmes, Sally; Lukas, Carol VanDeusen] Boston Univ, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S143 EP S143 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200337 ER PT J AU Kiefer, MM Silverman, JB Nelson, KM AF Kiefer, Meghan M. Silverman, Julie B. Nelson, Karin M. TI RACIAL AND ETHNIC DIFFERENCES IN SCREENING FOR DIABETES MELLITUS: NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2005-2012 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Kiefer, Meghan M.; Silverman, Julie B.; Nelson, Karin M.] Univ Washington, Sch Med, Seattle, WA USA. [Kiefer, Meghan M.; Silverman, Julie B.; Nelson, Karin M.] VA Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S190 EP S190 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201082 ER PT J AU Klein, JW Evans, GA Golob, A Rhoads, C AF Klein, Jared W. Evans, Ginger A. Golob, Anna Rhoads, Caroline TI ACCELERATING AMBULATORY APLOMB: A NOVEL IMMERSION BLOCK CURRICULUM FOR INTRODUCING INTERNAL MEDICINE HIS TO CONTINUITY CLINIC SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Klein, Jared W.; Evans, Ginger A.; Golob, Anna; Rhoads, Caroline] Univ Washington, Seattle, WA 98195 USA. [Klein, Jared W.; Rhoads, Caroline] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Evans, Ginger A.; Golob, Anna] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S505 EP S505 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203080 ER PT J AU Kullgren, JT Dicks, TN Fu, XY Tzanis, GL Tobi, M Marcus, SC AF Kullgren, Jeffrey T. Dicks, Tanisha N. Fu, Xiaoying Tzanis, George L. Tobi, Martin Marcus, Steven C. TI FINANCIAL INCENTIVES FOR COMPLETION OF FECAL OCCULT BLOOD TESTS AMONG VETERANS: A 2-STAGE PRAGMATIC CLUSTER RANDOMIZED, CONTROLLED TRIAL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Kullgren, Jeffrey T.] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA. [Kullgren, Jeffrey T.] Univ Michigan, Ann Arbor, MI 48109 USA. [Dicks, Tanisha N.; Fu, Xiaoying; Tzanis, George L.; Tobi, Martin; Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Tzanis, George L.; Tobi, Martin; Marcus, Steven C.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S98 EP S98 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200234 ER PT J AU Lee, JJ Sgro, G AF Lee, Jane J. Sgro, Gaetan TI THE UNUSUAL SUSPECT: PARANEOPLASTIC MONONEURITIS MULTIPLEX SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Lee, Jane J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Sgro, Gaetan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S451 EP S451 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996202393 ER PT J AU Levander, XA Takahashi, TA Ma, M AF Levander, Ximena A. Takahashi, Traci A. Ma, Maxwell TI REVERSIBLE MYELONEUROPATHY IN A YOUNG WOMAN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Levander, Ximena A.; Takahashi, Traci A.; Ma, Maxwell] Univ Washington, Seattle, WA 98195 USA. [Takahashi, Traci A.] VA Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S426 EP S427 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996202324 ER PT J AU Levitt, DS Meo, N Chen, CP Murphy, CM Vanderwarker, C Wipf, JE Kaminetzky, CP AF Levitt, David S. Meo, Nicholas Chen, Christopher P. Murphy, Christopher M. Vanderwarker, Christopher Wipf, Joyce E. Kaminetzky, Catherine P. TI QUALITY INITIATIVE TO INCREASE PROVIDER USE OF URINE DRUG TESTING FOR CHRONIC PAIN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Levitt, David S.; Meo, Nicholas; Chen, Christopher P.; Murphy, Christopher M.; Vanderwarker, Christopher; Wipf, Joyce E.; Kaminetzky, Catherine P.] Univ Washington, Seattle, WA 98195 USA. [Levitt, David S.; Meo, Nicholas; Chen, Christopher P.; Murphy, Christopher M.; Vanderwarker, Christopher; Wipf, Joyce E.; Kaminetzky, Catherine P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S493 EP S493 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203055 ER PT J AU Mayer, VL Hillier, A Bachhuber, MA Long, JA AF Mayer, Victoria L. Hillier, Amy Bachhuber, Marcus A. Long, Judith A. TI THE RELATIONSHIP BETWEEN NEIGHBORHOOD FOOD ACCESS AND FOOD INSECURITY IN AN URBAN ENVIRONMENT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Mayer, Victoria L.; Bachhuber, Marcus A.; Long, Judith A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Hillier, Amy] Univ Penn, Sch Design, Philadelphia, PA 19104 USA. [Bachhuber, Marcus A.; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S232 EP S232 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201179 ER PT J AU Mayer, VL McDonough, KH Seligman, HK Long, JA AF Mayer, Victoria L. McDonough, Kevin H. Seligman, Hilary K. Long, Judith A. TI FOOD INSECURITY, COPING STRATEGIES, AND GLYCEMIC CONTROL IN LOW-INCOME PATIENTS WITH DIABETES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Mayer, Victoria L.; McDonough, Kevin H.; Long, Judith A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Seligman, Hilary K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S101 EP S102 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200241 ER PT J AU Meo, N Wong, E Bryson, CL Sun, HL Curtis, I Gupta, I Batten, A Fihn, SD Nelson, KM AF Meo, Nicholas Wong, Edwin Bryson, Christopher L. Sun, Haili Curtis, Idamay Gupta, Indra Batten, Adam Fihn, Stephan D. Nelson, Karin M. TI ORGANIZATIONAL FACTORS ASSOCIATED WITH MEDICATION ADHERENCE AFTER PATIENT CENTERED MEDICAL HOME TRANSFORMATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Meo, Nicholas; Bryson, Christopher L.; Fihn, Stephan D.; Nelson, Karin M.] Univ Washington, Seattle, WA 98195 USA. [Wong, Edwin; Bryson, Christopher L.; Sun, Haili; Curtis, Idamay; Gupta, Indra; Batten, Adam; Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fihn, Stephan D.] Vet Hlth Adm, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S160 EP S161 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201016 ER PT J AU Merritt, FW Prochazka, AV Aagaard, EM Stickrath, C AF Merritt, Frank W. Prochazka, Allan V. Aagaard, Eva M. Stickrath, Chad TI MEDICINE ATTENDING ROUNDS: FREQUENCY OF OBSERVED TEACHING BEHAVIORS AND LEARNERS' PERCEPTIONS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Merritt, Frank W.; Prochazka, Allan V.; Aagaard, Eva M.; Stickrath, Chad] Univ Colorado, Sch Med, Denver, CO USA. [Prochazka, Allan V.; Stickrath, Chad] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S149 EP S150 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200349 ER PT J AU Moin, T Steers, N Ettner, S Duru, OK Turk, N Chan, C Luchs, RH Kirvan, A Ho, S Mangione, C AF Moin, Tannaz Steers, Neil Ettner, Susan Duru, O. Kenrik Turk, Norman Chan, Charles Luchs, Robert H. Kirvan, Anya Ho, Sam Mangione, Carol TI THE IMPACT OF A DIABETES-SPECIFIC HEALTH PLAN ON ED AND INPATIENT HOSPITAL USE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Moin, Tannaz] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Moin, Tannaz] HSR&D Ctr Healthcare Innovat, Los Angeles, CA USA. [Moin, Tannaz; Steers, Neil; Ettner, Susan; Duru, O. Kenrik; Turk, Norman; Mangione, Carol] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Chan, Charles; Luchs, Robert H.; Kirvan, Anya; Ho, Sam] UnitedHlth Grp, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S226 EP S227 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201166 ER PT J AU Moin, T Makki, F Weinreb, JE Steinle, N Billington, CJ Havens, K Yancy, W Maciejewski, ML Damschroder, L Richardson, CR AF Moin, Tannaz Makki, Fatima Weinreb, Jane E. Steinle, Nanette Billington, Charles J. Havens, Kathryn Yancy, William Maciejewski, Mathew L. Damschroder, Laura Richardson, Caroline R. TI THE BURDEN OF PRE-DIABETES AMONG OBESE VETERANS: UNDER-STANDLNG THE PREVALENCE OF DISEASE AND MERITS OF ROUTINE SCREENING PROGRAMS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Moin, Tannaz] VA Greater Los Angeles HSR&D Ctr Healthcare Innov, Los Angeles, CA USA. [Moin, Tannaz; Weinreb, Jane E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Makki, Fatima; Damschroder, Laura] Ann Arbor VA Ctr Clin Management Res, Ann Arbor, MI USA. [Steinle, Nanette] VA Baltimore Healthcare Syst, Baltimore, MD USA. [Steinle, Nanette] Univ Maryland, Baltimore, MD 21201 USA. [Billington, Charles J.] Minneapolis VA Healthcare Syst, Minneapolis, MN USA. [Billington, Charles J.] Univ Minnesota, Milwaukee, MN USA. [Havens, Kathryn] Zablocki VA, Milwaukee, WI USA. [Yancy, William; Maciejewski, Mathew L.] Duke Univ Med Ctr, Durham, NC USA. [Yancy, William; Maciejewski, Mathew L.] Durham VA, Durham, NC USA. [Richardson, Caroline R.] VA Diabet QUERI, Ann Arbor, MI USA. [Richardson, Caroline R.] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S220 EP S221 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201153 ER PT J AU Moin, T Li, JN Duru, OK Ettner, S Turk, N Luchs, RH Keckhafer, AM Kirvan, A Mangione, C AF Moin, Tannaz Li, Jinnan Duru, O. Kenrik Ettner, Susan Turk, Norman Luchs, Robert H. Keckhafer, Abigail M. Kirvan, Anya Mangione, Carol TI DIABETES PREVENTION: ARE WE TRANSLATING EVIDENCE INTO PRACTICE? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Moin, Tannaz] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Moin, Tannaz] HSR&D Ctr Healthcare Innovat, Los Angeles, CA USA. [Moin, Tannaz; Li, Jinnan; Duru, O. Kenrik; Ettner, Susan; Turk, Norman; Mangione, Carol] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Luchs, Robert H.; Keckhafer, Abigail M.; Kirvan, Anya] UnitedHlth Grp, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S70 EP S70 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200173 ER PT J AU Mortensen, E Halm, E Fine, MJ Johnson, C Anuzeto, A AF Mortensen, Eric Halm, Ethan Fine, Michael J. Johnson, Christopher Anuzeto, Antonio TI AZITHROMYCLIN IS ASSOCIATED WITH INCREASED CARDIAC EVENTS BUT LOWER MORTALITY FOR OLDER PATIENTS HOSPITALIZED WITH PNEUMONIA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Mortensen, Eric; Johnson, Christopher] VANTHCS, Dallas, TX USA. [Mortensen, Eric; Halm, Ethan; Johnson, Christopher] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Fine, Michael J.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Anuzeto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S37 EP S38 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200095 ER PT J AU Musgrove, J Kraemer, R Morris, JL Estrada, C AF Musgrove, John Kraemer, Ryan Morris, Jason L. Estrada, Carlos TI UTILIZING ITERATIVE CASE PRESENTATION TO DEMONSTRATE CONCEPTS OE CLINICAL REASONING SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Musgrove, John; Kraemer, Ryan; Morris, Jason L.; Estrada, Carlos] Univ Alabama Birmingham, Birmingham, AL USA. [Kraemer, Ryan; Morris, Jason L.; Estrada, Carlos] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S247 EP S248 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201214 ER PT J AU Musgrove, J Morris, JL Kraemer, R Estrada, C AF Musgrove, John Morris, Jason L. Kraemer, Ryan Estrada, Carlos TI PRIORITIZING CONCEPTS OF CLINICAL REASONING SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Musgrove, John; Morris, Jason L.; Kraemer, Ryan; Estrada, Carlos] Univ Alabama Birmingham, Birmingham, AL USA. [Morris, Jason L.; Kraemer, Ryan; Estrada, Carlos] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S183 EP S184 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201066 ER PT J AU Nasir, S Bates, JT AF Nasir, Saifullah Bates, Jeffrey T. TI THYROTOXIC HYPOKALEMIC PERIODIC PARALYSIS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Nasir, Saifullah; Bates, Jeffrey T.] Baylor Coll Med, Houston, TX 77030 USA. [Nasir, Saifullah; Bates, Jeffrey T.] Houston VAMC, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S454 EP S454 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996202402 ER PT J AU Nautiyal, K Bates, JI AF Nautiyal, Kirtan Bates, Jeffrey I. TI A SWING AND A MISS: HEPARIN INDUCED THROMBOCYTOPENIA (HIT) WITH AN INITIALLY NEGATIVE ANTIBODY SCREEN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Nautiyal, Kirtan; Bates, Jeffrey I.] Baylor Coll Med, Houston, TX 77030 USA. [Nautiyal, Kirtan; Bates, Jeffrey I.] Michael E DeBakey Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S287 EP S288 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201314 ER PT J AU Nelson, KM Helfrich, C Sun, HL Hebert, P Liu, CF Dolan, ED Taylor, L Wong, E Maynard, C Hernandez, S Sanders, WJ Curtis, I Randall, IA Schectman, G Stark, R Fihn, SD AF Nelson, Karin M. Helfrich, Christian Sun, Haili Hebert, Paul Liu, Chuan-Fen Dolan, Emily D. Taylor, Leslie Wong, Edwin Maynard, Charles Hernandez, Susan Sanders, William J. Curtis, Idamay Randall, Ian A. Schectman, Gordon Stark, Richard Fihn, Stephan D. TI IMPLEMENTATION OF THE PATIENT CENTERED MEDICAL HOME (PCMH) IN THE VETERANS HEALTH ADMINISTRATION (VHA); ASSOCIATIONS WITH CLINICAL OUTCOMES, PATIENT SATISFACTION, PROVIDER BURNOUT AND UTILIZATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Nelson, Karin M.; Helfrich, Christian; Sun, Haili; Hebert, Paul; Liu, Chuan-Fen; Dolan, Emily D.; Taylor, Leslie; Wong, Edwin; Maynard, Charles; Hernandez, Susan; Sanders, William J.; Curtis, Idamay; Randall, Ian A.; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fihn, Stephan D.] Vet Hlth Adm, Seattle, WA USA. [Schectman, Gordon; Stark, Richard] Vet Hlth Adm, Washington, DC USA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S123 EP S123 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200291 ER PT J AU Norcott, A Anderson, E Dann, S Hyson, A Luco, C Meyer, EM Zapatka, SA Brienza, R AF Norcott, Alexandra Anderson, Eskrina Dann, Sarah Hyson, Anne Luco, Cali Meyer, Emily M. Zapatka, Susan A. Brienza, Rebecca TI REDUCING NON-URGENT EMERGENCY ROOM VISITS DURING PRIMARY CARE BUSINESS HOURS: A COLLABORATIVE APPROACH SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Norcott, Alexandra; Anderson, Eskrina; Dann, Sarah; Hyson, Anne; Luco, Cali; Meyer, Emily M.; Zapatka, Susan A.; Brienza, Rebecca] US Dept Vet Affairs, West Haven, CT USA. [Norcott, Alexandra; Anderson, Eskrina; Dann, Sarah; Hyson, Anne; Luco, Cali; Meyer, Emily M.; Zapatka, Susan A.; Brienza, Rebecca] Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S494 EP S495 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203058 ER PT J AU OBrien, B Keene, T Shunk, RL AF OBrien, Bridget Keene, Terry Shunk, Rebecca L. TI TEAM HUDDLES AS WORKPLACE LEARNING OPPORTUNITIES: AN OBSERVATIONAL STUDY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [OBrien, Bridget; Shunk, Rebecca L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Keene, Terry; Shunk, Rebecca L.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S218 EP S219 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201148 ER PT J AU Overland, MK Pyke, L Poppe, AP Wipf, JE AF Overland, Maryann K. Pyke, Linda Poppe, Anne P. Wipf, Joyce E. TI TEACHING SHARED DECISION MAKING: IMPROVING RESIDENT COMMUNICATION THROUGH CURRICULAR INNOVATION AND OBSERVED VISITS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Overland, Maryann K.; Pyke, Linda; Poppe, Anne P.; Wipf, Joyce E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Overland, Maryann K.; Wipf, Joyce E.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S537 EP S537 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203159 ER PT J AU Pasha, A Kansagara, D Papak, J O'Neil, M Freeman, M Relevo, R Quinones, A Motu'apuaka, M Jou, JH AF Pasha, Amirala Kansagara, Devan Papak, Joel O'Neil, Maya Freeman, Michele Relevo, Rose Quinones, Ana Motu'apuaka, Makalapua Jou, Janice H. TI SCREENING FOR HEPATOCELLULAR CARCINOMA IN CHRONIC LIVER DISEASE: A SYSTEMATIC REVIEW SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Kansagara, Devan; Papak, Joel; O'Neil, Maya; Freeman, Michele; Relevo, Rose; Motu'apuaka, Makalapua; Jou, Janice H.] Portland VA Med Ctr, Portland, OR USA. [Pasha, Amirala; Kansagara, Devan; Papak, Joel; Quinones, Ana; Jou, Janice H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S206 EP S207 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201119 ER PT J AU Saha, S Gatchell, MS O'Neil, M Bates, JT Gordon, HS Long, JA Washington, DI Gerrity, M AF Saha, Somnath Gatchell, Melissa S. O'Neil, Maya Bates, Jeffrey T. Gordon, Howard S. Long, Judith A. Washington, Donna I. Gerrity, Martha TI PROVIDER CULTURAL COMPETENCE AND RACIAL DISPARITY IN DOCTOR-PATIENT RELATIONSHIPS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Saha, Somnath; Gatchell, Melissa S.; O'Neil, Maya; Gerrity, Martha] Portland VA Med Ctr, Portland, OR USA. [Bates, Jeffrey T.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Gordon, Howard S.] Jesse Brown VA Med Ctr, Chicago, IL USA. [Long, Judith A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Washington, Donna I.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S186 EP S186 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201072 ER PT J AU Schwartz, MD Rose, D Bennett, K Yano, EM AF Schwartz, Mark D. Rose, Danielle Bennett, Katelyn Yano, Elizabeth M. TI THE CHAOTIC PRACTICE ENVIRONMENT IN VA PRIMARY CARE CLINICS: :NATIONAL SURVEY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Schwartz, Mark D.; Bennett, Katelyn] VA New York Harbor Healthcare Syst, New York, NY USA. [Schwartz, Mark D.; Bennett, Katelyn] NYU Sch Med, New York, NY USA. [Rose, Danielle] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S221 EP S222 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201155 ER PT J AU Sheffrin, M Miao, YH Boscardin, WJ Steinman, MA AF Sheffrin, Meera Miao, Yinghui Boscardin, W. John Steinman, Michael A. TI WEIGHT LOSS ASSOCIATED WITH CHOLINESTERASE INHIBITORS IN PATIENTS WITH DEMENTIA IN A NATIONAL HEALTHCARE SYSTEM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 UCSF, San Francisco, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S253 EP S253 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201224 ER PT J AU Shunk, RL O'Brien, B Dulay, MH Keene, T Davis, DL Patel, S Bachhuber, M Chou, CL Weaver, K Kim, C O'Brien, L AF Shunk, Rebecca L. O'Brien, Bridget Dulay, Maya H. Keene, Terry Davis, Denise L. Patel, Shalini Bachhuber, Melissa Chou, Calvin L. Weaver, Kristen Kim, Christina O'Brien, Lynn TI TEACHING INTERPROFESSIONAL TRAINEES TO WORK IN CLINICAL CARE TEAMS: THE SAN FRANCISCO VA CENTER OF EXCELLENCE IN PRIMARY CARE EDUCATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Shunk, Rebecca L.; O'Brien, Bridget; Dulay, Maya H.; Keene, Terry; Davis, Denise L.; Patel, Shalini; Bachhuber, Melissa; Chou, Calvin L.; Weaver, Kristen; Kim, Christina; O'Brien, Lynn] UCSF, San Francisco, CA USA. [Shunk, Rebecca L.; Dulay, Maya H.; Keene, Terry; Davis, Denise L.; Patel, Shalini; Bachhuber, Melissa; Chou, Calvin L.; Weaver, Kristen; Kim, Christina; O'Brien, Lynn] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S535 EP S535 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203154 ER PT J AU Silverman, JB Krieger, J Kiefer, MM Hebert, P Drain, N Robinson, J Taylor, L Kapp, J Nelson, KM AF Silverman, Julie B. Krieger, Jim Kiefer, Meghan M. Hebert, Paul Drain, Nathan Robinson, June Taylor, Leslie Kapp, Janet Nelson, Karin M. TI THE ASSOCIATION OF FOOD INSECURITY AND DIABETES CONTROL AMONG LOW-INCOME INDIVIDUALS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Silverman, Julie B.; Kiefer, Meghan M.; Hebert, Paul; Nelson, Karin M.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Silverman, Julie B.; Krieger, Jim; Kiefer, Meghan M.; Hebert, Paul; Nelson, Karin M.] Univ Washington, Seattle, WA 98195 USA. [Krieger, Jim; Drain, Nathan; Robinson, June; Taylor, Leslie; Kapp, Janet] Seattle King Cty Publ Hlth, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S220 EP S220 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201152 ER PT J AU Simon, B Leykum, L O'Rorke, JE Freeman, M AF Simon, Bret Leykum, Luci O'Rorke, Jane E. Freeman, Megan TI USING COLLABORATIVE EVALUATION TO IDENTIFY CRITERIA FOR THE ASSESSMENT OF ATTENDING PHYSICIANS IN HOSPITAL MEDICINE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Simon, Bret; Leykum, Luci; O'Rorke, Jane E.; Freeman, Megan] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Leykum, Luci; O'Rorke, Jane E.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S541 EP S541 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203168 ER PT J AU Simon, B Moreland, C Kornsawad, K AF Simon, Bret Moreland, Christopher Kornsawad, Kanapa TI THE RESIDENT AS TEACHER: IMPLEMENTATION OF AN EVIDENCE-BASED, BEST-PRACTICES APPROACH TO CLINICAL EDUCATION THROUGH A TEACHING ELECTIVE FOR RESIDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Simon, Bret; Moreland, Christopher; Kornsawad, Kanapa] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Moreland, Christopher; Kornsawad, Kanapa] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S539 EP S540 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203165 ER PT J AU Simonetti, J Rowhani-Rahbar, A Zatzick, D Young, B Rivara, F AF Simonetti, Joseph Rowhani-Rahbar, Ali Zatzick, Douglas Young, Bessie Rivara, Frederick TI STATE FIREARM LEGISLATION AND NONFATAL FIREARM INJURIES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Simonetti, Joseph; Rowhani-Rahbar, Ali; Zatzick, Douglas; Rivara, Frederick] Univ Washington, Seattle, WA 98195 USA. [Simonetti, Joseph; Rowhani-Rahbar, Ali; Young, Bessie] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Young, Bessie] VA Puget Sound, Northwest Ctr Excellence, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S210 EP S210 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201128 ER PT J AU Simonetti, J Lapham, GT Williams, E AF Simonetti, Joseph Lapham, Gwen T. Williams, Emily TI RECEIPT OF ALCOHOL-RELATED ADVICE AND QUALITY OF CARE AMONG VETERAN OUTPATIENTS WITH UNHEALTHY ALCOHOL USE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Simonetti, Joseph; Williams, Emily] Univ Washington, Seattle, WA 98195 USA. [Lapham, Gwen T.; Williams, Emily] VA Puget Sound, Seattle Denver HSR&D COIN, Seattle, WA 98195 USA. [Lapham, Gwen T.] Grp Hlth Res Inst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S194 EP S194 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201091 ER PT J AU Sylling, PW Wong, E Liu, CF Hernandez, S Batten, A Helfrich, C Nelson, KM Fihn, SD Hebert, P AF Sylling, Philip W. Wong, Edwin Liu, Chuan-Fen Hernandez, Susan Batten, Adam Helfrich, Christian Nelson, Karin M. Fihn, Stephan D. Hebert, Paul TI PATIENT-CENTERED MEDICAL HOME IMPLEMENTATION AND PROVIDER JOB TURNOVER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Sylling, Philip W.; Wong, Edwin; Liu, Chuan-Fen; Hernandez, Susan; Batten, Adam; Helfrich, Christian; Nelson, Karin M.; Hebert, Paul] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Fihn, Stephan D.] Univ Washington, Seattle, WA 98195 USA. [Fihn, Stephan D.] Vet Hlth Adm, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S167 EP S168 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201033 ER PT J AU Thomas, HN Evans, GW Berlowitz, D Bonds, DE Chertow, GM Conroy, MB Foy, C Glasser, S Lewis, CE Riley, WT Russell, L Williams, O Hess, R AF Thomas, Holly N. Evans, Gregory W. Berlowitz, Dan Bonds, Denise E. Chertow, Glenn M. Conroy, Molly B. Foy, Capri Glasser, Stephen Lewis, Cora E. Riley, William T. Russell, Laurie Williams, Olubunmi Hess, Rachel TI THE RELATION BETWEEN ANTIHYPERTENSIVE MEDICATION AND SEXUAL FUNCTION IN WOMEN: BASELINE DATA FROM THE SPRINT STUDY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Thomas, Holly N.; Conroy, Molly B.; Hess, Rachel] Univ Pittsburgh, Pittsburgh, PA USA. [Thomas, Holly N.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Evans, Gregory W.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Berlowitz, Dan] Bedford VA Hosp, Bedford, MA USA. [Berlowitz, Dan] Boston Univ, Sch Med, Boston, MA 02118 USA. [Bonds, Denise E.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Foy, Capri; Russell, Laurie] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Glasser, Stephen; Lewis, Cora E.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Riley, William T.] NIMH, Bethesda, MD 20892 USA. [Williams, Olubunmi] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S231 EP S231 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201177 ER PT J AU Thomas, HN Hess, R AF Thomas, Holly N. Hess, Rachel TI CORRELATES OF SEXUAL SATISFACTION IN MIDLIFE WOMEN: COMMUNICATION IS KEY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Thomas, Holly N.; Hess, Rachel] Univ Pittsburgh, Pittsburgh, PA USA. [Thomas, Holly N.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S58 EP S59 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200143 ER PT J AU Walling, AM Tisnado, D Ettner, S Asch, S Dy, SM Pantoja, P Lee, M Ahluwalia, S Schreibeis-Baum, HC Lorenz, K AF Walling, Anne M. Tisnado, Diana Ettner, Susan Asch, Steven Dy, Sydney M. Pantoja, Philip Lee, Martin Ahluwalia, Sangeeta Schreibeis-Baum, Hannah C. Lorenz, Karl TI EARLY PALLIATIVE CARE CONSULTATION IS ASSOCIATED WITH IMPROVED SUPPORTIVE CARE CANCER QUALITY FOR VETERANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Walling, Anne M.; Ettner, Susan] Univ Calif Los Angeles, Los Angeles, CA USA. [Walling, Anne M.; Tisnado, Diana; Pantoja, Philip; Lee, Martin; Schreibeis-Baum, Hannah C.; Lorenz, Karl] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ahluwalia, Sangeeta] Oregon State Univ, Corvallis, OR 97331 USA. [Asch, Steven] VA Palo Alto, Palo Alto, CA USA. [Dy, Sydney M.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S77 EP S77 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200188 ER PT J AU Washington, DI Danz, M Cordasco, KM AF Washington, Donna I. Danz, Marjorie Cordasco, Kristina M. TI DEVELOPMENT OF QUALITY INDICATORS FOR THE CARE OF WOMEN WITH ABNORMAL UTERINE BLEEDING SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Washington, Donna I.; Danz, Marjorie; Cordasco, Kristina M.] VA Greater Los Angeles Healthcare, Los Angeles, CA USA. [Washington, Donna I.; Cordasco, Kristina M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Danz, Marjorie] RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S68 EP S69 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200169 ER PT J AU Woodard, LD Virani, SS Petersen, LA Amspoker, A Urecht, T Ramsey, D Adepoju, OE Mehta, P Murawsky, JA Naik, AD AF Woodard, LeChauncy D. Virani, Salim S. Petersen, Laura A. Amspoker, Amber Urecht, Tracy Ramsey, David Adepoju, Omolola E. Mehta, Praveen Murawsky, Jeffrey A. Naik, Aanand D. TI DISPARITIES IN GLYCEMIC AND LIPID CONTROL AMONG DIABETIC PATIENTS IN THE VETERANS ADMINISTRATION: IMPLICATIONS IN THE ERA OF THE AFFORDABLE CARE ACT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Woodard, LeChauncy D.; Virani, Salim S.; Petersen, Laura A.; Amspoker, Amber; Urecht, Tracy; Ramsey, David; Adepoju, Omolola E.; Naik, Aanand D.] Michael E DeBakey Med Ctr, HSR&D, Houston, TX USA. [Mehta, Praveen; Murawsky, Jeffrey A.] VISN 12 Great Lakes, Westchester, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S73 EP S73 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200180 ER PT J AU Young, EA Paulk, J Beck, JM Anderson, M Burck, M Szapor, S Roberts, A Stickrath, C AF Young, Eric A. Paulk, Jaime Beck, James M. Anderson, Mel Burck, McKenna Szapor, Stephen Roberts, Adam Stickrath, Chad TI A UNIQUE MODEL FOR MULTIDISCIPLINARY BEDSIDE ROUNDS IN AN ACADEMIC TEACHLNG HOSPITAL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Young, Eric A.; Paulk, Jaime; Beck, James M.; Anderson, Mel; Burck, McKenna; Szapor, Stephen; Roberts, Adam; Stickrath, Chad] Denver VA Med Ctr, Denver, CO USA. [Young, Eric A.; Beck, James M.; Anderson, Mel; Stickrath, Chad] Univ Colorado, Sch Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S476 EP S476 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996203019 ER PT J AU Zuchowski, J Hamilton, AB Washington, DL Cordasco, KM AF Zuchowski, Jessica Hamilton, Alison B. Washington, Donna L. Cordasco, Kristina M. TI LEARNING NEEDS OF VHA WOMEN'S HEALTH PROVIDERS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Zuchowski, Jessica; Hamilton, Alison B.; Washington, Donna L.; Cordasco, Kristina M.] US Dept Vet Affairs, North Hills, CA USA. [Hamilton, Alison B.; Washington, Donna L.; Cordasco, Kristina M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S138 EP S139 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200327 ER PT J AU Glassm, PA Schneider, PL Good, CB AF Glassm, Peter A. Schneider, Paul L. Good, Chester B. TI An Ethical Framework for Pharmacy Management: Balancing Autonomy and Other Principles SO JOURNAL OF MANAGED CARE PHARMACY LA English DT Editorial Material ID AMERICAN-COLLEGE; 6TH EDITION; CARE AB Decisions to control pharmaceutical costs can cause conflicts as to what medications are covered. Such conflicts have ethical implications, however implicit, and given this fact, an ethical framework can help address them In the following commentary, we discuss the more traditional, individual-level ethical considerations likely familiar to most clinicians. We, then, discuss population-level ethical constructs that clinicians may not as readily embrace. We also present a hypothetical cancer-care case to illustrate how imbalances in ethical foci between individual- and population-level constructs may lead to conflicts among health care actors and promote shifts in pharmaceutical decision making away from providers and toward payers, paradoxically reducing provider autonomy and hence patient autonomy. Finally, we propose a more comprehensive ethical framework to help converge individual, payer, and societal interests when making pharmaceutical use decisions. Pharmacists play a crucial role as pharmacy benefits managers and should be familiar with individual- and population-based ethical constructs. Copyright (C) 2014, Academy of Managed Care Pharmacy. All rights reserved. C1 [Glassm, Peter A.] VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA 90073 USA. [Glassm, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Schneider, Paul L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Schneider, Paul L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Pittsburgh, PA USA. RP Glassm, PA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, 11301 Wilshire Blvd,Mail Stop 111G, Los Angeles, CA 90073 USA. EM peter.glassman@va.gov NR 26 TC 0 Z9 1 U1 0 U2 0 PU ACAD MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 1083-4087 J9 J MANAGE CARE PHARM JI J. Manag. Care Pharm. PD APR PY 2014 VL 20 IS 4 BP 334 EP 338 PG 5 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA AO5RO UT WOS:000341403200001 PM 24684637 ER PT J AU Lutwak, N Byne, W AF Lutwak, Nancy Byne, William TI Deployment-Related Risk Factors of Low Back Pain: A Study Among Danish Soldiers Deployed to Iraq SO MILITARY MEDICINE LA English DT Letter C1 [Lutwak, Nancy] VA New York Harbor Healthcare Syst, New York, NY USA. [Byne, William] James J Peters VA Med Ctr, New York, NY USA. RP Lutwak, N (reprint author), VA New York Harbor Healthcare Syst, Manhattan Campus, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD APR PY 2014 VL 179 IS 4 BP VIII EP IX PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AN7UK UT WOS:000340806300019 ER PT J AU Zhang, W McQuitty, EB Olsen, R Fan, HX Hendrickson, H Tio, FO Newton, K Cagle, PT Jagirdar, J AF Zhang, Wei McQuitty, Elizabeth B. Olsen, Randall Fan, Hongxin Hendrickson, Heather Tio, Fermin O. Newton, Keith Cagle, Philip T. Jagirdar, Jaishree TI EGFR Mutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID FACTOR RECEPTOR MUTATIONS; ADJUVANT CHEMOTHERAPY; CANCER; GEFITINIB; RESISTANCE; FUTURE AB Context.-Lung cancer is the leading cause of cancer deaths worldwide. First-generation tyrosine kinase inhibitors improve progression-free survival in lung cancers with epidermal growth factor receptor (EGFR) mutations. EGFR mutations occur predominantly in exons 19 and 21 in lung adenocarcinomas of Asians (similar to 30%), whites (similar to 15%), and African Americans (similar to 19%). However, minimal information exists on the prevalence or type of genetic changes that occur in lung cancers in US Hispanic patients. We investigated the EGFR mutation frequency in primary lung adenocarcinomas in US Hispanics compared with non-Hispanic whites. Objective.-To evaluate EGFR mutations in lung adenocarcinomas from US Hispanic patients compared with those from non-Hispanic white patients. Design.-DNA samples were extracted from paraffin-embedded tissue of consecutive lung adenocarcinomas from 83 patients. Samples were collected from 40 Hispanics and 43 non-Hispanic whites. Mutations in EGFR were analyzed using a custom assay. Results.-Fourteen of 83 patients (16.9%) had EGFR mutations in their tumor DNA, including 6 of 40 Hispanics (15.0%) and 8 of 43 non-Hispanic whites (18.6%). No association with age, sex, or tumor stage was identified. Smoking history could not be obtained for most of the 83 patients, although 8 of the 11 patients with EGFR mutations for whom smoking history was obtained were nonsmokers. Most of the tumors with EGFR mutations (12 of 14; 85.7%) were acinar with lepidic or papillary subtypes. EGFR mutations occurred in exon 19 (42.8%), exon 18 (28.6%), exon 20 (28.6%), and exon 21 (14.3%). Two cases had 2 mutations identified in different exons. Conclusion.-The frequency of EGFR mutations is similar in US Hispanics compared with non-Hispanic whites. C1 [Zhang, Wei; Jagirdar, Jaishree] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Fan, Hongxin] Univ Texas Hlth Sci Ctr San Antonio, Mol Diagnost Lab, San Antonio, TX 78229 USA. [Tio, Fermin O.] Audie L Murphy Mem Vet Adm Med Ctr, Lab Serv, San Antonio, TX 78284 USA. [McQuitty, Elizabeth B.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Olsen, Randall; Hendrickson, Heather; Newton, Keith; Cagle, Philip T.] Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA. RP Jagirdar, J (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Mail Code 7750 7703,Floyd Curl Dr, San Antonio, TX 78229 USA. EM Jagirdar@UTHSCSA.edu NR 24 TC 5 Z9 5 U1 0 U2 0 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2014 VL 138 IS 4 BP 543 EP 545 DI 10.5858/arpa.2013-0311-OA PG 3 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA AM0QY UT WOS:000339552200011 PM 23937608 ER PT J AU Eastman, KL McFarland, LV Raugi, GJ AF Eastman, Kristin L. McFarland, Lynne V. Raugi, Gregory J. TI A Review of Topical Corrosive Black Salve SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Review ID BASAL-CELL CARCINOMA; NONMELANOMA SKIN-CANCER; ESCHAROTIC AGENTS; SELF-TREATMENT; SANGUINARINE; RECURRENCE; CHELERYTHRINE; APOPTOSIS; INTERNET; SURGERY AB Black salve is a compound derived from various inert ingredients, but it can be transformed into a corrosive ointment by the addition of bloodroot (Sanguinaria canadensis) or zinc chloride. Black salve products have been advertised as a natural remedy for many ailments, ranging from bee stings to skin cancer. This article reviews the current literature surrounding this compound, which in its corrosive form can be dangerous for use without medical supervision. Patients should be educated about the lack of objective evidence supporting the clinical efficacy of black salve as a skin cancer treatment, as well as the possible cosmetic defects resulting from tissue necrosis secondary to the effects of bloodroot and zinc chloride. C1 [Eastman, Kristin L.] Univ Washington, Sch Med, Seattle, WA USA. [Eastman, Kristin L.; McFarland, Lynne V.; Raugi, Gregory J.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Raugi, Gregory J.] Vet Affairs Puget Sound Hlth Care Syst, Dermatol Sect, Hosp & Specialty Med Serv, Seattle, WA 98101 USA. RP McFarland, LV (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Metropolitan Pk West,1100 Olive Way 1400, Seattle, WA 98101 USA. EM lynne.mcfarland@va.gov FU US Department of Veterans Affairs; Department of Health Services Research & Development of the Veterans Affairs Puget Sound Health Care System FX Supported by the US Department of Veterans Affairs and the Department of Health Services Research & Development of the Veterans Affairs Puget Sound Health Care System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 33 TC 7 Z9 7 U1 1 U2 11 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 EI 1557-7708 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD APR PY 2014 VL 20 IS 4 BP 284 EP 289 DI 10.1089/acm.2012.0377 PG 6 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA AK3TI UT WOS:000338347200010 PM 24175872 ER PT J AU Greninger, DA Lowry, EA Porco, TC Naseri, A Stamper, RL Han, Y AF Greninger, Daniel A. Lowry, Eugene A. Porco, Travis C. Naseri, Ayman Stamper, Robert L. Han, Ying TI Resident-Performed Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma SO JAMA OPHTHALMOLOGY LA English DT Article ID OCULAR HYPERTENSION; FOLLOW-UP; TRABECULECTOMY; FLUCTUATION; SURGERY AB IMPORTANCE To our knowledge, this is the first study to investigate effectiveness and complication rates of resident-performed selective laser trabeculoplasty (SLT). OBJECTIVES To evaluate the effectiveness and complications of SLT performed by resident ophthalmologists and to identify predictors for success. DESIGN, SETTING, AND PARTICIPANTS Retrospective case series of 81 patients with open-angle glaucoma undergoing 110 SLT procedures from November 17, 2009, through December 16, 2011, at the San Francisco Veterans Affairs Medical Center. INTERVENTION Resident-performed SLT. MAIN OUTCOMES AND MEASURES Intraocular pressure (IOP) reduction. Secondary outcomes included change in eyedrop medications, complication rates, and predictors of SLT success defined as a 20% reduction in IOP. RESULTS The mean IOP at baseline, defined as the average IOP of the 2 appointments prior to the SLT procedure, was 18.7 mm Hg. The mean decrease in postoperative IOP compared with baseline was 2.2 mm Hg (12%; 95% CI, 5%-19%) at 12 months and 3.3 mm Hg (18%; 95% CI, 13%-23%), 2.8 mm Hg (15%; 95% CI, 10%-21%), and 3.6 mm Hg (19%; 95% CI, 11%-27%) at 3, 6, and 24 months, respectively (all P <.001, linear mixed-effects regression). Success rates were 36% (95% CI, 27%-47%) at 12 months and 41% (95% CI, 31%-53%), 50% (95% CI, 40%-60%), and 39% (95% CI, 26%-53%) at 3, 6, and 24 months, respectively. The most common complication was a temporary IOP spike, with increases of at least 6 mm Hg occurring in 7% (95% CI, 4%-14%) of the population. The largest IOP spike was 11 mm Hg. Increased number of laser shots performed was not associated with better IOP control but was associated with a reduction in number of eyedrop medications (P =.02). Increased baseline IOP was associated with an odds ratio for success of 1.24 (95% CI, 1.08-1.44) at 3 months, 1.20 (95% CI, 1.05-1.37) at 6 months, and 1.31 (95% CI, 1.13-1.53) at 12 months of follow-up (P =.003, P =.006, and P <.001, respectively, logistic regression). In a multivariate analysis, baseline IOP remained the greatest predictor of effectiveness. CONCLUSIONS AND RELEVANCE Resident-performed SLT obtains outcomes similar to the IOP reduction reported in the literature for attending-performed SLT with low levels of complications. Increasing the number of shots in a treatment session may lead to less long-term need for eyedrop medications. In this patient group, higher baseline IOP was the strongest predictor of treatment effectiveness. C1 [Greninger, Daniel A.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Greninger, Daniel A.; Lowry, Eugene A.; Porco, Travis C.; Naseri, Ayman; Stamper, Robert L.; Han, Ying] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Porco, Travis C.] Univ Calif San Francisco, Div Prevent Med & Publ Hlth, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Porco, Travis C.; Naseri, Ayman; Han, Ying] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA. [Naseri, Ayman; Stamper, Robert L.; Han, Ying] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA USA. RP Han, Y (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA. EM ying.han@ucsf.edu NR 24 TC 5 Z9 5 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD APR PY 2014 VL 132 IS 4 BP 403 EP 408 DI 10.1001/jamaophthalmol.2013.7651 PG 6 WC Ophthalmology SC Ophthalmology GA AJ7QF UT WOS:000337890500006 PM 24435815 ER PT J AU Baker, JF Conaghan, PG Smolen, JS Aletaha, D Shults, J Emery, P Baker, DG Ostergaard, M AF Baker, Joshua F. Conaghan, Philip G. Smolen, Josef S. Aletaha, Daniel Shults, Justine Emery, Paul Baker, Daniel G. Ostergaard, Mikkel TI Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; METHOTREXATE THERAPY; CLINICAL-PRACTICE; ACTIVITY INDEX; DOUBLE-BLIND; GO-FORWARD; PHASE-III; GOLIMUMAB; ANTIBODY; VALIDITY AB Objective. To develop and validate composite disease activity scores, based on widely available clinical measures, that would demonstrate improved correlation with detection of synovitis on magnetic resonance imaging (MRI) and radiographic progression, in comparison with conventional measures, in patients with rheumatoid arthritis (RA). Methods. This study was conducted as a secondary study of 2 RA clinical trials, GO-BEFORE (development cohort) and GO-FORWARD (validation cohort). Generalized estimating equations were used to evaluate independent cross-sectional associations of component variables (from all time points) with concurrent MRI measures of synovitis and bone edema in the development cohort. Based on regression coefficients, modified versions of the Disease Activity Score in 28 joints (M-DAS28), Simplified Disease Activity Index (M-SDAI), and Clinical Disease Activity Index (M-CDAI) were generated for each subject in the validation cohort. The M-DAS28, M-SDAI, and M-CDAI scores were compared to conventional scores of disease activity with regard to associations with MRI measures of synovitis and radiographic progression, assessed using Pearson's and Spearman's correlations, linear/logistic regression, and receiver operating characteristic analysis. Results. Four variables were independently associated with MRI-detected synovitis and bone edema in the development cohort: C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), swollen joint count in 28 joints (SJC28), and evaluator's global assessment of disease activity using a visual analog scale (EvGA score). Modified disease activity scores were generated using the regression coefficients obtained in the synovitis models for all subjects in the validation cohort; modified scores were calculated as M-DAS28 x 0.49 x ln(CRP) + 0.15 x SJC28 + 0.22 x EvGA + 1 and M-SDAI = CRP + SJC28 + EvGA. Both modified and conventional disease activity scores correlated significantly with MRI measures of synovitis. Modified scores showed superior correlation with synovitis, as compared to conventional scores, at all time points (P < 0.05). Furthermore, the M-DAS28 and M-SDAI had superior test characteristics for prediction of radiographic progression at 52 weeks (both P < 0.05). Conclusion. Modified disease activity scores demonstrated superior correlation with MRI detection of synovitis at all time points, and more accurately predicted radiographic progression in patients with RA in a clinical trial setting. C1 [Baker, Joshua F.; Shults, Justine] Univ Penn, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Conaghan, Philip G.] Univ Leeds, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. [Conaghan, Philip G.] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England. [Smolen, Josef S.; Aletaha, Daniel] Med Univ Vienna, Vienna, Austria. [Emery, Paul] Univ Leeds, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds Inst Rheumat & Musculoskeletal Med, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England. [Emery, Paul] Chapel Allerton Hosp, Leeds, W Yorkshire, England. [Baker, Daniel G.] Janssen Res & Dev LLC, Spring House, PA USA. [Ostergaard, Mikkel] Glostrup Cty Hosp, Copenhagen, Denmark. [Ostergaard, Mikkel] Univ Copenhagen, Copenhagen, Denmark. RP Baker, JF (reprint author), Univ Penn, Dept Med, Div Rheumatol, Hosp Univ Penn, 8 Penn Tower Bldg,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu FU Janssen Biotech FX Funding for the original GO-BEFORE and GO-FORWARD randomized clinical trials was provided by Janssen Biotech. There was no additional funding for this secondary study. Dr. D. G. Baker is an employee of Janssen Biotech. NR 17 TC 16 Z9 16 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD APR PY 2014 VL 66 IS 4 BP 794 EP 802 DI 10.1002/art.38304 PG 9 WC Rheumatology SC Rheumatology GA AJ0QR UT WOS:000337361000005 PM 24757132 ER PT J AU Kwoh, CK Roemer, FW Hannon, MJ Moore, CE Jakicic, JM Guermazi, A Green, SM Evans, RW Boudreau, R AF Kwoh, C. Kent Roemer, Frank W. Hannon, Michael J. Moore, Carolyn E. Jakicic, John M. Guermazi, Ali Green, Stephanie M. Evans, Rhobert W. Boudreau, Robert TI Effect of Oral Glucosamine on Joint Structure in Individuals With Chronic Knee Pain SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID BONE-MARROW ABNORMALITIES; DOUBLE-BLIND; CHONDROITIN SULFATE; CARTILAGE LOSS; LONGITUDINAL CHANGES; LESION ASSESSMENT; CONTROLLED-TRIAL; HEALTH-STATUS; OSTEOARTHRITIS; PROGRESSION AB Objective. To determine the short-term efficacy of oral glucosamine supplementation by evaluating structural lesions in the knee joints, as assessed using 3T magnetic resonance imaging (MRI). Methods. This study was designed as a randomized, double-blind, placebo-controlled trial. Recruitment was performed via mass mailings and an arthritis registry in southwestern Pennsylvania. In total, 201 participants with mild-to-moderate pain in one or both knees, as defined by a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score >= 25 and <= 100, were enrolled. Of these subjects, 69.2% had a Kellgren/Lawrence grade >= 2 in at least 1 knee. Participants received 24 weeks of treatment with 1,500 mg glucosamine hydrochloride in beverage form or a placebo beverage. The primary outcome was decreased worsening of cartilage damage on 3T MRI of both knees, assessed according to a validated scoring system, the Whole-Organ MRI Score (WORMS). Secondary outcomes included change in bone marrow lesion (BML) scores in all knees and change in excretion of urinary C-terminal crosslinking telopeptide of type II collagen (CTX-II). Results. The adjusted odds ratio (OR) for the likelihood of decreased cartilage damage over 24 weeks in any WORMS-scored subregion of the knee in the glucosamine treatment group compared to the control group was 0.938 (95% confidence interval [ 95% CI] 0.528, 1.666). Compared to subjects treated with glucosamine, control subjects showed more improvement in BMLs (adjusted OR 0.537, 95% CI 0.291, 0.990) but no difference in worsening BMLs (adjusted OR 0.691, 95% CI 0.410, 1.166) over 24 weeks. There was no indication that treatment with glucosamine decreased the excretion of urinary CTX-II (beta = -0.10, 95% CI -0.21, 0.002). Conclusion. The results of this short-term study provide no evidence of structural benefits (i.e., improvements in MRI morphologic features or urinary CTX-II excretion) from glucosamine supplementation in individuals with chronic knee pain. C1 [Kwoh, C. Kent; Hannon, Michael J.; Jakicic, John M.; Green, Stephanie M.; Evans, Rhobert W.; Boudreau, Robert] Univ Pittsburgh, Pittsburgh, PA USA. [Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kwoh, C. Kent; Guermazi, Ali] Univ Arizona, Tucson, AZ USA. [Roemer, Frank W.] Boston Univ, Boston, MA 02215 USA. [Roemer, Frank W.] Klinikum Augsburg, Augsburg, Germany. [Moore, Carolyn E.] Texas Womans Univ, Houston, TX USA. RP Kwoh, CK (reprint author), Univ Arizona, 1501 North Campbell Ave,Room 8303, Tucson, AZ 85724 USA. EM kwoh@arthritis.arizona.edu FU Beverage Institute for Health & Wellness, The Coca-Cola Company; Multidisciplinary Clinical Research Center for Musculoskeletal and Skin Diseases FX Funding for this study was provided by the Beverage Institute for Health & Wellness, The Coca-Cola Company. All statistical analyses were performed at the University of Pittsburgh and were partially supported by the Multidisciplinary Clinical Research Center for Musculoskeletal and Skin Diseases. The Coca-Cola Company had no role in the performance of the statistical analyses. Dr. Moore, formerly Principal Scientist at the Beverage Institute for Health & Wellness, The Coca-Cola Company, was involved with monitoring all aspects of study progress for the funding agency and coordinated the production of the glucosamine beverage, as well as the quality assurance checks on the stability of the beverage contents. Since 2008, Dr. Moore has been a faculty member at Texas Woman's University and was not associated with the Beverage Institute when the study radiographs and MRIs were analyzed. Dr. Moore participated in writing and gave final approval of the manuscript. NR 53 TC 10 Z9 11 U1 5 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD APR PY 2014 VL 66 IS 4 BP 930 EP 939 DI 10.1002/art.38314 PG 10 WC Rheumatology SC Rheumatology GA AJ0QR UT WOS:000337361000018 PM 24616448 ER PT J AU Purvis, S Gion, T Kennedy, G Rees, S Safdar, N VanDenBergh, S Weber, J AF Purvis, Suzanne Gion, Therese Kennedy, Gregory Rees, Susan Safdar, Nasia VanDenBergh, Shelly Weber, Jessica TI Catheter-Associated Urinary Tract Infection A Successful Prevention Effort Employing a Multipronged Initiative at an Academic Medical Center SO JOURNAL OF NURSING CARE QUALITY LA English DT Article DE catheter-related infections; patient outcome assessment; quality improvement; urinary tract infections ID HOSPITALIZED-PATIENTS; EPIDURAL ANALGESIA; UNITED-STATES; CARE AB An interdisciplinary clinical improvement workgroup was formed at this academic medical center with the goal of reducing catheter-associated urinary tract infections (CAUTIs). In 2011, the CAUTI rate was noted to be 4.7 CAUTIs per 1000 catheter days. Rounding by 2 lead clinical nurse specialists revealed deficiencies in current practice, which were addressed with multifaceted strategies, including evidence-based indwelling urinary catheter and bladder management protocols, education of staff, reporting of data, and utilization of an icon in the electronic health record (EHR). After the implementation of these strategies, the CAUTI rate decreased and was noted to be 2.4 in February 2013. In addition to this, there was a downward trend line for catheter days. C1 [Purvis, Suzanne; Gion, Therese; VanDenBergh, Shelly; Weber, Jessica] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Rees, Susan] Univ Wisconsin Hosp & Clin, Dev Nursing & Patient Care Serv, Madison, WI 53792 USA. [Kennedy, Gregory] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Infect Dis, Madison, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Purvis, S (reprint author), Univ Wisconsin Hosp & Clin, 600 Highland Ave,MC 8340, Madison, WI 53792 USA. EM spurvis@uwhealth.org NR 16 TC 6 Z9 7 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1057-3631 EI 1550-5065 J9 J NURS CARE QUAL JI J. Nurs. Care Qual. PD APR-JUN PY 2014 VL 29 IS 2 BP 141 EP 148 DI 10.1097/NCQ.0000000000000037 PG 8 WC Nursing SC Nursing GA AI9VJ UT WOS:000337289200010 PM 24316667 ER PT J AU Hausmann, LRM Gao, S Mor, MK Schaefer, JH Fine, MJ AF Hausmann, Leslie R. M. Gao, Shasha Mor, Maria K. Schaefer, James H., Jr. Fine, Michael J. TI Patterns of Sex and Racial/Ethnic Differences in Patient Health Care Experiences in US Veterans Affairs Hospitals SO MEDICAL CARE LA English DT Article DE sex; race and ethnicity; HCAHPS; health care experiences; veterans ID MEDICAID MANAGED CARE; ETHNIC DISPARITIES; PATIENTS PERCEPTIONS; INPATIENT CARE; UNITED-STATES; SATISFACTION; ASSESSMENTS; RACE/ETHNICITY; PROVIDERS AB Background: Few studies have assessed sex or racial/ethnic differences in inpatient experiences in the Veterans Affairs (VA) Healthcare System. Objectives: This study aimed to compare inpatient experiences by sex and race/ethnicity within and between VA hospitals. Research Design: We used mixed-effects multinomial regression to assess within-facility and between-facility sex and racial/ethnic differences in the 2010 VA Survey of Healthcare Experiences of Patients. Subjects: 50,471 respondents from 144 VA hospitals (4.5% female; 75.4% non-Hispanic white, 14.7% non-Hispanic black, 5.4% Hispanic, and 4.4% other race/ethnicity). Measures: Negative and positive patient-reported experiences in 13 health care domains were included. Results: Adjusted within-facility sex differences indicated that women reported more negative and less positive experiences than men in 4 domains, and less negative and more positive experiences on domains related to noise and privacy. Patients at facilities with more female patients reported more negative and less positive experiences in 4 domains. Blacks and Hispanics reported less negative and/or more positive experiences than whites within the same facility, although patients at facilities with more black and Hispanic patients reported more negative and less positive experiences overall. There were few and inconsistent within-facility differences between other racial/ethnic patients and whites. Patients at facilities with more other racial/ethnic patients reported slightly less negative and more positive experiences. Conclusions: Male, black, and Hispanic patients treated in VA hospitals tend to report more positive experiences than female and white patients treated at the same facilities. However, less positive experiences are reported by patients overall in hospitals that serve larger populations of women and racial/ethnic minorities. C1 [Hausmann, Leslie R. M.; Gao, Shasha; Mor, Maria K.; Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hausmann, Leslie R. M.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Schaefer, James H., Jr.] Off Informat & Analyt, Dept Vet Affairs, Durham, NC USA. RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot CHERP, Bldg 30,Univ Dr 151C, Pittsburgh, PA 15240 USA. EM leslie.hausmann@gmail.com FU Center for Health Equity Research and Promotion (CHERP) VISN4 Pilot Research Program [LIP 72-056]; Veterans Affairs Health Services Research and Development Career Development Program [RCD 06-287] FX Supported by the Center for Health Equity Research and Promotion (CHERP) VISN4 Pilot Research Program (LIP 72-056). L.R.M.H.'s effort was supported by the Veterans Affairs Health Services Research and Development Career Development Program (RCD 06-287). The views expressed here are those of the authors and do not represent those of the Department of Veterans Affairs or the United States Government. NR 27 TC 4 Z9 4 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD APR PY 2014 VL 52 IS 4 BP 328 EP 335 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ0AC UT WOS:000337309800009 PM 24848206 ER PT J AU Ko, CW Dominitz, JA Neradilek, M Polissar, N Green, P Kreuter, W Baldwin, LM AF Ko, Cynthia W. Dominitz, Jason A. Neradilek, Moni Polissar, Nayak Green, Pam Kreuter, William Baldwin, Laura-Mae TI Determination of Colonoscopy Indication From Administrative Claims Data SO MEDICAL CARE LA English DT Article DE colonoscopy; health services research; electronic health records; algorithms ID COLORECTAL-CANCER; UNITED-STATES; ENDOSCOPY AB Background: Colonoscopy outcomes, such as polyp detection or complication rates, may differ by procedure indication. Objectives: To develop methods to classify colonoscopy indications from administrative data, facilitating study of colonoscopy quality and outcomes. Research Design: We linked 14,844 colonoscopy reports from the Clinical Outcomes Research Initiative, a national repository of endoscopic reports, to the corresponding Medicare Carrier and Outpatient File claims. Colonoscopy indication was determined from the procedure reports. We developed algorithms using classification and regression trees and linear discriminant analysis (LDA) to classify colonoscopy indication. Predictor variables included ICD-9CM and CPT/HCPCS codes present on the colonoscopy claim or in the 12 months prior, patient demographics, and site of colonoscopy service. Algorithms were developed on a training set of 7515 procedures, then validated using a test set of 7329 procedures. Results: Sensitivity was lowest for identifying average-risk screening colonoscopies, varying between 55% and 86% for the different algorithms, but specificity for this indication was consistently over 95%. Sensitivity for diagnostic colonoscopy varied between 77% and 89%, with specificity between 55% and 87%. Algorithms with classification and regression trees with 7 variables or LDA with 10 variables had similar overall accuracy, and generally lower accuracy than the algorithm using LDA with 30 variables. Conclusions: Algorithms using Medicare claims data have moderate sensitivity and specificity for colonoscopy indication, and will be useful for studying colonoscopy quality in this population. Further validation may be needed before use in alternative populations. C1 [Ko, Cynthia W.; Dominitz, Jason A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Neradilek, Moni; Polissar, Nayak] Mt Whisper Light Stat, Seattle, WA USA. [Green, Pam; Baldwin, Laura-Mae] Univ Washington, Dept Family Med, Seattle, WA 98195 USA. [Kreuter, William] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Ko, CW (reprint author), Univ Washington, Div Gastroenterol, Box 356424, Seattle, WA 98195 USA. EM cwko@u.washington.edu FU NIH [CA127659]; American Society for Gastrointestinal Endoscopy Endoscopic Research Career Development Award; VA Puget Sound Health Care System, Department of Veterans Affairs FX Supported by NIH grant CA127659. J.A.D. was supported by the American Society for Gastrointestinal Endoscopy Endoscopic Research Career Development Award. This material is based upon work supported in part by the VA Puget Sound Health Care System, Department of Veterans Affairs. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 16 TC 8 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD APR PY 2014 VL 52 IS 4 BP E21 EP E29 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ0AC UT WOS:000337309800001 PM 22437619 ER PT J AU Vandrey, R Babson, KA Herrmann, ES Bonn-Miller, MO AF Vandrey, Ryan Babson, Kimberly A. Herrmann, Evan S. Bonn-Miller, Marcel O. TI Interactions between disordered sleep, post-traumatic stress disorder, and substance use disorders SO INTERNATIONAL REVIEW OF PSYCHIATRY LA English DT Article ID ALCOHOL-DEPENDENT INDIVIDUALS; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; CHRONIC COCAINE USERS; DOUBLE-BLIND; MARIJUANA WITHDRAWAL; COMBAT VETERANS; CANNABIS USE; SMOKING-CESSATION; IMAGERY REHEARSAL AB Disordered sleep is associated with a number of adverse health consequences and is an integral component of many psychiatric disorders. Rates of substance use disorders (SUDs) are markedly higher among individuals with post-traumatic stress disorder (PTSD), and this relationship may be partly mediated by disturbed sleep. Sleep disturbances (e. g. insomnia, daytime sleepiness, vivid nightmares) are hallmark features of PTSD and there is evidence that individuals with PTSD engage in substance use as a means of coping with these symptoms. However, prolonged substance use can lead to more severe sleep disturbances due to the development of tolerance and withdrawal. Behavioural or pharmacological treatment of disordered sleep is associated with improved daytime symptoms and psychosocial functioning among individuals who have developed PTSD. Initial research also suggests that improving sleep could be similarly beneficial in reducing coping oriented substance use and preventing relapse among those seeking treatment for SUDs. Together, these findings suggest that ameliorating sleep disturbance among at-risk individuals would be a viable target for the prevention and treatment of PTSD and associated SUDs, but prospective research is needed to examine this hypothesis. Enhanced understanding of the interrelation between sleep, PTSD, and SUDs may yield novel prevention and intervention approaches for these costly, prevalent and frequently co-occurring disorders. C1 [Vandrey, Ryan; Herrmann, Evan S.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA. [Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Palo Alto, CA USA. [Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA. [Babson, Kimberly A.] Stanford Sch Med, Dept Psychiat & Behav Sci, Stanford, CA USA. [Bonn-Miller, Marcel O.] Philadelphia Vet Affairs Med Ctr, Ctr Excellence Substance Abuse Treatment & Educ, Philadelphia, PA USA. [Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Vandrey, R (reprint author), Johns Hopkins Univ, Sch Med, Behav Pharmacol Res Unit, 5510 Nathan Shock Dr, Baltimore, MD 21224 USA. EM rvandrey@jhmi.edu OI Babson, Kimberly/0000-0002-9233-8230 FU NIDA NIH HHS [T32-DA07209, U01 DA031784, U01-DA031784, T32 DA007209] NR 141 TC 11 Z9 11 U1 3 U2 15 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0954-0261 EI 1369-1627 J9 INT REV PSYCHIATR JI Int. Rev. Psych. PD APR PY 2014 VL 26 IS 2 BP 237 EP 247 DI 10.3109/09540261.2014.901300 PG 11 WC Psychiatry SC Psychiatry GA AI6XB UT WOS:000337019200009 PM 24892898 ER PT J AU Grady, D Redberg, RF Mallon, WK AF Grady, Deborah Redberg, Rita F. Mallon, William K. TI How Should Top-Five Lists Be Developed? What Is the Next Step? SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Grady, Deborah; Redberg, Rita F.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA. [Grady, Deborah] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Mallon, William K.] Univ So Calif, Keck Sch Med, Dept Clin Emergency Med, Los Angeles, CA 90033 USA. RP Grady, D (reprint author), Univ Calif San Francisco, Dept Med, 1635 Divisadero St,Ste 600, San Francisco, CA 94115 USA. NR 1 TC 7 Z9 7 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2014 VL 174 IS 4 BP 498 EP 499 DI 10.1001/jamainternmed.2013.8272 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AI4NK UT WOS:000336841900004 PM 24534809 ER PT J AU Aldridge, MD Schlesinger, M Barry, CL Morrison, RS McCorkle, R Hurzeler, R Bradley, EH AF Aldridge, Melissa D. Schlesinger, Mark Barry, Colleen L. Morrison, R. Sean McCorkle, Ruth Huerzeler, Rosemary Bradley, Elizabeth H. TI National Hospice Survey Results For-Profit Status, Community Engagement, and Service SO JAMA INTERNAL MEDICINE LA English DT Article ID FAMILY-MEMBERS; NURSING-HOME; CARE; ENROLLMENT; OWNERSHIP; NONPROFIT; PATTERNS; INDUSTRY; LIFE; END AB IMPORTANCE The impact of the substantial growth in for-profit hospices in the United States on quality and hospice access has been intensely debated, yet little is known about how for-profit and nonprofit hospices differ in activities beyond service delivery. OBJECTIVE To determine the association between hospice ownership and (1) provision of community benefits, (2) setting and timing of the hospice population served, and (3) community outreach. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional survey (the National Hospice Survey), conducted from September 2008 through November 2009, of a national random sample of 591 Medicare-certified hospices operating throughout the United States. EXPOSURES For-profit or nonprofit hospice ownership. MAIN OUTCOMES AND MEASURES Provision of community benefits; setting and timing of the hospice population served; and community outreach. RESULTS A total of 591 hospices completed our survey (84% response rate). For-profit hospices were less likely than nonprofit hospices to provide community benefits including serving as training sites (55% vs 82%; adjusted relative risk [ARR], 0.67 [95% CI, 0.59-0.76]), conducting research (18% vs 23%; ARR, 0.67 [95% CI, 0.46-0.99]), and providing charity care (80% vs 82%; ARR, 0.88 [95% CI, 0.80-0.96]). For-profit compared with nonprofit hospices cared for a larger proportion of patients with longer expected hospice stays including those in nursing homes (30% vs 25%; P =.009). For-profit hospices were more likely to exceed Medicare's aggregate annual cap (22% vs 4%; ARR, 3.66 [95% CI, 2.02-6.63]) and had a higher patient disenrollment rate (10% vs 6%; P <.001). For-profit were more likely than nonprofit hospices to engage in outreach to low-income communities (61% vs 46%; ARR, 1.23 [95% CI, 1.05-1.44]) and minority communities (59% vs 48%; ARR, 1.18 [95% CI, 1.02-1.38]) and less likely to partner with oncology centers (25% vs 33%; ARR, 0.59 [95% CI, 0.44-0.80]). CONCLUSIONS AND RELEVANCE Ownership-related differences are apparent among hospices in community benefits, population served, and community outreach. Although Medicare's aggregate annual cap may curb the incentive to focus on long-stay hospice patients, additional regulatory measures such as public reporting of hospice disenrollment rates should be considered as the share of for-profit hospices in the United States continues to increase. C1 [Aldridge, Melissa D.; Morrison, R. Sean] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Schlesinger, Mark; McCorkle, Ruth; Bradley, Elizabeth H.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Morrison, R. Sean] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Huerzeler, Rosemary] John Thompson Hosp Inst Educ Training & Res Inc, Branford, CT USA. RP Aldridge, MD (reprint author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, One Gustave L Levy Pl,POB 1070, New York, NY 10029 USA. EM Melissa.Aldridge@mssm.edu FU National Cancer Institute [1R01CA116398-01A2]; John D. Thompson Foundation; National Institute of Nursing Research [1K99NR010495-01] FX This study was supported by grant 1R01CA116398-01A2 from the National Cancer Institute (Dr Bradley); the John D. Thompson Foundation (Dr Bradley); and grant 1K99NR010495-01 from the National Institute of Nursing Research (Dr Aldridge). NR 28 TC 11 Z9 11 U1 7 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2014 VL 174 IS 4 BP 500 EP 506 DI 10.1001/jamainternmed.2014.3 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AI4NK UT WOS:000336841900005 PM 24567076 ER PT J AU Thomas, HN Chang, CCH Dillon, S Hess, R AF Thomas, Holly N. Chang, Chung-Chou H. Dillon, Stacey Hess, Rachel TI Sexual Activity in Midlife Women: Importance of Sex Matters SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Thomas, Holly N.; Chang, Chung-Chou H.; Dillon, Stacey; Hess, Rachel] Univ Pittsburgh, Ctr Res Healthcare, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Thomas, Holly N.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Thomas, HN (reprint author), Univ Pittsburgh, Ctr Res Healthcare, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. EM thomashn@upmc.edu FU NIA NIH HHS [AG024254] NR 5 TC 12 Z9 12 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2014 VL 174 IS 4 BP 631 EP + DI 10.1001/jamainternmed.2013.14402 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AI4NK UT WOS:000336841900030 PM 24515395 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI "Expert Opinion" Software for Medical Diagnosis and Treatment Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94131 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Dhaliwal, G (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, 4150 Clement St 111, San Francisco, CA 94131 USA. EM gurpreet.dhaliwal@ucsf.edu NR 3 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2014 VL 174 IS 4 BP 639 EP 640 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AI4NK UT WOS:000336841900037 PM 24711185 ER PT J AU Singh, H Meyer, AND AF Singh, Hardeep Meyer, Ashley N. D. TI "Expert Opinion" Software for Medical Diagnosis and Treatment Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Singh, Hardeep; Meyer, Ashley N. D.] Michael E DeBakey VA Med Ctr, Houston VA Hlth Serv Res & Dev, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. [Singh, Hardeep; Meyer, Ashley N. D.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu NR 6 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2014 VL 174 IS 4 BP 639 EP 639 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AI4NK UT WOS:000336841900036 PM 24711184 ER PT J AU Jackevicius, CA Krumholz, HM AF Jackevicius, Cynthia A. Krumholz, Harlan M. TI Role of Nicotinic Acid in Atherosclerosis Prevention Reply SO JAMA INTERNAL MEDICINE LA English DT Letter ID NIACIN; THERAPY C1 [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA 91766 USA. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Krumholz, Harlan M.] Sect Hlth Policy & Adm, Dept Epidemiol & Publ Hlth, New Haven, CT USA. [Krumholz, Harlan M.] Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu NR 6 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2014 VL 174 IS 4 BP 649 EP 649 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AI4NK UT WOS:000336841900053 PM 24711201 ER PT J AU Mitsui, Y Yasumoto, H Nagami, T Hiraki, M Arichi, N Ishikawa, N Araki, A Maruyama, R Tanaka, Y Dahiya, R Shiina, H AF Mitsui, Yozo Yasumoto, Hiroaki Nagami, Taichi Hiraki, Miho Arichi, Naoko Ishikawa, Noriyoshi Araki, Asuka Maruyama, Riruke Tanaka, Yuichiro Dahiya, Rajvir Shiina, Hiroaki TI Extracellular activation of Wnt signaling through epigenetic dysregulation of Wnt inhibitory factor-1 (Wif-1) is associated with pathogenesis of adrenocortical tumor SO ONCOTARGET LA English DT Article DE adrenocortical tumor; Wif-1; epigenetics; Wnt signaling; cyclin D1 ID RENAL-CELL CARCINOMA; BETA-CATENIN MUTATIONS; C-MYC; BLADDER-CANCER; LUNG-CANCER; CYCLIN D1; PATHWAY; EXPRESSION; FREQUENT; GENE AB Wnt/beta-catenin signaling is considered to be an essential regulator of adrenocortical oncogenesis. Wnt inhibitory factor-1 (Wif-1), an extracellular regulator of Wnt signaling, is frequently down-regulated by hypermethylation of the promoter CpG. We investigated epigenetic regulation of Wif-1 and its association with adrenocortical (AC) tumor pathogenesis in light of Wnt activation. The AC tumors showed a high prevalence of Wif-1 promoter methylation and low prevalence of Wif-1 mRNA transcription as compared to the normal adrenal (NA) samples. Furthermore, a significant correlation was found between Wif-1 promoter methylation and mRNA transcription in the tumors. Either intracellular beta-catenin accumulation or beta-catenin mRNA transcription was significantly elevated in the AC tumors, which also showed an inverse correlation with Wif-1 mRNA transcription. Cyclin D1, a target gene of Wnt signaling, was also up-regulated in the AC tumors as compared with the NA samples. In addition, down-regulation of Wif-1was correlated with increased cyclin D1 at both mRNA and protein levels. However, despite the proposed activation of Wnt signaling in AC tumors, only 2 of 20 with intracellular beta-catenin accumulation showed beta-catenin mutations. Thus, genetic alterations of beta-catenin and epigenetics-related Wif-1 promoter hypermethylation may be important mechanisms underlying AC tumor formation through aberrant canonical Wnt/beta-catenin signaling activation. C1 [Mitsui, Yozo; Yasumoto, Hiroaki; Nagami, Taichi; Hiraki, Miho; Arichi, Naoko; Shiina, Hiroaki] Shimane Univ, Fac Med, Dept Urol, Izumo, Shimane 6938501, Japan. [Ishikawa, Noriyoshi; Araki, Asuka; Maruyama, Riruke] Shimane Univ, Fac Med, Pathol Organ Pathol Unit, Izumo, Shimane 6938501, Japan. [Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Tanaka, Yuichiro; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Mitsui, Y (reprint author), Shimane Univ, Fac Med, Dept Urol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan. EM mitsui@med.shimane-u.ac.jp NR 35 TC 6 Z9 7 U1 0 U2 2 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD APR PY 2014 VL 5 IS 8 BP 2198 EP 2207 PG 10 WC Oncology; Cell Biology SC Oncology; Cell Biology GA AI6FC UT WOS:000336965800017 PM 24755523 ER PT J AU Perez-Rodriguez, MM Baca-Garcia, E Oquendo, MA Wang, S Wall, MM Liu, SM Blanco, C AF Mercedes Perez-Rodriguez, M. Baca-Garcia, Enrique Oquendo, Maria A. Wang, Shuai Wall, Melanie M. Liu, Shang-Min Blanco, Carlos TI Relationship Between Acculturation, Discrimination, and Suicidal Ideation and Attempts Among US Hispanics in the National Epidemiologic Survey of Alcohol and Related Conditions SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID UNITED-STATES 1991-1992; MENTAL-HEALTH; PSYCHIATRIC-DISORDERS; DEPRESSIVE SYMPTOMS; LATINO ADOLESCENTS; COMORBIDITY SURVEY; MEXICAN-AMERICANS; MAJOR DEPRESSION; IMMIGRATION; RATES AB Objective: Acculturation is the process by which immigrants acquire the culture of the dominant society. Little is known about the relationship between acculturation and suicidal ideation and attempts among US Hispanics. Our aim was to examine the impact of 5 acculturation measures (age at migration, time in the United States, social network composition, language, race/ethnic orientation) on suicidal ideation and attempts in the largest available nationally representative sample of US Hispanics. Method: Study participants were US Hispanics (N = 6,359) from Wave 2 of the 2004-2005 National Epidemiologic Survey of Alcohol and Related Conditions (N = 34,653). We used linear chi(2) tests and logistic regression models to analyze the association between acculturation and risk of suicidal ideation and attempts. Results: Factors associated with a linear increase in lifetime risk for suicidal ideation and attempts were (1) younger age at migration (linear chi(2)(1) = 57.15; P < .0001), (2) longer time in the United States (linear chi(2)(1) = 36.09; P < .0001), (3) higher degree of English-language orientation (linear chi(2)(1) = 74.08; P < .0001), (4) lower Hispanic composition of social network (linear chi(2)(1) = 36.34; P < .0001), and (5) lower Hispanic racial/ethnic identification (linear chi(2)(1) = 47.77; P < .0001). Higher levels of perceived discrimination were associated with higher lifetime risk for suicidal ideation (beta = 0.051; P < .001) and attempts (beta = 0.020; P = .003). Conclusions: There was a linear association between multiple dimensions of acculturation and lifetime suicidal ideation and attempts. Discrimination was also associated with lifetime risk for suicidal ideation and attempts. Our results highlight protective aspects of the traditional Hispanic culture, such as high social support, coping strategies, and moral objections to suicide, which are modifiable factors and potential targets for public health interventions aimed at decreasing suicide risk. Culturally sensitive mental health resources need to be made more available to decrease discrimination and stigma. C1 [Mercedes Perez-Rodriguez, M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Mercedes Perez-Rodriguez, M.] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY USA. [Mercedes Perez-Rodriguez, M.] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Mercedes Perez-Rodriguez, M.; Baca-Garcia, Enrique] CIBERSAM, Madrid, Spain. [Baca-Garcia, Enrique] Fdn Jimenez Diaz Hosp, Dept Psychiat, Madrid, Spain. [Baca-Garcia, Enrique] Univ Autonoma Madrid, Madrid, Spain. [Baca-Garcia, Enrique; Oquendo, Maria A.; Wang, Shuai; Liu, Shang-Min; Blanco, Carlos] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. [Baca-Garcia, Enrique; Oquendo, Maria A.; Wang, Shuai; Liu, Shang-Min; Blanco, Carlos] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Wall, Melanie M.] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA. RP Perez-Rodriguez, MM (reprint author), Mt Sinai Sch Med Psychiat, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM mercedes.perez@mssm.edu RI Perez Rodriguez, Maria/B-9410-2013; Baca-Garcia, Enrique/F-4106-2015 OI Perez Rodriguez, Maria/0000-0001-5137-1993; Baca-Garcia, Enrique/0000-0002-6963-6555 FU Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; Medical Research Service of the Veterans Affairs; James J. Peters VAMC; Department of Veterans Affairs NY/NJ (VISN3) Mental Illness Research, Education, and Clinical Center; Alicia Koplowitz Foundation; Instituto de Salud Carlos III; CIBERSAM; Spanish Ministry of Health [SAF2010-21849]; NIH [DA019606, DA020783, DA023200, MH076051]; American Foundation for Suicide Prevention; New York State Psychiatric Institute; NIAAA FX This research is supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the Veterans Affairs, James J. Peters VAMC; the Department of Veterans Affairs NY/NJ (VISN3) Mental Illness Research, Education, and Clinical Center (Dr Perez-Rodriguez); the Alicia Koplowitz Foundation (Dr Baca-Garcia); Instituto de Salud Carlos III, CIBERSAM, and Spanish Ministry of Health grant SAF2010-21849 (Drs Baca-Garcia and Perez-Rodriguez); NIH grants DA019606, DA020783, DA023200, and MH076051 (Dr Blanco); American Foundation for Suicide Prevention (Dr Blanco); and New York State Psychiatric Institute (Drs Blanco and Oquendo). NESARC was funded by NIAAA with supplemental support from the National Institute on Drug Abuse. NR 45 TC 11 Z9 12 U1 2 U2 16 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD APR PY 2014 VL 75 IS 4 BP 399 EP 407 DI 10.4088/JCP.13m08548 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AI0HA UT WOS:000336525700017 PM 24813407 ER PT J AU Donahue, JJ McClure, KS Moon, SM AF Donahue, John J. McClure, Kelly S. Moon, Simon M. TI The Relationship Between Emotion Regulation Difficulties and Psychopathic Personality Characteristics SO PERSONALITY DISORDERS-THEORY RESEARCH AND TREATMENT LA English DT Article DE psychopathy; emotion regulation; self-centered impulsivity; fearless dominance ID CONSTRUCT-VALIDITY; SELF-REPORT; INVENTORY; MODEL; DYSREGULATION; VALIDATION; DISORDER; BEHAVIOR; SUICIDE; RISK AB The factors of psychopathy assessment tools diverge in their relationships with numerous problematic behaviors and psychological disorders. Emotion dysregulation is a pathological process argued to cut across diagnoses, and may be important in better understanding these divergent associations. This study sought to clarify psychopathy's association with emotion regulation difficulties. It was predicted that the Fearless Dominance and Self-Centered Impulsivity factors of the Psychopathic Personality Inventory-Revised would demonstrate differential relationships with a multidimensional conceptualization of emotion regulation difficulties. Ninety-one male undergraduate students and 28 male court-mandated anger management participants completed self-report questionnaires measuring emotion regulation difficulties and psychopathic personality characteristics. Hierarchical regression analyses indicated that emotion regulation difficulties were negatively associated with Fearless Dominance psychopathic traits, but positively associated with Self-Centered Impulsivity and global psychopathic traits. In addition, emotion regulation difficulties explained incremental variance in psychopathic traits over and above negative affect alone. These findings may have clinical implications for the etiology and treatment of psychopathic personality disorder. C1 [Donahue, John J.] Portland VA Med Ctr, VISN Northwest Mental Illness Res Educ & Clin Ctr, Portland, OR 97239 USA. [McClure, Kelly S.; Moon, Simon M.] La Salle Univ, Dept Psychol, Philadelphia, PA 19141 USA. RP Donahue, JJ (reprint author), Portland VA Med Ctr, VISN Northwest Mental Illness Res Educ & Clin Ctr, P3MIRECC,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM John.Donahue4@va.gov NR 47 TC 5 Z9 5 U1 5 U2 20 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1949-2715 EI 1949-2723 J9 PERSONAL DISORD JI Personal. Disord. PD APR PY 2014 VL 5 IS 2 BP 186 EP 194 DI 10.1037/per0000025 PG 9 WC Psychology, Clinical SC Psychology GA AI3ES UT WOS:000336743400009 PM 24341861 ER PT J AU Lemay, AC Anzueto, A Restrepo, MI Mortensen, EM AF Lemay, Allyson C. Anzueto, Antonio Restrepo, Marcos I. Mortensen, Eric M. TI Predictors of Long-term Mortality After Severe Sepsis in the Elderly SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Sepsis; Predictors; Mortality; Comorbid conditions ID COMORBIDITY INDEX; VETERANS-AFFAIRS; UNITED-STATES; EPIDEMIOLOGY; CARE; VALIDATION; TRAUMA; LIFE AB Background: Mortality rates after severe sepsis are extremely high, and the main focus of most research is short-term mortality, which may not be associated with long-term outcomes. The purpose of this study was to examine long-term mortality after a severe sepsis and identify factors associated with this mortality. Methods: The authors performed a population-based study using Veterans' Affairs administrative data of patients aged 65 years and older. The outcome of interest was mortality > 90 days following hospitalization. Our primary analyses were Cox proportional hazard models to examine specific risk factors for long-term mortality. Results: There were 2,727 patients that met the inclusion criteria. Overall mortality was 55%, and 1- and 2-year mortality rates were 31% and 43%, respectively. Factors significantly associated with long-term mortality included congestive heart failure, peripheral vascular disease, dementia, diabetes with complications and use of mechanical ventilation. Smoking cessation and cardiac medications were associated with decreased long-term mortality rates. Conclusions: The authors identified several factors, including receipt of mechanical ventilation, which were significantly associated with increased long-term mortality for survivors of severe sepsis. This information will help clinicians discuss prognosis with patients and their families. C1 [Restrepo, Marcos I.; Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, VERDICT Res Program, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Lemay, Allyson C.; Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, Dept Med, San Antonio, TX 78229 USA. [Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Crit Care Med, Dept Med, San Antonio, TX 78229 USA. RP Mortensen, EM (reprint author), Dallas VA Med Ctr, 4500 South Lancaster, Dallas, TX 75216 USA. EM Eric.Mortensen@UTSouthwestern.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 FU National Institute of Nursing Research [R01NR010828] FX This study was supported by the National Institute of Nursing Research Grant R01NR010828. NR 24 TC 7 Z9 9 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD APR PY 2014 VL 347 IS 4 BP 282 EP 288 DI 10.1097/MAJ.0b013e318295a147 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AH0DG UT WOS:000335788700006 PM 23689053 ER PT J AU Swanson, RA AF Swanson, Raymond A. TI Glucose, Acid, and Aspartate: Friends and Foes of the Axon SO ANNALS OF NEUROLOGY LA English DT Editorial Material ID ISCHEMIC-INJURY; NEURONAL DEATH; NADPH OXIDASE; WHITE-MATTER; HYPOGLYCEMIA C1 [Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA USA. RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. OI Swanson, Raymond/0000-0002-3664-5359 FU NINDS NIH HHS [R01 NS081149, R01 NS041421] NR 12 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 2014 VL 75 IS 4 BP 490 EP 491 DI 10.1002/ana.24071 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AG2GL UT WOS:000335234200004 PM 24272667 ER PT J AU Chen, YZ Friedman, JR Chen, DH Chan, GCK Bloss, CS Hisama, FM Topol, SE Carson, AR Pham, PH Bonkowski, ES Scott, ER Lee, JK Zhang, GF Oliveira, G Xu, J Scott-Van Zeeland, AA Chen, Q Levy, S Topol, EJ Storm, D Swanson, PD Bird, TD Schork, NJ Raskind, WH Torkamani, A AF Chen, Ying-Zhang Friedman, Jennifer R. Chen, Dong-Hui Chan, Guy C. -K. Bloss, Cinnamon S. Hisama, Fuki M. Topol, Sarah E. Carson, Andrew R. Pham, Phillip H. Bonkowski, Emily S. Scott, Erick R. Lee, Janel K. Zhang, Guangfa Oliveira, Glenn Xu, Jian Scott-Van Zeeland, Ashley A. Chen, Qi Levy, Samuel Topol, Eric J. Storm, Daniel Swanson, Phillip D. Bird, Thomas D. Schork, Nicholas J. Raskind, Wendy H. Torkamani, Ali TI Gain-of-Function ADCY5 Mutations in Familial Dyskinesia with Facial Myokymia SO ANNALS OF NEUROLOGY LA English DT Article ID ESSENTIAL BENIGN CHOREA; ADENYLYL-CYCLASE; GENETIC-VARIATION; FDFM; MAP AB ObjectiveTo identify the cause of childhood onset involuntary paroxysmal choreiform and dystonic movements in 2 unrelated sporadic cases and to investigate the functional effect of missense mutations in adenylyl cyclase 5 (ADCY5) in sporadic and inherited cases of autosomal dominant familial dyskinesia with facial myokymia (FDFM). MethodsWhole exome sequencing was performed on 2 parent-child trios. The effect of mutations in ADCY5 was studied by measurement of cyclic adenosine monophosphate (cAMP) accumulation under stimulatory and inhibitory conditions. ResultsThe same de novo mutation (c.1252C>T, p.R418W) in ADCY5 was found in both studied cases. An inherited missense mutation (c.2176G>A, p.A726T) in ADCY5 was previously reported in a family with FDFM. The significant phenotypic overlap with FDFM was recognized in both cases only after discovery of the molecular link. The inherited mutation in the FDFM family and the recurrent de novo mutation affect residues in different protein domains, the first cytoplasmic domain and the first membrane-spanning domain, respectively. Functional studies revealed a statistically significant increase in -receptor agonist-stimulated intracellular cAMP consistent with an increase in adenylyl cyclase activity for both mutants relative to wild-type protein, indicative of a gain-of-function effect. InterpretationFDFM is likely caused by gain-of-function mutations in different domains of ADCY5the first definitive link between adenylyl cyclase mutation and human disease. We have illustrated the power of hypothesis-free exome sequencing in establishing diagnoses in rare disorders with complex and variable phenotype. Mutations in ADCY5 should be considered in patients with undiagnosed complex movement disorders even in the absence of a family history. Ann Neurol 2014;75:542-549 C1 [Chen, Ying-Zhang; Hisama, Fuki M.; Raskind, Wendy H.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA. [Chen, Dong-Hui; Bonkowski, Emily S.; Swanson, Phillip D.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Chan, Guy C. -K.; Storm, Daniel] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. [Bloss, Cinnamon S.; Topol, Sarah E.; Carson, Andrew R.; Pham, Phillip H.; Scott, Erick R.; Lee, Janel K.; Zhang, Guangfa; Oliveira, Glenn; Scott-Van Zeeland, Ashley A.; Levy, Samuel; Topol, Eric J.; Schork, Nicholas J.; Torkamani, Ali] Scripps Hlth, Scripps Translat Sci Inst, San Diego, CA USA. [Bloss, Cinnamon S.; Topol, Sarah E.; Carson, Andrew R.; Pham, Phillip H.; Scott, Erick R.; Lee, Janel K.; Zhang, Guangfa; Oliveira, Glenn; Scott-Van Zeeland, Ashley A.; Levy, Samuel; Topol, Eric J.; Schork, Nicholas J.; Torkamani, Ali] Scripps Res Inst, San Diego, CA USA. [Xu, Jian] Northwestern Univ, Dept Physiol, Chicago, IL 60611 USA. [Chen, Qi] Fujian Normal Univ, Southern Biomed Res Ctr, Fuzhou, Peoples R China. [Bird, Thomas D.; Raskind, Wendy H.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Raskind, Wendy H.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Raskind, Wendy H.] Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Torkamani, A (reprint author), 3344 North Torrey Pines Court,Ste 300, La Jolla, CA 92037 USA. EM atorkama@scripps.edu OI Topol, Eric/0000-0002-1478-4729 FU Scripps Genomic Medicine, an NIH National Center for Advancing Translational Sciences Clinical and Translational Science Award [5 UL1 RR025774]; Shaffer Family Foundation; Anne and Henry Zarrow Foundation; NIH/NHGRI [U01 HG006476]; NIH/NINDS [R01 NS069719, NS20498]; Department of Veterans Affairs; American Association for Cancer Research; Johnson Johnson FX This work is supported by Scripps Genomic Medicine, an NIH National Center for Advancing Translational Sciences Clinical and Translational Science Award (5 UL1 RR025774) to Scripps Translational Science Institute, as well as funding from the Shaffer Family Foundation and the Anne and Henry Zarrow Foundation. Further support is from NIH/NHGRI U01 HG006476 (A. T.), NIH/NINDS R01 NS069719 (W. H. R.), and NIH/NINDS NS20498 (D. S.), the Department of Veterans Affairs (T. D. B., W. H. R.), the American Association for Cancer Research (N.J.S.), and a research service contract with Johnson & Johnson (N.J.S.). NR 27 TC 26 Z9 27 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 2014 VL 75 IS 4 BP 542 EP 549 DI 10.1002/ana.24119 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AG2GL UT WOS:000335234200009 PM 24700542 ER PT J AU Harbin, JM Gelso, CJ Rojas, AEP AF Harbin, James M. Gelso, Charles J. Rojas, Andres E. Perez TI Therapist Work With Client Strengths: Development and Validation of a Measure SO COUNSELING PSYCHOLOGIST LA English DT Article DE positive psychotherapy; strengths; positive psychology; self-report measure ID COUNSELING PSYCHOLOGY RESEARCH; POSITIVE PSYCHOLOGY; SELF-CONSCIOUSNESS; PSYCHOTHERAPY; MODEL; PSYCHOPATHOLOGY; INTERVENTIONS; PERSPECTIVE; SUPPORT; SCALE AB Two studies were conducted to investigate the Inventory of Therapist Work With Client Assets and Strengths (IT-WAS), a new measure constructed to assess the importance therapists place on incorporating strength-based approaches in their therapeutic work. In the first study, a combined sample (N = 225), comprising therapists in independent practice, graduate students and faculty in counseling-related fields, and counseling center staff at a large mid-Atlantic university was gathered to conduct an exploratory factor analysis. Results yielded three factors (Theory of Intervention, Assessment of Strengths, and Supporting Progress). The data also provided evidence for the IT-WAS's internal consistency and validity, the latter being supported by correlations with measures of theoretically relevant constructs. In the second study, data from 31 counseling and clinical doctoral students provided evidence for the IT-WAS's test-retest reliability over a 2-week period. Implications for clinical training and practice are discussed, and areas of future research are provided. C1 [Harbin, James M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Harbin, James M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Gelso, Charles J.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Rojas, Andres E. Perez] Univ Maryland, Counseling Psychol Program, College Pk, MD 20742 USA. RP Gelso, CJ (reprint author), Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. EM gelso@umd.edu NR 52 TC 2 Z9 2 U1 2 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0011-0000 EI 1552-3861 J9 COUNS PSYCHOL JI Couns. Psychol. PD APR PY 2014 VL 42 IS 3 BP 345 EP 373 DI 10.1177/0011000012470570 PG 29 WC Psychology, Applied SC Psychology GA AB7KU UT WOS:000331969700003 ER PT J AU Pfeiffer, CD Cunningham, MC Poissant, T Furuno, JP Townes, JM Leitz, A Thomas, A Buser, GL Arao, RF Beldavs, ZG AF Pfeiffer, Christopher D. Cunningham, Margaret C. Poissant, Tasha Furuno, Jon P. Townes, John M. Leitz, Andrew Thomas, Ann Buser, Genevieve L. Arao, Robert F. Beldavs, Zintars G. TI Establishment of a Statewide Network for Carbapenem-Resistant Enterobacteriaceae Prevention in a Low-Incidence Region SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID TERM-CARE FACILITIES; KLEBSIELLA-PNEUMONIAE; INFECTION PREVENTION; SPREAD; EMERGENCE; MARYLAND AB Objective.To establish a statewide network to detect, control, and prevent the spread of carbapenem-resistant Enterobacteriaceae (CRE) in a region with a low incidence of CRE infection.Design.Implementation of the Drug Resistant Organism Prevention and Coordinated Regional Epidemiology (DROP-CRE) Network.Setting and participants.Oregon infection prevention and microbiology laboratory personnel, including 48 microbiology laboratories, 62 acute care facilities, and 140 long-term care facilities.Methods.The DROP-CRE working group, comprising representatives from academic institutions and public health, convened an interdisciplinary advisory committee to assist with planning and implementation of CRE epidemiology and control efforts. The working group established a statewide CRE definition and surveillance plan; increased the state laboratory capacity to perform the modified Hodge test and polymerase chain reaction for carbapenemases in real time; and administered surveys that assessed the needs and capabilities of Oregon infection prevention and laboratory personnel. Results of these inquiries informed CRE education and the response plan.Results.Of 60 CRE reported from November 2010 through April 2013, only 3 were identified as carbapenemase producers; the cases were not linked, and no secondary transmission was found. Microbiology laboratories, acute care facilities, and long-term care facilities reported lacking carbapenemase testing capability, reliable interfacility communication, and CRE awareness, respectively. Survey findings informed the creation of the Oregon CRE Toolkit, a state-specific CRE guide booklet.Conclusions.A regional epidemiology surveillance and response network has been implemented in Oregon in advance of widespread CRE transmission. Prospective surveillance will determine whether this collaborative approach will be successful at forestalling the emergence of this important healthcare-associated pathogen. C1 [Pfeiffer, Christopher D.; Townes, John M.] Portland VA Med Ctr, Dept Hosp & Specialty Med, Portland, OR 97239 USA. [Pfeiffer, Christopher D.; Leitz, Andrew] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Cunningham, Margaret C.; Poissant, Tasha; Thomas, Ann; Buser, Genevieve L.; Arao, Robert F.; Beldavs, Zintars G.] Oregon Hlth Author, Oregon Publ Hlth Div, Portland, OR USA. [Furuno, Jon P.] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR 97201 USA. RP Pfeiffer, CD (reprint author), Portland VA Med Ctr, POB 1034 P3 ID, Portland, OR 97239 USA. EM pfeiffec@ohsu.edu OI Poissant, Tasha/0000-0003-4407-272X FU Centers for Disease Control and Prevention Epidemiology and Laboratory Capacity Program through the Affordable Care Act FX Financial support. This work was funded by a cooperative agreement with Centers for Disease Control and Prevention Epidemiology and Laboratory Capacity Program through the Affordable Care Act. NR 19 TC 6 Z9 6 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR 1 PY 2014 VL 35 IS 4 SI SI BP 356 EP 361 DI 10.1086/675605 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AC2DP UT WOS:000332308400005 PM 24602939 ER PT J AU Zhao, X Cao, MQ Feng, HH Fan, H Chen, F Feng, ZJ Li, XS Zhou, XH AF Zhao, Xing Cao, Mingqin Feng, Hai-Huan Fan, Heng Chen, Fei Feng, Zijian Li, Xiaosong Zhou, Xiao-Hua TI Japanese Encephalitis Risk and Contextual Risk Factors in Southwest China: A Bayesian Hierarchical Spatial and Spatiotemporal Analysis SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE Japanese encephalitis; contextual risk factors; meteorological factors; southwest China; Bayesian hierarchical model ID CLIMATE-CHANGE; MALARIA; TRANSMISSION; CHALLENGES; VARIABLES; ECOLOGY; FUTURE; VIRUS AB It is valuable to study the spatiotemporal pattern of Japanese encephalitis (JE) and its association with the contextual risk factors in southwest China, which is the most endemic area in China. Using data from 2004 to 2009, we applied GISmapping and spatial autocorrelation analysis to analyze reported incidence data of JE in 438 counties in southwest China, finding that JE cases were not randomly distributed, and a Bayesian hierarchical spatiotemporal model identified the east part of southwest China as a high risk area. Meanwhile, the Bayesian hierarchical spatial model in 2006 demonstrated a statistically significant association between JE and the agricultural and climatic variables, including the proportion of rural population, the pig-to-human ratio, the monthly precipitation and the monthly mean minimum and maximum temperatures. Particular emphasis was placed on the time-lagged effect for climatic factors. The regression method and the Spearman correlation analysis both identified a two-month lag for the precipitation, while the regression method found a one-month lag for temperature. The results show that the high risk area in the east part of southwest China may be connected to the agricultural and climatic factors. The routine surveillance and the allocation of health resources should be given more attention in this area. Moreover, the meteorological variables might be considered as possible predictors of JE in southwest China. C1 [Zhao, Xing; Feng, Hai-Huan; Fan, Heng; Chen, Fei; Li, Xiaosong] Sichuan Univ, West China Sch Publ Hlth, Chengdu 610041, Peoples R China. [Zhao, Xing; Zhou, Xiao-Hua] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Cao, Mingqin] Xinjiang Med Univ, Sch Publ Hlth, Urumqi 830011, Peoples R China. [Feng, Zijian] Chinese Ctr Dis Control & Prevent China CDC, Off Dis Control & Emergency Response, Beijing 102206, Peoples R China. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. RP Li, XS (reprint author), Sichuan Univ, West China Sch Publ Hlth, Chengdu 610041, Peoples R China. EM zhaoxing731@gmail.com; cmq66@126.com; fenghaihuan@163.com; 13211020002@fudan.edu.cn; jacky2183@163.com; fengzj@chinacdc.cn; lixiaosong1101@126.com; azhou@u.washington.edu FU Natural Science Foundation of China [30571618]; China Scholarship Council FX This study was supported by the Natural Science Foundation of China (No. 30571618) and China Scholarship Council (http://en.csc.edu.cn/). NR 45 TC 4 Z9 4 U1 2 U2 15 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD APR PY 2014 VL 11 IS 4 BP 4201 EP 4217 DI 10.3390/ijerph110404201 PG 17 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AG9TM UT WOS:000335762700063 PM 24739769 ER PT J AU Dodge, HH Ybarra, O Kaye, JA AF Dodge, Hiroko H. Ybarra, Oscar Kaye, Jeffrey A. TI Tools for advancing research into social networks and cognitive function in older adults SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Editorial Material ID STRESS; SIZE AB People are good for your brain. Decades of research have shown that individuals who have a larger number of people in their social network or higher quality ties with individuals within their network have lower rates of morbidity and mortality across a wide range of health outcomes. Among these outcomes, cognitive function, especially in the context of brain aging, has been one area of particular interest with regard to social engagement, or more broadly, socially integrated lifestyles. Many studies have observed an association between the size of a person's social network or levels of social engagement and the risk for cognitive decline or dementia (e.g. see review by Fratiglioni et al., 2004). The dementia risk reduction associated with a larger social network or social engagement shown by some epidemiological studies is fairly large. The population effect size of increasing social engagement on delaying dementia disease progression could exceed that of current FDA approved medications for Alzheimer's disease. C1 [Dodge, Hiroko H.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Dodge, Hiroko H.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. [Dodge, Hiroko H.] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI USA. [Ybarra, Oscar] Univ Michigan, Inst Social Res, Dept Psychol, Res Ctr Grp Dynam, Ann Arbor, MI USA. [Kaye, Jeffrey A.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. [Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA. RP Dodge, HH (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. EM dodgeh@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU NIA NIH HHS [P30 AG008017, P30 AG024978, R01 AG024054, R01 AG033581]; NIGMS NIH HHS [R01 GM024054] NR 28 TC 8 Z9 8 U1 1 U2 11 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD APR PY 2014 VL 26 IS 4 BP 533 EP 539 DI 10.1017/S1041610213001750 PG 7 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA AD0MA UT WOS:000332926900002 PM 24152936 ER PT J AU Hurley, SL Strumpf, N Barg, FK Ersek, M AF Hurley, Susan Lysaght Strumpf, Neville Barg, Frances K. Ersek, Mary TI Not Quite Seamless: Transitions between Home and Inpatient Hospice SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID CARE; PLACE; LIFE AB Background: Although most hospice care occurs in the home, a growing number of patients utilize inpatient hospice settings. An inpatient hospice stay requires one or more transitions in care settings, although little is known about these transitions. Objective/Design: Using ethnographic methods, this study examined the beliefs and practices of older adults, their caregivers, and hospice interdisciplinary team (IDT) members surrounding transitions between home and inpatient hospice. Setting/Subjects: Data collection took place over 11 months in a large not-for-profit hospice agency in the northeast. Data were collected through 18 observations and 38 semistructured interviews with patients, family caregivers, and hospice IDT members. Results: Transitions from home to inpatient hospice centered on three processes: developing a plan for future needs, identifying triggers that signaled increased needs for care, and navigating through phases of increased care. Patients, family caregivers, or IDT members identified triggers for more care, and actions were taken to respond in the home care setting. Challenges to these actions occurred in many phases of care and when needs were ultimately unable to be addressed at home, patients were transferred to inpatient hospice. Conclusions: Understanding how care planning, increased needs, and phases of care influence decisions about transitioning patients to inpatient hospice can guide IDT members in minimizing transitions and providing a more seamless continuum of hospice care. C1 [Hurley, Susan Lysaght; Ersek, Mary] North Shore Med Ctr, Salem, MA 01970 USA. [Strumpf, Neville] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Barg, Frances K.] Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Ersek, Mary] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Hurley, SL (reprint author), North Shore Med Ctr, 81 Highland Ave, Salem, MA 01970 USA. EM slysaghthurley@alumni.upenn.edu FU John A. Hartford Building Academic Geriatric Nursing Capacity Scholar Award; Ruth L. Kirschstein Individual NRSA Predoctoral Fellowship [1F31NR013103] FX S. Lysaght Hurley was supported by a John A. Hartford Building Academic Geriatric Nursing Capacity Scholar Award 2010-2013 and a Ruth L. Kirschstein Individual NRSA Predoctoral Fellowship (1F31NR013103). NR 13 TC 3 Z9 3 U1 1 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD APR 1 PY 2014 VL 17 IS 4 BP 428 EP 434 DI 10.1089/jpm.2013.0359 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AE2OF UT WOS:000333811900012 ER PT J AU Long, AC Engelberg, RA Downey, L Kross, EK Reinke, LF Feemster, LC Dotolo, D Ford, DW Back, AL Curtis, JR AF Long, Ann C. Engelberg, Ruth A. Downey, Lois Kross, Erin K. Reinke, Lynn F. Feemster, Laura Cecere Dotolo, Danae Ford, Dee W. Back, Anthony L. Curtis, J. Randall TI Race, Income, and Education: Associations with Patient and Family Ratings of End-of-Life Care and Communication Provided by Physicians-in-Training SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID HEALTH-CARE; PERCEIVED DISCRIMINATION; SOCIOECONOMIC-STATUS; SEVERE COPD; QUALITY; PERSPECTIVES; DISPARITIES; MATTERS; IMPACT; CANCER AB Background: Minority race and lower socioeconomic status are associated with poorer patient ratings of health care quality and provider communication. Objective: To examine the association of race/ethnicity or socioeconomic status with patients' and families' ratings of end-of-life care and communication about end-of-life care provided by physicians-in-training. Methods: As a component of a randomized trial evaluating a program designed to improve clinician communication about end-of-life care, patients and patients' families completed preintervention survey data regarding care and communication provided by internal medicine residents and medical subspecialty fellows. We examined associations between patient and family race or socioeconomic status and ratings they gave trainees on two questionnaires: the Quality of End-of-Life Care (QEOLC) and Quality of Communication (QOC). Results: Patients from racial/ethnic minority groups, patients with lower income, and patients with lower educational attainment gave trainees higher ratings on the end-of-life care subscale of the QOC (QOCeol). In path models, patient educational attainment and income had a direct effect on outcomes, while race/ethnicity did not. Lower family educational attainment was also associated with higher trainee ratings on the QOCeol, while family non-white race was associated with lower trainee ratings on the QEOLC and general subscale of the QOC. Conclusions: Patient race is associated with perceptions of the quality of communication about end-of-life care provided by physicians-in-training, but the association was opposite to our hypothesis and appears to be mediated by socioeconomic status. Family member predictors of these perceptions differ from those observed for patients. Further investigation of these associations may guide interventions to improve care delivered to patients and families. C1 [Long, Ann C.; Engelberg, Ruth A.; Downey, Lois; Kross, Erin K.; Feemster, Laura Cecere; Dotolo, Danae; Curtis, J. Randall] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA. [Reinke, Lynn F.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Sch Nursing, Seattle, WA 98104 USA. [Back, Anthony L.] Univ Washington, Div Med Oncol, Dept Med, Seattle, WA 98104 USA. [Reinke, Lynn F.; Feemster, Laura Cecere] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Ford, Dee W.] Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Med, Charleston, SC 29425 USA. RP Long, AC (reprint author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359762, Seattle, WA 98104 USA. EM along11@uw.edu FU NIH-NINR [R01NR009987]; NIH-NHLBI [T32 HL007287]; TPM [61-037] FX Funding provided by: NIH-NINR R01NR009987, NIH-NHLBI T32 HL007287, TPM 61-037 NR 30 TC 4 Z9 4 U1 1 U2 11 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD APR 1 PY 2014 VL 17 IS 4 BP 435 EP 447 DI 10.1089/jpm.2013.0214 PG 13 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AE2OF UT WOS:000333811900013 PM 24592958 ER PT J AU Springer, AM Foster-Schubert, K Morton, GJ Schur, EA AF Springer, Alyse M. Foster-Schubert, Karen Morton, Gregory J. Schur, Ellen A. TI Is there evidence that estrogen therapy promotes weight maintenance via effects on leptin? SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Review DE Leptin; Estrogen; Hormone therapy; Obesity ID HORMONE REPLACEMENT THERAPY; NONOBESE POSTMENOPAUSAL WOMEN; INITIATIVE RANDOMIZED-TRIAL; SERUM LEPTIN; BODY-COMPOSITION; PLUS PROGESTIN; TRANSDERMAL ESTRADIOL; BILATERAL OVARIECTOMY; METABOLIC SYNDROME; DOUBLE-BLIND AB Objective Leptin, a hormone secreted by adipocytes, plays a crucial role in regulating energy balance. Estrogen, like leptin, reduces food intake and adiposity while increasing energy expenditure in animals and humans of both sexes through its actions on the central nervous system. We reviewed the literature for studies of the effects of exogenously administered estrogen on serum leptin concentrations and adiposity in women. Methods Using PubMed/Medline, we searched for studies of hormone therapy that enrolled healthy postmenopausal women. Studies were further evaluated to determine if leptin and adiposity were monitored both at baseline and throughout a treatment period of at least 2 months. Results Twenty articles met inclusion criteria. We found no consistent effects of exogenous estrogen on serum leptin concentrations, adiposity, or weight gain. Conclusions Despite suggestive data from animal studies, the current literature does not provide compelling evidence that estrogen therapy attenuates weight gain, alters circulating leptin levels, or improves leptin action in postmenopausal women. C1 [Springer, Alyse M.; Schur, Ellen A.] Univ Washington, Sch Med, Seattle, WA USA. [Foster-Schubert, Karen] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Foster-Schubert, Karen] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Morton, Gregory J.] Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. [Schur, Ellen A.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. RP Schur, EA (reprint author), Harborview Med Ctr, 325 Ninth Ave,Box 359780, Seattle, WA 98104 USA. EM ellschur@uw.edu FU National Institutes of Health [DK083502]; Diabetes and Endocrinology Research Center [P30DK017047] FX E.A.S. was supported by National Institutes of Health grant DK083502 and a Diabetes and Endocrinology Research Center Pilot and Feasibility Award (P30DK017047). NR 48 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 EI 1530-0374 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD APR PY 2014 VL 21 IS 4 BP 424 EP 432 DI 10.1097/GME.0000000000000117 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AH6AX UT WOS:000336214200019 PM 24149922 ER PT J AU Grubbs, V Wasse, H Vittinghoff, E Grimes, BA Johansen, KL AF Grubbs, Vanessa Wasse, Haimanot Vittinghoff, Eric Grimes, Barbara A. Johansen, Kirsten L. TI Health status as a potential mediator of the association between hemodialysis vascular access and mortality SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE elderly; hemodialysis; mortality; vascular access ID DIALYSIS PATIENTS; ELDERLY-PATIENT; REFER PATIENTS; RISK-FACTORS; FISTULA 1ST; OUTCOMES; PATTERNS; QUESTION; DISEASE AB Background. It is unknown whether the selection of healthier patients for ateriovenous fistula (AVF) placement explains higher observed catheter-associated mortality among elderly hemodialysis patients. Methods. From the United States Renal Data System 2005-2007, we used proportional hazard models to examine 117 277 incident hemodialysis patients aged 67-90 years for the association of initial vascular access type and 5-year mortality after accounting for health status. Health status was defined as functional status at dialysis initiation and number of hospital days within 2 years prior to dialysis initiation. Results. Patients with catheter alone had more limited functional status (25.5 versus 10.8% of those with AVF) and 3-fold more prior hospital days than those with AVF (mean 18.0 versus 5.4). In the unadjusted model, the likelihood of death was higher for arteriovenous grafts (AVG) {Hazard ratio (HR) 1.20 [95% CI (1.16-1.25)], catheter plus AVF [HR 1.34 (1.31-1.38)], catheter plus AVG [HR 1.46 (1.40-1.52)] and catheter only [HR 1.95 (1.90-1.99)]}, compared with AVF (P < 0.001). The association attenuated -23.7% (95% CI -22.0, -25.5) overall (AVF versus all other access types) after adjusting for the usual covariates (including sociodemographics, comorbidities and pre-dialysis nephrology care) {AVG [HR 1.21 (1.17-1.26)], catheter plus AVF [HR 1.27 (1.24-1.30)], catheter plus AVG [HR 1.38 (1.32-1.43)] and catheter only [HR 1.69 (1.66-1.73)], P < 0.001}. Additional adjustment for health status further attenuated the association by another -19.7% (-18.2, -21.3) overall but remained statistically significant < AVG [HR 1.18 (1.13-1.22)], catheter plus AVF [HR 1.20 (1.17-1.23)], catheter plus AVG {HR 1.38 [1.26 (1.21-1.31)]} and catheter only [HR 1.54 (1.50-1.58)], P < 0.001>. Conclusions. The observed attenuation in mortality differences previously attributed to access type alone suggests the existence of selection bias. Nevertheless, the persistence of an apparent survival advantage after adjustment for health status suggests that AVF should still be the access of choice for elderly individuals beginning hemodialysis until more definitive data eliminating selection bias become available. C1 [Grubbs, Vanessa; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Wasse, Haimanot] Emory Univ, Sch Med, Div Nephrol, Atlanta, GA USA. [Wasse, Haimanot] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Vittinghoff, Eric; Grimes, Barbara A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco Vet Adm Med Ctr, Div Nephrol, San Francisco, CA USA. RP Grubbs, V (reprint author), Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. EM grubbsv@medsfgh.ucsf.edu FU USRDS Nutrition Special Studies Center [N01-DK-7-0005]; National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) [1K23DK093710-01A1]; Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation; NIDDK [N01-DK-7-0005, 1K24DK085153] FX This project was sponsored by the USRDS Nutrition Special Studies Center (N01-DK-7-0005). The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. V. G. was supported by grant 1K23DK093710-01A1 from the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) and by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. K.L.J. was supported by contract N01-DK-7-0005 and grant 1K24DK085153 from NIDDK. NR 22 TC 14 Z9 14 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD APR PY 2014 VL 29 IS 4 BP 892 EP 898 DI 10.1093/ndt/gft438 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA AH4JR UT WOS:000336093700028 PM 24235075 ER PT J AU Ostrem, JL Markun, LC Glass, GA Racine, CA Volz, MM Heath, SL de Hemptinne, C Starr, PA AF Ostrem, Jill L. Markun, Leslie C. Glass, Graham A. Racine, Caroline A. Volz, Monica M. Heath, Susan L. de Hemptinne, Coralie Starr, Philip A. TI Effect of frequency on subthalamic nucleus deep brain stimulation in primary dystonia SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Subthalamic nucleus; Deep brain stimulation; Primary dystonia; Frequency ID PRIMARY GENERALIZED DYSTONIA; ADVANCED PARKINSON-DISEASE; CRANIAL-CERVICAL DYSTONIA; GLOBUS-PALLIDUS INTERNUS; STN-DBS; GAIT; PARAMETERS; EFFICACY; IMPACT AB Background: Subthalamic nucleus deep brain stimulation (DBS) is an alternative target choice for treating primary dystonia, but little is known about the most effective programming parameters. Objective: Here we prospectively evaluate the effect of low versus high frequency subthalamic nucleus DBS in patients with predominantly cervical or upper extremity primary dystonia. Methods: Seven patients were stimulated at low frequency stimulation (60 Hz) for the first three months and then switched to high frequency stimulation (130 Hz) until month six. Severity of dystonia was determined by a blinded rater (unaware of the patient's pre or post-operative status) who scored the Burke Fahn Marsden dystonia rating scale movement score (BFMDRS-M) and the Toronto Western Spasmodic Torticollis Rating Scale severity score (TWSTRS-S) preoperatively, three, six, and twelve months post-surgery. Results: Patients had a lower mean improvement of 16.6% in BFMDRS-M and 9.5% in TWSTRS-S at three months using low frequency stimulation compared to a 52.3% (p = 0.018) and 45.2% (p = 0.028), respectively, noted at six months using high frequency stimulation. At 12 months (using 130 Hz), the BFMDRS-M and TWSTRS-S improved by 51.8% (p = 0.022) and 56% (p = 0.034). Patients developed transient dyskinesia (during low and high frequency stimulation) which improved with programming adjustments. Conclusion: This study offers further support of the effectiveness of subthalamic nucleus DBS in the treatment of primary dystonia and finds that high frequency stimulation was more effective than low frequency stimulation. Published by Elsevier Ltd. C1 [Ostrem, Jill L.; Markun, Leslie C.; Glass, Graham A.; Volz, Monica M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94115 USA. [Racine, Caroline A.; de Hemptinne, Coralie; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Ostrem, Jill L.; Markun, Leslie C.; Glass, Graham A.; Heath, Susan L.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA. RP Ostrem, JL (reprint author), Univ Calif San Francisco, Dept Neurol, 1635 Divisadero St,5th Floor,Suites 520-530, San Francisco, CA 94115 USA. EM jill.ostrem@ucsf.edu FU Benign Essential Blepharospasm Research Foundation FX This study was supported in part from a grant from the Benign Essential Blepharospasm Research Foundation and from private donors Larry and Kana Miao. NR 31 TC 11 Z9 13 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD APR PY 2014 VL 20 IS 4 BP 432 EP 438 DI 10.1016/j.parkreldis.2013.12.012 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AH7ZV UT WOS:000336354800014 PM 24440061 ER PT J AU Remmers, C Sweet, RA Penzes, P AF Remmers, Christine Sweet, Robert A. Penzes, Peter TI Abnormal kalirin signaling in neuropsychiatric disorders SO BRAIN RESEARCH BULLETIN LA English DT Review DE Schizophrenia; Alzheimer's disease; Mental disorder; Genetic; Glutamatergic; Postmortem ID DENDRITIC SPINE PATHOLOGY; ALZHEIMERS-DISEASE HIPPOCAMPUS; NUCLEOTIDE EXCHANGE FACTOR; CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA-PEPTIDE; COGNITIVE IMPAIRMENT; SYNAPTIC PLASTICITY; MENTAL-RETARDATION; FRONTAL-CORTEX; PREFRONTAL CORTEX AB Changes in dendritic spines structure and function play a critical role in a number of physiological processes, including synaptic transmission and plasticity, and are intimately linked to cognitive function. Alterations in dendritic spine morphogenesis occur in a number of neuropsychiatric disorders and likely underlie the cognitive and behavioral changes associated with these disorders. The neuronal guanine nucleotide exchange factor (GEF) kalirin is emerging as a key regulator of structural and functional plasticity at dendritic spines. Moreover, a series of recent studies have genetically and functionally linked kalirin signaling to several disorders, including schizophrenia and Alzheimer's disease. Kalirin signaling may thus represent a disease mechanism and provide a novel therapeutic target. This article is part of a special Issue entitled 'Dendrites and Disease'. (C) 2013 Elsevier Inc. All rights reserved. C1 [Remmers, Christine; Penzes, Peter] Dept Physiol, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. RP Penzes, P (reprint author), Dept Physiol, 303 E Chicago Ave, Chicago, IL 60611 USA. EM p-penzes@northwestern.edu RI Penzes, Peter/L-3987-2016 OI Penzes, Peter/0000-0001-5449-1640 FU NIH-NIMH [R01MH071316]; Veterans Health Administration [BX000452]; NIH [MH071533, AG005133]; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS); National Institutes of Health (NIH) [8UL1TR000150] FX This work was supported by a grant from NIH-NIMH to P.P. (R01MH071316), by Veterans Health Administration (BX000452) and NIH grants (MH071533 and AG005133) to R.A.S, and by National Center for Research Resources (NCRR) and the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) through Grant number 8UL1TR000150 to C.R. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs or, the National Institutes of Health, or the United States Government. NR 112 TC 10 Z9 10 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0361-9230 EI 1873-2747 J9 BRAIN RES BULL JI Brain Res. Bull. PD APR PY 2014 VL 103 SI SI BP 29 EP 38 DI 10.1016/j.brainresbull.2013.12.006 PG 10 WC Neurosciences SC Neurosciences & Neurology GA AH0JV UT WOS:000335806100005 PM 24334022 ER PT J AU Filippatos, G Teerlink, JR Farmakis, D Cotter, G Davison, BA Felker, GM Greenberg, BH Hua, T Ponikowski, P Severin, T Unemori, E Voors, AA Metra, M AF Filippatos, Gerasimos Teerlink, John R. Farmakis, Dimitrios Cotter, Gad Davison, Beth A. Felker, G. Michael Greenberg, Barry H. Hua, Tsushung Ponikowski, Piotr Severin, Thomas Unemori, Elaine Voors, Adriaan A. Metra, Marco TI Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial SO EUROPEAN HEART JOURNAL LA English DT Article DE Serelaxin; Relaxin; Acute heart failure; Heart failure with preserved left ventricular ejection fraction; Diastolic heart failure; Dyspnoea ID TROPONIN ELEVATION; EXERCISE CAPACITY; SYSTOLIC FUNCTION; CLINICAL STATUS; TASK-FORCE; OUTCOMES; LEVOSIMENDAN; EPIDEMIOLOGY; ASSOCIATION; ANTAGONIST AB Aims Serelaxin is effective in relieving dyspnoea and improving multiple outcomes in acute heart failure (AHF). Many AHF patients have preserved ejection fraction (HFpEF). Given the lack of evidence-based therapies in this population, we evaluated the effects of serelaxin according to EF in RELAX-AHF trial. Methods and results RELAX-AHF randomized 1161 AHF patients to 48-h serelaxin (30 mu g/kg/day) or placebo within 16 h from presentation. We compared the effects of serelaxin on efficacy endpoints, safety endpoints, and biomarkers of organ damage between preserved (a parts per thousand yen50%) and reduced (< 50%, HFrEF) EF. HFpEF was present in 26% of patients. Serelaxin induced a similar dyspnoea relief in HFpEF vs. HFrEF patients by visual analogue scale-area under the curve (VAS-AUC) through Day 5 [mean change, 461 (-195, 1117) vs. 397 (10, 783) mm h, P = 0.87], but had possibly different effects on the proportion of patients with moderately or markedly dyspnoea improvement by Likert scale at 6, 12, and 24 h [odds ratio for favourable response, 1.70 (0.98, 2.95) vs. 0.85 (0.62, 1.15), interaction P = 0.030]. No differences were encountered in the effect of serelaxin on short- or long-term outcome between HFpEF and HFrEF patients including cardiovascular death or hospitalization for heart/renal failure through Day 60, cardiovascular death through Day 180, and all-cause death through Day 180. Similar safety and changes in biomarkers (high-sensitivity troponin T, cystatin-C, and alanine/aspartate aminotransferases) were found in both groups. Conclusions In AHF patients with HFpEF compared with those with HFrEF, serelaxin was well tolerated and effective in relieving dyspnoea and had a similar effect on short- and long-term outcome, including survival improvement. C1 [Filippatos, Gerasimos; Farmakis, Dimitrios] Univ Athens, Hosp Attikon, Athens, Greece. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA. [Felker, G. Michael] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA. [Greenberg, Barry H.] Univ Calif San Diego, Div Cardiovasc Med, San Diego, CA 92103 USA. [Hua, Tsushung] Novartis Pharmaceut, E Hanover, NJ USA. [Ponikowski, Piotr] Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Severin, Thomas] Novartis Pharma AG, Basel, Switzerland. [Unemori, Elaine] Corthera Inc, San Carlos, CA USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands. [Metra, Marco] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy. RP Filippatos, G (reprint author), 28 DoukissisPlakentias, Athens 11523, Greece. EM geros@otenet.gr RI Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568; Davison, Beth/0000-0003-2374-6449 FU Corthera Inc.; Novartis Pharma AG, Basel, Switzerland FX The RELAX-AHF trial was supported by Corthera Inc., a member of the Novartis group of companies. Steve Winter of Novartis Pharma AG, Basel, Switzerland and Graham Allcock of CircleScience (Tytherington, UK) helped in the preparation of the figures, which was funded by Novartis Pharma AG, Basel, Switzerland. Funding to pay the Open Access publication charges for this article was provided by Novartis Pharma AG. NR 31 TC 42 Z9 42 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD APR PY 2014 VL 35 IS 16 BP 1041 EP 1050 DI 10.1093/eurheartj/eht497 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AH0MH UT WOS:000335813500012 PM 24316514 ER PT J AU Henao, JP Peperzak, KA Lichvar, AB Orebaugh, SL Skledar, SJ Pippi, MA Williams, BA AF Henao, John P. Peperzak, Katherin A. Lichvar, Alicia B. Orebaugh, Steven L. Skledar, Susan J. Pippi, Michael A. Williams, Brian A. TI Extrapyramidal symptoms following administration of oral perphenazine 4 or 8 mg An 11-year retrospective analysis SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY LA English DT Article ID POSTOPERATIVE NAUSEA; PREVENTION; EFFICACY; ONDANSETRON; ANTIEMETICS; DROPERIDOL; MANAGEMENT; SURGERY AB BACKGROUNDPerphenazine is a treatment option in postoperative nausea and vomiting (PONV) prophylaxis. Chronic administration and high dose are known to cause extrapyramidal system (EPS) dysfunction at a frequency of 8%, but the incidence of acute EPS after a single 4 or 8mg dose is unknown.OBJECTIVEA retrospective analysis of patient medication billing data and departmental quality records was performed (January 2001 to 10 July 2012) to identify patients who experienced EPS dysfunction after oral perphenazine.DESIGNA retrospective analysis.SETTINGSurgical outpatients presenting to any one of 10 hospitals in the area of Pittsburgh, Pennsylvania, USA.PATIENTSOverall, 45766 patients received 4 or 8mg of perphenazine before same-day surgery.MAIN OUTCOME MEASURESEPS dysfunction was defined as acute dystonia, akathisia or pseudoparkinsonism. Records were reviewed to determine the likely number of reactions to perphenazine, the nature of these reactions and impact on patient care.RESULTSThere were four likely' cases of EPS dysfunction, and two possible' cases. Five reported events were consistent with akathisia, with the sixth being a dystonic reaction. All six patients had resolution of symptoms, with five receiving intravenous diphenhydramine for treatment. The incidence of EPS dysfunction was 1.3 events per 10000 patients (95% confidence interval (CI) 0.4 to 3.0, based on six events). All patients who experienced reactions pre-operatively were able to proceed to surgery without complications or delay. One patient required unplanned admission and 3-h observation owing to sedation from diphenhydramine. The incidence of EPS dysfunction after oral perphenazine is low. Reactions that did occur were mild and easily treated.CONCLUSIONGiven the infrequent side effects, this single, low dose of perphenazine should be encouraged as a low-risk adjunct to any multimodal PONV prophylaxis regimen, based on the selection criteria described. C1 [Henao, John P.; Peperzak, Katherin A.; Orebaugh, Steven L.] Univ Pittsburgh, Dept Anesthesiol, Med Ctr, Pittsburgh, PA 15261 USA. [Lichvar, Alicia B.; Skledar, Susan J.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15261 USA. [Pippi, Michael A.; Williams, Brian A.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Williams, Brian A.] Vet Affairs Pittsburgh Healthcare Syst, Dept Anesthesiol, Pittsburgh, PA USA. RP Williams, BA (reprint author), Univ Pittsburgh, Dept Anesthesiol, 200 Lothrop St,A-1305, Pittsburgh, PA 15261 USA. EM williamsba@anes.upmc.edu FU National Institutes of Health [UL1 RR024153, UL1TR000005] FX Financial support and sponsorship: assistance with IRB submission and statistical analysis for this project was supported by the National Institutes of Health through Grant Numbers UL1 RR024153 and UL1TR000005. NR 9 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0265-0215 EI 1365-2346 J9 EUR J ANAESTH JI Eur. J. Anaesth. PD APR PY 2014 VL 31 IS 4 BP 231 EP 235 DI 10.1097/EJA.0000000000000048 PG 5 WC Anesthesiology SC Anesthesiology GA AD5AO UT WOS:000333263900008 PM 24503705 ER PT J AU Kalapatapu, RK Ho, J Cai, X Vinogradov, S Batki, SL Mohr, DC AF Kalapatapu, Raj K. Ho, Joyce Cai, Xuan Vinogradov, Sophia Batki, Steven L. Mohr, David C. TI Cognitive-Behavioral Therapy in Depressed Primary Care Patients with Co-Occurring Problematic Alcohol Use: Effect of Telephone-Administered vs. Face-to-Face Treatment-A Secondary Analysis SO JOURNAL OF PSYCHOACTIVE DRUGS LA English DT Article DE alcohol; depressed; face-to-face; primary care; telephone ID RANDOMIZED-CONTROLLED-TRIAL; SUBSTANCE-ABUSE TREATMENT; QUALITY-OF-LIFE; CONTINUING CARE; SMOKING-CESSATION; PROBLEM DRINKING; DUAL DIAGNOSIS; MENTAL-HEALTH; ADDICTION TREATMENT; SELF-MEDICATION AB This secondary analysis of a larger study compared adherence to telephone-administered cognitive-behavioral therapy (T-CBT) vs. face-to-face CBT and depression outcomes in depressed primary care patients with co-occurring problematic alcohol use. To our knowledge, T-CBT has never been directly compared to face-to-face CBT in such a sample of primary care patients. Participants were randomized in a 1: 1 ratio to face-to-face CBT or T-CBT for depression. Participants receiving T-CBT (n = 50) and face-to-face CBT (n = 53) were compared at baseline, end of treatment (week 18), and three-month and six-month follow-ups. Face-to-face CBT and T-CBT groups did not significantly differ in age, sex, ethnicity, marital status, educational level, severity of depression, antidepressant use, and total score on the Alcohol Use Disorders Identification Test. Face-to-face CBT and T-CBT groups were similar on all treatment adherence outcomes and depression outcomes at all time points. T-CBT and face-to-face CBT had similar treatment adherence and efficacy for the treatment of depression in depressed primary care patients with co-occurring problematic alcohol use. When targeting patients who might have difficulties in accessing care, primary care clinicians may consider both types of CBT delivery when treating depression in patients with co-occurring problematic alcohol use. C1 [Kalapatapu, Raj K.; Vinogradov, Sophia; Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kalapatapu, Raj K.; Vinogradov, Sophia; Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Ho, Joyce; Cai, Xuan; Mohr, David C.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. RP Kalapatapu, RK (reprint author), San Francisco VA Med Ctr, Dept Psychiat, Opioid Replacement Treatment Clin, 4150 Clement St,Mailstop 116F,Bldg 1,Ground Floor, San Francisco, CA 94121 USA. EM kalapatapu.raj.k@gmail.com FU NIDA NIH HHS [K23 DA034883, K23DA034883]; NIMH NIH HHS [P20 MH090318, R01 MH059708, R01-MH059708, R34 MH078922] NR 61 TC 5 Z9 5 U1 3 U2 13 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0279-1072 EI 2159-9777 J9 J PSYCHOACTIVE DRUGS JI J. Psychoact. Drugs PD APR-JUN PY 2014 VL 46 IS 2 BP 85 EP 92 DI 10.1080/02791072.2013.876521 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA AH2RL UT WOS:000335968600001 PM 25052784 ER PT J AU Gros, DF Sarver, NW AF Gros, Daniel F. Sarver, Nina Wong TI An investigation of the psychometric properties of the Social Thoughts and Beliefs Scale (STABS) and structure of cognitive symptoms in participants with social anxiety disorder and healthy controls SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Social Thoughts and Beliefs Scale; STABS; Social phobia; Social anxiety disorder; Cognitive; Validity; Reliability ID RATING-SCALE; PHOBIA; THERAPY; MODEL; DEPRESSION; INVENTORY AB Despite the recent increase of measures developed to assess the cognitive symptoms of social anxiety disorder (SOC), their validation is still largely preliminary. Thus, the present studies sought to replicate and extend the psychometric evaluation of the Social Thoughts and Beliefs Scale (STABS). Study 1 involved both participants with SOC (n=206) and healthy controls (n=222) that completed the STABS and other related measures of anxiety. In Study 2, participants with SOC (n=66) completed exposure-based psychotherapy for SOC with the STABS used to track symptom changes. Together, the two studies provided additional support for the validity and reliability of the STABS as a measure of the cognitive symptoms of SOC. However, contrary to previous research with two subscales, a single total scale was suggested as the best interpretation of the STABS, as well as the possible general presentation of the cognitive symptoms of SOC. Published by Elsevier Ltd. C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv, Charleston, SC 29401 USA. [Gros, Daniel F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Sarver, Nina Wong] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU CSRD VA [IK2 CX000845]; NIMH NIH HHS [R01MH062547, R01 MH062547] NR 38 TC 4 Z9 4 U1 1 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD APR PY 2014 VL 28 IS 3 BP 283 EP 290 DI 10.1016/j.janxdis.2014.01.004 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AG7RO UT WOS:000335616000001 PM 24607834 ER PT J AU Wendt, JM Cohen, JA Mu, Y Dumyati, GK Dunn, JR Holzbauer, SM Winston, LG Johnston, HL Meek, JI Farley, MM Wilson, LE Phipps, EC Beldavs, ZG Gerding, DN McDonald, LC Gould, CV Lessa, FC AF Wendt, Joyanna M. Cohen, Jessica A. Mu, Yi Dumyati, Ghinwa K. Dunn, John R. Holzbauer, Stacy M. Winston, Lisa G. Johnston, Helen L. Meek, James I. Farley, Monica M. Wilson, Lucy E. Phipps, Erin C. Beldavs, Zintars G. Gerding, Dale N. McDonald, L. Clifford Gould, Carolyn V. Lessa, Fernanda C. TI Clostridium difficile Infection Among Children Across Diverse US Geographic Locations SO PEDIATRICS LA English DT Article DE Clostridium difficile; pediatric; community-associated; antimicrobial stewardship ID PROTON PUMP INHIBITORS; RETAIL MEAT; INFANTS; RISK; DISEASE; COLONIZATION; EPIDEMIOLOGY; COMMUNITY; INPATIENTS; DIARRHEA AB OBJECTIVE: Little is known about the epidemiology of Clostridium difficile infection (CDI) among children, particularly children <= 3 years of age in whom colonization is common but pathogenicity uncertain. We sought to describe pediatric CDI incidence, clinical presentation, and outcomes across age groups. METHODS: Data from an active population-and laboratory-based CDI surveillance in 10 US geographic areas during 2010-2011 were used to identify cases (ie, residents with C difficile-positive stool without a positive test in the previous 8 weeks). Community-associated (CA) cases had stool collected as outpatients or <= 3 days after hospital admission and no overnight health care facility stay in the previous 12 weeks. A convenience sample of CA cases were interviewed. Demographic, exposure, and clinical data for cases aged 1 to 17 years were compared across 4 age groups: 1 year, 2 to 3 years, 4 to 9 years, and 10 to 17 years. RESULTS: Of 944 pediatric CDI cases identified, 71% were CA. CDI incidence per 100 000 children was highest among 1-year-old (66.3) and white (23.9) cases. The proportion of cases with documented diarrhea (72%) or severe disease (8%) was similar across age groups; no cases died. Among the 84 cases interviewed who reported diarrhea on the day of stool collection, 73% received antibiotics during the previous 12 weeks. CONCLUSIONS: Similar disease severity across age groups suggests an etiologic role for C difficile in the high rates of CDI observed in younger children. Prevention efforts to reduce unnecessary antimicrobial use among young children in outpatient settings should be prioritized. C1 [Wendt, Joyanna M.; Cohen, Jessica A.; Mu, Yi; McDonald, L. Clifford; Gould, Carolyn V.; Lessa, Fernanda C.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Wendt, Joyanna M.] CDC, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Holzbauer, Stacy M.] CDC, Off Publ Hlth Preparedness & Response, Career Epidemiol Field Off Program, Atlanta, GA 30333 USA. [Cohen, Jessica A.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Dumyati, Ghinwa K.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. [Dunn, John R.] Tennessee Dept Hlth, Nashville, TN USA. [Holzbauer, Stacy M.] Minnesota Dept Hlth, Dept Med, St Paul, MN USA. [Winston, Lisa G.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Johnston, Helen L.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Meek, James I.] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. [Farley, Monica M.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Farley, Monica M.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Wilson, Lucy E.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Phipps, Erin C.] Univ New Mexico, Emerging Infect Program, Albuquerque, NM 87131 USA. [Beldavs, Zintars G.] Oregon Hlth Author, Publ Hlth Div, Portland, OR USA. [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Maywood, IL USA. [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Lessa, FC (reprint author), 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA. EM flessa@cdc.gov FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. No external funding was used for this study. NR 33 TC 30 Z9 33 U1 1 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2014 VL 133 IS 4 BP 651 EP 658 DI 10.1542/peds.2013-3049 PG 8 WC Pediatrics SC Pediatrics GA AG3TU UT WOS:000335343500012 PM 24590748 ER PT J AU Cooper, DC Trivedi, RB Nelson, KM Reiber, GE Eugenio, EC Beaver, KA Fan, VS AF Cooper, Denise C. Trivedi, Ranak B. Nelson, Karin M. Reiber, Gayle E. Eugenio, Evercita C. Beaver, Kristine A. Fan, Vincent S. TI ANTIDEPRESSANT ADHERENCE AND RISK OF CORONARY ARTERY DISEASE HOSPITALIZATIONS AMONG OLDER AND YOUNGER VETERANS WITH DEPRESSION SO PSYCHOSOMATIC MEDICINE LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Psychosomatic-Society CY MAR 12-15, 2014 CL San Francisco, CA SP Amer Psychosomat Soc C1 [Cooper, Denise C.] VA Puget Sound Hlth Care Serv, Hlth Serv Res & Dev, Seattle, WA USA. [Trivedi, Ranak B.] VA Palo Alto Hlth Care Syst, Hlth Serv Res & Dev, Menlo Pk, CA USA. [Nelson, Karin M.; Reiber, Gayle E.; Eugenio, Evercita C.; Beaver, Kristine A.; Fan, Vincent S.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD APR PY 2014 VL 76 IS 3 BP A113 EP A113 PG 1 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA AE8FN UT WOS:000334235100469 ER PT J AU Dinh, J Walser, R Best, S Cloitre, M McCaslin-Rodrigo, S AF Dinh, Julie Walser, Robyn Best, Suzanne Cloitre, Marylene McCaslin-Rodrigo, Shannon TI SELF-COMPASSION IS ASSOCIATED WITH EMOTIONAL STRESS AND PERCEIVED HEALTH-RELATED FUNCTIONING IN VETERANS SO PSYCHOSOMATIC MEDICINE LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Psychosomatic-Society CY MAR 12-15, 2014 CL San Francisco, CA SP Amer Psychosomat Soc C1 [Dinh, Julie] San Francisco VA Med Ctr, San Francisco, CA USA. [Walser, Robyn; Cloitre, Marylene; McCaslin-Rodrigo, Shannon] Natl Ctr PTSD, Dept Vet Affairs, Menlo Pk, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD APR PY 2014 VL 76 IS 3 BP A115 EP A115 PG 1 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA AE8FN UT WOS:000334235100477 ER PT J AU Talbot, LS Rao, MN Cohen, BE Mph, ARM Inslicht, SS O'Donovan, A Maguen, S Metzler, TJ Neylan, TC AF Talbot, Lisa S. Rao, Madhu N. Cohen, Beth E. Richards, Anne Inslicht, Sabra S. O'Donovan, Aoife Maguen, Shira Metzler, Thomas J. Neylan, Thomas C. TI METABOLIC RISK FACTORS, SLEEP, AND POSTTRAUMATIC STRESS DISORDER IN YOUNG, UNMEDICATED, MEDICALLY-HEALTHY ADULTS SO PSYCHOSOMATIC MEDICINE LA English DT Meeting Abstract CT 72nd Annual Meeting of the American-Psychosomatic-Society CY MAR 12-15, 2014 CL San Francisco, CA SP Amer Psychosomat Soc C1 [Talbot, Lisa S.; Metzler, Thomas J.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Rao, Madhu N.; Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Richards, Anne; Inslicht, Sabra S.; O'Donovan, Aoife; Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD APR PY 2014 VL 76 IS 3 BP A12 EP A13 PG 2 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA AE8FN UT WOS:000334235100052 ER PT J AU Campbell, D Bonner, L Bolkan, C Lanto, A Zivin, K Waltz, T Ruth, K Lisa, R Edmund, C AF Campbell, Duncan Bonner, Laura Bolkan, Cory Lanto, Andy Zivin, Kara Waltz, Thomas Ruth, Klap Lisa, Rubenstein Edmund, Chaney TI A PROSPECTIVE ANALYSIS OF STIGMA AS A PREDICTOR OF DEPRESSION TREATMENT PREFERENCES, MENTAL HEALTH TREATMENT ENGAGEMENT AND CARE QUALITY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Campbell, Duncan] Univ Montana, Missoula, MT 59812 USA. [Bonner, Laura; Edmund, Chaney] VA Puget Sound, Seattle, WA USA. [Bolkan, Cory] Washington State Univ, Vancouver, WA USA. [Lanto, Andy; Ruth, Klap; Lisa, Rubenstein] VA Greater Los Angeles, Los Angeles, CA USA. [Zivin, Kara] VA Ann Arbor, Ann Arbor, MI USA. [Waltz, Thomas] Eastern Michigan Univ, Ypsilanti, MI 48197 USA. EM duncan.campbell@umontana.edu NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S233 EP S233 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408301144 ER PT J AU Diefenbach, MA Hall, M Herrera, PC Lake, JR McWilliams, GW Hall, SJ AF Diefenbach, Michael A. Hall, Matt Herrera, Phapichaya Chaoprang Lake, Jessica R. McWilliams, Glen W. Hall, Simon J. TI AN IPOD INTERVENTION TO CONTROL HOT FLASHES IN ADVANCED PROSTATE CANCER PATIENTS ON HORMONE THERAPY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Diefenbach, Michael A.; Hall, Matt; Herrera, Phapichaya Chaoprang; Lake, Jessica R.; Hall, Simon J.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [McWilliams, Glen W.] James J Peters VA Med Ctr, Bronx, NY USA. EM michael.diefenbach@mountsinai.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S98 EP S98 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300372 ER PT J AU Evans, G Hoerster, K Stanley, M Dubbert, P AF Evans, Gina Hoerster, Katherine Stanley, Mindi Dubbert, Patricia TI A QUALITATIVE EVALUATION OF BARRIERS TO WEIGHT LOSS FOR OBESE VETERANS WITH CO-OCCURRING MENTAL ILLNESS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Evans, Gina; Stanley, Mindi] Micheal E DeBakey, Houston, TX 77030 USA. [Hoerster, Katherine] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Evans, Gina; Stanley, Mindi] Baylor Coll Med, Houston, TX 77030 USA. [Dubbert, Patricia] GRECC, VISN VA MIRECC 16, Little Rock, AR USA. EM ginae@bcm.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S144 EP S144 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300555 ER PT J AU Goodrich, DE Littman, AJ Damschroder, LJ Goldberg, R Jones, KR AF Goodrich, David E. Littman, Alyson J. Damschroder, Laura J. Goldberg, Richard Jones, Kenneth R. TI MENTAL HEALTH MATTERS: SCREENING, PARTICIPATION AND OUTCOMES OF WEIGHT MANAGEMENT PROGRAMS FOR VETERANS WITH MENTAL HEALTH CONDITIONS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Goodrich, David E.; Damschroder, Laura J.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI 48109 USA. [Littman, Alyson J.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Goldberg, Richard] VA Maryland Healthcare Syst, Baltimore Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA. [Jones, Kenneth R.] Vet Hlth Adm, Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA. EM david.goodrich2@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S50 EP S50 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300193 ER PT J AU Hall, KS Beckham, JC Bosworth, HB Hoerster, KD Jakupcak, M Sloane, R Crawford, E Morey, MC AF Hall, Katherine S. Beckham, Jean C. Bosworth, Hayden B. Hoerster, Katherine D. Jakupcak, Matthew Sloane, Richard Crawford, Eric Morey, Miriam C. TI PHYSICAL ACTIVITY COUNSELING IMPROVES HEALTH IN OLDER VETERANS WITH PTSD SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hall, Katherine S.; Beckham, Jean C.; Bosworth, Hayden B.; Crawford, Eric; Morey, Miriam C.] Durham Vet Affairs Med Ctr, Durham, NC USA. [Hall, Katherine S.; Beckham, Jean C.; Bosworth, Hayden B.; Sloane, Richard; Morey, Miriam C.] Duke Univ, Med Ctr, Durham, NC USA. [Hoerster, Katherine D.; Jakupcak, Matthew] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA USA. [Hoerster, Katherine D.; Jakupcak, Matthew] Univ Washington, Seattle, WA 98195 USA. EM katherine.hall@duke.edu NR 0 TC 0 Z9 0 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S129 EP S129 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300494 ER PT J AU Hoerster, KD Jakupcak, M Hanson, R McFall, M Reiber, G Hall, K Nelson, K AF Hoerster, Katherine D. Jakupcak, Matthew Hanson, Robert McFall, Miles Reiber, Gayle Hall, Katherine Nelson, Karin TI PTSD AND DEPRESSION ARE ASSOCIATED WITH BINGE EATING DISORDER AMONG US IRAQ AND AFGHANISTAN VETERANS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hoerster, Katherine D.; Jakupcak, Matthew; Hanson, Robert; McFall, Miles; Reiber, Gayle; Nelson, Karin] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA 98108 USA. [Hoerster, Katherine D.; Jakupcak, Matthew; Hanson, Robert; McFall, Miles; Reiber, Gayle; Nelson, Karin] Univ Washington, Seattle, WA 98195 USA. [Hall, Katherine] Durham Vet Affairs Med Ctr, Durham, NC USA. [Hall, Katherine] Duke Univ, Durham, NC USA. EM Katherine.Hoerster@va.gov NR 0 TC 0 Z9 0 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S145 EP S145 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300556 ER PT J AU Hoerster, KD Afari, N Gundy, J Evans, G Jones, K AF Hoerster, Katherine D. Afari, Niloofar Gundy, Jessica Evans, Gina Jones, Kenneth TI MENTAL HEALTH CONSIDERATIONS FOR OPTIMIZING BEHAVIORAL WEIGHT MANAGEMENT INTERVENTIONS WITH OBESE VETERANS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA 98108 USA. [Hoerster, Katherine D.] Univ Washington, Seattle, WA 98195 USA. [Afari, Niloofar] Univ Calif San Diego, VA Ctr Excellence Stress & Mental Hlth, San Diego, CA 92103 USA. [Afari, Niloofar] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Afari, Niloofar; Gundy, Jessica] VA San Diego Healthcare Syst, San Diego, CA USA. [Evans, Gina] Houston VA HSR&D, Houston, TX USA. [Jones, Kenneth] VA Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA. EM Katherine.Hoerster@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S144 EP S144 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300554 ER PT J AU Littman, AJ Damschroder, L Verchinia, L Lai, ZS Hoerster, K Owen, R Goodrich, D AF Littman, Alyson J. Damschroder, Laura Verchinia, Lilia Lai, Zongshan Hoerster, Katherine Owen, Richard Goodrich, David TI NATIONAL EVALUATION OF MOVE! OUTCOMES FOR VETERANS WITH AND WITHOUT MENTAL HEALTH DIAGNOSES: A RE-AIM ANALYSIS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Littman, Alyson J.; Hoerster, Katherine] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Damschroder, Laura; Verchinia, Lilia; Lai, Zongshan; Goodrich, David] VA Ctr Clin Management Res, Ann Arbor, MI USA. [Owen, Richard] VA Ctr Mental Healthcare & Outcomes Res, Little Rock, AR USA. EM alyson@u.washington.edu NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S50 EP S50 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300194 ER PT J AU Myaskovsky, L AF Myaskovsky, Larissa TI ASSOCIATION OF RACE, CULTURAL AND PSYCHOSOCIAL FACTORS, AND QUALITY OF LIFE IN VETERANS AND NON-VETERANS WITH SPINAL CORD INJURY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Myaskovsky, Larissa] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM larissa.myaskovsky@va.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S55 EP S55 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300215 ER PT J AU Myaskovsky, L Fyffe, D Botticello, A Meade, M AF Myaskovsky, Larissa Fyffe, Denise Botticello, Amanda Meade, Michelle TI THE ROLE OF PERSONAL, ENVIRONMENTAL, AND PROVIDER FACTORS IN HEALTH AND HEALTH CARE DISPARITIES IN ADULTS WITH SPINAL CORD INJURY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Myaskovsky, Larissa] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fyffe, Denise; Botticello, Amanda] Kessler Fdn Res Ctr, W Orange, NJ USA. [Fyffe, Denise; Botticello, Amanda] Rutgers State Univ, New Jersey Med Sch, W Orange, NJ USA. [Meade, Michelle] Univ Michigan, Ann Arbor, MI 48109 USA. EM larissa.myaskovsky@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S55 EP S55 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300213 ER PT J AU Ross, K Hooker, S Masters, K Park, C Allen, LA Bekelman, D Hale-Smith, A AF Ross, Kaile Hooker, Stephanie Masters, Kevin Park, Crystal Allen, Larry A. Bekelman, David Hale-Smith, Amy TI SPIRITUAL WELL-BEING PARALLELS PHYSICAL AND PSYCHOLOGICAL DISTRESS IN PATIENTS WITH HEART FAILURE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ross, Kaile; Hooker, Stephanie; Masters, Kevin; Allen, Larry A.; Bekelman, David] Univ Colorado, Denver, CO 80217 USA. [Hooker, Stephanie; Bekelman, David] Denver Vet Affairs Med Ctr, Denver, CO USA. [Park, Crystal; Hale-Smith, Amy] Univ Connecticut, Storrs, CT USA. EM kaile.ross@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S107 EP S107 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300407 ER PT J AU Chen, BB Coon, TA Glasser, JR Zou, CB Ellis, B Das, T McKelvey, AC Rajbhandari, S Lear, T Kamga, C Shiva, S Li, CJ Pilewski, JM Callio, J Chu, CT Ray, A Ray, P Tyurina, YY Kagan, VE Mallampalli, RK AF Chen, Bill B. Coon, Tiffany A. Glasser, Jennifer R. Zou, Chunbin Ellis, Bryon Das, Tuhin McKelvey, Alison C. Rajbhandari, Shristi Lear, Travis Kamga, Christelle Shiva, Sruti Li, Chenjian Pilewski, Joseph M. Callio, Jason Chu, Charleen T. Ray, Anuradha Ray, Prabir Tyurina, Yulia Y. Kagan, Valerian E. Mallampalli, Rama K. TI E3 Ligase Subunit Fbxo15 and PINK1 Kinase Regulate Cardiolipin Synthase 1 Stability and Mitochondrial Function in Pneumonia SO CELL REPORTS LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; NECROSIS-FACTOR-ALPHA; SCF UBIQUITIN LIGASE; PARKINSONS-DISEASE; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; OXYGEN DELIVERY; ORGAN FAILURE; SEPTIC SHOCK; CYTOCHROME-C AB Acute lung injury (ALI) is linked to mitochondrial injury, resulting in impaired cellular oxygen utilization; however, it is unknown how these events are linked on the molecular level. Cardiolipin, a mitochondrial- specific lipid, is generated by cardiolipin synthase (CLS1). Here, we show that S. aureus activates a ubiquitin E3 ligase component, Fbxo15, that is sufficient to mediate proteasomal degradation of CLS1 in epithelia, resulting in decreased cardiolipin availability and disrupted mitochondrial function. CLS1 is destabilized by the phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1), which binds CLS1 to phosphorylate and regulates CLS1 disposal. Like Fbxo15, PINK1 interacts with and regulates levels of CLS1 through a mechanism dependent upon Thr219. S. aureus infection upregulates this Fbxo15-PINK1 pathway to impair mitochondrial integrity, and Pink1 knockout mice are less prone to S. aureus-induced ALI. Thus, ALI-associated disruption of cellular bioenergetics involves bioeffectors that utilize a phosphodegron to elicit ubiquitin-mediated disposal of a key mitochondrial enzyme. C1 [Chen, Bill B.; Coon, Tiffany A.; Glasser, Jennifer R.; Zou, Chunbin; Ellis, Bryon; Das, Tuhin; McKelvey, Alison C.; Rajbhandari, Shristi; Lear, Travis; Pilewski, Joseph M.; Ray, Anuradha; Ray, Prabir; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Kamga, Christelle; Shiva, Sruti] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15213 USA. [Callio, Jason; Chu, Charleen T.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. [Tyurina, Yulia Y.; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA. [Li, Chenjian] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, 930 Scaife Hall, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu OI Chu, Charleen/0000-0002-5052-8271; Lear, Travis/0000-0001-9156-0844 FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; US Department of Veterans Affairs; National Institutes of Health R01 grant [HL096376, HL097376, HL098174, HL081784, P01HL114453, HL116472, NS065789, 12SDG12040330] FX This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL096376, HL097376, HL098174, HL081784, and P01HL114453 (to R.K.M.); HL116472 (to B.B.C.); NS065789 (to C.T.C.); and 12SDG12040330 (to C.Z.). The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government. NR 65 TC 14 Z9 15 U1 0 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD APR PY 2014 VL 7 IS 2 BP 476 EP 487 PG 12 WC Cell Biology SC Cell Biology GA AG5EO UT WOS:000335442300017 PM 24703837 ER PT J AU Wang, BCM Wong, ES Alfonso-Cristancho, R He, H Flum, DR Arterburn, DE Garrison, LP Sullivan, SD AF Wang, Bruce C. M. Wong, Edwin S. Alfonso-Cristancho, Rafael He, Hao Flum, David R. Arterburn, David E. Garrison, Louis P. Sullivan, Sean D. TI Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity SO EUROPEAN JOURNAL OF HEALTH ECONOMICS LA English DT Article DE Obesity; Bariatric surgery; Cost-effectiveness; QALY ID BODY-MASS INDEX; GASTRIC BYPASS-SURGERY; MORBID-OBESITY; US ADULTS; ECONOMIC-IMPACT; MORTALITY; WEIGHT; POPULATION; METAANALYSIS; ASSOCIATION AB Objective One-third of Americans are obese and an increasing number opt for bariatric surgery. This study estimates the cost-effectiveness of common bariatric surgical procedures from a healthcare system perspective. Methods We evaluated the three most common bariatric surgical procedures in the US: laparoscopic gastric bypass (LRYGB), conventional (open) Roux-en-Y gastric bypass (ORYGB), and laparoscopic adjustable gastric banding (LAGB) compared to no surgery. The reference case was defined as a 53-year old female with body mass index (BMI) of 44 kg/m(2). We developed a two-part model using a deterministic approach for the first 5-year period postsurgery and separate empirical forecasts for the natural history of BMI, costs and outcomes in the remaining years. We used a combination of datasets including Medicare and MarketScan (R) together with estimates from the literature to populate the model. Results Bariatric surgery produced additional life expectancy (80-81 years) compared to no surgery (78 years). The incremental cost-effectiveness ratios (ICERs) of the surgical procedures were US $ 6,600 per quality-adjusted life expectancy (QALY) gained for LRYGB, US $ 6,200 for LAGB, and US $ 17,300 for ORYGB (3 % discount rate for cost and QALYs). ICERs varied according to choice of BMI forecasting method and clinically plausible variation in parameter estimates. In most scenarios, the ICER did not exceed a threshold of US $ 50,000 per QALY gained. C1 [Wang, Bruce C. M.; Wong, Edwin S.; Alfonso-Cristancho, Rafael; Garrison, Louis P.; Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. [Wong, Edwin S.] VA Puget Sound, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA. [Alfonso-Cristancho, Rafael; He, Hao; Flum, David R.] Univ Washington, Surg Outcomes Res Ctr, Seattle, WA 98195 USA. [Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA 98101 USA. RP Sullivan, SD (reprint author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, 1959 NE Pacific Ave,H375Q, Seattle, WA 98195 USA. EM sdsull@uw.edu FU NIDDK NIH HHS [1R21DK069677] NR 47 TC 8 Z9 8 U1 1 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1618-7598 EI 1618-7601 J9 EUR J HEALTH ECON JI Eur. J. Health Econ. PD APR PY 2014 VL 15 IS 3 BP 253 EP 263 DI 10.1007/s10198-013-0472-5 PG 11 WC Economics; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA AF8XI UT WOS:000334998500004 PM 23526126 ER PT J AU Prasad, R Katiyar, SK AF Prasad, Ram Katiyar, Santosh K. TI Ultraviolet radiation- induced inflammation activates similar to- catenin signaling in mouse skin and skin tumors SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE cyclooxygenase-2; prostaglandins; ultraviolet radiation; -catenin; skin tumor; inflammation ID BETA-CATENIN; IMMUNE SUPPRESSION; CANCER; EXPRESSION; PHOTOCARCINOGENESIS; CARCINOGENESIS; MODELS; ALPHA; EP2 AB UVB-induced inflammation, in particular the overexpression of cyclooxygenase-2 (COX-2) and prostaglandin (PG) E2, has been implicated in photocarcinogenesis. UVB-induced COX-2 has been associated with -catenin signaling in keratinocytes. However, a definitive role for COX-2 in the activation of -catenin signaling as well as its role in UVB-induced skin tumors has not been established. We report that exposure of the skin to UVB resulted in a time- and dose-dependent activation of -catenin in C3H/HeN mice. This response was COX-2-dependent as UVB-exposed COX-2-deficient mice exhibited significantly lower levels of UVB-induced activation of -catenin. Moreover, treatment of mice with indomethacin, a COX-2 inhibitor, and an EP2 antagonist inhibited UVB-induced -catenin signaling. Exposure of SKH-1 hairless mice to UVB radiation (180 mJ/cm(2)) 3 times a week for 24 weeks resulted in activation of -catenin signaling in UVB-irradiated skin as well as UVB-induced skin tumors. Concomitantly, the levels of CK1 and GSK-3, which are responsible for -catenin signaling, were reduced while the levels of c-Myc and cyclin D1, which are downstream targets of -catenin, were increased. To further verify the role of UVB-induced inflammation in activation of -catenin signaling, a high-fat-diet model was used. Administration of high-fat diet exacerbated UVB-induced inflammation. Administration of the high-fat diet enhanced -catenin signaling and the levels of its downstream targets (c-Myc, cyclin D1, cyclin D2, MMP-2 and MMP-9) in UVB-exposed skin and skin tumors in SKH-1 mice. These data suggest that UV-induced COX-2/PGE(2) stimulates -catenin signaling, and that -catenin activation may contribute to skin carcinogenesis. C1 [Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU BLRD VA [I01 BX001410] NR 24 TC 6 Z9 7 U1 0 U2 2 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1019-6439 EI 1791-2423 J9 INT J ONCOL JI Int. J. Oncol. PD APR PY 2014 VL 44 IS 4 BP 1199 EP 1206 DI 10.3892/ijo.2014.2275 PG 8 WC Oncology SC Oncology GA AE9EI UT WOS:000334307100022 PM 24481495 ER PT J AU Wehner, MR Chren, MM Nameth, D Choudhry, A Gaskins, M Nead, KT Boscardin, WJ Linos, E AF Wehner, Mackenzie R. Chren, Mary-Margaret Nameth, Danielle Choudhry, Aditi Gaskins, Matthew Nead, Kevin T. Boscardin, W. John Linos, Eleni TI International Prevalence of Indoor Tanning A Systematic Review and Meta-analysis SO JAMA DERMATOLOGY LA English DT Review ID CUTANEOUS MALIGNANT-MELANOMA; NONMELANOMA SKIN-CANCER; HIGH-SCHOOL-STUDENTS; VITAMIN-D STATUS; SUNBED USE; COLLEGE-STUDENTS; UNITED-STATES; RISK-FACTORS; BED USE; SWEDISH ADOLESCENTS AB IMPORTANCE Indoor tanning is a known carcinogen, but the scope of exposure to this hazard is not known. OBJECTIVE To summarize the international prevalence of exposure to indoor tanning. DATA SOURCES Studies were identified through systematic searches of PubMed (1966 to present), Scopus (1823 to present), and Web of Science (1898 to present) databases, last performed on March 16, 2013. We also hand searched reference lists to identify records missed by database searches and publicly available data not yet published in the scientific literature. STUDY SELECTION Records reporting a prevalence of indoor tanning were eligible for inclusion. We excluded case-control studies, reports with insufficient study information, and reports of groups recruited using factors related to indoor tanning. Two independent investigators performed searches and study selection. Our search yielded 1976 unique records. After exclusions, 161 records were assessed for eligibility in full text, and 88 were included. DATA EXTRACTION AND SYNTHESIS Two independent investigators extracted data on characteristics of study participants, inclusion/exclusion criteria, data collection format, outcomes, and statistical methods. Random-effects meta-analyses were used to summarize the prevalence of indoor tanning in different age categories. We calculated the population proportional attributable risk of indoor tanning in the United States, Europe, and Australia for nonmelanoma skin cancer (NMSC) and melanoma. MAIN OUTCOMES AND MEASURES Ever and past-year exposure to indoor tanning. RESULTS The summary prevalence of ever exposure was 35.7% (95% Cl, 27.5% 44.0%) for adults, 55.0% (33.0%-77.1%) for university students, and 19.3% (14.7%-24.0%) for adolescents. The summary prevalence of past-year exposure was 14.0% (95% Cl, 11.5%-16.5%) for adults, 43.1% (21.7%-64.5%) for university students, and 18.3% (12.6%-24.0%) for adolescents. These results included data from 406 696 participants. The population proportional attributable risk were 3.0% to 21.8% for NMSC and 2.6% to 9.4% for melanoma, corresponding to more than 450 000 NMSC cases and more than 10 000 melanoma cases each year attributable to indoor tanning in the United States, Europe, and Australia. CONCLUSIONS AND RELEVANCE Exposure to indoor tanning is common in Western countries, especially among young persons. Given the large number of skin cancer cases attributable to indoor tanning, these findings highlight a major public health issue. C1 [Wehner, Mackenzie R.; Chren, Mary-Margaret; Linos, Eleni] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Wehner, Mackenzie R.; Nead, Kevin T.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Wehner, Mackenzie R.; Gaskins, Matthew] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England. [Chren, Mary-Margaret] San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA USA. [Nameth, Danielle] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Choudhry, Aditi] John Muir Med Ctr, Dept Internal Med, Walnut Creek, CA USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Linos, E (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,Mail Code 0808,Room N421, San Francisco, CA 94143 USA. EM linose@derm.ucsf.edu OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700 FU Doris Duke Charitable Foundation; Dermatology Foundation; National Center for Research Resources of the National Institutes of Health [KL2RR024130]; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health [RO1AR 054983, K24 AR052667] FX This study was supported in part by the Doris Duke Charitable Foundation (grants to Ms Wehner); the Dermatology Foundation (grant to Dr Linos); the National Center for Research Resources of the National Institutes of Health (grant KL2RR024130 to Dr Linos); and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (grants RO1AR 054983 and K24 AR052667 to Dr Chren). NR 106 TC 73 Z9 75 U1 3 U2 22 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD APR PY 2014 VL 150 IS 4 BP 390 EP 400 DI 10.1001/jamadermatol.2013.6896 PG 11 WC Dermatology SC Dermatology GA AF4HJ UT WOS:000334672300011 PM 24477278 ER PT J AU Paul, LA Price, M Gros, DF Gros, KS McCauley, JL Resnick, HS Acierno, R Ruggiero, KJ AF Paul, Lisa A. Price, Matthew Gros, Daniel F. Gros, Kirstin Stauffacher McCauley, Jenna L. Resnick, Heidi S. Acierno, Ron Ruggiero, Kenneth J. TI The Associations between Loss and Posttraumatic Stress and Depressive Symptoms Following Hurricane Ike SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE depression; loss of resources; hurricane; disaster; PTSD ID MENTAL-HEALTH PROBLEMS; PSYCHOLOGICAL DISTRESS; TRAUMATIC STRESS; NATURAL DISASTER; SOCIAL SUPPORT; RESOURCE LOSS; CONSERVATION; KATRINA; COMMUNITY; IMPACT AB Disasters can have wide-ranging effects on individuals and their communities. Loss of specific resources (e.g., household contents, job) following a disaster has not been well studied, despite the implications for preparedness efforts and postdisaster interventions. Objective To provide information about the effects of loss on postdisaster distress, the present study assessed associations between disaster-related variables, including the loss of specific resources, and postdisaster distress. Method Random-digit dialing methodology was used to recruit hurricane-affected adults from Galveston and Chambers, TX, counties one year after Hurricane Ike. Data from 1,249 survivors were analyzed to identify predictors of distress. Results Variables that were significantly associated with posttraumatic stress disorder symptoms included sustained losses, hurricane exposure, and sociodemographic characteristics; similar results were obtained for depressive symptoms. Conclusions Together, these findings suggest risk factors that may be associated with the development of posthurricane distress that can inform preparedness efforts and posthurricane interventions. C1 [Paul, Lisa A.; Price, Matthew; Gros, Daniel F.; Gros, Kirstin Stauffacher; McCauley, Jenna L.; Resnick, Heidi S.; Acierno, Ron; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC USA. [Paul, Lisa A.] No Illinois Univ, De Kalb, IL 60115 USA. [Price, Matthew; Gros, Daniel F.; Gros, Kirstin Stauffacher; Acierno, Ron; Ruggiero, Kenneth J.] Ralph H Johnson VAMC, Charleston, SC USA. RP Paul, LA (reprint author), No Illinois Univ, Dept Psychol, Psychol Comp Sci Bldg,Rm 400, De Kalb, IL 60115 USA. EM lpaul1@niu.edu FU NIDA NIH HHS [K12 DA031794]; NIMH NIH HHS [P60 MH082598, R01 MH081056, R34 MH077149, T32 MH018869] NR 43 TC 4 Z9 4 U1 4 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 EI 1097-4679 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD APR PY 2014 VL 70 IS 4 BP 322 EP 332 DI 10.1002/jclp.22026 PG 11 WC Psychology, Clinical SC Psychology GA AC4BN UT WOS:000332465700003 PM 23852826 ER PT J AU Alex, AM Verhulst, S Sundareshan, V Mclafferty, R AF Alex, A. M. Verhulst, S. Sundareshan, V. Mclafferty, R. TI FACTORS THAT INFLUENCE WOUND HEALING OF DIABETIC FOOT ULCERS (DFU) TREATED WITH SKIN SUBSTITUTES (SS) SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Combined Annual Meeting of the Central-Society-for-Clinical-and-Translational-Research (CSCTR) and Midwestern-Section-American-Federation-for-Medical-Research (MWAFMR) CY APR 24-25, 2014 CL Chicago, IL SP Cent Soc Clin & Translat Res, Midwestern Sect Amer Federat Med Res C1 [Alex, A. M.; Verhulst, S.; Sundareshan, V.] So Illinois Univ, Springfield, IL USA. [Mclafferty, R.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD APR PY 2014 VL 62 IS 4 BP 738 EP 739 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AE0ZQ UT WOS:000333695300127 ER PT J AU Lendon, JP Silverstein, M Giarrusso, R AF Lendon, Jessica P. Silverstein, Merril Giarrusso, Roseann TI Ambivalence in Older Parent-Adult Child Relationships: Mixed Feelings, Mixed Measures SO JOURNAL OF MARRIAGE AND FAMILY LA English DT Article DE intergenerational relationships; ambivalence; quantitative methodology ID INTERGENERATIONAL SOLIDARITY; LATER-LIFE; AMERICAN FAMILIES; CONFLICT; PERSPECTIVES; TIES AB This research compared direct and indirect measures of ambivalence, 2 commonly used strategies for measuring intergenerational ambivalence between older parents and their adult children. Directly and indirectly measured ambivalence, corresponding to felt and potential manifestations of the construct, were contrasted with each other and across generations. Data were derived from 253 older parent-adult child dyads participating in the Longitudinal Study of Generations in 2005. Direct and indirect measures of ambivalence were moderately correlated with each other within each generation. Children expressed greater indirect ambivalence than their parents but were no different than their mothers or fathers in their levels of direct ambivalence. Multivariate regression analyses examining the relationship between each type of ambivalence with individual and relationship characteristics found differences in associations across equations. The results suggest that direct and indirect measures are related but represent 2 distinct conceptions of ambivalence. This research highlights the challenges in understanding the full complexity of intergenerational relations and suggests that both generational perspectives be considered in future research. C1 [Lendon, Jessica P.] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev, Los Angeles, CA 90073 USA. [Silverstein, Merril] Syracuse Univ, Aging Studies Inst, Syracuse, NY 13244 USA. [Giarrusso, Roseann] Calif State Univ Los Angeles, Dept Sociol, Los Angeles, CA 90032 USA. RP Lendon, JP (reprint author), VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jessicapenn@gmail.com FU NIA NIH HHS [R01 AG007977] NR 37 TC 9 Z9 9 U1 0 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-2445 EI 1741-3737 J9 J MARRIAGE FAM JI J. Marriage Fam. PD APR PY 2014 VL 76 IS 2 BP 272 EP 284 DI 10.1111/jomf.12101 PG 13 WC Family Studies; Sociology SC Family Studies; Sociology GA AC0DH UT WOS:000332164500003 PM 25378714 ER PT J AU Colman, RJ Beasley, TM Kemnitz, JW Johnson, SC Weindruch, R Anderson, RM AF Colman, Ricki J. Beasley, T. Mark Kemnitz, Joseph W. Johnson, Sterling C. Weindruch, Richard Anderson, Rozalyn M. TI Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys SO NATURE COMMUNICATIONS LA English DT Article ID DIETARY RESTRICTION; LIFE-SPAN; BODY-COMPOSITION; CANCER; HEALTH; MICE AB Caloric restriction (CR) without malnutrition increases longevity and delays the onset of age-associated disorders in short-lived species, from unicellular organisms to laboratory mice and rats. The value of CR as a tool to understand human ageing relies on translatability of CR's effects in primates. Here we show that CR significantly improves age-related and allcause survival in monkeys on a long-term similar to 30% restricted diet since young adulthood. These data contrast with observations in the 2012 NIA intramural study report, where a difference in survival was not detected between control-fed and CR monkeys. A comparison of body weight of control animals from both studies with each other, and against data collected in a multi-centred relational database of primate ageing, suggests that the NIA control monkeys were effectively undergoing CR. Our data indicate that the benefits of CR on ageing are conserved in primates. C1 [Colman, Ricki J.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. [Beasley, T. Mark] Birmingham Atlanta Vet Adm Hosp, Geriatr Res Educ & Clin Ctr, Birmingham, AL 35233 USA. [Beasley, T. Mark] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Kemnitz, Joseph W.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI 53706 USA. [Johnson, Sterling C.; Weindruch, Richard; Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Johnson, Sterling C.; Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. RP Anderson, RM (reprint author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. EM rmanderson@medicine.wisc.edu RI Biguzzi, Felipe/E-4724-2015 FU NIH [P01AG011915, R01AG040178, R01AG037000]; Department of Medicine, School of Medicine and Public Health UW Madison; NCRR/ORIP [P51RR000167, P51OD011106] FX Funding for this study was provided by NIH grants P01AG011915, R01AG040178 and R01AG037000, and the Department of Medicine, School of Medicine and Public Health UW Madison. This publication was made possible in part by NCRR/ORIP grants P51RR000167/P51OD011106 to the Wisconsin National Primate Research Center, University of Wisconsin- Madison. The study was conducted with the use of resources and facilities at the William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA. NR 21 TC 128 Z9 128 U1 14 U2 74 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD APR PY 2014 VL 5 AR 3557 DI 10.1038/ncomms4557 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG2BI UT WOS:000335219800005 PM 24691430 ER PT J AU Stewart, L AF Stewart, Lygia TI latrogenic Biliary Injuries Identification, Classification, and Management SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article DE Bile duct injury; Biliary stricture; Laparoscopic cholecystectomy; Management; Biliary-enteric anastomosis ID BILE-DUCT INJURIES; HEPATIC-ARTERY INJURY; QUALITY-OF-LIFE; LAPAROSCOPIC CHOLECYSTECTOMY; SURGICAL REPAIR; VASCULAR INJURIES; REFERRAL PATTERN; NATIONAL-SURVEY; RISK-FACTORS; FOLLOW-UP AB Because it offers several advantages over open cholecystectomy, laparoscopic cholecystectomy has largely replaced open cholecystectomy for the management of symptomatic gallstone disease. The only potential disadvantage is a higher incidence of major bile duct injury. Although prevention of these biliary injuries is ideal, when they do occur, early identification and appropriate treatment are critical to improving the outcomes of patients suffering a major bile duct injury. This report delineates the key factors in classification (and its relationship to mechanism and management), identification (intraoperative and postoperative), and management principles of these bile duct injuries. C1 [Stewart, Lygia] Univ Calif San Francisco, Dept Surg 112, San Francisco, CA 94121 USA. [Stewart, Lygia] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Stewart, L (reprint author), Univ Calif San Francisco, Dept Surg 112, San Francisco, CA 94121 USA. EM lygia.stewart@va.gov NR 85 TC 11 Z9 14 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0039-6109 EI 1558-3171 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD APR PY 2014 VL 94 IS 2 BP 297 EP + DI 10.1016/j.suc.2014.01.008 PG 15 WC Surgery SC Surgery GA AG4WM UT WOS:000335421100008 PM 24679422 ER PT J AU Baker, RR AF Baker, Rodney R. TI Jule Dewayne Moravec (1933-2013) OBITUARY SO AMERICAN PSYCHOLOGIST LA English DT Biographical-Item C1 Dept Vet Affairs, San Antonio, TX USA. RP Baker, RR (reprint author), Dept Vet Affairs, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X EI 1935-990X J9 AM PSYCHOL JI Am. Psychol. PD APR PY 2014 VL 69 IS 3 BP 303 EP 303 DI 10.1037/a0035719 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF4LZ UT WOS:000334685500011 PM 24750082 ER PT J AU Williams, RM Turner, AP Green, M Norvell, DC Henderson, AW Hakimi, KN Blake, DJ Czerniecki, JM AF Williams, Rhonda M. Turner, Aaron P. Green, Monica Norvell, Daniel C. Henderson, Alison W. Hakimi, Kevin N. Blake, Donna J. Czerniecki, Joseph M. TI Changes in Cognitive Function From Presurgery to 4 Months Postsurgery in Individuals Undergoing Dysvascular Amputation SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Amputation; Cognition; Postoperative period; Rehabilitation ID PERIPHERAL ARTERIAL-DISEASE; LOWER-LIMB AMPUTATION; SELF-RATED HEALTH; VASCULAR-DISEASE; NONCARDIAC SURGERY; DIABETES-MELLITUS; REHABILITATION; PERFORMANCE; DYSFUNCTION; PREDICTORS AB Objective: To describe cognition among individuals with new amputations at 3 time points: presurgical, 6 weeks postamputation, and 4 months postamputation. Design: Prospective cohort. Setting: Medical centers. Participants: Referred sample Veterans who were primarily men (N=80) experiencing their first lower extremity amputation as a result of complications of diabetes mellitus or peripheral arterial disease. Patients were screened for the absence of gross cognitive impairment using the Short Portable Mental Status Questionnaire (SPMSQ). Of those 87 individuals who were eligible, 64% enrolled; 29 were enrolled presurgically and have cognitive data for all 3 time points, and 58 were enrolled postamputation. Eighty of the 87 individuals enrolled by 6 weeks remained enrolled at 4 months. Interventions: Not applicable. Main Outcome Measures: Demographic and general health information, general mental status (SPMSQ), and 4 brief, well-established neuropsychological measures. Results: Most mean neuropsychological test scores fell in the low average or average range. For most participants, overall cognitive status improved from pre- to postsurgery and then remained stable between 6 weeks and 4 months. There were significant improvements between pre- and postsurgical test scores in verbal learning and memory, and these remained unchanged between 6 weeks and 4 months. Better 4 month cognitive performance was associated with higher perceived general health. Conclusions: Overall cognitive performance is poorest presurgically. Though there is improvement between pre- and postamputation, cognition appears generally stable between 6 weeks and 4 months. (C) 2014 by the American Congress of Rehabilitation Medicine C1 [Williams, Rhonda M.; Turner, Aaron P.; Green, Monica; Henderson, Alison W.; Hakimi, Kevin N.; Czerniecki, Joseph M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Williams, Rhonda M.; Turner, Aaron P.; Green, Monica; Henderson, Alison W.; Hakimi, Kevin N.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Norvell, Daniel C.] Spectrum Res Inc, Tacoma, WA USA. [Blake, Donna J.] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA. [Blake, Donna J.] Univ Colorado, Denver, CO 80202 USA. RP Williams, RM (reprint author), VA Puget Sound Hlth Care Syst, RCS-117,1660 S Columbian Way, Seattle, WA 98108 USA. EM Rhonda.Williams1@va.gov OI Turner, Aaron/0000-0001-6897-8003 FU U.S. Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development [A41241, B4927W] FX Supported by the U.S. Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development (merit review no. A41241 and career development award no. B4927W). NR 54 TC 1 Z9 1 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2014 VL 95 IS 4 BP 663 EP 669 DI 10.1016/j.apmr.2013.11.013 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA AF3YJ UT WOS:000334648300012 PM 24316326 ER PT J AU Lilly, SM Jacobs, DR Kronmal, R Bluemke, DA Criqui, M Lima, J Allison, M Duprez, D Segers, P Chirinos, JA AF Lilly, Scott M. Jacobs, David R., Jr. Kronmal, Richard Bluemke, David A. Criqui, Michael Lima, Joao Allison, Matthew Duprez, Daniel Segers, Patrick Chirinos, Julio A. TI Arterial compliance across the spectrum of ankle-brachial index: The multiethnic study of atherosclerosis SO ATHEROSCLEROSIS LA English DT Article DE Cardiovascular disease; Medial artery calcification; Vascular compliance; Atherosclerosis ID INCIDENT CARDIOVASCULAR EVENTS; CORONARY-HEART-DISEASE; CHRONIC KIDNEY-DISEASE; PULSE-WAVE VELOCITY; AORTIC STIFFNESS; INDEPENDENT PREDICTOR; HYPERTENSIVE PATIENTS; BLOOD-PRESSURE; RISK-FACTORS; ALL-CAUSE AB Objective: A low ankle-brachial index is associated with cardiovascular disease and reduced arterial compliance. A high ankle-brachial index is also associated with an increased risk of cardiovascular events. We tested the hypothesis that subjects with a high ankle-brachial index demonstrate a lower arterial compliance. In addition, we assessed whether pulse pressure amplification is increased among subjects with a high ankle-brachial index. Methods: We studied 6814 adults enrolled in the multiethnic study of atherosclerosis who were, by definition, free of clinical cardiovascular disease at baseline. Differences in total arterial compliance (ratio of stroke volume to pulse pressure), aortic and carotid distensibility (measured with magnetic resonance imaging and duplex ultrasound, respectively) were compared across ankle-brachial index subclasses (<= 0.90, 0.91-1.29; >= 1.30) with analyses adjusted for cardiovascular risk factors and subclinical atherosclerosis. Results: Peripheral arterial disease was detected in 230 (3.4%) and high ABI in 648 (9.6%) of subjects. Those with high ankle-brachial index demonstrated greater aortic/radial pulse pressure amplification than those with a normal ankle-brachial index. In adjusted models aortic and carotid distensibility as well as total arterial compliance, were lowest among those with ankle-brachial index <= 0.9 (p < 0.01 vs. all), but were not reduced in subjects with an ankle-brachial index >= 1.3. Conclusion: Lower aortic, carotid and total arterial compliance is not present in subjects free of overt cardiovascular disease and with a high ankle-brachial index. However, increased pulse pressure amplification contributes to a greater ankle-brachial index in the general population and may allow better characterization of individuals with this phenotype. Published by Elsevier Ireland Ltd. C1 [Lilly, Scott M.] Ohio State Univ, Heart & Vasc Ctr, Div Cardiovasc Med, Columbus, OH 43210 USA. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA. [Kronmal, Richard] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Bluemke, David A.; Lima, Joao] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA. [Bluemke, David A.; Lima, Joao] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Criqui, Michael] Univ Calif San Diego, Div Prevent Med, San Diego, CA 92103 USA. [Duprez, Daniel] Univ Minnesota, Div Cardiovasc, Minneapolis, MN 55455 USA. [Segers, Patrick] Univ Ghent, Inst Biomed Technol, B-9000 Ghent, Belgium. [Chirinos, Julio A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Chirinos, JA (reprint author), Room 8B111,5800 Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu OI Bluemke, David/0000-0002-8323-8086; Allison, Matthew/0000-0003-0777-8272 FU Multi-Ethnic Study of Atherosclerosis (MESA) FX The authors would like to thank the staff and investigators of the Multi-Ethnic Study of Atherosclerosis (MESA) for the support and contributions. NR 42 TC 1 Z9 1 U1 0 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD APR PY 2014 VL 233 IS 2 BP 691 EP 696 DI 10.1016/j.atherosclerosis.2014.01.029 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AE9OM UT WOS:000334337200057 PM 24583417 ER PT J AU Yukl, SA Kaiser, P Kim, P Li, PL Wong, JK AF Yukl, Steven A. Kaiser, Philipp Kim, Peggy Li, Peilin Wong, Joseph K. TI Advantages of using the QIAshredder instead of restriction digestion to prepare DNA for droplet digital PCR SO BIOTECHNIQUES LA English DT Article DE digital PCR; Droplet Digital PCR; DNA; QIAshredder; restriction enzyme; BsaJI; RsaI ID QUANTITATION; EXTRACTION AB The viscosity of genomic DNA can interfere with digital PCR systems that partition samples into oil droplets or microfluidic wells. Restriction digestion may reduce the viscosity, but the process is labor-intensive, and the buffer can alter the conditions for PCR. DNA fragmentation using the QIAshredder (a biopolymer spin column) is faster, may result in more predictable and uniformly-sized fragments, and avoids the need for restriction buffers that can inhibit downstream PCR. In 10 separate head-to-head experiments comparing aliquots of DNA processed using the QIAshredder to those digested with RsaI or BsaJI prior to droplet digital PCR, we found that the copy numbers measured from the QIAshredded DNA tended to be greater than those measured from the digested DNA (average of 1.35-fold compared with BsaJI; P < 0.0001), even for inputs as high as 1.8 mu g or dilution down to the single copy level. C1 [Yukl, Steven A.; Kaiser, Philipp; Li, Peilin; Wong, Joseph K.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Yukl, Steven A.; Kaiser, Philipp; Kim, Peggy; Li, Peilin; Wong, Joseph K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Yukl, SA (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM Steven.yukl@ucsf.edu FU U.S. Department of Veterans Affairs [1 IK2 CX000520-01, 101 BX000192]; National Institute of Allergy and Infectious Diseases at the National Institutes of Health [R56AI091573, U19AI096109]; Swiss National Science Foundation [PBZHP3_147260] FX The authors thank the blood donors and the Blood Systems Research Institute for PBMCs. The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 8E5/LAV from Dr. Thomas Folks. This work was supported by the U.S. Department of Veterans Affairs [1 IK2 CX000520-01 (to S.Y.), 101 BX000192 (to J.W.)], the National Institute of Allergy and Infectious Diseases at the National Institutes of Health [R56AI091573 (J.W., S.Y.), U19AI096109 (to J.W.)], and the Swiss National Science Foundation [PBZHP3_147260 (to P.K.)]. This paper is subject to the NIH Public Access Policy. NR 9 TC 6 Z9 7 U1 0 U2 6 PU BIOTECHNIQUES OFFICE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0736-6205 EI 1940-9818 J9 BIOTECHNIQUES JI Biotechniques PD APR PY 2014 VL 56 IS 4 BP 194 EP 196 DI 10.2144/000114159 PG 3 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AG0SV UT WOS:000335126800008 PM 24724845 ER PT J AU Sudore, RL Knight, SJ McMahan, RD Feuz, M Farrell, D Miao, YH Barnes, DE AF Sudore, Rebecca L. Knight, Sara J. McMahan, Ryan D. Feuz, Mariko Farrell, David Miao, Yinghui Barnes, Deborah E. TI A Novel Website to Prepare Diverse Older Adults for Decision Making and Advance Care Planning: A Pilot Study SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Advance care planning; medical decision making; aging; technology ID HEALTH BEHAVIOR-CHANGE; ELDERLY-PATIENTS; LIFE; END; DIRECTIVES; LITERACY; BARRIERS; SKILLS; TRIAL; VIDEO AB Context. We have reconceptualized advance care planning (ACP) as a multistep process focused on preparing patients with skills needed for communication and in-the-moment decision making. Objectives. To operationalize this paradigm, we created an easy-to-use ACP website (prepareforyourcare. org) based on a theoretical framework of behavior change and pilot-tested its efficacy to engage older adults in ACP. Methods. At baseline and 1 week after viewing the PREPARE website, we assessed behavior change in ACP by using a validated survey that includes Process Measures (knowledge, contemplation, self-efficacy, and readiness, 5-point Likert scales) and Action Measures (yes/no whether an ACP behavior was completed). We also assigned participants into behavior change stages (i.e., precontemplation, contemplation, preparation, action, maintenance) and determined the percentage of participants who moved from precontemplation at baseline to higher stages at 1 week. We also assessed PREPARE ease-of-use (10-point scale, 10 being the easiest). Changes were assessed with Wilcoxon signed rank sum tests and McNemar's tests. Results. Mean age of the participants was 68.4 years (SD 6.6), and 65% were nonwhite. Behavior Change Process Measures average Likert scores increased from 3.1 (0.9) to 3.7 (0.7), P < 0.001. Action Measures did not change significantly. However, precontemplation significantly decreased for most actions (e. g., talking to doctor about desired medical care, 61% to 35%, P < 0.003), with a mean decrease of 21% (range, 16%-33%). PREPARE was rated a nine of ten (+/- 1.9) for ease-of-use. Conclusion. A new, patient-centered ACP website that focuses on preparing patients for communication and decision making significantly improves engagement in the process of ACP and behavior change. A clinical trial of PREPARE is currently underway. J Pain Symptom Manage 2014;47:674-686. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee. C1 [Sudore, Rebecca L.; McMahan, Ryan D.; Feuz, Mariko; Miao, Yinghui; Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca L.; McMahan, Ryan D.; Feuz, Mariko; Miao, Yinghui] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. [Knight, Sara J.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Knight, Sara J.] Vet Adm, Hlth Serv Res & Dev Serv, Washington, DC USA. [Farrell, David] People Designs Inc, Durham, NC USA. RP Sudore, RL (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 4150 Clement St,151R, San Francisco, CA 94121 USA. EM rebecca.sudore@ucsf.edu FU U.S. Department of Veterans Affairs; National Palliative Care Research Center Foundation FX This study was supported by the U.S. Department of Veterans Affairs and the National Palliative Care Research Center Foundation. The funding sources had no role in the creation of study materials, data collection, analysis, or interpretation of the data. No authors report any conflicts of interest. NR 32 TC 27 Z9 27 U1 4 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD APR PY 2014 VL 47 IS 4 BP 674 EP 686 DI 10.1016/j.jpainsymman.2013.05.023 PG 13 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AF3CC UT WOS:000334588100007 PM 23972574 ER PT J AU Soones, T Ahalt, C Garrigues, S Faigman, D Williams, BA AF Soones, Tacara Ahalt, Cyrus Garrigues, Sarah Faigman, David Williams, Brie A. TI "My Older Clients Fall Through Every Crack in the System": Geriatrics Knowledge of Legal Professionals SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE qualitative; geriatric; prisoners; attorneys ID HEALTH; CARE; RESIDENTS; ATTITUDES AB With the number of older adult arrestees and prisoners increasing rapidly, legal professionals increasingly provide front-line identification and response to age-related health conditions (including cognitive and physical impairments) that may affect legal outcomes, such as the ability to participate in one's defense or stay safe in jail. The goals of this study were to assess the ability of legal professionals to recognize and respond to age-related conditions that could affect legal outcomes and to identify recommendations to address important knowledge gaps. This was a mixed quantitative-qualitative study. Legal professionals (N=72) in the criminal justice system were surveyed to describe their demographic characteristics, expertise, and prior aging-related training and to inform the qualitative interview guide. Those surveyed included attorneys (district attorneys (25%), public defenders and legal advocates (58%)), judges (6%), and court-affiliated social workers (11%). In-depth qualitative interviews were then conducted with a subset of 10 legal professionals who worked with older adults at least weekly. Results from the surveys and interviews revealed knowledge deficits in four important areas: age-related health, identification of cognitive impairment, assessment of safety risk, and optimization of services upon release from jail. Four recommendations to close these gaps emerged: educate legal professionals about age-related health, train professionals to identify cognitive and sensory impairment, develop checklists to identify those at risk of poor health or safety, and improve knowledge of and access to transitional services for older adults. These findings suggest that geriatrics knowledge gaps of legal professionals exist that may contribute to adverse medical or legal outcomes for older adults involved in the criminal justice system and that partnerships between healthcare and legal professionals are needed to address these challenges. C1 [Soones, Tacara; Ahalt, Cyrus; Garrigues, Sarah; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94118 USA. [Faigman, David] Univ Calif San Francisco, Hastings Coll Law, San Francisco, CA 94102 USA. [Faigman, David] Univ Calif San Francisco, Univ Calif Hastings Consortium Law Sci & Hlth Pol, San Francisco, CA 94143 USA. [Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, 3333 Calif St,Suite 380, San Francisco, CA 94118 USA. EM brie.williams@ucsf.edu FU National Institute on Aging [K23AG033102]; Jacob and Valeria Langeloth Foundation; UCSF Program for the Aging Century FX Dr. Williams is supported by the National Institute on Aging (K23AG033102), the Jacob and Valeria Langeloth Foundation, and the UCSF Program for the Aging Century. The opinions expressed in this manuscript do not necessarily represent those of the Department of Veterans Affairs. NR 28 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2014 VL 62 IS 4 BP 734 EP 739 DI 10.1111/jgs.12751 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AE8YV UT WOS:000334289900021 PM 24611718 ER PT J AU Chandrasekhar, SS AF Chandrasekhar, Sujana S. TI Vertiginous Headache and Its Management SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Headache; Migraine; Dizziness; Vertigo; Meniere syndrome; Ocular movement disorder ID MIGRAINOUS VERTIGO; VESTIBULAR MIGRAINE; DIZZINESS; REHABILITATION; SYMPTOMS; PATIENT AB Vertiginous headache encompasses patients with dizziness or vertigo as well as headache, even though the symptoms may not occur in an obvious temporal relationship. The type of dizziness experienced by patients is different from the heavy-headedness experienced during rhinogenic headache. Patients may have a personal or family history of typical or atypical migraine. They should be evaluated for possible Meniere syndrome, migraine headaches, and/or eye movement disorders. Management is directed to treatment of the underlying abnormality. Long-term follow-up of these patients is necessary, because further otologic abnormalities may present later. C1 [Chandrasekhar, Sujana S.] New York Otol, New York, NY 10028 USA. [Chandrasekhar, Sujana S.] James J Peters Vet Adm Med Ctr, Bronx, NY USA. [Chandrasekhar, Sujana S.] Northshore LIJ Med Ctr, New York Head & Neck Inst, New York, NY USA. [Chandrasekhar, Sujana S.] Mt Sinai Sch Med, New York, NY USA. RP Chandrasekhar, SS (reprint author), New York Otol, 1421 Third Ave,4th Floor, New York, NY 10028 USA. EM ssc@nyotology.com NR 29 TC 0 Z9 0 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0030-6665 EI 1557-8259 J9 OTOLARYNG CLIN N AM JI Otolaryngol. Clin. N. Am. PD APR PY 2014 VL 47 IS 2 BP 333 EP + DI 10.1016/j.otc.2013.11.001 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA AF7KR UT WOS:000334894500012 PM 24680497 ER PT J AU Lown, RN Marsh, SGE Switzer, GE Latham, KA Madrigal, JA Shaw, BE AF Lown, R. N. Marsh, S. G. E. Switzer, G. E. Latham, K. A. Madrigal, J. A. Shaw, B. E. TI Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage SO BONE MARROW TRANSPLANTATION LA English DT Article DE marrow and SCT; allogeneic transplantation; donor attrition; unrelated donor; ethnicity ID BONE-MARROW DONATION; STEM-CELL DONORS; POTENTIAL DONORS; BLOOD-DONORS; TRANSPLANTATION AB Despite over 20 million unrelated donors being listed worldwide, donor attrition at the confirmatory typing (CT) stage of donor acquisition is a key source of delay. Anthony Nolan undertook a study of CT requests from 2010 to 2011 to identify factors associated with attrition. Of 7541 CT requests, 38.2% were cancelled for donor reasons. Of these, 19.4% were personal, 34.1% medical, 36% no contact, 7.9% emigrated and 2.6% others. African (odds ratio (OR) 2.78, P < 0.001), African-Caribbean (OR 3.07, P < 0.001), Asian (OR 2.65, P < 0.001), Jewish (OR=1.54, P < 0.009) and Mediterranean (OR=2.38, P < 0.001) donors were more likely not to be available compared to Caucasian donors. Female donors were also more likely not to be available (OR=1.32, P < 0.001): primarily due to pregnancy. Older donors were less likely to be available in univariate analysis, but this association was not significant after controlling for other factors. Blood donors and those recruited within the past five years had lower rates of attrition. Accumulation of additional attrition-associated characteristics for a given donor was associated with progressively greater odds of attrition (OR 1.99, 2.52, 3.4 and 5.53, respectively, for 1, 2, 3 and 4 risk factors, P < 0.001). Donor registries must develop evidence-driven strategies to recruit and retain the most reliable donors. C1 [Lown, R. N.; Marsh, S. G. E.; Latham, K. A.; Madrigal, J. A.; Shaw, B. E.] Royal Free Hosp, Anthony Nolan Res Inst, London NW3 2QG, England. [Lown, R. N.; Marsh, S. G. E.; Madrigal, J. A.; Shaw, B. E.] UCL, UCL Canc Inst, London, England. [Switzer, G. E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Switzer, G. E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Switzer, G. E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Switzer, G. E.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. [Shaw, B. E.] Royal Marsden NHS Fdn Trust, London, England. RP Lown, RN (reprint author), Royal Free Hosp, Anthony Nolan Res Inst, Pond St, London NW3 2QG, England. EM robert.lown@anthonynolan.org NR 18 TC 2 Z9 2 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2014 VL 49 IS 4 BP 525 EP 531 DI 10.1038/bmt.2013.206 PG 7 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA AF1VB UT WOS:000334500900010 PM 24419516 ER PT J AU Iyer, AS Wells, JM Vishin, S Bhatt, SP Wille, KM Dransfield, MT AF Iyer, Anand S. Wells, J. Michael Vishin, Sonia Bhatt, Surya P. Wille, Keith M. Dransfield, Mark T. TI CT Scan-Measured Pulmonary Artery to Aorta Ratio and Echocardiography for Detecting Pulmonary Hypertension in Severe COPD SO CHEST LA English DT Article ID RIGHT-VENTRICULAR-FUNCTION; COMPUTED-TOMOGRAPHY; LUNG-DISEASE; SEVERE EMPHYSEMA; DIAMETER; PATHOPHYSIOLOGY; EXACERBATION; MANAGEMENT; PRESSURES; SERIES AB Background: COPD is associated with significant morbidity primarily driven by acute exacerbations. Relative pulmonary artery (PA) enlargement, defined as a PA to ascending aorta (A) diameter ratio greater than one (PA:A>1) identifies patients at increased risk for exacerbations. However, little is known about the correlation between PA:A, echocardiography, and invasive hemodynamics in COPD. Methods: A retrospective observational study of patients with severe COPD being evaluated for lung transplantation at a single center between 2007 and 2011 was conducted. Clinical characteristics, CT scans, echocardiograms, and right-sided heart catheterizations were reviewed. The PA diameter at the bifurcation and A diameter from the same CT image were measured. Linear and logistic regression were used to examine the relationships between PA:A ratio by CT scan and PA systolic pressure (PASP) by echocardiogram with invasive hemodynamics. Receiver operating characteristic analysis assessed the usefulness of the PA:A ratio and PASP in predicting resting pulmonary hypertension (PH) (mean pulmonary artery pressure [mPAP]>25 mm Hg). Results: Sixty patients with a mean predicted FEV1 of 27% +/- 12% were evaluated. CT scan-measured PA:A correlated linearly with mPAP after adjustment for multiple covariates (r = 0.30, P = .03), a finding not observed with PASP. In a multivariate logistic model, mPAP was independently associated with PA:A>1 (OR, 1.44; 95% CI, 1.02-2.04; P =.04). PA:A>1 was 73% sensitive and 84% specific for identifying patients with resting PH (area under the curve, 0.83; 95% CI, 0.72-0.93; P<.001), whereas PASP was not useful. Conclusions: A PA:A ratio > 1 on CT scan outperforms echocardiography for diagnosing resting PH in patients with severe COPD. C1 [Iyer, Anand S.; Wells, J. Michael; Vishin, Sonia; Wille, Keith M.; Dransfield, Mark T.] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL USA. [Wells, J. Michael; Vishin, Sonia; Bhatt, Surya P.; Wille, Keith M.; Dransfield, Mark T.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care, Dept Med, Birmingham, AL USA. Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL USA. [Wells, J. Michael; Dransfield, Mark T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Wells, JM (reprint author), 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA. EM jmwells@uab.edu FU National Institutes of Health; Aeris Therapeutics; AstraZeneca; Boehringer Ingelheim GmbH; Boston Scientific; Janssen Biotech, Inc; Forest Laboratories, Inc; GlaxoSmithKline; Ikaria, Inc; Medimmune, LLC; Olmsted Medical Center; Otsuka America Pharmaceutical, Inc; Pfizer, Inc; Pulmonx FX Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Dransfield has served as a consultant to Boehringer Ingelheim GmbH, GlaxoSmithKline, and Ikaria, Inc, and his institution has received research support from the National Institutes of Health; Aeris Therapeutics; AstraZeneca; Boehringer Ingelheim GmbH; Boston Scientific; Janssen Biotech, Inc; Forest Laboratories, Inc; GlaxoSmithKline; Ikaria, Inc; Medimmune, LLC; Olmsted Medical Center; Otsuka America Pharmaceutical, Inc; Pfizer, Inc; and Pulmonx. Drs Iyer, Wells, Vishin, Bhatt, and Wille have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article NR 42 TC 32 Z9 35 U1 1 U2 6 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD APR PY 2014 VL 145 IS 4 BP 824 EP 832 DI 10.1378/chest.13-1422 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AE6JO UT WOS:000334097700027 PM 24114440 ER PT J AU Gould, MK Wagner, TH Schultz, EM Xu, XY Ghaus, SJ Provenzale, D Au, DH AF Gould, Michael K. Wagner, Todd H. Schultz, Ellen M. Xu, Xiangyan Ghaus, Sharfun J. Provenzale, Dawn Au, David H. CA Canc Care Outcomes Res TI Facility-Level Analysis of PET Scanning for Staging Among US Veterans With Non-small Cell Lung Cancer SO CHEST LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; MEDICARE BENEFICIARIES; COMPUTED-TOMOGRAPHY; RANDOMIZED-TRIAL; COMORBIDITY; CARE AB Background: PET scanning has been shown in randomized trials to reduce the frequency of surgery without cure among patients with potentially resectable non-small cell lung cancer (NSCLC). We examined whether more frequent use of PET scanning at the facility level improves survival among patients with NSCLC in real-world practice. Methods: In this prospective cohort study of 622 US veterans with newly diagnosed NSCLC, we compared groups defined by the frequency of PET scan use measured at the facility level and categorized as low (<25%), medium (25%-60%), or high (>60%). Results: The median age of the sample was 69 years. Ninety-eight percent were men, 36% were Hispanic or nonwhite, and 54% had moderate or severe comorbidities. At low-, medium-, and high-use facilities, PET scan was performed in 13%, 40%, and 72% of patients, respectively (P<.0001). Baseline characteristics were similar across groups, including clinical stage based on CT scanning. More frequent use of PET scanning was associated with more frequent invasive staging (P<.001) and nonsignificant improvements in downstaging (P = .13) and surgery without cure (P = .12). After a median of 352 days of follow-up, 22% of the sample was still alive, including 22% at low- and medium- use facilities and 20% at high-use facilities. After adjustment and compared with patients at low- use facilities, the hazard of death was greater for patients at high-use facilities (adjusted hazard ratio [HR], 1.35; 95% CI, 1.05-1.74) but not different for patients at medium-use facilities (adjusted HR, 1.14; 95% CI, 0.88-1.46). Conclusions: In this study of veterans with NSCLC, markedly greater use of PET scanning at the facility level was associated with more frequent use of invasive staging and possible improvements in downstaging and surgery without cure, but greater use of PET scanning was not associated with better survival. C1 [Gould, Michael K.] Dept Vet Affairs, Palo Alto, CA USA. [Wagner, Todd H.; Ghaus, Sharfun J.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Wagner, Todd H.] VA Hlth Econ Res Ctr, Menlo Pk, CA USA. [Schultz, Ellen M.] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. [Xu, Xiangyan] Palo Alto Inst Res & Educ, Palo Alto, CA USA. [Provenzale, Dawn] Durham VA Med Ctr, Durham Epidemiol Res & Informat Ctr, Durham, NC USA. [Provenzale, Dawn] Duke Univ, Durham, NC USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. [Au, David H.] Univ Washington, Dept Med, Seattle, WA USA. RP Gould, MK (reprint author), Kaiser Permanente So Calif, Dept Res & Evaluat, 100 S Los Robles, Pasadena, CA 91101 USA. EM michael.k.gould@kp.org FU NCI NIH HHS [U01 CA93329, U01 CA93332, U01 CA093326, U01 CA093348, U01 CA93348, U01 CA093332, U01 CA093324, U01 CA093339, U01 CA093344, U01 CA93326, U01 CA93344, U01 CA93324, U01 CA93339, U01 CA093329] NR 21 TC 0 Z9 1 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD APR PY 2014 VL 145 IS 4 BP 839 EP 847 DI 10.1378/chest.13-1073 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AE6JO UT WOS:000334097700029 PM 24306819 ER PT J AU Lyon, SM Wunsch, H Asch, DA Carr, BG Kahn, JM Cooke, CR AF Lyon, Sarah M. Wunsch, Hannah Asch, David A. Carr, Brendan G. Kahn, Jeremy M. Cooke, Colin R. TI Use of Intensive Care Services and Associated Hospital Mortality After Massachusetts Healthcare Reform SO CRITICAL CARE MEDICINE LA English DT Article DE critical care; health insurance; health policy; healthcare reform ID CRITICAL ILLNESS; INSURANCE STATUS; UNITED-STATES; OUTCOMES; ACCESS; PERFORMANCE; MEDICINE; COSTS AB Objective: To use the natural experiment of health insurance reform in Massachusetts to study the impact of increased insurance coverage on ICU utilization and mortality. Design: Population-based cohort study. Setting: Massachusetts and four states (New York, Washington, Nebraska, and North Carolina) that did not enact reform. Patients: All nonpregnant nonelderly adults (age 18-64 yr) admitted to nonfederal acute care hospitals in one of the five states of interest were eligible, excluding patients who were not residents of a respective state at the time of admission. Measurements: We used a difference-in-differences approach to compare trends in ICU admissions and outcomes of in-hospital mortality and discharge destination for ICU patients. Main Result: Healthcare reform in Massachusetts was associated with a decrease in ICU patients without insurance from 9.3% to 5.1%. There were no significant changes in adjusted ICU admission rates, mortality, or discharge destination. In a sensitivity analysis excluding a state that enacted Medicaid reform prior to the study period, our difference-in-differences analysis demonstrated a significant increase in mortality of 0.38% per year (95% CI, 0.12-0.64%) in Massachusetts, attributable to a greater per-year decrease in mortality postreform in comparison states (-0.37%; 95% CI, -0.52% to -0.21%) compared with Massachusetts (0.01%; 95% CI, -0.20% to 0.11%). Conclusion: Massachusetts healthcare reform increased the number of ICU patients with insurance but was not associated with significant changes in ICU use or discharge destination among ICU patients. Reform was also not associated with changed in-hospital mortality for ICU patients; however, this association was dependent on the comparison states chosen in the analysis. C1 [Lyon, Sarah M.] Hosp Univ Penn, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. [Wunsch, Hannah] Columbia Univ, Dept Anesthesiol, New York, NY USA. [Asch, David A.; Carr, Brendan G.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Carr, Brendan G.] Hosp Univ Penn, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, Philadelphia, PA 19104 USA. [Carr, Brendan G.] Hosp Univ Penn, Dept Emergency Med, Ctr Policy Res, Philadelphia, PA 19104 USA. [Kahn, Jeremy M.] Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA USA. [Cooke, Colin R.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA. [Cooke, Colin R.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA. RP Lyon, SM (reprint author), Hosp Univ Penn, Div Pulm Allergy & Crit Care, 3400 Spruce St, Philadelphia, PA 19104 USA. EM arah.lyon@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X; Cooke, Colin/0000-0001-9713-5371 FU National Institutes of Health (NIH) [F32 10762329]; Leonard Davis Institute, University of Pennsylvania; NIH [AHRQ F32]; U.S. Department of Health and Human Services; University of Michigan's Robert Wood Johnson Foundation; Agency for Healthcare Research and Quality [K08]; Robert Wood Johnson Foundation FX Dr. Lyon received support for article research from National Institutes of Health (NIH, F32 10762329) and received grant support from the Leonard Davis Institute, University of Pennsylvania (Pilot Grant). She received support for travel from the American Thoracic Society (ATS Travel Award 2012) and is employed by the Chester County Hospital. Her institution received grant support from the NIH (AHRQ F32). Dr. Wunsch received grant support from NIH. Dr. Carr was supported by Leonard Davis Institute, University of Pennsylvania. He spends a portion of his time as a Senior Policy Analyst in the Office of the Assistant Secretary for Preparedness and Response. Dr. Kahn consulted for the U. S. Department of Veterans Affairs. He received speaking honoraria from the National Association of Long-term Acute Care hospitals and Barlow Respiratory Hospital. His institution received grant support from the U.S. Department of Health and Human Services (research grants). Dr. Cooke was supported by the University of Michigan's Robert Wood Johnson Foundation Clinical Scholars and Health and Society Programs. He and his institution received grant support from the Agency for Healthcare Research and Quality (K08), and his institution received support from Robert Wood Johnson Foundation. The findings and conclusions in this report are those of the author and do not necessarily represent the views of the Department of Health and Human Services or its components. Dr. Asch has disclosed that he does not have any potential conflicts of interest. NR 32 TC 4 Z9 4 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2014 VL 42 IS 4 BP 763 EP 770 DI 10.1097/CCM.0000000000000044 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA AC9FL UT WOS:000332839700017 PM 24275512 ER PT J AU Au, DH Wong, ES AF Au, David H. Wong, Edwin S. TI Use of Intensive Care and Healthcare Reform: More Questions Following the Massachusetts Experience SO CRITICAL CARE MEDICINE LA English DT Editorial Material DE health insurance; healthcare costs; healthcare reform; Medicaid; quality of care C1 [Au, David H.] VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98108 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98108 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2014 VL 42 IS 4 BP 970 EP 971 DI 10.1097/CCM.0000000000000110 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA AC9FL UT WOS:000332839700041 PM 24633090 ER PT J AU Dvoriak, S Karachevsky, A Chhatre, S Booth, R Metzger, D Schumacher, J Chychula, N Pecoraro, A Woody, G AF Dvoriak, Sergii Karachevsky, Andrey Chhatre, Sumedha Booth, Robert Metzger, David Schumacher, Joseph Chychula, Nina Pecoraro, Anna Woody, George TI Methadone maintenance for HIV positive and HIV negative patients in Kyiv: Acceptability and treatment response SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Methadone maintenance; HIV risk; Ukraine; PWID ID INJECTION-DRUG USERS; ADDICTION SEVERITY INDEX; OPIOID DEPENDENCE; ANTIRETROVIRAL THERAPY; UKRAINE; BUPRENORPHINE; TRIAL; INTERVENTIONS; INFECTION; EPIDEMIC AB Background: With up to 40% of opioid injectors infected with HIV, Ukraine has one of the most concentrated HIV epidemics in the world, mainly due to unsterile injection practices and a historical absence of effective prevention services. Harm reduction programs, including syringe exchange and a small buprenorphine treatment program, were introduced in 2004 and methadone maintenance was allowed in 2007. Despite an initial expansion, by 2009, only 3221 injectors were receiving methadone treatment. A growing body of research on methadone maintenance has found high retention rates with reduction in opioid use and HIV risk behaviors. We report on the acceptability and initial outcome of methadone treatment as a function of HIV status, an issue that has not yet been reported for injectors in Ukraine. Methods: Longitudinal observational study of a 12-week course of methadone treatment in 25 HIV+ and 25 HIV opioid addicted individuals recruited from a harm reduction program and the city AIDS Center. Drug use and HIV risk were assessed at baseline and weeks 4, 8, 12 and 20; all patients were offered continued methadone maintenance in the Kyiv city program at the end of 12 weeks. Results: Fifty-four individuals were asked if they were interested in the study and 50, demographically similar to other samples of opioid addicted Ukrainians, agreed to participate. Two died of non-study related causes; the other 48 completed assessments at weeks 4, 8 and 12, and 47 completed followups at week 20. Significant reductions were seen in use of heroin (p < 0.0001), other opiates/analgesics (p < 0.0001), and HIV risk behaviors (drug, sex, total; all p < 0.0001). All 48 patients chose to continue methadone after the 12-weeks of study medication ended. Unlike most opioid treatment studies, sexual risk was somewhat higher than injecting risk at study intake. Conclusions: Methadone maintenance was well accepted by HIV+ and HIV opioid dependent individuals and has the potential for significant public health impact if made more widely available with sustained access and support. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Dvoriak, Sergii] Ukrainian Inst Publ Hlth Policy, UA-01001 Kiev, Ukraine. [Karachevsky, Andrey] OO Bogomolets Natl Med Univ, Dept Psychiat & Drug Abuse, UA-01601 Kiev, Ukraine. [Chhatre, Sumedha; Metzger, David; Pecoraro, Anna; Woody, George] Treatment Res Inst, Philadelphia, PA 19106 USA. [Booth, Robert] Univ Colorado, Dept Psychiat, Denver, CO 80206 USA. [Metzger, David; Pecoraro, Anna; Woody, George] Univ Penn, Perelman Sch Med, Philadelphia, PA 19106 USA. [Schumacher, Joseph] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Chychula, Nina] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Woody, G (reprint author), Univ Penn, Perelman Sch Med, Suite 600,150 South Independence Mall W, Philadelphia, PA 19106 USA. EM woody@tresearch.org RI Metzger, David/D-9499-2012 FU NIDA [5R21DA21073]; INVEST/CTN [U10 DA-13043, KO5 DA-17009, DA024590] FX This research was supported by NIDA grants 5R21DA21073, INVEST/CTN fellowship award to Dr. Dvoryak; U10 DA-13043; KO5 DA-17009 (Woody PI on all); DA024590 (Booth). NR 37 TC 6 Z9 6 U1 5 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2014 VL 137 BP 62 EP 67 DI 10.1016/j.drugalcdep.2014.01.008 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA AE6UT UT WOS:000334134200008 PM 24548802 ER PT J AU Kaz, AM Wong, CJ Dzieciatkowski, S Luo, YX Schoen, RE Grady, WM AF Kaz, Andrew M. Wong, Chao-Jen Dzieciatkowski, Slavomir Luo, Yanxin Schoen, Robert E. Grady, William M. TI Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age SO EPIGENETICS LA English DT Article DE DNA methylation; field effect; colorectal cancer; normal colon methylation; methylation microarray ID CPG ISLAND METHYLATION; COLORECTAL-CANCER; ULCERATIVE-COLITIS; RECTAL MUCOSA; FIELD; GENE; HYPOMETHYLATION; CANCERIZATION; ADENOMAS; TUMORS AB Alterations in DNA methylation have been proposed to create a field cancerization state in the colon, where molecular alterations that predispose cells to transformation occur in histologically normal tissue. However, our understanding of the role of DNA methylation in field cancerization is limited by an incomplete characterization of the methylation state of the normal colon. In order to determine the colon's normal methylation state, we extracted DNA from normal colon biopsies from the rectum, sigmoid, transverse, and ascending colon and assessed the methylation status of the DNA by pyrosequencing candidate loci as well as with HumanMethylation450 arrays. We found that methylation levels of repetitive elements LINE-1 and SAT-alpha showed minimal variability throughout the colon in contrast to other loci. Promoter methylation of EVL was highest in the rectum and progressively lower in the proximal segments, whereas ESR1 methylation was higher in older individuals. Genome-wide methylation analysis of normal DNA revealed 8388, 82, and 93 differentially methylated loci that distinguished right from left colon, males from females, and older vs. younger individuals, respectively. Although variability in methylation between biopsies and among different colon segments was minimal for repetitive elements, analyses of specific cancer-related genes as well as a genome-wide methylation analysis demonstrated differential methylation based on colon location, individual age, and gender. These studies advance our knowledge regarding the variation of DNA methylation in the normal colon, a prerequisite for future studies aimed at understanding methylation differences indicative of a colon field effect. C1 [Kaz, Andrew M.; Wong, Chao-Jen; Dzieciatkowski, Slavomir; Luo, Yanxin; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Luo, Yanxin] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510275, Guangdong, Peoples R China. [Luo, Yanxin] Sun Yat Sen Univ, Gastrointestinal Inst, Guangzhou 510275, Guangdong, Peoples R China. [Schoen, Robert E.] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA. RP Kaz, AM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. EM akaz@fhcrc.org FU NCI NIH HHS [U01 CA152756] NR 39 TC 17 Z9 17 U1 1 U2 3 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1559-2294 EI 1559-2308 J9 EPIGENETICS-US JI Epigenetics PD APR 1 PY 2014 VL 9 IS 4 BP 492 EP 502 DI 10.4161/epi.27650 PG 11 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA AE9DP UT WOS:000334305100003 PM 24413027 ER PT J AU Robertson, JO Ebrahimi, R Lansky, AJ Mehran, R Stone, GW Lincoff, AM AF Robertson, Jason O. Ebrahimi, Ramin Lansky, Alexandra J. Mehran, Roxana Stone, Gregg W. Lincoff, A. Michael TI Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non-ST-Segment Elevation Acute Coronary Syndromes SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE ACUITY; non-ST-segment elevation acute coronary syndrome; smoker; smoker's paradox ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK-FACTORS; THROMBOLYTIC THERAPY; SMOKERS PARADOX; ACUITY TRIAL; ATHEROSCLEROTIC PLAQUES; CLINICAL-IMPLICATIONS; 30-DAY MORTALITY; OUTCOMES; INSIGHTS AB Objectives This study sought to evaluate the short-and long-term outcomes for smokers with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). Background Smoking has been associated with the "paradox"of reduced mortality after acute myocardial infarction (MI). This is thought to be due to favorable baseline characteristics and less diffuse coronary artery disease (CAD) among smokers. Methods In the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial, 13,819 patients (29.1% smokers) with moderate-to high-risk NSTE-ACS underwent angiography and, if indicated, revascularization. Results Smokers were significantly younger and had fewer comorbidities than nonsmokers. Incidence of death and MI were comparable at 30 days, although smokers had significantly reduced risks of 30-day major bleeding (hazard ratio [HR]: 0.80, 95% confidence interval [CI]: 0.67 to 0.96; p = 0.016) and 1-year mortality (HR: 0.797, 95% CI: 0.65 to 0.97; p = 0.027). After correction for baseline and clinical differences, smoking was no longer predictive of major bleeding (odds ratio: 1.06, 95% CI: 0.86 to 1.32; p = 0.56) and was associated with higher 1-year mortality (HR: 1.37, 95% CI: 1.07 to 1.7; p = 0.013). This pattern of reversed risk after multivariable correction held true for those smokers requiring percutaneous coronary intervention. Core laboratory angiographic analysis showed that smokers and nonsmokers were comparable in terms of the extent of CAD, Thrombolysis In Myocardial Infarction flow, myocardial blush, and the presence of thrombi. Conclusions In contrast to the paradox previously described in ST-segment elevation MI, our analysis finds smoking to be an independent predictor of higher 1-year mortality in patients presenting with NSTE-ACS, and our angiographic study demonstrates CAD in smokers that is comparable to that in nonsmokers but evident similar to 1 decade earlier. (C) 2014 by the American College of Cardiology Foundation C1 [Robertson, Jason O.; Lincoff, A. Michael] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Los Angeles, CA USA. [Ebrahimi, Ramin] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [Lansky, Alexandra J.] Yale Univ, Sch Med, New Haven, CT USA. [Mehran, Roxana] Icahn Sch Med Mt Sinai, New York, NY USA. [Mehran, Roxana; Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA. [Stone, Gregg W.] Columbia Univ, Med Ctr, New York, NY USA. RP Lincoff, AM (reprint author), Cleveland Clin, Dept Cardiovasc Med F25, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM lincofa@ccf.org NR 37 TC 11 Z9 11 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD APR PY 2014 VL 7 IS 4 BP 372 EP 379 DI 10.1016/j.jcin.2013.11.017 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AF1YK UT WOS:000334509600007 PM 24630881 ER PT J AU Pickerodt, PA Francis, RC Hohne, C Neubert, F Telalbasic, S Boemke, W Swenson, ER AF Pickerodt, Philipp A. Francis, Roland C. Hoehne, Claudia Neubert, Friederike Telalbasic, Stella Boemke, Willehad Swenson, Erik R. TI Pulmonary vasodilation by acetazolamide during hypoxia: impact of methyl-group substitutions and administration route in conscious, spontaneously breathing dogs SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE hypoxic pulmonary vasoconstriction; acetazolamide; N-methyl-acetazolamide; pulmonary arterial pressure; pulmonary vascular resistance ID CARBONIC-ANHYDRASE INHIBITION; ARTERIAL SMOOTH-MUSCLE; INTRACELLULAR PH; RAT LUNGS; VASOCONSTRICTION; EDEMA; RESPONSES; PRESSURE; CHANNELS; NITRITE AB Acetazolamide (ACZ) prevents hypoxic pulmonary vasoconstriction (HPV) in isolated lungs, animals, and humans, but not by carbonic anhydrase (CA) inhibition. We studied administration routes in, and certain structural aspects of, ACZ critical to HPV inhibition. Analogs of ACZ during acute hypoxia were tested in unanesthetized dogs. Dogs breathed normoxic gas for 1 h (inspired O-2 fraction = 0.21), followed by 10% O-2 for 2 h ( hypoxia) in these protocols: 1) controls; 2) ACZ intravenously (2 mg center dot kg(-1) center dot h(-1)); 3) ACZ orally (5 mg/kg, 12 and 1 h before the experiment); 4) inhaled ACZ (750 mg); 5) methazolamide (MTZ) intravenously (3 mg center dot kg(-1) center dot h(-1)); and 6) N-methyl-acetazolamide (NMA) intravenously (10 mg center dot kg(-1) center dot h(-1)). In controls, mean pulmonary arterial pressure (MPAP) increased 7 mmHg, and pulmonary vascular resistance (PVR) 224 dyn center dot s center dot cm(-5) with hypoxia (P < 0.05). With intravenous and inhaled ACZ, MPAP and PVR did not change during hypoxia. With oral ACZ, HPV was only slightly suppressed; MPAP increased 5 mmHg and PVR by 178 dyn center dot s center dot cm(-5) during hypoxia. With MTZ and NMA, the MPAP rise (4 +/- 2 mmHg) was reduced, and PVR did not increase during hypoxia compared with normoxia (MTZ intravenous: 81 +/- 77 and 68 +/- 82 dyn center dot s center dot cm(-5) with NMA intravenous). Inhaled ACZ prevents HPV, but not without causing systemic CA inhibition. NMA, a compound lacking CA inhibiting effects by methylation at the sulfonamide moiety, and MTZ, a CA-inhibiting analog methylated at the thiadiazole ring, are only slightly less effective than ACZ in reducing HPV. C1 [Pickerodt, Philipp A.; Francis, Roland C.; Neubert, Friederike; Telalbasic, Stella; Boemke, Willehad] Charite, Campus Charite Mitte, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany. [Pickerodt, Philipp A.; Francis, Roland C.; Neubert, Friederike; Telalbasic, Stella; Boemke, Willehad] Charite, Campus Virchow Klinikum, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany. [Hoehne, Claudia] Univ Leipzig, Dept Anesthesiol & Crit Care Med, D-04109 Leipzig, Germany. [Swenson, Erik R.] Univ Washington, Dept Pulm & Crit Care Med, Seattle, WA 98195 USA. [Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Pickerodt, PA (reprint author), Charite, Campus Charite Mitte, Dept Anesthesiol & Intens Care Med, Augustenburger Pl 1, D-13353 Berlin, Germany. EM philipp.pickerodt@charite.de FU Deutsche Forschungsgemeinschaft [Ho 3295/2-1, Pi 795/2-1]; National Heart, Lung, and Blood Institute [HL-24163] FX This study was supported by a grant from the Deutsche Forschungsgemeinschaft to C. Hohne (Ho 3295/2-1), to P. Pickerodt and W. Boemke (Pi 795/2-1), and by a grant from the National Heart, Lung, and Blood Institute to E. R. Swenson (HL-24163). NR 28 TC 7 Z9 7 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD APR PY 2014 VL 116 IS 7 BP 715 EP 723 DI 10.1152/japplphysiol.01235.2013 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA AE6PK UT WOS:000334115800003 PM 24481964 ER PT J AU McElderry, T Waxman, A Gomberg-Maitland, M Burke, M Ross, E Bersohn, M Tarver, J Zwicke, D Feldman, J Chakinala, M Frantz, R Torres, F Li, P Morris, M Peterson, L Bourge, R AF McElderry, T. Waxman, A. Gomberg-Maitland, M. Burke, M. Ross, E. Bersohn, M. Tarver, J. Zwicke, D. Feldman, J. Chakinala, M. Frantz, R. Torres, F. Li, P. Morris, M. Peterson, L. Bourge, R. TI Totally Implantable IV Treprostinil Therapy in Pulmonary Arterial Hypertension: Assessment of the Implantation Procedure SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Meeting Abstract CT 34th Annual Meeting and Scientific Sessions of the International-Society-for-Heart-and-Lung-Transplantation CY APR 10-13, 2014 CL San Diego, CA SP Int Soc Heart & Lung Transplantat C1 [McElderry, T.; Bourge, R.] Univ Alabama Birmingham, Birmingham, AL USA. [Waxman, A.; Ross, E.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Gomberg-Maitland, M.; Burke, M.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Bersohn, M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tarver, J.] Orlando Reg Med Ctr Orlando Hlth, Orlando, FL USA. [Zwicke, D.] Aurora Cardiovasc Serv, Milwaukee, WI USA. [Feldman, J.] Arizona Pulm Specialists Ltd, Cardiol, Phoenix, AZ USA. [Chakinala, M.] Washington Univ, Sch Med, St Louis, MO USA. [Frantz, R.] Mayo Clin, Rochester, MN USA. [Torres, F.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Li, P.; Morris, M.] Medtronic, Mounds View, MN USA. [Peterson, L.] United Therapeut Corp, Res Triangle Pk, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 EI 1557-3117 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD APR PY 2014 VL 33 IS 4 SU S MA 624 BP S231 EP S231 PG 1 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA AE3HD UT WOS:000333866700625 ER PT J AU McQuaid, J Peterzell, D Rutledge, T Cone, R Nance, P Velez, D Coeshott, R Ortega, I Van Duyn, M Otilingam, P Atkinson, J AF McQuaid, J. Peterzell, D. Rutledge, T. Cone, R. Nance, P. Velez, D. Coeshott, R. Ortega, I. Van Duyn, M. Otilingam, P. Atkinson, J. TI Integrated Cognitive-Behavioral Therapy (CBT) and Mirror Visual Feedback (MVF) for phantom limb pain: a randomized clinical trial SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [McQuaid, J.; Peterzell, D.; Rutledge, T.; Cone, R.; Nance, P.; Velez, D.; Coeshott, R.; Ortega, I.; Van Duyn, M.; Otilingam, P.; Atkinson, J.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 3 U2 26 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2014 VL 15 IS 4 SU 1 MA 529 BP S108 EP S108 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AF3YN UT WOS:000334648700428 ER PT J AU Morasco, B Peters, D Krebs, E Kovas, A Dobscha, S AF Morasco, B. Peters, D. Krebs, E. Kovas, A. Dobscha, S. TI Rates and predictors of urine drug testing in a national sample of VA patients SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Morasco, B.; Peters, D.; Krebs, E.; Kovas, A.; Dobscha, S.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2014 VL 15 IS 4 SU 1 MA 142 BP S11 EP S11 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AF3YN UT WOS:000334648700043 ER PT J AU Stevenson, K Blair, T Collins, E Ebert, I Johnson, D Schiffman, J AF Stevenson, K. Blair, T. Collins, E. Ebert, I. Johnson, D. Schiffman, J. TI Establishment of a Controlled Substance Advisory Review consult process for patients on chronic opioid therapy SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Stevenson, K.; Blair, T.; Collins, E.; Ebert, I.; Johnson, D.; Schiffman, J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2014 VL 15 IS 4 SU 1 MA 261 BP S41 EP S41 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AF3YN UT WOS:000334648700161 ER PT J AU Turner, BJ Navuluri, NL Vale, S Finley, E AF Turner, Barbara J. Navuluri, Nee Lima Vale, Shruthi Finley, Erin TI A Qualitative Study of Family Healthy Lifestyle Behaviors of Mexican-American and Mexican Immigrant Fathers and Mothers SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Obesity; Children; Mexican-American; Stages of change; Parenting styles ID PHYSICAL-ACTIVITY; CHILDHOOD OBESITY; PARENTING STYLES; CHILDREN; WEIGHT; US AB This study qualitatively examines contrasting parental decision-making styles about family food choices and physical activities as well as willingness to change behaviors among Mexican-American and Mexican immigrant mothers and fathers of school-aged children. Twelve sex-specific focus groups were held in English or Spanish in 2012. Qualitative analysis informed by grounded theory examined parenting styles (ie, authoritative, authoritarian, or permissive), barriers to healthy lifestyle, and parents' stage of change about healthy lifestyles. One third of the 33 participating couples were born in Mexico. The majority of mothers and fathers described being permissive and allowing unhealthy food choices, and a minority of mothers reported more authoritarian approaches to promoting a healthier diet for their children. Mothers were more permissive than fathers about family physical activities and less engaged in these activities. Most mothers and fathers described only contemplating a healthier diet and more physical activity, while wanting their children to have a healthier lifestyle. These data suggest that clinicians need to assess and address differential parental roles when promoting a healthy lifestyle for children. Clinicians should also adopt culturally competent approaches to overcome barriers to parental engagement in diverse aspects of a healthy family lifestyle. C1 [Turner, Barbara J.] ReACH Ctr, San Antonio, TX 78229 USA. [Turner, Barbara J.] Univ Texas Hlth Sci Ctr San Antonio, Univ Texas Sch Publ Hlth, San Antonio, TX USA. [Navuluri, Nee Lima] South Cent Area Hlth Educ Ctr, San Antonio, TX USA. [Vale, Shruthi] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Finley, Erin] South Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Finley, Erin] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. RP Turner, BJ (reprint author), ReACH Ctr, One Technol Ctr,411 John Smith Rd,Suite 1050, San Antonio, TX 78229 USA. EM turner@uthscsa.e_du OI Finley, Erin/0000-0003-4497-7721 FU National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative (QUERI) FX E. Finley is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work, Washington University in St Louis through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative (QUERI). NR 21 TC 5 Z9 5 U1 1 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 EI 2212-2680 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD APR PY 2014 VL 114 IS 4 BP 562 EP 569 DI 10.1016/j.jand.2013.12.010 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AE6DT UT WOS:000334081500009 PM 24529984 ER PT J AU Mullur, R Liu, YY Brent, GA AF Mullur, Rashmi Liu, Yan-Yun Brent, Gregory A. TI THYROID HORMONE REGULATION OF METABOLISM SO PHYSIOLOGICAL REVIEWS LA English DT Review ID BROWN ADIPOSE-TISSUE; THYROTROPIN-RELEASING-HORMONE; ACTIVATED PROTEIN-KINASE; TYPE-2 IODOTHYRONINE DEIODINASE; RECEPTOR-ALPHA GENE; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; RESTING ENERGY-EXPENDITURE; COLD-INDUCED THERMOGENESIS; MESSENGER-RNA EXPRESSION AB Thyroid hormone (TH) is required for normal development as well as regulating metabolism in the adult. The thyroid hormone receptor (TR) isoforms, alpha and beta, are differentially expressed in tissues and have distinct roles in TH signaling. Local activation of thyroxine (T-4), to the active form, triiodothyronine (T-3), by 5'-deiodinase type 2 (D2) is a key mechanism of TH regulation of metabolism. D2 is expressed in the hypothalamus, white fat, brown adipose tissue (BAT), and skeletal muscle and is required for adaptive thermogenesis. The thyroid gland is regulated by thyrotropin releasing hormone (TRH) and thyroid stimulating hormone (TSH). In addition to TRH/TSH regulation by TH feedback, there is central modulation by nutritional signals, such as leptin, as well as peptides regulating appetite. The nutrient status of the cell provides feedback on TH signaling pathways through epigentic modification of histones. Integration of TH signaling with the adrenergic nervous system occurs peripherally, in liver, white fat, and BAT, but also centrally, in the hypothalamus. TR regulates cholesterol and carbohydrate metabolism through direct actions on gene expression as well as cross-talk with other nuclear receptors, including peroxisome proliferator-activated receptor (PPAR), liver X receptor (LXR), and bile acid signaling pathways. TH modulates hepatic insulin sensitivity, especially important for the suppression of hepatic gluconeogenesis. The role of TH in regulating metabolic pathways has led to several new therapeutic targets for metabolic disorders. Understanding the mechanisms and interactions of the various TH signaling pathways in metabolism will improve our likelihood of identifying effective and selective targets. C1 [Brent, Gregory A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. RP Brent, GA (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu FU Veterans Affairs Merit Review Funds; National Institute of Diabetes and Digestive and Kidney Diseases Grant [RO1 DK98576] FX This work was supported by Veterans Affairs Merit Review Funds and National Institute of Diabetes and Digestive and Kidney Diseases Grant RO1 DK98576. NR 284 TC 145 Z9 150 U1 16 U2 102 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0031-9333 EI 1522-1210 J9 PHYSIOL REV JI Physiol. Rev. PD APR PY 2014 VL 94 IS 2 BP 355 EP 382 DI 10.1152/physrev.00030.2013 PG 28 WC Physiology SC Physiology GA AF2YD UT WOS:000334577500002 PM 24692351 ER PT J AU Amore, M Innamorati, M Di Vittorio, C Weinberg, I Turecki, G Sher, L Paris, J Girardi, P Pompili, M AF Amore, Mario Innamorati, Marco Di Vittorio, Cristina Weinberg, Igor Turecki, Gustavo Sher, Leo Paris, Joel Girardi, Paolo Pompili, Maurizio TI Suicide Attempts in Major Depressed Patients with Personality Disorder SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID NEUROPSYCHIATRIC INTERVIEW MINI; II COMPARISON SUBJECTS; IOWA RECORD-LINKAGE; DSM-IV PERSONALITY; TOWER-OF-BABEL; BORDERLINE PERSONALITY; FOLLOW-UP; MENTAL-DISORDERS; FUNCTIONAL IMPAIRMENT; RISK-FACTORS AB Suicide attempters who met criteria for borderline personality disorder (BPD) comorbid with major depressive disorder (MDD) were compared to both suicide attempters suffering from MDD alone and to attempters with comorbid MDD and other personality disorders (PD). Participants were 239 (158 patients with comorbid PD and 81 patients with MDD without comorbidity) inpatients consecutively admitted after a suicide attempt made in the last 24hours. Suicide attempters with comorbid MDD and BPD had more frequent previous suicide attempts and were more likely to have a history of aggressive behaviors and alcohol and drug use disorders compared with patients suffering from MDD without Axis II comorbidity. C1 [Amore, Mario] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Sect Psychiat, Genoa, Italy. [Innamorati, Marco; Di Vittorio, Cristina] Univ Parma, Div Psychiat, Dept Neurosci, I-43100 Parma, Italy. [Weinberg, Igor] Harvard Univ, Sch Med, McLean Hosp, Boston, MA USA. [Turecki, Gustavo; Paris, Joel] McGill Univ, Dept Psychiat, Montreal, PQ, Canada. [Sher, Leo] James J Peters VA Med Ctr, New York, NY USA. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. [Girardi, Paolo; Pompili, Maurizio] Univ Roma La Sapienza, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, I-00185 Rome, Italy. RP Pompili, M (reprint author), St Andrea Hosp, Dept Psychiat, Via Grottarossa,Rome 1035, Rome, Italy. EM maurizio.pompili@uniroma1.it OI Pompili, Maurizio/0000-0003-1886-4977 NR 68 TC 4 Z9 4 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD APR PY 2014 VL 44 IS 2 BP 155 EP 166 DI 10.1111/sltb.12059 PG 12 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA AE9RO UT WOS:000334346700004 PM 24138208 ER PT J AU Basu, PP Aloysius, MM Shah, NJ Brown, RS AF Basu, P. P. Aloysius, M. M. Shah, N. J. Brown, R. S., Jr. TI Review article: the endocannabinoid system in liver disease, a potential therapeutic target SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Review ID HEPATIC ISCHEMIA/REPERFUSION INJURY; CANNABINOID CB2 RECEPTORS; ALCOHOLIC FATTY LIVER; AMP-ACTIVATED KINASE; MOLECULAR CHARACTERIZATION; ENDOGENOUS CANNABINOIDS; METABOLIC SYNDROME; NONALCOHOLIC STEATOHEPATITIS; AUTOIMMUNE HEPATITIS; STELLATE CELLS AB Background Endocannabinoids are a family of potent lipid-soluble molecules, acting on the cannabinoid (CB) receptors that mediate the effects of marijuana. The CB receptors, endocannabinoids and the enzymes involved in their synthesis and degradation are located in the brain and peripheral tissues, including the liver. Aims To review the current understanding of the role of the endocannabinoid system in liver disease-associated pathophysiological conditions, and drugs targeting the endocannabinoid system as therapy for liver disease. Methods Original articles and reviews were used to summarise the relevant pre-clinical and clinical research findings relating to this topic. Results The endocannabinoid system as a whole plays an important role in liver diseases (i.e. non-alcoholic liver disease, alcoholic liver disease, hepatic encephalopathy and autoimmune hepatitis) and related pathophysiological conditions (i.e. altered hepatic haemodynamics, cirrhotic cardiomyopathy, metabolic syndrome and ischaemia/reperfusion disease). Pharmacological targeting of the endocannabinoid system has had success as treatment for patients with liver disease, but adverse events led to withdrawal of marketing approval. However, there is optimism over novel therapeutics targeting the endocannabinoid system currently in the pre-clinical stage of development. Conclusions The endocannabinoid system plays an important role in the pathophysiology of liver disease and its associated conditions. While some drugs targeting the endocannabinoid system have deleterious neurological adverse events, there is promise for a newer generation of therapies that do not cross the blood-brain barrier. C1 [Basu, P. P.] Columbia Univ, Med Ctr, Div Digest & Liver Dis, New York, NY 10027 USA. [Basu, P. P.] Columbia Univ, Med Ctr, Ctr Liver Dis & Transplantat, New York, NY 10027 USA. [Aloysius, M. M.; Brown, R. S., Jr.] Kings Cty Hosp, Med Ctr, Brooklyn, NY 11203 USA. [Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA. RP Aloysius, MM (reprint author), Kings Cty Hosp, Med Ctr, 451 Clarkson Ave, Brooklyn, NY 11203 USA. EM mark.aloysius5@gmail.com NR 90 TC 9 Z9 10 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD APR PY 2014 VL 39 IS 8 BP 790 EP 801 DI 10.1111/apt.12673 PG 12 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA AC8PO UT WOS:000332796200005 PM 24612021 ER PT J AU Bartel, AP Beaulieu, ND Phibbs, CS Stone, PW AF Bartel, Ann P. Beaulieu, Nancy D. Phibbs, Ciaran S. Stone, Patricia W. TI Human Capital and Productivity in a Team Environment: Evidence from the Healthcare Sector SO AMERICAN ECONOMIC JOURNAL-APPLIED ECONOMICS LA English DT Article ID PATIENT OUTCOMES; HOSPITALS; QUALITY; PERFORMANCE; IMPACT; WORK AB Using panel data from a large hospital system, this paper presents estimates of the productivity effects of human capital in a team production environment. Proxying nurses' general human capital by education and their unit-specific human capital by experience on the nursing unit, we find that greater amounts of both types of human capital significantly improve patient outcomes. Disruptions to team functioning attributable to the departure of experienced nurses, the absorption of new hires, and the inclusion of temporary contract nurses are associated with significant decreases in productivity beyond those attributable to changes in nurses' skill and experience. C1 [Bartel, Ann P.] Columbia Business Sch, New York, NY 10027 USA. [Bartel, Ann P.] NBER, New York, NY 10027 USA. [Beaulieu, Nancy D.; Phibbs, Ciaran S.] US Dept Vet Affairs, Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA. [Beaulieu, Nancy D.; Phibbs, Ciaran S.] Stanford Univ, Sch Med, Hlth Econ Resource Ctr, Vet Affairs Med Ctr, Menlo Pk, CA 94025 USA. [Stone, Patricia W.] Columbia Univ, Sch Nursing, New York, NY 10032 USA. RP Bartel, AP (reprint author), Columbia Business Sch, 623 Uris Hall,3022 Broadway, New York, NY 10027 USA. EM apb2@columbia.edu; ndbeaulieu@gmail.com; cphibbs@stanford.edu; ps2024@columbia.edu NR 28 TC 12 Z9 12 U1 4 U2 19 PU AMER ECONOMIC ASSOC PI NASHVILLE PA 2014 BROADWAY, STE 305, NASHVILLE, TN 37203 USA SN 1945-7782 EI 1945-7790 J9 AM ECON J-APPL ECON JI Am. Econ. J.-Appl. Econ. PD APR PY 2014 VL 6 IS 2 BP 231 EP 259 DI 10.1257/app.6.2.231 PG 29 WC Economics SC Business & Economics GA AE4UL UT WOS:000333980000010 ER PT J AU Reddy, AK Jogendra, MRD Rosendorff, C AF Reddy, Arun K. Jogendra, Mather R. D. Rosendorff, Clive TI Blood pressure measurement in the geriatric population SO BLOOD PRESSURE MONITORING LA English DT Review DE orthostatic hypotension; ambulatory blood pressure monitoring; geriatric; blood pressure; elderly; home blood pressure monitoring; pseudohypertension; blood pressure variability; blood pressure measurement ID ISOLATED SYSTOLIC HYPERTENSION; AMERICAN-HEART-ASSOCIATION; CROSS-SECTIONAL ANALYSIS; WHITE-COAT HYPERTENSION; ELDERLY-PATIENTS; AMBULATORY HYPERTENSION; ORTHOSTATIC HYPOTENSION; INTERNATIONAL DATABASE; CARDIOVASCULAR EVENTS; MASKED HYPERTENSION AB As the population above 60 years of age is the fastest growing and hypertension is highly prevalent in this group, accurate blood pressure (BP) measurement in the elderly is a very important and widely applicable subject. As with any other population, an accurate measurement of BP is essential to plan therapy and this remains an important consideration in the elderly as well. There are some unique problems of BP measurement in the elderly, including drug-induced orthostatic hypotension, white-coat hypertension, and advanced atherosclerotic disease with stiff arteries. For clinical use, home blood pressure monitoring (HBPM), office measurement, and ambulatory blood pressure monitoring all play a role in patient management. In the office setting, aneroid devices, hybrid devices with electronic transducers, and oscillometric devices are available; all of these require frequent calibration, well-trained operators and technically sound execution. Because the white-coat effect is common in this group, there is a good case for the use of HBPM, which could also be used to detect orthostatic changes at home. Also, HBPM predicts cardiovascular events better than clinical BP, and is also useful in monitoring treatment. Ambulatory blood pressure monitoring provides the most precise assessment of BP over an extended period, but is more complex and expensive. Finally, the utility of noninvasive central arterial pressure through radial artery applanation tonometry, especially in patients with resistant hypertension and likely in the elderly because of advanced atherosclerotic disease and stiff arteries, may prove to be a useful tool to guide or modify drug therapy in the future and requires further study. C1 [Reddy, Arun K.; Jogendra, Mather R. D.; Rosendorff, Clive] Mt Sinai Heart, Icahn Sch Med Mt Sinai, New York, NY USA. [Reddy, Arun K.; Jogendra, Mather R. D.; Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 67 TC 1 Z9 1 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1359-5237 EI 1473-5725 J9 BLOOD PRESS MONIT JI Blood Press. Monit. PD APR PY 2014 VL 19 IS 2 BP 59 EP 63 DI 10.1097/MBP.0000000000000021 PG 5 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AD1ZJ UT WOS:000333031900001 PM 24621822 ER PT J AU Rogus-Pulia, NM Pierce, MC Mittal, BB Zecker, SG Logemann, JA AF Rogus-Pulia, Nicole M. Pierce, Margaret C. Mittal, Bharat B. Zecker, Steven G. Logemann, Jeri A. TI Changes in Swallowing Physiology and Patient Perception of Swallowing Function Following Chemoradiation for Head and Neck Cancer SO DYSPHAGIA LA English DT Article DE Deglutition; Deglutition disorders; Dysphagia; Chemoradiation; Head and neck cancer; Perception; Swallow efficiency ID QUALITY-OF-LIFE; RADIATION-THERAPY; SJOGRENS-SYNDROME; DYSPHAGIA; PERFORMANCE; XEROSTOMIA; VIDEOFLUOROSCOPY; RADIOTHERAPY; ASPIRATION; AWARENESS AB Patients treated with chemoradiation for head and neck cancer often report difficulty with swallowing and are frequently diagnosed with dysphagia. The extent to which patient awareness of dysphagia corresponds to observed physiologic changes in swallowing is unclear. The purpose of this study was to determine how both patient awareness of swallowing function and swallowing physiology individually change following chemoradiation and then to clarify the relationship between them. Twenty-one patients with head and neck cancer treated with chemoradiation were assessed before and after treatment and matched with twenty-one control subjects. The modified barium swallow test was utilized to examine swallowing physiology. Each subject was also given a series of items regarding awareness of specific dysphagia symptoms. Results showed decreased swallow efficiencies, higher percentages of residue, and more occurrences of penetration and aspiration following chemoradiation. Patients also had significantly higher ratings for 4 of the 12 items ("dry mouth," "food sticking in my mouth," "need water to help food go down," and "change in sense of taste"). Only one strong and significant correlation was found between ratings for "I have difficulty swallowing" and swallow efficiency values. Based on these findings, it appears that patients sense a general difficulty with swallowing but have less awareness of specific symptoms of dysphagia. C1 [Rogus-Pulia, Nicole M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Rogus-Pulia, Nicole M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Speech Swallowing & Dining Enhancement Program, Madison, WI USA. [Pierce, Margaret C.] NW Mem Hosp, Chicago, IL 60611 USA. [Mittal, Bharat B.] Northwestern Univ, Dept Radiat Oncol, Feinberg Sch Med, Chicago, IL 60611 USA. [Zecker, Steven G.; Logemann, Jeri A.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60208 USA. RP Rogus-Pulia, NM (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Madison GRECC 11G,Room, Madison, WI 53705 USA. EM Nicole.Pulia@va.gov NR 43 TC 12 Z9 12 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X EI 1432-0460 J9 DYSPHAGIA JI Dysphagia PD APR PY 2014 VL 29 IS 2 BP 223 EP 233 DI 10.1007/s00455-013-9500-y PG 11 WC Otorhinolaryngology SC Otorhinolaryngology GA AE6SS UT WOS:000334125800005 PM 24402239 ER PT J AU Labarere, J Bertrand, R Fine, MJ AF Labarere, Jose Bertrand, Renaud Fine, Michael J. TI How to derive and validate clinical prediction models for use in intensive care medicine SO INTENSIVE CARE MEDICINE LA English DT Article DE Clinical prediction models; Clinical decision rule; Prognosis; Severity of illness index; Intensive care ID COMMUNITY-ACQUIRED PNEUMONIA; LOGISTIC-REGRESSION ANALYSIS; CLUSTER RANDOMIZED-TRIALS; MISSING OUTCOME DATA; EXTERNAL VALIDATION; PROGNOSTIC MODELS; METHODOLOGICAL STANDARDS; INTERNAL VALIDATION; EARLY ADMISSION; CRITICALLY-ILL AB Clinical prediction models are formal combinations of historical, physical examination and laboratory or radiographic test data elements designed to accurately estimate the probability that a specific illness is present (diagnostic model), will respond to a form of treatment (therapeutic model) or will have a well-defined outcome (prognostic model) in an individual patient. They are derived and validated using empirical data and used to assist physicians in their clinical decision-making that requires a quantitative assessment of diagnostic, therapeutic or prognostic probabilities at the bedside. To provide intensivists with a comprehensive overview of the empirical development and testing phases that a clinical prediction model must satisfy before its implementation into clinical practice. The development of a clinical prediction model encompasses three consecutive phases, namely derivation, (external) validation and impact analysis. The derivation phase consists of building a multivariable model, estimating its apparent predictive performance in terms of both calibration and discrimination, and assessing the potential for statistical over-fitting using internal validation techniques (i.e. split-sampling, cross-validation or bootstrapping). External validation consists of testing the predictive performance of a model by assessing its calibration and discrimination in different but plausibly related patients. Impact analysis involves comparative research [i.e. (cluster) randomized trials] to determine whether clinical use of a prediction model affects physician practices, patient outcomes or the cost of healthcare delivery. This narrative review introduces a checklist of 19 items designed to help intensivists develop and transparently report valid clinical prediction models. C1 [Labarere, Jose] Univ Hosp, Qual Care Unit, F-38043 Grenoble, France. [Labarere, Jose] Univ Grenoble 1, TIMC UMR CNRS 5525, Grenoble, France. [Bertrand, Renaud] Cochin Hosp, Emergency Dept, AP HP, Paris, France. [Bertrand, Renaud] Hop Hotel Dieu, Emergency Dept, AP HP, F-75181 Paris, France. [Bertrand, Renaud] Fac Med Paris Descartes, Paris, France. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Vet Affairs Ctr Hlth Equ & Res Promot, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh Med Ctr, Div Gen Internal Med, Pittsburgh, PA USA. [Labarere, Jose] UQEM, F-38043 Grenoble 9, France. RP Labarere, J (reprint author), UQEM, Pavillon Taillefer,CHU BP217, F-38043 Grenoble 9, France. EM JLabarere@chu-grenoble.fr RI Labarere, Jose/N-1688-2014 OI Labarere, Jose/0000-0001-7621-6586 NR 64 TC 28 Z9 28 U1 1 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD APR PY 2014 VL 40 IS 4 BP 513 EP 527 DI 10.1007/s00134-014-3227-6 PG 15 WC Critical Care Medicine SC General & Internal Medicine GA AE6BW UT WOS:000334074400005 PM 24570265 ER PT J AU Boehme, AK Kapoor, N Albright, KC Lyerly, MJ Rawal, PV Shahripour, RB Alvi, M Houston, JT Sisson, A Beasley, TM Alexandrov, AW Alexandrov, AV Miller, DW AF Boehme, Amelia K. Kapoor, Niren Albright, Karen C. Lyerly, Michael J. Rawal, Pawan V. Shahripour, Reza Bavarsad Alvi, Muhammad Houston, J. Thomas Sisson, April Beasley, T. Mark Alexandrov, Anne W. Alexandrov, Andrei V. Miller, David W. TI Predictors of Systemic Inflammatory Response Syndrome in Ischemic Stroke Undergoing Systemic Thrombolysis with Intravenous Tissue Plasminogen Activator SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Thrombolysis; systemic inflammatory response syndrome; stroke outcome; inflammation ID MEDICINE CONSENSUS CONFERENCE; CHEST-PHYSICIANS SOCIETY; AMERICAN-COLLEGE; LDL RECEPTOR; SEVERITY; DEFINITIONS; OUTCOMES; SEPSIS; RISK AB Background: Systemic inflammatory response syndrome (SIRS) is an inflammatory process associated with poor outcomes in acute ischemic stroke (AIS) patients. However, no study to date has investigated predictors of SIRS in AIS patients treated with intravenous (IV) tissue plasminogen activator (tPA). Methods: Consecutive patients were retrospectively reviewed for evidence of SIRS during their acute hospitalization. SIRS was defined as the presence of 2 or more of the following: (1) body temperature less than 36 degrees C or greater than 38 degrees C, (2) heart rate greater than 90, (3) respiratory rate greater than 20, or (4) white blood cell count less than 4000/mm or greater than 12,000/mm or more than 10% bands for more than 24 hours. Those diagnosed with an infection were excluded. A scoring system was created to predict SIRS based on patient characteristics available at the time of admission. Logistic regression was used to evaluate potential predictors of SIRS using a sensitivity cutoff of >= 65% or area under the curve of .6 or more. Results: Of 212 patients, 44 had evidence of SIRS (21%). Patients with SIRS were more likely to be black (61% versus 54%; P - .011), have lower median total cholesterol at baseline (143 versus 167 mg/dL; P = .0207), and have history of previous stroke (51% versus 35%; P = .0810). Ranging from 0 to 6, the SIRS prediction score consists of African American (2 points), history of hypertension (1 point), history of previous stroke (1 point), and admission total cholesterol less than 200 (2 points). Patients with an SIRS score of 4 or more were 3 times as likely to develop SIRS when compared with patients with a score of <= 3 (odds ratio = 2.815, 95% confidence interval 1.43-5.56, P = .0029). Conclusions: In our sample of IV tPA-treated AIS patients, clinical and laboratory characteristics available on presentation were able to identify patients likely to develop SIRS during their acute hospitalization. Validation is required in other populations. If validated, this score could assist providers in predicting who will develop SIRS after treatment with IV tPA. C1 [Boehme, Amelia K.; Albright, Karen C.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Kapoor, Niren; Lyerly, Michael J.; Rawal, Pawan V.; Shahripour, Reza Bavarsad; Alvi, Muhammad; Houston, J. Thomas; Sisson, April; Alexandrov, Anne W.; Alexandrov, Andrei V.] Univ Alabama Birmingham, Dept Neurol, Stroke Ctr, Birmingham, AL 35294 USA. [Albright, Karen C.] Hlth Serv & Outcomes Res Ctr Outcome & Effectiven, Birmingham, AL USA. [Albright, Karen C.] Ctr Excellence Comparat Effectiveness Res Elimina, Minor Hlth & Hlth Dispar Res Ctr, Birmingham, AL USA. [Lyerly, Michael J.] Birmingham VA Med Ctr, Stroke Ctr, Birmingham, AL USA. [Beasley, T. Mark] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Alexandrov, Anne W.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL 35294 USA. [Miller, David W.] Univ Alabama Birmingham, Sch Med, Dept Anesthesiol, Birmingham, AL 35294 USA. RP Miller, DW (reprint author), Univ Alabama Birmingham, Sch Med, Dept Anesthesiol, Jefferson Tower 922, Birmingham, AL 35294 USA. EM dwmiller@uab.edu OI Alexandrov, Andrei V/0000-0001-8871-1023; Lyerly, Michael/0000-0003-4236-1018 FU Agency for Healthcare Research and Quality [5 T32 HS013852-10]; National Institute on Minority Health and Health Disparities, National Institutes of Health [3 P60 MD000502-08S1]; American Heart Association [13PRE13830003] FX The project described was supported by award numbers 5 T32 HS013852-10 from the Agency for Healthcare Research and Quality, 3 P60 MD000502-08S1 from the National Institute on Minority Health and Health Disparities, National Institutes of Health and 13PRE13830003 from the American Heart Association. NR 21 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD APR PY 2014 VL 23 IS 4 BP E271 EP E276 DI 10.1016/j.jstrokecerebrovasdis.2013.11.022 PG 6 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AE2OV UT WOS:000333813700005 PM 24424334 ER PT J AU Duong, TQ AF Duong, Timothy Q. TI Magnetic Resonance Imaging of the Retina: From Mice to Men SO MAGNETIC RESONANCE IN MEDICINE LA English DT Review DE BOLD; choroid; blood flow; blood volume; contrast-enhanced MRI; manganese-enhanced MRI; diabetic retinopathy; glaucoma; retinal degeneration; age-related macular degeneration; ocular imaging; optical imaging; eye motion; BOLD fMRI; visual stimulation ID MANGANESE-ENHANCED MRI; BLOOD-FLOW MRI; EXPERIMENTAL DIABETIC-RETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY; DBA/2J MOUSE MODEL; IN-VIVO; OXYGENATION RESPONSE; FUNCTIONAL MRI; RAT RETINA; VASCULAR LAYERS AB This mini-review provides an overview of magnetic resonance imaging (MRI) applications to study rodent, cat, non-human primate, and human retinas. These techniques include T-1- and T-2-weighted anatomical, diffusion, blood flow, blood volume, blood-oxygenation level dependent, manganese-enhanced, physiological, and functional MRI. Applications to study the retinas in diabetic retinopathy, glaucoma, and retinal degeneration are also reviewed. MRI offers some unique advantages compared with existing imaging techniques and has the potential to further our understanding of physiology and function in healthy and diseased retinas. Magn Reson Med 71:1526-1530, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, South Texas Vet Hlth Care Syst, Dept Ophthalmol, San Antonio, TX 78229 USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu FU NIH/NEI [EY014211, EY018855]; CA MERIT FX Grant sponsor: NIH/NEI; Grant numbers: EY014211, EY018855; Grant sponsor: CA MERIT. NR 56 TC 6 Z9 6 U1 0 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0740-3194 EI 1522-2594 J9 MAGN RESON MED JI Magn. Reson. Med. PD APR PY 2014 VL 71 IS 4 BP 1526 EP 1530 DI 10.1002/mrm.24797 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AD2CL UT WOS:000333040500019 PM 23716429 ER PT J AU Driver, TH Loh, AR Joseph, D Keenan, JD Naseri, A AF Driver, Todd H. Loh, Allison R. Joseph, Damien Keenan, Jeremy D. Naseri, Ayman TI Predictors of Matching in Ophthalmology Residency for International Medical Graduates SO OPHTHALMOLOGY LA English DT Editorial Material C1 [Driver, Todd H.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Loh, Allison R.; Keenan, Jeremy D.; Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. [Joseph, Damien] San Francisco Match Program, San Francisco, CA USA. [Keenan, Jeremy D.; Naseri, Ayman] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA. [Naseri, Ayman] San Francisco Vet Adm Med Ctr, Dept Ophthalmol, San Francisco, CA USA. RP Driver, TH (reprint author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. NR 5 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD APR PY 2014 VL 121 IS 4 BP 974 EP + PG 7 WC Ophthalmology SC Ophthalmology GA AE2MV UT WOS:000333808100033 PM 24433973 ER PT J AU Quinones, AR Richardson, J Freeman, M Fu, R O'Neil, ME Motu'apuaka, M Kansagara, D AF Quinones, Ana R. Richardson, Jeannette Freeman, Michele Fu, Rochelle O'Neil, Maya E. Motu'apuaka, Makalapua Kansagara, Devan TI Educational group visits for the management of chronic health conditions: A systematic review SO PATIENT EDUCATION AND COUNSELING LA English DT Review DE Group visits; Chronic disease; Health education; Chronic disease self-management ID RANDOMIZED-CONTROLLED-TRIAL; DIABETES SELF-MANAGEMENT; OBSTRUCTIVE PULMONARY-DISEASE; COGNITIVE-BEHAVIORAL THERAPY; CENTERED MEDICAL HOME; RHEUMATOID-ARTHRITIS; MEXICAN-AMERICANS; OLDER-ADULTS; PRIMARY-CARE; PATIENT EDUCATION AB Objective: Review the effectiveness of group visits (appointments of multiple patients) on quality of life, function, self-efficacy, utilization, and biophysical outcomes in randomized controlled trials of patients with chronic conditions. Methods: We searched MEDLINE (R), Cochrane, CINAHL, and PsycINFO to January 2013 for English-language trials of educational group visits led by non-prescribing facilitators (e.g., peer educators). Results: We report on 80 arthritis/falls (n = 22), asthma/COPD (n = 10), CHF/hypertension (n = 12), diabetes (n = 29), multiple conditions (n = 4), and pain (n = 4) studies. We found moderate evidence of improved short-term self-efficacy in patients with arthritis (10 studies) and diabetes (10 studies). We found no consistent evidence of improved quality of life; however a moderately strong body of evidence suggests peer-led community-based programs might improve quality of life and utilization in patients with multiple chronic conditions. Meta-analyses found short- (14 studies; mean change HbA1c = -0.27, CI = -0.44, 0.11) and long-term (10 studies; mean change HbA1c = -0.23, Cl = -0.44, -0.02) glycemic improvement. Conclusions: Group visits may improve self-efficacy and glycemic control. There was little consistent evidence of improved quality of life, functional status, or utilization. Practice implications: Group visits represent a reasonable alternative for educating patients with chronic illness, though varied participation/retention suggests they should not be the sole alternative. Published by Elsevier Ireland Ltd. C1 [Quinones, Ana R.; Richardson, Jeannette; Freeman, Michele; Fu, Rochelle; O'Neil, Maya E.; Motu'apuaka, Makalapua; Kansagara, Devan] Portland VA Med Ctr, Portland, OR USA. [Quinones, Ana R.; Fu, Rochelle; O'Neil, Maya E.; Kansagara, Devan] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Quinones, AR (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA. EM quinones@ohsu.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Evidence-based Synthesis Program (ESP) [05-225]; American Diabetes Association [7-13-CD-08] FX Funders: The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Evidence-based Synthesis Program (ESP) project #05-225. Dr. Quinones is a Health Science Specialist at the Portland VA Medical Center. Dr. Quinones is also supported by American Diabetes Association Grant 7-13-CD-08. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs nor the American Diabetes Association. NR 107 TC 6 Z9 6 U1 8 U2 26 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD APR PY 2014 VL 95 IS 1 BP 3 EP 29 DI 10.1016/j.pec.2013.12.021 PG 27 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA AE6GJ UT WOS:000334088300002 PM 24468199 ER PT J AU An, CR Shi, YJ Li, PY Hu, XM Gan, Y Stetler, RA Leak, RK Gao, YQ Sun, BL Zheng, P Chen, J AF An, Chengrui Shi, Yeije Li, Peiying Hu, Xiaoming Gan, Yu Stetler, Ruth A. Leak, Rehana K. Gao, Yanqin Sun, Bao-Liang Zheng, Ping Chen, Jun TI Molecular dialogs between the ischemic brain and the peripheral immune system: Dualistic roles in injury and repair SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE Cerebral ischemic injury; Innate immunity; Inflammation; Brain repair ID FOCAL CEREBRAL-ISCHEMIA; REGULATORY T-CELLS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INTERCELLULAR-ADHESION MOLECULE-1; MYELIN BASIC-PROTEIN; NEURAL STEM-CELLS; CHOLINERGIC ANTIINFLAMMATORY PATHWAY AB Immune and inflammatory responses actively modulate the pathophysiological processes of acute brain injuries such as stroke. Soon after the onset of stroke, signals such as brain-derived antigens, danger-associated molecular patterns (DAMPs), cytokines, and chemokines are released from the injured brain into the systemic circulation. The injured brain also communicates with peripheral organs through the parasympathetic and sympathetic branches of the autonomic nervous system. Many of these diverse signals not only activate resident immune cells in the brain, but also trigger robust immune responses in the periphery. Peripheral immune cells then migrate toward the site of injury and release additional cytokines, chemokines, and other molecules, causing further disruptive or protective effects in the ischemic brain. Bidirectional communication between the injured brain and the peripheral immune system is now known to regulate the progression of stroke pathology as well as tissue repair. In the end, this exquisitely coordinated crosstalk helps determine the fate of animals after stroke. This article reviews the literature on ischemic brain-derived signals through which peripheral immune responses are triggered, and the potential impact of these peripheral responses on brain injury and repair. Pharmacological strategies and cell-based therapies that target the dialog between the brain and peripheral immune system show promise as potential novel treatments for stroke. Published by Elsevier Ltd. C1 [An, Chengrui; Shi, Yeije; Li, Peiying; Hu, Xiaoming; Gan, Yu; Stetler, Ruth A.; Gao, Yanqin; Zheng, Ping; Chen, Jun] Fudan Univ, State Key Laboratoty Med Neurobiol, Shanghai 200032, Peoples R China. [An, Chengrui; Shi, Yeije; Li, Peiying; Hu, Xiaoming; Gan, Yu; Stetler, Ruth A.; Gao, Yanqin; Zheng, Ping; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Sun, Bao-Liang] Taishan Med Univ, Affiliated Hosp, Dept Neurol, Key Lab Cerebral Microcirculat Univ Shandong, Tai An 271000, Shandong, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Shi, Yeije; Li, Peiying; Hu, Xiaoming; Gan, Yu; Stetler, Ruth A.; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Shi, Yeije; Hu, Xiaoming; Stetler, Ruth A.; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. RP Chen, J (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15260 USA. EM blsun88@163.com; pzheng@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417; Shi, Yejie/0000-0001-7502-9201 FU NIH [NS036736, NS045048, NS056118]; AHA grant [13SDG14570025]; Chinese Natural Science Foundation [81271275, 81070947, 30770759, 81020108021, 81171149, 81228008]; Natural Science Foundation of Shandong [ZR2012HZ006]; Department of Veterans Affairs; RK Mellon Endowed Chair for Cerebrovascular Disease Research from the University of Pittsburgh Medical Center FX This work was supported by NIH grants NS036736, NS045048, and NS056118 (to J.C.), AHA grant 13SDG14570025 (to X.H.), Chinese Natural Science Foundation grants (81271275, 81070947 and 30770759 to B-L Sun; 81020108021 and 81171149 to Y.G.; and 81228008 to J.C. and P.Z.), Natural Science Foundation of Shandong grant ZR2012HZ006 (to B-L Sun). J.C. is a recipient of the Research Career Scientist Award from Department of Veterans Affairs and the RK Mellon Endowed Chair for Cerebrovascular Disease Research from the University of Pittsburgh Medical Center. We thank Dr. Beth Fischer for editorial assistance. NR 262 TC 50 Z9 52 U1 6 U2 43 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD APR PY 2014 VL 115 SI SI BP 6 EP 24 DI 10.1016/j.pneurobio.2013.12.002 PG 19 WC Neurosciences SC Neurosciences & Neurology GA AE6ET UT WOS:000334084100002 PM 24374228 ER PT J AU Leng, TD Shi, YJ Xiong, ZG Sun, DD AF Leng, Tiandong Shi, Yejie Xiong, Zhi-Gang Sun, Dandan TI Proton-sensitive cation channels and ion exchangers in ischemic brain injury: New therapeutic targets for stroke? SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE Acidosis; ASIC; Calcium; NHE1; TRPM7; Zinc ID FOCAL CEREBRAL-ISCHEMIA; POTENTIAL MELASTATIN 7; SODIUM-HYDROGEN EXCHANGE; MOUSE CORTICAL-NEURONS; CENTRAL-NERVOUS-SYSTEM; ACID-EVOKED CURRENTS; UNCONDITIONED FEAR RESPONSES; ARTERY OCCLUSION MODEL; EXCITATORY AMINO-ACIDS; CANCER CELL-MIGRATION AB Ischemic brain injury results from complicated cellular mechanisms. The present therapy for acute ischemic stroke is limited to thrombolysis with the recombinant tissue plasminogen activator (rtPA) and mechanical recanalization. Therefore, a better understanding of ischemic brain injury is needed for the development of more effective therapies. Disruption of ionic homeostasis plays an important role in cell death following cerebral ischemia. Glutamate receptor-mediated ionic imbalance and neurotoxicity have been well established in cerebral ischemia after stroke. However, non-NMDA receptor-dependent mechanisms, involving acid-sensing ion channel 1 a (ASIC1a), transient receptor potential melastatin 7 (TRPM7), and Na+/H+ exchanger isoform 1 (NHE1), have recently emerged as important players in the dysregulation of ionic homeostasis in the CNS under ischemic conditions. These H+-sensitive channels and/or exchangers are expressed in the majority of cell types of the neurovascular unit. Sustained activation of these proteins causes excessive influx of cations, such as Ca2+, Na+, and Zn2+, and leads to ischemic reperfusion brain injury. In this review, we summarize recent pre-clinical experimental research findings on how these channels/exchangers are regulated in both in vitro and in vivo models of cerebral ischemia. The blockade or transgenic knockdown of these proteins was shown to be neuroprotective in these ischemia models. Taken together, these non-NMDA receptor-dependent mechanisms may serve as novel therapeutic targets for stroke intervention. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Leng, Tiandong; Xiong, Zhi-Gang] Morehouse Sch Med, Inst Neurosci, Atlanta, GA 30310 USA. [Shi, Yejie; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA. RP Sun, DD (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, S-598 South Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA. EM zxiong@msm.edu; sund@upmc.edu OI Shi, Yejie/0000-0001-7502-9201 FU NIH [R01-NS48216, R01-NS38118, R01-NS66027]; NIMHD [S21-MD000101, U54NS083932]; ALZ [IIRG-10-173350] FX This work was supported by the NIH grants R01-NS48216 and R01-NS38118 (D. Sun), NIH R01-NS66027, NIMHD S21-MD000101, U54NS083932, and ALZ IIRG-10-173350 (Z. Xiong). NR 357 TC 26 Z9 27 U1 3 U2 32 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD APR PY 2014 VL 115 SI SI BP 189 EP 209 DI 10.1016/j.pneurobio.2013.12.008 PG 21 WC Neurosciences SC Neurosciences & Neurology GA AE6ET UT WOS:000334084100010 PM 24467911 ER PT J AU Merlin, JS Walcott, MM Herbey, I Chamot, E Ritchie, C Saag, MS Kertesz, S AF Merlin, Jessica S. Walcott, Melonie M. Herbey, Ivan Chamot, Eric Ritchie, Christine Saag, Michael S. Kertesz, Stefan TI Qualitative Investigation of a Brief Chronic Pain Screening Tool in HIV-Infected Patients SO AIDS PATIENT CARE AND STDS LA English DT Article ID ANTIRETROVIRAL THERAPY; GENERAL-POPULATION; REPORTED OUTCOMES; SYMPTOMS; CARE; PREVALENCE; QUESTIONNAIRE; VALIDATION; ADHERENCE; TAXONOMY AB Chronic pain in HIV-infected patients is prevalent but understudied. A limitation of HIV/chronic pain research to date is the lack of a widely used chronic pain screening tool. A Brief Chronic Pain Screening tool (BCPS) has been described, but has not yet been tested in a clinical population. This study sought to evaluate how the BCPS is experienced by HIV-infected individuals, and adapt its questions if necessary. We conducted cognitive interviews using cognitive inquiry in participants from the UAB 1917 HIV Clinic Cohort. Data were analyzed using a process of inductive, iterative coding by three investigators. Results: Of 30 participants, most were male, African American, and less than 50 years old. Participants reported that the questions were understandable; however, feedback suggested concerns regarding lack of specificity in regard to the intensity and consistency of pain. An introductory statement aimed at improving clarity resulted in more divergent responses. This research team concluded that the version of the BCPS used in the first 30 interviews was optimum. Its inclusive language allows the respondent to decide what pain merits reporting. This study is the first investigation of the BCPS in a clinical population, and should lead to further quantitative validation studies of this tool. C1 [Merlin, Jessica S.; Walcott, Melonie M.; Herbey, Ivan; Saag, Michael S.] Univ Alabama Birmingham, Sch Publ Hlth, Div Infect Dis, Birmingham, AL 35294 USA. [Merlin, Jessica S.] Univ Alabama Birmingham, Sch Publ Hlth, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Kertesz, Stefan] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Kertesz, Stefan] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Chamot, Eric] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Ritchie, Christine] Univ Calif San Francisco, Dept Med, Div Geriatr, Jewish Home San Francisco Ctr Res Aging, San Francisco, CA USA. RP Merlin, JS (reprint author), BBRB 222 1530 3rd Ave South, Birmingham, AL 35294 USA. EM jmerlin@uab.edu FU University of Alabama at Birmingham (UAB) Center for AIDS Research CFAR; NIH [P30 A1027767]; NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; FIC; OAR; AHRQ [1K12HS02169401]; NIA [7K07AG031779]; Mary Fisher CARE Fund at UAB FX This research was supported by the University of Alabama at Birmingham (UAB) Center for AIDS Research CFAR, an NIH funded program (P30 A1027767) that was made possible by the following institutes: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR. JSM is supported by 1K12HS02169401 (AHRQ). CSR is supported by 7K07AG031779 (NIA). Funding was also provided by the Mary Fisher CARE Fund at UAB. NR 34 TC 5 Z9 5 U1 0 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD APR 1 PY 2014 VL 28 IS 4 BP 176 EP 182 DI 10.1089/apc.2014.0006 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AE1WY UT WOS:000333764700003 PM 24621145 ER PT J AU Grubbs, V Lin, F Vittinghoff, E Shlipak, MG Peralta, CA Bansal, N Jacobs, DR Siscovick, DS Lewis, CE Bibbins-Domingo, K AF Grubbs, Vanessa Lin, Feng Vittinghoff, Eric Shlipak, Michael G. Peralta, Carmen A. Bansal, Nisha Jacobs, David R. Siscovick, David S. Lewis, Cora E. Bibbins-Domingo, Kirsten TI Body Mass Index and Early Kidney Function Decline in Young Adults: A Longitudinal Analysis of the CARDIA (Coronary Artery Risk Development in Young Adults) Study SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Kidney function decline; obesity; risk factor ID GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; RENAL-FUNCTION; ALBUMIN EXCRETION; BARIATRIC SURGERY; OBESE-PATIENTS; OLDER-ADULTS; WEIGHT-LOSS; CREATININE; DISEASE AB Background: Identifying potentially modifiable risk factors is critically important for reducing the burden of chronic kidney disease. We sought to examine the association of body mass index (BMI) with kidney function decline in a cohort of young adults with preserved glomerular filtration at baseline. Study Design: Longitudinal cohort. Setting & Participants: 2,839 black and white young adults with cystatin C-based estimated glomerular filtration rate (eGFR(cys)). > 90 mL/min/1.73 m(2) taking part in the year-10 examination (in 1995-1996) of the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Predictor: BMI, categorized as 18.5-24.9 (reference), 25.0-29.9, 30.0-39.9, and 40.0 kg/m(2). Outcomes: Trajectory of kidney function decline, rapid decline (>3% per year), and incident eGFR(cys) < 60 mL/min/1.73 m(2) over 10 years of follow-up. Measurements: GFR(cys) estimated from the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation for calibrated cystatin C at CARDIA years 10, 15, and 20. Results: At year 10, participants had a mean age of 35.1 years, median eGFRcys of 114 mL/min/1.73 m(2), and 24.5% had BMI 30.0 kg/m(2). After age 30 years, average eGFR(cys) was progressively lower with each increment in BMI after adjustment for baseline age, race, sex, hyperlipidemia, smoking status, and physical activity. Higher BMI category was associated with successively higher odds of rapid decline (for 25.0-29.9, 30.0-39.9, and $ 40.0 kg/m(2), adjusted ORs were 1.50 [95% CI, 1.21-1.87], 2.01 [95% CI, 1.57-2.87], and 2.57 [95% CI, 1.67-3.94], respectively). 18 participants (0.6%) had incident eGFR(cys) < 60 mL/min/1.73 m(2). In unadjusted analysis, higher BMI category was associated with incident eGFR(cys) < 60 mL/min/1.73 m (2) (for 25.0-29.9, 30.0-39.9, and 40.0 kg/m(2), ORs were 5.17 [95% CI, 1.10-25.38], 7.44 [95% CI, 1.54-35.95], and 5.55 [95% CI, 0.50-61.81], respectively); adjusted associations were no longer significant. Limitations: Inability to describe kidney function before differences by BMI category were already evident. Absence of data for measured GFR or GFR estimated from serum creatinine level. Conclusions: Higher BMI categories are associated with greater declines in kidney function in a cohort of young adults with preserved GFR at baseline. Clinicians should vigilantly monitor overweight and obese patients for evidence of early kidney function decline. (C) 2014 by the National Kidney Foundation, Inc. C1 [Grubbs, Vanessa; Lin, Feng; Vittinghoff, Eric; Peralta, Carmen A.; Bansal, Nisha; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94110 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Jacobs, David R.] Univ Minnesota, Minneapolis, MN USA. [Siscovick, David S.] Univ Washington, Seattle, WA 98195 USA. [Lewis, Cora E.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA. RP Grubbs, V (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Nephrol, Renal Ctr, Box 1341,1001 Potrero Ave,Bldg 100,Rm 342, San Francisco, CA 94110 USA. EM grubbsv@medsfgh.ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [1K23DK093710-01A1]; Robert Wood Johnson Foundation; NIDDK [R01DK078124, P30-DK092924]; National Heart, Lung and Blood Institute (NHLBI) [N01HC48050]; Center for Health and Risk in Minority Youth and Adults (CHARM); National Institute on Minority Health and Health Disparities, Comprehensive Centers of Excellence [1P60MD006902]; National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through UCSF-CTSI [KL2 TR000143]; NHLBI [HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN26820-1300028C, HHSN268201300029C, HHSN268200900041C]; Intramural Research Program of the National Institute on Aging FX Dr Grubbs was supported by grant 1K23DK093710-01A1 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Dr Bibbins-Domingo was supported in part by grant R01DK078124 from the NIDDK, grant N01HC48050 from the National Heart, Lung and Blood Institute (NHLBI), and from the Center for Health and Risk in Minority Youth and Adults (CHARM) grant 1P60MD006902 from the National Institute on Minority Health and Health Disparities, Comprehensive Centers of Excellence, and from grant P30-DK092924 from the NIDDK. This project was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through UCSF-CTSI grant KL2 TR000143. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The CARDIA Study is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN26820-1300028C, HHSN268201300029C, and HHSN268200900041C from the NHLBI and the Intramural Research Program of the National Institute on Aging. The manuscript was reviewed by CARDIA for scientific content prior to submission. NR 37 TC 18 Z9 18 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2014 VL 63 IS 4 BP 590 EP 597 DI 10.1053/j.ajkd.2013.10.055 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AD7GB UT WOS:000333429500013 PM 24295611 ER PT J AU Stewart, T Liu, CQ Ginghina, C Cain, KC Auinger, P Cholerton, B Shi, M Zhang, J AF Stewart, Tessandra Liu, Changqin Ginghina, Carmen Cain, Kevin C. Auinger, Peggy Cholerton, Brenna Shi, Min Zhang, Jing CA Parkinson Study Grp DATATOP Invest TI Cerebrospinal Fluid alpha-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID CORTICAL LEWY BODIES; ALZHEIMERS-DISEASE; DEMENTIA; CSF; IMPAIRMENT; LEVODOPA; MODEL; TRANSPORTERS; ASSOCIATION; DEFICITS AB Most patients with Parkinson disease (PD) develop both cognitive and motor impairment, and biomarkers for progression are urgently needed. Although alpha-synuclein is altered in cerebrospinal fluid of patients with PD, it is not known whether it predicts motor or cognitive deterioration. We examined clinical data and alpha-synuclein in >300 unmedicated patients with PD who participated in the deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP) study, with up to 8 years of follow-up. Longitudinal measures of motor and cognitive function were studied before (phase 1) and during (phase 2) levodopa therapy; cerebrospinal fluid was collected at the beginning of each phase. Correlations and linear mixed models were used to assess alpha-synuclein association with disease severity and prediction of progression in the subsequent follow-up period. Despite decreasing cc-synuclein (phase 1 to phase 2 change of -0.05 +/- 0.21 log-transformed values, P < 0.001), no correlations were observed between alpha-synuclein and motor symptoms. Longitudinally, lower alpha-synuclein predicted better preservation of cognitive function by several measures [Selective Reminding Test total recall alpha-synuclein x time interaction effect coefficient, -0.12 (P = 0.037); delayed recall, -0.05 (P = 0.002); New Dot Test, -0.03 (P = 0.002)]. Thus, alpha-synuclein, although not clinically useful for motor progression, might predict cognitive decline, and future longitudinal studies should include this outcome for further validation. C1 [Stewart, Tessandra; Liu, Changqin; Ginghina, Carmen; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Cholerton, Brenna] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Liu, Changqin] Xiamen Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Xiamen, Peoples R China. [Liu, Changqin] Xiamen Univ, Affiliated Hosp 1, Xiamen Diabet Inst, Xiamen, Peoples R China. [Cain, Kevin C.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98104 USA. [Auinger, Peggy] Univ Rochester, Sch Med & Dent, Dept Neurol, Ctr Human Expt Therapeut, Rochester, NY 14642 USA. [Cholerton, Brenna] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, Harborview Med Ctr Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU Michael J. Fox Foundation; Parkinson Study Group; NTH grants [NIEHS T32ES015459, AG033398, ES004696-5897, ES007033-6364, ES016873, ES019277, NS057567, NS060252, NS062684-6221, NS082137] FX This work was supported by the Michael J. Fox Foundation, the Parkinson Study Group, and NTH grants NIEHS T32ES015459 (T.S.) and AG033398, ES004696-5897, ES007033-6364, ES016873, ES019277, NS057567, NS060252, NS062684-6221, and NS082137 (J.Z.). NR 41 TC 37 Z9 38 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 2014 VL 184 IS 4 BP 966 EP 975 DI 10.1016/j.ajpath.2013.12.007 PG 10 WC Pathology SC Pathology GA AD8XI UT WOS:000333548600009 PM 24625392 ER PT J AU Wang, HZ Melton, DW Porter, L Sarwar, ZU McManus, LM Shireman, PK AF Wang, Hanzhou Melton, David W. Porter, Laurel Sarwar, Zaheer U. McManus, Linda M. Shireman, Paula K. TI Altered Macrophage Phenotype Transition Impairs Skeletal Muscle Regeneration SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID IN-VIVO; FIBRO/ADIPOGENIC PROGENITORS; MONONUCLEAR PHAGOCYTES; INFLAMMATORY MONOCYTES; CELLS CONTRIBUTE; EPITHELIAL-CELLS; DIPHTHERIA-TOXIN; GENE-EXPRESSION; DENDRITIC CELLS; TISSUE-REPAIR AB Monocyte/macrophage polarization in skeletal muscle regeneration is ill defined. We used CD11b-diphtheria toxin receptor transgenic mice to transiently deplete monocytes/macrophages at multiple stages before and after muscle injury induced by cardiotoxin. Fat accumulation within regenerated muscle was maximal when ablation occurred at the same time as cardiotoxin-induced injury. Early ablation (day 1 after cardiotoxin) resulted in the smallest regenerated myofiber size together with increased residual necrotic myofibers and fat accumulation. However, muscle regeneration after late (day 4) ablation was similar to controls. Levels of inflammatory cells in injured muscle following early ablation and associated with impaired muscle regeneration were determined by flow cytometry. Delayed, but exaggerated, monocyte [CD11b(+)(CD90/B220/CD49b/NK1.1/Ly6G)(-)(F4/80/I-Ab/CD11c)(-)Ly6C(+/-)] accumulation occurred; interestingly, Ly6C(+) and Ly6C(-) monocytes were present concurrently in ablated animals and control mice. In addition to monocytes, proinflammatory, Ly6C(+) macrophage accumulation following early ablation was delayed compared to controls. In both groups, CD11b(+)F4/80(+) cells exhibited minimal expression of the M2 markers CD206 and CD301. Nevertheless, early ablation delayed and decreased the transient accumulation of CD11b(+)F4/80(+)Ly6C(-)CD301(-) macrophages; in control animals, the later tissue accumulation of these cells appeared to correspond to that of anti-inflammatory macrophages, determined by cytokine production and arginase activity. In summary, impairments in muscle regeneration were associated with exaggerated monocyte recruitment and reduced Ly6C(-) macrophages; the switch of macrophage/monocyte subsets is critical to muscle regeneration. C1 [Wang, Hanzhou; Melton, David W.; Porter, Laurel; Sarwar, Zaheer U.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Melton, David W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Melton, David W.; McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Shireman, Paula K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU NIH NHLBI grants [R01 HL074236, F30 HL110743]; NIH NCATS grant [UL1TR001120]; NIH NCI grant [P30 CA054174]; Veterans Administration Merit Review grant [1I01BX001186] FX Supported by NIH NHLBI grants R01 HL074236 and F30 HL110743, NIH NCATS grant UL1TR001120, NIH NCI grant P30 CA054174 [to the Core Flow Cytometry Facility (Cancer Therapy & Research Center) of the University of Texas Health Science Center, San Antonio] and Veterans Administration Merit Review grant 1I01BX001186. NR 93 TC 31 Z9 32 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 2014 VL 184 IS 4 BP 1167 EP 1184 DI 10.1016/j.ajpath.2013.12.020 PG 18 WC Pathology SC Pathology GA AD8XI UT WOS:000333548600027 PM 24525152 ER PT J AU Psoter, KJ Roudsari, BS Dighe, MK Richardson, ML Katz, DS Bhargava, P AF Psoter, Kevin J. Roudsari, Bahman S. Dighe, Manjiri K. Richardson, Michael L. Katz, Douglas S. Bhargava, Puneet TI Biostatistics Primer for the Radiologist SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE data analysis; medical statistics; regression analysis; statistical education; statistical tests ID CLINICAL-RESEARCH; STATISTICAL-ANALYSIS; CT; CONTRAST; FUNDAMENTALS; MAMMOGRAPHY; PERFORMANCE; AGREEMENT; CANCER; TRAUMA AB OBJECTIVE. The purpose of this article is to review the most common data analysis methods encountered in radiology-based studies. Initially, description of variable types and their corresponding summary measures are provided; subsequent discussion focuses on comparison of these summary measures between groups, with a particular emphasis on regression analysis. CONCLUSION. Knowledge of statistical applications is critical for radiologists to accurately evaluate the current literature and to conduct scientifically rigorous studies. Misapplication of statistical methods can lead to inappropriate conclusions and clinical recommendations. C1 [Psoter, Kevin J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Roudsari, Bahman S.; Dighe, Manjiri K.; Richardson, Michael L.; Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Roudsari, Bahman S.] Univ Washington, Comparat Effectiveness Cost & Outcomes Res Ctr, Seattle, WA 98195 USA. [Richardson, Michael L.] Roosevelt Radiol, Seattle, WA USA. [Katz, Douglas S.] Winthrop Univ Hosp, Dept Radiol, Mineola, NY 11501 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Roudsari, BS (reprint author), Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM roudsari@u.washington.edu OI Bhargava, Puneet/0000-0002-3849-9666 FU National Institutes of Health [R01-AA017497] FX Supported by grant R01-AA017497 from the National Institutes of Health. NR 56 TC 1 Z9 1 U1 0 U2 9 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD APR PY 2014 VL 202 IS 4 BP W365 EP W375 DI 10.2214/AJR.13.11657 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AD7OU UT WOS:000333454300007 PM 24660735 ER PT J AU Hartung, DM Zarin, DA Guise, JM McDonagh, M Paynter, R Helfand, M AF Hartung, Daniel M. Zarin, Deborah A. Guise, Jeanne-Marie McDonagh, Marian Paynter, Robin Helfand, Mark TI Reporting Discrepancies Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIALS; BONE MORPHOGENETIC PROTEIN-2; CLINICAL-TRIALS; OUTCOMES; DISSEMINATION; ISSUES AB Background: ClinicalTrials.gov requires reporting of result summaries for many drug and device trials. Purpose: To evaluate the consistency of reporting of trials that are registered in the ClinicalTrials.gov results database and published in the literature. Data Sources: ClinicalTrials.gov results database and matched publications identified through ClinicalTrials.gov and a manual search of 2 electronic databases. Study Selection: 10% random sample of phase 3 or 4 trials with results in the ClinicalTrials.gov results database, completed before 1 January 2009, with 2 or more groups. Data Extraction: One reviewer extracted data about trial design and results from the results database and matching publications. A subsample was independently verified. Data Synthesis: Of 110 trials with results, most were industry-sponsored, parallel-design drug studies. The most common inconsistency was the number of secondary outcome measures reported (80%). Sixteen trials (15%) reported the primary outcome description inconsistently, and 22 (20%) reported the primary outcome value inconsistently. Thirty-eight trials inconsistently reported the number of individuals with a serious adverse event (SAE); of these, 33 (87%) reported more SAEs in ClinicalTrials.gov. Among the 84 trials that reported SAEs in ClinicalTrials.gov, 11 publications did not mention SAEs, 5 reported them as zero or not occurring, and 21 reported a different number of SAEs. Among 29 trials that reported deaths in ClinicalTrials.gov, 28% differed from the matched publication. Limitation: Small sample that included earliest results posted to the database. Conclusion: Reporting discrepancies between the ClinicalTrials.gov results database and matching publications are common. Which source contains the more accurate account of results is unclear, although ClinicalTrials.gov may provide a more comprehensive description of adverse events than the publication. C1 Oregon Hlth & Sci Univ, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. Natl Lib Med, Bethesda, MD USA. RP Hartung, DM (reprint author), Oregon Hlth & Sci Univ, Coll Pharm, Oregon State Univ, 3303 SW Bond Ave,CH12C, Portland, OR 97239 USA. EM hartungd@ohsu.edu OI Paynter, Robin/0000-0002-6969-4261 FU National Library of Medicine [HHSN 276-2009-00128P]; Agency for Healthcare Research and Quality [K12HS019456]; Agency for Healthcare Research and Quality career development award [K12 HS019456]; intramural research program of the National Library of Medicine FX By contract HHSN 276-2009-00128P from the National Library of Medicine and grant K12HS019456 from the Agency for Healthcare Research and Quality. Dr. Hartung received support from an Agency for Healthcare Research and Quality career development award (K12 HS019456). Dr. Zarin was funded by the intramural research program of the National Library of Medicine. NR 18 TC 40 Z9 40 U1 0 U2 10 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 1 PY 2014 VL 160 IS 7 BP 477 EP + DI 10.7326/M13-0480 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA AE6IL UT WOS:000334093800005 PM 24687070 ER PT J AU Li, J Dufrene, SL Okulicz, JF AF Li, Julius Dufrene, Staci L. Okulicz, Jason F. TI Systemic Preexposure Prophylaxis for HIV: Translating Clinical Data to Clinical Practice SO ANNALS OF PHARMACOTHERAPY LA English DT Review DE human immunodeficiency virus; HIV; preexposure prophylaxis; prevention; tenofovir; emtricitabine ID TENOFOVIR DISOPROXIL FUMARATE; ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; INTERMITTENT PROPHYLAXIS; POSTEXPOSURE PROPHYLAXIS; SERODISCORDANT COUPLES; COST-EFFECTIVENESS; ORAL PREEXPOSURE; INTERIM GUIDANCE; RISK BEHAVIOR AB Objective: To assess the real-world implications of oral tenofovir emtricitabine (TDF-FTC) for HIV preexposure prophylaxis (PrEP) in clinical practice and highlight important considerations for its implementation. Data Sources: A search of PubMed (January 1996 through June 2013) was conducted using the terms HIV preexposure prophylaxis, HIV prevention, tenofovir, and emtricitabine. Abstracts from 2012-2013 HIV/AIDS conferences were also reviewed. Study Selection and Data Extraction: All pertinent original studies and review articles published in English were evaluated for inclusion. Reference citations from identified articles were examined for additional content. Data Synthesis: Although antiretroviral therapy has been highly successful in reducing AIDS outcomes and death in HIV-infected patients worldwide, transmission of HIV remains a major global health problem. The recent approval of oral TDF-FTC for HIV PrEP represents the latest biomedical intervention to help control this epidemic. Four published randomized studies evaluated the efficacy and safety of this combination to prevent HIV transmission in several at-risk populations, including men who have sex with men, serodiscordant couples, and heterosexuals residing in endemic regions. Overall, these studies demonstrated significant risk reductions in the incidence of new HIV infections with good short-term tolerability. Despite promising results from clinical studies, several limitations may hinder the utility of PrEP in clinical practice. Most importantly, PrEP was studied in the context of a comprehensive prevention program, including intensive counseling on adherence, high-risk behaviors, and traditional preventative measures. If PrEP is implemented without these adjunct measures, concerns about failure and increased resistance may eventually be realized. Conclusion: The greatest impact of PrEP, both clinically and financially, will likely arise from judicious application in select high-risk populations. If used appropriately, PrEP has the potential to augment reductions in the current incidence of new HIV infections, and pharmacists will have an important role in the careful selection and counseling of these targeted populations. C1 [Li, Julius; Dufrene, Staci L.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Okulicz, Jason F.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA. RP Okulicz, JF (reprint author), San Antonio Mil Med Ctr, Infect Dis Serv, HIV Med Educ Unit, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM jason.f.okulicz.mil@mail.mil NR 78 TC 0 Z9 0 U1 2 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD APR PY 2014 VL 48 IS 4 BP 507 EP 518 DI 10.1177/1060028014520880 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AD8IP UT WOS:000333510000010 PM 24473492 ER PT J AU Eschenauer, GA Nguyen, MH Shoham, S Vazquez, JA Morris, AJ Pasculle, WA Kubin, CJ Klinker, KP Carver, PL Hanson, KE Chen, S Lam, SW Potoski, BA Clarke, LG Shields, RK Clancy, CJ AF Eschenauer, Gregory A. Nguyen, M. Hong Shoham, Shmuel Vazquez, Jose A. Morris, Arthur J. Pasculle, William A. Kubin, Christine J. Klinker, Kenneth P. Carver, Peggy L. Hanson, Kimberly E. Chen, Sharon Lam, Simon W. Potoski, Brian A. Clarke, Lloyd G. Shields, Ryan K. Clancy, Cornelius J. TI Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID MINIMUM INHIBITORY CONCENTRATIONS; EUCAST TECHNICAL NOTE; INVASIVE CANDIDIASIS; ANTIFUNGAL AGENTS; CASPOFUNGIN MICS; GLABRATA; ANIDULAFUNGIN; BREAKPOINTS; RESISTANCE; CLSI AB Reference broth microdilution methods of Candida echinocandin susceptibility testing are limited by interlaboratory variability in caspofungin MICs. Recently revised Clinical and Laboratory Standards Institute (CLSI) breakpoint MICs for echinocandin nonsusceptibility may not be valid for commercial tests employed in hospital laboratories. Indeed, there are limited echinocandin susceptibility testing data from hospital laboratories. We conducted a multicenter retrospective study of 9 U. S., Australian, and New Zealand hospitals that routinely tested Candida bloodstream isolates for echinocandin susceptibility from 2005 to 2013. Eight hospitals used Sensititre YeastOne assays. The Candida spp. were C. albicans (n = 1,067), C. glabrata (n = 911), C. parapsilosis (n = 476), C. tropicalis (n = 185), C. krusei (n = 104), and others (n = 154). Resistance and intermediate rates were <= 1.4% and <= 3%, respectively, for each echinocandin against C. albicans, C. parapsilosis, and C. tropicalis. Resistance rates among C. glabrata and C. krusei isolates were <= 7.5% and <= 5.6%, respectively. Caspofungin intermediate rates among C. glabrata and C. krusei isolates were 17.8% and 46.5%, respectively, compared to <= 4.3% and <= 4.4% for other echinocandins. Using CLSI breakpoints, 18% and 19% of C. glabrata isolates were anidulafungin susceptible/caspofungin nonsusceptible and micafungin susceptible/caspofungin nonsusceptible, respectively; similar discrepancies were observed for 38% and 39% of C. krusei isolates. If only YeastOne data were considered, interhospital modal MIC variability was low (within 2 doubling dilutions for each agent). In conclusion, YeastOne assays employed in hospitals may reduce the interlaboratory variability in caspofungin MICs against Candida species that are observed between reference laboratories using CLSI broth microdilution methods. The significance of classifying isolates as caspofungin intermediate and anidulafungin/micafungin susceptible will require clarification in future studies. C1 [Eschenauer, Gregory A.; Clarke, Lloyd G.] Univ Pittsburgh, Med Ctr, Dept Pharm, Pittsburgh, PA 15260 USA. [Eschenauer, Gregory A.; Nguyen, M. Hong; Potoski, Brian A.; Clarke, Lloyd G.; Shields, Ryan K.; Clancy, Cornelius J.] Univ Pittsburgh, Med Ctr, Antibiot Management Program, Pittsburgh, PA USA. [Nguyen, M. Hong; Shields, Ryan K.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Shoham, Shmuel] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA. [Vazquez, Jose A.] Henry Ford Hosp, Detroit, MI 48202 USA. [Morris, Arthur J.] Auckland City Hosp, Clin Microbiol Lab, Auckland, New Zealand. [Pasculle, William A.] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA. [Kubin, Christine J.] New York Presbyterian Hosp, Dept Pharm, New York, NY USA. [Klinker, Kenneth P.] UF Hlth Shands Hosp, Dept Pharm, Gainesville, FL USA. [Carver, Peggy L.] Univ Michigan, Coll Pharm, Dept Clin Social & Adm Sci, Ann Arbor, MI 48109 USA. [Carver, Peggy L.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Hanson, Kimberly E.] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Chen, Sharon] Westmead Hosp, Ctr Infect Dis & Microbiol, Westmead, NSW, Australia. [Lam, Simon W.] Cleveland Clin Fdn, Dept Pharm, Cleveland, OH 44195 USA. [Potoski, Brian A.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Clancy, Cornelius J.] VA Pittsburgh Hlth Syst, Dept Med, Pittsburgh, PA USA. RP Eschenauer, GA (reprint author), Univ Pittsburgh, Med Ctr, Dept Pharm, Pittsburgh, PA 15260 USA. EM geschena@gmail.com FU Pfizer; Merck; CSL Behring; Biotherapies for Life; Astellas; Forest; National Center for Advancing Translational Sciences of the National Institutes of Health [KL2TR000146]; Gilead Sciences; Pfizer (Australia); Astra-Zeneca FX M.H.N. has received investigator-initiated research funding from Pfizer, Merck, CSL Behring, and Biotherapies for Life. S. S. has received research funding from Pfizer, Merck, and Astellas. J.A.V. has received grant support from Forest, Pfizer, and Merck and has served on speaker bureaus for Pfizer and Astellas. R. K. S. is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR000146 and has received investigator-initiated funding from Merck and Astellas. P. L. C. has received funding from Astellas (consulting and grant support) and Merck (grant support). S. C. has served on antifungal advisory boards for Merck, Gilead Sciences, and Pfizer (Australia) and has received grant support from Merck, Gilead Sciences, and Pfizer (Australia). C.J.C. has received grant support for investigator-initiated research projects from Pfizer, Merck, and Astra-Zeneca. We have no other disclosures to report. NR 18 TC 27 Z9 28 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2014 VL 58 IS 4 BP 1897 EP 1906 DI 10.1128/AAC.02163-13 PG 10 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AD9SU UT WOS:000333605600008 PM 24395235 ER PT J AU Caplan, L Wolfe, F Michaud, K Quinzanos, I Hirsh, JM AF Caplan, Liron Wolfe, Frederick Michaud, Kaleb Quinzanos, Itziar Hirsh, Joel M. TI Strong Association of Health Literacy With Functional Status Among Rheumatoid Arthritis Patients: A Cross-Sectional Study SO ARTHRITIS CARE & RESEARCH LA English DT Article ID NATIONAL-DATA-BANK; QUALITY-OF-LIFE; WORK DISABILITY; IDENTIFY PATIENTS; DISEASE SEVERITY; OUTCOMES; ADHERENCE; SKILLS AB ObjectiveStudies linking health literacy to outcomes in rheumatoid arthritis (RA) have been underpowered and have not adequately accounted for confounders. We examined the association of health literacy with functional status in 6,052 subjects participating in a prospective observational study, controlling for numerous important covariates. MethodsUsing linear regression, we analyzed the cross-sectional association of health literacy, as measured by 2 validated single-item literacy screening questions (SILS1 and SILS2), and functional status, assessed by the Health Assessment Questionnaire (HAQ) disability index. Subjects reported demographics, comorbidities, social support, educational attainment, visual problems, and memory problems, as well as use of prednisone, disease-modifying antirheumatic drugs, and biologic agents. Each SILS measure was forced into the final model. ResultsLow health literacy was present in 7.0% and 4.3% of subjects (per SILS1 and SILS2, respectively). When controlling for all covariates, low health literacy was associated with a 0.376-point greater HAQ score, compared to subjects with adequate health literacy (95% confidence interval 0.306, 0.447; P < 0.001). This relationship persisted, even after modeling educational attainment. Results were similar for the 2 SILS instruments. Low health literacy was also associated with poorer self-reported adherence to RA medications. Visual and memory problems were associated with worse functional status. ConclusionHealth literacy was more strongly associated with functional status than prednisone use, smoking history, and biologic agent use, and independent of educational attainment. Health literacy may play an important role in understanding functional status in RA patients. Single-item questions amenable to use in the clinical setting may identify subjects with low health literacy, who are at risk for poor RA outcomes. C1 [Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. [Caplan, Liron; Quinzanos, Itziar; Hirsh, Joel M.] Univ Colorado, Sch Med, Denver, CO 80045 USA. [Wolfe, Frederick; Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Wolfe, Frederick] Univ Kansas, Sch Med, Wichita, KS 67214 USA. [Michaud, Kaleb] Univ Nebraska Med Ctr, Wichita, KS USA. [Quinzanos, Itziar; Hirsh, Joel M.] Denver Hlth Med Ctr, Denver, CO USA. RP Caplan, L (reprint author), Univ Colorado, Sch Med, POB 6511,B115, Denver, CO 80045 USA. EM liron.caplan@ucdenver.edu FU US Department of Veterans Affairs Health Services Research and Development Career Development Award [CDA 07-221, CDP 09-388] FX Dr. Caplan's work was supported by a US Department of Veterans Affairs Health Services Research and Development Career Development Award (CDA 07-221 and CDP 09-388). NR 35 TC 14 Z9 14 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD APR PY 2014 VL 66 IS 4 BP 508 EP 514 DI 10.1002/acr.22165 PG 7 WC Rheumatology SC Rheumatology GA AD6OK UT WOS:000333380400002 PM 24023051 ER PT J AU Geary, K Knaub, LA Schauer, IE Keller, AC Watson, PA Miller, MW Garat, CV Nadeau, KJ Cree-Green, M Pugazhenthi, S Regensteiner, JG Klemm, DJ Reusch, JEB AF Geary, Kate Knaub, Leslie A. Schauer, Irene E. Keller, Amy C. Watson, Peter A. Miller, Matthew W. Garat, Chrystelle V. Nadeau, Kristen J. Cree-Green, Melanie Pugazhenthi, Subbiah Regensteiner, Judith G. Klemm, Dwight J. Reusch, Jane E. B. TI Targeting mitochondria to restore failed adaptation to exercise in diabetes SO BIOCHEMICAL SOCIETY TRANSACTIONS LA English DT Article DE cAMP-response-element-binding protein (CREB); cardiovascular disease; diabetes; exercise; mitochondrion; nitric oxide synthase (NOS) ID ELEMENT-BINDING PROTEIN; SMOOTH-MUSCLE-CELLS; UPTAKE KINETIC RESPONSES; MEDIATED DOWN-REGULATION; NITRIC-OXIDE; TRANSCRIPTION FACTOR; DILATED CARDIOMYOPATHY; PEPTIDE-1 RECEPTOR; METABOLIC SYNDROME; BCL-2 PROMOTER AB Our translational research group focuses on addressing the problem of exercise defects in diabetes with basic research efforts in cell and rodent models and clinical research efforts in subjects with diabetes mellitus. CREB (cAMP-response-element-binding protein) regulates cellular differentiation of neurons, beta-cells, adipocytes and smooth muscle cells; it is also a potent survival factor and an upstream regulator of mitochondrial biogenesis. In diabetes and cardiovascular disease, CREB protein content is decreased in the vascular media, and its regulation in aberrant in beta-cells, neurons and cardiomyocytes. Loss of CREB content and function leads to decreased vascular target tissue resilience when exposed to stressors such as metabolic, oxidative or sheer stress. This basic research programme set the stage for our central hypothesis that diabetes-mediated CREB dysfunction predisposes the diabetes disease progression and cardiovascular complications. Our clinical research programme revealed that diabetes mellitus leads to defects in functional exercise capacity. Our group has determined that the defects in exercise correlate with insulin resistance, endothelial dysfunction, decreased cardiac perfusion and diastolic dysfunction, slowed muscle perfusion kinetics, decreased muscle perfusion and slowed oxidative phosphorylation. Combined basic and clinical research has defined the relationship between exercise and vascular function with particular emphasis on how the signalling to CREB and eNOS [endothelial NOS (nitric oxide synthase)] regulates tissue perfusion, mitochondrial dynamics, vascular function and exercise capacity. The present review summarizes our current working hypothesis that restoration of eNOS/NOS dysfunction will restore cellular homoeostasis and permit an optimal tissue response to an exercise training intervention. C1 [Geary, Kate; Knaub, Leslie A.; Schauer, Irene E.; Keller, Amy C.; Watson, Peter A.; Miller, Matthew W.; Garat, Chrystelle V.; Nadeau, Kristen J.; Cree-Green, Melanie; Pugazhenthi, Subbiah; Regensteiner, Judith G.; Klemm, Dwight J.; Reusch, Jane E. B.] Univ Colorado, Aurora, CO 80045 USA. [Knaub, Leslie A.; Schauer, Irene E.; Keller, Amy C.; Watson, Peter A.; Pugazhenthi, Subbiah; Reusch, Jane E. B.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. [Nadeau, Kristen J.; Cree-Green, Melanie] Childrens Hosp, Aurora, CO 80045 USA. RP Reusch, JEB (reprint author), Univ Colorado, Anschutz Med Campus,13001 E 17th Pl, Aurora, CO 80045 USA. EM jane.reusch@ucdenver.edu FU Veterans' Administration Merit Award; Denver Research Institute; National Institutes of Health [RO1-DK064741, T32HL007171, P01HL014985, UL1RR025780]; Bristol-Myers Squibb; University of Colorado Center for Women's Health Research; American Diabetes Association; American Heart Association; Juvenile Diabetes Research Foundation International FX Our work is funded by a Veterans' Administration Merit Award (Basic and Clinical), Denver Research Institute, National Institutes of Health [grant numbers RO1-DK064741, T32HL007171, P01HL014985 and UL1RR025780], Bristol-Myers Squibb, the University of Colorado Center for Women's Health Research, American Diabetes Association, American Heart Association and Juvenile Diabetes Research Foundation International. NR 49 TC 5 Z9 5 U1 1 U2 10 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0300-5127 EI 1470-8752 J9 BIOCHEM SOC T JI Biochem. Soc. Trans. PD APR PY 2014 VL 42 BP 231 EP 238 DI 10.1042/BST20130283 PN 2 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AE0LX UT WOS:000333658900002 PM 24646223 ER PT J AU Ferrario, CM Ahmad, S Nagata, S Simington, SW Varagic, J Kon, N Dell'italia, LJ AF Ferrario, Carlos Maria Ahmad, Sarfaraz Nagata, Sayaka Simington, Stephen W. Varagic, Jasmina Kon, Neal Dell'italia, Louis Joseph TI An evolving story of angiotensin-II-forming pathways in rodents and humans SO CLINICAL SCIENCE LA English DT Review DE angiotensin-(1-7); angiotensin-(1-12); angiotensin-converting enzyme (ACE); atrial fibrillation; chymase; pro-angiotensin-12; renin ID HYPOTHALAMO-NEUROHYPOPHYSEAL SYSTEM; CONVERTING ENZYME 2; MAST-CELL CHYMASE; CARDIOVASCULAR ACTIONS; BLOOD-PRESSURE; HUMAN HEART; PROANGIOTENSIN-12 PA12; VASOPRESSIN RELEASE; RECEPTOR BLOCKERS; ALTITUDE TRIAL AB Lessons learned from the characterization of the biological roles of Ang-(1-7) [angiotensin-(1-7)] in opposing the vasoconstrictor, proliferative and prothrombotic actions of Angll (angiotensin II) created an underpinning for a more comprehensive exploration of the multiple pathways by which the RAS (renin angiotensin system) of blood and tissues regulates homoeostasis and its altered state in disease processes. The present review summarizes the progress that has been made in the novel exploration of intermediate shorter forms of angiotensinogen through the characterization of the expression and functions of the dodecapeptide Ang-(1-12) [angiotensin-(1-12)] in the cardiac production of Angll. The studies reveal significant differences in humans compared with rodents regarding the enzymatic pathway by which Ang-(1-12) undergoes metabolism. Highlights of the research include the demonstration of chymase-directed formation of Angll from Ang-(1-12) in human left atrial myocytes and left ventricular tissue, the presence of robust expression of Ang-(1-12) and chymase in the atrial appendage of subjects with resistant atrial fibrillation, and the preliminary observation of significantly higher Ang-(1-12) expression in human left atrial appendages. C1 [Ferrario, Carlos Maria; Ahmad, Sarfaraz; Nagata, Sayaka; Simington, Stephen W.; Varagic, Jasmina; Kon, Neal] Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA. [Ferrario, Carlos Maria; Ahmad, Sarfaraz; Nagata, Sayaka; Simington, Stephen W.; Varagic, Jasmina; Kon, Neal] Wake Forest Univ, Bowman Gray Sch Med, Dept Cardiothorac Surg, Winston Salem, NC 27157 USA. [Varagic, Jasmina] Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC 27157 USA. [Dell'italia, Louis Joseph] Univ Alabama Birmingham, Med Ctr, Birmingham Vet Affair Med Ctr, Birmingham, AL 35294 USA. RP Ferrario, CM (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA. EM cferrari@wakehealth.edu FU National Heart, Lung and Blood Institute of the National Institutes of Health [HL-051952] FX The authors were primarily supported by the National Heart, Lung and Blood Institute of the National Institutes of Health [grant number HL-051952]. NR 95 TC 23 Z9 24 U1 0 U2 6 PU PORTLAND PRESS LTD PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND SN 0143-5221 EI 1470-8736 J9 CLIN SCI JI Clin. Sci. PD APR PY 2014 VL 126 IS 7-8 BP 461 EP 469 DI 10.1042/CS20130400 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AE1KU UT WOS:000333729000001 PM 24329563 ER PT J AU Garvey, WT Ryan, DH Henry, R Bohannon, NJV Toplak, H Schwiers, M Troupin, B Day, WW AF Garvey, W. Timothy Ryan, Donna H. Henry, Robert Bohannon, Nancy J. V. Toplak, Hermann Schwiers, Michael Troupin, Barbara Day, Wesley W. TI Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; WEIGHT-LOSS; FOLLOW-UP; CARDIOVASCULAR-DISEASE; OBESE ADULTS; RISK; OVERWEIGHT; MANAGEMENT; REDUCTION AB OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline. RESEARCH DESIGN AND METHODS Subanalysis of a phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI >= 27 to <= 45 kg/m(2)) with two or more comorbidities. Subjects were randomized to placebo, PHEN 7.5 mg/TPM ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92) plus lifestyle modifications for 108 weeks. Percent weight loss in the intent-to-treat population using multiple imputation (ITT-MI), annualized incidence rate of progression to type 2 diabetes, and changes in glycemia, lipid parameters, blood pressure, and waist circumference were evaluated. RESULTS At baseline, 475 subjects met the criteria for prediabetes and/or MetS. After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo. The ability of PHEN/TPM ER to prevent diabetes was related to degree of weight lost and was accompanied by significant improvements in cardiometabolic parameters. PHEN/TPM ER was well tolerated by this subgroup over 2 years. CONCLUSIONS PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors. C1 [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. [Ryan, Donna H.] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Henry, Robert] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Henry, Robert] San Diego VA Med Ctr, San Diego, CA USA. [Bohannon, Nancy J. V.] Monteagle Med Ctr, San Francisco, CA USA. [Toplak, Hermann] Med Univ Graz, Graz, Austria. [Schwiers, Michael] Medpace, Cincinnati, OH USA. [Troupin, Barbara; Day, Wesley W.] VIVUS Inc, Mountain View, CA USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. EM garveyt@uab.edu FU VIVUS, Inc.; Merck; Calibra Medical; Intuity Medical; Halozyme Therapeutics; Johnson Johnson; Eli Lilly and Company; Novartis; Sanofi; Valeritus Medical Solutions; Boehringer Ingelheim; Bristol-Myers Squibb; AstraZeneca; Novo Nordisk; Takeda Pharmaceutical Company FX Funding for the study and for editorial assistance was provided by VIVUS, Inc. VIVUS, Inc. was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. W.T.G. has participated in clinical trials with Merck, Weight Watchers, National Institutes of Health, the Veterans Administration, Amylin Pharmaceuticals, VIVUS, Inc., Abbott Laboratories, and Daiichi-Sankyo, Inc. He has served as an advisor, consultant, and/or speaker for Alkermes, Daiichi-Sankyo, Inc., LipoScience, VIVUS, Inc., Janssen Pharmaceuticals, Inc., and Tethys Bioscience. He is a scientific advisory board member at Daiichi-Sankyo, Inc., Tethys Bioscience, LipoScience, and Alkermes; he holds stock in Bristol-Myers Squibb, Isis/Genzyme, Merck, Pfizer, Eli Lilly and Company, and VIVUS, Inc. He has grants/grants pending with Merck, Amylin Pharmaceuticals, and Weight Watchers. He has received payment for lectures, including service on speakers' bureaus, from Merck. He has received payment from VIVUS, Inc. for consulting fee/honorarium and support for travel to meetings for the current study or for other purposes. D.H.R. has received payment from VIVUS, Inc. for consulting fee/honorarium and support for travel to meetings for the current study or for other purposes. She is a board member for Nutrisystem and Alere Wellbeing and a consultant for VIVUS, Inc., Novo Nordisk, Eisai Pharmaceuticals, Dainippon Sumitoma Pharma, and Scientific Intake. She holds stock in Scientific Intake. She has received honoraria from the Cleveland Clinic Foundation, Medical Exchange International, CME Incite, Academy of Nutrition and Dietetics, American Society of Bariatric Physicians, Continuing Education Alliance, American Heart Association, Vindico, Obesity Action Coalition, George Washington University, American Society of Bariatric Physicians, Minimally Invasive Surgery Symposium, Professional TV Network, National Institutes of Health, and the European Union Innovative Medicines Initiative. R.H. has served as a consultant and/or an advisor for Amgen, Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Inc., Elcelyx Therapeutics, Inc., Gilead Sciences, Inc., Intarcia Therapeutics, Inc., Isis Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson, Janssen Pharmaceuticals, Inc., Merck, Novo Nordisk, Roche/Genentech, Sanofi, and VIVUS, Inc. He has grants/grants pending for AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Medtronic, Inc., and Sanofi. N.J.V.B.'s institution has received payment from VIVUS, Inc. for a research grant and an investigators' meeting. N.J.V.B. has grants from Calibra Medical, Intuity Medical, Halozyme Therapeutics, Johnson & Johnson, Eli Lilly and Company, Novartis, Sanofi, and Valeritus Medical Solutions. She has received payment for lectures and consulting and advisory boards, including service on speakers' bureaus, from VIVUS, Inc., Amylin Pharmaceuticals, Bristol-Myers Squibb, Daiichi-Sankyo, Inc., Eli Lilly and Company, Johnson & Johnson, Janssen, Merck, Merck/Schering-Plough, Novartis, Quest Diagnostics, Santarus, Sanofi, and Tethys Bioscience. She holds stock in VIVUS, Inc., Eli Lilly and Company, Johnson & Johnson, Merck, Novartis, Pfizer, Santarus, and Sanofi. H.T. has received consulting fees/honoraria from VIVUS, Inc., Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Novo Nordisk, Sanofi, Takeda Pharmaceutical Company, Merck, and Novartis.; He has grants/grants pending with Merck, Takeda Pharmaceutical Company, and Novartis. He has received payment for lectures, including service on speakers' bureaus, for Merck, Takeda Pharmaceutical Company, Novartis, Novo Nordisk, and Sanofi. He has received travel/accommodations/meeting expenses from VIVUS, Inc. unrelated to the current study. M.S. was employed as the lead statistician for Medpace, the study clinical research organization, throughout the study design, execution, and analysis; he was paid for his statistical analysis of all data presented in the manuscript by VIVUS, Inc. B.T. and W.W.D. are employees of VIVUS, Inc. No other potential conflicts of interest relevant to this article were reported. NR 39 TC 38 Z9 38 U1 2 U2 11 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 2014 VL 37 IS 4 BP 912 EP 921 DI 10.2337/dc13-1518 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD7BB UT WOS:000333414700019 PM 24103901 ER PT J AU Sosenko, JM Skyler, JS Mahon, J Krischer, JP Greenbaum, CJ Rafkin, LE Beam, CA Boulware, DC Matheson, D Cuthbertson, D Herold, KC Eisenbarth, G Palmer, JP AF Sosenko, Jay M. Skyler, Jay S. Mahon, Jeffrey Krischer, Jeffrey P. Greenbaum, Carla J. Rafkin, Lisa E. Beam, Craig A. Boulware, David C. Matheson, Della Cuthbertson, David Herold, Kevan C. Eisenbarth, George Palmer, Jerry P. CA Type 1 Diabet TrialNet Study Grp Diabet Prevention Trial-Type 1 TI Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; ZINC TRANSPORTER 8; NATURAL-HISTORY; CLINICAL ONSET; RELATIVES; INSULIN; PREDICTION; AUTOANTIBODIES; TRIAL-TYPE-1; PARTICIPANTS AB OBJECTIVE We studied the utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of type 1 diabetes (T1D) risk classification in TrialNet Natural History Study (TNNHS) participants. RESEARCH DESIGN AND METHODS The cumulative incidence of T1D was compared between normoglycemic individuals with DPTRS values > 7.00 and dysglycemic individuals in the TNNHS (n = 991). It was also compared between individuals with DPTRS values < 7.00 or > 7.00 among those with dysglycemia and those with multiple autoantibodies in the TNNHS. DPTRS values > 7.00 were compared with dysglycemia for characterizing risk in Diabetes Prevention Trial-Type 1 (DPT-1) (n = 670) and TNNHS participants. The reliability of DPTRS values > 7.00 was compared with dysglycemia in the TNNHS. RESULTS The cumulative incidence of T1D for normoglycemic TNNHS participants with DPTRS values > 7.00 was comparable to those with dysglycemia. Among those with dysglycemia, the cumulative incidence was much higher (P < 0.001) for those with DPTRS values > 7.00 than for those with values < 7.00 (3-year risks: 0.16 for < 7.00 and 0.46 for > 7.00). Dysglycemic individuals in DPT-1 were at much higher risk for T1D than those with dysglycemia in the TNNHS (P < 0.001); there was no significant difference in risk between the studies among those with DPTRS values > 7.00. The proportion in the TNNHS reverting from dysglycemia to normoglycemia at the next visit was higher than the proportion reverting from DPTRS values > 7.00 to values < 7.00 (36 vs. 23%). CONCLUSIONS DPTRS thresholds can improve T1D risk classification accuracy by identifying high-risk normoglycemic and low-risk dysglycemic individuals. The 7.00 DPTRS threshold characterizes risk more consistently between populations and has greater reliability than dysglycemia. C1 [Sosenko, Jay M.; Skyler, Jay S.; Rafkin, Lisa E.; Matheson, Della] Univ Miami, Div Endocrinol, Miami, FL USA. [Mahon, Jeffrey] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON N6A 3K7, Canada. [Krischer, Jeffrey P.; Beam, Craig A.; Boulware, David C.] Univ S Florida, Div Informat & Biostat, Tampa, FL USA. [Greenbaum, Carla J.] Virginia Mason, Benaroya Res Inst, Seattle, WA USA. [Cuthbertson, David] Univ S Florida, Pediat Epidemiol Ctr, Tampa, FL USA. [Herold, Kevan C.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA. [Eisenbarth, George] Univ Colorado, Barbara Davis Ctr Childhood Diabet, Denver, CO 80202 USA. [Palmer, Jerry P.] Univ Washington, Div Endocrinol Metab & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Sosenko, JM (reprint author), Univ Miami, Div Endocrinol, Miami, FL USA. EM jsosenko@med.miami.edu RI Skyler, Jay/F-4211-2016 FU National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; Juvenile Diabetes Research Foundation International; American Diabetes Association FX This work was funded by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Center for Research Resources; the Juvenile Diabetes Research Foundation International; and the American Diabetes Association. NR 21 TC 9 Z9 9 U1 3 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 2014 VL 37 IS 4 BP 979 EP 984 DI 10.2337/dc13-2359 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD7BB UT WOS:000333414700027 PM 24550217 ER PT J AU Simonetti, JA Fine, MJ Chen, YF Simak, D Hess, R AF Simonetti, Joseph A. Fine, Michael J. Chen, Yi-Fan Simak, Deborah Hess, Rachel TI Racial Comparisons of Diabetes Care and Intermediate Outcomes in a Patient-Centered Medical Home SO DIABETES CARE LA English DT Article ID QUALITY-OF-CARE; BLOOD-PRESSURE CONTROL; RACIAL/ETHNIC DIFFERENCES; INFLUENZA VACCINATION; HEALTH LITERACY; MANAGED CARE; DISPARITIES; CONTINUITY; ETHNICITY; ADHERENCE AB OBJECTIVE To assess racial differences in diabetes processes and intermediate outcomes of care in an internal medicine, patient-centered medical home (PCMH) group practice. RESEARCH DESIGN AND METHODS We conducted a retrospective cohort study of 1,457 adults with diabetes receiving care from 89 medical providers within a PCMH-designated academic practice between 1 July 2009 and 31 July 2010. We used mixed models to assess independent associations between patient race (non-Hispanic white or black) and 1) receipt of processes of care (A1C and LDL testing, foot and retinal examination, and influenza and pneumococcal vaccination) and 2) achievement of intermediate outcomes (LDL < 100 mg/dL, blood pressure [BP] < 140/90 mmHg, A1C < 7.0% [< 53 mmol/mol], and A1C > 9.0% [> 75 mmol/mol]), controlling for sociodemographic factors, health status, treatment intensity, and clinical continuity. RESULTS Compared with non-Hispanic white patients, black patients were younger, were more often single, had lower educational attainment, and were less likely to have commercial insurance. In unadjusted analyses, fewer black patients received a retinal examination and influenza vaccination during the study period or any lifetime pneumococcal vaccination (P < 0.05 [all comparisons]). Fewer black patients achieved an LDL < 100 mg/dL, BP < 140/90 mmHg, or A1C < 7.0% (< 53 mmol/mol), while more black patients had an A1C > 9.0% (> 75 mmol/mol) (P < 0.05 [all comparisons]). In multivariable models, black patients were less likely to receive A1C testing (odds ratio [OR] 0.57 [95% CI 0.34-0.95]) or influenza vaccination (OR 0.75 [95% CI 0.57-0.99]) or to achieve an LDL < 100 mg/dL (OR 0.74 [95% CI 0.55-0.99]) or BP < 140/90 mmHg (OR 0.64 [95% CI 0.49-0.84]). CONCLUSIONS Racial differences in processes and intermediate outcomes of diabetes care were present within this PCMH-designated practice, controlling for differences in sociodemographic, clinical, and treatment factors. C1 [Simonetti, Joseph A.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. [Fine, Michael J.; Hess, Rachel] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Chen, Yi-Fan] Univ Illinois, Ctr Clin & Translat Sci, Chicago, IL USA. [Simak, Deborah] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Simonetti, JA (reprint author), Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. EM simonja@uw.edu OI simonetti, joseph/0000-0002-1092-160X FU National Institutes of Health [UL1-RR-024153, UL1-TR-000005] FX This project was supported by National Institutes of Health grants UL1-RR-024153 and UL1-TR-000005. NR 42 TC 6 Z9 6 U1 0 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 2014 VL 37 IS 4 BP 993 EP 1001 DI 10.2337/dc13-1332 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD7BB UT WOS:000333414700029 PM 24255103 ER PT J AU Goodstein, G Milanesi, A Weinreb, JE AF Goodstein, Gelsey Milanesi, Anna Weinreb, Jane E. TI Ketosis-Prone Type 2 Diabetes in a Veteran Population SO DIABETES CARE LA English DT Letter C1 [Goodstein, Gelsey] Cedars Sinai Med Ctr, Dept Internal Med, Los Angeles, CA 90048 USA. [Goodstein, Gelsey] VA Greater Los Angeles Healthcare Syst, Dept Internal Med, Los Angeles, CA USA. [Milanesi, Anna; Weinreb, Jane E.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA 90073 USA. [Milanesi, Anna; Weinreb, Jane E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA 90095 USA. RP Weinreb, JE (reprint author), VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA 90073 USA. EM jane.weinerb@va.gov FU NIDDK NIH HHS [K08 DK097295] NR 4 TC 6 Z9 7 U1 1 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 2014 VL 37 IS 4 BP E74 EP E75 DI 10.2337/dc13-2824 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD7BB UT WOS:000333414700007 PM 24652736 ER PT J AU Dubin, RF Beatty, AL Teerlink, JR Schiller, NB Bolger, AF Alokozai, D Peralta, CA Johansen, KL AF Dubin, Ruth F. Beatty, Alexis L. Teerlink, John R. Schiller, Nelson B. Bolger, Ann F. Alokozai, Dean Peralta, Carmen A. Johansen, Kirsten L. TI Determinants of hemodialysis-induced segmental wall motion abnormalities SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE Heart failure; hemodialysis; end-stage renal disease ID STAGE RENAL-DISEASE; FILLING PRESSURES; DIALYSIS PATIENTS; TROPONIN-T; ECHOCARDIOGRAPHY; ASSOCIATION; DYSFUNCTION; PREVALENCE; VALSARTAN; FAILURE AB Patients who demonstrate worsening of cardiac wall motion (WM) during hemodialysis have higher 1-year mortality. We sought to identify risk factors for dialysis-induced WM abnormalities. Additionally, we examined the effects of hemodialysis on other parameters of cardiac function. Forty patients underwent echocardiography directly before dialysis and during the last hour of dialysis (79 dialysis sessions). Candidate predictors for intradialytic worsening of WM included age, a history of heart failure (HF) or coronary artery disease, changes in blood pressure or heart rate, high sensitivity cardiac troponin T and N-terminal brain natriuretic peptide. Among 40 patients, WM worsened segmentally in eight patients (20%), worsened globally in one patient (3%), and improved segmentally in four patients (10%). Diastolic function worsened in 44% of patients, and left ventricular ejection fraction was largely unchanged during dialysis. The case of globally worsened WM occurred in the setting of intradialytic hypertension in a patient without HF. Surprisingly, history of coronary artery disease, hemodynamics, and serologic factors were not associated with worsened segmental WM during dialysis. After adjustment for history of coronary artery disease and other cardiac risk factors, patients with a history of HF had a threefold higher risk of worsening segmental WM during dialysis (RR 3.1, 95% CI [1.1, 9], p = 0.04). In conclusion, patients with a history of clinical HF were at higher risk of intradialytic worsening of segmental WM. Further studies are needed to determine the mechanism of this association and whether cardioprotective medications could ameliorate this adverse cardiac effect of hemodialysis. C1 [Dubin, Ruth F.; Peralta, Carmen A.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med Nephrol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Beatty, Alexis L.; Teerlink, John R.; Schiller, Nelson B.] Univ Calif San Francisco, Dept Med Cardiol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Bolger, Ann F.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med Cardiol, San Francisco, CA USA. [Alokozai, Dean] Cardiocore, San Francisco, CA USA. RP Dubin, RF (reprint author), San Francisco VA Med Ctr, 4150 Clement St Box 111A1, San Francisco, CA 94121 USA. EM ruth.dubin@ucsf.edu FU University of California San Francisco Academic Senate, San Francisco, CA; Research Evaluation and Allocation Committee in the University of California San Francisco, School of Medicine Dean's Office, San Francisco, CA; National Institute of Diabetes and Digestive and Kidney Diseases [1K24-DK085153-02, 1K23-DK092354-01A1]; UCSF Clinical and Translational Science Institute [UL1 TR000004] FX Funding for this project came from the following sources: 1. Individual Investigator Grant, University of California San Francisco Academic Senate, San Francisco, CA; 2. Grant Huntington Fund provided by the Research Evaluation and Allocation Committee in the University of California San Francisco, School of Medicine Dean's Office, San Francisco, CA; 3. National Institute of Diabetes and Digestive and Kidney Diseases, 1K24-DK085153-02; 4. National Institute of Diabetes and Digestive and Kidney Diseases 1K23-DK092354-01A1; 5. UCSF Clinical and Translational Science Institute Grant Number UL1 TR000004. Roche Diagnostics Corporation (Indianapolis, Indiana) supplied reagents for the hs-TnT and NT-proBNP assays, but did not provide study funding. NR 21 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1492-7535 EI 1542-4758 J9 HEMODIAL INT JI Hemodial. Int. PD APR PY 2014 VL 18 IS 2 BP 396 EP 405 DI 10.1111/hdi.12111 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA AE1QF UT WOS:000333743600006 PM 24224868 ER PT J AU Albert, TJ Swenson, ER AF Albert, Tyler J. Swenson, Erik R. TI Peripheral Chemoreceptor Responsiveness and Hypoxic Pulmonary Vasoconstriction in Humans SO HIGH ALTITUDE MEDICINE & BIOLOGY LA English DT Article DE hypoxic ventilatory response; peripheral chemoreceptor responsiveness; hypoxic pulmonary vasoconstriction ID AUTONOMIC NERVOUS-SYSTEM; PRESSURE-FLOW PLOTS; VENTILATORY RESPONSES; CONSCIOUS DOGS; BODY CHEMORECEPTORS; HIGH-ALTITUDE; RAT LUNG; STIMULATION; MODULATION; REFLEX AB Albert, Tyler J., and Erik R. Swenson. Peripheral chemoreceptor responsiveness and hypoxic pulmonary vasoconstriction in humans. High Alt Med Biol. 15:1520, 2014.Objective: Studies in animals have shown that interruption of carotid body afferent hypoxic signaling or efferent CNS activity to the lung enhances hypoxic pulmonary vasoconstriction (HPV). Whether a similar influence of the CNS on HPV strength is present in humans has never been studied, owing to the invasive nature of physical neural ablation or nonspecific systemic effects of pharmacological blockade of putative neural pathways. In order to demonstrate a peripheral chemoreceptor-mediated modulation of HPV in man, we hypothesized that individuals with high hypoxic ventilatory responsiveness, indicative of strong peripheral hypoxic chemosensitivity, should have less HPV in response to inspired hypoxia. Methods: In 15 healthy men and women, we measured the normobaric poikilocapnic hypoxic ventilatory response (HVR; L min(-1) % S(P)o(2)(-1)) during 15min of hypoxia (F(I)o(2)=0.12). On the following day, we then measured pulmonary artery systolic pressure (PASP) using echosonography while subjects randomly breathed 0.21, 0.18, 0.15, and 0.12 F(I)o(2), each for periods of 15min. We chose this strategy to obtain an equivalent stimulus for HPV in all subjects, using S(P)o(2) as a surrogate for alveolar Po-2. HPV was assessed as PASP at a common interpolated arterial oxygen saturation (S(P)o(2)) of 85%. Results: We recorded a sufficient six-fold range of HVR (0.05-0.30, mean 0.13L min(-1) % S(P)o(2)(-1)) similar to previously published data on normobaric, poikilocapnic HVR. HPV at S(P)o(2) of 85% was 28.5mmHg (range 21.7-41.3). There was a significant inverse relationship between poikilocapnic HVR and HPV (p=0.006, R-2=0.38). Discussion: Previous studies of individuals with susceptibility to high altitude pulmonary edema (HAPE) have suggested that both low HVR and high HPV are important risk factors. We show that these two responses are inversely correlated and conclude that a greater magnitude of peripheral chemoreceptor response to hypoxia limits hypoxic pulmonary vasoconstriction in healthy subjects. C1 [Albert, Tyler J.; Swenson, Erik R.] Univ Washington, Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA USA. RP Albert, TJ (reprint author), Univ Washington, Med Ctr, Div Pulm & Crit Care Med, 1959 NE Pacific St,Box 366522, Seattle, WA 98195 USA. EM talbert@uw.edu NR 40 TC 8 Z9 8 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1527-0297 EI 1557-8682 J9 HIGH ALT MED BIOL JI High Alt. Med. Biol. PD APR 1 PY 2014 VL 15 IS 1 BP 15 EP 20 DI 10.1089/ham.2013.1072 PG 6 WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences GA AD7RW UT WOS:000333464100003 PM 24444139 ER PT J AU Zhang, Z Adappa, ND Lautenbach, E Chiu, AG Doghramji, L Howland, TJ Cohen, NA Palmer, JN AF Zhang, Zi Adappa, Nithin D. Lautenbach, Ebbing Chiu, Alexander G. Doghramji, Laurel Howland, Timothy J. Cohen, Noam A. Palmer, James N. TI The effect of diabetes mellitus on chronic rhinosinusitis and sinus surgery outcome SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE diabetes mellitus; Pseudomonas aeruginosa; quality of life; chronic rhinosinusitis; infection ID GASTROESOPHAGEAL-REFLUX DISEASE; SOFT-TISSUE INFECTIONS; QUALITY-OF-LIFE; ANTIMICROBIAL RESISTANCE; NASAL POLYPS; TYPE-2 DIABETICS; ASTHMA; RISK; BACTERIOLOGY; INFLAMMATION AB Background Patients with diabetes mellitus (DM) are known to be prone to infection. However, the association between diabetes and chronic rhinosinusitis (CRS) has not been well studied. We sought to determine the effects of DM on CRS culture results and quality of life (QOL) after functional endoscopic sinus surgery (FESS). Methods We conducted a retrospective cohort study. Adult CRS patients undergoing FESS were recruited from October 1, 2007 to December 31, 2011. Patient demographics, comorbidities, medication use, and Lund-Mackay CT scores were collected prior to FESS. Intraoperative culture was obtained. Preoperative and 1-month, 3-month, and 6-month postoperative QOL was measured by scores on the 22-item Sinonasal Outcome Test (SNOT-22). A mixed effects model was performed for analysis. Results Among the 376 CRS patients included, 19 patients (5.05%) had DM. Compared to non-DM patients, DM patients were significantly more likely to have Pseudomonas aeruginosa (26.32% vs 7.56%; p= 0.004) and Gram-negative rods (26.32% vs 8.96%; p= 0.013), but there was no significant difference in the prevalence of Staphylococcus aureus; DM patients were also significantly more likely to have nasal polyps and gastroesophageal reflux disease. Additionally, DM patients had significantly less improvement of postoperative SNOT-22 scores from baseline to 6-month follow-up than non-DM patients (adjusted mean = 11.14, 95% CI (0.14, 22.15), p = 0.047) after adjusting for all the other risk factors for CRS. Conclusion DM patients may be prone to Gram-negative bacterial sinus infections, and have significantly worse short-term postoperative QOL. Special postoperative care may need to be considered in CRS patients with DM. C1 [Zhang, Zi; Lautenbach, Ebbing] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Adappa, Nithin D.; Doghramji, Laurel; Howland, Timothy J.; Cohen, Noam A.; Palmer, James N.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Lautenbach, Ebbing] Univ Penn, Dept Med, Div Infect Dis, Perelman Sch Med, Philadelphia, PA 19104 USA. [Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Zhang, Z (reprint author), 8th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM zizhang@mail.med.upenn.edu RI Chiu, Alexander/J-1230-2014 OI Chiu, Alexander/0000-0002-7592-6575; Cohen, Noam/0000-0002-9462-3932 FU National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) (NIH HHS/United States) [K24 AI080942/AI/NIAID] FX National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) (K24 AI080942/AI/NIAID NIH HHS/United States). NR 44 TC 15 Z9 15 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD APR PY 2014 VL 4 IS 4 BP 315 EP 320 DI 10.1002/alr.21269 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA AD8VA UT WOS:000333542600010 PM 24415555 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Challenges Faced by Patients in Gout Treatment SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article ID NOMINAL GROUP TECHNIQUE; GENERAL-PRACTICE; MEDICATION; CARE; ADHERENCE; BELIEFS C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Division of Rheumatology at the University of Alabama at Birmingham; Agency for Health Quality and Research Center for Education and Research on Therapeutics; National Institute of Arthritis, Musculoskeletal and Skin Diseases; National Institute of Aging; National Cancer Institute; Takeda; Savient; Regeneron; Allergan FX This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, AL. J.A.S. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics; National Institute of Arthritis, Musculoskeletal and Skin Diseases; National Institute of Aging; and National Cancer Institute.; J.A.S. has received research and travel grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron and Allergan. J.A.S. is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. NR 12 TC 8 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 EI 1536-7355 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD APR PY 2014 VL 20 IS 3 BP 172 EP 174 DI 10.1097/RHU.0000000000000091 PG 3 WC Rheumatology SC Rheumatology GA AE2MF UT WOS:000333806400013 PM 24662562 ER PT J AU Guyatt, GH Mulla, SM Scott, IA Jackevicius, CA You, JJ AF Guyatt, Gordon H. Mulla, Sohail M. Scott, Ian A. Jackevicius, Cynthia A. You, John J. TI Patient Engagement and Shared Decision-Making SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Letter C1 [Guyatt, Gordon H.; Mulla, Sohail M.; You, John J.] McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada. [Guyatt, Gordon H.; You, John J.] McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada. [Scott, Ian A.] Princess Alexandra Hosp, Dept Internal Med & Clin Epidemiol, Brisbane, Qld 4102, Australia. [Jackevicius, Cynthia A.; You, John J.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Guyatt, GH (reprint author), McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, 1200 Main St West,Room 2C12, Hamilton, ON L8N 3Z5, Canada. EM guyatt@mcmaster.ca RI Scott, Ian/F-1482-2011 NR 3 TC 1 Z9 1 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 IS 4 BP 562 EP 562 DI 10.1007/s11606-013-2727-3 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AD8RF UT WOS:000333532600007 PM 24464283 ER PT J AU Michaelidis, CI Zimmerman, RK Nowalk, MP Fine, MJ Smith, KJ AF Michaelidis, Constantinos I. Zimmerman, Richard K. Nowalk, Mary Patricia Fine, Michael J. Smith, Kenneth J. TI Cost-Effectiveness of Procalcitonin-Guided Antibiotic Therapy for Outpatient Management of Acute Respiratory Tract Infections in Adults SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE procalcitonin; antibiotics; respiratory tract infection; cost-effectiveness ID C-REACTIVE PROTEIN; UNITED-STATES; PRIMARY-CARE; RESISTANCE; COMMUNITY; IMPACT AB Two clinical trials suggest that procalcitonin-guided antibiotic therapy can safely reduce antibiotic prescribing in outpatient management of acute respiratory tract infections (ARTIs) in adults. Yet, it remains unclear whether procalcitonin testing is cost-effective in this setting. To evaluate the cost-effectiveness of procalcitonin-guided antibiotic therapy in outpatient management of ARTIs in adults. Cost-effectiveness model based on results from two published European clinical trials, with all parameters varied widely in sensitivity analyses. Two hypothetical cohorts were modeled in separate trial-based analyses: adults with ARTIs judged by their physicians to require antibiotics and all adults with ARTIs. Procalcitonin-guided antibiotic therapy protocols versus usual care. Costs and cost per antibiotic prescription safely avoided. We estimated the health care system willingness-to-pay threshold as $43 (range $0-$333) per antibiotic safely avoided, reflecting the estimated cost of antibiotic resistance per outpatient antibiotic prescribed. In the cohort including all adult ARTIs judged to require antibiotics by their physicians, procalcitonin cost $31 per antibiotic prescription safely avoided and the likelihood of procalcitonin use being favored compared to usual care was 58.4 % in a probabilistic sensitivity analysis. In the analysis that included all adult ARTIs, procalcitonin cost $149 per antibiotic prescription safely avoided and the likelihood of procalcitonin use being favored was 2.8 %. Procalcitonin-guided antibiotic therapy for outpatient management of ARTIs in adults would be cost-effective when the costs of antibiotic resistance are considered and procalcitonin testing is limited to adults with ARTIs judged by their physicians to require antibiotics. C1 [Michaelidis, Constantinos I.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia] Univ Pittsburgh, Sch Med, Dept Family Med & Clin Epidemiol, Pittsburgh, PA 15261 USA. [Fine, Michael J.; Smith, Kenneth J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15261 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Michaelidis, CI (reprint author), Univ Pittsburgh, Sch Med, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM michaelidis.constant@medstudent.pitt.edu OI Zimmerman, Richard/0000-0001-5941-6092 FU National Institute of Allergy and Infectious Diseases [R01AI076256]; National Institute of Health [AG21885]; Doris Duke Charitable Foundation FX This study was supported by the National Institute of Allergy and Infectious Diseases (Grant No. R01AI076256), the National Institute of Health (T32 Grant No. AG21885) and the Doris Duke Charitable Foundation. This study has not previously been presented in part or in full at any prior conference. NR 31 TC 13 Z9 13 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 IS 4 BP 579 EP 586 DI 10.1007/s11606-013-2679-7 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AD8RF UT WOS:000333532600010 PM 24234394 ER PT J AU Uhlig, K Leff, B Kent, D Dy, S Brunnhuber, K Burgers, JS Greenfield, S Guyatt, G High, K Leipzig, R Mulrow, C Schmader, K Schunemann, H Walter, LC Woodcock, J Boyd, CM AF Uhlig, Katrin Leff, Bruce Kent, David Dy, Sydney Brunnhuber, Klara Burgers, Jako S. Greenfield, Sheldon Guyatt, Gordon High, Kevin Leipzig, Rosanne Mulrow, Cynthia Schmader, Kenneth Schunemann, Holger Walter, Louise C. Woodcock, James Boyd, Cynthia M. TI A Framework for Crafting Clinical Practice Guidelines that are Relevant to the Care and Management of People with Multimorbidity SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE guidelines; multimorbidity; comorbidity; grading evidence ID MULTIPLE CHRONIC CONDITIONS; SERVICES TASK-FORCE; ED AMERICAN-COLLEGE; OLDER-ADULTS; HEALTH-CARE; ANTITHROMBOTIC THERAPY; RECOMMENDATIONS; QUALITY; TRIALS; GRADE AB Many patients of all ages have multiple conditions, yet clinicians often lack explicit guidance on how to approach clinical decision-making for such people. Most recommendations from clinical practice guidelines (CPGs) focus on the management of single diseases, and may be harmful or impractical for patients with multimorbidity. A major barrier to the development of guidance for people with multimorbidity stems from the fact that the evidence underlying CPGs derives from studies predominantly focused on the management of a single disease. In this paper, the investigators from the Improving Guidelines for Multimorbid Patients Study Group present consensus-based recommendations for guideline developers to make guidelines more useful for the care of people with multimorbidity. In an iterative process informed by review of key literature and experience, we drafted a list of issues and possible approaches for addressing important coexisting conditions in each step of the guideline development process, with a focus on considering relevant interactions between the conditions, their treatments and their outcomes. The recommended approaches address consideration of coexisting conditions at all major steps in CPG development, from nominating and scoping the topic, commissioning the work group, refining key questions, ranking importance of outcomes, conducting systematic reviews, assessing quality of evidence and applicability, summarizing benefits and harms, to formulating recommendations and grading their strength. The list of issues and recommendations was reviewed and refined iteratively by stakeholders. This framework acknowledges the challenges faced by CPG developers who must make complex judgments in the absence of high-quality or direct evidence. These recommendations require validation through implementation, evaluation and refinement. C1 [Uhlig, Katrin] Tufts Univ, Sch Med, Ctr Clin Evidence Synth, Tufts Med Ctr,Dept Med,Div Nephrol, Boston, MA 02111 USA. [Uhlig, Katrin] Tufts Univ, Sch Med, Ctr Clin Evidence Synth, Tufts Med Ctr,Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA. [Leff, Bruce; Boyd, Cynthia M.] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA. [Kent, David] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Leff, Bruce; Dy, Sydney; Boyd, Cynthia M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Brunnhuber, Klara] BMJ Evidence Ctr, London, England. [Burgers, Jako S.] Dutch Coll Gen Practitioners, Dept Guideline Dev & Res, Utrecht, Netherlands. [Greenfield, Sheldon] Univ Calif Irvine, Sch Med, Hlth Policy Res Inst, Irvine, CA 92717 USA. [Guyatt, Gordon; Schunemann, Holger] McMaster Univ, Hamilton, ON, Canada. [High, Kevin] Wake Forest Sch Med, Infect Dis Sect, Winston Salem, NC USA. [Leipzig, Rosanne] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Mulrow, Cynthia] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Schmader, Kenneth] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA. [Schmader, Kenneth] Durham VA Med Ctr, GRECC, Durham, NC USA. [Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Woodcock, James] Univ Cambridge, Inst Publ Hlth, UKCRC Ctr Diet & Act Res CEDAR, Cambridge, England. RP Boyd, CM (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA. EM cyboyd@jhmi.edu OI Woodcock, James/0000-0003-4769-5375 FU AHRQ [R21 HS018597-01, R21 HS017653]; Johns Hopkins Bayview Center for Innovative Medicine, The Robert Wood Johnson Foundation Physician Faculty Scholars Program; Paul Beeson Career Development Award Program [NIA K23 AG032910]; AFAR, The John A. Hartford Foundation, The Atlantic Philanthropies, The Starr Foundation; National Cancer Institute [R01 CA134425]; National Institute on Aging [K24 AG041180] FX Funding: This work was funded by AHRQ R21 HS018597-01 (PI Boyd) and AHRQ R21 HS017653. Dr. Boyd's effort was supported in part by the Johns Hopkins Bayview Center for Innovative Medicine, The Robert Wood Johnson Foundation Physician Faculty Scholars Program, and the Paul Beeson Career Development Award Program (NIA K23 AG032910, AFAR, The John A. Hartford Foundation, The Atlantic Philanthropies, The Starr Foundation, and an anonymous donor). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Walter's effort was supported by the National Cancer Institute (grant number R01 CA134425) and the National Institute on Aging (grant number K24 AG041180). NR 57 TC 31 Z9 32 U1 2 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 IS 4 BP 670 EP 679 DI 10.1007/s11606-013-2659-y PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AD8RF UT WOS:000333532600028 PM 24442332 ER PT J AU Smith, KM Chesin, MS Jeglic, EL AF Smith, Kellie M. Chesin, Megan S. Jeglic, Elizabeth L. TI Minority College Student Mental Health: Does Majority Status Matter? Implications for College Counseling Services SO JOURNAL OF MULTICULTURAL COUNSELING AND DEVELOPMENT LA English DT Article DE estudiantes universitarios de minorias; salud mental; mental health; minority college students ID DEPRESSION INVENTORY-II; BARRATT IMPULSIVENESS SCALE; AFRICAN-AMERICAN; SUICIDAL IDEATION; BINGE DRINKING; ACCULTURATIVE STRESS; NATIONAL-SURVEY; SOCIAL SUPPORT; YOUNG-ADULTS; PREVALENCE AB This study compared mental health among diverse college students to understand whether majority status buffered hypothesized relationships between poor mental health outcomes and minority status. Contrary to expectations, students at the majority-minority college (i.e., the college in which the majority of students were ethnic minorities), regardless of race or ethnicity, reported poorer mental health than their White peers at the predominantly White college. Internalizing symptoms were associated with minority race or ethnicity. These findings may inform the adaptation of college mental health services for diverse student bodies. C1 [Smith, Kellie M.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Smith, Kellie M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chesin, Megan S.; Jeglic, Elizabeth L.] CUNY John Jay Coll Criminal Justice, Dept Psychol, New York, NY 10019 USA. RP Jeglic, EL (reprint author), CUNY John Jay Coll Criminal Justice, Dept Psychol, 445 West 59th St, New York, NY 10019 USA. EM ejeglic@jjay.cuny.edu NR 89 TC 3 Z9 3 U1 4 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0883-8534 EI 2161-1912 J9 J MULTICULT COUNS D JI J. Multicult. Couns. Dev. PD APR PY 2014 VL 42 IS 2 SI SI BP 77 EP 92 DI 10.1002/j.2161-1912.2014.00046.x PG 16 WC Psychology, Applied SC Psychology GA AE1DD UT WOS:000333705700003 ER PT J AU Sadat, K Ather, S Aljaroudi, W Heo, J Iskandrian, AE Hage, FG AF Sadat, Kamel Ather, Sameer Aljaroudi, Wael Heo, Jaekyeong Iskandrian, Ami E. Hage, Fadi G. TI The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Bone marrow stem cell; myocardial perfusion imaging; single-photon emission computed tomography; cardiac magnetic resonance imaging; echocardiography; myocardial infarction; stable coronary artery disease; heart failure ID CHRONIC HEART-FAILURE; ENDOTHELIAL PROGENITOR CELLS; CHRONIC ISCHEMIC CARDIOMYOPATHY; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL; EJECTION FRACTION; DOUBLE-BLIND; INTRAMYOCARDIAL INJECTION; FOLLOW-UP; INTRACORONARY INJECTION AB Bone morrow stem cell (BMC) transfer is an emerging therapy with potential to salvage cardiomyocytes during acute myocardial infarction and promote regeneration and endogenous repair of damaged myocardium in patients with left ventricular (LV) dysfunction. We performed a meta-analysis to examine the association between administration of BMC and LV functional recovery as assessed by imaging. Our meta-analysis included data from 32 trials comprising information on 1,300 patients in the treatment arm and 1,006 patients in the control arm. Overall, BMC therapy was associated with a significant increase in LV ejection fraction by 4.6% +/- A 0.7% (P < .001) (control-adjusted increase of 2.8% +/- A 0.9%, P = .001), and a significant decrease in perfusion defect size by 9.5% +/- A 1.4% (P < .001) (control-adjusted decrease of 3.8% +/- A 1.2%, P = .002). The effect of BMC therapy was similar whether the cells were administered via intra-coronary or intra-myocardial routes and was not influenced by baseline ejection fraction or perfusion defect size. BMC transfer appears to have a positive impact on LV recovery in patients with acute coronary syndrome and those with stable coronary disease with or without heart failure. Most studies were small and a minority used a core laboratory for image analysis. C1 [Sadat, Kamel; Ather, Sameer; Heo, Jaekyeong; Iskandrian, Ami E.; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Aljaroudi, Wael] Amer Univ Beirut Med Ctr, Div Cardiovasc Dis, Beirut, Lebanon. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Sadat, K (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1900 Univ Blvd, Birmingham, AL 35294 USA. EM ksadat01@gmail.com OI ather, sameer/0000-0002-5579-0658; Hage, Fadi/0000-0002-1397-4942 NR 77 TC 10 Z9 11 U1 2 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD APR PY 2014 VL 21 IS 2 BP 351 EP 367 DI 10.1007/s12350-013-9846-4 PG 17 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AD8SL UT WOS:000333535800013 PM 24379128 ER PT J AU Buffum, MD Buccheri, RK Trygstad, LN Dowling, GA AF Buffum, Martha D. Buccheri, Robin Kay Trygstad, Louise Nigh Dowling, Glenna A. TI Disseminating an Evidence-Based Course to Teach Self-Management of Auditory Hallucinations SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES LA English DT Article ID COMMAND HALLUCINATIONS; INTERVENTION FIDELITY; BEHAVIORAL-MANAGEMENT; IMPLEMENTATION; HARM AB This multi-site project extended course dissemination of the 10-session Behavioral Management of Auditory Hallucinations Course to U. S. Department of Veterans Affairs (VA) mental health outpatient settings. The VA Quality Enhancement Research Initiative (QUERI) model and Rogers' theory of diffusion of innovations served as the theoretical framework. The course was taught to mental health professionals using teleconferencing, electronic media, and monthly conference calls across 24 VA mental health outpatient sites. Twenty course leaders provided feedback. One hundred percent reported being better able to communicate with patients about their voices and 96% reported improved understanding of the voice-hearing experience. Thirty-three course participants provided feedback. Ninety-four percent would recommend the course, 85% reported being better able to communicate with staff about their voices, and 66% reported being better able to manage their voices. Facilitators and barriers to course implementation are described. C1 [Buffum, Martha D.] San Francisco VA Med Ctr, San Francisco, CA USA. [Buffum, Martha D.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Buccheri, Robin Kay; Trygstad, Louise Nigh] Univ Calif San Francisco, Sch Nursing & Hlth Profess, San Francisco, CA 94143 USA. [Dowling, Glenna A.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA. RP Buffum, MD (reprint author), 655 Bamboo Terrace, San Rafael, CA 94903 USA. EM marti.buffum@gmail.com FU University of San Francisco Faculty Development Funds FX The authors have disclosed no potential conflicts of interest, financial or otherwise. This material is the result of work supported with resources and the use of facilities at San Francisco VA Medical Center. This project was funded in part by a grant from University of San Francisco Faculty Development Funds. NR 16 TC 2 Z9 2 U1 1 U2 5 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0279-3695 EI 1938-2413 J9 J PSYCHOSOC NURS MEN JI J. Psychosoc. Nurs. Ment. Health Serv. PD APR PY 2014 VL 52 IS 4 BP 32 EP 41 DI 10.3928/02793695-20131029-04 PG 10 WC Nursing SC Nursing GA AE1NM UT WOS:000333736100009 PM 24200916 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI COGNITIVE FUNCTION SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter ID DEMENTIA; LIFE; NUN C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] UCLA Dent Sch, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan Univ, Calif Med Ctr, Qual Assurance Hosp Dent Serv, Los Angeles, CA USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. NR 6 TC 0 Z9 0 U1 0 U2 2 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD APR PY 2014 VL 145 IS 4 BP 324 EP 327 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA AE2OG UT WOS:000333812000003 ER PT J AU Friedlander, AH El-Saden, SM Aghazadehsanai, N Chang, TI Harada, ND Garrett, NR AF Friedlander, Arthur H. El-Saden, Suzie M. Aghazadehsanai, Nona Chang, Tina I. Harada, Nancy D. Garrett, Neal R. TI Association of calcified carotid atheromas visualized on panoramic images and aortic arch calcifications seen on chest radiographs of postmenopausal women SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Atherosclerosis; panoramic radiography ID CORONARY-ARTERY CALCIFICATION; RISK-FACTORS; CARDIOVASCULAR RISK; VASCULAR-DISEASE; HEART-DISEASE; BONE LOSS; X-RAY; ATHEROSCLEROSIS; PROGRESSION; POPULATION AB Background. Occult atherosclerotic disease is the leading cause of death among older women. The authors hypothesized that women with calcified carotid artery plaque (CCAP) visualized on panoramic images were more likely to have aortic arch calcifications (AAC) that were visible on chest radiographs (CRs), a risk indicator of experiencing cardiovascular events, than would matched cohorts who did not have atheromas. Methods. The authors obtained the CRs of 36 female veterans (>= 50 years) who had CCAP and atherogenically risk-matched them to those of 36 women without CCAP. A radiologist evaluated the CRs for AAC. Other study variables included age, ethnicity, body mass index and presence or absence of hypertension, diabetes and dyslipidemia. The authors computed descriptive and bivariate statistics. Results. Women 60 years or older who had evidence of CCAP on their panoramic radiographs were significantly (P =. 022; 95 percent confidence interval, 1.29826.223) more likely to have evidence of AAC on their CRs than were similarly aged women who did not have evidence of CCAP. This association was not evident in women younger than 60 years. Among women who were both younger and older than 60 years, there was no evident association between the presence of CCAP and the severity (on a four point scale [0-3]) of AAC calcification. Conclusion. Prevalence of carotid plaque on panoramic images of women 60 years or older is significantly associated with presence of aortic arch calcifications on CRs. Practical Implications. Panoramic images of women 60 years or older must be evaluated for CCAP, given their association with AAC. Patients with atheromas should be referred to their physicians for further evaluation given the systemic implications. C1 [Friedlander, Arthur H.; El-Saden, Suzie M.; Aghazadehsanai, Nona; Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Ronald Reagan Univ Calif Los Angeles, Hosp Dent Serv, Med Ctr, Los Angeles, CA USA. [Friedlander, Arthur H.; Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [El-Saden, Suzie M.; Harada, Nancy D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov FU Research Facilities Improvement Program grant from the National Center for Research Resources, National Institutes of Health [CO6 RR-14529-01] FX Elements of the study described in this article were conducted in a facility constructed with support from Research Facilities Improvement Program grant CO6 RR-14529-01 from the National Center for Research Resources, National Institutes of Health. NR 37 TC 0 Z9 0 U1 0 U2 1 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD APR PY 2014 VL 145 IS 4 BP 345 EP 351 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA AE2OG UT WOS:000333812000012 PM 24686967 ER PT J AU McLaughlin, PM Wright, MJ LaRocca, M Nguyen, PT Teng, E Apostolova, LG Ringman, JM Zhou, Y Cummings, JL Woo, E AF McLaughlin, Paula M. Wright, Matthew J. LaRocca, Michael Nguyen, Peter T. Teng, Edmond Apostolova, Liana G. Ringman, John M. Zhou, Yan Cummings, Jeffrey L. Woo, Ellen TI The "Alzheimer's Type" Profile of Semantic Clustering in Amnestic Mild Cognitive Impairment SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Dementia; Memory disorders; Verbal learning; Diagnosis; Disease progression; Memory ID VERBAL-LEARNING TEST; MEMORY IMPAIRMENT; FREE-RECALL; WORKING-MEMORY; DISEASE; PATTERNS; PERFORMANCE; KNOWLEDGE; DEMENTIA; DEFICITS AB Impairments in learning and recall have been well established in amnestic mild cognitive impairment (aMCI). However, a relative dearth of studies has examined the profiles of memory strategy use in persons with aMCI relative to those with Alzheimer's disease (AD). Participants with aMCI, nonamnestic MCI, AD, and healthy older adults were administered the California Verbal Learning Test-II (CVLT-II). Measures of semantic clustering and recall were obtained across learning and delayed recall trials. In addition, we investigated whether deficits in semantic clustering were related to progression from healthy aging to aMCI and from aMCI to AD. The aMCI group displayed similar semantic clustering performance as the AD participants, whereas the AD group showed greater impairments on recall relative to the aMCI participants. Control participants who progressed to aMCI showed reduced semantic clustering at the short delay at baseline compared to individuals who remained diagnostically stable across follow-up visits. These findings show that the ability to engage in an effective memory strategy is compromised in aMCI, before AD has developed, suggesting that disruptions in semantic networks are an early marker of the disease. (JINS, 2014, 20, 1-11) C1 [McLaughlin, Paula M.; Teng, Edmond; Apostolova, Liana G.; Ringman, John M.; Zhou, Yan; Woo, Ellen] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [McLaughlin, Paula M.; Wright, Matthew J.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Wright, Matthew J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Dept Psychiat, Los Angeles, CA USA. [LaRocca, Michael] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA. [Nguyen, Peter T.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA. [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cummings, Jeffrey L.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA. RP Woo, E (reprint author), 10911 Weyburn Ave,Ste 200, Los Angeles, CA 90095 USA. EM ewoo@mednet.ucla.edu OI Zhou, Yan/0000-0002-1659-1672 FU National Institutes of Health [NIH P50 AG016570]; Alzheimer's Disease Research Centers of California; Sidell-Kagan Foundation; Jim Easton Consortium for Alzheimer's Disease Drug Discovery and Biomarkers at UCLA FX This work was funded by the National Institutes of Health (NIH P50 AG016570), the Alzheimer's Disease Research Centers of California, the Sidell-Kagan Foundation, and the Jim Easton Consortium for Alzheimer's Disease Drug Discovery and Biomarkers at UCLA. None of the authors have potential conflicts of interest. NR 47 TC 2 Z9 2 U1 5 U2 21 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD APR PY 2014 VL 20 IS 4 BP 402 EP 412 DI 10.1017/S135561771400006X PG 11 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA AD9CI UT WOS:000333561900006 PM 24521694 ER PT J AU Hung, JY Horn, D Woodruff, K Prihoda, T LeSaux, C Peters, J Tio, F Abboud-Werner, SL AF Hung, Jaclyn Y. Horn, Diane Woodruff, Kathleen Prihoda, Thomas LeSaux, Claude Peters, Jay Tio, Fermin Abboud-Werner, Sherry L. TI Colony-stimulating factor 1 potentiates lung cancer bone metastasis SO LABORATORY INVESTIGATION LA English DT Article DE bone; cancer; CSF1; lung; metastasis ID FACTOR CSF-1; CELL-LINES; TUMOR PROGRESSION; STEM-CELLS; RECEPTOR; MODELS; GROWTH; EXPRESSION; OSTEOCLASTS; XENOGRAFTS AB Colony-stimulating factor 1 (CSF1) is essential for osteoclastogenesis that mediates osteolysis in metastatic tumors. Patients with lung cancer have increased CSF1 in serum and high levels are associated with poor survival. Adenocarcinomas metastasize rapidly and many patients suffer from bone metastasis. Lung cancer stem-like cells sustain tumor growth and potentiate metastasis. The purpose of this study was to determine the role of CSF1 in lung cancer bone metastasis and whether inhibition of CSF1 ameliorates the disease. Human lung adenocarcinoma A549 cells were examined in vitro for CSF1/CSF1R. A549-luc cells were injected intracardiac in NOD/SCID mice and metastasis was assessed. To determine the effect of CSF1 knockdown (KD) in A549 cells on bone metastasis, cells were stably transfected with a retroviral vector containing short-hairpin CSF1 (KD) or empty vector (CT). Results showed that A549 cells express CSF1/CSF1R; CSF1 increased their proliferation and invasion, whereas soluble CSF1R inhibited invasion. Mice injected with A549-luc cells showed osteolytic bone lesions 3.5 weeks after injection and lesions increased over 5 weeks. Tumors recapitulated adenocarcinoma morphology and showed osteoclasts along the tumor/bone interface, trabecular, and cortical bone loss. Analyses of KD cells showed decreased CSF1 protein levels, reduced colony formation in soft agar assay, and decreased fraction of stem-like cells. In CSF1KD mice, the incidence of tumor metastasis was similar to controls, although fewer CSF1KD mice had metastasis in both hind limbs. KD tumors showed reduced CSF1 expression, Ki-67 + cells, and osteoclasts. Importantly, there was a low incidence of large tumors >0.1 mm(2) in CSF1KD mice compared with control mice (10% vs 62.5%). This study established a lung osteolytic bone metastasis model that resembles human disease and suggests that CSF1 is a key determinant of cancer stem cell survival and tumor growth. Results may lead to novel strategies to inhibit CSF1 in lung cancer and improve management of bone metastasis. C1 [Hung, Jaclyn Y.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, Dept Pediat, Div Hematol & Oncol, San Antonio, TX 78229 USA. [Horn, Diane; Woodruff, Kathleen; Prihoda, Thomas; Tio, Fermin; Abboud-Werner, Sherry L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Horn, Diane; Woodruff, Kathleen; Prihoda, Thomas; Peters, Jay; Tio, Fermin; Abboud-Werner, Sherry L.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [LeSaux, Claude] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Peters, Jay] Univ Texas Hlth Sci Ctr San Antonio, Dept Pulm Med, San Antonio, TX 78229 USA. RP Abboud-Werner, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM abboudwerner@uthscsa.edu FU Biomedical Research Foundation of South Texas FX We thank Roberto Fajardo, PhD, and James Schmitz at RAYO, the Daniel W Carlisle Center for Bone and Mineral Imaging at UTHSCSA for their assistance in analyzing the skeletal tissues. We also thank the Flow Cytometry Shared Resource Facility at UTHSCSA, which is supported by NIH-NCI P30CA54174 (CTRC at UTHSCSA) for fluorescence-activated cell-sorting analysis. This work was supported by the Biomedical Research Foundation of South Texas (SA-W, FT). NR 43 TC 7 Z9 8 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD APR PY 2014 VL 94 IS 4 BP 371 EP 381 DI 10.1038/labinvest.2014.1 PG 11 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AD9HB UT WOS:000333574900002 PM 24468794 ER PT J AU Chinman, M George, P Dougherty, RH Daniels, AS Ghose, SS Swift, A Delphin-Rittmon, ME AF Chinman, Matthew George, Preethy Dougherty, Richard H. Daniels, Allen S. Ghose, Sushmita Shoma Swift, Anita Delphin-Rittmon, Miriam E. TI Peer Support Services for Individuals With Serious Mental Illnesses: Assessing the Evidence SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; INTENSIVE CASE-MANAGEMENT; CONSUMER CASE-MANAGEMENT; HEALTH-SERVICES; WELLNESS RECOVERY; CLIENT OUTCOMES; EVIDENCE BASE; PROVIDERS; COMMUNITY; EDUCATION AB Objective: This review assessed the level of evidence and effectiveness of peer support services delivered by individuals in recovery to those with serious mental illnesses or co-occurring mental and substance use disorders. Methods: Authors searched PubMed, PsycINFO, Applied Social Sciences Index and Abstracts, Sociological Abstracts, Social Services Abstracts, Published International Literature on Traumatic Stress, the Educational Resources Information Center, and the Cumulative Index to Nursing and Allied Health Literature for outcome studies of peer support services from 1995 through 2012. They found 20 studies across three service types: peers added to traditional services, peers in existing clinical roles, and peers delivering structured curricula. Authors judged the methodological quality of the studies using three levels of evidence (high, moderate, and low). They also described the evidence of service effectiveness. Results: The level of evidence for each type of peer support service was moderate. Many studies had methodological shortcomings, and outcome measures varied. The effectiveness varied by service type. Across the range of methodological rigor, a majority of studies of two service types peers added and peers delivering curricula showed some improvement favoring peers. Compared with professional staff, peers were better able to reduce inpatient use and improve a range of recovery outcomes, although one study found a negative impact. Effectiveness of peers in existing clinical roles was mixed. Conclusions: Peer support services have demonstrated many notable outcomes. However, studies that better differentiate the contributions of the peer role and are conducted with greater specificity, consistency, and rigor would strengthen the evidence. C1 [Chinman, Matthew] US Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Pittsburgh Med Ctr, Pittsburgh, PA 15206 USA. [George, Preethy; Daniels, Allen S.; Ghose, Sushmita Shoma] WESTAT Corp, Rockville, MD 20850 USA. [Dougherty, Richard H.] DMA Hlth Strategies, Lexington, MA USA. [Swift, Anita] Swift Consulting, Newport, KY USA. [Delphin-Rittmon, Miriam E.] SAMHSA, Off Policy Planning & Innovat, Rockville, MD USA. RP Chinman, M (reprint author), US Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Pittsburgh Med Ctr, Pittsburgh, PA 15206 USA. EM chinman@rand.org; preethygeorge@westat.com FU Substance Abuse and Mental Health Services Administration (SAMHSA) [HHSS283200700029I/HHSS28342002T HHSS283200700006I/HHSS28342003T, HHSS2832007000171/HHSS28300001T]; U.S. Department of Veterans Affairs [RRP 06-147]; Evidence-Based Review of Peer Support [IIR 06-227] FX Development of the Assessing the Evidence Base Series was supported by contracts HHSS283200700029I/HHSS28342002T, HHSS283200700006I/HHSS28342003T, and HHSS2832007000171/HHSS28300001T from 2010 through 2013 from the Substance Abuse and Mental Health Services Administration (SAMHSA). Development of this review was also partly supported by two grants from the U.S. Department of Veterans Affairs: grant RRP 06-147, Evidence-Based Review of Peer Support; and grant IIR 06-227 PEers Enhancing Recovery. The authors acknowledge the contributions of Wilma Townsend, M.S.W., Kevin Malone, B.A., and Suzanne Fields, M.S.W., from SAMHSA: John O'Brien, M.A., from the Centers for Medicare & Medicaid Services; Garrett Moran, Ph.D., from Westat; and John Easterday, Ph.D., Linda Lee, Ph.D., Rosanna Coffey, Ph.D., and Tami Mark, Ph.D., from Truven Health Analytics. The views expressed in this article are those of the authors and do not necessarily represent the views of SAMHSA. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States government. NR 52 TC 62 Z9 62 U1 4 U2 31 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2014 VL 65 IS 4 BP 429 EP 441 DI 10.1176/appi.ps.201300244 PG 13 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA AD8WE UT WOS:000333545600006 PM 24549400 ER PT J AU Slade, EP Wissow, LS Davis, M Abrams, MT Dixon, LB AF Slade, Eric P. Wissow, Lawrence S. Davis, Maryann Abrams, Michael T. Dixon, Lisa B. TI Medicaid Lapses and Low-Income Young Adults' Receipt of Outpatient Mental Health Care After an Inpatient Stay SO PSYCHIATRIC SERVICES LA English DT Article ID INSTRUMENTAL VARIABLES; UNITED-STATES; TRANSITION; SERVICES; ILLNESS; IDENTIFICATION; SCHIZOPHRENIA; DEPRESSION; INSURANCE; OUTCOMES AB Objective: This study examined low-income young adults' use of outpatient mental health services after an inpatient mental health stay, with a focus on Medicaid enrollment lapses and public mental health safety-net coverage. Methods: The sample included 1,174 young adults ages 18 to 26 who had been discharged from inpatient psychiatric care in a mid-Atlantic state. All were enrolled in Medicaid at the time of discharge, and all were eligible for continued outpatient public mental health services regardless of Medicaid enrollment Administrative claims data were used to examine outpatient mental health clinic use, psychotropic medication possession, inpatient readmission, and emergency department admission during the 365-day period after the index discharge. The main independent variable was a lapse in Medicaid enrollment. An instrumental-variables regression model was used to minimize estimation bias resulting from unmeasured confounding between lapses and service use. Results: Nearly a third (30%) of the young adults had an enrollment lapse. In instrumental-variables analysis, those whose coverage lapsed were less likely than those who had continuous Medicaid coverage to have at least two clinic visits (38% versus 80%); they also had a lower average psychotropic medication possession ratio (25% versus 55%). Conclusions: Age-related Medicaid enrollment lapses were common in this sample of young adults and were associated with receipt of less clinical care postdischarge despite continued eligibility for public services. States should examine opportunities to assist young adults with serious mental health problems who are aging out of Medicaid enrollment categories for children. C1 [Slade, Eric P.] US Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Capitol Healthcare Network VISN5, Baltimore, MD 21201 USA. [Slade, Eric P.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. [Wissow, Lawrence S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Davis, Maryann] Univ Massachusetts, Sch Med, Dept Psychiat, Syst & Psychosocial Adv Res Ctr,Adulthood Rehabil, Worcester, MA 01655 USA. [Abrams, Michael T.] Univ Maryland Baltimore Cty, HillTop Inst, Baltimore, MD 21228 USA. [Dixon, Lisa B.] Columbia Univ, Med Ctr, Dept Psychiat, New York, NY USA. [Dixon, Lisa B.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Slade, EP (reprint author), US Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Capitol Healthcare Network VISN5, Baltimore, MD 21201 USA. EM eslade@psych.umaryland.edu FU National Institute of Mental Health [R34-MH081303]; Maryland's Medicaid authority; H. Lundbeck A/S FX This research was funded by the National Institute of Mental Health under grant number R34-MH081303. The authors thank Jack Clark, M.A., for expert database programming.; Dr. Slade has served as a paid consultant to H. Lundbeck A/S. Mr. Abrams has served as a paid consultant to Maryland's Medicaid authority. The other authors report no competing interests. NR 40 TC 0 Z9 0 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2014 VL 65 IS 4 BP 454 EP 460 DI 10.1176/appi.ps.201200375 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA AD8WE UT WOS:000333545600008 PM 24382558 ER PT J AU Davis, M Abrams, MT Wissow, LS Slade, EP AF Davis, Maryann Abrams, Michael T. Wissow, Lawrence S. Slade, Eric P. TI Identifying Young Adults at Risk of Medicaid Enrollment Lapses After Inpatient Mental Health Treatment SO PSYCHIATRIC SERVICES LA English DT Article ID INSURANCE-COVERAGE; CARE; MASSACHUSETTS; CHILDREN; REFORM; YOUTH; CLASSIFICATION; POPULATIONS; TRANSITION; DISORDERS AB Objective: This study sought to describe Medicaid disenrollment rates and risk factors among young adults after discharge from inpatient psychiatric treatment. Methods: The sample included 1,176 Medicaid-enrolled young adults ages 18 to 26 discharged from inpatient psychiatric care in a mid-Atlantic state. Medicaid disenrollment in the 365 days postdischarge and disenrollment predictors from the 180-day predischarge period (antecedent period) were identified from administrative records. Classification and regression free and probit regression analysis were used. Results: Thirty-two percent were disenrolled from Medicaid within a year of discharge. Both analytical approaches converged on four main risk factors: being in the Medicaid enrollment category for persons with a nondisabled low-income parent or for a child in a low-income household, being age 18 or 20 at discharge, having a Medicaid enrollment gap in the antecedent period, and having no primary care utilization in the antecedent period. For the 48% of the sample continuously enrolled in the antecedent period who were in the enrollment categories for disabled adults or foster care children, the disenrollment rate was 13%. Conclusions: A substantial minority of Medicaid-enrolled young adults discharged from inpatient care were disenrolled from Medicaid within a year. About half the sample had a low disenrollment risk, but the other half was at substantial risk. Risk factors largely reflected legal status changes that occur among these transition-age youths. Identifying inpatients at high risk of disenrollment and ensuring continuous coverage should improve access to needed postdischarge supports. Regular primary care visits may also help reduce unintended Medicaid disenrollment in this population. C1 [Davis, Maryann] Univ Massachusetts, Sch Med, Dept Psychiat, Ctr Mental Hlth Serv Res,Adulthood Rehabil Res &, Worcester, MA 01655 USA. [Abrams, Michael T.] Univ Maryland Baltimore Cty, Hilltop Inst, Baltimore, MD 21228 USA. [Wissow, Lawrence S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. [Slade, Eric P.] US Dept Vet Affairs, Capitol Healthcare Network VISN5, Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA. [Slade, Eric P.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. RP Davis, M (reprint author), Univ Massachusetts, Sch Med, Dept Psychiat, Ctr Mental Hlth Serv Res,Adulthood Rehabil Res &, Worcester, MA 01655 USA. EM maryann.davis@umassmed.edu FU National Institutes of Health [R34-MH081303]; National Institute on Disability and Rehabilitation Research [H133B090018]; H. Lundbeck A/S; Maryland's Medicaid authority FX This work was funded by grants to Dr. Slade from the National Institutes of Health (R34-MH081303) and to Dr. Davis from the National Institute on Disability and Rehabilitation Research (H133B090018). The authors thank Jack Clark, M.A., for expert database programming, and Amanda Costa, A.A., for assistance.; Dr. Slade has served as a paid consultant to H. Lundbeck A/S. Mr. Abrams has served as a paid consultant to Maryland's Medicaid authority. The other authors report no competing interests. NR 44 TC 2 Z9 2 U1 4 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2014 VL 65 IS 4 BP 461 EP 468 DI 10.1176/appi.ps.201300199 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA AD8WE UT WOS:000333545600009 PM 24382689 ER PT J AU Koiliari, E Roussos, P Pasparakis, E Lencz, T Malhotra, A Siever, LJ Giakoumaki, SG Bitsios, P AF Koiliari, Erasmia Roussos, Panos Pasparakis, Emmanouil Lencz, Todd Malhotra, Anil Siever, Larry J. Giakoumaki, Stella G. Bitsios, Panos TI The CSMD1 genome-wide associated schizophrenia risk variant rs10503253 affects general cognitive ability and executive function in healthy males SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Cognition; Executive function; Endophenotypes; CSMD1 gene; Schizophrenia ID HUMAN PREFRONTAL CORTEX; INHIBITED LIGHT REFLEX; WORKING-MEMORY; PERSONALITY-TRAITS; DECISION-MAKING; TASK; ABNORMALITIES; PERFORMANCE; COMPONENTS; DISORDER AB Background: The single-nucleotide polymorphism(SNP) rs10503253, located within the CUB and Sushi multiple domains-1 (CSMD1) gene on 8p23.2, has reached genome-wide support as a risk factor for schizophrenia. There is initial but inconclusive evidence for a role of this variant in aspects of cognition. Methods: We investigated the neurocognitive effects of the CSMD1 rs10503253 (C/A) polymorphism in a large, demographically homogeneous sample of young, healthy Greek Caucasian males (n=1149) phenotyped for a wide range of neuropsychological measures, most of which have been shown to be reliable endophenotypes for schizophrenia. Results: The risk 'A' allele was associated with poorer performance on measures of general cognitive ability, strategy formation, spatial and visual working memory, set shifting, target detection and planning for problem solving but not for emotional decision making. Most of these effects were dependent on risk "A" allele dose, with AA and CC homozygotes being the worse and the best respectively, while CA individuals were intermediate. Potential genotype effects in Stroop and verbal memory performance were also suggested by our dataset. Discussion: These results underline the relevance of the risk "A" allele to neurocognitive functioning and suggest that its detrimental effects on cognition, may be part of the mechanism by which the CSMD1 mediates risk for schizophrenia. (C) 2014 Elsevier B. V. All rights reserved. C1 [Koiliari, Erasmia; Pasparakis, Emmanouil; Bitsios, Panos] Univ Crete, Fac Med, Dept Psychiat, Iraklion, Crete, Greece. [Roussos, Panos; Siever, Larry J.] Mt Sinai, Dept Psychiat, New York, NY USA. [Roussos, Panos] Mt Sinai, Inst Multiscale Biol, Dept Genet & Genom Sci, New York, NY USA. [Roussos, Panos; Siever, Larry J.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY USA. [Lencz, Todd; Malhotra, Anil] Zucker Hillside Hosp, Div Psychiat Res, Glen Oaks, NY USA. [Lencz, Todd; Malhotra, Anil] Feinstein Inst Med Res, Manhasset, NY USA. [Giakoumaki, Stella G.] Univ Crete, Dept Psychol, Rethimnon, Crete, Greece. RP Bitsios, P (reprint author), Univ Crete, Fac Med, Dept Psychiat, Iraklion, Crete, Greece. EM pbitsios@med.uoc.gr RI Roussos, Panos/J-7090-2013; Lencz, Todd/J-3418-2014 OI Roussos, Panos/0000-0002-4640-6239; Lencz, Todd/0000-0001-8586-338X NR 52 TC 8 Z9 9 U1 1 U2 45 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2014 VL 154 IS 1-3 BP 42 EP 47 DI 10.1016/j.schres.2014.02.017 PG 6 WC Psychiatry SC Psychiatry GA AD7EU UT WOS:000333425800006 PM 24630139 ER PT J AU Blackwell, T Yaffe, K Laffan, A Ancoli-Israel, S Redline, S Ensrud, KE Song, Y Stone, KL AF Blackwell, Terri Yaffe, Kristine Laffan, Alison Ancoli-Israel, Sonia Redline, Susan Ensrud, Kristine E. Song, Yeonsu Stone, Katie L. CA Osteoporotic Fractures Men MrOS TI Associations of Objectively and Subjectively Measured Sleep Quality with Subsequent Cognitive Decline in Older Community-Dwelling Men: The MrOS Sleep Study SO SLEEP LA English DT Article DE Aging; cognitive function; disturbed sleep; total sleep time ID JAPANESE-AMERICAN MEN; OSTEOPOROTIC FRACTURES; DAYTIME SLEEPINESS; DEMENTIA; IMPAIRMENT; HEALTH; ADULTS; ACTIGRAPHY; WOMEN; SCALE AB Study Objectives: To examine associations of objectively and subjectively measured sleep with subsequent cognitive decline. Design: A population-based longitudinal study. Setting: Six centers in the United States. Participants: Participants were 2,822 cognitively intact community-dwelling older men (mean age 76.0 +/- 5.3 y) followed over 3.4 +/- 0.5 y. Interventions: None. Measurements and Results: Objectively measured sleep predictors from wrist actigraphy: total sleep time (TST), sleep efficiency (SE), wake after sleep onset (WASO), number of long wake episodes (LWEP). Self-reported sleep predictors: sleep quality (Pittsburgh Sleep Quality Index [PSQI]), daytime sleepiness (Epworth Sleepiness Scale [ESS]), TST. Clinically significant cognitive decline: five-point decline on the Modified Mini-Mental State examination (3MS), change score for the Trails B test time in the worse decile. Associations of sleep predictors and cognitive decline were examined with logistic regression and linear mixed models. After multivariable adjustment, higher levels of WASO and LWEP and lower SE were associated with an 1.4 to 1.5-fold increase in odds of clinically significant decline (odds ratio 95% confidence interval) Trails B test: SE < 70% versus SE >= 70%: 1.53 (1.07, 2.18); WASO >= 90 min versus WASO < 90 min: 1.47 (1.09, 1.98); eight or more LWEP versus fewer than eight: 1.38 (1.02, 1.86). 3MS: eight or more LWEP versus fewer than eight: 1.36 (1.09, 1.71), with modest relationships to linear change in cognition over time. PSQI was related to decline in Trails B performance (3 sec/y per standard deviation increase). Conclusions: Among older community-dwelling men, reduced sleep efficiency, greater nighttime wakefulness, greater number of long wake episodes, and poor self-reported sleep quality were associated with subsequent cognitive decline. C1 [Blackwell, Terri; Laffan, Alison; Song, Yeonsu; Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco VA Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat & Med, La Jolla, CA 92093 USA. [Ancoli-Israel, Sonia] Vet Affairs San Diego Ctr Excellence Stress & Men, San Diego, CA USA. [Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Ensrud, Kristine E.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. RP Blackwell, T (reprint author), San Francisco Coordinating Ctr, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM tblackwell@sfcc-cpmc.net; kstone@sfcc-cpmc.net FU National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA); National Cancer Institute (NCI); National Center for Research Resources (NCRR); NIH Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140]; National Heart, Lung, and Blood Institute (NHLBI) [R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, R01 HL070839]; NIA [K24 AG031155]; NIH; ResMed, Inc; Philips Respironics; ResMed Foundation FX This was not an industry supported study. The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Cancer Institute (NCI), the National Center for Research Resources (NCRR), and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. The National Heart, Lung, and Blood Institute (NHLBI) provides funding for the MrOS Sleep ancillary study "Outcomes of Sleep Disorders in Older Men" under the following grant numbers: R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839. Dr. Yaffe is supported by a grant from the NIA, K24 AG031155; serves on DSMB's for Takeda, Inc and a study sponsored by the NIH; is a member of the Beeson Advisory Committee; and is a consultant for Novartis and Eli Lilly. Dr. Ancoli- Israel is a consultant or on the advisory board for Astra Zeneca, Ferring Pharmaceuticals Inc, GaxoSmithKline, Hypnocore, Johnson & Johnson, Merck, NeuroVigil Inc, and Purdue Pharma LP. Dr. Redline's institution has received grant funding from ResMed, Inc, Philips Respironics, and ResMed Foundation and equipment from them for use in NIH studies. The other authors have indicated no financial conflicts of interest. The analysis was performed at California Pacific Medical Center Research Institute, San Francisco, CA. NR 50 TC 23 Z9 23 U1 2 U2 14 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD APR 1 PY 2014 VL 37 IS 4 BP 655 EP 663 DI 10.5665/sleep.3562 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AE0RF UT WOS:000333673100004 PM 24899757 ER PT J AU Blosnich, JR Farmer, GW Lee, JGL Silenzio, VMB Bowen, DJ AF Blosnich, John R. Farmer, Grant W. Lee, Joseph G. L. Silenzio, Vincent M. B. Bowen, Deborah J. TI Health Inequalities Among Sexual Minority Adults Evidence from Ten US States, 2010 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES; BISEXUAL POPULATIONS; SUBSTANCE USE; ORIENTATION; GAY; PREVALENCE; BEHAVIORS; RISK; DISPARITIES; DISORDERS AB Background: Improving the health of lesbian, gay, and bisexual (LGB) individuals is a Healthy People 2020 goal; however, the IOM highlighted the paucity of information currently available about LGB populations. Purpose: To compare health indicators by gender and sexual orientation statuses. Methods: Data are from Behavioral Risk Factor Surveillance System surveys conducted January-December of 2010 with population-based samples of non-institutionalized U. S. adults aged over 18 years (N=93,414) in ten states that asked about respondents' sexual orientation (response rates=41.1%-65.6%). Analyses were stratified by gender and sexual orientation to compare indicators of mental health, physical health, risk behaviors, preventive health behaviors, screening tests, health care utilization, and medical diagnoses. Analyses were conducted in March 2013. Results: Overall, 2.4% (95% CI=2.2, 2.7) of the sample identified as LGB. All sexual minority groups were more likely to be current smokers than their heterosexual peers. Compared with heterosexual women, lesbian women had more than 30% decreased odds of having an annual routine physical exam, and bisexual women had more than 2.5 times the odds of not seeking medical care owing to cost. Compared with heterosexual men, gay men were less likely to be overweight or obese, and bisexual men were twice as likely to report a lifetime asthma diagnosis. Conclusions: This study represents one of the largest samples of LGB adults and finds important health inequalities, including that bisexual women bear particularly high burdens of health disparities. Further work is needed to identify causes of and intervention for these disparities. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Blosnich, John R.; Silenzio, Vincent M. B.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA. [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Farmer, Grant W.] St Louis Univ, Coll Publ Hlth & Social Justice, Dept Epidemiol, St Louis, MO 63103 USA. [Lee, Joseph G. L.] Univ N Carolina, Dept Hlth Behav, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Bowen, Deborah J.] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 30,Univ Dr 151C, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov RI Lee, Joseph/B-7475-2009 OI Lee, Joseph/0000-0001-9698-649X FU Institutional National Research Service Award from the National Institute of Mental Health [5T32MH020061]; predoctoral National Research Service Award from the National Institute on Drug Abuse [F31DA032220] FX This work was supported partially by a postdoctoral fellowship to John R. Blosnich in an Institutional National Research Service Award from the National Institute of Mental Health (5T32MH020061) and a predoctoral National Research Service Award to Grant W. Farmer from the National Institute on Drug Abuse (F31DA032220). The opinions expressed in this work are those of the authors and do not represent those of the funders, institutions, the Department of Veterans Affairs, or the U.S. Government. NR 35 TC 38 Z9 38 U1 1 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2014 VL 46 IS 4 BP 337 EP 349 DI 10.1016/j.amepre.2013.11.010 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AD4YM UT WOS:000333257900003 PM 24650836 ER PT J AU Batki, SL Pennington, DL AF Batki, Steven L. Pennington, David L. TI Toward Personalized Medicine in the Pharmacotherapy of Alcohol Use Disorder: Targeting Patient Genes and Patient Goals SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID FUNCTIONAL POLYMORPHISM; NALTREXONE RESPONSE; DEPENDENT PATIENTS; HEAVY DRINKERS; TOPIRAMATE; RISK C1 [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. San Francisco Vet Adm Med Ctr, Addict Res Program, San Francisco, CA 94121 USA. RP Batki, SL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM steven.batki@ucsf.edu NR 15 TC 4 Z9 5 U1 0 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2014 VL 171 IS 4 BP 391 EP 394 DI 10.1176/appi.ajp.2014.14010061 PG 4 WC Psychiatry SC Psychiatry GA AD8FD UT WOS:000333501000004 PM 24687193 ER PT J AU Novick, DM Allbaugh, L Zhao, Z Henshaw, E Vazquez, DM Armitage, R Flynn, H AF Novick, Danielle M. Allbaugh, Lucy Zhao, Zhuo Henshaw, Erin Vazquez, Delia M. Armitage, Roseanne Flynn, Heather CA Womens Mental Hlth Infants Program TI Representativeness of obstetric patients who participate in perinatal depression research: findings from the Women's Mental Health and Infants Program (WMHIP) integrated dataset SO ARCHIVES OF WOMENS MENTAL HEALTH LA English DT Article DE Perinatal; Depression; Selection bias; Validity; Recruitment ID TRIALS; RECRUITMENT; SYMPTOMS; IMPACT AB The aims of this study were to evaluate the feasibility of integrating archival datasets from depression projects involving pregnant women recruited from obstetric clinics and then assess the representativeness of the integrated dataset. Datasets from six studies were standardized and integrated. Chi-square, t-, and Wilcoxon rank-sum tests were used to compare characteristics between women who completed a depression screening questionnaire (DSQ) and were (1) eligible and ineligible for research participation and (2) eligible women who accepted and declined participation. The integrated dataset comprises 9,112 pregnant women, of whom 71.0 % (n = 6,472) were ineligible for participation because their DSQ scores indicated no-to-minimal depressive symptoms (NDS). Among the 23.9 % (2,176) of women identified as eligible, in part, because their DSQ scores indicated elevated levels of depressive symptoms (EDS), 29.6 % (644) of women participated (P-EDS) and 47.6 % (1,036) of women did not participate (D-EDS). While the NDS and EDS groups were significantly different on almost all variables, the P-EDS and D-EDS groups were significantly different on only a few variables. Compared to the D-EDS group, the P-EDS group was earlier in pregnancy and, on the Edinburgh Postnatal Depression Screen, was more likely to endorse impaired "ability to laugh" and "enjoy oneself", and endorse at greater severity "ability to laugh." It is a reasonable and feasible strategy to integrate thematically similar datasets to increase statistical power. Additionally, typical recruitment strategies for minimal risk perinatal depression research at obstetric clinics, during routine prenatal care visits, appear to produce an externally valid study cohort. C1 [Novick, Danielle M.; Zhao, Zhuo; Armitage, Roseanne; Flynn, Heather; Womens Mental Hlth Infants Program] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Novick, Danielle M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Allbaugh, Lucy] Miami Univ, Dept Psychol, Oxford, OH 45056 USA. [Henshaw, Erin] Denison Univ, Granville, OH 43023 USA. [Vazquez, Delia M.] Univ Michigan, Dept Pediat Endocrinol, Ann Arbor, MI 48109 USA. [Flynn, Heather] Florida State Univ, Dept Med Humanities & Social Sci, Tallahassee, FL 32306 USA. RP Novick, DM (reprint author), Univ Michigan, Dept Psychiat, 4250 Plymouth Rd,SPC 5769, Ann Arbor, MI 48109 USA. EM dnovick@med.umich.edu FU Department of Psychiatry at University of Michigan; National Institute of Mental Health [MH065062, MH063880]; Psychiatry Research Council; Rachel Upjohn Scholars Award, University of Michigan Depression Center FX The Women's Mental Health and Infants Program (WMHIP) was established with support from the Department of Psychiatry at University of Michigan. Original research was supported with grants from the National Institute of Mental Health MH065062 and MH063880, Psychiatry Research Council, and Rachel Upjohn Scholars Award, University of Michigan Depression Center. The authors gratefully acknowledge feedback on a previous draft from Cynthia Battle. NR 22 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 1434-1816 EI 1435-1102 J9 ARCH WOMEN MENT HLTH JI Arch. Womens Ment. Health PD APR PY 2014 VL 17 IS 2 BP 97 EP 105 DI 10.1007/s00737-013-0385-4 PG 9 WC Psychiatry SC Psychiatry GA AD3HY UT WOS:000333130200002 PM 24248412 ER PT J AU Gandy, S AF Gandy, Sam TI Alzheimer's Disease: New Data Highlight Nonneuronal Cell Types and the Necessity for Presymptomatic Prevention Strategies SO BIOLOGICAL PSYCHIATRY LA English DT Review DE Amyloid plaques; amyloidosis; microglia; neuro-degeneration; systems biology; tauopathy ID AMYLOID-BETA PEPTIDE; MICE; ANTIBODIES; MICROGLIA; PATHOLOGY; VARIANTS; CD33; APOE; CR-1 AB Despite compelling genetic evidence indicating that cerebral amyloidosis can be, at least sometimes, the primary cause of Alzheimer's disease (AD), clinical trials for symptomatic AD with amyloid-reducing agents have succeeded at target engagement but failed to cause clinical benefit. In a landmark shift, the U.S. Food and Drug Administration now proposes to approve prophylaxis that alters the trajectory of what is now believed to be typical AD biomarker evolution. The first prevention trials are now beginning in patients with genetic guarantees for or high genetic risks for AD. The expectation is that clues to their outcomes will begin to emerge from these trials in approximately 2018. In the meantime, new strategies point to nonneuronal cells and to system pathology. A review of the current state of the art of AD science follows herein. C1 [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Mt Sinai Alzheimers Dis Res Ctr, New York, NY USA. [Gandy, Sam] James J Peters VA Med Ctr, New York, NY USA. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM samuel.gandy@mssm.edu FU National Institute of Neurological Disorders and Stroke; National Institute on Aging; Veterans Administration; American Health Assistance Foundation; Cure Alzheimer's Fund FX SG acknowledges the support of National Institute of Neurological Disorders and Stroke, National Institute on Aging, the Veterans Administration, the American Health Assistance Foundation, and the Cure Alzheimer's Fund. NR 24 TC 4 Z9 4 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2014 VL 75 IS 7 BP 553 EP 557 DI 10.1016/j.biopsych.2013.11.019 PG 5 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AD2RD UT WOS:000333081900006 PM 24373429 ER PT J AU Kim, B Hing, ZA Wu, A Schiller, T Struble, EB Liuwantara, D Kempert, PH Broxham, EJ Edwards, NC Marder, VJ Simhadri, VL Sauna, ZE Howard, TE Kimchi-Sarfaty, C AF Kim, Benjamin Hing, Zachary A. Wu, Andrew Schiller, Tal Struble, Evi B. Liuwantara, David Kempert, Pamela H. Broxham, Eric J. Edwards, Nathan C. Marder, Victor J. Simhadri, Vijaya L. Sauna, Zuben E. Howard, Tom E. Kimchi-Sarfaty, Chava TI Single-nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Letter DE haplotypes; congenital thrombotic thrombocytopenic purpura; phenotypes; quantitative trait nucleotides; ADAMTS13 ID MUTATIONS; DISEASE C1 [Kim, Benjamin] Univ Calif San Francisco, Sch Med, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA. [Hing, Zachary A.; Wu, Andrew; Schiller, Tal; Edwards, Nathan C.; Simhadri, Vijaya L.; Sauna, Zuben E.; Kimchi-Sarfaty, Chava] US FDA, Lab Hemostasis, Div Hematol, CBER, Bethesda, MD 20014 USA. [Struble, Evi B.] US FDA, Lab Plasma Derivat, Div Hematol, CBER, Bethesda, MD 20014 USA. [Liuwantara, David; Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Kempert, Pamela H.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Pediat, Los Angeles, CA 90095 USA. [Broxham, Eric J.; Howard, Tom E.] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90033 USA. [Marder, Victor J.; Howard, Tom E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Med, Los Angeles, CA 90095 USA. RP Kim, B (reprint author), Univ Calif San Francisco, Sch Med, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA. EM tom.howard@va.gov; chava.kimchi-sarfaty@fda.hhs.gov FU NHLBI NIH HHS [1RC2-HL101851, HL-71130, HL-72533] NR 10 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD APR PY 2014 VL 165 IS 1 BP 154 EP 158 DI 10.1111/bjh.12713 PG 5 WC Hematology SC Hematology GA AC8BH UT WOS:000332757500020 PM 24433405 ER PT J AU Walling, AM Wenger, NS AF Walling, Anne M. Wenger, Neil S. TI Palliative Care and End-Stage Liver Disease SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID TRANSPLANT; CIRRHOSIS; BURDEN; LIFE C1 [Walling, Anne M.; Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Walling, Anne M.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Walling, Anne M.; Wenger, Neil S.] RAND Hlth, Santa Monica, CA USA. [Wenger, Neil S.] UCLA, Hlth Eth Ctr, Los Angeles, CA USA. RP Walling, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. FU NCATS NIH HHS [KL2 TR000122, UL1 TR000124, KL2TR000122] NR 10 TC 3 Z9 3 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD APR PY 2014 VL 12 IS 4 BP 699 EP 700 DI 10.1016/j.cgh.2013.11.010 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AD2IF UT WOS:000333057500030 PM 24246765 ER PT J AU La Fountaine, MF Toda, M Testa, A Bauman, WA AF La Fountaine, Michael F. Toda, Michita Testa, Anthony Bauman, William A. TI Cardioautonomic instability following a sports-related concussion in a 20-year-old male SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Letter DE Concussion; Electrocardiogram; Wandering atrial pacemaker; Atrial ectopy ID QT INTERVAL VARIABILITY C1 [La Fountaine, Michael F.; Toda, Michita; Testa, Anthony] Seton Hall Univ, S Orange, NJ 07079 USA. [La Fountaine, Michael F.; Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA. [Bauman, William A.] Icahn Sch Med Mt Sinai, New York, NY USA. RP La Fountaine, MF (reprint author), Seton Hall Univ, Sch Hlth & Med Sci, 400 South Orange Ave, S Orange, NJ 07079 USA. EM michael.lafountaine@shu.edu NR 10 TC 1 Z9 1 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD APR 1 PY 2014 VL 172 IS 3 BP E511 EP E512 DI 10.1016/j.ijcard.2014.01.095 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AD2XU UT WOS:000333101000050 PM 24491870 ER PT J AU Sutton, MY Lasswell, SM Lanier, Y Miller, KS AF Sutton, Madeline Y. Lasswell, Sarah M. Lanier, Yzette Miller, Kim S. TI Impact of Parent-Child Communication Interventions on Sex Behaviors and Cognitive Outcomes for Black/African-American and Hispanic/Latino Youth: A Systematic Review, 1988-2012 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE Youth; Black/African-American; Hispanic/Latino; Parent-child communication; Sex outcomes; Disparities ID SEXUALLY-TRANSMITTED-DISEASES; PREGNANCY PREVENTION PROGRAM; AFRICAN-AMERICAN; HIV PREVENTION; RISK BEHAVIORS; RANDOMIZED-TRIAL; MONITORING INTERVENTION; ADOLESCENT PREGNANCY; FAMILIES PROGRAM; REDUCTION AB Purpose: We reviewed human immunodeficiency virus (HIV) and sexually transmitted infection (STI)- behavioral interventions implemented with disproportionately affected black/African-American and Hispanic/Latino youth and designed to improve parent-child communications about sex. We compared their effectiveness in improving sex-related behavior or cognitive outcomes. Methods: A search of electronic databases identified peer-reviewed studies published between 1988 and 2012. Eligible studies were U. S.-based parent-child communication interventions with active parent components, experimental and quasiexperimental designs, measurement of youth sexual health outcomes, and enrollment of >= 50% black/African-American or Hispanic/Latino youth. We conducted systematic, primary reviews of eligible papers to abstract data on study characteristics and youth outcomes. Results: Fifteen studies evaluating 14 interventions were eligible. Although youth outcome measures and follow-up times varied, 13 of 15 studies (87%) showed at least one significantly improved youth sexual health outcome compared with controls (p < .05). Common components of effective interventions included joint parent and child session attendance, promotion of parent/family involvement, sexuality education for parents, developmental and/or cultural tailoring, and opportunities for parents to practice new communication skills with their youth. Conclusions: Parent-child communication interventions that include parents of youth disproportionately affected by HIV/STIs can effectively reduce sexual risk for youth. These interventions may help reduce HIV/STI-related health disparities and improve sexual health outcomes. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Sutton, Madeline Y.; Lasswell, Sarah M.; Lanier, Yzette; Miller, Kim S.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Lanier, Yzette] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Lanier, Yzette] Ctr Hlth Equ Res, Philadelphia, PA USA. RP Sutton, MY (reprint author), DHAP NCHHSTP CDC, 1600 Clifton Rd NE MS E-45, Atlanta, GA 30333 USA. EM msutton@cdc.gov NR 74 TC 12 Z9 12 U1 4 U2 32 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD APR PY 2014 VL 54 IS 4 BP 369 EP 384 DI 10.1016/j.jadohealth.2013.11.004 PG 16 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA AD4YT UT WOS:000333258700003 PM 24388108 ER PT J AU Nguyen, HM Shier, KL Graber, CJ AF Nguyen, Hien M. Shier, Kileen L. Graber, Christopher J. TI Determining a clinical framework for use of cefepime and -lactam/-lactamase inhibitors in the treatment of infections caused by extended-spectrum--lactamase-producing Enterobacteriaceae SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Review DE ESBLs; antimicrobial resistance; pharmacokinetics; pharmacodynamics; piperacillin; tazobactam ID BLOOD-STREAM INFECTIONS; MONTE-CARLO-SIMULATION; BETA-LACTAMASE; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; PIPERACILLIN-TAZOBACTAM; CTX-M; CLAVULANIC ACID; RISK-FACTORS; BREAKPOINTS AB Traditionally, physicians have not used cefepime (a fourth-generation cephalosporin with greater stability against -lactamases) or -lactam/-lactamase inhibitors (BLBLIs) for infections caused by bacteria (generally Escherichia coli and Klebsiella species) that produce an extended-spectrum -lactamase (ESBL). Many microbiology laboratories have historically labelled these ESBL-producing organisms as resistant to all cephalosporins regardless of their MIC. The recommendation to eliminate ESBL identification started with EUCAST in 2009, followed by CLSI in 2010. As a consequence, many ESBL-producing organisms that were previously labelled as resistant to all cephalosporins may be reclassified as susceptible to some (particularly cefepime), depending on their MICs. Because there are limited treatment options against ESBL-producing organisms, there is growing interest in using cefepime and BLBLIs. In this review, we examine the clinical outcomes of therapy directed against ESBL-producing Enterobacteriaceae and the pharmacokinetics/pharmacodynamics of cefepime and BLBLIs to construct a clinical framework for how physicians can best employ these carbapenem-sparing alternatives for the treatment of infections caused by ESBL-producing Enterobacteriaceae. We conclude that standard-dose cefepime is a reasonable option for the definitive therapy of invasive infections resulting from ESBL-producing E. coli and Klebsiella species when the MIC for the organism is 2 mg/L (CLSI) or 1 mg/L (EUCAST), although higher doses may be considered for MICs in the 48 mg/L range. Piperacillin/tazobactam is also a reasonable option when the MIC is 16 mg/L. C1 [Nguyen, Hien M.] Northwest Permanente, Portland, OR 97227 USA. [Shier, Kileen L.] Quest Diagnost Nichols Inst, Chantilly, VA USA. [Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Nguyen, HM (reprint author), Northwest Permanente, Portland, OR 97227 USA. EM hien.m.nguyen@kp.org NR 85 TC 26 Z9 26 U1 3 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD APR PY 2014 VL 69 IS 4 BP 871 EP 880 DI 10.1093/jac/dkt450 PG 10 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA AD5EQ UT WOS:000333275000002 PM 24265230 ER PT J AU Weiner, M Egelund, EF Engle, M Kiser, M Prihoda, TJ Gelfond, JAL Mac Kenzie, W Peloquin, CA AF Weiner, Marc Egelund, Eric F. Engle, Melissa Kiser, Melissa Prihoda, Thomas J. Gelfond, Jonathan A. L. Mac Kenzie, William Peloquin, Charles A. TI Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE rifamycin; latent tuberculosis infection; antiretroviral therapy; integrase strand transfer inhibitor; HIV ID HIV-INFECTED PATIENTS; PLASMA-CONCENTRATIONS; LATENT TUBERCULOSIS; RIFAMPIN; VARIABILITY; METABOLISM; INHIBITOR; REGIMENS; ATORVASTATIN; INDUCTION AB Latent tuberculosis infection and tuberculosis disease are prevalent worldwide. However, antimycobacterial rifamycins have drug interactions with many antiretroviral drugs. We evaluated the effect of rifapentine on the pharmacokinetic properties of raltegravir. In this open-label, fixed-sequence, three-period study, 21 healthy volunteers were given: raltegravir alone (400 mg every 12 h for 4 days) on days 14 of Period 1; rifapentine (900 mg once weekly for 3 weeks) on days 1, 8 and 15 of Period 2 and raltegravir (400 mg every 12 h for 4 days) on days 1215 of Period 2; and rifapentine (600 mg once daily for 10 scheduled doses) on days 1, 48 and 1114 of Period 3 and raltegravir (400 mg every 12 h for 4 days) on days 1114 of Period 3. Plasma raltegravir concentrations were measured. ClinicalTrials.gov database: NCT00809718. In 16 subjects who completed the study, coadministration of raltegravir with rifapentine (900 mg once weekly; Period 2) compared with raltegravir alone resulted in the geometric mean of the raltegravir AUC from 0 to 12 h (AUC(012)) being increased by 71; the peak concentration increased by 89 and the trough concentration decreased by 12. Coadministration of raltegravir with rifapentine in Period 3 did not change the geometric mean of the raltegravir AUC(012) or the peak concentration, but it decreased the trough concentration by 41. Raltegravir coadministered with rifapentine was generally well tolerated. The increased raltegravir exposure observed with once-weekly rifapentine was safe and tolerable. Once-weekly rifapentine can be used with raltegravir to treat latent tuberculosis infection in patients who are infected with HIV. C1 [Weiner, Marc] Dept Vet Affairs Med Ctr, Med Serv, San Antonio, TX 78229 USA. [Weiner, Marc; Engle, Melissa] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Egelund, Eric F.; Peloquin, Charles A.] Univ Florida, Coll Pharm, Gainesville, FL USA. [Kiser, Melissa] Bioanalyt Syst Inc, Mcminnville, OR USA. [Prihoda, Thomas J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Gelfond, Jonathan A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Mac Kenzie, William] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Weiner, M (reprint author), Dept Vet Affairs Med Ctr, Med Serv, San Antonio, TX 78229 USA. EM weiner@uthscsa.edu FU Investigator-Initiated Studies Program of Merck Co., Inc.; Veterans Administration, United States Centers for Disease Control and Prevention (Tuberculosis Trials Consortium); National Center for Advancing Translational Sciences [8UL1TR000149] FX This study was supported in part by a research grant from the Investigator-Initiated Studies Program of Merck & Co., Inc. Support was also provided by the Veterans Administration, United States Centers for Disease Control and Prevention (Tuberculosis Trials Consortium), and National Center for Advancing Translational Sciences, through Grant 8UL1TR000149. NR 40 TC 7 Z9 7 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD APR PY 2014 VL 69 IS 4 BP 1079 EP 1085 DI 10.1093/jac/dkt483 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA AD5EQ UT WOS:000333275000031 PM 24343893 ER PT J AU Fett, N Haynes, K Propert, KJ Margolis, DJ AF Fett, Nicole Haynes, Kevin Propert, Kathleen Joy Margolis, David J. TI Five-year malignancy incidence in patients with chronic pruritus: A population-based cohort study aimed at limiting unnecessary screening practices SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE chronic pruritus; generalized pruritus; itch; paraneoplastic signs; pruritus; skin signs of systemic disease ID HEALTH IMPROVEMENT NETWORK; GENERALIZED PRURITUS; LUNG-CANCER; COMPUTED-TOMOGRAPHY; SYSTEMIC-DISEASE; ITCH; PREVALENCE; VALIDATION; RISK; EPIDEMIOLOGY AB Background: The incidence of malignancy in patients with chronic pruritus and nondiseased skin is unknown. Objective: We sought to assess the hazard ratio (HR) of incident overall malignancy and incident malignancy by subtype in patients with chronic pruritus during the 5 years after diagnosis. Methods: A population-based cohort study was performed in the Health Improvement Network. In all, 8744 patients with chronic pruritus were matched with 31,580 patients without chronic pruritus based on sex, age, and practice. Primary outcomes were HR of incident malignancy and HR of malignancy subtypes. Results: The fully adjusted HR for incident malignancy in patients with chronic pruritus was 1.14 (95% confidence interval 0.98-1.33). The fully adjusted HR for incident hematologic malignancy and incident bile duct malignancy in patients with chronic pruritus was 2.02 (95% confidence interval 1.48-2.75) and 3.73 (95% confidence interval 1.55-8.97), respectively. The incidence of hematologic malignancy and cholangiocarcinoma in patients with chronic pruritus was 0.0016 and 0.0003 per person-year, respectively. Limitations: Potential for misclassification and detection biases is a limitation. Conclusions: Chronic pruritus without concomitant skin changes is a risk factor for having undiagnosed hematologic and bile duct malignancies, but not other malignancies. The overall incidence of these malignancies in patients with chronic pruritus is very low. C1 [Fett, Nicole] Philadelphia Dept Vet Affairs Med Ctr, Philadelphia, PA USA. [Fett, Nicole; Margolis, David J.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Haynes, Kevin; Propert, Kathleen Joy] Univ Penn, Ctr Pharmacoepidermiol Res & Training, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol,Perelman Sch Med, Philadelphia, PA 19104 USA. RP Fett, N (reprint author), Oregon Hlth & Sci Univ, Dept Dermatol, 3303 SW Bond Ave, Portland, OR 97239 USA. EM fett@ohsu.edu FU National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health (NIH) [UL1TR000003] FX The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant UL1TR000003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 46 TC 13 Z9 13 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 2014 VL 70 IS 4 BP 651 EP 658 DI 10.1016/j.jaad.2013.11.045 PG 8 WC Dermatology SC Dermatology GA AC8FP UT WOS:000332769200020 PM 24485529 ER PT J AU Richardson, RC Tarleton, JC Bird, TD Gospe, SM AF Richardson, Randal C. Tarleton, Jack C. Bird, Thomas D. Gospe, Sidney M., Jr. TI TRUNCATING CLCN1 MUTATIONS IN MYOTONIA CONGENITA: VARIABLE PATTERNS OF INHERITANCE SO MUSCLE & NERVE LA English DT Article DE allelic variability; CLC-1; CLCN1; myotonia; myotonia congenita ID CHLORIDE CHANNEL; DOMINANT; BECKER AB Introduction: Myotonia congenita due to protein truncating CLCN1 mutations is associated with variable patterns of inheritance. Methods: Three family kindreds are described, all of whom possess protein truncating mutations (Y33X, fs503X, R894X). One lineage also has coexistent R894X, A313T, and A320V mutations. Results: The Y33X mutation kinship has autosomal recessive inheritance and a severe phenotype when homozygous. The fs503X family has autosomal dominant inheritance and a moderate-to-severe phenotype. The A313T mutation kindred also has autosomal dominant inheritance but expresses a mild phenotype, except for the more severely affected compound heterozygotes. Conclusions: Early truncating mutations precluding dimerization are expected to be autosomal recessive and express a severe phenotype, while later mutations may be variable. The pedigrees presented here demonstrate that intrafamilial phenotypic variability may result from a dosage effect of an additional mutation, not necessarily variable expressivity. Mutations that have unexpected patterns of inheritance may represent allelic variability. Muscle Nerve 49:593-600, 2014 C1 [Richardson, Randal C.; Gospe, Sidney M., Jr.] Univ Washington, Div Pediat Neurol, Dept Neurol, Seattle, WA 98105 USA. [Richardson, Randal C.; Gospe, Sidney M., Jr.] Univ Washington, Div Pediat Neurol, Dept Pediat, Seattle, WA 98105 USA. [Richardson, Randal C.; Gospe, Sidney M., Jr.] Seattle Childrens Hosp, Seattle, WA 98105 USA. [Tarleton, Jack C.] Mission Hosp, Fullerton Genet Lab, Asheville, NC USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ Clin Ctr, Seattle, WA USA. [Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98105 USA. RP Gospe, SM (reprint author), Univ Washington, Div Pediat Neurol, Dept Neurol, 4800 Sand Point Way NE,MB 7-420, Seattle, WA 98105 USA. EM sgospe@uw.edu OI Gospe Jr, Sidney/0000-0002-0099-109X FU Athena Diagnostics, Inc. FX Dr. Bird has received licensing fees from Athena Diagnostics, Inc. Mission Hospitals' Fullerton Genetics Laboratory has provided in-kind support for analysis and interpretation of DNA sequence data for patients included in the study. Dr. Tarleton is an employee of this nonprofit institution. All remaining authors have nothing to disclose. NR 19 TC 5 Z9 5 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0148-639X EI 1097-4598 J9 MUSCLE NERVE JI Muscle Nerve PD APR PY 2014 VL 49 IS 4 BP 593 EP 600 DI 10.1002/mus.23976 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AD4CE UT WOS:000333193100020 PM 23893571 ER PT J AU Somsouk, M To'o, K Ali, M Vittinghoff, E Yeh, BM Yee, J Monto, A Inadomi, JM Aslam, R AF Somsouk, Ma To'o, Katherine Ali, Mujtaba Vittinghoff, Eric Yeh, Benjamin M. Yee, Judy Monto, Alex Inadomi, John M. Aslam, Rizwan TI Esophageal varices on computed tomography and subsequent variceal hemorrhage SO ABDOMINAL IMAGING LA English DT Article DE Portal hypertension; Variceal hemorrhage; CT; Cirrhosis ID UPPER GI ENDOSCOPY; PROSPECTIVE MULTICENTER; PORTAL-HYPERTENSION; CIRRHOTIC-PATIENTS; CAPSULE ENDOSCOPY; LIVER CT; SEDATION AB Endoscopy is recommended to screen for esophageal varices in patients with cirrhosis. The objective of this study was to identify features on abdominal CT imaging associated variceal hemorrhage (VH). A case-control study was performed among patients with cirrhosis who had a CT scan. Consecutive patients who experienced VH were included as cases, and patients without VH served as controls. Two radiologists recorded the maximal esophageal varix diameter in addition to other measures of portal hypertension at CT. The most powerful CT parameter associated with VH was the esophageal varix diameter (5.8 vs. 2.7 mm, p < 0.001; adjusted OR 1.84 per mm, p = 0.009). 63% of individuals with VH had a maximal varix diameter a parts per thousand yen5 mm compared to 7.5% of cirrhotic patients without VH (p < 0.001). In contrast, the proportion of individuals whose largest varix was < 3 mm was 7.4% among VH cases compared to 54.7% among controls (p = 0.001). The varix diameter powerfully discriminated those with and without VH (C-statistic 0.84). A large esophageal varix diameter is strongly associated with subsequent VH. A threshold of < 3 and a parts per thousand yen5 mm appears to identify patients with cirrhosis at low and high risk for hemorrhage. C1 [Somsouk, Ma] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94110 USA. [To'o, Katherine; Yeh, Benjamin M.; Yee, Judy; Aslam, Rizwan] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94110 USA. [Ali, Mujtaba] Univ Colorado Hosp, Dept Radiol, Aurora, CO USA. [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA. [Monto, Alex] San Francisco VA Med Ctr, Div Gastroenterol & Hepatol, Dept Med, San Francisco, CA USA. [Inadomi, John M.] Univ Washington, Dept Med, Div Gastroenterol & Hepatol, Seattle, WA USA. RP Somsouk, M (reprint author), Univ Calif San Francisco, Dept Med, Div Gastroenterol, 1001 Potrero Ave, San Francisco, CA 94110 USA. EM ma.somsouk@ucsf.edu FU American Society for Gastrointestinal Endoscopy Endoscopic Research Award; National Institute of Diabetes and Digestive and Kidney Diseases [K24 DK080941] FX This work was supported by the American Society for Gastrointestinal Endoscopy Endoscopic Research Award (MS) and from the National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK080941, JI). The funding agencies did not have any role in the design, interpretation, or preparation of the manuscript. NR 16 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0942-8925 EI 1432-0509 J9 ABDOM IMAGING JI Abdom. Imaging PD APR PY 2014 VL 39 IS 2 BP 251 EP 256 DI 10.1007/s00261-013-0057-x PG 6 WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging GA AD2IB UT WOS:000333057000003 PM 24366107 ER PT J AU Harrison, DE Strong, R Allison, DB Ames, BN Astle, CM Atamna, H Fernandez, E Flurkey, K Javors, MA Nadon, NL Nelson, JF Pletcher, S Simpkins, JW Smith, D Wilkinson, JE Miller, RA AF Harrison, David E. Strong, Randy Allison, David B. Ames, Bruce N. Astle, Clinton M. Atamna, Hani Fernandez, Elizabeth Flurkey, Kevin Javors, Martin A. Nadon, Nancy L. Nelson, James F. Pletcher, Scott Simpkins, James W. Smith, Daniel Wilkinson, J. Erby Miller, Richard A. TI Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males SO AGING CELL LA English DT Article DE acarbose; estradiol; heterogeneous mice; lifespan; methylene blue; NDGA ID GENETICALLY HETEROGENEOUS MICE; N-SH CELLS; POSTPRANDIAL HYPERGLYCEMIA; ESTROGEN-RECEPTOR; DIABETES-MELLITUS; ALPHA-GLUCOSIDASE; HORMONE-LEVELS; RAPAMYCIN; 17-BETA-ESTRADIOL; MODULATION AB Four agents acarbose (ACA), 17--estradiol (EST), nordihydroguaiaretic acid (NDGA), and methylene blue (MB) were evaluated for lifespan effects in genetically heterogeneous mice tested at three sites. Acarbose increased male median lifespan by 22% (P<0.0001), but increased female median lifespan by only 5% (P=0.01). This sexual dimorphism in ACA lifespan effect could not be explained by differences in effects on weight. Maximum lifespan (90th percentile) increased 11% (P<0.001) in males and 9% (P=0.001) in females. EST increased male median lifespan by 12% (P=0.002), but did not lead to a significant effect on maximum lifespan. The benefits of EST were much stronger at one test site than at the other two and were not explained by effects on body weight. EST did not alter female lifespan. NDGA increased male median lifespan by 8-10% at three different doses, with P-values ranging from 0.04 to 0.005. Females did not show a lifespan benefit from NDGA, even at a dose that produced blood levels similar to those in males, which did show a strong lifespan benefit. MB did not alter median lifespan of males or females, but did produce a small, statistically significant (6%, P=0.004) increase in female maximum lifespan. These results provide new pharmacological models for exploring processes that regulate the timing of aging and late-life diseases, and in particular for testing hypotheses about sexual dimorphism in aging and health. C1 [Harrison, David E.; Astle, Clinton M.; Flurkey, Kevin] Jackson Lab, Bar Harbor, ME 04609 USA. [Strong, Randy; Fernandez, Elizabeth; Javors, Martin A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Strong, Randy; Fernandez, Elizabeth] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Strong, Randy; Fernandez, Elizabeth] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA. [Strong, Randy; Fernandez, Elizabeth] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Allison, David B.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Ames, Bruce N.; Atamna, Hani] Childrens Hosp Oakland Res Inst, Oakland, CA 94609 USA. [Javors, Martin A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Nadon, Nancy L.] NIA, Div Aging Biol, Bethesda, MD 20892 USA. [Nelson, James F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Pletcher, Scott] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA. [Pletcher, Scott; Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA. [Simpkins, James W.] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA. [Smith, Daniel] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Wilkinson, J. Erby] Univ Michigan, Sch Med, Unit Lab Anim Med, Ann Arbor, MI 48109 USA. [Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. RP Harrison, DE (reprint author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA. EM david.harrison@jax.org OI Allison, David/0000-0003-3566-9399 FU NIA [AG022308, AG022303, AG022307]; Department of Veterans Affairs Office of Research and Development; [CA034196] FX This work was funded in part by NIA Grants AG022308 (D. E. H.), AG022303 (R. A. M.), and AG022307 (R. S.), with important facilities supported by CA034196 (TJL). RS is supported by a Senior Research Career Scientist Award from the Department of Veterans Affairs Office of Research and Development. We wish to thank P. J. Krason, V. Ingalls, Lisa Burmeister, Sabrina van Roekel, N. Durgin, and Vivian Diaz for reliable technical assistance. NR 36 TC 57 Z9 57 U1 3 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD APR PY 2014 VL 13 IS 2 BP 273 EP 282 DI 10.1111/acel.12170 PG 10 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA AC4VG UT WOS:000332518600009 PM 24245565 ER PT J AU Cooper, DC Thayer, JF Waldstein, SR AF Cooper, Denise C. Thayer, Julian F. Waldstein, Shari R. TI Coping with Racism: The Impact of Prayer on Cardiovascular Reactivity and Post-stress Recovery in African American Women SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE Prayer; Blood pressure; Heart rate variability; Racism; Coping; Cardiovascular reactivity ID HEART-RATE-VARIABILITY; BLOOD-PRESSURE; STRESS REACTIVITY; PERCEIVED STRESS; ANGER EXPRESSION; HEALTH; DISEASE; HYPERTENSION; RESPONSES; ADULTS AB Prayer is often used to cope with racism-related stress. Little is known about its impact on cardiovascular function. This study examined how prayer coping relates to cardiovascular reactivity (CVR), post-stress recovery, and affective reactivity in response to racism-related stress. African American women (n = 81; mean age=20 years) reported their use of prayer coping on the Perceived Racism Scale and completed anger recall and racism recall tasks while undergoing monitoring of systolic and diastolic blood pressure (DBP), heart rate, heart rate variability (HRV), and hemodynamic measures. Prayer coping was examined for associations with CVR, recovery, and affective change scores using general linear models with repeated measures. Higher prayer coping was associated with decreased state stress and DBP reactivity during racism recall (p's < 0.05) and with decreased DBP and increased HRV during racism recall recovery(p's < 0.05). Coping with racism by utilizing prayer may have cardiovascular benefits for African American women. C1 [Cooper, Denise C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Thayer, Julian F.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA. [Waldstein, Shari R.] Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA. [Cooper, Denise C.] VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, Seattle, WA 98101 USA. RP Cooper, DC (reprint author), VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM cooped2@uw.edu FU NIGMS NIH HHS [R25-GM55036] NR 55 TC 2 Z9 2 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 IS 2 BP 218 EP 230 DI 10.1007/s12160-013-9540-4 PG 13 WC Psychology, Multidisciplinary SC Psychology GA AD7BO UT WOS:000333416300013 PM 24122482 ER PT J AU Okonkwo, OC Xu, GF Oh, JM Dowling, NM Carlsson, CM Gallagher, CL Birdsill, AC Palotti, M Wharton, W Hermann, BP Larue, A Bendlin, BB Rowley, HA Asthana, S Sager, MA Johnson, SC AF Okonkwo, Ozioma C. Xu, Guofan Oh, Jennifer M. Dowling, N. Maritza Carlsson, Cynthia M. Gallagher, Catherine L. Birdsill, Alex C. Palotti, Matthew Wharton, Whitney Hermann, Bruce P. LaRue, Asenath Bendlin, Barbara B. Rowley, Howard A. Asthana, Sanjay Sager, Mark A. Johnson, Sterling C. TI Cerebral Blood Flow is Diminished in Asymptomatic Middle-Aged Adults with Maternal History of Alzheimer's Disease SO CEREBRAL CORTEX LA English DT Article DE Alzheimers disease; cerebral blood flow; maternal family history; preclinical; pseudocontinuous arterial spin labeling ID MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; BRAIN GLUCOSE-METABOLISM; FAMILY-HISTORY; NORMAL INDIVIDUALS; OXIDATIVE STRESS; PERFUSION MRI; TEST-BATTERY; LIFE-SPAN; FDG-PET AB Cerebral blood flow (CBF) provides an indication of the metabolic status of the cortex and may have utility in elucidating preclinical brain changes in persons at risk for Alzheimers disease (AD) and related diseases. In this study, we investigated CBF in 327 well-characterized adults including patients with AD (n 28), patients with amnestic mild cognitive impairment (aMCI, n 23), older cognitively normal (OCN, n 24) adults, and asymptomatic middle-aged adults (n 252) with and without a family history (FH) of AD. Compared with the asymptomatic cohort, AD patients displayed significant hypoperfusion in the precuneus, posterior cingulate, lateral parietal cortex, and the hippocampal region. Patients with aMCI exhibited a similar but less marked pattern of hypoperfusion. Perfusion deficits within the OCN adults were primarily localized to the inferior parietal lobules. Asymptomatic participants with a maternal FH of AD showed hypoperfusion in hippocampal and parietofrontal regions compared with those without a FH of AD or those with only a paternal FH of AD. These observations persisted when gray matter volume was included as a voxel-wise covariate. Our findings suggest that having a mother with AD might confer a particular risk for AD-related cerebral hypoperfusion in midlife. In addition, they provide further support for the potential utility of arterial spin labeling for the measurement of AD-related neurometabolic dysfunction, particularly in situations where [18F]fluorodeoxyglucose imaging is infeasible or clinically contraindicated. C1 [Okonkwo, Ozioma C.; Xu, Guofan; Oh, Jennifer M.; Dowling, N. Maritza; Carlsson, Cynthia M.; Gallagher, Catherine L.; Birdsill, Alex C.; Palotti, Matthew; Wharton, Whitney; Bendlin, Barbara B.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Okonkwo, Ozioma C.; Xu, Guofan; Oh, Jennifer M.; Dowling, N. Maritza; Carlsson, Cynthia M.; Birdsill, Alex C.; Palotti, Matthew; Wharton, Whitney; Hermann, Bruce P.; LaRue, Asenath; Bendlin, Barbara B.; Rowley, Howard A.; Asthana, Sanjay; Sager, Mark A.; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53705 USA. [Okonkwo, Ozioma C.; Hermann, Bruce P.; LaRue, Asenath; Bendlin, Barbara B.; Sager, Mark A.; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53705 USA. [Xu, Guofan; Rowley, Howard A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53705 USA. [Dowling, N. Maritza] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53705 USA. [Gallagher, Catherine L.; Hermann, Bruce P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53705 USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU Veterans Administration Merit Review grant [I01CX000165]; National Institute on Aging [AG021155, AG027161, P50 AG033514, P50 AG033514-S1]; Clinical and Translational Science Award [UL1RR025011] FX This work was supported by a Veterans Administration Merit Review grant I01CX000165 (S.C.J.); by National Institute on Aging grants AG021155 (to S.C.J.), AG027161 (to M. A. S.), P50 AG033514 (to S. A.), and P50 AG033514-S1 (to O.C.O.); and by a Clinical and Translational Science Award (UL1RR025011) to the University of Wisconsin, Madison. Additionally, portions of this research were supported by facilities and resources at the Geriatric Research Education and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison, WI. This is GRECC manuscript #2012-03. NR 58 TC 14 Z9 15 U1 2 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD APR PY 2014 VL 24 IS 4 BP 978 EP 988 DI 10.1093/cercor/bhs381 PG 11 WC Neurosciences SC Neurosciences & Neurology GA AD2FC UT WOS:000333048200012 PM 23236200 ER PT J AU Melia, MT Brau, N Poordad, F Lawitz, EJ Shiffman, ML McHutchison, JG Muir, AJ Galler, GW Nyberg, LM Lee, WM Schiff, E Long, JM Noviello, S Brass, CA Pedicone, LD Sulkowski, MS AF Melia, Michael T. Braeu, Norbert Poordad, Fred Lawitz, Eric J. Shiffman, Mitchell L. McHutchison, John G. Muir, Andrew J. Galler, Greg W. Nyberg, Lisa M. Lee, William M. Schiff, Eugene Long, Jianmin Noviello, Stephanie Brass, Clifford A. Pedicone, Lisa D. Sulkowski, Mark S. TI Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE hepatitis C virus; lymphopenia; infections; neutropenia; interferon ID CHRONIC HEPATITIS-C; COMBINATION THERAPY; PLUS RIBAVIRIN; CLINICAL-PRACTICE; INTERFERON-ALPHA; NEUTROPENIA; DISEASES; UPDATE AB Background. Myelosuppression due to pegylated interferon (peg-IFN) is common during treatment for hepatitis C virus. The relationship between infection risk and decreases in leukocyte lines, however, is not well established. The objective of this analysis was to determine the incidence of and risk factors for infections during peg-IFN/ribavirin (RBV) therapy. Methods. A total of 3070 treatment-naive, chronic hepatitis C genotype 1-infected patients were treated for up to 48 weeks with peg-IFN alfa-2b 1.5 mu g/kg/week or 1 mu g/kg/week, or peg-IFN alfa-2a 180 mu g/week plus RBV. On-treatment leukocyte counts were obtained every 2-6 weeks. Dose reduction was required for a neutrophil count <0.75 x 10(9) cells/L, and treatment discontinuation was required for a neutrophil count <0.5 x 10(9) cells/L. Granulocyte colony-stimulating factor was prohibited. Data on infections were captured at each study visit and categorized according to MedDRA version 13.0. Results. A total of 581 (19%) patients experienced moderate, severe, or life-threatening infections as assessed by the investigator; 648 (21%) patients had at least 1 neutrophil count <0.75 x 10(9) cells/L, but only 242 (8%) sustained an infection and had a neutrophil count <0.75 x 10(9) cells/L at any time while on treatment. Twelve patients had severe or life-threatening infection and grade 3/4 neutropenia, but only 4 had temporally related infections. In a multivariate logistic regression model, nadir lymphocyte count, history of depression, and female sex, but not nadir neutrophil count, were associated with moderate, severe, or life-threatening infection. Conclusions. Nadir lymphocyte count, not nadir neutrophil count, was independently associated with moderate, severe, or life-threatening infections in the IDEAL study. Clinicians should be aware of their patients' absolute lymphocyte counts during peg-IFN/RBV therapy; peg-IFN dose reductions may be a consideration in patients with significant lymphocytopenia (<0.5 x 10(9) cells/L). C1 [Melia, Michael T.; Sulkowski, Mark S.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA. [Braeu, Norbert] Bronx Vet Affairs Med Ctr, New York, NY USA. [Poordad, Fred; Lawitz, Eric J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shiffman, Mitchell L.] Bon Secours Hlth Syst, Liver Inst Virginia, Richmond, VA USA. [McHutchison, John G.] Gilead Sci Inc, Foster City, CA 94404 USA. [Muir, Andrew J.] Duke Univ, Med Ctr, Durham, NC USA. [Galler, Greg W.] Kelsey Res Fdn, Houston, TX USA. [Nyberg, Lisa M.] Kaiser Permanente, San Diego Med Ctr, San Diego, CA USA. [Lee, William M.] Univ Texas SW Med Ctr Dallas, Clin Ctr Liver Dis, Dallas, TX 75390 USA. [Schiff, Eugene] Univ Miami, Ctr Liver Dis, Coral Gables, FL 33124 USA. [Long, Jianmin; Noviello, Stephanie; Brass, Clifford A.; Pedicone, Lisa D.] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA. RP Melia, MT (reprint author), Johns Hopkins Univ, Sch Med, 1830 E Monument St,448, Baltimore, MD 21287 USA. EM mmelia4@jhmi.edu FU Schering-Plough Research Institute FX Financial support. This work was supported by grants from Schering-Plough Research Institute, now Merck Research Laboratories. NR 20 TC 5 Z9 5 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2014 VL 58 IS 7 BP 960 EP 969 DI 10.1093/cid/ciu009 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AD2HM UT WOS:000333055400009 PM 24399086 ER PT J AU Swenson, ER AF Swenson, Erik R. TI Safety of carbonic anhydrase inhibitors SO EXPERT OPINION ON DRUG SAFETY LA English DT Review DE acetazolamide; carbonic anhydrase; side effects; sulfamate; sulfonamide ID CEREBRAL-BLOOD-FLOW; CROSS-REACTIVITY; RENAL-FUNCTION; ACETAZOLAMIDE TERATOGENESIS; OCULAR HYPERTENSION; SMOOTH-MUSCLE; IN-VIVO; METHAZOLAMIDE; ACIDOSIS; GLAUCOMA AB Introduction: Carbonic anhydrase (CA) inhibitors have an impressive safety record despite the multiple functions that CA isozymes serve because they are not fully inhibited with most dosing. While reducing the targeted CA-dependent process sufficiently for disease control, residual activity and uncatalyzed rates in combination with compensations are adequate to avoid lethal consequences. Some drugs have in vitro selectivity differences against the 13 active isozymes, but none are convincingly selective in vivo or clinically. Efforts to synthesize selective inhibitors should result in safer drugs with fewer side effects. Areas covered: This review will focus on approved drugs with CA-inhibiting activity, whether used directly for this purpose or others. Side effects are discussed in relation to various organ systems and the disease being treated. Causes of side effects are considered, and strategies for symptom reduction are given. Expert opinion: Common side effects of paresthesias, dyspepsia, lassitude and fatigue in 30-40% of patients are generally tolerable or abate, but if not can be partially relieved by bicarbonate supplementation. The most important safety concerns are severe acidosis, respiratory failure and encephalopathy in patients with renal, pulmonary and hepatic disease where caution is critical, as is also the case in persons with sulfa drug allergies. C1 Univ Washington, Med Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Swenson, ER (reprint author), Univ Washington, Med Serv, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111 PLUM, Seattle, WA 98108 USA. EM Erik.Swenson@va.gov NR 128 TC 11 Z9 11 U1 1 U2 15 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1474-0338 EI 1744-764X J9 EXPERT OPIN DRUG SAF JI Expert Opin. Drug Saf. PD APR PY 2014 VL 13 IS 4 BP 459 EP 472 DI 10.1517/14740338.2014.897328 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AD2ET UT WOS:000333047200006 PM 24611470 ER PT J AU Saunders, GH Dann, SM Griest, SE Frederick, MT AF Saunders, Gabrielle H. Dann, Serena M. Griest, Susan E. Frederick, Melissa T. TI Development and evaluation of a questionnaire to assess knowledge, attitudes, and behaviors towards hearing loss prevention SO INTERNATIONAL JOURNAL OF AUDIOLOGY LA English DT Article DE Hearing conservation; health behaviors; health belief model; questionnaires ID MENTAL-STATE-EXAMINATION; HEALTH-PROMOTION MODEL; PRIMARY-CARE; NOISE; MUSIC; INTERVENTIONS; CONSERVATION; PREVALENCE; PROTECTION; EXPOSURE AB Objective: To develop and evaluate a questionnaire assessing knowledge, attitudes, and behaviors (KAB) as they pertain to hearing conservation, using the constructs of the health belief model (HBM). Design: The KAB was completed by 235 participants. Relationships between knowledge and attitudes about hearing and hearing conservation, participation in noisy activities, and use of hearing protection were examined. Study sample: 117 males and 118 females aged between 18 and 80 years (mean = 42.3, SD = 4.1) recruited from the Portland VA Medical Center, local universities, and a community college. Results: Knowledge scores ranged from 15.6% to 93.8%. Factor analyses revealed six attitude factors, interpreted as measuring perceived susceptibility, perceived severity, perceived benefits, perceived barriers, perceived self-efficacy, and cues to action. Over 95% of participants routinely participated in at least one noisy activity but few used hearing protection while doing so. The attitude scores of individuals who used hearing protection differed significantly from the scores of those who did not. Conclusions: Significant relationships between use of hearing protection and scores on the KAB provide validation that the HBM is a valuable framework for understanding hearing health behaviors, and evidence that the KAB is a valid tool for assessing these attitudes and behaviors. C1 [Saunders, Gabrielle H.; Dann, Serena M.; Griest, Susan E.; Frederick, Melissa T.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Saunders, Gabrielle H.; Griest, Susan E.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Saunders, GH (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM gabrielle.saunders@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Grant [C7214R] FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Grant # #C7214R. Aspects of these data were presented at the National Hearing Conservation Association (NHCA), Mesa, USA, February 24-26, 2011, at the Academy of Rehabilitative Audiology Institute, San Francisco, USA, September 12 - 14, 2010. NR 46 TC 5 Z9 5 U1 2 U2 20 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1499-2027 EI 1708-8186 J9 INT J AUDIOL JI Int. J. Audiol. PD APR PY 2014 VL 53 IS 4 BP 209 EP 218 DI 10.3109/14992027.2013.860487 PG 10 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA AC9PR UT WOS:000332867100001 PM 24467444 ER PT J AU Sumino, K O'Brian, K Bartle, B Au, DH Castro, M Lee, TA AF Sumino, Kaharu O'Brian, Katiuscia Bartle, Brian Au, David H. Castro, Mario Lee, Todd A. TI Coexisting chronic conditions associated with mortality and morbidity in adult patients with asthma SO JOURNAL OF ASTHMA LA English DT Article DE Comorbidities; mental disorders; observational study; outcome research; veterans ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; POORLY CONTROLLED ASTHMA; SLEEP-APNEA SYNDROME; HEALTH-CARE; MULTIMORBIDITY; PREVALENCE; RHINITIS; RISK; DEPRESSION AB Objective: Many asthma patients suffer from chronic conditions other than asthma. We investigated the specific contribution of common comorbidities on mortality and morbidity in adult asthma. Methods: In an observational study of adults with incident asthma identified between 1999 and 2003 using National Veterans Affairs and Centers for Medicare and Medicaid Services encounter databases (n = 25 975, follow-up 3.0 +/- 1.7 years), association between 13 most prevalent comorbidities (hypertension, ischemic heart disease (IHD), osteoarthritis, rheumatoid arthritis, diabetes, mental disorders, substance/drug abuse, enlarged prostate, depression, cancer, alcoholism, HIV and heart failure) and four conditions previously associated with asthma (sleep apnea, gastroesophageal reflux disease (GERD), rhinitis and sinusitis) and mortality, hospitalizations and asthma exacerbations were assessed using multivariate regression analyses adjusted for other clinically important covariates. Results: HIV followed by alcoholism and mental disorders among 18-45-years old, and heart failure, diabetes, IHD and cancer among those >= 65 years old were associated with an increased risk of all-cause mortality. Many conditions were associated with increased risk for all-cause hospitalizations, but the increased risk was consistent across all ages for mental disorders. For asthma exacerbations, mental disorder followed by substance abuse and IHD were associated with increased risk among those 18-45 years old, and chronic sinusitis, mental disorder and IHD among those >= 65-years old. GERD was associated with decreased risk for asthma exacerbation in all ages. Conclusions: Many comorbidities are associated with poor outcome in adult asthmatics and their effect differs by age. Mental disorders are associated with increased risk of mortality and morbidity across ages. C1 [Sumino, Kaharu; O'Brian, Katiuscia; Castro, Mario] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Sumino, Kaharu; O'Brian, Katiuscia] St Louis VA Med Ctr, St Louis, MO USA. [Bartle, Brian] Hines VA Hosp, Hines, IL USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Au, David H.] Univ Washington, Dept Med, Seattle, WA USA. [Lee, Todd A.] Univ Illinois, Dept Pharm Practice, Chicago, IL USA. RP Sumino, K (reprint author), Washington Univ, Sch Med, Dept Med, 660 Euclid Ave,Campus Box 8052, St Louis, MO 63110 USA. EM ksumino@dom.wustl.edu FU NIH, American Lung Association and Veterans administration; Department of Veterans Affairs, Health Services Research and Development; NIH [1KM1CA156708-1]; American Lung Association; U.S. Department of Veterans Affairs Health Services Research and Development FX KS received Institutional grant monies from NIH, American Lung Association and Veterans administration. No potential conflicts exist with companies/organizations whose product or services pertinent to this article.; AU is funded by the Department of Veterans Affairs, Health Services Research and Development. AU is an unpaid research consultant for Bosch LLC.; MC receives University Grant monies from NIH and American Lung Association. No potential conflicts exist with other companies/organizations whose product or services pertinent to this article.; This research was funded by the U.S. Department of Veterans Affairs Health Services Research and Development. The funding agency did not play any role in the design, conduct, data analysis, or interpretation of the study. KS was supported by NIH 1KM1CA156708-1. NR 39 TC 15 Z9 15 U1 2 U2 12 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 EI 1532-4303 J9 J ASTHMA JI J. Asthma PD APR PY 2014 VL 51 IS 3 BP 306 EP 314 DI 10.3109/02770903.2013.879881 PG 9 WC Allergy; Respiratory System SC Allergy; Respiratory System GA AD2VO UT WOS:000333094100013 PM 24432868 ER PT J AU Jahshan, C Wynn, JK McCleery, A Glahn, DC Altshuler, LL Green, MF AF Jahshan, Carol Wynn, Jonathan K. McCleery, Amanda Glahn, David C. Altshuler, Lori L. Green, Michael F. TI Cross-diagnostic comparison of visual processing in bipolar disorder and schizophrenia SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Bipolar disorder; Schizophrenia; Visual processing; Perception; Masking; Attentional blink ID BACKWARD-MASKING PERFORMANCE; PSYCHIATRIC RATING-SCALE; ATTENTIONAL BLINK; OBJECT SUBSTITUTION; QUALITY-ASSURANCE; PERCEPTION; DEPRESSION; COGNITION; DEFICITS; MANIA AB Patients with Schizophrenia (SZ) show deficits across various stages of visual information processing. Whether patients with Bipolar Disorder (BD) exhibit these deficits is unclear. In this study, we conducted a detailed comparison of specific stages of early visual perception in BD and SZ. Forty-three BD patients, 43 SZ patients, and 51 matched healthy control subjects (HC) were administered three visual processing paradigms emphasizing: 1) an early stage of object formation (location backward masking), 2) a middle stage of object substitution (four-dot backward masking), and 3) a later stage at the perception-attention interface (rapid serial visual processing (RSVP) task eliciting the attentional blink). SZ performed significantly worse than BD and HC on location and four-dot masking. BD did not significantly differ from HC on either masking task. Both patient groups performed significantly worse than HC on the RSVP task; unlike SZ, BD did not show a significant attentional blink effect compared to HC. Our results indicate that BD patients were intact at the early and middle stages of visual processing (object formation and substitution) but intermediate between the SZ and HC groups at a later processing stage involving perceptual and attentional processes (RSVP task). These findings suggest that SZ is characterized by a diffuse pathophysiology affecting all stages of visual processing whereas in BD disruption is only at the latest stage involving higher order attentional functions. Published by Elsevier Ltd. C1 [Jahshan, Carol; Wynn, Jonathan K.; Altshuler, Lori L.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC, Los Angeles, CA 90073 USA. [Jahshan, Carol; Wynn, Jonathan K.; McCleery, Amanda; Altshuler, Lori L.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Glahn, David C.] Olin Neuropsychiat Res Ctr, Inst Living, New Haven, CT USA. [Glahn, David C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Jahshan, C (reprint author), VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC, Bldg 210,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM carol.jahshan@ucla.edu RI Wynn, Jonathan/H-3749-2014; McCleery, Amanda/D-5471-2016 OI Wynn, Jonathan/0000-0002-1763-8540; McCleery, Amanda/0000-0003-2714-6897 FU NIH [MH089634, MH43292] FX Funding for this study was provided by NIH Grants MH089634 and MH43292 (MFG). The NIH had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 42 TC 6 Z9 7 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD APR PY 2014 VL 51 BP 42 EP 48 DI 10.1016/j.jpsychires.2013.12.014 PG 7 WC Psychiatry SC Psychiatry GA AD0FI UT WOS:000332909500006 PM 24433849 ER PT J AU Lorenzini, A Salmon, AB Lerner, C Torres, C Ikeno, Y Motch, S McCarter, R Sell, C AF Lorenzini, Antonello Salmon, Adam B. Lerner, Chad Torres, Claudio Ikeno, Yuji Motch, Susan McCarter, Roger Sell, Christian TI Mice Producing Reduced Levels of Insulin-Like Growth Factor Type 1 Display an Increase in Maximum, but not Mean, Life Span SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE IGF-1; Insulin; Metabolism; Obesity; Gluconeogenesis ID LONGITUDINAL BONE-GROWTH; I RECEPTOR GENE; IGF-I; CAENORHABDITIS-ELEGANS; MOLECULAR EVOLUTION; POSTNATAL-GROWTH; CELL-PROLIFERATION; LIT MUTATION; MUTANT MICE; HORMONE AB Reduced signaling through the IGF type 1 (IGF-1) receptor increases life span in multiple invertebrate organisms. Studies on mammalian longevity suggest that reducing levels of IGF-1 may also increase life span. However, the data are conflicting and complicated by the physiology of the mammalian neuroendocrine system. We have performed life-span analysis on mice homozygous for an insertion in the Igf1 gene. These mice produce reduced levels of IGF-1 and display a phenotype consistent with a significant decrease in IGF-1. Life-span analysis was carried out at three independent locations. Although the life-span data varied between sites, the maximum life span of the IGF-1-deficient mice was significantly increased and age-specific mortality rates were reduced in the IGF-1-deficient mice; however, mean life span did not differ except at one site, where mean life span was increased in female IGF-1-deficient animals. Early life mortality was noted in one cohort of IGF-1-deficient mice. The results are consistent with a significant role for IGF-1 in the modulation of life span but contrast with the published life-span data for the hypopituitary Ames and Snell dwarf mice and growth hormone receptor null mice, indicating that a reduction in IGF-1 alone is insufficient to increase both mean and maximal life span in mice. C1 [Lorenzini, Antonello] Univ Bologna, Dept Biomed & Neuromotor Sci, I-40126 Bologna, Italy. [Lorenzini, Antonello; Lerner, Chad; Torres, Claudio; Sell, Christian] Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19104 USA. [Salmon, Adam B.; Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Res, San Antonio, TX 78229 USA. [Salmon, Adam B.; Ikeno, Yuji] Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Helathcare Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78284 USA. [Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Motch, Susan] Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA. [McCarter, Roger] Penn State Univ, Ctr Dev & Hlth Genet, University Pk, PA 16802 USA. RP Sell, C (reprint author), Drexel Univ COM, Dept Pathol, 245 N 15th St, Philadelphia, PA 19102 USA. EM Christian.sell@dexelmed.edu RI Lorenzini, Antonello/G-4463-2012; LORENZINI, ANTONELLO/E-6582-2016 OI LORENZINI, ANTONELLO/0000-0001-9615-9697 FU National Institutes of Health from the National Institute on Aging [T32 AG021890-05, AG223343]; Drexel University Aging Initiative FX This work was supported by National Institutes of Health training grants (T32 AG021890-05, AG223343) from the National Institute on Aging and by funds from the Drexel University Aging Initiative. NR 63 TC 10 Z9 10 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2014 VL 69 IS 4 BP 410 EP 419 DI 10.1093/gerona/glt108 PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6QI UT WOS:000333385500005 PM 23873963 ER PT J AU Koyama, A Steinman, M Ensrud, K Hillier, TA Yaffe, K AF Koyama, Alain Steinman, Michael Ensrud, Kristine Hillier, Teresa A. Yaffe, Kristine TI Long-term Cognitive and Functional Effects of Potentially Inappropriate Medications in Older Women SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Dementia; Cognitive aging; Medication; Epidemiology; Physical function ID ELDERLY-PATIENTS; CONTROLLED-TRIAL; ALZHEIMERS TYPE; SEX-DIFFERENCES; ADULTS; IMPAIRMENT; DEMENTIA; RISK; ANTICHOLINERGICS; METAANALYSIS AB Background. The use of potentially inappropriate medications in older adults can lead to known adverse drug events, but long-term effects are less clear. We therefore conducted a prospective cohort study of older women to determine whether PIM use is associated with risk of functional impairment or low cognitive performance. Methods. We followed up 1,429 community-dwelling women (>= 75 years) for a period of 5 years at four clinical sites in the United States. The primary predictor at baseline was PIM use based on 2003 Beers Criteria. We also assessed anticholinergic load using the Anticholinergic Cognitive Burden scale. Outcomes included scores on a battery of six cognitive tests at follow-up and having one or more incident impairments in instrumental activities of daily living. Regression models were adjusted for baseline age, race, education, smoking, physical activity, a modified Charlson Comorbidity Index, and cognitive score. Results. The mean +/- SD age of women at baseline was 83.2 +/- 3.3. In multivariate models, baseline PIM use and higher ACB scores were significantly associated with poorer performance in category fluency (PIM: p = .01; ACB: p = .02) and immediate (PIM: p = .04; ACB: p = .03) and delayed recall (PIM: p = .04). Both PIM use (odds ratio [OR]: 1.36 [1.05-1.75]) and higher ACB scores (OR: 1.11 [1.04-1.19]) were also strongly associated with incident functional impairment. Conclusions. The results provide suggestive evidence that PIM use and increased anticholinergic load may be associated with risk of functional impairment and low cognitive performance. More cautious selection of medications in older adults may reduce these potential risks. C1 [Koyama, Alain] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Koyama, Alain; Steinman, Michael; Yaffe, Kristine] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA. [Steinman, Michael] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Ensrud, Kristine] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Ensrud, Kristine] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Ensrud, Kristine] Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Hillier, Teresa A.] Kaiser Permanente Northwest Hawaii, Ctr Hlth Res, Portland, OR USA. [Hillier, Teresa A.] Kaiser Permanente Northwest Hawaii, Ctr Hlth Res, Honolulu, HI USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat Neurol & Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Koyama, A (reprint author), 4150 Clement St,VAMC 116H, San Francisco, CA 94121 USA. EM akk412@mail.harvard.edu FU National Institute of Aging at the National Institutes of Health [K24 AG 031155, R01 AG 026720]; Alzheimer's Association [IIRG-08-88872]; National Institutes of Health; National Institute on Aging (NIA) [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 AG027576] FX This work was supported by the National Institute of Aging at the National Institutes of Health (grants K24 AG 031155, R01 AG 026720) and the Alzheimer's Association (grant IIRG-08-88872). The Study of Osteoporotic Fractures is supported by the National Institutes of Health. The National Institute on Aging (NIA) provides support under the following grant numbers: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. NR 41 TC 20 Z9 20 U1 2 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2014 VL 69 IS 4 BP 423 EP 429 DI 10.1093/gerona/glt192 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6QI UT WOS:000333385500006 PM 24293516 ER PT J AU Wetherill, RR Childress, AR Jagannathan, K Bender, J Young, KA Suh, JJ O'Brien, CP Franklin, TR AF Wetherill, Reagan R. Childress, Anna Rose Jagannathan, Kanchana Bender, Julian Young, Kimberly A. Suh, Jesse J. O'Brien, Charles P. Franklin, Teresa R. TI Neural responses to subliminally presented cannabis and other emotionally evocative cues in cannabis-dependent individuals SO PSYCHOPHARMACOLOGY LA English DT Article DE Addiction; Cannabis cues; Neuroimaging; Cannabis craving; Subliminal; Marijuana cues; Marijuana craving; Reward ID LIKELIHOOD ESTIMATION METAANALYSIS; ORBITOFRONTAL CORTEX; LIMBIC ACTIVATION; QUANTITATIVE METAANALYSIS; CONDITIONED-RESPONSES; ANTERIOR CINGULATE; INHIBITORY CONTROL; DECISION-MAKING; HUMAN AWARENESS; PERFUSION FMRI AB Addiction theories posit that drug-related cues maintain and contribute to drug use and relapse. Indeed, our recent study in cocaine-dependent patients demonstrated that subliminally presented cocaine-related stimuli activate reward neurocircuitry without being consciously perceived. Activation of reward neurocircuitry may provoke craving and perhaps prime an individual for subsequent drug-seeking behaviors. Using an equivalent paradigm, we tested whether cannabis cues activate reward neurocircuitry in treatment-seeking, cannabis-dependent individuals and whether activation was associated with relevant behavioral anchors: baseline cannabis craving (drug-seeking behavior) and duration of use (degree of conditioning). Twenty treatment-seeking, cannabis-dependent individuals (12 males) underwent event-related blood oxygen level-dependent functional magnetic resonance imaging during exposure to 33-ms cannabis, sexual, and aversive cues presented in a backward-masking paradigm. Drug use history and cannabis craving were assessed prior to imaging. Participants showed increased activity to backward-masked cannabis cues in regions supporting reward detection and interoception, including the left anterior insula, left ventral striatum/amygdala, and right ventral striatum. Cannabis cue-related activity in the bilateral insula and perigenual anterior cingulate cortex was positively associated with baseline cannabis craving, and cannabis cue-related activity in the medial orbitofrontal cortex was positively correlated with years of cannabis use. Neural responses to backward-masked sexual cues were similar to those observed during cannabis cue exposure, while activation to aversive cues was observed only in the left anterior insula and perigenual anterior cingulate cortex. These data highlight the sensitivity of the brain to subliminal reward signals and support hypotheses promoting a common pathway of appetitive motivation. C1 [Wetherill, Reagan R.; Childress, Anna Rose; Jagannathan, Kanchana; Bender, Julian; Young, Kimberly A.; Suh, Jesse J.; O'Brien, Charles P.; Franklin, Teresa R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Childress, Anna Rose; Suh, Jesse J.; O'Brien, Charles P.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Wetherill, RR (reprint author), Univ Penn, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM rweth@mail.med.upenn.edu FU Pennsylvania Department of Health Commonwealth Universal Research Enhancement (CURE) FX This research was made possible by the Pennsylvania Department of Health Commonwealth Universal Research Enhancement (CURE) funding. NR 80 TC 14 Z9 15 U1 6 U2 22 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD APR PY 2014 VL 231 IS 7 BP 1397 EP 1407 DI 10.1007/s00213-013-3342-z PG 11 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AD0WI UT WOS:000332954600012 PM 24186078 ER PT J AU Siler, DA Gonzalez, JA Wang, RK Cetas, JS Alkayed, NJ AF Siler, Dominic A. Gonzalez, Jorge A. Wang, Ruikang K. Cetas, Justin S. Alkayed, Nabil J. TI Intracisternal Administration of Tissue Plasminogen Activator Improves Cerebrospinal Fluid Flow and Cortical Perfusion After Subarachnoid Hemorrhage in Mice SO TRANSLATIONAL STROKE RESEARCH LA English DT Article DE Early brain injury; Global ischemia; Intracranial pressure; Subarachnoid hemorrhage; Tissue plasminogen activator; Cerebral blood flow ID ANEURYSMAL INTRAVENTRICULAR HEMORRHAGE; EARLY BRAIN-INJURY; PRIMATE MODEL; INTRATHECAL FIBRINOLYSIS; THROMBOLYTIC THERAPY; CEREBRAL-ISCHEMIA; ACUTE-PHASE; VASOSPASM; PREVENTION; CLOT AB Early brain injury (EBI) during the first 72 h after subarachnoid hemorrhage (SAH) is an important determinant of clinical outcome. A hallmark of EBI, global cerebral ischemia, occurs within seconds of SAH and is thought to be related to increased intracranial pressure (ICP). We tested the hypothesis that ICP elevation and cortical hypoperfusion are the result of physical blockade of cerebrospinal fluid (CSF) flow pathways by cisternal microthrombi. In mice subjected to SAH, we measured cortical blood volume (CBV) using optical imaging, ICP using pressure transducers, and patency of CSF flow pathways using intracisternally injected tracer dye. We then assessed the effects of intracisternal injection of recombinant tissue plasminogen activator (tPA). ICP rose immediately after SAH and remained elevated for 24 h. This was accompanied by a decrease in CBV and impaired dye movement. Intracisternal administration of tPA immediately after SAH lowered ICP, increased CBV, and partially restored CSF flow at 24 h after SAH. Lowering ICP without tPA, by draining CSF, improved CBV at 1 h, but not 24 h after SAH. These findings suggest that blockade of CSF flow by microthrombi contributes to the early decline in cortical perfusion in an ICP-dependent and ICP-independent manner and that intracisternal tPA may reduce EBI and improve outcome after SAH. C1 [Siler, Dominic A.; Gonzalez, Jorge A.; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Siler, Dominic A.; Cetas, Justin S.; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA. [Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA. [Cetas, Justin S.] Portland VA Med Ctr, Portland, OR 97239 USA. [Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA. RP Alkayed, NJ (reprint author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd,UHN 2, Portland, OR 97239 USA. EM alkayedn@ohsu.edu FU NHLBI [F30 HL108624, R01 HL093140]; Oregon Brain Institute; NINDS [R01 NS044313, NS070837]; NIBIB [R01 EB009682] FX Dominic A. Siler-NHLBI F30 HL108624, Oregon Brain Institute.; Nabil J. Alkayed-NINDS R01 NS044313 and NS070837; Ruikang K. Wang-NHLBI R01 HL093140 and NIBIB R01 EB009682 NR 42 TC 9 Z9 9 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD APR PY 2014 VL 5 IS 2 BP 227 EP 237 DI 10.1007/s12975-014-0329-y PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AD2FT UT WOS:000333050000007 PM 24526376 ER PT J AU Hiramoto, JS Katz, R Ix, JH Wassel, C Rodondi, N Windham, BG Harris, T Koster, A Satterfield, S Newman, A Shlipak, MG AF Hiramoto, Jade S. Katz, Ronit Ix, Joachim H. Wassel, Christina Rodondi, Nicolas Windham, B. Gwen Harris, Tamara Koster, Annemarie Satterfield, Suzanne Newman, Anne Shlipak, Michael G. CA Hlth ABC Study TI Sex differences in the prevalence and clinical outcomes of subclinical peripheral artery disease in the Health, Aging, and Body Composition (Health ABC) study SO VASCULAR LA English DT Article DE women; peripheral artery disease; epidemiology; sex-specific ID ANKLE-BRACHIAL INDEX; CRITICAL LIMB ISCHEMIA; PREDICT CARDIOVASCULAR EVENTS; NUTRITION EXAMINATION SURVEY; AMERICAN-HEART-ASSOCIATION; MIDDLE-AGED POPULATION; BLOOD-PRESSURE INDEX; LOWER-EXTREMITY; ARM INDEX; NATIONAL-HEALTH AB The objective of the study was to determine if there are sex-based differences in the prevalence and clinical outcomes of subclinical peripheral artery disease (PAD). We evaluated the sex-specific associations of ankle-brachial index (ABI) with clinical cardiovascular disease outcomes in 2797 participants without prevalent clinical PAD and with a baseline ABI measurement in the Health, Aging, and Body Composition study. The mean age was 74 years, 40% were black, and 52% were women. Median follow-up was 9.37 years. Women had a similar prevalence of ABI < 0.9 (12% women versus 11% men; P = 0.44), but a higher prevalence of ABI 0.9-1.0 (15% versus 10%, respectively; P < 0.001). In a fully adjusted model, ABI < 0.9 was significantly associated with higher coronary heart disease (CHD) mortality, incident clinical PAD and incident myocardial infarction in both women and men. ABI < 0.9 was significantly associated with incident stroke only in women. ABI 0.9-1.0 was significantly associated with CHD death in both women (hazard ratio 4.84, 1.53-15.31) and men (3.49, 1.39-8.72). However, ABI 0.9-1.0 was significantly associated with incident clinical PAD (3.33, 1.44-7.70) and incident stroke (2.45, 1.38-4.35) only in women. Subclinical PAD was strongly associated with adverse CV events in both women and men, but women had a higher prevalence of subclinical PAD. C1 [Hiramoto, Jade S.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA. [Wassel, Christina] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, La Jolla, CA 92093 USA. [Rodondi, Nicolas] Univ Bern, Inselspital, Dept Gen Internal Med, CH-3012 Bern, Switzerland. [Windham, B. Gwen] Univ Mississippi, Med Ctr, Dept Internal Med, Jackson, MS 39216 USA. [Harris, Tamara] NIA, Intramural Res Program, Bethesda, MD 20892 USA. [Koster, Annemarie] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Koster, Annemarie] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Social Med, Maastricht, Netherlands. [Satterfield, Suzanne] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Newman, Anne] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Newman, Anne] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Hiramoto, JS (reprint author), UCSF Vasc Surg, 400 Parnassus Ave,A-581,Box 0222, San Francisco, CA 94143 USA. EM jade.hiramoto@ucsfmedctr.org RI Koster, Annemarie/E-7438-2010; Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NIH/NCRR/OD UCSF-CTSI [KL2 RR024130, IH R01DK087961-01A1, R01AG027002-05A1, R01AG034853]; National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050]; NINR [R01-NR012459]; Intramural Research Program of the NIH, National Institute on Aging FX This publication was supported by NIH/NCRR/OD UCSF-CTSI grant Number KL2 RR024130 (Dr Hiramoto), NIH R01DK087961-01A1, R01AG027002-05A1 and R01AG034853 (Dr Shlipak). Its contents are the responsibility of the authors and do not necessarily represent the official views of the NIH. This research was also supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050 and NINR grant R01-NR012459, and in part by the Intramural Research Program of the NIH, National Institute on Aging. NR 36 TC 9 Z9 10 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1708-5381 EI 1708-539X J9 VASCULAR JI Vascular PD APR PY 2014 VL 22 IS 2 BP 142 EP 148 DI 10.1177/1708538113476023 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC9HY UT WOS:000332846400011 PM 23512905 ER PT J AU Duboc, H Tache, Y Hofmann, AF AF Duboc, Henri Tache, Yvette Hofmann, Alan F. TI The bile acid TGR5 membrane receptor: From basic research to clinical application SO DIGESTIVE AND LIVER DISEASE LA English DT Review DE Bile acids; Diabetes; Inflammation; Motility; TGR5 receptor ID IRRITABLE-BOWEL-SYNDROME; PRIMARY SCLEROSING CHOLANGITIS; ENTERIC NERVOUS-SYSTEM; FUNCTIONAL GASTROINTESTINAL DISORDERS; GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; BENIGN ULCER DISEASE; FARNESOID X RECEPTOR; TARGETED DISRUPTION; CULTURED ASTROCYTES AB The TGR5 receptor (or GP-BAR1, or M-BAR) was characterized ten years ago as the first identified G-coupled protein receptor specific for bile acids. TGR5 gene expression is widely distributed, including endocrine glands, adipocytes, muscles, immune organs, spinal cord, and the enteric nervous system. The effect of TGR5 activation depends on the tissue where it is expressed and the signalling cascade that it induces. Animal studies suggest that TGR5 activation influences energy production and thereby may be involved in obesity and diabetes. TGR5 activation also influences intestinal motility. This review provides an overview of TGR5-bile acid interactions in health as well as the possible involvement of TGR5 in human disease. (c) 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. C1 [Duboc, Henri; Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Ctr, Los Angeles, CA 90024 USA. [Duboc, Henri; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA USA. [Duboc, Henri; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Duboc, Henri] Univ Paris Diderot, Louis Mourier Hosp, AP HP, Sorbonne Paris Cite,Dept Gastroenterol & Hepatol, Paris, France. [Duboc, Henri] Univ Paris 06, Hop St Antoine, AP HP, ERL,INSERM,U1057,UMR 7203, Paris, France. [Hofmann, Alan F.] Univ Calif San Diego, Dept Med, Div Gastroenterol, San Diego, CA 92103 USA. RP Duboc, H (reprint author), Hop Louis Mourier, Serv Gastroenterol, F-92700 Colombes, France. EM henri.duboc@gmail.com; AFHofmann@gmail.com FU Robert Tournut Grant from the Societe Nationale Francaise de Gastroenterologie; Philippe Foundation; Assistance-Publique Hopitaux de Paris; Research Career Scientist Award; NIHDDK [R01 57238, DK-41301] FX H.D. was supported by a Robert Tournut Grant from the Societe Nationale Francaise de Gastroenterologie, a research grant from the Philippe Foundation, a Mobility Grant from Assistance-Publique Hopitaux de Paris. Y.T is a recipient of a Research Career Scientist Award, and NIHDDK R01 57238 and DK-41301 (Animal Core). NR 93 TC 58 Z9 60 U1 5 U2 39 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1590-8658 EI 1878-3562 J9 DIGEST LIVER DIS JI Dig. Liver Dis. PD APR PY 2014 VL 46 IS 4 BP 302 EP 312 DI 10.1016/j.dld.2013.10.021 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AC3LL UT WOS:000332420200004 PM 24411485 ER PT J AU Hafkin, JS Osborn, MK Localio, AR Amorosa, VK Kostman, JR Stern, JJ De LaTorre, P Mounzer, K Frank, I Gross, R Chang, KM Lo Re, V AF Hafkin, J. S. Osborn, M. K. Localio, A. R. Amorosa, V. K. Kostman, J. R. Stern, J. J. De LaTorre, P. Mounzer, K. Frank, I. Gross, R. Chang, K. -M. Lo Re, V., III TI Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE HIV; hepatitis B virus; lamivudine; HIV/hepatitis B virus co-infection; tenofovir ID CHRONIC HEPATITIS-B; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; NATURAL-HISTORY; INTERNATIONAL PANEL; DISOPROXIL-FUMARATE; COINFECTED PATIENTS; TREATMENT RESPONSE; HIV COINFECTION; 2008 UPDATE AB Suppression of hepatitis B virus (HBV)-DNA to undetectable levels is an important goal for HIV/HBV-co-infected patients receiving anti-HBV-active antiretroviral therapy (ART), and current guidelines recommend that this outcome should be reached by 1year of treatment. However, the proportion of patients that fail to achieve an undetectable HBV DNA at this time point and its determinants remain unknown in clinical practice. The objective of this study was to determine the incidence and risk factors for incomplete HBV suppression following 1year of tenofovir-based ART. We performed a cohort study among tenofovir-treated HIV/HBV-co-infected patients. Patients had HBV viraemia, initiated tenofovir-based ART and had HBV DNA measured at 1year of therapy. The primary outcome was incomplete HBV suppression (HBV DNA >= 2.6 log IU/mL) at 1year. Logistic regression determined odds ratio (ORs) of incomplete HBV suppression for risk factors of interest. Among 133 patients, 54% (95% CI, 46-63%) had incomplete HBV suppression at 1year. Incomplete suppression was associated with higher baseline HBV DNA (OR, 1.46 per log IU/mL increase; 95% CI, 1.1-1.94) and detectable HIV viraemia at 1year (OR, 2.52; 95% CI, 1.19-5.32). Among 66 patients with suppressed HIV RNA at 1year, 28 (42%) failed to achieve an undetectable HBV DNA. Failure to suppress HBV DNA by 1year occurred in a sizeable proportion of tenofovir-treated HIV/HBV-co-infected patients. Higher HBV DNA and detectable HIV viraemia were risk factors for incomplete HBV suppression. C1 [Hafkin, J. S.; Amorosa, V. K.; Kostman, J. R.; Stern, J. J.; Mounzer, K.; Frank, I.; Gross, R.; Lo Re, V., III] Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Hafkin, J. S.; Localio, A. R.; Gross, R.; Lo Re, V., III] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Hafkin, J. S.; Amorosa, V. K.; Gross, R.; Chang, K. -M.; Lo Re, V., III] Philadelphia Vet Affairs Med Ctr, Med Serv, Philadelphia, PA USA. [Osborn, M. K.] Emory Sch Med, Div Infect Dis, Dept Med, Atlanta, GA USA. [Kostman, J. R.; Lo Re, V., III] Penn Presbyterian Med Ctr, Dept Med, Philadelphia, PA USA. [Stern, J. J.] Penn Hosp, Dept Med, Philadelphia, PA 19107 USA. [De LaTorre, P.] Cooper Univ Hosp, Dept Med, Div Infect Dis, Camden, NJ USA. [Mounzer, K.] Philadelphia Field Initiating Grp HIV Trials, Jonathan Lax Treatment Ctr, Philadelphia, PA USA. [Chang, K. -M.] Univ Penn, Perelman Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. RP Lo Re, V (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 836 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM vincentl@mail.med.upenn.edu RI Lo Re, Vincent/N-7817-2015 FU National Institutes of Health [K01 AI070001]; Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics [HS10399]; Penn Center for AIDS Research [P30 AI 045008] FX This work was supported by National Institutes of Health research grant K01 AI070001 [to V.L.R.], an Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics cooperative agreement (grant #HS10399) [to J.S.H., V.L.R., A.R.L. and R.G.] and the Penn Center for AIDS Research (P30 AI 045008). The funding sources played no role in study design or conduct, data collection, management, analysis or interpretation or in manuscript development. NR 47 TC 6 Z9 6 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 EI 1365-2893 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD APR PY 2014 VL 21 IS 4 BP 288 EP 296 DI 10.1111/jvh.12142 PG 9 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA AC1EU UT WOS:000332237800008 PM 24597697 ER PT J AU Everett, CM Thorpe, CT Palta, M Carayon, P Gilchrist, VJ Smith, MA AF Everett, Christine M. Thorpe, Carolyn T. Palta, Mari Carayon, Pascale Gilchrist, Valerie J. Smith, Maureen A. TI The roles of primary care PAs and NPs caring for older adults with diabetes SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS LA English DT Article DE physician assistant; nurse practitioner; diabetes; primary care; patient-centered medical home; teams ID PHYSICIAN ASSISTANTS; NURSE-PRACTITIONERS; AMBULATORY CARE; UNITED-STATES; CHRONIC ILLNESS; ROLE-CONFLICT; MANAGEMENT; PERFORMANCE; FUTURE; TEAMS AB Electronic health record data linked with Medicare data from an academic physician group were used to propose a multidimensional characterization of PA and NP roles on panels of primary care patients with diabetes. Seven PA and NP roles were defined based on level of involvement, visits with complex patients, and delivery of chronic care. Findings suggest that PAs and NPs in primary care perform a variety of roles and frequently perform multiple roles within a clinic. C1 [Everett, Christine M.] Duke Univ, Sch Med, PA Program, Durham, NC 27708 USA. [Thorpe, Carolyn T.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Palta, Mari; Smith, Maureen A.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53706 USA. [Carayon, Pascale] Univ Wisconsin, Dept Ind & Syst Engn, Ctr Qual & Prod Improvement, Madison, WI 53706 USA. [Gilchrist, Valerie J.; Smith, Maureen A.] Univ Wisconsin, Dept Family Med, Madison, WI 53706 USA. [Smith, Maureen A.] Univ Wisconsin, Dept Surg, Madison, WI 53706 USA. RP Everett, CM (reprint author), Duke Univ, Sch Med, PA Program, Durham, NC 27708 USA. FU Agency for Healthcare Research and Quality [R21 HS017646, R01 HS018368]; Health Innovation Program; Community-Academic Partnerships core of the University of Wisconsin Institute for [1UL1RR025011]; UW School of Medicine and Public Health from the Wisconsin Partnership Program; AHRQ/National Research Service [5-T32-HS00083]; American Academy of Physician Assistants' Breitman-Dorn Fellowship FX The authors disclose that funding for this project was provided by the Agency for Healthcare Research and Quality, grant numbers R21 HS017646 and R01 HS018368. Additional support was provided by the Health Innovation Program, which assisted with institutional review board application, Medicare data management, variable creation, and manuscript formatting; the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health; and the UW School of Medicine and Public Health from the Wisconsin Partnership Program. One author was supported by the AHRQ/National Research Service Award T-32 Institutional Training Program Grant Number: 5-T32-HS00083 and the American Academy of Physician Assistants' Breitman-Dorn Fellowship. No other funding source had a role in the design or conduct; data collection, management, analysis or interpretation; or preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. NR 43 TC 2 Z9 2 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1547-1896 EI 0893-7400 J9 JAAPA-J AM ACAD PHYS JI JAAPA-J. Am. Acad. Physician Assist. PD APR PY 2014 VL 27 IS 4 BP 45 EP 49 DI 10.1097/01.JAA.0000444736.16669.76 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CM3GG UT WOS:000357569400013 PM 24662258 ER PT J AU Butler, J Fonarow, GC Zile, MR Lam, CS Roessig, L Schelbert, EB Shah, SJ Ahmed, A Bonow, RO Cleland, JGF Cody, RJ Chioncel, O Collins, SP Dunnmon, P Filippatos, G Lefkowitz, MP Marti, CN McMurray, JJ Misselwitz, F Nodari, S O'Connor, C Pfeffer, MA Pieske, B Pitt, B Rosano, G Sabbah, HN Senni, M Solomon, SD Stockbridge, N Teerlink, JR Georgiopoulou, VV Gheorghiade, M AF Butler, Javed Fonarow, Gregg C. Zile, Michael R. Lam, Carolyn S. Roessig, Lothar Schelbert, Erik B. Shah, Sanjiv J. Ahmed, Ali Bonow, Robert O. Cleland, John G. F. Cody, Robert J. Chioncel, Ovidiu Collins, Sean P. Dunnmon, Preston Filippatos, Gerasimos Lefkowitz, Martin P. Marti, Catherine N. McMurray, John J. Misselwitz, Frank Nodari, Savina O'Connor, Christopher Pfeffer, Marc A. Pieske, Burkert Pitt, Bertram Rosano, Giuseppe Sabbah, Hani N. Senni, Michele Solomon, Scott D. Stockbridge, Norman Teerlink, John R. Georgiopoulou, Vasiliki V. Gheorghiade, Mihai TI Developing Therapies for Heart Failure With Preserved Ejection Fraction Current State and Future Directions SO JACC-HEART FAILURE LA English DT Article DE epidemiology; heart failure; preserved ejection fraction; prognosis; treatment ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; VENTRICULAR DIASTOLIC DYSFUNCTION; CONVERTING ENZYME-INHIBITORS; PRIOR MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE LEVELS; SINGLE-BLIND TRIAL; EXERCISE CAPACITY; SYSTOLIC FUNCTION; ELDERLY-PATIENTS AB The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting. (C) 2014 by the American College of Cardiology Foundation C1 [Butler, Javed; Marti, Catherine N.; Georgiopoulou, Vasiliki V.] Emory Univ, Dept Med, Emory Cardiovasc Clin Res Inst, Atlanta, GA 30322 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Zile, Michael R.] Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA. [Zile, Michael R.] RHJ Dept Vet Affairs Med Ctr, Charleston, SC USA. [Lam, Carolyn S.] Natl Univ Hlth Syst, Cardiovasc Res Inst, Singapore, Singapore. [Roessig, Lothar; Misselwitz, Frank] Bayer HealthCare, Global Clin Dev, Wuppertal, Germany. [Schelbert, Erik B.] Univ Pittsburgh, Dept Med, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA USA. [Shah, Sanjiv J.; Bonow, Robert O.; Gheorghiade, Mihai] Northwestern Univ, Dept Med, Ctr Cardiovasc Innovat, Feinberg Sch Med, Chicago, IL 60611 USA. [Ahmed, Ali] Univ Alabama Birmingham, Div Gerontol, Birmingham, AL USA. [Cleland, John G. F.] Castle Hill Hosp, Hull York Med Sch, Dept Cardiol, Kingston Upon Hull, Yorks, England. [Cody, Robert J.] Janssen Pharmaceut, Cardiovasc & Metab Div, Raritan, NJ USA. [Chioncel, Ovidiu] Inst Emergency Cardiovasc Dis, Cardiol, Bucharest, Romania. [Collins, Sean P.] Vanderbilt Univ, Dept Emergency Med, Nashville, TN 37235 USA. [Dunnmon, Preston; Stockbridge, Norman] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Filippatos, Gerasimos] Athens Univ Hosp, Dept Cardiol, Athens, Greece. [Lefkowitz, Martin P.] Novartis Pharmaceut Inc, E Hanover, NJ USA. [McMurray, John J.] Univ Glasgow, Glasgow Cardiovasc Res Ctr, British Heart Fdn, Glasgow, Lanark, Scotland. [Nodari, Savina] Univ Brescia, Div Cardiol, Brescia, Italy. [O'Connor, Christopher] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Pfeffer, Marc A.; Solomon, Scott D.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. [Pieske, Burkert] Med Univ Graz, Dept Cardiol, Graz, Austria. [Pitt, Bertram] Univ Michigan, Sch Med, Dept Med, Div Cardiol, Ann Arbor, MI 48104 USA. [Rosano, Giuseppe] Ctr Clin & Basic Sci, Rome, Italy. [Sabbah, Hani N.] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA. [Senni, Michele] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Butler, J (reprint author), Emory Clin, Cardiovasc Res Inst, 1462 Clifton Rd Northeast,Suite AT 504, Atlanta, GA 30322 USA. EM javed.butler@emory.edu OI chioncel, ovidiu/0000-0002-3197-3628; Cleland, John/0000-0002-1471-7016; mcmurray, john/0000-0002-6317-3975 FU NHLBI NIH HHS [U10 HL110302] NR 93 TC 68 Z9 69 U1 3 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD APR PY 2014 VL 2 IS 2 BP 97 EP 112 PG 16 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CX4CX UT WOS:000365647100002 PM 24720916 ER PT J AU Aytaman, A Fox, RK Nunez, M Jain, M Vispo, E Kikuchi, L Page, E Taylor, L Minguez, B Ventura, M Merchante, N Kaplan, DE Harris, M Klinker, H Hernandez, MD Hunt, KK Pineda, JA Nelson, M Barreiro, P Brau, N AF Aytaman, A. Fox, R. K. Nunez, M. Jain, M. Vispo, E. Kikuchi, L. Page, E. Taylor, L. Minguez, B. Ventura, M. Merchante, N. Kaplan, D. E. Harris, M. Klinker, H. Hernandez, M. D. Hunt, K. K. Pineda, J. A. Nelson, M. Barreiro, P. Braeu, N. CA Liver Canc HIV Study Grp TI IMPACT OF SCREENING ON SURVIVAL OF HEPATOCELLULAR CARCINOMA (HCC) IN HIV/HBV-COINFECTED PATIENTS SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Aytaman, A.] VA New York Harbor HCS, Brooklyn, NY USA. [Aytaman, A.] SUNY Downstate Hlth Sci Ctr, Brooklyn, NY USA. [Fox, R. K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Nunez, M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Jain, M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Vispo, E.; Barreiro, P.] Hosp Carlos III, Madrid, Spain. [Kikuchi, L.] Univ Sao Paulo, Sao Paulo, Brazil. [Page, E.; Nelson, M.] Chelsea & Westminster Hosp, London, England. [Page, E.; Nelson, M.] Univ London Imperial Coll Sci Technol & Med, London, England. [Taylor, L.] Miriam Hosp, Providence, RI 02906 USA. [Taylor, L.] Brown Univ, Providence, RI 02912 USA. [Minguez, B.; Ventura, M.] Hosp Univ Vall dHebron, Barcelona, Spain. [Minguez, B.] CIBERehd, Barcelona, Spain. [Merchante, N.; Pineda, J. A.] Hosp Univ Valme, Seville, Spain. [Kaplan, D. E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kaplan, D. E.] Univ Penn, Philadelphia, PA 19104 USA. [Harris, M.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada. [Harris, M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Klinker, H.] Univ Klinikum Wurzburg, Wurzburg, Germany. [Hernandez, M. D.] Univ Cincinnati, Cincinnati, OH USA. [Hunt, K. K.; Braeu, N.] JJP Vet Affairs Med Ctr, Bronx, NY USA. [Hunt, K. K.; Braeu, N.] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA. [Braeu, N.] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA. EM ayse.aytaman@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P558 BP S255 EP S255 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CS3HB UT WOS:000361961700719 ER PT J AU Basu, PP Aloysius, M Shah, NJ AF Basu, P. P. Aloysius, M. Shah, N. J. TI RESTLESS LEG SYNDROME (RLS) IS ASSOCIATED WITH HEPATIC ENCEPHALOPATHY (HE) IN DECOMPENSATED CIRRHOSIS. A CLINICAL PILOT STUDY SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Basu, P. P.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Basu, P. P.; Aloysius, M.] Kings Cty Hosp, Med Ctr, New York, NY USA. [Shah, N. J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Bronx, NY USA. EM basu.patrick@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P528 BP S246 EP S246 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CS3HB UT WOS:000361961700689 ER PT J AU Basu, PP Aloysius, M Shah, NJ Brown, RS AF Basu, P. P. Aloysius, M. Shah, N. J. Brown, R. S., Jr. TI ROLE OF MYCOPHENOLATE MOFETIL (MMF) IN STEROID NON RESPONSIVE SEVERE ACUTE ALCOHOLIC HEPATITIS: A RANDOMIZED OPEN LABEL PLACEBO CONTROL PROSPECTIVE CLINICAL PILOT TRIAL - MASH TRIAL SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Basu, P. P.; Brown, R. S., Jr.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Basu, P. P.; Aloysius, M.] Kings Cty Hosp, Med Ctr, New York, NY USA. [Shah, N. J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Bronx, NY USA. EM basu.patrick@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P328 BP S175 EP S176 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CS3HB UT WOS:000361961700489 ER PT J AU Basu, PP Shah, NJ Aloysius, M Brown, RS AF Basu, P. P. Shah, N. J. Aloysius, M. Brown, R. S., Jr. TI BERBERINE WITH ALFA LIPOIC ACID (ALA) IN NON ALCOHOLIC STEATO-HEPATITIS (NASH). A RANDOMIZED DOUBLE BLINDED PLACEBO CONTROL TRIAL. A CLINICAL PILOT - THE BANISH TRIAL SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Basu, P. P.; Brown, R. S., Jr.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Basu, P. P.; Aloysius, M.] Kings Cty Hosp, Med Ctr, New York, NY USA. [Shah, N. J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Bronx, NY USA. EM basu.patrick@gmail.com NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P853 BP S356 EP S356 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5DT UT WOS:000362828600270 ER PT J AU Mangia, A Marcellin, P Kwo, P Foster, GR Buti, M Brau, N Muir, A Yang, JC Mo, H Ding, X Pang, PS Symonds, WT McHutchison, JG Zeuzem, S Afdhal, N AF Mangia, A. Marcellin, P. Kwo, P. Foster, G. R. Buti, M. Braeu, N. Muir, A. Yang, J. C. Mo, H. Ding, X. Pang, P. S. Symonds, W. T. McHutchison, J. G. Zeuzem, S. Afdhal, N. TI ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Mangia, A.] Osped Casa Sollievo Sofferenza, Unita Epatol, Foggia, Italy. [Marcellin, P.] Hop Beaujon, Serv Hepatol, Ile De France, France. [Kwo, P.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Foster, G. R.] Barts Hlth NHS Trust, Royal London Hosp, London, England. [Foster, G. R.] Ambrose King Cent, Grahame Hayton Unit, London, England. [Buti, M.] Hosp Univ Vall dHebron, Barcelona, Spain. [Braeu, N.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Muir, A.] Duke Univ, Durham, NC USA. [Yang, J. C.; Mo, H.; Ding, X.; Pang, P. S.; Symonds, W. T.; McHutchison, J. G.] Gilead Sci Inc, Foster City, CA 94404 USA. [Zeuzem, S.] Klinikum Johann Wolfgang Goethe Univ, Med Klin 1, Frankfurt, Germany. [Afdhal, N.] Beth Israel Deaconess Med Ctr, Boston, MA USA. EM a.mangia@tin.it NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA O164 BP S523 EP S524 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5DT UT WOS:000362828600715 ER PT J AU Merchante, N Minguez, B Tural, C Kikuchi, L Rodriguez-Arrondo, F Chen, TY Ventura, M Harris, M Daruich, J Kaplan, DE Merino, E Silva, MF Rockstroh, J Munoz, J Jover, F Klinker, H Delgado-Fernandez, M Marcus, S Aberg, J Pineda, JA Sherman, M Hoshida, Y Marrero, J Brau, N AF Merchante, N. Minguez, B. Tural, C. Kikuchi, L. Rodriguez-Arrondo, F. Chen, T-Y. Ventura, M. Harris, M. Daruich, J. Kaplan, D. E. Merino, E. Silva, M. F. Rockstroh, J. Munoz, J. Jover, F. Klinker, H. Delgado-Fernandez, M. Marcus, S. Aberg, J. Pineda, J. A. Sherman, M. Hoshida, Y. Marrero, J. Braeu, N. CA Liver Canc HIV Study Grp TI PREDICTING SURVIVAL OF HIV-INFECTED PATIENTS WITH LIVER CANCER - THE SHILCA SCORE AND STAGING MODEL SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Merchante, N.; Pineda, J. A.] Hosp Univ Valme, Seville, Spain. [Merchante, N.; Delgado-Fernandez, M.; Pineda, J. A.] SAEI, Grp Andaluz Estudio Hepatitis Vir HEPAVIR, Seville, Spain. [Minguez, B.; Ventura, M.] Hosp Univ Vall dHebron, Barcelona, Spain. [Minguez, B.] CIBERehd, Barcelona, Spain. [Tural, C.] Hosp Badalona Germans Trias & Pujol, Badalona, Spain. [Kikuchi, L.] Univ Sao Paulo, Sao Paulo, Brazil. [Rodriguez-Arrondo, F.] Hosp Univ Donostia, San Sebastian, Spain. [Rodriguez-Arrondo, F.; Munoz, J.] Soc Enfermedades Infecciosas Norte SEINORTE, Pamplona, Spain. [Chen, T-Y.; Marrero, J.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Harris, M.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada. [Harris, M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Daruich, J.] Univ Buenos Aires, Buenos Aires, DF, Argentina. [Kaplan, D. E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kaplan, D. E.] Univ Penn, Philadelphia, PA 19104 USA. [Merino, E.] Hosp Gen Univ Alicante, Alicante, Spain. [Merino, E.; Jover, F.] SEICV, Valencia, Spain. [Silva, M. F.] Univ Fed Ciencias Saude Porto Alegre, Porto Alegre, RS, Brazil. [Rockstroh, J.] Univ Bonn, Bonn, Germany. [Munoz, J.] Hosp Basurto, Bilbao, Spain. [Jover, F.] Hosp Clin Univ San Juan, Alicante, Spain. [Klinker, H.] Univ Klinikum Wurzburg, Wurzburg, Germany. [Delgado-Fernandez, M.] Hosp Reg Carlos Haya, Malaga, Spain. [Marcus, S.; Braeu, N.] JJP Vet Affairs Med Ctr, Bronx, NY USA. [Aberg, J.] Bellevue Hosp Ctr, New York, NY 10016 USA. [Aberg, J.] NYU, Sch Med, New York, NY USA. [Sherman, M.] Toronto Gen Hosp, Toronto, ON, Canada. [Sherman, M.] Univ Toronto, Toronto, ON, Canada. [Hoshida, Y.; Braeu, N.] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA. [Braeu, N.] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA. EM norbert.brau@va.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA O35 BP S15 EP S15 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CS3HB UT WOS:000361961700036 ER PT J AU Park, JJ Wong, DK Wahed, AS Lee, WM Feld, JJ Terrault, N Khalili, M Kowdley, KV Lau, DT Sterling, RK Kim, WR Smith, C Carithers, R Levine, DL Keith, J Valiga, ME Lok, ASF Chang, KM AF Park, J. -J. Wong, D. K. Wahed, A. S. Lee, W. M. Feld, J. J. Terrault, N. Khalili, M. Kowdley, K. V. Lau, D. T. Sterling, R. K. Kim, W. R. Smith, C. Carithers, R. Levine, D. L. Keith, J. Valiga, M. E. Lok, A. S. F. Chang, K. -M. TI IMMUNE CORRELATES OF VACCINE-MEDIATED PROTECTIVE IMMUNITY VERSUS VIRAL PERSISTENCE IN HEPATITIS B VIRUS INFECTION SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Park, J. -J.; Levine, D. L.; Keith, J.; Valiga, M. E.; Chang, K. -M.] Univ Penn, Philadelphia, PA 19104 USA. [Park, J. -J.; Levine, D. L.; Keith, J.; Valiga, M. E.; Chang, K. -M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Wong, D. K.; Feld, J. J.] Univ Toronto, Toronto, ON, Canada. [Wahed, A. S.] Univ Pittsburgh, Pittsburgh, PA USA. [Lee, W. M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA. [Terrault, N.] Div Gastroenterol, San Francisco, CA USA. [Khalili, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kowdley, K. V.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Lau, D. T.] Harvard Univ, Div Gastroenterol, Boston, MA 02115 USA. [Sterling, R. K.] Virginia Commonwealth Univ, Richmond, VA USA. [Kim, W. R.] Mayo Clin Rochester, Rochester, MN USA. [Smith, C.] Mayo Clin, Rochester, MN USA. [Smith, C.] Univ Minnesota, Plymouth, MN USA. [Carithers, R.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Lok, A. S. F.] Univ Michigan Hlth Syst, Div Gastroenterol, Ann Arbor, MI USA. EM kmchang@mail.med.upenn.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P163 BP S120 EP S120 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CS3HB UT WOS:000361961700324 ER PT J AU Hage, FG AlJaroudi, W AF Hage, Fadi G. AlJaroudi, Wael TI Review of Cardiovascular Literature SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material C1 [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [AlJaroudi, Wael] Amer Univ Beirut, Med Ctr, Div Cardiovasc Med Cardiovasc Imaging, Beirut, Lebanon. RP AlJaroudi, W (reprint author), Amer Univ Beirut, Med Ctr, Div Cardiovasc Med Cardiovasc Imaging, Beirut, Lebanon. EM wjaroudi@hotmail.com OI Hage, Fadi/0000-0002-1397-4942 NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD APR PY 2014 VL 21 IS 2 BP 229 EP 232 DI 10.1007/s12350-013-9839-3 PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA V42GV UT WOS:000209603200002 ER PT J AU Le, DTE Wei, KV Zhao, Y Nugent, M Kaul, S AF Le, Dai-Trang Elizabeth Wei, Kevin Zhao, Yan Nugent, Matthew Kaul, Sanjiv TI RANOLAZINE RELIEVES ISCHEMIA BY DECREASING MYOCARDIAL WORK WITHOUT ALTERING MYOCARDIAL BLOOD FLOW: INSIGHTS FROM AN EXPERIMENTAL MODEL SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 1 PY 2014 VL 63 IS 12 SU S MA 1279M-365A BP A1519 EP A1519 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CP0QC UT WOS:000359579102277 ER PT J AU Lu, LY Jackevicius, C de Leon, N Warner, A Chang, D Mody, F AF Lu, Lingyun Jackevicius, Cynthia de Leon, Noelle Warner, Alberta Chang, Donald Mody, Freny TI IMPACT OF A MULTI-DISCIPLINARY HEART FAILURE POST-DISCHARGE MANAGEMENT CLINIC ON MEDICATION ADHERENCE SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles HealthCare Syst, Los Angeles, CA USA. Western Univ Hlth Sci, Pomona, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 1 PY 2014 VL 63 IS 12 SU S MA 1186-180 BP A539 EP A539 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CP0QC UT WOS:000359579101197 ER PT J AU Russell, DC Goodfriend, T Haworth, R AF Russell, Douglas C. Goodfriend, Theodore Haworth, Robert TI MECHANISM OF ARRHYTHMOGENESIS INDUCED BY FATTY ACIDS: A ROLE OF MODIFICATION OF MITOCHONDRIAL CREATINE KINASE AND CITRATE SYNTHASE? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 1 PY 2014 VL 63 IS 12 SU S MA 1180-91 BP A370 EP A370 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CP0QC UT WOS:000359579101028 ER PT J AU Tietjens, J Whooley, M Schiller, N Mishra, R AF Tietjens, Jeremy Whooley, Mary Schiller, Nelson Mishra, Rakesh TI THE PROGNOSTIC UTILITY OF AN ECHO-ESTIMATED LEFT VENTRICULAR END-DIASTOLIC PRESSURE-VOLUME RELATIONSHIP IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: THE HEART & SOUL STUDY SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 1 PY 2014 VL 63 IS 12 SU S MA 1129M-363C BP A975 EP A975 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CP0QC UT WOS:000359579101633 ER PT J AU Birdsill, AC Koscik, RL Jonaitis, EM Johnson, SC Okonkwo, OC Hermann, BP Larue, A Sager, MA Bendlin, BB AF Birdsill, Alex C. Koscik, Rebecca L. Jonaitis, Erin M. Johnson, Sterling C. Okonkwo, Ozioma C. Hermann, Bruce P. Larue, Asenath Sager, Mark A. Bendlin, Barbara B. TI Regional white matter hyperintensities: aging, Alzheimer's disease risk, and cognitive function SO NEUROBIOLOGY OF AGING LA English DT Article DE White matter hyperintensities; Aging; Processing speed; Cognition; MRI ID EXECUTIVE FUNCTION; EPISODIC MEMORY; OLDER-ADULTS; ROTTERDAM SCAN; LESIONS; MRI; AGE; BRAIN; APOE; HYPERTENSION AB White matter hyperintensities (WMH) of presumed vascular origin, as seen on T2-weighted fluid attenuated inversion recovery magnetic resonance imaging, are known to increase with age and are elevated in Alzheimer's disease (AD). The cognitive implications of these common markers are not well understood. Previous research has primarily focused on global measures of WMH burden and broad localizations that contain multiple white matter tracts. The aims of this study were to determine the pattern of WMH accumulation with age, risk for AD, and the relationship with cognitive function utilizing a voxel-wise analysis capable of identifying specific white matter regions. A total of 349 participants underwent T1-weighted and high-resolution T2-weighted fluid attenuated inversion recovery magnetic resonance imaging and neuropsychological testing. Increasing age and lower cognitive speed and flexibility (a component of executive function), were both significantly associated with regional WMH throughout the brain. When age was controlled, lower cognitive speed and flexibility was independently associated with WMH in the superior corona radiata. Apolipoprotein E epsilon 4 and parental family history of AD were not associated with higher burden of WMH. The results contribute to a larger body of literature suggesting that white matter measures are linked with processing speed, and illustrate the utility of voxel-wise analysis in understanding the effect of lesion location on cognitive function. (C) 2014 Elsevier Inc. All rights reserved. C1 [Birdsill, Alex C.; Johnson, Sterling C.; Okonkwo, Ozioma C.; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Birdsill, Alex C.; Johnson, Sterling C.; Okonkwo, Ozioma C.; Sager, Mark A.; Bendlin, Barbara B.] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Dept Med, Madison, WI 53792 USA. [Koscik, Rebecca L.; Jonaitis, Erin M.; Hermann, Bruce P.; Larue, Asenath; Sager, Mark A.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53792 USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Clin Sci J5 1M, 600 Highland Ave, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU Alzheimer's Association [NIRG-09-132626]; National Institute on Aging [R01 AG027161, ADRC P50 AG033514, R01 AG021155, R01 AG037639]; Veteran's Administration Merit Review award [I01CX000165] FX This project was supported by the Alzheimer's Association, NIRG-09-132626, the National Institute on Aging (R01 AG027161 [MAS], ADRC P50 AG033514 [SA], R01 AG021155 [SCJ], R01 AG037639 [BBB]), and by the Veteran's Administration Merit Review award I01CX000165. The project was also facilitated by the facilities and resources at the Geriatric Research, Education, and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. GRECC MS # 2013-03. The authors gratefully acknowledge Nancy Davenport-Sis, Amy Hawley, Jennifer Bond, Caitlin Cleary, Jennifer Oh, Chuck Illingworth, and the support of researchers and staff at the Waisman Center, University of Wisconsin-Madison, for their assistance in recruitment, data collection, and data analysis. Above all, the authors wish to thank our dedicated volunteers for their participation in this research. NR 61 TC 18 Z9 18 U1 1 U2 38 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD APR PY 2014 VL 35 IS 4 BP 769 EP 776 DI 10.1016/j.neurobiolaging.2013.10.072 PG 8 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 297VN UT WOS:000330283300007 PM 24199958 ER PT J AU Tache, Y AF Tache, Yvette TI HANS SELYE AND THE STRESS RESPONSE: FROM "THE FIRST MEDIATOR" TO THE IDENTIFICATION OF THE HYPOTHALAMIC CORTICOTROPIN-RELEASING FACTOR SO IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE LA English DT Article DE corticotropin releasing factor; hypothalamus; Selye; stress ID RECEPTORS; CRF AB Selye pioneered the stress concept that is ingrained in the vocabulary of daily life. This was originally build on experimental observations that divers noxious agents can trigger a similar triad of endocrine (adrenal enlargement), immune (involution of thymus) and gut (gastric erosion formation) responses as reported in a letter to Nature in 1936. Subsequently, he articulated the underlying mechanisms and hypothesized the existence of a "first mediator" in the hypothalamus able to orchestrate this bodily changes. However he took two generations to identify this mediator. The Nobel Laureate, Roger Guillemin, alpha former Selye's PhD student, demonstrated in 1955 the existence of a hypothalamic factor that elicited adrenocorticotropic hormone release from the rat pituitary and named it corticotropin releasing factor (CRF). In 1981, Wylie Vale, a former Guillemin's Ph Student, characterized CRF as 41 amino acid and cloned the CRF1 and CRF2 receptors. This paves the way to experimental studies establishing that the activation of the CRF signaling pathways in the brain plays a key role in mediating the stress-related endocrine, behavioral, autonomic and visceral responses. The unraveling of the biochemical coding of stress is rooted in Selye legacy continues to have increasing impact on the scientific community. C1 [Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress,Digest Dis Div, Los Angeles, CA 90024 USA. [Tache, Yvette] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress,Digest Dis Div, Los Angeles, CA 90024 USA. EM yvette.tache@va.gov NR 13 TC 0 Z9 0 U1 4 U2 8 PU LITERATURA MEDICA PI BUDAPEST PA MARGIT KRT 31-33, BUDAPEST, 1024, HUNGARY SN 0019-1442 J9 IDEGGYOGY SZEMLE JI Ideggyogy. Szle. PD MAR 30 PY 2014 VL 67 IS 3-4 BP 95 EP 98 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AX1BU UT WOS:000346684200007 PM 26118248 ER PT J AU Black, AC McMahon, TJ Rosenheck, RA Ball, SA Ries, RK Ames, D Rosen, MI AF Black, Anne C. McMahon, Thomas J. Rosenheck, Robert A. Ball, Samuel A. Ries, Richard K. Ames, Donna Rosen, Marc I. TI Development of the Clinician Assessment of Financial Incapability (CAFI) SO PSYCHIATRY RESEARCH LA English DT Article DE Assessment; Financial capability; Representative payee; Social Security; Psychiatric; Income ID REPRESENTATIVE PAYEE PROGRAM; SEVERE MENTAL-ILLNESS; SUBSTANCE USE DISORDERS; MONEY MANAGEMENT; BENEFICIARIES; ADDICTION; LEVERAGE; THERAPY; CLIENTS; ADULTS AB The Social Security Administration (SSA) provides financial support to adults disabled by psychiatric conditions to provide for their basic needs. For beneficiaries identified as incapable of managing their funds, representative payee assignment is mandated: However, studies indicate that the current SSA method of determining capability leads to idiosyncratic payee assignment, with a tendency to under-identify beneficiaries needing payees. Over two phases with data from 78 mental health clinicians treating 134 patient-beneficiaries, we describe the development of a new assessment, the Clinician Assessment of Financial Incapability (CAFI). Item generation, subscale construction, and preliminary assessments of validity are described. We also describe the simultaneous development of a criterion measure of capability, a comprehensive review of all data. Experts identified four subscales mapping to four criteria of incapability; factor analysis provided support for this item structure. Close to one-half of patients were determined to be incapable by review of all data. CAFI and SSA methods correctly classified 73% of cases, but errors with CAFI were more evenly distributed between false negatives and false positives. The implications of classification error are considered, and advantages of CAFI over the SSA method are enumerated. Plans for future instrument revision are briefly described. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Black, Anne C.; McMahon, Thomas J.; Rosenheck, Robert A.; Ball, Samuel A.; Rosen, Marc I.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Black, Anne C.; Rosen, Marc I.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Ries, Richard K.] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. [Ames, Donna] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Ames, Donna] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Black, AC (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave 116A-4, West Haven, CT 06516 USA. EM anne.black@yale.edu FU National Institute on Drug Abuse [R01 DA025613] FX This study was funded by the National Institute on Drug Abuse R01 DA025613 (MIR). NR 30 TC 4 Z9 4 U1 3 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAR 30 PY 2014 VL 215 IS 3 BP 784 EP 789 DI 10.1016/j.psychres.2014.01.021 PG 6 WC Psychiatry SC Psychiatry GA AE2AU UT WOS:000333776500045 PM 24495575 ER PT J AU Noel, PH Parchman, ML Palmer, RF Romero, RL Leykum, LK Lanham, HJ Zeber, JE Bowers, KW AF Noel, Polly H. Parchman, Michael L. Palmer, Ray F. Romero, Raquel L. Leykum, Luci K. Lanham, Holly J. Zeber, John E. Bowers, Krista W. TI Alignment of patient and primary care practice member perspectives of chronic illness care: a cross-sectional analysis SO BMC FAMILY PRACTICE LA English DT Article DE Chronic care; Primary care; Patient surveys ID PREVENTIVE SERVICE DELIVERY; SELF-MANAGEMENT; UNDERSTANDING PRACTICE; RANDOMIZED-TRIAL; CLINICAL-TRIAL; QUALITY; MODEL; OUTCOMES; SATISFACTION; BEHAVIORS AB Background: Little is known as to whether primary care teams' perceptions of how well they have implemented the Chronic Care Model (CCM) corresponds with their patients' own experience of chronic illness care. We examined the extent to which practice members' perceptions of how well they organized to deliver care consistent with the CCM were associated with their patients' perceptions of the chronic illness care they have received. Methods: Analysis of baseline measures from a cluster randomized controlled trial testing a practice facilitation intervention to implement the CCM in small, community-based primary care practices. All practice "members" (i.e., physician providers, non-physician providers, and staff) completed the Assessment of Chronic Illness Care(ACIC) survey and adult patients with 1 or more chronic illnesses completed the Patient Assessment of Chronic Illness Care (PACIC) questionnaire. Results: Two sets of hierarchical linear regression models accounting for nesting of practice members (N = 283) and patients (N = 1,769) within 39 practices assessed the association between practice member perspectives of CCM implementation (ACIC scores) and patients' perspectives of CCM (PACIC). ACIC summary score was not significantly associated with PACIC summary score or most of PACIC subscale scores, but four of the ACIC subscales [Self- management Support (p < 0.05); Community Linkages (p < 0.02), Delivery System Design (p < 0.02), and Organizational Support (p < 0.02)] were consistently associated with PACIC summary score and the majority of PACIC subscale scores after controlling for patient characteristics. The magnitude of the coefficients, however, indicates that the level of association is weak. Conclusions: The ACIC and PACIC scales appear to provide complementary and relatively unique assessments of how well clinical services are aligned with the CCM. Our findings underscore the importance of assessing both patient and practice member perspectives when evaluating quality of chronic illness care. Trial registration: NCT00482768 C1 [Noel, Polly H.; Leykum, Luci K.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Noel, Polly H.; Palmer, Ray F.; Romero, Raquel L.; Leykum, Luci K.; Lanham, Holly J.; Bowers, Krista W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Parchman, Michael L.] MacColl Ctr Healthcare Innovat, Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA 98101 USA. [Lanham, Holly J.] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. [Zeber, John E.] Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA. [Zeber, John E.] Scott & White Healthcare Ctr Appl Hlth Res, Temple, TX 76508 USA. RP Noel, PH (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM noelp@uthscsa.edu OI Parchman, Michael/0000-0001-7129-2889 FU National Institute of Health (NIDDK) [R18DK075692]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service; South Texas Veterans Health Care System FX The research reported here was supported by the National Institute of Health (NIDDK Grant R18DK075692) and the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service. Investigator salary support was also provided through the South Texas Veterans Health Care System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The study team would like to acknowledge technical assistance from Poomachand Veerapaneni, Janet Hendricks, and Paul Hartman, and the assistance of Amr Mazen Arar, Brendan Nadeau, and Alan B. Romero in collecting patient surveys, as well as the primary care practices and their anonymous patients who participated in the project. We would also like to posthumously acknowledge the overall contributions of Dr. Nedal H. Arar, who was an integral member of the study team. NR 39 TC 5 Z9 5 U1 1 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2296 J9 BMC FAM PRACT JI BMC Fam. Pract. PD MAR 29 PY 2014 VL 15 AR 57 DI 10.1186/1471-2296-15-57 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA AF4TJ UT WOS:000334706700001 PM 24678983 ER PT J AU Baek, JI Choi, SY Chacon-Heszele, MF Zuo, XF Lipschutz, JH AF Baek, Jeong-In Choi, Soo Young Chacon-Heszele, Maria F. Zuo, Xiaofeng Lipschutz, Joshua H. TI Expression of Drosophila forkhead transcription factors during kidney development SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Drosophila forkhead; Transcription factor; Nephrogenesis ID DISRUPTION; FAMILY; BF-2 AB The Drosophila forkhead (Dfkh) family of transcription factors has over 40 family members. One Dfkh family member, BF2 (aka FoxD1), has been shown, by targeted disruption, to be essential for kidney development. In order to determine if other Dfkh family members were involved in kidney development and to search for new members of this family, reverse transcriptase polymerase chain reaction (RT-PCR) was performed using degenerate primers of the consensus sequence of the DNA binding domain of this family and developing rat kidney RNA. The RT-PCR product was used to probe RNA from a developing rat kidney (neonatal), from a 20-day old kidney, and from an adult kidney. The RT-PCR product hybridized only to a developing kidney RNA transcript of similar to 2.3 kb (the size of BF2). A lambda gt10 mouse neonatal kidney library was then screened, using the above-described RT-PCR product as a probe. Three lambda phage clones were isolated that strongly hybridized to the RT-PCR probe. Sequencing of the RT-PCR product and the lambda phage clones isolated from the developing kidney library revealed Dfkh BF2. In summary, only MI6 family member BF2, which has already been shown to be essential for nephrogenesis, was identified in our screen and no other candidate Dfkh family members were identified. Published by Elsevier Inc. C1 [Baek, Jeong-In; Choi, Soo Young; Chacon-Heszele, Maria F.; Zuo, Xiaofeng; Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Baek, Jeong-In; Choi, Soo Young; Chacon-Heszele, Maria F.; Zuo, Xiaofeng; Lipschutz, Joshua H.] VAMC, Philadelphia, PA 19104 USA. [Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA 19104 USA. RP Lipschutz, JH (reprint author), Room 405C,Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA. EM jhlipsch@mail.med.upenn.edu FU Veteran Affairs; NIH [RO1 DK069909, DK047757]; NephHope Foundation FX This work was supported in part by the Veteran Affairs (Merit Award to J.H.L.), the NIH (RO1 DK069909 and DK047757 to J.H.L.), and the NephHope Foundation (Fellowship award to M.F.C.H.). NR 7 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAR 28 PY 2014 VL 446 IS 1 BP 15 EP 17 DI 10.1016/j.bbrc.2014.01.135 PG 3 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA AF4AX UT WOS:000334654900003 PM 24491558 ER PT J AU Salado, IG Redondo, M Bello, ML Perez, C Liachko, NF Kraemer, BC Miguel, L Lecourtois, M Gil, C Martinez, A Perez, DI AF Salado, Irene G. Redondo, Miriam Bello, Murilo L. Perez, Concepcion Liachko, Nicole F. Kraemer, Brian C. Miguel, Laetitia Lecourtois, Magalie Gil, Carmen Martinez, Ana Perez, Daniel I. TI Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID FRONTOTEMPORAL LOBAR DEGENERATION; BLOOD-BRAIN-BARRIER; TDP-43 PROTEINOPATHIES; HEXANUCLEOTIDE REPEAT; MUTATIONS; ALS; PHOSPHORYLATION; MODEL; OPTIMIZATION; EXPRESSION AB Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease where motor neurons in cortex, brain stem, and spinal cord die progressively, resulting in muscle wasting, paralysis, and death. Currently, effective therapies for ALS are lacking; however, identification of pathological TAR DNA-binding protein 43 (TDP-43) as the hallmark lesion in sporadic ALS suggests new therapeutic targets for pharmacological intervention. Pathological TDP-43 phosphorylation appears to drive the onset and progression of ALS and may result from upregulation of the protein kinase CK-1 in affected neurons, resulting in postranslational TDP-43 modification. Consequently, brain penetrant specific CK-1 inhibitors may provide a new therapeutic strategy for treating ALS and other TDP-43 proteinopathies. Using a chemical genetic approach, we report the discovery and further optimization of a number of potent CK-1 delta inhibitors. Moreover, these small heterocyclic molecules are able to prevent TDP-43 phosphorylation in cell cultures, to increase Drosophila lifespan by reduction of TDP-43 neurotoxicity, and are predicted to cross the blood brain barrier. Thus, N-(benzothiazolyl)-2-phenyl-acetamides are valuable drug candidates for further studies and may be a new therapeutic approach for ALS and others pathologies in which TDP-43 is involved. C1 [Salado, Irene G.; Redondo, Miriam; Bello, Murilo L.; Perez, Concepcion; Gil, Carmen; Martinez, Ana; Perez, Daniel I.] CSIC, Inst Quim Med, E-28006 Madrid, Spain. [Bello, Murilo L.] Univ Fed Rio de Janeiro, Fac Farm, BR-21949900 Rio De Janeiro, Brazil. [Liachko, Nicole F.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Liachko, Nicole F.; Kraemer, Brian C.] Univ Washington, Gerontol Div, Dept Med, Seattle, WA 98104 USA. [Kraemer, Brian C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Miguel, Laetitia; Lecourtois, Magalie] INSERM, U1079, F-76183 Rouen, France. [Miguel, Laetitia; Lecourtois, Magalie] Univ Rouen, Normandie Univ, IRIB, F-76183 Rouen, France. RP Martinez, A (reprint author), CSIC, Inst Quim Med, Juan Cierva 3, E-28006 Madrid, Spain. EM amartinez@iqm.csic.es; dperez@iqm.csic.es RI Gil, Carmen/J-8932-2014; Perez Fernandez, Daniel Ignacio/L-6245-2014; Martinez, Ana/L-6414-2014; Perez, Concepcion/K-3684-2014 OI Gil, Carmen/0000-0002-3882-6081; Perez Fernandez, Daniel Ignacio/0000-0003-1774-4471; Martinez, Ana/0000-0002-2707-8110; FU MINECO [SAF2012-37979-C03-01]; Association Francaise contre les Myopathies [AFM-16169]; Department of Veterans Affairs [1147891]; CDA2 [I01BX007080]; Ligue Europeenne Contre la Maladie d'Alzheimer (LECMA); National Institutes of Health [R01NS064131]; MICINN (FPI program); CSIC (JAE program); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) FX This work was supported by grants from MINECO (SAF2012-37979-C03-01 to A.M.), Association Francaise contre les Myopathies (AFM-16169 to D.I.P.), the Department of Veterans Affairs (Merit Review grant no. 1147891 to B.K.) and CDA2 no. I01BX007080 to N.L.), Ligue Europeenne Contre la Maladie d'Alzheimer (LECMA to M.L.), and National Institutes of Health (R01NS064131 to B.K.). I.G.S. and D.I.P. acknowledge a pre- and postdoctoral fellowship from MICINN (FPI program) and CSIC (JAE program), respectively. M.L.B. acknowledges a travel grant from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). We thank Elaine Loomis for outstanding technical assistance with immunoblotting NR 48 TC 9 Z9 9 U1 0 U2 18 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 EI 1520-4804 J9 J MED CHEM JI J. Med. Chem. PD MAR 27 PY 2014 VL 57 IS 6 BP 2755 EP 2772 DI 10.1021/jm500065f PG 18 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA AD9IK UT WOS:000333578400046 PM 24592867 ER PT J AU Muller, LPD Sargoy, A Rodriguez, AR Brecha, NC AF Mueller, Luis Perez de Sevilla Sargoy, Allison Rodriguez, Allen R. Brecha, Nicholas C. TI Melanopsin Ganglion Cells Are the Most Resistant Retinal Ganglion Cell Type to Axonal Injury in the Rat Retina SO PLOS ONE LA English DT Article ID OPTIC-NERVE SECTION; MOUSE RETINA; ADULT-RATS; SURVIVAL; PROTEIN; NEURONS; MICE; AKT; MORPHOLOGY; APOPTOSIS AB We report that the most common retinal ganglion cell type that remains after optic nerve transection is the M1 melanopsin ganglion cell. M1 ganglion cells are members of the intrinsically photosensitive retinal ganglion cell population that mediates non-image-forming vision, comprising similar to 2.5% of all ganglion cells in the rat retina. In the present study, M1 ganglion cells comprised 1.7 +/- 1%, 28 +/- 14%, 55 +/- 13% and 82 +/- 8% of the surviving ganglion cells 7, 14, 21 and 60 days after optic nerve transection, respectively. Average M1 ganglion cell somal diameter and overall morphological appearance remained unchanged in non-injured and injured retinas, suggesting a lack of injury-induced degeneration. Average M1 dendritic field size increased at 7 and 60 days following optic nerve transection, while average dendritic field size remained similar in non-injured retinas and in retinas at 14 and 21 days after optic nerve transection. These findings demonstrate that M1 ganglion cells are more resistant to injury than other ganglion cell types following optic nerve injury, and provide an opportunity to develop pharmacological or genetic therapeutic approaches to mitigate ganglion cell death and save vision following optic nerve injury. C1 [Mueller, Luis Perez de Sevilla; Sargoy, Allison; Rodriguez, Allen R.; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Sargoy, Allison; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA USA. RP Muller, LPD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. EM luisperez@mednet.ucla.edu FU Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD [W81XWH-10-2-0077]; NIH [EY04067]; NIDDK [P30 DK41301]; VA Merit Review; VA Career Research Scientist FX This research and development project was conducted by the authors at the David Geffen School of Medicine at UCLA and is made possible by a contract agreement that was awarded and administered by the U.S. Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD under Contract Number: W81XWH-10-2-0077. Support for these studies also came from NIH EY04067, NIDDK P30 DK41301 (UCLA Cure Center Core) and a VA Merit Review (NB). NCB is a VA Career Research Scientist. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 62 TC 17 Z9 17 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 26 PY 2014 VL 9 IS 3 AR e93274 DI 10.1371/journal.pone.0093274 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE0SR UT WOS:000333677000130 ER PT J AU Nettiksimmons, J Simonsick, EM Harris, T Satterfield, S Rosano, C Yaffe, K AF Nettiksimmons, Jasmine Simonsick, Eleanor M. Harris, Tamara Satterfield, Suzanne Rosano, Caterina Yaffe, Kristine CA Hlth ABC Study TI The Associations between Serum Brain-Derived Neurotrophic Factor, Potential Confounders, and Cognitive Decline: A Longitudinal Study SO PLOS ONE LA English DT Article ID BDNF MESSENGER-RNA; ALZHEIMERS-DISEASE; CARDIORESPIRATORY FITNESS; DECREASED-LEVELS; BLOOD-BRAIN; IMPAIRMENT; DEPRESSION; SURVIVAL; NEURONS; MEN AB Brain-derived neurotrophic factor (BDNF) plays a role in the maintenance and function of neurons. Although persons with Alzheimer's disease have lower cortical levels of BDNF, evidence regarding the association between circulating BDNF and cognitive function is conflicting. We sought to determine the correlates of BDNF level and whether BDNF level was prospectively associated with cognitive decline in healthy older adults. We measured serum BDNF near baseline in 912 individuals. Cognitive status was assessed repeatedly with the modified Mini-Mental Status Examination and the Digit Symbol Substitution test over the next 10 years. We evaluated the association between BDNF and cognitive decline with longitudinal models. We also assessed the association between BDNF level and demographics, comorbidities and health behaviors. We found an association between serum BDNF and several characteristics that are also associated with dementia (race and depression), suggesting that future studies should control for these potential confounders. We did not find evidence of a longitudinal association between serum BDNF and subsequent cognitive test trajectories in older adults, although we did identify a potential trend toward a cross-sectional association. Our results suggest that serum BDNF may have limited utility as a biomarker of prospective cognitive decline. C1 [Nettiksimmons, Jasmine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Simonsick, Eleanor M.] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Harris, Tamara] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Rosano, Caterina] Univ Pittsburgh, Dept Epidemiol, Ctr Aging & Populat Hlth, Pittsburgh, PA 15261 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Nettiksimmons, J (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM Jasmine.nettiksimmons@ucsf.edu OI Rosano, Caterina/0000-0002-0909-1506; Rosano, Caterina/0000-0002-4271-6010 FU NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; NINR [R01-NR012459]; Intramural Research Program of the NIH, National Institute of Aging; American Health Assistance Foundation [A201-0029]; National Institute of Aging [K24AG031155] FX This research was supported by the following: NIA contract numbers: N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant numbers: R01-AG028050, NINR grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, National Institute of Aging and by a grant from the American Health Assistance Foundation, grant number A201-0029. Dr. Yaffe is supported in part by a National Institute of Aging Grant (K24AG031155). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 35 TC 16 Z9 17 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 26 PY 2014 VL 9 IS 3 AR e91339 DI 10.1371/journal.pone.0091339 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE0SR UT WOS:000333677000018 PM 24670553 ER PT J AU Wang, J Land, D Ono, K Galvez, J Zhao, W Vempati, P Steele, JW Cheng, A Yamada, M Levine, S Mazzola, P Pasinetti, GM AF Wang, Jun Land, David Ono, Kenjiro Galvez, Jorge Zhao, Wei Vempati, Prashant Steele, John W. Cheng, Alice Yamada, Masahito Levine, Samara Mazzola, Paolo Pasinetti, Giulio M. TI Molecular Topology as Novel Strategy for Discovery of Drugs with A beta Lowering and Anti-Aggregation Dual Activities for Alzheimer's Disease SO PLOS ONE LA English DT Article ID MOUSE MODEL; PROTEIN; OLIGOMERS; NEUROPATHOLOGY; TOXICITY; PATHWAY; DESIGN; MEMORY AB Background and Purpose: In this study, we demonstrate the use of Molecular topology (MT) in an Alzheimer's disease (AD) drug discovery program. MT uses and expands upon the principles governing the molecular connectivity theory of numerically characterizing molecular structures, in the present case, active anti-AD drugs/agents, using topological descriptors to build models. Topological characterization has been shown to embody sufficient molecular information to provide strong correlation to therapeutic efficacy. Experimental Approach: We used MT to include multiple bioactive properties that allows for the identification of multifunctional single agent compounds, in this case, the dual functions of beta-amyloid (A beta) -lowering and anti-oligomerization. Using this technology, we identified and designed novel compounds in chemical classes unrelated to current anti-AD agents that exert dual A beta lowering and anti-A beta oligomerization activities in animal models of AD. AD is a multifaceted disease with different pathological features. Conclusion and Implications: Our study, for the first time, demonstrated that MT can provide novel strategy for discovering drugs with A beta lowering and anti-aggregation dual activities for AD. C1 [Wang, Jun; Zhao, Wei; Vempati, Prashant; Steele, John W.; Cheng, Alice; Levine, Samara; Mazzola, Paolo; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Land, David] Medisyn Technol Inc, Minnetonka, MN USA. [Ono, Kenjiro; Yamada, Masahito] Kanazawa Univ, Dept Neurol & Neurobiol Aging, Kanazawa, Ishikawa, Japan. [Galvez, Jorge] Univ Valencia, Mol Topol & Drug Design Unit, Valencia, Spain. [Wang, Jun; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Altschul Foundation; Icahn School of Medicine at Mount Sinai FX This study is supported in part by the Altschul Foundation and by Discretionary Funds to Giulio Maria Pasinetti from the Icahn School of Medicine at Mount Sinai. NR 33 TC 0 Z9 0 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 26 PY 2014 VL 9 IS 3 AR e92750 DI 10.1371/journal.pone.0092750 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE0SR UT WOS:000333677000072 PM 24671215 ER PT J AU Goldberg, DS French, B Forde, KA Groeneveld, PW Bittermann, T Backus, L Halpern, SD Kaplan, DE AF Goldberg, David S. French, Benjamin Forde, Kimberly A. Groeneveld, Peter W. Bittermann, Therese Backus, Lisa Halpern, Scott D. Kaplan, David E. TI Association of Distance From a Transplant Center With Access to Waitlist Placement, Receipt of Liver Transplantation, and Survival Among US Veterans SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID HEPATITIS-C VIRUS; BARIATRIC SURGERY; UNITED-STATES; PRIMARY-CARE; SERVICES; POLICY; MODEL; IMPLEMENTATION; EXCELLENCE; GUIDELINES AB IMPORTANCE Centralization of specialized health care services such as organ transplantation and bariatric surgery is advocated to improve quality, increase efficiency, and reduce cost. The effect of increased travel on access and outcomes from these services is not fully understood. OBJECTIVE To evaluate the association between distance from a Veterans Affairs (VA) transplant center (VATC) and access to being waitlisted for liver transplantation, actually having a liver transplant, and mortality. DESIGN, SETTING, AND PARTICIPANTS Retrospective study of veterans meeting liver transplantation eligibility criteria from January 1, 2003, until December 31, 2010, using data from the Veterans Health Administration's integrated, national, electronic medical record linked to Organ Procurement and Transplantation Network data. MAIN OUTCOMES AND MEASURES The primary outcome was being waitlisted for transplantation at a VATC. Secondary outcomes included being waitlisted at any transplant center, undergoing a transplantation, and survival. RESULTS From 2003-2010, 50 637 veterans were classified as potentially eligible for transplant; 2895 (6%) were waitlisted and 1418 of those were waitlisted (49%) at 1 of the 5 VATCs. Of 3417 veterans receiving care at a VA hospital located within 100 miles from a VATC, 244 (7.1%) were waitlisted at a VATC and 372 (10.9%) at any transplant center (VATC and non-VATCs). Of 47 219 veterans receiving care at a VA hospital located more than 100 miles from a VATC, 1174 (2.5%) were waitlisted at a VATC and 2523 (5.3%) at any transplant center (VATC and non-VATCs). In multivariable models, increasing distance to closest VATC was associated with significantly lower odds of being waitlisted at a VATC (odds ratio [OR], 0.91 [95% CI, 0.89-0.93] for each doubling in distance) or any transplant center (OR, 0.94 [95% CI, 0.92-0.96] for each doubling in distance). For example, a veteran living 25 miles from a VATC would have a 7.4%(95% CI, 6.6%-8.1%) adjusted probability of being waitlisted, whereas a veteran 100 miles from a VATC would have a 6.2%(95% CI, 5.7%-6.6%) adjusted probability. In adjusted models, increasing distance from a VATC was associated with significantly lower transplantation rates (subhazard ratio, 0.97; 95% CI, 0.95-0.98 for each doubling in distance). There was significantly increased mortality among waitlisted veterans from the time of first hepatic decompensation event in multivariable survival models (hazard ratio, 1.03; 95% CI, 1.01-1.04 for each doubling in distance). For example, a waitlisted veteran living 25 miles from a VATC would have a 62.9% (95% CI, 59.1%-66.1%) 5-year adjusted probability of survival from first hepatic decompensation event compared with a 59.8%(95% CI, 56.3%-63.1%) 5-year adjusted probability of survival for a veteran living 100 miles from a VATC. CONCLUSIONS AND RELEVANCE Among VA patients meeting eligibility criteria for liver transplantation, greater distance from a VATC or any transplant center was associated with lower likelihood of being waitlisted, receiving a liver transplant, and greater likelihood of death. The relationship between these findings and centralizing specialized care deserves further investigation. C1 [Goldberg, David S.; Forde, Kimberly A.; Kaplan, David E.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. [Goldberg, David S.; French, Benjamin; Forde, Kimberly A.; Halpern, Scott D.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Goldberg, David S.; French, Benjamin; Groeneveld, Peter W.; Halpern, Scott D.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Bittermann, Therese] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Backus, Lisa] Dept Vet Affairs, Off Publ Hlth, Philadelphia, PA USA. [Halpern, Scott D.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. [Kaplan, David E.] Philadelphia VA Med Ctr, Gastroenterol Sect, Philadelphia, PA USA. RP Goldberg, DS (reprint author), Hosp Univ Penn, 3400 Civ Ctr Blvd,9 Penn Tower, Philadelphia, PA 19104 USA. EM david.goldberg@uphs.upenn.edu FU Health Resources and Services Administration [234-2005-37011C] FX This work was supported in part by Health Resources and Services Administration contract 234-2005-37011C. NR 40 TC 25 Z9 25 U1 3 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 26 PY 2014 VL 311 IS 12 BP 1234 EP 1243 DI 10.1001/jama.2014.2520 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA AD6CE UT WOS:000333340500027 PM 24668105 ER PT J AU James, BD Leurgans, SE Hebert, LE Scherr, PA Yaffe, K Bennett, DA AF James, Bryan D. Leurgans, Sue E. Hebert, Liesi E. Scherr, Paul A. Yaffe, Kristine Bennett, David A. TI Contribution of Alzheimer disease to mortality in the United States SO NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; COMMUNITY-BASED COHORT; CLINICAL-DIAGNOSIS; AGING PROJECT; OLDER PERSONS; RUSH MEMORY; DEMENTIA; SURVIVAL; DEATH; POPULATION AB Objective:To assess the burden of mortality attributable to Alzheimer disease (AD) dementia in the United States.Methods:Data came from 2,566 persons aged 65 years and older (mean 78.1 years) without dementia at baseline from 2 cohort studies of aging with identical annual diagnostic assessments of dementia. Because both studies require organ donation, ascertainment of mortality was complete and dates of death accurate. Mortality hazard ratios (HRs) after incident AD dementia were estimated per 10-year age strata from proportional hazards models. Population attributable risk percentage was derived to estimate excess mortality after a diagnosis of AD dementia. The number of excess deaths attributable to AD dementia in the United States was then estimated.Results:Over an average of 8 years, 559 participants (21.8%) without dementia at baseline developed AD dementia and 1,090 (42.4%) died. Median time from AD dementia diagnosis to death was 3.8 years. The mortality HR for AD dementia was 4.30 (confidence interval = 3.33, 5.58) for ages 75-84 years and 2.77 (confidence interval = 2.37, 3.23) for ages 85 years and older (too few deaths after AD dementia in ages 65-74 were available to estimate HR). Population attributable risk percentage was 37.0% for ages 75-84 and 35.8% for ages 85 and older. An estimated 503,400 deaths in Americans aged 75 years and older were attributable to AD dementia in 2010.Conclusions:A larger number of deaths are attributable to AD dementia in the United States each year than the number (<84,000 in 2010) reported on death certificates. C1 [James, Bryan D.; Leurgans, Sue E.; Bennett, David A.] Rush Univ, Rush Alzheimers Dis Ctr, Med Ctr, Chicago, IL 60612 USA. [James, Bryan D.] Rush Univ, Dept Internal Med, Med Ctr, Chicago, IL 60612 USA. [Leurgans, Sue E.; Bennett, David A.] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. [Hebert, Liesi E.; Scherr, Paul A.] Rush Univ, Rush Inst Hlth Aging, Med Ctr, Chicago, IL 60612 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP James, BD (reprint author), Rush Univ, Rush Alzheimers Dis Ctr, Med Ctr, Chicago, IL 60612 USA. EM Bryan_James@rush.edu FU National Institute on Aging [P30 AG10161, R01AG15819, R01AG17917, K24AG031155]; Illinois Department of Public Health [23282007] FX Directly supported by the National Institute on Aging (P30 AG10161, R01AG15819, R01AG17917, K24AG031155), and the Illinois Department of Public Health (contract 23282007). NR 35 TC 53 Z9 54 U1 1 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAR 25 PY 2014 VL 82 IS 12 BP 1045 EP 1050 DI 10.1212/WNL.0000000000000240 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA AH9XW UT WOS:000336500100012 PM 24598707 ER PT J AU Brown, ST Tate, JP Kyriakides, TC Kirkwood, KA Holodniy, M Goulet, JL Angus, BJ Cameron, DW Justice, AC AF Brown, Sheldon T. Tate, Janet P. Kyriakides, Tassos C. Kirkwood, Katherine A. Holodniy, Mark Goulet, Joseph L. Angus, Brian J. Cameron, D. William Justice, Amy C. CA OPTIMA Team TI The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study SO PLOS ONE LA English DT Article ID VETERANS AGING COHORT; NON-AIDS EVENTS; NONFATAL AIDS; RISK; THERAPY; PROGRESSION; EFFICACY; DISEASE; TRIALS; SAFETY AB Objectives: The VACS Index is highly predictive of all-cause mortality among HIV infected individuals within the first few years of combination antiretroviral therapy (cART). However, its accuracy among highly treatment experienced individuals and its responsiveness to treatment interventions have yet to be evaluated. We compared the accuracy and responsiveness of the VACS Index with a Restricted Index of age and traditional HIV biomarkers among patients enrolled in the OPTIMA study. Methods: Using data from 324/339 (96%) patients in OPTIMA, we evaluated associations between indices and mortality using Kaplan-Meier estimates, proportional hazards models, Harrel's C-statistic and net reclassification improvement (NRI). We also determined the association between study interventions and risk scores over time, and change in score and mortality. Results: Both the Restricted Index (c = 0.70) and VACS Index (c = 0.74) predicted mortality from baseline, but discrimination was improved with the VACS Index (NRI = 23%). Change in score from baseline to 48 weeks was more strongly associated with survival for the VACS Index than the Restricted Index with respective hazard ratios of 0.26 (95% CI 0.14-0.49) and 0.39(95% CI 0.22-0.70) among the 25% most improved scores, and 2.08 (95% CI 1.27-3.38) and 1.51 (95% CI 0.90-2.53) for the 25% least improved scores. Conclusions: The VACS Index predicts all-cause mortality more accurately among multi-drug resistant, treatment experienced individuals and is more responsive to changes in risk associated with treatment intervention than an index restricted to age and HIV biomarkers. The VACS Index holds promise as an intermediate outcome for intervention research. C1 [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Brown, Sheldon T.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA. [Tate, Janet P.; Goulet, Joseph L.; Justice, Amy C.] VA Connecticut Healthcare Syst, Gen Internal Med Sect, West Haven, CT USA. [Tate, Janet P.; Goulet, Joseph L.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Tate, Janet P.; Goulet, Joseph L.; Justice, Amy C.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Kyriakides, Tassos C.; Kirkwood, Katherine A.] VA Connecticut Healthcare Syst, VA Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA. [Holodniy, Mark] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Holodniy, Mark] Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA. [Angus, Brian J.] Univ Oxford, Nuffield Dept Med, Oxford, England. [Cameron, D. William] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON, Canada. RP Brown, ST (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA. EM sheldon.brown@va.gov OI Cameron, Bill/0000-0002-0090-3539; Goulet, Joseph/0000-0002-0842-804X FU Office of Research and Development (Cooperative Studies Program), US Department of Veterans Affairs; US National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism [U01-13566]; Canadian Institutes for Health Research; United Kingdom Medical Research Council; Ontario HIV Treatment Network/Ministry of Health, Canada FX This work was supported by the Office of Research and Development (Cooperative Studies Program), US Department of Veterans Affairs; US National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism [U01-13566]; Canadian Institutes for Health Research; and United Kingdom Medical Research Council. DWC is a Career Scientist supported by the Ontario HIV Treatment Network/Ministry of Health, Canada. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 25 TC 5 Z9 5 U1 2 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 25 PY 2014 VL 9 IS 3 AR e92606 DI 10.1371/journal.pone.0092606 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE0SD UT WOS:000333675600053 PM 24667813 ER PT J AU Mukherjee, A Larson, EA Klein, RF Rotwein, P AF Mukherjee, Aditi Larson, Emily A. Klein, Robert F. Rotwein, Peter TI Distinct Actions of Akt1 on Skeletal Architecture and Function SO PLOS ONE LA English DT Article ID MICE LACKING; OSTEOBLAST DIFFERENTIATION; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-HOMEOSTASIS; BONE; GROWTH; KINASE; OSTEOPOROSIS; OSTEOCLAST AB Skeletal integrity is dependent on the coordinated actions of bone-forming osteoblasts and bone-resorbing osteoclasts, which recognize and respond to multiple environmental inputs. Here we have studied the roles in bone development and growth of Akt1 and Akt2, two closely related signaling proteins, by evaluating mice lacking either of these enzymes. Global deficiency of Akt1 but not Akt2 caused a reduction in whole body and femoral bone mineral density, in femoral cortical thickness and volume, and in trabecular thickness in both males and females when measured at 20-weeks of age, which was reflected in diminished femoral resistance to fracture. Haplo-deficiency of Akt1 in male mice also decreased femoral cortical and trabecular skeletal parameters, and reduced bone strength. Cell-based studies showed that genetic Akt1 deficiency diminished the rate of proliferation of osteoblast progenitors and impaired osteoclast differentiation in primary culture but that loss of Akt2 did not. Our results demonstrate differential effects of Akt1 and Akt2 on skeletal maturation and architecture through actions on both osteoblast and osteoclast precursors. C1 [Mukherjee, Aditi; Rotwein, Peter] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA. [Larson, Emily A.; Klein, Robert F.] Oregon Hlth & Sci Univ, Dept Med, Bone & Mineral Res Unit, Portland, OR 97201 USA. [Klein, Robert F.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Rotwein, P (reprint author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA. EM rotweinp@ohsu.edu FU NIH [R01 DK42748]; VA Medical Research Service; OHSU Medical Research Foundation FX These studies were supported in part by NIH grant R01 DK42748 (to P. R.), by the VA Medical Research Service (R. F. K.), and by an OHSU Medical Research Foundation new investigator grant (to A. M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 2 Z9 2 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 24 PY 2014 VL 9 IS 3 AR e93040 DI 10.1371/journal.pone.0093040 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AD7QO UT WOS:000333459900147 PM 24663486 ER PT J AU Kahn, SE Cooper, ME Del Prato, S AF Kahn, Steven E. Cooper, Mark E. Del Prato, Stefano TI Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future SO LANCET LA English DT Review ID BETA-CELL FUNCTION; GLUCAGON-LIKE PEPTIDE-1; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; TODAY CLINICAL-TRIAL; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; PREVENTION PROGRAM OUTCOMES; FIBROBLAST GROWTH-FACTORS; INSULIN-TREATED PATIENTS AB Glucose metabolism is normally regulated by a feedback loop including islet beta cells and insulin-sensitive tissues, in which tissue sensitivity to insulin affects magnitude of beta-cell response. If insulin resistance is present, beta cells maintain normal glucose tolerance by increasing insulin output. Only when beta cells cannot release sufficient insulin in the presence of insulin resistance do glucose concentrations rise. Although beta-cell dysfunction has a clear genetic component, environmental changes play an essential part. Modern research approaches have helped to establish the important role that hexoses, aminoacids, and fatty acids have in insulin resistance and beta-cell dysfunction, and the potential role of changes in the microbiome. Several new approaches for treatment have been developed, but more effective therapies to slow progressive loss of beta-cell function are needed. Recent findings from clinical trials provide important information about methods to prevent and treat type 2 diabetes and some of the adverse effects of these interventions. However, additional long-term studies of drugs and bariatric surgery are needed to identify new ways to prevent and treat type 2 diabetes and thereby reduce the harmful effects of this disease. C1 [Kahn, Steven E.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Cooper, Mark E.] Baker IDI Heart & Diabet Inst, Diabet Div, Melbourne, Vic, Australia. [Del Prato, Stefano] Univ Pisa, Sch Med, Dept Clin & Expt Med, I-56100 Pisa, Italy. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM skahn@uw.edu RI Del Prato, Stefano/K-3405-2016 OI Del Prato, Stefano/0000-0002-5388-0270; Kahn, Steven/0000-0001-7307-9002 FU US Department of Veterans Affairs; NIH [DK-017047]; National Health and Medical Research Council of Australia; Italian Ministry of Education and Research [2010YK7Z5K_006] FX SEK is supported partly by the US Department of Veterans Affairs and NIH grant DK-017047. MEC is supported by an Australia Fellowship from the National Health and Medical Research Council of Australia. SDP was supported by grant 2010YK7Z5K_006 from the Italian Ministry of Education and Research. NR 202 TC 209 Z9 219 U1 21 U2 155 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD MAR 22 PY 2014 VL 383 IS 9922 BP 1068 EP 1083 DI 10.1016/S0140-6736(13)62154-6 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA AD8MV UT WOS:000333521200033 PM 24315620 ER PT J AU Subudhi, AW Bourdillon, N Bucher, J Davis, C Elliott, JE Eutermoster, M Evero, O Fan, JL Houten, SJV Julian, CG Kark, J Kark, S Kayser, B Kern, JP Kim, SE Lathan, C Laurie, SS Lovering, AT Paterson, R Polaner, DM Ryan, BJ Spira, JL Tsao, JW Wachsmuth, NB Roach, RC AF Subudhi, Andrew W. Bourdillon, Nicolas Bucher, Jenna Davis, Christopher Elliott, Jonathan E. Eutermoster, Morgan Evero, Oghenero Fan, Jui-Lin Jameson-Van Houten, Sonja Julian, Colleen G. Kark, Jonathan Kark, Sherri Kayser, Bengt Kern, Julia P. Kim, See Eun Lathan, Corinna Laurie, Steven S. Lovering, Andrew T. Paterson, Ryan Polaner, David M. Ryan, Benjamin J. Spira, James L. Tsao, Jack W. Wachsmuth, Nadine B. Roach, Robert C. TI AltitudeOmics: The Integrative Physiology of Human Acclimatization to Hypobaric Hypoxia and Its Retention upon Reascent SO PLOS ONE LA English DT Article ID ACUTE MOUNTAIN-SICKNESS; OPERATION EVEREST-II; PULMONARY GAS-EXCHANGE; PLASMA-VOLUME EXPANSION; RED-CELL MASS; COGNITIVE PERFORMANCE; EXTREME ALTITUDE; OXYGEN-TRANSPORT; SIMULATED ASCENT; CARDIAC-OUTPUT AB An understanding of human responses to hypoxia is important for the health of millions of people worldwide who visit, live, or work in the hypoxic environment encountered at high altitudes. In spite of dozens of studies over the last 100 years, the basic mechanisms controlling acclimatization to hypoxia remain largely unknown. The AltitudeOmics project aimed to bridge this gap. Our goals were 1) to describe a phenotype for successful acclimatization and assess its retention and 2) use these findings as a foundation for companion mechanistic studies. Our approach was to characterize acclimatization by measuring changes in arterial oxygenation and hemoglobin concentration [Hb], acute mountain sickness (AMS), cognitive function, and exercise performance in 21 subjects as they acclimatized to 5260 m over 16 days. We then focused on the retention of acclimatization by having subjects reascend to 5260 m after either 7 (n = 14) or 21 (n = 7) days at 1525 m. At 16 days at 5260 m we observed: 1) increases in arterial oxygenation and [Hb] (compared to acute hypoxia: PaO2 rose 964 mmHg to 45 +/- 4 while PaCO2 dropped a further 6 +/- 3 mmHg to 21 +/- 3, and [Hb] rose 1.8 +/- 0.7 g/dL to 16 +/- 2 g/dL; 2) no AMS; 3) improved cognitive function; and 4) improved exercise performance by 8 +/- 8% (all changes p<0.01). Upon reascent, we observed retention of arterial oxygenation but not [Hb], protection from AMS, retention of exercise performance, less retention of cognitive function; and noted that some of these effects lasted for 21 days. Taken together, these findings reveal new information about retention of acclimatization, and can be used as a physiological foundation to explore the molecular mechanisms of acclimatization and its retention. C1 [Subudhi, Andrew W.; Davis, Christopher; Eutermoster, Morgan; Evero, Oghenero; Jameson-Van Houten, Sonja; Julian, Colleen G.; Kark, Jonathan; Kark, Sherri; Paterson, Ryan; Roach, Robert C.] Univ Colorado, Altitude Res Ctr, Dept Emergency Med, Aurora, CO 80045 USA. [Subudhi, Andrew W.] Univ Colorado, Dept Biol, Colorado Springs, CO 80907 USA. [Bourdillon, Nicolas; Fan, Jui-Lin; Kayser, Bengt] Univ Lausanne, Fac Biol & Med, Inst Sports Sci, Lausanne, Switzerland. [Bourdillon, Nicolas; Fan, Jui-Lin] Univ Lausanne, Fac Biol & Med, Dept Physiol, Lausanne, Switzerland. [Bucher, Jenna; Elliott, Jonathan E.; Kern, Julia P.; Kim, See Eun; Laurie, Steven S.; Lovering, Andrew T.] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA. [Fan, Jui-Lin] Univ Lausanne, Leman Doctoral Sch Neurosci, Lausanne, Switzerland. [Lathan, Corinna] AnthroTronix Inc, Silver Spring, MD USA. [Polaner, David M.] Univ Colorado, Sch Med, Dept Anesthesiol, Aurora, CO USA. [Polaner, David M.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Polaner, David M.] Childrens Hosp Colorado, Aurora, CO USA. [Ryan, Benjamin J.] Univ Colorado, Dept Integrat Physiol, Boulder, CO USA. [Spira, James L.] Univ Hawaii, US Dept Vet Affairs, Pacific Islands Hlth Care Syst, Natl Ctr PTSD, Honolulu, HI 96822 USA. [Spira, James L.] Univ Hawaii, John A Burns Sch Med, Dept Psychiat, Honolulu, HI 96822 USA. [Tsao, Jack W.] US Navy Bur Med & Surg, Wounded Ill & Injured Directorate M9, Falls Church, VA USA. [Wachsmuth, Nadine B.] Univ Bayreuth, Dept Sports Med Sports Physiol, Bayreuth, Germany. RP Roach, RC (reprint author), Univ Colorado, Altitude Res Ctr, Dept Emergency Med, Anschutz Med Campus, Aurora, CO 80045 USA. EM Robert.Roach@ucdenver.edu RI Kayser, Bengt/M-8643-2013 OI Kayser, Bengt/0000-0002-9776-7501; Polaner, David/0000-0001-8716-6289; Elliott, Jonathan/0000-0002-6992-6851 FU United States Department of Defense [W81XWH-11-2-0040 TATRC, W81XWH-10-2-0114]; National Institutes of Health (NIH)/National Center for Advancing Translational Sciences Colorado CTSI [UL1 TR000154]; Cardiopulmonary & Respiratory Physiology Laboratory, University of Oregon; Altitude Research Center; Charles S. Houston Endowed Professorship, Department of Emergency Medicine, School of Medicine, University of Colorado Denver FX The overall AltitudeOmics study was funded, in part, by grants from the United States Department of Defense (W81XWH-11-2-0040 TATRC to RCR and W81XWH-10-2-0114 to ATL). The project was also supported, in part, by National Institutes of Health (NIH)/National Center for Advancing Translational Sciences Colorado CTSI Grant Number UL1 TR000154. Contents are the author's sole responsibility and do not necessarily represent official NIH views. Major additional support came from the Cardiopulmonary & Respiratory Physiology Laboratory, University of Oregon; the Altitude Research Center and the Charles S. Houston Endowed Professorship, Department of Emergency Medicine, School of Medicine, University of Colorado Denver. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 74 TC 16 Z9 16 U1 0 U2 17 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 21 PY 2014 VL 9 IS 3 AR e92191 DI 10.1371/journal.pone.0092191 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AD6GL UT WOS:000333355300059 PM 24658407 ER PT J AU Cornejo-Olivas, MR Yu, CE Mazzetti, P Mata, IF Meza, M Lindo-Samanamud, S Leverenz, JB Bird, TD AF Cornejo-Olivas, Mario R. Yu, Chang-En Mazzetti, Pilar Mata, Ignacio F. Meza, Maria Lindo-Samanamud, Saul Leverenz, James B. Bird, Thomas D. TI Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease SO NEUROSCIENCE LETTERS LA English DT Article DE Presenilin-1; Peruvian; Early-onset Alzheimer's disease ID PRECURSOR PROTEIN; PRESENILIN; GENETICS; FREQUENCY; GENES AB Presenilin 1 (PSEN1) gene mutations are found in 30-70% of familial early-onset Alzheimer disease (EOAD) cases (onset <60 years). Prevalence of these mutations is highly variable including ethnic differences worldwide. No Peruvian kindred with familial AD (FAD) have been described. Standardized clinical evaluation and cognitive assessment were completed in a Peruvian family with severe EOAD. Clinical course was characterized by very early onset (before age 35 years), progressive cognitive impairment with early memory loss, spatial disorientation and executive dysfunction. We sequenced all exons of PSEN1 in the proband and identified a c.475C>G DNA change resulting in a p.L153V missense mutation in the transmembrane domain 2 of the gene. This mutation is also present in the three additional affected siblings but not in a non-affected family member consistent with segregation of this mutation with the disease. This is the first report of a Peruvian family affected with EOAD associated with a PSEN1 mutation. This same mutation has been reported previously in English and French families, but a novel variants very close to the mutation and ancestry informative markers analysis suggests the mutation might be of Amerindian or African origin in this Peruvian family. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Cornejo-Olivas, Mario R.; Mazzetti, Pilar; Lindo-Samanamud, Saul] Inst Nacl Ciencias Neurol, Neurogenet Res Ctr, Lima 01, Peru. [Cornejo-Olivas, Mario R.] Northern Pacific Global Hlth Res Fellows Training, Bethesda, MD USA. [Mazzetti, Pilar; Meza, Maria] Univ Nacl Mayor San Marcos, Sch Med, Lima 14, Peru. [Yu, Chang-En; Leverenz, James B.; Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Mata, Ignacio F.; Leverenz, James B.; Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Parkinsons Res Educ & Clin Ctr, Seattle, WA USA. [Mata, Ignacio F.; Leverenz, James B.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, James B.; Bird, Thomas D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Cornejo-Olivas, MR (reprint author), Inst Nacl Ciencias Neurol, Neurogenet Res Ctr, 1271 Ancash St Lima, Lima 01, Peru. EM mario.cornejo.o@incngen.org.pe OI Cornejo-Olivas, Mario /0000-0001-6313-5680 FU NIH [R25 TW009345]; Fogarty International Center; National Institute of Mental Health; NIH Office of the Director Office of Research on Women's Health; NIH Office of AIDS Research FX We want to thank the Latin American Research Consortium on the Genetics of Parkinson's disease (LARGE PD) for providing healthy control samples from Peru. This project was supported by NIH Research Training Grant # R25 TW009345 funded by the Fogarty International Center, the National Institute of Mental Health, and the NIH Office of the Director Office of Research on Women's Health and the Office of AIDS Research. NR 18 TC 1 Z9 3 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 EI 1872-7972 J9 NEUROSCI LETT JI Neurosci. Lett. PD MAR 20 PY 2014 VL 563 BP 140 EP 143 DI 10.1016/j.neulet.2014.01.016 PG 4 WC Neurosciences SC Neurosciences & Neurology GA AE5CR UT WOS:000334005900029 PM 24495933 ER PT J AU Olfson, M Marcus, SC Bridge, JA AF Olfson, Mark Marcus, Steven C. Bridge, Jeffrey A. TI Focusing Suicide Prevention on Periods of High Risk SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID DELIBERATE SELF-HARM; CARE C1 [Olfson, Mark] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Bridge, Jeffrey A.] Nationwide Childrens Hosp, Res Inst, Ctr Innovat Pediat Practice, Columbus, OH USA. [Bridge, Jeffrey A.] Ohio State Univ, Columbus, OH 43210 USA. RP Olfson, M (reprint author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York State Psychiat Inst, 1051 Riverside Dr, New York, NY 10032 USA. EM mo49@columbia.edu FU AHRQ HHS [U19 HS021112] NR 10 TC 27 Z9 28 U1 2 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 19 PY 2014 VL 311 IS 11 BP 1107 EP 1108 DI 10.1001/jama.2014.501 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AD1RC UT WOS:000333010100011 PM 24515285 ER PT J AU Stengel, A Tache, Y AF Stengel, Andreas Tache, Yvette TI CRF and urocortin peptides as modulators of energy balance and feeding behavior during stress SO FRONTIERS IN NEUROSCIENCE LA English DT Review DE body weight; CRF; food intake; stress; urocortin ID CORTICOTROPIN-RELEASING-FACTOR; CONDITIONED TASTE-AVERSION; FACTOR-RECEPTOR EXPRESSION; ENTERIC NERVOUS-SYSTEM; FASTED PLASMA GHRELIN; REDUCES FOOD-INTAKE; C-FOS EXPRESSION; RAT-BRAIN; INDUCED ANOREXIA; SIGNALING PATHWAYS AB Early on, corticotropin-releasing factor (CRF), a hallmark brain peptide mediating many components of the stress response, was shown to affect food intake inducing a robust anorexigenic response when injected into the rodent brain. Subsequently, other members of the CRF signaling family have been identified, namely urocortin (Ucn) 1, Ucn 2, and Ucn 3 which were also shown to decrease food intake upon central or peripheral injection. However, the kinetics of feeding suppression was different with an early decrease following intracerebroventricular injection of CRF and a delayed action of Ucns contrasting with the early onset after systemic injection. CRF and Ucns bind to two distinct G-protein coupled membrane receptors, the CRF1 and CRF2. New pharmacological tools such as highly selective peptide CRF1 or CRF2 agonists or antagonists along with genetic knock-in or knock-out models have allowed delineating the primary role of CRF2 involved in the anorexic response to exogenous administration of CRF and Ucns. Several stressors trigger behavioral changes including suppression of feeding behavior which are mediated by brain CRF receptor activation. The present review will highlight the state-of-knowledge on the effects and mechanisms of action of CRF/Ucns-CRF112 signaling under basal conditions and the role in the alterations of food intake in response to stress. C1 [Stengel, Andreas] Charite, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, D-12200 Berlin, Germany. [Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress & Womens Hlth,Digest Dis Div, Los Angeles, CA 90024 USA. [Tache, Yvette] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Stengel, A (reprint author), Charite, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany. EM andreas.stengel@charite.de; ytache@mednet.ucla.edu FU NIH (Animal Core) [RO1 DK-33061, DK-41301]; VA Research Career Scientist (Yvette Tache), German Research Foundation STE [1765/3-1]; Charite University Funding UFF [89-441176] FX This work was supported by NIH RO1 DK-33061, NIH Center Grant DK-41301 (Animal Core), VA Research Career Scientist (Yvette Tache), German Research Foundation STE 1765/3-1 (Andreas Stengel) and Charite University Funding UFF 89-441176 (Andreas Stengel). NR 154 TC 22 Z9 23 U1 2 U2 13 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-453X J9 FRONT NEUROSCI-SWITZ JI Front. Neurosci. PD MAR 18 PY 2014 VL 8 AR 52 DI 10.3389/fnins.2014.00052 PG 10 WC Neurosciences SC Neurosciences & Neurology GA AW7HO UT WOS:000346435500003 PM 24672423 ER PT J AU Lo Re, V Kallan, MJ Tate, JP Localio, AR Lim, JK Goetz, MB Klein, MB Rimland, D Rodriguez-Barradas, MC Butt, AA Gibert, CL Brown, ST Park, L Dubrow, R Reddy, KR Kostman, JR Strom, BL Justice, AC AF Lo Re, Vincent, III Kallan, Michael J. Tate, Janet P. Localio, A. Russell Lim, Joseph K. Goetz, Matthew Bidwell Klein, Marina B. Rimland, David Rodriguez-Barradas, Maria C. Butt, Adeel A. Gibert, Cynthia L. Brown, Sheldon T. Park, Lesley Dubrow, Robert Reddy, K. Rajender Kostman, Jay R. Strom, Brian L. Justice, Amy C. TI Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients A Cohort Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC LIVER-DISEASE; POLYMERASE CHAIN-REACTION; SIMPLE NONINVASIVE INDEX; VETERANS AGING COHORT; PROTEIN-S DEFICIENCY; SOCIETY-USA PANEL; FIBROSIS PROGRESSION; HEPATOCELLULAR-CARCINOMA; HIV/HCV COINFECTION AB Background: The incidence and determinants of hepatic decompensation have been incompletely examined among patients co-infected with HIV and hepatitis C virus (HCV) in the antiretroviral therapy (ART) era, and few studies have compared outcome rates with those of patients with chronic HCV alone. Objective: To compare the incidence of hepatic decompensation between antiretroviral-treated patients co-infected with HIV and HCV and HCV-monoinfected patients and to evaluate factors associated with decompensation among co-infected patients receiving ART. Design: Retrospective cohort study. Setting: Veterans Health Administration. Patients: 4280 co-infected patients who initiated ART and 6079 HCV-monoinfected patients receiving care between 1997 and 2010. All patients had detectable HCV RNA and were HCV treatment-naive. Measurements: Incident hepatic decompensation, determined by diagnoses of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage. Results: The incidence of hepatic decompensation was greater among co-infected than monoinfected patients (7.4% vs. 4.8% at 10 years; P < 0.001). Compared with HCV-monoinfected patients, co-infected patients had a higher rate of hepatic decompensation (hazard ratio [HR] accounting for competing risks, 1.56 [95% CI, 1.31 to 1.86]). Co-infected patients who maintained HIV RNA levels less than 1000 copies/mL still had higher rates of decompensation than HCV-monoinfected patients (HR, 1.44 [CI, 1.05 to 1.99]). Baseline advanced hepatic fibrosis (FIB-4 score >3.25) (HR, 5.45 [CI, 3.79 to 7.84]), baseline hemoglobin level less than 100 g/L (HR, 2.24 [CI, 1.20 to 4.20]), diabetes mellitus (HR, 1.88 [CI, 1.38 to 2.56]), and nonblack race (HR, 2.12 [CI, 1.65 to 2.72]) were each associated with higher rates of decompensation among co-infected patients. Limitation: Observational study of predominantly male patients. Conclusion: Despite receiving ART, patients co-infected with HIV and HCV had higher rates of hepatic decompensation than HCV-monoinfected patients. Rates of decompensation were higher for co-infected patients with advanced liver fibrosis, severe anemia, diabetes, and nonblack race. C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. Yale Univ, Sch Med, West Haven, CT 06516 USA. Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. McGill Univ, Ctr Hlth, Montreal, PQ, Canada. Atlanta VA Med Ctr, Atlanta, GA 30033 USA. Emory Univ, Sch Med, Atlanta, GA USA. Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates. Washington DC VA Med Ctr, Washington, DC 20422 USA. George Washington Univ, Med Ctr, Washington, DC 20037 USA. James J Peters VA Med Ctr, New York, NY USA. Mt Sinai Sch Med, New York, NY USA. Rutgers State Univ, Newark, NJ 07103 USA. RP Lo Re, V (reprint author), Univ Penn, Penn Ctr AIDS Res, Ctr Clin Epidemiol & Biostat, Div Infect Dis,Dept Med,Perelman Sch Med, 836 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM vincentl@mail.med.upenn.edu RI Lo Re, Vincent/N-7817-2015 OI Butt, Adeel/0000-0002-1118-1826; Goetz, Matthew/0000-0003-4542-992X FU National Institute of Allergy and Infectious Diseases [K01 AI070001]; National Institute on Alcohol Abuse and Alcoholism [U01 AA13566]; National Institute of Mental Health [T32 MH020031]; National Institutes of Health FX National Institutes of Health. NR 67 TC 73 Z9 73 U1 1 U2 7 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 18 PY 2014 VL 160 IS 6 BP 369 EP + DI 10.7326/M13-1829 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA AD8MW UT WOS:000333521300013 PM 24723077 ER PT J AU Hirata, H Hinoda, Y Shahryari, V Deng, G Tanaka, Y Tabatabai, ZL Dahiya, R AF Hirata, H. Hinoda, Y. Shahryari, V. Deng, G. Tanaka, Y. Tabatabai, Z. L. Dahiya, R. TI Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells SO BRITISH JOURNAL OF CANCER LA English DT Article DE genistein; miR-1260b; PC; sFRP1; Smad4; apoptosis ID WNT SIGNALING PATHWAY; UNITED-STATES; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; INCIDENCE TRENDS; ALTERS GROWTH; GENES; METHYLATION; PROGRESSION; EXPRESSION AB Background: Recently several microRNAs (miRNAs) have been found to be regulated by genistein in cancer cells. In this study, we focused on the gene regulatory effect of genistein on microRNA and its target genes in prostate cancer (PC). Methods: Initially, we investigated the effect of genistein on prostate cancer cells and identified that the expression of miRNA1260b was decreased by genistein. We performed functional analyses and investigated the relationship between miRNA-1260b expression and prostate cancer patient outcomes. Two target genes (sFRP1 and Smad4) of miR-1260b were identified based on computer algorithm and 3 ' UTR luciferase assay was carried out to determine direct miRNA regulation of the genes. Results: Genistein promoted apoptosis while inhibiting prostate cancer cell proliferation, invasion and TCF reporter activity in PC cells. MiR-1260b was highly expressed in prostate cancer tissues and significantly downregulated by genistein in PC cells. After knocking down miR-1260b, cell proliferation, invasion, migration and TCF reporter activity were decreased in PC cells. Western analysis and 30UTR luciferase assay showed that the two target genes (sFRP1 and Smad4) were directly regulated by miR-1260b. The expression of sFRP1 and Smad4 was significantly decreased in prostate cancer tissues. Genistein also increased expression of these two genes via DNA demethylation and histone modifications. Conclusions: Our data suggest that genistein exerts its anti-tumour effect via downregulation of miR-1260b that targeted sRRP1 and Smad4 genes in prostate cancer cells. The expression of sFRP1 and Smad4 was also modulated by genistein via DNA methylation or histone modifications in PC cell lines. C1 [Hirata, H.; Shahryari, V.; Deng, G.; Tanaka, Y.; Dahiya, R.] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. [Hirata, H.; Shahryari, V.; Deng, G.; Tanaka, Y.; Tabatabai, Z. L.; Dahiya, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hinoda, Y.] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan. [Tabatabai, Z. L.] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu FU National Center for Research Resources of the National Institutes of Health [RO1CA138642, RO1CA130860, RO1CA160079, I01BX001123]; VA Merit Review, VA Program Project; Yamada Science Foundation FX We thank Dr Roger Erickson for his support and assistance with the preparation of the manuscript. This study was supported by National Center for Research Resources of the National Institutes of Health through Grant Number RO1CA138642, RO1CA130860, RO1CA160079, I01BX001123, VA Merit Review, VA Program Project (PI: R Dahiya) and Yamada Science Foundation. NR 46 TC 21 Z9 24 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 EI 1532-1827 J9 BRIT J CANCER JI Br. J. Cancer PD MAR 18 PY 2014 VL 110 IS 6 BP 1645 EP 1654 DI 10.1038/bjc.2014.48 PG 10 WC Oncology SC Oncology GA AD4DB UT WOS:000333195800029 PM 24504368 ER PT J AU Li, XY Tao, H Xie, KW Ni, ZH Yan, YC Wei, K Chuang, PY He, JC Gu, LY AF Li, Xiaoying Tao, Hua Xie, Kewei Ni, Zhaohui Yan, Yucheng Wei, Kai Chuang, Peter Y. He, John Cijiang Gu, Leyi TI cAMP Signaling Prevents Podocyte Apoptosis via Activation of Protein Kinase A and Mitochondrial Fusion SO PLOS ONE LA English DT Article ID GLOMERULAR PODOCYTES; EPITHELIAL-CELLS; MOUSE MODEL; IN-VITRO; PATHWAY; EXPRESSION; RECEPTOR; NEPHROPATHY; DAMAGE; STRESS AB Our previous in vitro studies suggested that cyclic AMP (cAMP) signaling prevents adriamycin (ADR) and puromycin aminonucleoside (PAN)-induced apoptosis in podocytes. As cAMP is an important second messenger and plays a key role in cell proliferation, differentiation and cytoskeleton formation via protein kinase A (PKA) or exchange protein directly activated by cAMP (Epac) pathways, we sought to determine the role of PKA or Epac signaling in cAMP-mediated protection of podocytes. In the ADR nephrosis model, we found that forskolin, a selective activator of adenylate cyclase, attenuated albuminuria and improved the expression of podocyte marker WT-1. When podocytes were treated with pCPT-cAMP (a selective cAMP/PKA activator), PKA activation was increased in a time-dependent manner and prevented PAN-induced podocyte loss and caspase 3 activation, as well as a reduction in mitochondrial membrane potential. We found that PAN and ADR resulted in a decrease in Mfn1 expression and mitochondrial fission in podocytes. pCPT-cAMP restored Mfn1 expression in puromycin or ADR-treated podocytes and induced Drp1 phosphorylation, as well as mitochondrial fusion. Treating podocytes with arachidonic acid resulted in mitochondrial fission, podocyte loss and cleaved caspase 3 production. Arachidonic acid abolished the protective effects of pCPT-cAMP on PAN-treated podocytes. Mdivi, a mitochondrial division inhibitor, prevented PAN-induced cleaved caspase 3 production in podocytes. We conclude that activation of cAMP alleviated murine podocyte caused by ADR. PKA signaling resulted in mitochondrial fusion in podocytes, which at least partially mediated the effects of cAMP. C1 [Li, Xiaoying; Tao, Hua; Xie, Kewei; Ni, Zhaohui; Yan, Yucheng; Wei, Kai; Gu, Leyi] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Renal, Shanghai 200030, Peoples R China. [Li, Xiaoying; Tao, Hua; Xie, Kewei; Ni, Zhaohui; Yan, Yucheng; Wei, Kai; Gu, Leyi] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Mol Cell Lab Kidney Dis, Shanghai 200030, Peoples R China. [Chuang, Peter Y.; He, John Cijiang] Icahn Sch Med Mt Sinai, Div Nephrol, New York, NY USA. [He, John Cijiang] James J Peter Vet Affairs Med Ctr, Renal Sect, Bronx, NY USA. RP Gu, LY (reprint author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Renal, Shanghai 200030, Peoples R China. EM guleyi@aliyun.com FU National Nature Science Foundation Grant of China [30971363, 81270781]; Nature Science Foundation Grant of Shanghai [08ZR1413200]; National Basic Research Program of China 973 Program [2012CB517602]; Nature Science Foundation of Shanghai [10JC1410200] FX This work was supported by the National Nature Science Foundation Grant of China (30971363 and 81270781, http://www.nsfc.gov.cn) and Nature Science Foundation Grant of Shanghai (08ZR1413200, http://www.stcsm.gov.cn) to Dr Gu. National Basic Research Program of China 973 Program (2012CB517602,http://program.most.gov.cn) to Dr Ni as well as by a grant (10JC1410200,http://www.stcsm.gov.cn) from the Nature Science Foundation of Shanghai to Dr Yan. The funders had no role in study design, data collection and analysis, decision to publish, or preparaton of the manuscript. NR 43 TC 6 Z9 8 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 18 PY 2014 VL 9 IS 3 AR e92003 DI 10.1371/journal.pone.0092003 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AD4ZE UT WOS:000333259900058 PM 24642777 ER PT J AU Anderson, RF Shinde, SS Hille, R Rothery, RA Weiner, JH Rajagukguk, S Maldashina, E Cecchini, G AF Anderson, Robert F. Shinde, Sujata S. Hille, Russ Rothery, Richard A. Weiner, Joel H. Rajagukguk, Sany Maldashina, Elena Cecchini, Gary TI Electron-Transfer Pathways in the Heme and Quinone-Binding Domain of Complex II (Succinate Dehydrogenase) SO BIOCHEMISTRY LA English DT Article ID ESCHERICHIA-COLI; UBIQUINONE OXIDOREDUCTASE; FUMARATE REDUCTASE; CATALYTIC-ACTIVITY; RESPIRATORY-CHAIN; SITE; PARAGANGLIOMAS; SUPEROXIDE; MUTATIONS; OXIDASE AB Single electron transfers have been examined in complex II (succinate:ubiquinone oxidoreductase) by the method of pulse radiolysis. Electrons are introduced into the enzyme initially at the [3Fe-4S] and ubiquinone sites followed. by intramolecular equilibration with the b heme of the enzyme. To define thermodynamic and other controlling parameters for the pathways of electron transfer in complex II, site-directed variants were constructed and analyzed. Variants at SdhB-His207 and SdhB-Ile209 exhibit significantly perturbed electron transfer between the [3Fe-4S] cluster and ubiquinone. Analysis of the data using Marcus theory shows that the electronic coupling constants for wild-type and variant enzyme are all small, indicating that electron transfer occurs by diabatic tunneling. The presence of the ubiquinone is necessary for efficient electron transfer to the heme, which only slowly equilibrates with the [3Fe-4S] cluster in the absence of the quinone. C1 [Anderson, Robert F.; Shinde, Sujata S.] Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Auckland 1142, New Zealand. [Hille, Russ] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA. [Rothery, Richard A.; Weiner, Joel H.] Univ Alberta, Dept Biochem, Membrane Protein Res Grp, Edmonton, AB T6G 2H7, Canada. [Rajagukguk, Sany; Maldashina, Elena; Cecchini, Gary] San Francisco VA Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA. [Maldashina, Elena; Cecchini, Gary] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA. RP Cecchini, G (reprint author), Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Auckland 1142, New Zealand. EM r.anderson@auckland.ac.nz; gary.cecchini@ucsf.edu OI Rothery, Richard/0000-0003-3265-1783 FU Department of Veterans Affairs Biomedical Laboratory Research and Development Merit Award [BX001077]; National Institutes of Health [GM61606]; U.S. Department of Energy [DE-SC0010666]; Canadian Institutes of Health Research [MOP89735] FX The work in the authors' laboratories was supported in whole or in part by the Department of Veterans Affairs Biomedical Laboratory Research and Development Merit Award (BX001077), the National Institutes of Health (GM61606), the U.S. Department of Energy (DE-SC0010666), and the Canadian Institutes of Health Research (MOP89735). NR 49 TC 1 Z9 1 U1 1 U2 30 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD MAR 18 PY 2014 VL 53 IS 10 BP 1637 EP 1646 DI 10.1021/bi401630m PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AD4QM UT WOS:000333235600012 PM 24559074 ER PT J AU Feemster, LC Au, DH AF Feemster, Laura C. Au, David H. TI Penalizing Hospitals for Chronic Obstructive Pulmonary Disease Readmissions SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE quality indicators; chronic obstructive pulmonary disease; patient readmission; Medicate ID MEDICARE BENEFICIARIES; ACUTE EXACERBATIONS; HEALTH OUTCOMES; INPATIENT CARE; QUALITY; PROGRAM; RATES; REHOSPITALIZATION; HOSPITALIZATIONS; ASSOCIATION AB In October 2014, the U.S. Centers for Medicare and Medicaid Services (CMS) Will expand its Hospital Readmission Reduction Program (HRRP) to include chronic obstructive pulinonary disease (COPD). Under the new policy, hospitals with high risk-adjusted, 30-day all-cause unplanned readmission rates after an index hospitalization for a COPD exacerbation will be penalized with reduced reimbursement for the treatment of Medicare beneficiaries. In this perspective, we review the history of the HRRP, including the recent addition of COPD to the policy. We critically assess the use of 30-day all-cause COPD readmissions as an accountability measure, discussing potential benefits and then highlighting the substantial drawbacks and potential unintended consequences of the measure that could adversely affect providers, hospitals, and patients with COPD. We conclude by emphasizing the need to place the 30-day COPD readmission measure in the context of a reconceived model for postdischarge quality and review several frameworks that could help guide this process. C1 [Feemster, Laura C.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Feemster, Laura C.; Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Feemster, LC (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM lcecere@uw.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health [K23HL111116]; VA Puget Sound Health Care System; Health Services Research and Developmen FX Supported by a National Heart, Lung, and Blood Institute, National Institutes of Health, K23 Award K23HL111116 (L.C.F.) and the VA Puget Sound Health Care System, Health Services Research and Development (LCF., D.H.A.). NR 36 TC 20 Z9 20 U1 1 U2 6 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAR 15 PY 2014 VL 189 IS 6 BP 634 EP 639 DI 10.1164/rccm.201308-1541PP PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AD6OQ UT WOS:000333381100007 PM 24460431 ER PT J AU Kang, HK Cypel, Y Kilbourne, AM Magruder, KM Serpi, T Collins, JF Frayne, SM Furey, J Huang, GD Kimerling, R Reinhard, MJ Schumacher, K Spiro, A AF Kang, Han K. Cypel, Yasmin Kilbourne, Amy M. Magruder, Kathy M. Serpi, Tracey Collins, Joseph F. Frayne, Susan M. Furey, Joan Huang, Grant D. Kimerling, Rachel Reinhard, Matthew J. Schumacher, Karen Spiro, Avron, III TI HealthViEWS: Mortality Study of Female US Vietnam Era Veterans, 1965-2010 SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE HealthViEWS; mortality; veterans; Vietnam; women ID UNITED-STATES-ARMY; CANCER MORTALITY; PROPORTIONATE MORTALITY; POSTSERVICE MORTALITY; REGISTERED NURSES; MILITARY SERVICE; LUNG-CANCER; FOLLOW-UP; DEATH; WOMEN AB We conducted a retrospective study among 4,734 women who served in the US military in Vietnam (Vietnam cohort), 2,062 women who served in countries near Vietnam (near-Vietnam cohort), and 5,313 nondeployed US military women (US cohort) to evaluate the associations of mortality outcomes with Vietnam War service. Veterans were identified from military records and followed for 40 years through December 31, 2010. Information on underlying causes of death was obtained from death certificates and the National Death Index. Based on 2,743 deaths, all 3 veteran cohorts had lower mortality risk from all causes combined and from several major causes, such as diabetes mellitus, heart disease, chronic obstructive pulmonary disease, and nervous system disease relative to comparable US women. However, excess deaths from motor vehicle accidents were observed in the Vietnam cohort (standardized mortality ratio = 3.67, 95% confidence interval (CI): 2.30, 5.56) and in the US cohort (standardized mortality ratio = 1.91, 95% CI: 1.02, 3.27). More than two-thirds of women in the study were military nurses. Nurses in the Vietnam cohort had a 2-fold higher risk of pancreatic cancer death (adjusted relative risk = 2.07, 95% CI: 1.00, 4.25) and an almost 5-fold higher risk of brain cancer death compared with nurses in the US cohort (adjusted relative risk = 4.61, 95% CI: 1.27, 16.83). Findings of all-cause and motor vehicle accident deaths among female Vietnam veterans were consistent with patterns of postwar mortality risk among other war veterans. C1 [Kang, Han K.; Cypel, Yasmin] US Dept Vet Affairs, Off Publ Hlth, Postdeployment Hlth Grp, Washington, DC 20420 USA. [Kilbourne, Amy M.; Schumacher, Karen] Vet Affairs Ann Arbor Ctr Clin Management Res, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Magruder, Kathy M.] Med Univ S Carolina, Dept Psychiat, Mental Hlth Serv, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Serpi, Tracey; Collins, Joseph F.] Vet Affairs Maryland Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. [Frayne, Susan M.; Kimerling, Rachel] Vet Affairs Palo Alto Hlth Care Syst, Vet Affairs Hlth Serv Res & Dev Ctr Innovat Imple, Palo Alto, CA USA. [Frayne, Susan M.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Palo Alto, CA 94304 USA. [Furey, Joan] US Dept Vet Affairs, Ctr Women Vet, Washington, DC 20420 USA. [Huang, Grant D.] US Dept Vet Affairs, Cooperat Studies Program, Cent Off, Off Res & Dev, Washington, DC 20420 USA. [Kimerling, Rachel] Natl Ctr Postttraumat Stress Disorder, Palo Alto, CA USA. [Reinhard, Matthew J.] DC Vet Affairs Med Ctr, War Related Illness & Injury Study Ctr, Washington, DC USA. [Reinhard, Matthew J.] Georgetown Univ, Sch Med, Dept Psychiat, Washington, DC USA. [Spiro, Avron, III] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. [Spiro, Avron, III] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Spiro, Avron, III] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. RP Cypel, Y (reprint author), US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth Strateg Healthcare Grp 10P3A, Off Publ Hlth, Washington, DC 20420 USA. EM yasmin.cypel@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Cooperative Studies Program FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Cooperative Studies Program. NR 53 TC 9 Z9 9 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 15 PY 2014 VL 179 IS 6 BP 721 EP 730 DI 10.1093/aje/kwt319 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD4UP UT WOS:000333246800009 PM 24488510 ER PT J AU Downey, LA Loftis, JM AF Downey, Luke A. Loftis, Jennifer M. TI Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Review DE Methamphetamine; 3,4-Methylenedioxy-N-methylamphetamine (MDMA); Neurodegenerative diseases; Inflammation; Oxidative stress; Bioenergetics ID OXIDATIVE STRESS; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; ECSTASY USERS; RAT-BRAIN; POSITRON EMISSION; USE DISORDERS; NEUROTOXICITY; IMPAIRMENT; GLUCOSE; DOPAMINE AB Central nervous system (CNS) damage associated with psychostimulant dependence may be an ongoing, degenerative process with adverse effects on neuropsychiatric function. However, the molecular mechanisms regarding how altered energy regulation affects immune response in the context of substance use disorders are not fully understood. This review summarizes the current evidence regarding the effects of psychostimulant [particularly 3,4-methylenedioxy-N-methylamphetamine (MDMA) and methamphetamine] exposure on brain energy regulation, immune response, and neuropsychiatric function. Importantly, the neuropsychiatric impairments (e.g., cognitive deficits, depression, and anxiety) that persist following abstinence are associated with poorer treatment outcomes - increased relapse rates, lower treatment retention rates, and reduced daily functioning. Qualifying the molecular changes within the CNS according to the exposure and use patterns of specifically abused substances should inform the development of new therapeutic approaches for addiction treatment. Published by Elsevier B.V. C1 [Downey, Luke A.] Swinburne Univ Technol, Ctr Human Psychopharmacol, Hawthorn, Vic 3122, Australia. [Downey, Luke A.] Swansea Univ, Dept Psychol, Swansea, W Glam, Wales. [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland VA Med Ctr, Portland, OR 97239 USA. RP Loftis, JM (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. EM loftisj@ohsu.edu FU National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) [DA028537, DA018165]; National Health and Medical Research Council (NHMRC) [APP1054279] FX The research discussed in this review was in part supported by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) Grants (DA028537 and DA018165). This material was also supported with resources and the use of facilities at the Portland Veterans Affairs (VA) Medical Center and Oregon Health & Sciences University. Dr. Jennifer Loftis is a Research Scientist at the Portland VA Medical Center, Dr. Luke Downey is supported by a National Health and Medical Research Council (NH&MRC) biomedical fellowship (APP1054279). NR 66 TC 5 Z9 5 U1 2 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 EI 1879-0712 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD MAR 15 PY 2014 VL 727 BP 125 EP 129 DI 10.1016/j.ejphar.2014.01.032 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AC8EY UT WOS:000332767500016 PM 24485894 ER PT J AU Kim-Howard, X Sun, C Molineros, JE Maiti, AK Chandru, H Adler, A Wiley, GB Kaufman, KM Kottyan, L Guthridge, JM Rasmussen, A Kelly, J Sanchez, E Raj, P Li, QZ Bang, SY Lee, HS Kim, TH Kang, YM Suh, CH Chung, WT Park, YB Choe, JY Shim, SC Lee, SS Han, BG Olsen, NJ Karp, DR Moser, K Pons-Estel, BA Wakeland, EK James, JA Harley, JB Bae, SC Gaffney, PM Alarcon-Riquelme, M Looger, LL Nath, SK AF Kim-Howard, Xana Sun, Celi Molineros, Julio E. Maiti, Amit K. Chandru, Hema Adler, Adam Wiley, Graham B. Kaufman, Kenneth M. Kottyan, Leah Guthridge, Joel M. Rasmussen, Astrid Kelly, Jennifer Sanchez, Elena Raj, Prithvi Li, Quan-Zhen Bang, So-Young Lee, Hye-Soon Kim, Tae-Hwan Kang, Young Mo Suh, Chang-Hee Chung, Won Tae Park, Yong-Beom Choe, Jung-Yoon Shim, Seung Cheol Lee, Shin-Seok Han, Bok-Ghee Olsen, Nancy J. Karp, David R. Moser, Kathy Pons-Estel, Bernardo A. Wakeland, Edward K. James, Judith A. Harley, John B. Bae, Sang-Cheol Gaffney, Patrick M. Alarcon-Riquelme, Marta Looger, Loren L. Nath, Swapan K. CA GENLES TI Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations SO HUMAN MOLECULAR GENETICS LA English DT Article ID CHRONIC GRANULOMATOUS-DISEASE; PHAGOCYTE NADPH OXIDASE; GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; GENETIC SUSCEPTIBILITY; RNA SURVEILLANCE; REVISED CRITERIA; OXIDATIVE STRESS; CROHNS-DISEASE; RISK LOCI AB Recent reports have associated NCF2, encoding a core component of the multi-protein NADPH oxidase (NADPHO), with systemic lupus erythematosus (SLE) susceptibility in individuals of European ancestry. To identify ethnicity-specific and -robust variants within NCF2, we assessed 145 SNPs in and around the NCF2 gene in 5325 cases and 21 866 controls of European-American (EA), African-American (AA), Hispanic (HS) and Korean(KR) ancestry. Subsequent imputation, conditional, haplotype and bioinformatic analyses identified seven potentially functional SLE-predisposing variants. Association with non-synonymous rs17849502, previously reported in EA, was detected in EA, HS and AA (P-EA = 1.01 x 10(-54), P-HS = 3.68 x 10(-10), P-AA = 0.03); synonymous rs17849501 was similarly significant. These SNPs were monomorphic in KR. Novel associations were detected with coding variants at rs35937854 in AA (P-AA = 1.49 x 10(-9)), and rs13306575 in HS and KR (P-HS = 7.04 x 10(-7), P-KR = 3.30 x 10(-3)). In KR, a3-SNP haplotype was significantly associated (P 5 4.20 3 10 27), implying that SLE predisposing variants were tagged. Significant SNP-SNP interaction (P 5 0.02) was detected between rs13306575 and rs17849502 in HS, and adramatically increased risk(OR 5 6.55) with a risk allele at each locus. Molecular modeling predicts that these non-synonymous mutations could disrupt NADPHO complex assembly. The risk allele of rs17849501, located in a conserved transcriptional regulatory region, increased reporter gene activity, suggesting in vivo enhancer function. Our results not only establish allelic heterogeneity within NCF2 associated with SLE, but also emphasize the utility of multi-ethnic cohorts to identify predisposing variants explaining additional phenotypic variance ('missing heritability') of complex diseases like SLE. C1 [Kim-Howard, Xana; Sun, Celi; Molineros, Julio E.; Maiti, Amit K.; Chandru, Hema; Adler, Adam; Wiley, Graham B.; Guthridge, Joel M.; Rasmussen, Astrid; Kelly, Jennifer; Sanchez, Elena; Moser, Kathy; James, Judith A.; Gaffney, Patrick M.; Alarcon-Riquelme, Marta; Nath, Swapan K.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Kaufman, Kenneth M.; Kottyan, Leah; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.; Kottyan, Leah; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Raj, Prithvi; Li, Quan-Zhen; Wakeland, Edward K.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Bang, So-Young; Lee, Hye-Soon; Kim, Tae-Hwan; Bae, Sang-Cheol] Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul 133791, South Korea. [Kang, Young Mo] Kyungpook Natl Univ Hosp, Taegu, South Korea. [Suh, Chang-Hee] Ajou Univ Hosp, Suwon, South Korea. [Chung, Won Tae] Dong A Univ Hosp, Pusan, South Korea. [Park, Yong-Beom] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea. [Choe, Jung-Yoon] Daegu Catholic Univ Hosp, Taegu, South Korea. [Shim, Seung Cheol] Chungnam Natl Univ Hosp, Daejeon Rheumatoid & Degenerat Arthrit Ctr, Taejon, South Korea. [Lee, Shin-Seok] Chonnam Natl Univ Hosp, Kwangju, South Korea. [Han, Bok-Ghee] Korea Natl Inst Hlth, Osong, South Korea. [Olsen, Nancy J.] Penn State Med Sch, Dept Med, Div Rheumatol, Hershey, PA USA. [Karp, David R.] Univ Texas Southwest Med Ctr, Dept Med, Div Rheumat Dis, Dallas, TX USA. [Pons-Estel, Bernardo A.] Sanat Parque, Rosario, Santa Fe, Argentina. [Looger, Loren L.] Howard Hughes Med Inst, Ashburn, VA USA. RP Nath, SK (reprint author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 1025 NE 13th St, Oklahoma City, OK 73104 USA. EM swapan-nath@omrf.org RI Sanchez, Elena/B-4140-2017 OI Sanchez, Elena/0000-0002-7041-5485; Kottyan, Leah/0000-0003-3979-2220; Suh, Chang-Hee/0000-0001-6156-393X FU US National Institutes of Health [AI103399, AR060366, AI094377, AI083194, CA141700, AR058621, AI101934, AI082714, AR053483, GM103510, GM103456, A121983]; Ministry for Health & Welfare, Republic of Korea FX This work was supported by grants from the US National Institutes of Health (AI103399, AR060366, AI094377, AI083194, CA141700, AR058621, AI101934, AI082714, AR053483, GM103510, GM103456) and A121983, the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea. NR 98 TC 15 Z9 15 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAR 15 PY 2014 VL 23 IS 6 BP 1656 EP 1668 DI 10.1093/hmg/ddt532 PG 13 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA AB8MK UT WOS:000332044300022 PM 24163247 ER PT J AU Perez, VB Woods, SW Roach, BJ Ford, JM McGlashan, TH Srihari, VH Mathalon, DH AF Perez, Veronica B. Woods, Scott W. Roach, Brian J. Ford, Judith M. McGlashan, Thomas H. Srihari, Vinod H. Mathalon, Daniel H. TI Automatic Auditory Processing Deficits in Schizophrenia and Clinical High-Risk Patients: Forecasting Psychosis Risk with Mismatch Negativity SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Auditory cortex; clinical high-risk for psychosis; event-related potential; longitudinal; mismatch negativity; psychosis; schizophrenia ID EVENT-RELATED POTENTIALS; D-ASPARTATE RECEPTORS; ULTRA-HIGH-RISK; 1ST-EPISODE SCHIZOPHRENIA; INTERRATER RELIABILITY; SELECTIVE-ATTENTION; PREDICTIVE-VALIDITY; PRODROMAL SYNDROMES; SPECTRUM DISORDERS; STIMULUS DEVIANCE AB Background: Only about one third of patients at high risk for psychosis based on current clinical criteria convert to a psychotic disorder within a 2.5-year follow-up period. Targeting clinical high-risk (CHR) individuals for preventive interventions could expose many to unnecessary treatments, underscoring the need to enhance predictive accuracy with nonclinical measures. Candidate measures include event-related potential components with established sensitivity to schizophrenia. Here, we examined the mismatch negativity (MMN) component of the event-related potential elicited automatically by auditory deviance in CHR and early illness schizophrenia (ESZ) patients. We also examined whether MMN predicted subsequent conversion to psychosis in CHR patients. Methods: Mismatch negativity to auditory deviants (duration, frequency, and duration + frequency double deviant) was assessed in 44 healthy control subjects, 19 ESZ, and 38 CHR patients. Within CHR patients, 15 converters to psychosis were compared with 16 nonconverters with at least 12 months of clinical follow-up. Hierarchical Cox regression examined the ability of MMN to predict time to psychosis onset in CHR patients. Results: Irrespective of deviant type, MMN was significantly reduced in ESZ and CHR patients relative to healthy control subjects and in CHR converters relative to nonconverters. Mismatch negativity did not significantly differentiate ESZ and CHR patients. The duration + frequency double deviant MMN, but not the single deviant MMNs, significantly predicted the time to psychosis onset in CHR patients. Conclusions: Neurophysiological mechanisms underlying automatic processing of auditory deviance, as reflected by the duration + frequency double deviant MMN, are compromised before psychosis onset and can enhance the prediction of psychosis risk among CHR patients. C1 [Perez, Veronica B.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Perez, Veronica B.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Woods, Scott W.; McGlashan, Thomas H.; Srihari, Vinod H.] Yale Univ, Sch Med, New Haven, CT USA. RP Mathalon, DH (reprint author), Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Mental Hlth Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Mathalon, Daniel/0000-0001-6090-4974; Roach, Brian/0000-0002-3264-1465; Srihari, Vinod/0000-0003-1556-2332 FU National Institutes of Health [R01 MH076989, U01 MH082022, K02 MH067967, T32 MH089920]; Brain and Behavior Research Foundation FX This study was supported by grants from the National Institutes of Health (R01 MH076989, U01 MH082022, K02 MH067967, and T32 MH089920) and from the Brain and Behavior Research Foundation. NR 89 TC 33 Z9 35 U1 3 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 2014 VL 75 IS 6 BP 459 EP 469 DI 10.1016/j.biopsych.2013.07.038 PG 11 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AB4AK UT WOS:000331731100006 PM 24050720 ER PT J AU Wang, J Bi, WN Cheng, A Freire, D Vempati, P Zhao, W Gong, B Janle, EM Chen, TY Ferruzzi, MG Schmeidler, J Ho, L Pasinetti, GM AF Wang, Jun Bi, Weina Cheng, Alice Freire, Daniel Vempati, Prashant Zhao, Wei Gong, Bing Janle, Elsa M. Chen, Tzu-Ying Ferruzzi, Mario G. Schmeidler, James Ho, Lap Pasinetti, Giulio M. TI Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Article DE Alzheimer's disease (AD); polyphenols; grape seed extract; grape juice; resveratrol; J20 mice ID LONG-TERM POTENTIATION; MOUSE MODEL; COGNITIVE DETERIORATION; TRANSGENIC MICE; RESVERATROL; NEUROPATHOLOGY; BRAIN; INFLAMMATION; SUPPLEMENTATION; CONSUMPTION AB Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging and currently has no cure. Its onset and progression are influenced by multiple factors. There is growing consensus that successful treatment will rely on simultaneously targeting multiple pathological features of AD. Polyphenol compounds have many proven health benefits. In this study, we tested the hypothesis that combining three polyphenolic preparations (grape seed extract, resveratrol, and Concord grape juice extract), with different polyphenolic compositions and partially redundant bioactivities, may simultaneously and synergistically mitigate amyloid-beta (A beta) mediated neuropathology and cognitive impairments in a mouse model of AD. We found that administration of the polyphenols in combination did not alter the profile of bioactive polyphenol metabolites in the brain. We also found that combination treatment resulted in better protection against cognitive impairments compared to individual treatments, in J20 AD mice. Electrophysiological examination showed that acute treatment with select brain penetrating polyphenol metabolites, derived from these polyphenols, improved oligomeric A beta (oA beta)-induced long term potentiation (LIP) deficits in hippocampal slices. Moreover, we found greatly reduced total amyloid content in the brain following combination treatment. Our studies provided experimental evidence that application of polyphenols targeting multiple disease-mechanisms may yield a greater likelihood of therapeutic efficacy. C1 [Wang, Jun; Bi, Weina; Cheng, Alice; Freire, Daniel; Vempati, Prashant; Zhao, Wei; Gong, Bing; Ho, Lap; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA. [Wang, Jun; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Janle, Elsa M.; Chen, Tzu-Ying; Ferruzzi, Mario G.] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Janle, Elsa M.; Chen, Tzu-Ying; Ferruzzi, Mario G.] Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA. [Schmeidler, James] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu NR 51 TC 23 Z9 25 U1 0 U2 29 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD MAR 14 PY 2014 VL 6 AR 42 DI 10.3389/fnagi.2014.00042 PG 10 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA AC9HX UT WOS:000332846300001 PM 24672477 ER PT J AU Mulak, A Tache, Y Larauche, M AF Mulak, Agata Tache, Yvette Larauche, Muriel TI Sex hormones in the modulation of irritable bowel syndrome SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Brain-gut axis; Irritable bowel syndrome; Microbiota; Pain modulation; Sex hormones ID INDUCED VISCERAL HYPERSENSITIVITY; CORTICOTROPIN-RELEASING HORMONE; MESSENGER-RNA EXPRESSION; ESTROGEN-RECEPTOR-ALPHA; FUNCTIONAL GASTROINTESTINAL DISORDERS; MAST-CELL SECRETION; MENSTRUAL-CYCLE; FEMALE RATS; GUT MICROBIOTA; POSTMENOPAUSAL WOMEN AB Compelling evidence indicates sex and gender differences in epidemiology, symptomatology, pathophysiology, and treatment outcome in irritable bowel syndrome (IBS). Based on the female predominance as well as the correlation between IBS symptoms and hormonal status, several models have been proposed to examine the role of sex hormones in gastrointestinal (GI) function including differences in GI symptoms expression in distinct phases of the menstrual cycle, in pre- and post-menopausal women, during pregnancy, hormonal treatment or after oophorectomy. Sex hormones may influence peripheral and central regulatory mechanisms of the brain-gut axis involved in the pathophysiology of IBS contributing to the alterations in visceral sensitivity, motility, intestinal barrier function, and immune activation of intestinal mucosa. Sex differences in stress response of the hypothalamic-pituitary-adrenal axis and autonomic nervous system, neuroimmune interactions triggered by stress, as well as estrogen interactions with serotonin and corticotropin-releasing factor signaling systems are being increasingly recognized. A concept of "microgenderome" related to the potential role of sex hormone modulation of the gut microbiota is also emerging. Significant differences between IBS female and male patients regarding symptomatology and comorbidity with other chronic pain syndromes and psychiatric disorders, together with differences in efficacy of serotonergic medications in IBS patients confirm the necessity for more sex-tailored therapeutic approach in this disorder. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved. C1 [Mulak, Agata] Wroclaw Med Univ, Dept Gastroenterol & Hepatol, PL-50556 Wroclaw, Poland. [Tache, Yvette; Larauche, Muriel] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. [Tache, Yvette; Larauche, Muriel] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Oppenheimer Family Ctr Neurobiol Stress, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA. RP Mulak, A (reprint author), Wroclaw Med Univ, Dept Gastroenterol & Hepatol, Borowska 213, PL-50556 Wroclaw, Poland. EM agata.mulak@wp.pl OI Larauche, Muriel/0000-0003-3320-3675 FU The Veterans Administration Research Career Scientist Award; National Institute of Health [P50 DK-64539, K01-DK088937] FX Supported by The Veterans Administration Research Career Scientist Award (to Tache Y); National Institute of Health grants No. P50 DK-64539 (to Tache Y); and No. K01-DK088937 (to Larauche M) NR 164 TC 32 Z9 32 U1 3 U2 40 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD MAR 14 PY 2014 VL 20 IS 10 BP 2433 EP 2448 DI 10.3748/wjg.v20.i10.2433 PG 16 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AC7GY UT WOS:000332697400002 PM 24627581 ER PT J AU Mackin, RS Insel, P Truran, D Vichinsky, EP Neumayr, LD Armstrong, FD Gold, JI Kesler, K Brewer, J Weiner, MW AF Mackin, R. Scott Insel, Philip Truran, Diana Vichinsky, Elliot P. Neumayr, Lynne D. Armstrong, F. D. Gold, Jeffrey I. Kesler, Karen Brewer, Joseph Weiner, Michael W. CA Neuropsychological Dysfunction Neu TI Neuroimaging abnormalities in adults with sickle cell anemia Associations with cognition SO NEUROLOGY LA English DT Article ID HUMAN CEREBRAL-CORTEX; CORTICAL THICKNESS; BIOLOGICAL MARKERS; BASAL GANGLIA; RISK-FACTORS; GRAY-MATTER; BACK-PAIN; DISEASE; CHILDREN; BRAIN AB Objective:This study was conducted to determine the relationship of frontal lobe cortical thickness and basal ganglia volumes to measures of cognition in adults with sickle cell anemia (SCA).Methods:Participants included 120 adults with SCA with no history of neurologic dysfunction and 33 healthy controls (HCs). Participants were enrolled at 12 medical center sites, and raters were blinded to diagnostic group. We hypothesized that individuals with SCA would exhibit reductions in frontal lobe cortex thickness and reduced basal ganglia and thalamus volumes compared with HCs and that these structural brain abnormalities would be associated with measures of cognitive functioning (Wechsler Adult Intelligence Scale, 3rd edition).Results:After adjusting for age, sex, education level, and intracranial volume, participants with SCA exhibited thinner frontal lobe cortex (t = -2.99, p = 0.003) and reduced basal ganglia and thalamus volumes compared with HCs (t = -3.95, p < 0.001). Reduced volume of the basal ganglia and thalamus was significantly associated with lower Performance IQ (model estimate = 3.75, p = 0.004) as well as lower Perceptual Organization (model estimate = 1.44, p = 0.007) and Working Memory scores (model estimate = 1.37, p = 0.015). Frontal lobe cortex thickness was not significantly associated with any cognitive measures.Conclusions:Our findings suggest that basal ganglia and thalamus abnormalities may represent a particularly salient contributor to cognitive dysfunction in adults with SCA. C1 [Mackin, R. Scott] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mackin, R. Scott; Insel, Philip; Truran, Diana; Brewer, Joseph; Weiner, Michael W.] San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Vichinsky, Elliot P.; Neumayr, Lynne D.] Childrens Hosp & Res Ctr Oakland, Dept Hematol Oncol, Oakland, CA 94609 USA. [Gold, Jeffrey I.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA. [Gold, Jeffrey I.] Childrens Hosp Los Angeles, Dept Anesthesiol, Los Angeles, CA 90027 USA. [Gold, Jeffrey I.] Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA. [Kesler, Karen] Rho Inc, Res Triangle Pk, NC USA. [Armstrong, F. D.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA. [Armstrong, F. D.] Holtz Childrens Hosp, Miami, FL USA. [Weiner, Michael W.] Univ Calif San Francisco, Vet Adm Med Ctr, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Mackin, RS (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM scottm@lppi.ucsf.edu FU National Heart, Lung, and Blood Institute [U54HL070587]; National Institute of Mental Health [K08MH081065] FX Supported by the National Heart, Lung, and Blood Institute (U54HL070587) and the National Institute of Mental Health (K08MH081065). NR 40 TC 15 Z9 15 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAR 11 PY 2014 VL 82 IS 10 BP 835 EP 841 DI 10.1212/WNL.0000000000000188 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AH9TJ UT WOS:000336485100008 PM 24523480 ER PT J AU Eisendrath, SJ Gillung, EP Delucchi, KL Chartier, M Mathalon, DH Sullivan, JC Segal, ZV Feldman, MD AF Eisendrath, Stuart J. Gillung, Erin P. Delucchi, Kevin L. Chartier, Maggie Mathalon, Daniel H. Sullivan, Jude C. Segal, Zindel V. Feldman, Mitchell D. TI Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article DE Depression; Treatment-resistant; Mindfulness; Meditation; MBCT ID QUALITY-OF-LIFE; COMORBIDITY SURVEY REPLICATION; ILLNESS RATING-SCALE; MAJOR DEPRESSION; LONGITUDINAL DATA; PRIMARY-CARE; DISORDER; ANXIETY; OUTPATIENTS; CLINICIAN AB Background: Major depressive disorder (MDD) is the leading cause of disability in the developed world, yet broadly effective treatments remain elusive. Up to 40% of patients with depression are unresponsive to at least two trials of antidepressant medication and thus have "treatment-resistant depression" (TRD). There is an urgent need for cost-effective, non-pharmacologic, evidence-based treatments for TRD. Mindfulness-Based Cognitive Therapy (MBCT) is an effective treatment for relapse prevention and residual depression in major depression, but has not been previously studied in patients with TRD in a large randomized trial. Methods/Design: The purpose of this study was to evaluate whether MBCT is an effective augmentation of antidepressants for adults with MDD who failed to respond to standard pharmacotherapy. MBCT was compared to an active control condition, the Health-Enhancement Program (HEP), which incorporates physical activity, functional movement, music therapy and nutritional advice. HEP was designed as a comparator condition for mindfulness-based interventions to control for non-specific effects. Originally investigated in a non-clinical sample to promote stress reduction, HEP was adapted for a depressed population for this study. Individuals age 18 and older with moderate to severe TRD, who failed to respond to at least two trials of antidepressants in the current episode, were recruited to participate. All participants were taking antidepressants (Treatment as usual; TAU) at the time of enrollment. After signing an informed consent, participants were randomly assigned to either MBCT or HEP condition. Participants were followed for 1 year and assessed at weeks 1-7, 8, 24, 36, and 52. Change in depression severity, rate of treatment response and remission after 8 weeks were the primary outcomes measured by the clinician-rated Hamilton Depression Severity Rating (HAM-D) 17-item scale. The participant-rated Quick Inventory of Depression Symptomology (QIDS-SR) 16-item scale was the secondary outcome measure of depression severity, response, and remission. Discussion: Treatment-resistant depression entails significant morbidity and has few effective treatments. We studied the effect of augmenting antidepressant medication with MBCT, compared with a HEP control, for patients with TRD. Analyses will focus on clinician and patient assessment of depression, participants' clinical global impression change, employment and social functioning scores and quality of life and satisfaction ratings. C1 [Eisendrath, Stuart J.; Gillung, Erin P.; Delucchi, Kevin L.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Chartier, Maggie; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sullivan, Jude C.] Univ Wisconsin, Madison Hosp, Madison, WI 53711 USA. [Sullivan, Jude C.] Univ Wisconsin, Clin Sports Med Ctr, Madison, WI 53711 USA. [Segal, Zindel V.] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada. [Feldman, Mitchell D.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Eisendrath, SJ (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave,Box 0984 AIP, San Francisco, CA 94143 USA. EM StuartE@lppi.ucsf.edu RI Segal, Zindel/F-8008-2014 FU NIH/National Center for Complementary and Alternative Medicine (NCCAM) [R01AT004572] FX This study is funded by the NIH/National Center for Complementary and Alternative Medicine (NCCAM) grant number R01AT004572. The authors would like to gratefully thank Ms. Lauren Erickson, Christa Hogan, Natalie Holbrook and other members of the research staff who were responsible for subject recruitment, tracking/scheduling and data collection. NR 64 TC 13 Z9 13 U1 10 U2 68 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6882 J9 BMC COMPLEM ALTERN M JI BMC Complement. Altern. Med. PD MAR 11 PY 2014 VL 14 AR 95 DI 10.1186/1472-6882-14-95 PG 11 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA AD8LZ UT WOS:000333518800002 PM 24612825 ER PT J AU Chen, LQ Bourguignon, LYW AF Chen, Liqun Bourguignon, Lilly Y. W. TI Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells SO MOLECULAR CANCER LA English DT Article ID CYTOSKELETON ACTIVATION; CARCINOMA PROGRESSION; CYCLE PROGRESSION; TUMOR PROGRESSION; HOMING RECEPTOR; BINDING PROTEIN; GENE-EXPRESSION; UP-REGULATION; MARKER NANOG; KINASE AB MicroRNA-21 (miR-21) is associated with the development of solid tumors progression including breast cancer. In this study we investigated matrix hyaluronan (HA)-CD44 (a primary HA receptor) interaction with c-Jun N-Terminal Kinase (JNK)/c-Jun signaling in MDA-MB-468 breast cancer cells [a triple-negative (estrogen receptor-negative/progesterone receptor-negative/HER2-negative) breast cancer cell line]. Our results indicated that HA binding to CD44 promotes c-Jun nuclear translocation and transcriptional activation. Further analyses revealed that miR-21 is regulated by an upstream promoter containing AP1 binding site(s), and chromatin immunoprecipitation (CHIP) assays demonstrated that stimulation of miR-21 expression by HA/CD44 interaction is c-Jun-dependent in these breast cancer cells. This process results in an increase of the anti-apoptosis protein Bcl-2 and upregulation of inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in MDA-MB-468 cells. Treatment with c-Jun specific small interfering RNAs effectively blocks HA-mediated c-Jun signaling and abrogates miR-21 production as well as causes downregulation of survival proteins (Bcl-2 and IAPs) and enhancement of chemosensitivity. In addition, our results demonstrated that anti-miR-21 inhibitor not only downregulates Bcl-2/IAP expression but also increases chemosensitivity in HA-treated breast cancer cells. Together, these findings suggest that the HA/CD44-induced c-Jun signaling plays a pivotal role in miR-21 production leading to survival protein (Bcl-2/IAP) upregulation and chemoresistance in triple negative breast cancer cells such as MDA-MB-468 cell line. This novel HA/CD44-mediated c-Jun signaling pathway and miR-21 production provide a new drug target for the future intervention strategies to treat breast cancer. C1 [Bourguignon, Lilly Y. W.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. Endocrine Unit 111N2, San Francisco, CA 94121 USA. RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM lilly.bourguignon@ucsf.edu FU Veterans Affairs (VA) [RR & D-1101 RX000601, BIR & D-5101 BX000628]; United States Public Health [R01 CA66163, P01 CA0052925]; DOD grant FX We gratefully acknowledge the assistance of Dr. Gerard J. Bourguignon in the preparation and review of this manuscript. This work was supported by Veterans Affairs (VA) Merit Review Awards (RR & D-1101 RX000601 and BIR & D-5101 BX000628), United States Public Health grants (R01 CA66163; P01 CA0052925) and DOD grant. L.Y.W.B is a VA Senior Research Career NR 60 TC 28 Z9 30 U1 1 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-4598 J9 MOL CANCER JI Mol. Cancer PD MAR 8 PY 2014 VL 13 AR 52 DI 10.1186/1476-4598-13-52 PG 13 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA AF2KY UT WOS:000334542200002 PM 24606718 ER PT J AU Lakshmi, SP Reddy, AT Zhang, YZ Sciurba, FC Mallampalli, RK Duncan, SR Reddy, RC AF Lakshmi, Sowmya P. Reddy, Aravind T. Zhang, Yingze Sciurba, Frank C. Mallampalli, Rama K. Duncan, Steven R. Reddy, Raju C. TI Down-regulated Peroxisome Proliferator-activated Receptor gamma (PPAR gamma) in Lung Epithelial Cells Promotes a PPAR gamma Agonist-reversible Proinflammatory Phenotype in Chronic Obstructive Pulmonary Disease (COPD) SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Chromatin Histone Modification; Cigarette Smoke; Glucocorticoid Receptor; Histone Deacetylase; Inflammation; NF-kappa B (NF-KB); I-kappa-B Kinase; Human Bronchial Epithelial Cells; Oxidative Stress ID KAPPA-B; GLUCOCORTICOID-RECEPTOR; OXIDATIVE STRESS; PROTEIN-KINASE; PHOSPHORYLATION; EXPRESSION; RATS; DEGRADATION; INHIBITION; NITRATION AB Background: The mechanistic role of peroxisome proliferator-activated receptor (PPAR) in chronic obstructive pulmonary disease (COPD) is poorly understood. Results: COPD and cigarette smoke exposure down-regulated PPAR and produced inflammation that PPAR agonists reversed through multiple pathways. Conclusion: PPAR plays a pivotal role in COPD. Significance: PPAR agonists may be the first effective treatment for COPD. Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory condition and a leading cause of death, with no available cure. We assessed the actions in pulmonary epithelial cells of peroxisome proliferator-activated receptor (PPAR), a nuclear hormone receptor with anti-inflammatory effects, whose role in COPD is largely unknown. We found that PPAR was down-regulated in lung tissue and epithelial cells of COPD patients, via both reduced expression and phosphorylation-mediated inhibition, whereas pro-inflammatory nuclear factor-B (NF-B) activity was increased. Cigarette smoking is the main risk factor for COPD, and exposing airway epithelial cells to cigarette smoke extract (CSE) likewise down-regulated PPAR and activated NF-B. CSE also down-regulated and post-translationally inhibited the glucocorticoid receptor (GR-) and histone deacetylase 2 (HDAC2), a corepressor important for glucocorticoid action and whose down-regulation is thought to cause glucocorticoid insensitivity in COPD. Treating epithelial cells with synthetic (rosiglitazone) or endogenous (10-nitro-oleic acid) PPAR agonists strongly up-regulated PPAR expression and activity, suppressed CSE-induced production and secretion of inflammatory cytokines, and reversed its activation of NF-B by inhibiting the IB kinase pathway and by promoting direct inhibitory binding of PPAR to NF-B. In contrast, PPAR knockdown via siRNA augmented CSE-induced chemokine release and decreases in HDAC activity, suggesting a potential anti-inflammatory role of endogenous PPAR. The results imply that down-regulation of pulmonary epithelial PPAR by cigarette smoke promotes inflammatory pathways and diminishes glucocorticoid responsiveness, thereby contributing to COPD pathogenesis, and further suggest that PPAR agonists may be useful for COPD treatment. C1 [Lakshmi, Sowmya P.; Reddy, Aravind T.; Zhang, Yingze; Sciurba, Frank C.; Mallampalli, Rama K.; Duncan, Steven R.; Reddy, Raju C.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Sch Med, Pittsburgh, PA 15213 USA. [Lakshmi, Sowmya P.; Reddy, Aravind T.; Mallampalli, Rama K.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Reddy, RC (reprint author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Univ Dr C, Pittsburgh, PA 15240 USA. EM reddyrc@upmc.edu FU United States Department of Veterans Affairs; National Institutes of Health [HL093196] FX This work was supported by a Merit Review award from the United States Department of Veterans Affairs and National Institutes of Health Grant HL093196 (to R. C. R). NR 33 TC 19 Z9 20 U1 0 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 7 PY 2014 VL 289 IS 10 BP 6383 EP 6393 DI 10.1074/jbc.M113.536805 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AC3BG UT WOS:000332389400007 PM 24368768 ER PT J AU Chen, Y Li, J Dunn, S Xiong, S Chen, W Zhao, YT Chen, BB Mallampalli, RK Zou, CB AF Chen, Yan Li, Jin Dunn, Sarah Xiong, Sheng Chen, Wei Zhao, Yutong Chen, Bill B. Mallampalli, Rama K. Zou, Chunbin TI Histone Deacetylase 2 (HDAC2) Protein-dependent Deacetylation of Mortality Factor 4-like 1 (MORF4L1) Protein Enhances Its Homodimerization SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Epigenetics; Histone Acetylase; Histone Deacetylase; Posttranslational Modification; Proliferation; Protein Complexes; Protein Structure; Site-directed Mutagenesis ID CELL-DIFFERENTIATION; CHROMODOMAIN PROTEIN; MESSENGER-RNA; DNA-REPAIR; MRG15; COMPLEX; GENE; PROLIFERATION; DOMAIN; DIMERIZATION AB Background: Histone acetyltransferase MORF4L1 forms a homodimer to perform its epigenetic function, but the molecular mechanisms for its homodimerization are unknown. Results: Histone deacetylase HDAC2 deacetylates MORF4L1 at Lys-148 to enhance MORF4L1 homodimerization. Conclusion: HDAC2-dependent deacetylation of MORF4L1 enhances MORF4L1 homodimerization, which facilitates complex formation to repress cellular proliferation. Significance: The molecular control of MORF4L1 homodimerization may impact fundamental cellular processes such as proliferation. Histone acetyltransferase mortality factor 4-like 1 (MORF4L1) is a relatively new histone acetyltransferase component that exists as a homodimer to exert its epigenetic function. The mechanism of MORF4L1 self-assembly is unknown. Here we report that Lys-148 deacetylation is indispensable for facilitating MORF4L1 self-assembly into a homodimeric unit. Among a stretch of approximate to 10 amino acids in the NH2 terminus between the chromodomain and MORF4-related gene (MRG) domain within MORF4L1, Lys-148 is normally acetylated. Substitution of Lys-148 with arginine augments MORF4L1 self-assembly. However, acetylation mimics of MORF4L1, including K148L and K148Q, abolished its self-assembly of the histone acetyltransferase component. HDAC2, a deacetylase, interacts with and keeps MORF4L1 in a deacetylation status at Lys(148) that triggers MORF4L1 self-assembly. Knockdown of HDAC2 reduces MORF4L1 self-assembly. HDAC2-dependent deacetylation of MORF4L1 enhances MORF4L1 homodimerization, thus facilitating the functionality of complex formation to repress cell proliferation. C1 [Chen, Yan; Li, Jin; Dunn, Sarah; Xiong, Sheng; Chen, Wei; Zhao, Yutong; Chen, Bill B.; Mallampalli, Rama K.; Zou, Chunbin] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Zhao, Yutong; Chen, Bill B.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Zhao, Yutong; Chen, Bill B.; Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Chen, Yan] Cent S Univ, Xiangya Hosp 2, Dept Resp Med, Changsha 410011, Hunan, Peoples R China. RP Chen, Y (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Resp Med, Changsha 410011, Hunan, Peoples R China. EM chenyan99727@163.com; zouc@upmc.edu FU National Institutes of Health [HL096376, HL097376, HL098174, P01 HL114453]; American Heart Association [12SDG12040330]; United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; United States Department of Veterans Affairs; Natural Science Foundation of China [81070039, 81270100] FX This work was supported, in whole or in part, National Institutes of Health Grants HL096376, HL097376, HL098174, and P01 HL114453 (to R. K. M.). This work was also supported by American Heart Association Award 12SDG12040330 (to C. Z.); by the United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; and by a merit review award from the United States Department of Veterans Affairs.; Supported by Natural Science Foundation of China Grants 81070039 and 81270100. To whom correspondence may be addressed: Dept. of Respiratory Medicine, The Second Xiangya Hospital, Central-South University, Changsha, Hunan 410011, China. E-mail: chenyan99727@163.com. NR 30 TC 2 Z9 2 U1 1 U2 11 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 7 PY 2014 VL 289 IS 10 BP 7092 EP 7098 DI 10.1074/jbc.M113.527507 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AC3BG UT WOS:000332389400068 PM 24451372 ER PT J AU Cardo, LF Coto, E de Mena, L Ribacoba, R Mata, IF Menendez, M Moris, G Alvarez, V AF Cardo, Lucia F. Coto, Eliecer de Mena, Lorena Ribacoba, Rene Mata, Ignacio F. Menendez, Manuel Moris, German Alvarez, Victoria TI Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms SO NEUROSCIENCE LETTERS LA English DT Article DE Parkinson's disease; Alpha-synuclein isoforms; DNA polymorphisms; Genetic risk ID MESSENGER-RNA EXPRESSION; GENE; SUSCEPTIBILITY; VARIANTS AB Mutations in the alpha-synuclein (SNCA) gene cause autosomal dominant Parkinson's disease (PD). Common SNCA polymorphisms have been associated with the risk of developing PD. Abnormal expression and post-translational modification of SNCA has been found in PD-brains. In addition to a full length transcript (SNCA-140) there are three short isoforms (SNCA-98, -112, and -126) that could be prone to aggregation. The association between SNCA polymorphisms and PD could be explained through an increased expression of these alternative transcripts. Our aim was to measure the different SNCA transcripts in the substantia nigra (SN), cerebellum (CB), and occipital cortex (OC) from PD-patients (n = 9) and healthy subjects (n = 6). In addition, we determined whether two SNCA polymorphisms (SNPs rs356165 and rs11931074) were related to differences in transcript isoform expression. PD brain tissues showed higher levels of the three short transcripts in the SN, but only SNCA-112 and SNCA-98 were significantly increased in the CB of patients vs. controls (p = 0.02, p = 0.03). The genotyping of a large cohort of PD-patients and controls showed that haplotype rs356165-A+rs11931074-G had a protective effect (OR = 0.71; CI = 0.59-0.83), while the G-T haplotype increased the risk for PD (OR = 1.44; CI = 1.06-1.96). We did not find significant differences for the SNCA levels between the haplotypes. In conclusion, we found statistically significant higher levels of the SNCA-112 and SNCA-98 transcripts in the CB of PD brains, and a trend toward higher levels of the short transcript isoforms in the SN of PD brains. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Cardo, Lucia F.; Coto, Eliecer; de Mena, Lorena; Alvarez, Victoria] Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo, Spain. [Ribacoba, Rene; Menendez, Manuel; Moris, German] Hosp Univ Cent Asturias, Asturias, Spain. [Ribacoba, Rene; Menendez, Manuel; Moris, German] Alvarez Buylla Mieres, Asturias, Spain. [Mata, Ignacio F.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Mata, Ignacio F.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. RP Alvarez, V (reprint author), Hosp Cent Asturias Maternidad, Oviedo 33006, Spain. EM victoria.alvarez@sespa.princast.es FU Spanish "Fondo de Investigaciones Sanitarias-Fondos FEDER" European Union [FIS 11/0093]; FICYT-Principado de Asturias; Fundacion Parkinson Asturias; Obra Social Cajastur FX We thank Dr. Claire Troakes and the London Neurodegenerative Diseases Brain Bank for supplying all postmortem brain samples. Authors thank the "Fundacion Parkinson Asturias" and "Obra Social Cajastur" for their support. This work was supported by grants from the Spanish "Fondo de Investigaciones Sanitarias-Fondos FEDER" European Union (FIS 11/0093). LFC and LDM are predoctoral fellowships of FICYT-Principado de Asturias. NR 20 TC 10 Z9 10 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 EI 1872-7972 J9 NEUROSCI LETT JI Neurosci. Lett. PD MAR 6 PY 2014 VL 562 BP 45 EP 49 DI 10.1016/j.neulet.2014.01.009 PG 5 WC Neurosciences SC Neurosciences & Neurology GA AD0FM UT WOS:000332909900009 PM 24418406 ER PT J AU Begum, G Yan, HQ Li, L Singh, A Dixon, CE Sun, D AF Begum, Gulnaz Yan, Hong Q. Li, Liaoliao Singh, Amneet Dixon, C. Edward Sun, Dandan TI Docosahexaenoic Acid Reduces ER Stress and Abnormal Protein Accumulation and Improves Neuronal Function Following Traumatic Brain Injury SO JOURNAL OF NEUROSCIENCE LA English DT Article DE amyloid precursor protein; controlled cortical impact injury; docosahexaenoic acid; phosphorylated tau; unfolded protein response ID ENDOPLASMIC-RETICULUM STRESS; DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; CORTICAL IMPACT MODEL; K+-CL-COTRANSPORTER; CELL-DEATH; CHEMICAL CHAPERONES; ASTROCYTES; ISCHEMIA; BETA AB In this study, we investigated the development of endoplasmic reticulum (ER) stress after traumatic brain injury (TBI) and the efficacy of post-TBI administration of docosahexaenoic acid (DHA) in reducing ER stress. TBI was induced by cortical contusion injury in Sprague-Dawley rats. Either DHA (16 mg/kg in DMSO) or vehicle DMSO (1 ml/kg) was administered intraperitoneally at 5 min after TBI, followed by a daily dose for 3-21 d. TBI triggered sustained expression of the ER stress marker proteins including phosphorylated eukaryotic initiation factor-2 alpha, activating transcription factor 4, inositol requiring kinase 1, and C/EBP homologous protein in the ipsilateral cortex at 3-21 d after TBI. The prolonged ER stress was accompanied with an accumulation of abnormal ubiquitin aggregates and increased expression of amyloid precursor protein (APP) and phosphorylated tau (p-Tau) in the frontal cortex after TBI. The ER stress marker proteins were colocalized with APP accumulation in the soma. Interestingly, administration of DHA attenuated all ER stress marker proteins and reduced the accumulation of both ubiquitinated proteins and APP/p-Tau proteins. In addition, the DHA-treated animals exhibited early recovery of their sensorimotor function after TBI. In summary, our study demonstrated that TBI induces a prolonged ER stress, which is positively correlated with abnormal APP accumulation. The sustained ER stress may play a role in chronic neuronal damage after TBI. Our findings illustrate that post-TBI administration of DHA has therapeutic potentials in reducing ER stress, abnormal protein accumulation, and neurological deficits. C1 [Begum, Gulnaz; Li, Liaoliao; Singh, Amneet; Sun, Dandan] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurol, Pittsburgh, PA 15213 USA. [Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA. [Dixon, C. Edward; Sun, Dandan] Geriatr Res Educ & Clin Ctr, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA 15213 USA. RP Sun, D (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S 598 S Biomedical Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA. EM sund@upmc.edu FU University of Pittsburgh Neurology Departmental startup funds; University of Pittsburgh Medical Center endowed Chair Professorship on Brain Disorder Diseases; United States Department of Veterans Affairs VA RRD [B6761R] FX This work was supported in part by University of Pittsburgh Neurology Departmental startup funds and University of Pittsburgh Medical Center endowed Chair Professorship on Brain Disorder Diseases (D.S.) and the United States Department of Veterans Affairs VA RR&D#B6761R Grant (C.E.D.). NR 70 TC 24 Z9 27 U1 1 U2 9 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAR 5 PY 2014 VL 34 IS 10 BP 3743 EP 3755 DI 10.1523/JNEUROSCI.2872-13.2014 PG 13 WC Neurosciences SC Neurosciences & Neurology GA AC7HN UT WOS:000332698900027 PM 24599472 ER PT J AU Volpp, KG Galvin, R AF Volpp, Kevin G. Galvin, Robert TI Reward-Based Incentives for Smoking Cessation How a Carrot Became a Stick SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID FINANCIAL INCENTIVES C1 [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Galvin, Robert] Equ Healthcare, Blackstone Grp, Philadelphia, PA USA. [Galvin, Robert] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. RP Volpp, KG (reprint author), Univ Penn, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, 423 Guardian Dr,1120 Blockley Hall, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu FU NIA NIH HHS [P30 AG034546] NR 7 TC 13 Z9 13 U1 2 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 5 PY 2014 VL 311 IS 9 BP 909 EP 910 DI 10.1001/jama.2014.418 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AC0FS UT WOS:000332170800015 PM 24493405 ER PT J AU Downs, J Good, C AF Downs, John Good, Chester TI New Cholesterol Guidelines: Has Godot Finally Arrived? SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. RP Downs, J (reprint author), South Texas Vet Hlth Care Syst, Med Serv 111, 7400 Merton Minter, San Antonio, TX 78229 USA. EM john.downs@va.gov NR 9 TC 8 Z9 8 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 4 PY 2014 VL 160 IS 5 BP 354 EP + DI 10.7326/M13-2850 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AC8OT UT WOS:000332793900008 PM 24473934 ER PT J AU Capasso, R Kezirian, E Jacobowitz, O Weaver, EM AF Capasso, Robson Kezirian, Eric Jacobowitz, Ofer Weaver, Edward M. TI Management of Obstructive Sleep Apnea in Adults SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID POSITIVE AIRWAY PRESSURE C1 [Capasso, Robson] Stanford Univ, Palo Alto, CA 94304 USA. [Kezirian, Eric] Univ So Calif, Los Angeles, CA USA. [Jacobowitz, Ofer] Mt Sinai Sch Med, New York, NY USA. [Weaver, Edward M.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Capasso, R (reprint author), Stanford Univ, Palo Alto, CA 94304 USA. NR 5 TC 1 Z9 2 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 4 PY 2014 VL 160 IS 5 BP 367 EP 367 DI 10.7326/L14-5005 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AC8OT UT WOS:000332793900014 PM 24589933 ER PT J AU Shekelle, P Holty, JEC Owens, DK Qaseem, A AF Shekelle, Paul Holty, Jon-Erik C. Owens, Douglas K. Qaseem, Amir TI Management of Obstructive Sleep Apnea in Adults IN RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID TRIAL C1 [Shekelle, Paul] Greater Los Angeles Vet Affairs Hlth Ctr, Los Angeles, CA 90073 USA. [Shekelle, Paul] RAND Corp, Los Angeles, CA USA. [Holty, Jon-Erik C.; Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA USA. RP Shekelle, P (reprint author), Greater Los Angeles Vet Affairs Hlth Ctr, Los Angeles, CA 90073 USA. NR 4 TC 2 Z9 4 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 4 PY 2014 VL 160 IS 5 BP 367 EP 368 DI 10.7326/L14-5005-2 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AC8OT UT WOS:000332793900015 PM 24737275 ER PT J AU Laitman, BM Gajewski, ND Mann, GL Kubin, L Morrison, AR Ross, RJ AF Laitman, Benjamin M. Gajewski, Nicholas D. Mann, Graziella L. Kubin, Leszek Morrison, Adrian R. Ross, Richard J. TI The alpha(1) adrenoceptor antagonist prazosin enhances sleep continuity in fear-conditioned Wistar-Kyoto rats SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Article DE Fear conditioning; Norepinephrine; Posttraumatic stress disorder; REM sleep; Wistar-Kyoto rats ID POSTTRAUMATIC-STRESS-DISORDER; RECEPTOR MESSENGER-RNA; EYE-MOVEMENT SLEEP; NEURONS IN-VITRO; NON-REM SLEEP; BRAIN NOREPINEPHRINE; DEPENDENT PLASTICITY; CLONIDINE INJECTIONS; COMBAT VETERANS; WKY RATS AB Fragmentation of rapid eye movement sleep (REMS) is well described in individuals with posttraumatic stress disorder (PTSD) and likely has significant functional consequences. Fear-conditioned rodents may offer an attractive-model of the changes in sleep that characterize PTSD. Following fear conditioning (FC), Wistar-Kyoto (WKY) rats, a strain known to be particularly stress-sensitive, have increased REMS fragmentation that can be quantified as a shift in the distribution of REMS episodes towards themore frequent occurrence of sequential REMS (inter-REMS episode interval <= 3min) vs. single REMS(interval > 3min). The alpha(1) adrenoceptor antagonist prazosin has demonstrated efficacy in normalizing sleep in PTSD. To determine the utility of fear-conditioned WKY rats as a model of sleep disturbances typical of PTSD and as a platformfor the development of new treatments, we tested the hypothesis that prazosin would reduce REMS fragmentation in fear-conditionedWKY rats. Sleep parameters and freezing (a standardmeasure of anxiety in rodents) were quantified at baseline and on Days 1, 7, and 14 following FC, with either prazosin (0.01 mg/kg, i. p.) or vehicle injections administered prior to testing in a betweengroup design. Fear conditioning was achieved by pairing tones with a mild electric foot shock (1.0 mA, 0.5 s). One, 7, and 14 days following FC, prazosin or vehicle was injected, the tone was presented, freezing was measured, and then sleep was recorded from 11 AM to 3 PM. WKY rats given prazosin, compared to those given vehicle, had a lower amount of seq-REMS relative to total REMS time 14 days after FC. They also had a shorter nonREMS latency and fewer non-REMS arousals at baseline and on Days 1 and 7 after FC. Thus, in FC rats, prazosin reduced both REMS fragmentation and non-REMS discontinuity. Published by Elsevier Inc. C1 [Laitman, Benjamin M.; Gajewski, Nicholas D.; Mann, Graziella L.; Kubin, Leszek; Morrison, Adrian R.; Ross, Richard J.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA. [Ross, Richard J.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ross, Richard J.] Vet Affairs Med Ctr, Philadelphia, PA USA. RP Laitman, BM (reprint author), Mt Sinai Sch Med, Grad Sch Biol Sci, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM benjamin.laitman@mssm.edu FU NIH [RO1-MH072897] FX The study was supported by NIH grant RO1-MH072897. The authors thank Dr. Philip R. Gehrman for his assistance with statistical analysis. The views presented in this article do not represent those of the Department of Veterans Affairs or of the US Government. NR 61 TC 2 Z9 2 U1 1 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD MAR 3 PY 2014 VL 49 BP 7 EP 15 DI 10.1016/j.pnpbp.2013.11.004 PG 9 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 280WA UT WOS:000329060300002 PM 24246572 ER PT J AU Boyd, JE Otilingam, PG DeForge, BR AF Boyd, Jennifer E. Otilingam, Poorni G. DeForge, Bruce R. TI Brief Version of the Internalized Stigma of Mental Illness (ISMI) Scale: Psychometric Properties and Relationship to Depression, Self Esteem, Recovery Orientation, Empowerment, and Perceived Devaluation and Discrimination SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE stigma of mental illness; questionnaire; depression; self-esteem; empowerment ID PEOPLE; CONSEQUENCES; SCHIZOPHRENIA; EXPERIENCES; OUTPATIENTS; DISORDERS; VALIDITY; PARADOX; MODEL AB Objective: The internalized stigma of mental illness impedes recovery and is associated with increased depression, reduced self-esteem, reduced recovery orientation, reduced empowerment, and increased perceived devaluation and discrimination. The Internalized Stigma of Mental Illness (ISMI) scale is a 29-item self-report questionnaire developed with consumer input that includes the following subscales: Alienation, Discrimination Experience, Social Withdrawal, Stereotype Endorsement, and Stigma Resistance. Here we present a 10-item version of the ISMI containing the two strongest items from each subscale. Method: Participants were all outpatient veterans with serious mental illness. Following the rigorous scale-reduction methods set forth by Stanton and colleagues (2002), we selected the 10 items, tested the psychometrics of the shortened scale in the original validation sample (N = 127), and cross-checked the results in a second dataset (N = 760). Results: As expected, the ISMI-10 retained the essential properties of the ISMI-29, including adequate internal consistency reliability and external validity in relation to depression, self-esteem, recovery orientation, perceived devaluation and discrimination, and empowerment. The ISMI-10 scores are normally distributed and have similar descriptive statistics to the ISMI-29. The reliability and depression findings were replicated in a cross-validation sample. Conclusions and Implications for Practice: We conclude that the ISMI-10 has strong psychometric properties and is a practical, reliable, and valid alternative to the original ISMI-29. Future work should test the ISMI-10 in more diverse samples. This shorter version should reduce respondent burden in program evaluation projects that seek to determine whether participation in psychosocial rehabilitation programming reduces internalized stigma. C1 [Boyd, Jennifer E.] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA 94121 USA. [Boyd, Jennifer E.] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Otilingam, Poorni G.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. [DeForge, Bruce R.] Univ Maryland, Sch Social Work, Baltimore, MD 21201 USA. RP Boyd, JE (reprint author), San Francisco VA Med Ctr, Dept Psychiat, 4150 Clement St 116A, San Francisco, CA 94121 USA. EM jennifer.boyd@va.gov NR 38 TC 11 Z9 11 U1 4 U2 16 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X EI 1559-3126 J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD MAR PY 2014 VL 37 IS 1 BP 17 EP 23 DI 10.1037/prj0000035 PG 7 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA CA0RP UT WOS:000348624600004 PM 24660946 ER PT J AU Huckans, M Fuller, BE Olavarria, H Sasaki, AW Chang, M Flora, KD Kolessar, M Kriz, D Anderson, JR Vandenbark, AA Loftis, JM AF Huckans, Marilyn Fuller, Bret E. Olavarria, Hannah Sasaki, Anna W. Chang, Michael Flora, Kenneth D. Kolessar, Michael Kriz, Daniel Anderson, Jeanne R. Vandenbark, Arthur A. Loftis, Jennifer M. TI Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection SO BRAIN AND BEHAVIOR LA English DT Article DE Anxiety; biological markers; chronic infection; cytokines; depression; fatigue; pain ID MAJOR DEPRESSIVE DISORDER; NECROSIS-FACTOR-ALPHA; INTERFERON-INDUCED DEPRESSION; QUALITY-OF-LIFE; NEUROTROPHIC FACTOR; CYTOKINE LEVELS; TNF-ALPHA; HEPATOCELLULAR-CARCINOMA; BEHAVIORAL CONSEQUENCES; PSYCHIATRIC-DISORDERS AB Background: The purpose of this study was to characterize hepatitis C virus (HCV)-associated differences in the expression of 47 inflammatory factors and to evaluate the potential role of peripheral immune activation in HCV-associated neuropsychiatric symptoms-depression, anxiety, fatigue, and pain. An additional objective was to evaluate the role of immune factor dysregulation in the expression of specific neuropsychiatric symptoms to identify biomarkers that may be relevant to the treatment of these neuropsychiatric symptoms in adults with or without HCV. Methods: Blood samples and neuropsychiatric symptom severity scales were collected from HCV-infected adults (HCV+, n = 39) and demographically similar noninfected controls (HCV-, n = 40). Multi-analyte profile analysis was used to evaluate plasma biomarkers. Results: Compared with HCV- controls, HCV+ adults reported significantly (P < 0.050) greater depression, anxiety, fatigue, and pain, and they were more likely to present with an increased inflammatory profile as indicated by significantly higher plasma levels of 40% (19/47) of the factors assessed (21%, after correcting for multiple comparisons). Within the HCV+ group, but not within the HCV- group, an increased inflammatory profile (indicated by the number of immune factors > the LDC) significantly correlated with depression, anxiety, and pain. Within the total sample, neuropsychiatric symptom severity was significantly predicted by protein signatures consisting of 4-10 plasma immune factors; protein signatures significantly accounted for 19-40% of the variance in depression, anxiety, fatigue, and pain. Conclusions: Overall, the results demonstrate that altered expression of a network of plasma immune factors contributes to neuropsychiatric symptom severity. These findings offer new biomarkers to potentially facilitate pharmacotherapeutic development and to increase our understanding of the molecular pathways associated with neuropsychiatric symptoms in adults with or without HCV. C1 [Huckans, Marilyn; Fuller, Bret E.; Olavarria, Hannah; Vandenbark, Arthur A.; Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Huckans, Marilyn; Fuller, Bret E.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Huckans, Marilyn; Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Sasaki, Anna W.; Chang, Michael] Portland VA Med Ctr, Gastroenterol Serv, Portland, OR 97239 USA. [Sasaki, Anna W.; Chang, Michael] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA. [Flora, Kenneth D.] Oregon Clin, Portland Gastroenterol Div, Clackamas, OR 97015 USA. [Kolessar, Michael; Kriz, Daniel; Anderson, Jeanne R.] Pacific Univ, Sch Profess Psychol, Hillsboro, OR 97123 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, R&D 16, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM loftisj@ohsu.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development FX This study was supported by career development awards to M. Huckans (Staff Psychologist and Neuropsychologist) and J. M. Loftis (Research Scientist) from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development. NR 131 TC 11 Z9 12 U1 1 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2162-3279 J9 BRAIN BEHAV JI Brain Behav. PD MAR PY 2014 VL 4 IS 2 BP 123 EP 142 DI 10.1002/brb3.200 PG 20 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA AX5NJ UT WOS:000346973200003 PM 24683507 ER PT J AU Thompson, JM Zamorski, MA Sweet, J VanTil, L Sareen, J Pietrzak, RH Hopman, WH MacLean, MB Pedlar, D AF Thompson, James M. Zamorski, Mark A. Sweet, Jill VanTil, Linda Sareen, Jitender Pietrzak, Robert H. Hopman, Wilma H. MacLean, Mary Beth Pedlar, David TI Roles of physical and mental health in suicidal ideation in Canadian Armed Forces Regular Force veterans SO CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE LA English DT Article DE Veterans; suicidal ideation; physical health; mental health; suicide ID OLDER MALE VETERANS; RISK-FACTORS; MILITARY PERSONNEL; NATIONAL-HEALTH; PREVALENCE; SOLDIERS; COMBAT; ASSOCIATION; AFGHANISTAN; PERSPECTIVE AB OBJECTIVES: Suicide in recent veterans is an international concern. An association between mental disorders and suicide has been established, but less information is available about an association between physical health problems and suicide among veterans. This study extends this area of inquiry by examining the relationship of both physical and mental health problems with suicidal ideation in a representative national sample of Canadian veterans. METHODS: Subjects were a stratified random sample of 2,658 veterans who had been released from the Canadian Armed Forces Regular Force during 1998-2007 and had participated in the 2010 Survey on Transition to Civilian Life. Associations between physical and mental health and past-year suicidal ideation were explored in multivariable regression models using three measures of physical and mental health. RESULTS: The prevalence of suicidal ideation was 5.8% (95% confidence interval [CI]: 5.0%-6.8%). After adjustment for covariates, ideation was associated with gastrointestinal disorders (adjusted odds ratio [AOR] 1.66, CI: 1.03-2.65), depression or anxiety (AOR 5.06, CI: 2.97-8.62) and mood disorders (AOR 2.91, CI: 1.67-5.07); number of physical (AOR 1.22, CI: 1.05-1.42) and mental conditions (AOR 2.32, CI: 2.01-2.68); and SF-12 Health Survey physical health (AOR 0.98, CI: 0.96-0.99 for each 1 point increase) and mental health (AOR 0.88, CI: 0.87-0.89). CONCLUSIONS: Physical health was independently associated with suicidal ideation after adjustment for mental health status and socio-demographic characteristics. The findings underscore the importance of considering physical health in population-based suicide prevention efforts and in mitigating suicide risk in individual veterans. C1 [Thompson, James M.; Sweet, Jill; VanTil, Linda; MacLean, Mary Beth; Pedlar, David] Vet Affairs Canada, Res Directorate, Charlottetown, PE C1A 8M9, Canada. [Thompson, James M.; Hopman, Wilma H.] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada. [Zamorski, Mark A.] Canadian Forces Hlth Serv Grp, Directorate Mental Hlth, Ottawa, ON, Canada. [Sareen, Jitender] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada. [Sareen, Jitender] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada. [Sareen, Jitender] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, West Haven, CT USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Hopman, Wilma H.] Kingston Gen Hosp, Clin Res Ctr, Kingston, ON K7L 2V7, Canada. RP Thompson, JM (reprint author), Vet Affairs Canada, POB 7700,Rm 406 DJM Bldg,161 Grafton St, Charlottetown, PE C1A 8M9, Canada. EM research-recherche@vac-acc.gc.ca NR 31 TC 2 Z9 2 U1 4 U2 6 PU CANADIAN PUBLIC HEALTH ASSOC PI OTTAWA PA 1565 CARLING AVE, SUITE 300, OTTAWA, ONTARIO K1Z 8R1, CANADA SN 0008-4263 EI 1920-7476 J9 CAN J PUBLIC HEALTH JI Can. J. Public Health-Rev. Can. Sante Publ. PD MAR-APR PY 2014 VL 105 IS 2 BP E109 EP E115 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AS9UG UT WOS:000344586200004 PM 24886845 ER PT J AU Garcia, HA Finley, EP Ketchum, N Jakupcak, M Dassori, A Reyes, SC AF Garcia, Hector A. Finley, Erin P. Ketchum, Norma Jakupcak, Matthew Dassori, Albana Reyes, Stephanie C. TI A Survey of Perceived Barriers and Attitudes Toward Mental Health Care Among OEF/OIF Veterans at VA Outpatient Mental Health Clinics SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COMBAT DEPLOYMENT; HELP-SEEKING; WAR VETERANS; OIF VETERANS; IRAQ; AFGHANISTAN; MASCULINITY; THERAPY; PTSD AB Objective: In an effort to improve our understanding of perceived treatment barriers among veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) relative to other era veterans, the current study examined veteran attitudes and beliefs about mental health treatment and treatment-seeking, and perceived patient and institution-level logistical barriers to care. Method: A survey was conducted. among 434 Combat veterans seeking care in nine Veterans Affairs mental health care outpatient clinics. Results: When compared to Vietnam and Gulf War veterans, OEF/OIF veterans were significantly more likely to endorse negative treatment attitudes as possible barriers to care. OEF/OIF veterans were also more likely than Vietnam veterans to endorse conflicting work demands as a potential barrier, although this was the only logistical barrier for which OEF/OIF veterans' responses differed significantly from those of veterans of other eras. Among OEF/OIF veterans, older veterans were more likely than younger veterans to endorse barriers related to cost and time commitments. Conclusions: These findings suggest an important role for outreach and engagement strategies that address attitudinal barriers to treatment utilization among veteran populations. C1 [Garcia, Hector A.; Finley, Erin P.; Dassori, Albana] South Texas Vet Hlth Care Syst, Mental Hlth Outpatient Serv, San Antonio, TX 78240 USA. [Garcia, Hector A.; Finley, Erin P.; Dassori, Albana] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ketchum, Norma] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Jakupcak, Matthew] Puget Sound Hlth Care Syst, Deployment Hlth Clin S 116, Seattle, WA 98108 USA. [Reyes, Stephanie C.] Univ Texas Hlth Sci Ctr San Antonio, PBRN Resource Ctr, Inst Integrat Med & Sci, San Antonio, TX 78229 USA. RP Garcia, HA (reprint author), South Texas Vet Hlth Care Syst, Mental Hlth Outpatient Serv, 5788 Eckhert Rd 116A1, San Antonio, TX 78240 USA. OI Finley, Erin/0000-0003-4497-7721 FU Institute for the Integration of Medicine and Science at the University of Texas Health Science Center, San Antonio; National Institutes of Health Clinical Translational Science Award (CTSA) FX This project was supported by the Institute for the Integration of Medicine and Science at the University of Texas Health Science Center, San Antonio, and an National Institutes of Health Clinical Translational Science Award (CTSA). NR 28 TC 8 Z9 8 U1 1 U2 6 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAR PY 2014 VL 179 IS 3 BP 273 EP 278 DI 10.7205/MILMED-D-13-00076 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA AN7UJ UT WOS:000340806200011 PM 24594461 ER PT J AU Kazerooni, R Vu, K Takizawa, A Broadhead, C Morreale, AP AF Kazerooni, Rashid Khanh Vu Takizawa, Atsuhiko Broadhead, Christine Morreale, Anthony P. TI Association of Copayment and Socioeconomic Status with Hormonal Contraceptive Adherence in a Female Veteran Population SO WOMENS HEALTH ISSUES LA English DT Article ID AFFORDABLE CARE ACT; UNINTENDED PREGNANCY; UNITED-STATES; LOW-INCOME; DISPARITIES; EXPERIENCES; PREDICTORS; OUTCOMES; POVERTY; WOMEN AB Background: There are limited studies available analyzing association between copayment and hormonal contraception adherence. The study was conducted to investigate the association between copayment status and hormonal contraceptive adherence in a female veteran population when stratified by socioeconomic status. Methods: This 4-year, retrospective, cohort study of women Veterans from the Veterans Integrated Service Network 22, a network of Veterans Affairs facilities that includes Southern California and Nevada, included patients who received a new hormonal contraceptive prescription between October 1, 2008, and September 30, 2012. Patients were split into five quintiles (one having the lowest income and five the highest) dependent on zip code-based median annual household income from the 2007-2011 American Community Survey data. Medication possession ratio difference of copayment versus no copayment group for each respective quintile was the primary outcome. Analysis was done using multiple linear regression models. Results: A total of 3,622 patients met the inclusion criteria and were included in the analysis. Over the entire population, copayment was significantly associated with reduced adherence (-0.034; 95% confidence interval [CI], -0.06 to -0.008). Patients in the highest socioeconomic group, quintile five, had the largest reduction in adherence associated with having a copayment (-0.073; 95% CI, -0.129 to -0.017). Patients in the other four quintiles saw varying levels of decreased adherence respectively, although the differences did not achieve statistical significance. Conclusion: The association between adherence and copayment status varied by socioeconomic status. Our findings suggest that even affluent patients may be discouraged from adherence when subject to a copayment. If larger studies substantiate these findings, consideration should be given to a policy that exempts women veterans from copayments for hormonal contraceptives. Published by Elsevier Inc. C1 [Kazerooni, Rashid; Khanh Vu; Takizawa, Atsuhiko] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA. [Kazerooni, Rashid; Khanh Vu; Takizawa, Atsuhiko] UCSD Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA USA. [Broadhead, Christine] Sharp HealthCare, San Diego, CA USA. [Morreale, Anthony P.] US Dept Vet Affairs, Natl Pharm Benefits Management Serv, San Diego, CA USA. RP Kazerooni, R (reprint author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr 119, San Diego, CA 92161 USA. EM rashid.kazerooni@va.gov OI Kazerooni, Rashid/0000-0003-3223-2597 NR 28 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAR-APR PY 2014 VL 24 IS 2 BP E237 EP E241 DI 10.1016/j.whi.2013.12.002 PG 5 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA AO1ZG UT WOS:000341113500011 PM 24533983 ER PT J AU McQuitty, E Zhang, W Hendrickson, H Tio, FO Jagirdar, J Olsen, R Cagle, PT AF McQuitty, Elizabeth Zhang, Wei Hendrickson, Heather Tio, Fermin O. Jagirdar, Jaishree Olsen, Randall Cagle, Philip T. TI Lung Adenocarcinoma Biomarker Incidence in Hispanic Versus Non-Hispanic White Patients SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID CANCER PATIENTS; KRAS MUTATIONS; PIK3CA MUTATION; GENE; EGFR; FREQUENCY; SURVIVAL; FEATURES; THERAPY AB Context.-Lung cancer is the leading cause of cancer deaths in the United States and worldwide. Biomarker testing is critical to personalized therapy in lung adenocarcinoma and has been extensively investigated in non-Hispanic whites, Asians, and African Americans. However, little information addresses the underlying genetic changes in lung adenocarcinoma among Hispanic patients in the United States. Objective.-To identify targetable biomarkers other than EGFR and EML4-ALK in Hispanic patients with lung adenocarcinoma. Design.-We tested DNA extracted from 85 lung adenocarcinoma specimens collected from 40 Hispanic and 43 non-Hispanic white patients for previously reported mutations in KRAS, MET, BRAF, mTOR, STAT3, JAK2, PIK3CA, AKT1 through AKT3, and PTEN with a custom Sequenom massARRAY assay (Sequenom, San Diego, California). Results.-Mutations in KRAS were identified in 11 cases (13%; 6 Hispanic [7%], 5 non-Hispanic white [6%]) and had no correlation with sex, age, or smoking history. Mutations in PIK3CA were identified in 2 of the 40 Hispanic patients (5%), including one patient (2.5%) with a concurrent KRAS mutation. The tumors were wild type for all other genes tested. Conclusions.-Targetable biomarkers other than EGFR and EML4-ALK were identified in 7 of the 40 Hispanic patients (18%) and 5 of the 43 non-Hispanic white patients (12%), suggesting a similar mutational frequency. Our highly multiplexed genotyping assay detected actionable mutations in 14% (12 of 83) more patients than would have been identified by EGFR and EML4-ALK testing alone. C1 [Zhang, Wei; Jagirdar, Jaishree] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Tio, Fermin O.] South Texas Vet Hlth Care Syst, Dept Anat & Clin Pathol, San Antonio, TX USA. [McQuitty, Elizabeth; Hendrickson, Heather; Olsen, Randall; Cagle, Philip T.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA. RP Cagle, PT (reprint author), Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St,M227, Houston, TX 77030 USA. EM pcagle@HoustonMethodist.org NR 30 TC 3 Z9 3 U1 2 U2 5 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD MAR PY 2014 VL 138 IS 3 BP 390 EP 394 DI 10.5858/arpa.2013-0225-OA PG 5 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA AM0QI UT WOS:000339550300017 PM 23802852 ER PT J AU O'Neil, ME Carlson, KF Storzbach, D Brenner, LA Freeman, M Quinones, AR Motu'apuaka, M Kansagara, D AF O'Neil, Maya E. Carlson, Kathleen F. Storzbach, Daniel Brenner, Lisa A. Freeman, Michele Quinones, Ana R. Motu'apuaka, Makalapua Kansagara, Devan TI Factors Associated with Mild Traumatic Brain Injury in Veterans and Military Personnel: A Systematic Review SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Review DE Mild traumatic brain injury; Veteran; Military; Systematic review; Combat deployment; Cognitive functioning; Deployment related conditions ID POSTTRAUMATIC-STRESS-DISORDER; SERVICE MEMBERS; NEUROPSYCHOLOGICAL PERFORMANCE; POSTCONCUSSIVE SYMPTOMS; OEF/OIF VETERANS; OIF/OEF VETERANS; WAR VETERANS; US SOLDIERS; COMBAT; BLAST AB A history of mild traumatic brain injury (mTBI) is common among military members who served in Operations Enduring Freedom, Iraqi Freedom, and New Dawn (OEF/OIF/OND). We completed a systematic review to describe the cognitive, mental health, physical health, functional, social, and cost consequences of mTBI in Veteran and military personnel. Of 2668 reviewed abstracts, the 31 included studies provided very low strength evidence for the questions of interest. Cognitive, physical, and mental health symptoms were commonly reported by Veterans/military members with a history of mTBI. On average, these symptoms were not significantly more common in those with a history of mTBI than in those without, although a lack of significant mean differences does not preclude the possibility that some individuals could experience substantial effects related to mTBI history. Evidence of potential risk or protective factors moderating mTBI outcomes was unclear. Although the overall strength of evidence is very low due to methodological limitations of included studies, our findings are consistent with civilian studies. Appropriate re-integration services are needed to address common comorbid conditions, such as treatment for post-traumatic stress disorder, substance use disorders, headaches, and other difficulties that Veterans and members of the military may experience after deployment regardless of mTBI history. C1 [O'Neil, Maya E.; Carlson, Kathleen F.; Storzbach, Daniel; Freeman, Michele; Quinones, Ana R.; Motu'apuaka, Makalapua; Kansagara, Devan] Portland VA Med Ctr, Portland, OR USA. [O'Neil, Maya E.; Carlson, Kathleen F.; Storzbach, Daniel; Freeman, Michele; Kansagara, Devan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Brenner, Lisa A.] VISN 19 MIRECC, Denver VA Med Ctr, Denver, CO USA. [Brenner, Lisa A.] Univ Colorado, Denver, CO 80202 USA. RP O'Neil, ME (reprint author), 3710 SW US Vet Hosp Rd,Mail Code R&D 71, Portland, OR 97239 USA. EM maya.oneil@va.gov FU Veterans Affairs Quality Enhancement Research Initiative (QUERI) Evidence-based Synthesis Program (ESP) FX This study was funded by the Veterans Affairs Quality Enhancement Research Initiative (QUERI) Evidence-based Synthesis Program (ESP). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. All authors declare no conflicts of interests involved in the research presented in the manuscript. The corresponding author (MEO) declares she had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. We thank Edwin Reid and Tomiye Akagi for their editorial assistance, and Rose Relevo for library assistance. NR 40 TC 11 Z9 11 U1 2 U2 16 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAR PY 2014 VL 20 IS 3 BP 249 EP 261 DI 10.1017/S135561771300146X PG 13 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA AM0UG UT WOS:000339561800001 PM 24622505 ER PT J AU Gellad, WF Choi, P Mizah, M Good, CB Kesselheim, AS AF Gellad, Walid F. Choi, Phillip Mizah, Margaret Good, Chester B. Kesselheim, Aaron S. TI Assessing the Chiral Switch: Approval and Use of Single-Enantiomer Drugs, 2001 to 2011 SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; 8-WEEK COMPARATIVE TRIAL; EROSIVE ESOPHAGITIS; DOUBLE-BLIND; OMEPRAZOLE; COST; MULTICENTER; MEDICATION; HEALTH; NAMES AB Objectives: A "chiral switch" occurs in the pharmaceutical market when a drug made up of 2 enantiomer forms is replaced with a purified single-enantiomer version, often in the context of a patent expiration.We studied the prevalence of chiral switching in the United States over the past decade, including trends in use of, and expenditures on, these products in Medicaid. Study Design: Retrospective analysis. Methods: We used US Adopted Names prefixes (lev/levo/ar/es/dex/dextro) to identify all single-enantiomer drugs approved from 2001 to 2011. From publicly available US Food and Drug Administration (FDA) approval documents, we extracted the characteristics of the pivotal premarket trials for the single enantiomers. Specifically, we evaluated whether the single enantiomer was directly compared with the precursor racemic drug and whether there was evidence of superior efficacy. We used quarterly drug expenditure data from each state Medicaid program to chart trends in use of, and spending on, the single-enantiomer products and their racemic precursors during the study period. Results: From 2001 to 2011, the FDA approved 9 single-enantiomer products: dexlansoprazole, levoleucovorin, levocetirizine, armodafinil, arformoterol, eszopiclone, escitalopram, dexmethyl-phenidate, and esomeprazole. Of those 9 drugs, 3 had at least 1 pre-approval randomized trial that included the racemic precursor as a direct comparator, but there was no evidence of superiority of the single enantiomer over the racemic at comparable doses. Between 2001 and 2011, US Medicaid programs spent approximately $6.3 billion on these 9 single-enantiomer drugs. Conclusions: Recently approved single-enantiomer drugs showed no evidence of superior efficacy over the older racemic precursors in the pivotal trials leading to their approval, and in a majority of cases, they were not directly compared. C1 [Gellad, Walid F.; Mizah, Margaret; Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA. [Gellad, Walid F.; Choi, Phillip; Good, Chester B.] Univ Pittsburgh, Dept Med, Santa Monica, CA USA. [Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, Boston, MA 02115 USA. [Kesselheim, Aaron S.] Harvard Univ, Sch Med, Boston, MA USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM walid.gellad@va.gov FU VA Health Services Research & Development (HSR&D) career development award [CDA 09-207]; Harvard Program in Therapeutic Science, Greenwall Faculty Scholarship in Bioethics; Agency for Healthcare Research Quality [K08HS18465-01]; Robert Wood Johnson Foundation Investigator Award in Health Policy Research FX Dr Gellad is supported by a VA Health Services Research & Development (HSR&D) career development award (CDA 09-207). Dr Kesselheim is supported by the Harvard Program in Therapeutic Science, Greenwall Faculty Scholarship in Bioethics, a career development award from the Agency for Healthcare Research & Quality (K08HS18465-01) and a Robert Wood Johnson Foundation Investigator Award in Health Policy Research. None of the funders played any role in the preparation of this article. NR 44 TC 4 Z9 4 U1 3 U2 20 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAR PY 2014 VL 20 IS 3 BP E90 EP E97 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AL5AO UT WOS:000339146100006 PM 24773330 ER PT J AU Nutt, JG Siderowf, AD Guttman, M Schmidt, PN Zamudio, JI Wu, SS Okun, MS Simuni, T Parashos, FSA Dahodwala, NA Davis, TL Giladi, N Gurevich, T Hauser, RA Jankovic, J Lyons, KE Marsh, L Miyasaki, JM Morgan, JC Santiago, AJ Tarsy, D Mari, Z Malaty, IA Nelson, EC AF Nutt, J. G. Siderowf, A. D. Guttman, M. Schmidt, P. N. Zamudio, J. I. Wu, S. S. Okun, M. S. Simuni, T. Parashos, F. S. A. Dahodwala, N. A. Davis, T. L. Giladi, N. Gurevich, T. Hauser, R. A. Jankovic, J. Lyons, K. E. Marsh, L. Miyasaki, J. M. Morgan, J. C. Santiago, A. J. Tarsy, D. Mari, Z. Malaty, I. A. Nelson, E. C. CA Natl Parkinson Fdn Quality TI Mobility, mood and site of care impact health related quality of life in Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease; Health related quality of life; Best practices; Quality improvement ID CONTROLLED-TRIAL; MORTALITY; QUESTIONNAIRE; DEPRESSION; DISABILITY; SYMPTOMS; NONMOTOR; CRITERIA AB Objective: Examine the correlates of Health Related Quality of Life (HRQL) in a large cohort of Parkinson's disease (PD) patients from National Parkinson Foundation (NPF) Centers of Excellence (COEs). Background: Improving outcomes for PD will depend upon uncovering disease features impacting HRQL to identify targets for intervention and variables for risk-adjustment models. Differences in HRQL outcomes between COEs could uncover modifiable aspects of care delivery. Methods: This cross-sectional study examined the relative contribution of demographic, social, clinical and treatment features potentially related to HRQL, as measured by the PDQ-39, in 4601 consecutive subjects from 18 COEs. Stepwise linear regression was utilized to identify correlates of HRQL. Results: The variability in the PDQ-39 summary index score correlated with MY stage (R-2 = 22%), Timed up and Go (TUG) (17%), disease duration (11%), comorbidities (8%), cognitive status (8%), antidepressant use (6%) and center at which a patient received care (5%). Stepwise regression reordered the importance of the variables, with the H&Y first and TUG and the center becoming equal and the second most important variables determining the PDQ-39 total score. All independent variables together accounted for 44% of the variability in HRQL. Conclusions: We confirmed many but not all HRQL associations found in smaller studies. A novel observation was that the site of care was an important contributor to HRQL, suggesting that comparison of outcomes and processes among centers may identify best practices. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Nutt, J. G.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Siderowf, A. D.; Dahodwala, N. A.] Univ Penn, Philadelphia, PA 19104 USA. [Guttman, M.] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Schmidt, P. N.; Zamudio, J. I.; Okun, M. S.] Natl Parkinson Fdn, Miami, FL USA. [Wu, S. S.; Malaty, I. A.] Univ Florida, Gainesville, FL 32611 USA. [Simuni, T.] Northwestern Univ, Evanston, IL 60208 USA. [Parashos, F. S. A.] Struthers Parkinson Ctr, Golden Valley, MN USA. [Davis, T. L.] Vanderbilt Univ, Nashville, TN USA. [Giladi, N.; Gurevich, T.] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel. [Hauser, R. A.] Univ S Florida, Tampa, FL 33620 USA. [Jankovic, J.] Baylor Coll Med, Houston, TX 77030 USA. [Lyons, K. E.] Univ Kansas, Lawrence, KS 66045 USA. [Marsh, L.] DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Morgan, J. C.] Georgia Regents Univ, Augusta, GA USA. [Santiago, A. J.] Muhammad Ali Parkinson Ctr, Phoenix, AZ USA. [Santiago, A. J.] Barrow Neurol Inst, Phoenix, AZ USA. [Tarsy, D.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Mari, Z.] Johns Hopkins Med Ctr, Baltimore, MD USA. [Nelson, E. C.] Dartmouth Hitchcock Med Ctr, Lebanon, NH USA. RP Nutt, JG (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. EM nuttj@ohsu.edu OI Okun, Michael/0000-0002-6247-9358; Miyasaki, Janis/0000-0002-6372-6007 FU National Parkinson Foundation FX National Parkinson Foundation. NR 29 TC 5 Z9 5 U1 3 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD MAR PY 2014 VL 20 IS 3 BP 274 EP 279 DI 10.1016/j.parkreldis.2013.10.004 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA AK4RX UT WOS:000338412900002 PM 24182524 ER PT J AU Bellows, CF Robinson, C Fitzgibbons, RJ Webber, LS Berger, DH AF Bellows, Charles F. Robinson, Celia Fitzgibbons, Robert J., Jr. Webber, Larry S. Berger, David H. TI Watchful Waiting for Ventral Hernias: A Longitudinal Study SO AMERICAN SURGEON LA English DT Article ID QUALITY-OF-LIFE; INCISIONAL HERNIA; INGUINAL-HERNIA; CLINICAL-TRIAL; REPAIR AB Ventral hernias are a common clinical problem. Immediate repair is recommended for most ventral hernias despite significant recurrence rates. This practice may be related to a lack of understanding of the natural history of ventral hernias. The purpose of this study was to determine the natural history of ventral hernias and to determine if watchful waiting is an acceptable and safe option. Forty-one patients with ventral hernias were enrolled in a longitudinal cohort study of watchful waiting. Primary outcomes were functional impairment resulting from hernia disease as measured by the Activities Assessment Scale (AAS) and changes from baseline to two years in the physical and mental component score of the SF-36 Health Survey. Secondary outcomes included complications such as incarceration. Mixed-effects model for repeated measures and Student's t tests were used to evaluate scale performance. The mean age of enrollees was 64 years, and the mean hernia size was 239 cm(2). Eleven patients were lost to follow-up, and seven patients died of other causes. All remaining patients were followed for two years. There was one incarceration during the follow-up period. There was no deterioration in the AAS score (baseline vs 24 months = 28 vs 25, P = 0.60). There was deterioration of the physical functioning dimension of the SF-36 (baseline vs 24 months = 40 vs 32, P < 0.01), but the mental functioning dimension was improved (45 vs 51; P = 0.01). Watchful waiting was a safe option for patients in this study with ventral hernias. C1 [Bellows, Charles F.; Fitzgibbons, Robert J., Jr.] Tulane Univ, Dept Surg, New Orleans, LA 70115 USA. [Robinson, Celia; Berger, David H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Webber, Larry S.] Creighton Univ, Sch Med, Omaha, NE USA. RP Bellows, CF (reprint author), Tulane Univ, Dept Surg, 1430 Tulane Ave, New Orleans, LA 70115 USA. EM cbellows@tulane.edu NR 18 TC 11 Z9 11 U1 0 U2 1 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD MAR PY 2014 VL 80 IS 3 BP 245 EP 252 PG 8 WC Surgery SC Surgery GA AJ5RJ UT WOS:000337743400019 PM 24666865 ER PT J AU Berry, C Ley, EJ Margulies, DR Pruett, J Miller, C Bukur, M Palestrant, D Malinoski, D Salim, A AF Berry, Cherisse Ley, Eric J. Margulies, Daniel R. Pruett, Jessica Miller, Chad Bukur, Marko Palestrant, David Malinoski, Darren Salim, Ali TI Prospective Evaluation of Posttraumatic Vasospasm: Determining Its Clinical Significance after Traumatic Brain Injury SO AMERICAN SURGEON LA English DT Article C1 [Berry, Cherisse; Ley, Eric J.; Margulies, Daniel R.; Pruett, Jessica] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA. [Miller, Chad] Wexner Med Ctr, Dept Neurol, Div Cerebrovasc Dis & Neurocrit Care, Columbus, OH USA. [Bukur, Marko] Broward Hlth & Del Ray Med Ctr, Dept Trauma & Crit Care, Ft Lauderdale, FL USA. [Palestrant, David] Cedars Sinai Med Ctr, Dept Neurol, Div Neurocrit Care, Los Angeles, CA 90048 USA. [Malinoski, Darren] Portland VA Med Ctr, Surg Crit Care Sect, Portland, OR USA. [Salim, Ali] Brigham & Womens Hosp, Dept Surg, Div Trauma Burns & Surg Crit Care, Boston, MA 02115 USA. RP Salim, A (reprint author), Brigham & Womens Hosp, Dept Surg, Div Trauma Burns & Surg Crit Care, 75 Francis St, Boston, MA 02115 USA. EM asalim1@partners.org NR 4 TC 1 Z9 1 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD MAR PY 2014 VL 80 IS 3 BP 310 EP 312 PG 3 WC Surgery SC Surgery GA AJ5RJ UT WOS:000337743400030 PM 24666876 ER PT J AU Paulson, D Bowen, ME Lichtenberg, PA AF Paulson, Daniel Bowen, Mary Elizabeth Lichtenberg, Peter A. TI Does Brain Reserve Protect Older Women from Vascular Depression? SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Cerebrovascular burden; Education; Mood ID LATE-LIFE DEPRESSION; COGNITIVE RESERVE; RISK-FACTORS; GERIATRIC DEPRESSION; SYMPTOMS; STROKE; ADULTS; HYPOTHESIS; MORTALITY; SAMPLE AB Objectives. Brain reserve theory, typically discussed in relation to dementia, was examined with regard to late-life depression symptomatology and cerebrovascular burden (CVB) in older-old women. Method. It was predicted that in a 6-year longitudinal sample (Health and Retirement Study) of 1,355 stroke-free women aged 80 years and older, higher levels of depressive symptomatology (8-item Center for Epidemiologic Studies-Depression score) would be predicted by high CVB, less educational attainment, and the education x CVB interaction after controlling for age and cognitive functioning (Telephone Interview for Cognitive Status). A latent growth curve model was used to identify differences in depression symptomatology at baseline and over time. Logistic regression analyses were used to predict clinically significant depressive symptomatology at each wave based on CVB, education, and the education x CVB interaction. Results. Results indicate that among older women, greater educational attainment predicted fewer depression symptoms at baseline, but this advantage was partially eroded over time. The education x CVB interaction predicted clinically significant depressive symptoms at baseline when the benefits of education were most robust. Discussion. Brain reserve, characterized by educational attainment, may counterbalance the effect of high CVB with respect to depressive symptoms, thereby preserving mood in late life. These findings support the application of brain reserve theory to late-life depression. C1 [Paulson, Daniel; Lichtenberg, Peter A.] Wayne State Univ, Inst Gerontol, Detroit, MI 48202 USA. [Paulson, Daniel; Lichtenberg, Peter A.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA. [Paulson, Daniel] Ralph H Johnson VA Med Ctr, Dept Mental Hlth, Charleston, SC USA. [Bowen, Mary Elizabeth] Vet Hlth Adm, HSR & D RR & D Ctr Excellence, Tampa, FL USA. RP Paulson, D (reprint author), Wayne State Univ, Inst Gerontol, 87 East Ferry St,226 Knapp Bldg, Detroit, MI 48202 USA. EM Paulson@wayne.edu FU Blue Cross Blue Shield of Michigan Foundation [1680.SAP]; T32 grant [T-32 AG00275-06] FX This work was generously supported by the Blue Cross Blue Shield of Michigan Foundation (1680.SAP); and by the T32 grant-supported NIH Pre-Doctoral Training Program in Aging and Urban Health at the Institute of Gerontology (T-32 AG00275-06). NR 55 TC 4 Z9 4 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAR PY 2014 VL 69 IS 2 BP 157 EP 167 DI 10.1093/geronb/gbt007 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA AJ9EG UT WOS:000338009400002 PM 23448867 ER PT J AU Di Paolo, NC Baldwin, LK Irons, EE Papayannopoulou, T Tomlinson, S Shayakhmetov, DM AF Di Paolo, Nelson C. Baldwin, Lisa K. Irons, Eric E. Papayannopoulou, Thalia Tomlinson, Stephen Shayakhmetov, Dmitry M. TI IL-1 alpha and Complement Cooperate in Triggering Local Neutrophilic Inflammation in Response to Adenovirus and Eliminating Virus-Containing Cells SO PLOS PATHOGENS LA English DT Article ID INNATE IMMUNE-RESPONSE; IN-VIVO; GENE-TRANSFER; IMMUNOCOMPROMISED PATIENTS; INTRAVENOUS-INJECTION; STERILE INFLAMMATION; ALTERNATIVE PATHWAY; CXCR4 ANTAGONIST; MICE DEFICIENT; KUPFFER CELLS AB Inflammation is a highly coordinated host response to infection, injury, or cell stress. In most instances, the inflammatory response is pro-survival and is aimed at restoring physiological tissue homeostasis and eliminating invading pathogens, although exuberant inflammation can lead to tissue damage and death. Intravascular injection of adenovirus (Ad) results in virus accumulation in resident tissue macrophages that trigger activation of CXCL1 and CXCL2 chemokines via the IL-1 alpha-IL-1RI signaling pathway. However, the mechanistic role and functional significance of this pathway in orchestrating cellular inflammatory responses to the virus in vivo remain unclear. Resident metallophilic macrophages expressing macrophage receptor with collagenous structure (MARCO(+)) in the splenic marginal zone (MZ) play the principal role in trapping Ad from the blood. Here we show that intravascular Ad administration leads to the rapid recruitment of Ly-6G(+)7/4(+) polymorphonuclear leukocytes (PMNs) in the splenic MZ, the anatomical compartment that remains free of PMNs when these cells are purged from the bone marrow via a non-inflammatory stimulus. Furthermore, PMN recruitment in the splenic MZ resulted in elimination of virus-containing cells. IL-1a-IL-1RI signaling is only partially responsible for PMN recruitment in the MZ and requires CXCR2, but not CXCR1 signaling. We further found reduced recruitment of PMNs in the splenic MZ in complement C3-deficient mice, and that pre-treatment of IL-1 alpha-deficient, but not wild-type mice, with complement inhibitor CR2-Crry (inhibits all complement pathways at C3 activation) or CR2-fH (inhibits only the alternative complement activation pathway) prior to Ad infection, abrogates PMN recruitment to the MZ and prevents elimination of MARCO(+) macrophages from the spleen. Collectively, our study reveals a non-redundant role of the molecular factors of innate immunity - the chemokine-activating IL-1 alpha-IL-1RI-CXCR2 axis and complement - in orchestrating local inflammation and functional cooperation of PMNs and resident macrophages in the splenic MZ, which collectively contribute to limiting disseminated pathogen spread via elimination of virus-containing cells. C1 [Di Paolo, Nelson C.; Shayakhmetov, Dmitry M.] Emory Univ, Sch Med, Dept Pediat, Lowance Ctr Human Immunol, Atlanta, GA 30322 USA. [Di Paolo, Nelson C.; Shayakhmetov, Dmitry M.] Emory Univ, Sch Med, Dept Med, Lowance Ctr Human Immunol, Atlanta, GA USA. [Baldwin, Lisa K.; Irons, Eric E.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. [Papayannopoulou, Thalia] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA. [Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Di Paolo, NC (reprint author), Emory Univ, Sch Med, Dept Pediat, Lowance Ctr Human Immunol, Atlanta, GA 30322 USA. EM dmitryshay@emory.edu FU US NIH [AI065429, CA141439, CA158179]; VA [BX001218] FX This study was supported by US NIH grants AI065429 and CA141439 to DMS, CA158179 to ST, and VA grant BX001218 to ST. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 74 TC 7 Z9 7 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAR PY 2014 VL 10 IS 3 AR e1004035 DI 10.1371/journal.ppat.1004035 PG 19 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA AJ2FF UT WOS:000337470300065 PM 24651866 ER PT J AU Zhang, YJ Lenart, BA Lee, JK Chen, D Shi, P Ren, J Muehleman, C Chen, D An, HS AF Zhang, Yejia Lenart, Brett A. Lee, Joseph K. Chen, Ding Shi, Peng Ren, Jing Muehleman, Carol Chen, Di An, Howard S. TI Histological Features of Endplates of the Mammalian Spine From Mice to Men SO SPINE LA English DT Article DE endplate; intervertebral disc; mammals; human ID INTERVERTEBRAL DISC DEGENERATION; HUMAN LUMBAR DISC; SOLUTE TRANSPORT; ANIMAL-MODELS; NUTRITION; COMPRESSION; VERTEBRAE; DENSITY; WINNER AB Study Design. Histological features of the intervertebral disc (IVD)-endplate interface were analyzed. Objective. To define cartilaginous and bony vertebral endplate in commonly used laboratory animals and compare with that of the humans. Summary of Background Data. Endplates are crucial for the IVD nutrient supply: the IVDs have limited blood supply; most nutrients diffuse through endplates to nourish the discs. Various animal models of IVD and endplate degeneration have been used to study the etiology and treatments of spinal disorders. However, because humans are biped, the spine mechanics differ significantly from other mammals. Translation of animal research findings requires a characterization and comparison of the vertebral endplate in the respective species. In this study, we compared the endplate structure of laboratory animal species at the age range commonly used for modeling spine degeneration with that of an adult human. Methods. Mouse, rat, rabbit, goat, and human IVDs and the adjacent vertebral bodies were isolated from the lower lumbar spine. Tissues were stained with Alcian Blue, counterstained with hematoxylin and eosin. Results. Structure of the vertebral endplate varied significantly between the adult animal species and that of the humans. Growth plates persisted in all adult animals studied, whereas the growth plate is absent in the adult humans. In the mice and rats, the cartilaginous endplates are in continuation with the growth plates, with only a small bony center. Rabbits and goats have a bony layer between cartilaginous endplate and the growth plate. The human endplate consist of a cartilaginous layer and the bony endplate. Conclusion. Significant differences exist in histological features of the endplate across animal species and that of the humans. Consideration should be given when animal models are used to study IVD degeneration and surgical treatments. C1 [Zhang, Yejia; Lenart, Brett A.; Lee, Joseph K.; Chen, Ding; Shi, Peng; An, Howard S.] Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA. [Zhang, Yejia] Rush Univ, Med Ctr, Dept Phys Med & Rehabil, Chicago, IL 60612 USA. [Zhang, Yejia; Muehleman, Carol; Chen, Di] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA. [Zhang, Yejia] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. [Zhang, Yejia] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chen, Ding] Cent S Univ, Hosp Xiangya 2, Dept Orthoped Surg, Changsha, Hunan, Peoples R China. [Ren, Jing] Qujing 1 Hosp, Dept Orthoped, Qujing, Yunnan Province, Peoples R China. RP Zhang, YJ (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. EM yejia.zhang@uphs.upenn.edu FU NIAMS NIH HHS [R01 AR054465, R01 AR055915]; NICHD NIH HHS [K08 HD049598] NR 25 TC 10 Z9 12 U1 4 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD MAR 1 PY 2014 VL 39 IS 5 BP E312 EP E317 DI 10.1097/BRS.0000000000000174 PG 6 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA AJ1BN UT WOS:000337390700003 PM 24365894 ER PT J AU Cadoni, S Gallittu, P Sanna, S Fanari, V Porcedda, ML Erriu, M Leung, FW AF Cadoni, Sergio Gallittu, Paolo Sanna, Stefano Fanari, Viviana Porcedda, Maria L. Erriu, Matteo Leung, Felix W. TI A two-center randomized controlled trial of water-aided colonoscopy versus air insufflation colonoscopy SO ENDOSCOPY LA English DT Article ID UNSEDATED COLONOSCOPY; WARM WATER; CECAL INTUBATION; QUALITY INDICATORS; COLORECTAL-CANCER; US VETERANS; SEDATION; INFUSION; IMMERSION; EXCHANGE AB Background and study aim: Water-aided colonoscopy includes water immersion and water exchange. Several small single-center studies have suggested that the use of water rather than air insufflation during colonoscopy reduces pain on insertion. The aim of this study was to investigate whether water-aided colonoscopy is less painful than air insufflation in a large cohort of patients. Patients and methods: This was a two-center, randomized controlled trial. Consecutive patients who agreed to start colonoscopy without premedication were included. Sedation was administered on demand. Water-aided colonoscopy was performed using water immersion in the early phase of the study, and subsequently water exchange was used. The primary endpoint was cecal intubation with pain scores of <= 2 and sedation with no or <= 2mg midazolam. Secondary outcomes were pain score at discharge, cecal intubation rate and time, and adenoma detection rate (ADR). Results: A total of 672 patients were randomized to water exchange (n=338) or air insufflation (n=334). The primary endpoint was achieved in more patients in the water exchange group (83.8% vs. 62%; P<0.0005). On-demand sedation was also required less (11.5% vs. 26.0 %; P<0.0005) and mean pain score was lower (1.3 vs. 2.3; P<0.0005) in the water exchange group. The cecal intubation rates were comparable. Water exchange had a significantly higher overall ADR (25.8% vs. 19.1 %; P=0.041), proximal ADR (10.1% vs. 4.8 %; P=0.014), and proximal <10mm ADR (7.7% vs. 3.9 %; P=0.046); proximal ADR was also higher in screening-only patients in the water exchange group (18.9% vs. 7.4 %; P=0.015). No detailed analysis was possible for the air insufflation vs. water immersion comparison. Conclusion: The current results confirmed that water exchange minimized the requirement for sedation and increased the ADR. C1 [Cadoni, Sergio; Gallittu, Paolo] S Barbara Hosp, Digest Endoscopy Unit, Iglesias, Carbonia Iglesi, Italy. [Sanna, Stefano; Fanari, Viviana; Porcedda, Maria L.] NS di Bonaria Hosp, Digest Endoscopy Unit, San Gavino Monreale, Villacidro Sanl, Italy. [Erriu, Matteo] Univ Cagliari, Dept Surg, Cagliari, Italy. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Cadoni, S (reprint author), S Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy. EM cadonisergio@gmail.com OI Erriu, Matteo/0000-0002-9818-5861 NR 34 TC 19 Z9 19 U1 0 U2 5 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PD MAR PY 2014 VL 46 IS 3 BP 212 EP 218 DI 10.1055/s-0033-1353604 PG 7 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA AI8HL UT WOS:000337152400009 PM 24218307 ER PT J AU Garrido, MM AF Garrido, Melissa M. TI Propensity Scores and Palliative Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Letter ID MODELS C1 [Garrido, Melissa M.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Garrido, Melissa M.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. RP Garrido, MM (reprint author), 130 W Kingsbridge Rd,Room 4A-17, Bronx, NY 10468 USA. EM melissa.garrido@mssm.edu FU NIA NIH HHS [P30 AG028741] NR 4 TC 3 Z9 3 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2014 VL 17 IS 3 BP 261 EP 261 DI 10.1089/jpm.2013.0587 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AI6ZL UT WOS:000337027700004 PM 24517275 ER PT J AU Goebel, JR Ahluwalia, SC Chong, K Shreve, ST Goldzweig, CL Austin, C Asch, SM Lorenz, KA AF Goebel, Joy R. Ahluwalia, Sangeeta C. Chong, Kelly Shreve, Scott T. Goldzweig, Caroline L. Austin, Colletta Asch, Steven M. Lorenz, Karl A. TI Developing an Informatics Tool To Advance Supportive Care: The Veterans Health Care Administration Palliative Care National Clinical Template SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID SET AB Background: Increasing emphasis in performance-based payment, public reporting, and quality improvement (QI) has led to widespread interest in measuring and improving the quality of care. By 2014, hospice programs will be required to report quality data to the federal government or incur financial penalties. With this increased interest in quality reporting comes an opportunity to develop informatics tools to capture data that reflect the complex practices involved in palliative care (PC). Therefore, there is a need to disseminate information on developing tools that facilitate capturing data and fostering improved performance. The Veterans Health Care Administration, a national leader in health information technology (HIT) and PC, established the Quality Improvement Resource Center (QuIRC) to develop innovative HIT tools to standardize and improve PC practices throughout the 153 Department of Veterans Affairs (VA) medical centers nationwide. Objective: The aim of the paper is to describe the development of the Palliative Care-National Clinical Template (PC-NCT) for documenting initial PC consults. Results: Domains of quality of life provided the foundation for this template. Principles of user-centered informatics design guided development activities. A national consensus panel of PC experts prioritized quality indicators as targets for QI. An interdisciplinary team of PC providers identified desired aspects of template functionality. QuIRC balanced PC providers' desired aspects of functionality against the feasibility within the VA HIT system. Formal pilot and usability testing contributed to numerous iterations of the PC-NCT currently piloted in five geographically distributed sites. Conclusion: This paper presents a robust approach to developing an informatics tool for PC practice. Data collected via the PC-NCT will bring variations in current practice into view and assist in directing resources at "important targets'' for QI. Although the development of HIT tools to quantify PC practice is complex, there is enormous potential to improve the quality of care for patients and families facing serious illnesses. C1 [Goebel, Joy R.] Calif State Univ Long Beach, Sch Nursing, Long Beach, CA 90804 USA. [Ahluwalia, Sangeeta C.] Oregon State Univ, Sch Social & Behav Hlth Sci, Corvallis, OR 97331 USA. [Chong, Kelly; Lorenz, Karl A.] Greater Los Angeles VA Hlth Care Syst, Qual Improvement Resource Ctr, Los Angeles, CA USA. [Shreve, Scott T.] Lebanon VA Hlth Care Syst, Hosp & Palliat Care, Lebanon, PA USA. [Shreve, Scott T.] Penn State Coll Med, Lebanon, PA USA. [Goldzweig, Caroline L.; Austin, Colletta] Greater Los Angeles VA Hlth Care Syst, Clin Informat, Los Angeles, CA USA. [Asch, Steven M.] Palo Alto VA Hlth Care Syst, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ, Div Gen Med Disciplines, Palo Alto, CA 94304 USA. [Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Goebel, JR (reprint author), Calif State Univ Long Beach, Sch Nursing, 1250 Bellflower Blvd, Long Beach, CA 90804 USA. EM joy.goebel@csulb.edu NR 19 TC 0 Z9 0 U1 0 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2014 VL 17 IS 3 BP 266 EP 273 DI 10.1089/jpm.2013.0288 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AI6ZL UT WOS:000337027700007 PM 24548178 ER PT J AU Beristianos, M Yaffe, K Cohen, B Byers, AL AF Beristianos, Matthew Yaffe, Kristine Cohen, Beth Byers, Amy L. TI The Impact of Late-Life PTSD on Vascular-Related Disorders SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Beristianos, Matthew; Yaffe, Kristine; Cohen, Beth; Byers, Amy L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Beristianos, Matthew; Yaffe, Kristine; Cohen, Beth; Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S55 EP S55 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800049 ER PT J AU Byers, AL AF Byers, Amy L. TI Suicidal Behavior in Racially and Ethnically Diverse Older Americans SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Byers, Amy L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S125 EP S125 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800137 ER PT J AU Epstein-Lubow, G Boland, R Cheong, JA Llorente, MD AF Epstein-Lubow, Gary Boland, Robert Cheong, Josepha A. Llorente, Maria D. TI TRAINING PSYCHIATRY RESIDENTS AND FELLOWS IN QUALITY IMPROVEMENT: GERIATRIC PSYCHIATRY CAN HELP LEAD THE WAY SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Epstein-Lubow, Gary; Boland, Robert] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Cheong, Josepha A.] Univ Florida, Coll Med, Gainesville, FL USA. [Llorente, Maria D.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S34 EP S35 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800044 ER PT J AU Fries, AE Leong, S Benson, A Streim, JE DiFilippo, S Oslin, DW AF Fries, Allison E. Leong, Shirley Benson, Amy Streim, Joel E. DiFilippo, Suzanne Oslin, David W. TI Suicidal ideation and health outcomes in an 'old-old' population SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Fries, Allison E.; Leong, Shirley; Benson, Amy; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David W.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Leong, Shirley; Benson, Amy; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David W.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S61 EP S62 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800057 ER PT J AU Haratz, J Zimmerman, J Leong, S Helstrom, A Benson, A DiFilippo, S Streim, JE Oslin, DW AF Haratz, Josh Zimmerman, Jacob Leong, Shirley Helstrom, Amy Benson, Amy DiFilippo, Suzanne Streim, Joel E. Oslin, David W. TI A telephone-based intervention for chronic pain in older adults enrolled in a behavioral health care management program SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Haratz, Josh] Drexel Univ Coll Med, Philadelphia, PA USA. [Zimmerman, Jacob; Leong, Shirley; Helstrom, Amy; Benson, Amy; DiFilippo, Suzanne; Streim, Joel E.; Oslin, David W.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Leong, Shirley; Helstrom, Amy; Benson, Amy; DiFilippo, Suzanne; Streim, Joel E.; Oslin, David W.] Philadelphia VA Med Ctr, VISN4 Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S103 EP S104 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800111 ER PT J AU Kasckow, J Harvey, PD Cohen, CI Rajii, T AF Kasckow, John Harvey, Philip D. Cohen, Carl I. Rajii, Tarek TI COGNITION AND FUNCTIONING IN OLDER PATIENTS WITH SCHIZOPHRENIA: RECENT RESEARCH SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Kasckow, John] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Cohen, Carl I.] SUNY Downstate, Brooklyn, NY USA. [Harvey, Philip D.] Univ Miami, Miami, FL USA. [Rajii, Tarek] Univ Toronto, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S8 EP S8 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800006 ER PT J AU Liptzin, B Streim, JE Colenda, CC AF Liptzin, Benjamin Streim, Joel E. Colenda, Christopher C. TI THE GERIATRIC PSYCHIATRIST AS FAMILY CAREGIVER: LESSONS LEARNED SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Liptzin, Benjamin] Baystate Med Ctr, Springfield, MA USA. [Liptzin, Benjamin] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Colenda, Christopher C.] W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA. [Streim, Joel E.] Univ Penn, Sch Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S33 EP S33 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800042 ER PT J AU Mathur, N Leong, S DiLeone, BA Casares, J Streim, JE Oslin, DW DiFilippo, S AF Mathur, Nivedita Leong, Shirley DiLeone, Brooke A. Casares, Jose Streim, Joel E. Oslin, David W. DiFilippo, Suzanne TI Disparity in Antidepressant Prescription between African American and Caucasian Elderly Veterans: A Retrospective Descriptive Study SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Mathur, Nivedita; Streim, Joel E.; Oslin, David W.; DiFilippo, Suzanne] Univ Penn, Philadelphia, PA 19104 USA. [Mathur, Nivedita; Leong, Shirley; DiLeone, Brooke A.; Casares, Jose; Streim, Joel E.; Oslin, David W.; DiFilippo, Suzanne] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S90 EP S91 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800097 ER PT J AU Mintzer, J Steinberg, E AF Mintzer, Jacobo Steinberg, Ellen TI Elder courts: transforming a crisis into a therapeutic opportunity SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Steinberg, Ellen] Charleston Cty Magistrate Court, Charleston, SC USA. [Mintzer, Jacobo] Roper St Francis Healthcare, Charleston, SC USA. [Mintzer, Jacobo] Med Univ S Carolina, Charleston, SC 29425 USA. [Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S143 EP S143 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800160 ER PT J AU Streim, JE Boustani, M Unutzer, J Oslin, DW AF Streim, Joel E. Boustani, Malaz Unutzer, Jurgen Oslin, David W. TI IMPLEMENTATION OF INTEGRATED COLLABORATIVE GERIATRIC MENTAL HEALTH CARE MODELS: WHAT HAVE WE LEARNED FROM A DECADE OF EXPERIENCE? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Streim, Joel E.; Oslin, David W.] Univ Penn, Philadelphia, PA 19104 USA. [Streim, Joel E.; Oslin, David W.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Boustani, Malaz] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Unutzer, Jurgen] Univ Washington, Sch Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S18 EP S18 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800020 ER PT J AU Streim, JE Liptzin, B Chung, H Rosen, J AF Streim, Joel E. Liptzin, Benjamin Chung, Henry Rosen, Jules TI EARLY EXPERIENCES WITH IMPLEMENTATION OF ACCOUNTABLE CARE ORGANIZATIONS (ACOS): HOW ARE GERIATRIC MENTAL HEALTH SERVICES PROVIDED? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Streim, Joel E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Liptzin, Benjamin] Baystate Med Ctr, Springfield, MA USA. [Liptzin, Benjamin] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Chung, Henry] Albert Einstein Coll Med, New York, NY USA. [Chung, Henry] Montefiore Care Management Co, New York, NY USA. [Rosen, Jules] Univ Colorado, Sch Med, Denver, CO 80202 USA. [Rosen, Jules] Colorado West Mental Hlth, Frisco, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S12 EP S13 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800012 ER PT J AU Wang, LY Murphy, RR Robinson, G Fredrickson, KR Thielke, SM Tsuang, DW Borson, S AF Wang, Lucy Y. Murphy, Richard R. Robinson, Gayle Fredrickson, Kristine R. Thielke, Stephen M. Tsuang, Debby W. Borson, Soo TI Telemedicine Adaptation of a Dementia Care Shared Medical Visit Model SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Wang, Lucy Y.; Murphy, Richard R.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. [Wang, Lucy Y.; Thielke, Stephen M.; Tsuang, Debby W.; Borson, Soo] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Murphy, Richard R.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Robinson, Gayle; Fredrickson, Kristine R.; Thielke, Stephen M.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S128 EP S128 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800141 ER PT J AU Wiechers, I Ruderman, L Levy, I AF Wiechers, Ilse Ruderman, Lital Levy, Ifat TI Does Patient Age Affect Physician Decision Making Under Varying Risk and Ambiguity? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) CY MAR, 2014 CL Orlando, FL SP Amer Assoc Geriatr Psychiat C1 [Wiechers, Ilse] Yale Univ, Sch Med, US Dept Vet Affairs, RWJF Clin Scholars Program, New Haven, CT USA. [Ruderman, Lital; Levy, Ifat] Yale Univ, Sch Med, New Haven, CT USA. [Levy, Ifat] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 22 IS 3 SU S BP S98 EP S98 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH4FE UT WOS:000336081800106 ER PT J AU Carillo, S Zhang, Y Fay, R Angioi, M Vincent, J Sutradhor, SC Ahmed, A Pitt, B Zannad, F AF Carillo, Sylvain Zhang, Yan Fay, Renaud Angioi, Michael Vincent, John Sutradhor, Santosh C. Ahmed, Ali Pitt, Bertram Zannad, Faiez TI Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial SO ARCHIVES OF CARDIOVASCULAR DISEASES LA English DT Article DE NSTEMI; STEMI; Heart failure; Eplerenone ID ACUTE CORONARY SYNDROMES; PRACTICE GUIDELINES COMMITTEE; LEFT-VENTRICULAR DYSFUNCTION; ASSOCIATION TASK-FORCE; MEDITERRANEAN BASIN; ACC/AHA GUIDELINES; HOSPITAL MORTALITY; NATIONAL REGISTRY; AMERICAN-COLLEGE; UNSTABLE ANGINA AB Background. - Differential outcomes in patients with acute systolic heart failure (HF) complicating acute myocardial infarction (AMI) and the efficacy of mineralocorticoid receptor antagonists according to non-ST-segment and ST-segment elevation myocardial infarction (NSTEMI, STEM!) status has not been specifically investigated. Methods. - In the EPHESUS study, 6632 patients with acute HF and left ventricular ejection fraction <40% were randomized 3-14 days post-AMI (median 7.3+/-3.0 days) to receive eplerenone (n=3319) or placebo (n=3313). Among them, 6392 patients with available data on baseline ST-segment status (4634 STEMI; 1758 NSTEMI) were compared using a Cox model analysis stratified according to quintiles of propensity score (PS), taking into account major baseline risk factors, including revascularization. Results. - STEMI and NSTEMI patients differed significantly across a large variety of baseline characteristics. During 30 months of follow-up, all-cause death occurred in 19% and 13% (P<0.0001), cardiovascular death in 16% and 12% (P<0.0001), cardiovascular death and hospitalization in 33% and 26% (P<0.0001) and death from progression of HF in 5% and 3% (P<0.0001) of unadjusted NSTEMI and STEMI patients, respectively. After Cox model PS adjustment without revascularization, NSTEMI status still proved to be a risk factor for all-cause death, cardiovascular death and death from progression of HE After Cox model PS adjustment including revascularization, none of the outcomes differed between STEMI and NSTEMI patients. Eplerenone morbidity and mortality benefits were consistent in the STEMI and NSTEMI subgroups. Conclusion. - In patients with acute systolic HF complicating AMI, eplerenone improves outcomes equally in STEMI and NSTEMI patients. Worse outcomes associated with NSTEMI could be explained by more co-morbidities, less aggressive therapies and, mainly, less frequent revascularization. (C) 2014 Elsevier Masson SAS. All rights reserved. C1 [Carillo, Sylvain; Fay, Renaud; Zannad, Faiez] CHU Nancy, CIC9501, Inst Lorrain Coeur & Vaisseaux, Inserm U961, F-54500 Vandoeuvre Les Nancy, France. [Zhang, Yan; Ahmed, Ali] Univ Alabama Birmingham, Birmingham & VA Med Ctr, Birmingham, AL USA. [Angioi, Michael] Clin Louis Pasteur, F-54270 Esseys Les Nancy, France. [Vincent, John; Sutradhor, Santosh C.] Pfizer Inc, New York, NY USA. [Pitt, Bertram] Univ Michigan, Ann Arbor, MI 48109 USA. RP Carillo, S (reprint author), CHU Nancy, CIC9501, Inst Lorrain Coeur & Vaisseaux, Inserm U961, 2 Ave Morvan, F-54500 Vandoeuvre Les Nancy, France. EM s.carillo@chu-nancy.fr FU Novartis; Medtronic; Forrest Laboratories; BG Medicine; Roche Diagnostics FX Sylvain Carillo, Renaud Fay and Mickael Angioi: none. Yan Zhang: affiliation with UAB. John Vincent and Santosh C. Sutradhor: Pfizer Inc. employees. Ali Ahmed: affiliation with UAB and VA. Bertram Pitt: consultant for Pfizer, Merck, Novartis, Bayer, Takeda, AstraZeneca, Lilly, BMS, BG Medicine (stock options), Relypsa (stock options), Cytopherx, Amorcyte, Aurasence (stock options) and Ardelyx; grants from Novartis, Medtronic and Forrest Laboratories. Faiez Zannad: grants to institution from BG Medicine and Roche Diagnostics; consultant/member of steering committees, event committees and data safety monitoring boards for Bayer, Biomerieux, Biotronik, Boston Scientific, CVCT, Novartis, Pfizer, Resmed, Servier and Takeda. NR 38 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER MASSON PI MILANO PA VIA PALEOCAPA 7, 20121 MILANO, ITALY SN 1875-2136 EI 1875-2128 J9 ARCH CARDIOVASC DIS JI Arch. Cardiovasc. Dis. PD MAR PY 2014 VL 107 IS 3 BP 149 EP 157 DI 10.1016/j.acvd.2014.01.010 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AH7XA UT WOS:000336347500002 PM 24630753 ER PT J AU Hegde, M Lowenstein, DH AF Hegde, Manu Lowenstein, Daniel H. TI The search for circulating epilepsy biomarkers SO BIOMARKERS IN MEDICINE LA English DT Article DE autoantibodies; biomarkers; blood; cerebrospinal fluid; epilepsy center dot epileptogenesis; inflammation; pharmacoresistance ID TEMPORAL-LOBE EPILEPSY; PYRIDOXINE-DEPENDENT EPILEPSY; NMDA RECEPTOR ENCEPHALITIS; STEVENS-JOHNSON-SYNDROME; ALPHA-AMINOADIPIC SEMIALDEHYDE; GLUTAMIC-ACID DECARBOXYLASE; TUBEROUS SCLEROSIS COMPLEX; IMMATURE RAT MODEL; DYSPLASIA TYPE IIB; STATUS EPILEPTICUS AB Few would experience greater benefit from the development of biomarkers than those who suffer from epilepsy. Both the timing of individual seizures and the overall course of the disease are highly unpredictable, and the associated morbidity is considerable. Thus, there is an urgent need to develop biomarkers that can predict the progression of epilepsy and treatment response. Doing so may also shed light on the mechanisms of epileptogenesis and pharmacoresistance, which remain elusive despite decades of study. However, recent advances suggest the possible identification of circulating epilepsy biomarkers - accessible in blood, cerebrospinal fluid or urine. In this review, we focus on advances in several areas: neuroimmunology and inflammation; neurological viral infection; exemplary pediatric syndromes; and the genetics of pharmacoresistance, as relevant to epilepsy. These are fertile areas of study with great potential to yield accessible epilepsy biomarkers. C1 [Hegde, Manu; Lowenstein, Daniel H.] Univ Calif San Francisco, Dept Neurol, UCSF Epilepsy Ctr, San Francisco, CA 94143 USA. [Hegde, Manu] San Francisco VA Med Ctr, Epilepsy Ctr Excellence, San Francisco, CA 94121 USA. RP Hegde, M (reprint author), Univ Calif San Francisco, Dept Neurol, UCSF Epilepsy Ctr, 521 Parnassus Ave C-440, San Francisco, CA 94143 USA. EM manu.hegde@ucsf.edu NR 99 TC 10 Z9 11 U1 1 U2 9 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1752-0363 EI 1752-0371 J9 BIOMARK MED JI Biomark. Med. PD MAR PY 2014 VL 8 IS 3 BP 413 EP 427 DI 10.2217/BMM.13.142 PG 15 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AE4RN UT WOS:000333970700018 PM 24712433 ER PT J AU Thrift, AP Kramer, JR Alsarraj, A El-Serag, HB AF Thrift, Aaron P. Kramer, Jennifer R. Alsarraj, Abeer El-Serag, Hashem B. TI Fat Mass by Bioelectrical Impedance Analysis is not Associated With Increased Risk of Barrett Esophagus SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE Barrett esophagus; obesity; bioelectrical impedance analysis; risk factors ID APPENDICULAR BODY-COMPOSITION; BIOIMPEDANCE ANALYSIS; GENERAL-POPULATION; ABDOMINAL OBESITY; INDEX; ADIPOSITY; ACCURACY; ADENOCARCINOMA; METAANALYSIS; ADULTS AB Goal:To evaluate whether the association between obesity and Barrett esophagus (BE) is due to total body fatness, abdominal obesity, or both.Background:BE risk seems to be more strongly related to central obesity than total obesity. However, no studies have investigated the association between total obesity and BE using direct measures of total body fatness.Study:We conducted a case-control study among patients scheduled for elective esophagogastroduodenoscopy, and a sample of patients eligible for screening colonoscopy recruited from primary care clinics. BE cases were patients with specialized intestinal metaplasia, whereas controls had no endoscopic or histopathologic BE. All patients underwent a study esophagogastroduodenoscopy and had body measurements taken. Fat mass and fat-free mass were estimated from bioelectrical impedance analysis (BIA). We calculated odds ratios (OR) and 95% confidence intervals (95% CI) using multivariable logistic regression.Results:There were 70 BE cases, 229 endoscopy controls, and 118 primary care controls. BMI and BIA-derived fat mass were highly correlated; however, we found no association between BMI, fat mass, and BE (vs. all controls: BMI, OR/1 SD=1.01; 95% CI, 0.76-1.34; fat mass, OR=1.02; 95% CI, 0.77-1.36). Waist-to-hip ratio was significantly associated with increased BE risk (vs. all controls: OR/1 SD=1.45; 95% CI, 1.03-2.04). We found similar results when we analyzed the control groups separately.Conclusion:Waist-to-hip ratio, but not fat mass or BMI, was associated with increased BE risk. This study provides strong evidence that BE is related to body size and composition through central adiposity and not through total body fatness. C1 [Thrift, Aaron P.] Queensland Inst Med Res, Dept Populat Hlth, Brisbane, Qld 4006, Australia. [Kramer, Jennifer R.; Alsarraj, Abeer; El-Serag, Hashem B.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA. [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Kramer, Jennifer R.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.edu FU NIH [NCI R01 116845]; Houston VA, HSR&D Center of Excellence [HFP90-020]; Texas Digestive Disease Center NIH [DK58338]; NIDDK [K24-04-107] FX Supported in part by NIH grant NCI R01 116845, the Houston VA, HSR&D Center of Excellence (HFP90-020), and the Texas Digestive Disease Center NIH, DK58338. H.B.E.-S. is also supported by NIDDK K24-04-107. NR 28 TC 8 Z9 8 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD MAR PY 2014 VL 48 IS 3 BP 218 EP 223 DI 10.1097/MCG.0b013e31829ae98c PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF7UU UT WOS:000334921100004 PM 23842216 ER PT J AU Jin, J Machado, ER Yu, H Zhang, X Lu, Z Li, Y Lopes-Virella, MF Kirkwood, KL Huang, Y AF Jin, J. Machado, E. R. Yu, H. Zhang, X. Lu, Z. Li, Y. Lopes-Virella, M. F. Kirkwood, K. L. Huang, Y. TI Simvastatin Inhibits LPS-induced Alveolar Bone Loss during Metabolic Syndrome SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE lipopolysaccharide; inflammation obesity; periodontal disease; statin; insulin resistance ID PERIODONTAL-DISEASE; STATIN THERAPY; CARDIOVASCULAR-DISEASE; TNF-ALPHA; OBESITY; INFLAMMATION; ASSOCIATION; METAANALYSIS; ARTHRITIS; MICE AB Studies in recent years have shown a positive relationship between metabolic syndrome (MS) and periodontal disease (PD). Given that patients with MS take statins to reduce cholesterol, and statins also have anti-inflammatory effects, it is important to determine if statin intake hinders the progression of MS-associated PD. In this study, PD was induced in Zucker fat rats (ZFRs), an animal model for MS, and in control lean rats by periodontal injection of Aggregatibacter actinomycetemcomitans lipopolysaccharide (LPS), while simvastatin was given to some of the rats via gavage. After 4 wk of treatment, alveolar bone loss was determined by micro-computed tomography. To explore the underlying mechanisms, we determined the effect of simvastatin on tissue inflammation and the expression of molecules involved in osteoclastogenesis. Results showed that while bone loss was increased by LPS in both ZFRs and the control lean rats, it was significantly more in the former than the latter. Simvastatin effectively alleviated bone loss in both ZFRs and the control rats. Results also showed that LPS stimulated leukocyte tissue infiltration and expression of molecules for osteoclastogenesis, but simvastatin significantly modulated the stimulation. This study demonstrated that simvastatin inhibited LPS-induced alveolar bone loss and periodontal tissue inflammation in rats with MS. C1 [Jin, J.; Zhang, X.; Lu, Z.; Li, Y.; Lopes-Virella, M. F.; Huang, Y.] Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Lopes-Virella, M. F.; Huang, Y.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Machado, E. R.; Yu, H.; Kirkwood, K. L.] Med Univ S Carolina, Coll Dent Med, Dept Craniofacial Biol, Charleston, SC 29425 USA. [Machado, E. R.; Yu, H.; Kirkwood, K. L.] Med Univ S Carolina, Coll Dent Med, Ctr Oral Hlth Res, Charleston, SC 29425 USA. [Jin, J.] Guilin Med Univ, Affiliated Hosp, Lab Hepatobiliary & Pancreat Surg, Guilin 541001, Guangxi, Peoples R China. RP Huang, Y (reprint author), Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. EM huangyan@musc.edu FU National Institutes of Health [DE016353]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs; National Institute of General Medical Sciences of the National Institutes of Health [P30103331] FX This work was supported by National Institutes of Health grant DE016353 and by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs (to Y.H.). Research reported in this publication was also supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P30103331. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article. NR 30 TC 9 Z9 10 U1 1 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0345 EI 1544-0591 J9 J DENT RES JI J. Dent. Res. PD MAR PY 2014 VL 93 IS 3 BP 294 EP 299 DI 10.1177/0022034513516980 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA AA9SM UT WOS:000331433200013 PM 24352501 ER PT J AU Crabtree, D Dodson, M Ouyang, XS Boyer-Guittaut, M Liang, QL Ballestas, ME Fineberg, N Zhang, JH AF Crabtree, Donna Dodson, Matthew Ouyang, Xiaosen Boyer-Guittaut, Michael Liang, Qiuli Ballestas, Mary E. Fineberg, Naomi Zhang, Jianhua TI Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE autophagy; cathepsin D; lysosome; alpha-synuclein ID CHAPERONE-MEDIATED AUTOPHAGY; FAMILIAL PARKINSONS-DISEASE; LYSOSOMAL STORAGE; IN-VIVO; MACROAUTOPHAGY; DEGRADATION; AGGREGATION; DUPLICATION; TOXICITY; NEURONS AB Parkinson's disease is a neurodegenerative movement disorder. The histopathology of Parkinson's disease comprises proteinaceous inclusions known as Lewy bodies, which contains aggregated -synuclein. Cathepsin D (CD) is a lysosomal protease previously demonstrated to cleave -synuclein and decrease its toxicity in both cell lines and mouse brains in vivo. Here, we show that pharmacological inhibition of CD, or introduction of catalytically inactive mutant CD, resulted in decreased CD activity and increased cathepsin B activity, suggesting a possible compensatory response to inhibition of CD activity. However, this increased cathepsin B activity was not sufficient to maintain -synuclein degradation, as evidenced by the accumulation of endogenous -synuclein. Interestingly, the levels of LC3, LAMP1, and LAMP2, proteins involved in autophagy-lysosomal activities, as well as total lysosomal mass as assessed by LysoTracker flow cytometry, were unchanged. Neither autophagic flux nor proteasomal activities differs between cells over-expressing wild-type versus mutant CD. These observations point to a critical regulatory role for that endogenous CD activity in dopaminergic cells in -synuclein homeostasis which cannot be compensated for by increased Cathepsin B. These data support the potential need to enhance CD function in order to attenuate -synuclein accumulation as a therapeutic strategy against development of synucleinopathy. C1 [Crabtree, Donna; Dodson, Matthew; Ouyang, Xiaosen; Boyer-Guittaut, Michael; Liang, Qiuli; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Dodson, Matthew; Ouyang, Xiaosen; Boyer-Guittaut, Michael; Liang, Qiuli; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Ouyang, Xiaosen; Liang, Qiuli; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA. [Boyer-Guittaut, Michael] Univ Franche Comte, Biochim Lab, UFR Sci & Tech, F-25030 Besancon, France. [Ballestas, Mary E.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA. [Fineberg, Naomi] UAB Sch Publ Hlth, Dept Biostat, Birmingham, AL USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, BMRII 534,901 19th St S, Birmingham, AL 35294 USA. EM zhanja@uab.edu OI Ballestas, Mary/0000-0003-0660-9477; Zhang, Jianhua/0000-0002-2128-9574 FU Michael J Fox Foundation [NIHR01-NS064090]; VA merit award; UAB Neuroscience NINDS Protein Interaction Core C [NINDSP30-NS047466]; NIH [P30 AR48311] FX We are grateful to Dr Aimee Landar, Ms Stephanie Wall, Victor Darley-Usmar and members of the Zhang laboratory for technical help and discussions. This study was supported by Michael J Fox Foundation, NIHR01-NS064090 and a VA merit award (to JZ), NINDSP30-NS047466 (UAB Neuroscience NINDS Protein Interaction Core C), and NIH P30 grant #P30 AR48311 (RDCC-APCC core). The authors have no conflict of interest to declare. NR 33 TC 14 Z9 14 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2014 VL 128 IS 6 BP 950 EP 961 DI 10.1111/jnc.12497 PG 12 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA AC2PV UT WOS:000332347300016 PM 24138030 ER PT J AU Petrie, EC Cross, DJ Yarnykh, VL Richards, T Martin, NM Pagulayan, K Hoff, D Hart, K Mayer, C Tarabochia, M Raskind, MA Minoshima, S Peskind, ER AF Petrie, Eric C. Cross, Donna J. Yarnykh, Vasily L. Richards, Todd Martin, Nathalie M. Pagulayan, Kathleen Hoff, David Hart, Kim Mayer, Cynthia Tarabochia, Matthew Raskind, Murray A. Minoshima, Satoshi Peskind, Elaine R. TI Neuroimaging, Behavioral, and Psychological Sequelae of Repetitive Combined Blast/ Impact Mild Traumatic Brain Injury in Iraq and Afghanistan War Veterans SO JOURNAL OF NEUROTRAUMA LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER; AXONAL INJURY; MULTIPLE-SCLEROSIS; DIFFUSION MRI; STEADY-STATE; HEAD-INJURY; FDG-PET; IMAGES; ENCEPHALOPATHY C1 [Petrie, Eric C.; Pagulayan, Kathleen; Hoff, David; Hart, Kim; Mayer, Cynthia; Tarabochia, Matthew; Raskind, Murray A.; Peskind, Elaine R.] VA Puget Sound, MIRECC, Vet Affairs VA Northwest Network VISN 20, Seattle, WA 98108 USA. [Petrie, Eric C.; Pagulayan, Kathleen; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Petrie, Eric C.; Cross, Donna J.; Yarnykh, Vasily L.; Richards, Todd; Martin, Nathalie M.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. RP Petrie, EC (reprint author), VA Puget Sound, MIRECC, 1660 S Columbian Way,Mail Code S-116, Seattle, WA 98108 USA. EM epetrie@uw.edu RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014 OI Yarnykh, Vasily/0000-0002-1583-8979; FU Department of Veterans Affairs Rehabilitation Research and Development Service [B77421]; VA Clinical Science Research and Development CAREER development award [TK2 CX000516]; VA Northwest Network MIRECC; National Institute of Health [AG05136, 5K08AG23670, R21EB009908] FX This material is based on work supported, in part, by the Department of Veterans Affairs Rehabilitation Research and Development Service (B77421), VA Clinical Science Research and Development CAREER development award TK2 CX000516, and VA Northwest Network MIRECC; National Institute of Health grants AG05136, 5K08AG23670, and R21EB009908; and an anonymous foundation. NR 71 TC 36 Z9 36 U1 4 U2 17 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD MAR 1 PY 2014 VL 31 IS 5 BP 425 EP 436 DI 10.1089/NEU.2013.2952 PG 12 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA AB4ZV UT WOS:000331799600241 PM 24102309 ER PT J AU Hook, GR Yu, J Sipes, N Pierschbacher, MD Hook, V Kindy, MS AF Hook, Gregory R. Yu, Jin Sipes, Nancy Pierschbacher, Michael D. Hook, Vivian Kindy, Mark S. TI The Cysteine Protease Cathepsin B Is a Key Drug Target and Cysteine Protease Inhibitors Are Potential Therapeutics for Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE cathepsin B; cysteine protease inhibitor; motor function; traumatic brain injury ID CELL-FREE DNA; ALZHEIMERS-DISEASE; MITOCHONDRIAL-DNA; PREDICTIVE MARKER; RAT-BRAIN; DAMAGE; REPAIR; NEUROTRAUMA; RADIATION; NUCLEAR AB There are currently no effective therapeutic agents for traumatic brain injury (TBI), but drug treatments for TBI can be developed by validation of new drug targets and demonstration that compounds directed to such targets are efficacious in TBI animal models using a clinically relevant route of drug administration. The cysteine protease, cathepsin B, has been implicated in mediating TBI, but it has not been validated by gene knockout (KO) studies. Therefore, this investigation evaluated mice with deletion of the cathepsin B gene receiving controlled cortical impact TBI trauma. Results indicated that KO of the cathepsin B gene resulted in amelioration of TBI, shown by significant improvement in motor dysfunction, reduced brain lesion volume, greater neuronal density in brain, and lack of increased proapoptotic Bax levels. Notably, oral administration of the small-molecule cysteine protease inhibitor, E64d, immediately after TBI resulted in recovery of TBI-mediated motor dysfunction and reduced the increase in cathepsin B activity induced by TBI. E64d outcomes were as effective as cathepsin B gene deletion for improving TBI. E64d treatment was effective even when administered 8h after injury, indicating a clinically plausible time period for acute therapeutic intervention. These data demonstrate that a cysteine protease inhibitor can be orally efficacious in a TBI animal model when administered at a clinically relevant time point post-trauma, and that E64d-mediated improvement of TBI is primarily the result of inhibition of cathepsin B activity. These results validate cathepsin B as a new TBI therapeutic target. C1 [Hook, Gregory R.; Sipes, Nancy; Pierschbacher, Michael D.] Amer Life Sci Pharmaceut, San Diego, CA USA. [Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Yu, Jin; Kindy, Mark S.] Appl Neurotechnol Inc, Charleston, SC USA. [Hook, Vivian] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA. [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,BSB 403, Charleston, SC 29425 USA. EM kindyms@musc.edu FU NIH [R44AG032784, 5R01ES016774-02]; VA Merit Review [1I01RX000331-01] FX The authors thank Christoph Peters, MD, of Albert Ludwig University (Freiburg, Germany) for providing the cathepsin B-deficient mice and Lawrence Marshall, MD, for reviewing the manuscript. This work was supported, in part, by NIH grants R44AG032784 (to American Life Science Pharmaceuticals; ALSP) and 5R01ES016774-02 (to M. S. K.) and VA Merit Review 1I01RX000331-01 (to M.S.K.). NR 31 TC 10 Z9 10 U1 0 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD MAR 1 PY 2014 VL 31 IS 5 BP 515 EP 529 DI 10.1089/NEU.2013.2944 PG 15 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA AB4ZV UT WOS:000331799600250 PM 24083575 ER PT J AU Lehavot, K Katon, JG Williams, EC Nelson, KM Gardella, CM Reiber, GE Simpson, TL AF Lehavot, Keren Katon, Jodie G. Williams, Emily C. Nelson, Karin M. Gardella, Carolyn M. Reiber, Gayle E. Simpson, Tracy L. TI Sexual Behaviors and Sexually Transmitted Infections in a Nationally Representative Sample of Women Veterans and Nonveterans SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HUMAN-PAPILLOMAVIRUS INFECTION; SIMPLEX-VIRUS TYPE-2; UNITED-STATES; HEALTH-CARE; CHLAMYDIAL INFECTION; MINORITY VETERANS; RISK BEHAVIOR; US MILITARY; CONDOM USE; GONORRHEA AB Background: Women veterans are a growing population with unique characteristics and documented health disparities. Few studies have examined their sexual behaviors and rates of sexually transmitted infections (STIs), and none have compared women veterans to nonveterans to identify potential sexual health disparities. Methods: We used data from the 1999-2010 National Health and Nutrition Examination Survey, a nationally representative U.S. survey. We compared lifetime sexual history (age at first intercourse, number of partners), sexual activity in the last year, and STIs between women veterans (n=151) and nonveterans (n=8738), adjusting for age, race/ethnicity, education, marital status, binge drinking, and survey year. Results: Compared to nonveterans, women veterans reported a younger age at first intercourse and a greater number of female and male lifetime sexual partners, and they were more likely to have ever had sex with a woman. They were also more likely than nonveterans to have genital herpes and genital warts. Conclusions: Women veterans reported higher rates of sexual activity and STIs than nonveterans. Future research is needed to assess high-risk behaviors and determine what factors may underlie these associations. Providers should ensure thorough screening and intervention services are provided for this growing population. C1 [Lehavot, Keren; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Katon, Jodie G.; Williams, Emily C.; Nelson, Karin M.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev HSR&D, Seattle, WA 98108 USA. [Katon, Jodie G.] Dept Vet Affairs, VA Off Womens Hlth Serv, Washington, DC USA. [Katon, Jodie G.; Williams, Emily C.; Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. [Gardella, Carolyn M.] VA Puget Sound Hlth Care Syst, Gynecol Serv, Seattle, WA 98108 USA. [Gardella, Carolyn M.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, MIRECC, 1660 S Columbian Way S-116 POC, Seattle, WA 98108 USA. EM klehavot@uw.edu FU Associated Health Postdoctoral Fellowship [TPP 61-026]; Career Development Award [CDA 12-276]; Senior Career Scientist Award grant [RCS 98-353]; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI) FX This material is the result of work supported by resources from the U.S. Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment (K.L.), Associated Health Postdoctoral Fellowship (J.K., no. TPP 61-026), Career Development Award (E.W., CDA 12-276), Senior Career Scientist Award grant (G.R., no. RCS 98-353), and the VA Puget Sound Health Care System, Seattle, Washington. EW is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). The authors would like to thank Jeff Rodenbaugh for managing the data. The views expressed in this article are those of the authors and do not represent the views of the Department of Veterans Affairs or the United States government. NR 47 TC 8 Z9 8 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD MAR 1 PY 2014 VL 23 IS 3 BP 246 EP 252 DI 10.1089/jwh.2013.4327 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AC4BQ UT WOS:000332466000010 PM 24328438 ER PT J AU Frank, JW Bair, MJ Becker, WC Krebs, EE Liebschutz, JM Alford, DP AF Frank, Joseph W. Bair, Matthew J. Becker, William C. Krebs, Erin E. Liebschutz, Jane M. Alford, Daniel P. TI Update in Pain Medicine for Primary Care Providers: A Narrative Review, 2010-2012 SO PAIN MEDICINE LA English DT Review DE Pain Management; Primary Care; Interventional; Opioids; Neuropathic Pain; Exercise; Psychotherapy; Physical Therapy ID LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; NEUROPATHIC PAIN; STEPPED CARE; MANAGEMENT; YOGA; INTERVENTIONS; METAANALYSIS; POPULATION; PREVALENCE AB ObjectiveThis manuscript reviews peer-reviewed literature published from 2010-2012 relevant to the management of chronic pain in the primary care setting. DesignNarrative review of peer-reviewed literature. MethodsWe searched MEDLINE, PubMed, and reference lists and queried expert contacts for English-language studies related to the management of chronic noncancer pain in adult patients in primary care settings. One investigator reviewed all eligible studies for relevance, and 47 studies were reviewed by all authors and rated according to their impact on 1) primary care clinical practice, 2) policy, 3) research, and 4) quality of study methods. Through iterative discussion, nine articles were selected for detailed review and discussion. ResultsWe present articles in six topic areas: interventional pain management; opioid dose and risk of overdose death; neuropathic pain; yoga for chronic low back pain; cognitive behavioral therapy; and systematic approaches to treating back pain. We discuss implications for pain management in primary care. ConclusionsThere is growing evidence for the risks, benefits, and limitations of the multiple modalities available to primary care providers for the management of chronic pain. The dissemination and implementation of the evidence from these studies as well as novel system-level interventions warrant additional study and support from clinicians, educators, and policy makers. C1 [Frank, Joseph W.] Univ Colorado, Sch Med, Div Gen Internal Med, Denver VA Med Ctr, Aurora, CO 80045 USA. [Bair, Matthew J.] Indiana Univ, Sch Med, Roudebush VA Med Ctr, Indianapolis, IN USA. [Becker, William C.] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA. [Krebs, Erin E.] Univ Minnesota, Sch Med, Minneapolis VA Med Ctr, Minneapolis, MN 55455 USA. [Liebschutz, Jane M.; Alford, Daniel P.] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA. [Liebschutz, Jane M.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Frank, JW (reprint author), Univ Colorado, Sch Med, Div Gen Internal Med, 8th Floor,Acad Off 1,Mailstop B180, Aurora, CO 80045 USA. EM joseph.frank@ucdenver.edu FU an institutional National Research Service Award [T32HP10251]; VA HSR&D Research Career Development Awards FX All authors are members of the Society of General Internal Medicine's Pain Medicine Interest Group. This article derives from the presentation "Update in Pain Medicine" at the 36th annual meeting of SGIM in April 2013 in Denver, Colorado. Dr. Frank was supported by an institutional National Research Service Award (T32HP10251). Drs. Becker and Krebs are supported by VA HSR&D Research Career Development Awards. NR 34 TC 3 Z9 3 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAR PY 2014 VL 15 IS 3 BP 425 EP 431 DI 10.1111/pme.12337 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AC2GU UT WOS:000332318600010 PM 24423083 ER PT J AU Bouldin, EL Littman, AJ Rice, K Reiber, GE AF Bouldin, E. L. Littman, A. J. Rice, K. Reiber, G. E. TI RURAL RESIDENCE, DUAL USE, AND CHRONIC WOUND OUTCOMES AMONG VETERANS SO WOUND REPAIR AND REGENERATION LA English DT Meeting Abstract C1 [Bouldin, E. L.; Littman, A. J.; Reiber, G. E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Bouldin, E. L.; Littman, A. J.; Rice, K.; Reiber, G. E.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1067-1927 EI 1524-475X J9 WOUND REPAIR REGEN JI Wound Repair Regen. PD MAR PY 2014 VL 22 IS 2 BP A33 EP A33 PG 1 WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery GA AC9DV UT WOS:000332835400024 ER PT J AU Mehta, SJ Asch, DA AF Mehta, Shivan J. Asch, David A. TI When are effective medications just too expensive? SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Editorial Material ID COST C1 [Mehta, Shivan J.] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA. [Mehta, Shivan J.; Asch, David A.] Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Mehta, SJ (reprint author), Univ Penn, Perelman Sch Med, 1133 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shivan.mehta@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X NR 9 TC 1 Z9 1 U1 1 U2 1 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 EI 1939-2869 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD MAR PY 2014 VL 81 IS 3 BP 173 EP 175 DI 10.3949/ccjm.81a.14010 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AH1WA UT WOS:000335911200008 PM 24591472 ER PT J AU Frech, T Redd, D Rhiannon, J Murtaugh, M Zeng, Q AF Frech, T. Redd, D. Rhiannon, J. Murtaugh, M. Zeng, Q. TI INFORMATICS CAN IDENTIFY SYSTEMIC SCLEROSIS PATIENTS AT RISK FOR SCLERODERMA RENAL CRISIS SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY LA English DT Meeting Abstract C1 [Frech, T.; Redd, D.; Murtaugh, M.; Zeng, Q.] Univ Utah, Salt Lake VAMC, Salt Lake City, UT USA. [Rhiannon, J.] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CLINICAL & EXPER RHEUMATOLOGY PI PISA PA VIA SANTA MARIA 31, 56126 PISA, ITALY SN 0392-856X J9 CLIN EXP RHEUMATOL JI Clin. Exp. Rheumatol. PD MAR-APR PY 2014 VL 32 IS 2 SU 81 BP S115 EP S116 PG 2 WC Rheumatology SC Rheumatology GA AH2FH UT WOS:000335936400308 ER PT J AU Gray-Miceli, D Ratcliffe, S Thomasson, A AF Gray-Miceli, Deanna Ratcliffe, Sarah Thomasson, Arwin TI Patient Level Risk Factors to Assess in Older Adult Fallers with Orthostatic Hypotension SO NURSING RESEARCH LA English DT Meeting Abstract C1 [Gray-Miceli, Deanna] Rutgers State Univ, Coll Nursing, Piscataway, NJ 08855 USA. [Ratcliffe, Sarah] Univ Penn, Sch Med & Biostat, Philadelphia, PA 19104 USA. [Thomasson, Arwin] Ctr Hlth Equ Res & Promot, Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 EI 1538-9847 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2014 VL 63 IS 2 BP E7 EP E8 PG 2 WC Nursing SC Nursing GA AE6JP UT WOS:000334098000019 ER PT J AU Moriarty, H Winter, L Robinson, K Piersol, C Vause-Earland, T Iacavone, D True, G Hodgson, N Holbert, L Newhart, B Fishman, D AF Moriarty, Helene Winter, Laraine Robinson, Keith Piersol, Catherine Vause-Earland, Tracey Iacavone, Dolores True, Gala Hodgson, Nancy Holbert, Laura Newhart, Brian Fishman, Deborah TI Challenges in Mental Health Predictors of Community Reintegration in Military Veterans with Mild to Moderate Traumatic Brain Injury SO NURSING RESEARCH LA English DT Meeting Abstract C1 [Moriarty, Helene] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA. [Winter, Laraine; Robinson, Keith; Iacavone, Dolores; True, Gala; Holbert, Laura; Newhart, Brian; Fishman, Deborah] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Piersol, Catherine; Vause-Earland, Tracey] Thomas Jefferson Univ, Sch Hlth Profess, Philadelphia, PA USA. [Hodgson, Nancy] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 EI 1538-9847 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2014 VL 63 IS 2 BP E71 EP E72 PG 2 WC Nursing SC Nursing GA AE6JP UT WOS:000334098000199 ER PT J AU Moriarty, H Winter, L Piersol, C Vause-Earland, T Robinson, K Lacavone, D True, G Holbert, L Newhart, B Hodgson, N Fishman, D AF Moriarty, Helene Winter, Laraine Piersol, Catherine Vause-Earland, Tracey Robinson, Keith Lacavone, Dolores True, Gala Holbert, Laura Newhart, Brian Hodgson, Nancy Fishman, Deborah TI Using Dyadic Analyses with Veterans with Traumatic Brain Injury and their Family Members: Implications for Family Relationships SO NURSING RESEARCH LA English DT Meeting Abstract C1 [Moriarty, Helene] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA. [Winter, Laraine; Robinson, Keith; Lacavone, Dolores; Holbert, Laura; Newhart, Brian; Fishman, Deborah] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Piersol, Catherine; Vause-Earland, Tracey] Thomas Jefferson Univ, Sch Hlth Profess, Philadelphia, PA USA. [True, Gala] CHERP, Philadelphia VA Med Ctr, Philadelphia, PA USA. [Hodgson, Nancy] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 EI 1538-9847 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2014 VL 63 IS 2 BP E11 EP E12 PG 2 WC Nursing SC Nursing GA AE6JP UT WOS:000334098000030 ER PT J AU Stetler, RA Leak, RK Gan, Y Li, PY Zhang, F Hu, XM Jing, Z Chen, J Zigmond, MJ Gao, YQ AF Stetler, R. Anne Leak, Rehana K. Gan, Yu Li, Peiying Zhang, Feng Hu, Xiaoming Jing, Zheng Chen, Jun Zigmond, Michael J. Gao, Yanqin TI Preconditioning provides neuroprotection in models of CNS disease: Paradigms and clinical significance SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE Preconditioning; Neuroprotection; Ischemia; Traumatic brain injury ID FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; METHYL-D-ASPARTATE; OXYGEN-GLUCOSE DEPRIVATION; MESENCHYMAL STEM-CELLS; K-ATP CHANNEL; HYPOTHERMIC CIRCULATORY ARREST; SENSITIVE POTASSIUM CHANNELS; NEONATAL HYPOXIA-ISCHEMIA; CEREBELLAR GRANULE CELLS AB Preconditioning is a phenomenon in which brief episodes of a sublethal insult induce robust protection against subsequent lethal injuries. Preconditioning has been observed in multiple organisms and can occur in the brain as well as other tissues. Extensive animal studies suggest that the brain can be preconditioned to resist acute injuries, such as ischemic stroke, neonatal hypoxia/ischemia, surgical brain injury, trauma, and agents that are used in models of neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Effective preconditioning stimuli are numerous and diverse, ranging from transient ischemia, hypoxia, hyperbaric oxygen, hypothermia and hyperthermia, to exposure to neurotoxins and pharmacological agents. The phenomenon of "cross-tolerance," in which a sublethal stress protects against a different type of injury, suggests that different preconditioning stimuli may confer protection against a wide range of injuries. Research conducted over the past few decades indicates that brain preconditioning is complex, involving multiple effectors such as metabolic inhibition, activation of extra- and intracellular defense mechanisms, a shift in the neuronal excitatory/inhibitory balance, and reduction in inflammatory sequelae. An improved understanding of brain preconditioning should help us identify innovative therapeutic strategies that prevent or at least reduce neuronal damage in susceptible patients. In this review, we focus on the experimental evidence of preconditioning in the brain and systematically survey the models used to develop paradigms for neuroprotection, and then discuss the clinical potential of brain preconditioning. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Stetler, R. Anne; Gan, Yu; Li, Peiying; Zhang, Feng; Chen, Jun; Zigmond, Michael J.; Gao, Yanqin] Fudan Univ, Shanghai Med Coll, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Stetler, R. Anne; Gan, Yu; Li, Peiying; Zhang, Feng; Chen, Jun; Zigmond, Michael J.; Gao, Yanqin] Fudan Univ, Shanghai Med Coll, Inst Brain Sci, Shanghai 200032, Peoples R China. [Stetler, R. Anne; Gan, Yu; Li, Peiying; Zhang, Feng; Hu, Xiaoming; Jing, Zheng; Chen, Jun; Zigmond, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Stetler, R. Anne; Gan, Yu; Li, Peiying; Zhang, Feng; Hu, Xiaoming; Jing, Zheng; Chen, Jun; Zigmond, Michael J.] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Stetler, R. Anne; Zhang, Feng; Hu, Xiaoming; Jing, Zheng; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Gao, YQ (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. EM yqgao@shmu.edu.cn RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417 FU National Institutes of Health/NINDS [NS36736, NS43802, NS56118, NS45048, NS070825]; VA Merit Review Grant; Chinese Natural Science Foundation [81020108021, 81171149, 81371306, 30870794, 81228008, 81271276]; VA Career Scientist Award; RK Mellon Endowed Chair from the University of Pittsburgh Medical Center; Changjiang Chair Professorship from the Chinese Ministry of Education; International Distinguished Professorship from the Chinese Ministry of Education [MS2011FDDX025] FX This work was supported by National Institutes of Health/NINDS Grants NS36736, NS43802, NS56118, and NS45048 (to JC) and NS070825 (to MZ and JC), the VA Merit Review Grant (to JC), and Chinese Natural Science Foundation grants 81020108021, 81171149, 81371306 and 30870794 (to YG); 81228008 (to JC); 81271276 (to FZ). J.C. is a recipient of the VA Career Scientist Award, the RK Mellon Endowed Chair from the University of Pittsburgh Medical Center, and the Changjiang Chair Professorship from the Chinese Ministry of Education. M.Z. is the recipient of the International Distinguished Professorship from the Chinese Ministry of Education (MS2011FDDX025). We thank Ms. Carol Culver for excellent editorial assistance and Ms. Pat Strickler for secretarial support. NR 415 TC 56 Z9 59 U1 3 U2 39 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD MAR PY 2014 VL 114 BP 58 EP 83 DI 10.1016/j.pneurobio.2013.11.005 PG 26 WC Neurosciences SC Neurosciences & Neurology GA AH1JQ UT WOS:000335876800004 PM 24389580 ER PT J AU Ellingson, LD Koltyn, KF Kim, JS Cook, DB AF Ellingson, Laura D. Koltyn, Kelli F. Kim, Jee-Seon Cook, Dane B. TI Does exercise induce hypoalgesia through conditioned pain modulation? SO PSYCHOPHYSIOLOGY LA English DT Article ID NOXIOUS INHIBITORY CONTROLS; BLOOD-PRESSURE; PHYSICAL-ACTIVITY; FIBROMYALGIA SYNDROME; ISOMETRIC-EXERCISE; UNITED-STATES; MUSCLE PAIN; ACCELEROMETER; ANALGESIA; MECHANISMS C1 [Ellingson, Laura D.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Ellingson, Laura D.; Koltyn, Kelli F.; Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA. [Kim, Jee-Seon] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA. RP Cook, DB (reprint author), Univ Wisconsin, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA. EM dcook@education.wisc.edu NR 48 TC 18 Z9 19 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD MAR PY 2014 VL 51 IS 3 BP 267 EP 276 PG 10 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA AA8OZ UT WOS:000331356100006 PM 24354707 ER PT J AU Wellinghoff, MA Bunchman, AM Dean, JC AF Wellinghoff, Molly A. Bunchman, Alison M. Dean, Jesse C. TI Gradual mechanics-dependent adaptation of medial gastrocnemius activity during human walking SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE dual-task walking; locomotion; motor adaptation; muscle activity ID MUSCLE-ACTIVITY; STEP FREQUENCY; PROLONGED WALKING; TENDON VIBRATION; MOTOR ADAPTATION; DOWNHILL WALKING; ACHILLES-TENDON; UPHILL WALKING; HUMAN MOVEMENT; SOLEUS MUSCLE AB While performing a simple bouncing task, humans modify their preferred movement period and pattern of plantarflexor activity in response to changes in system mechanics. Over time, the preferred movement pattern gradually adapts toward the resonant frequency. The purpose of the present experiments was to determine whether humans undergo a similar process of gradually adapting their stride period and plantarflexor activity after a change in mechanical demand while walking. Participants walked on a treadmill while we measured stride period and plantarflexor activity (medial gastrocnemius and soleus). Plantarflexor activity during stance was divided into a storage phase (30-65% stance) and a return phase (65-100% stance) based on when the Achilles tendon has previously been shown to store and return mechanical energy. Participants walked either on constant inclines (0%, 1%, 5%, 9%) or on a variable incline (0-1%) for which they were unaware of the incline changes. For variable-incline trials, participants walked under both single-task and dual-task conditions in order to vary the cognitive load. Both stride period and plantarflexor activity increased at steeper inclines. During single-task walking, small changes in incline were followed by gradual adaptation of storage-phase medial gastrocnemius activity. However, this adaptation was not present during dual-task walking, indicating some level of cognitive involvement. The observed adaptation may be the result of using afferent feedback in order to optimize the contractile conditions of the plantarflexors during the stance phase. Such adaptation could serve to improve metabolic economy but may be limited in clinical populations with disrupted proprioception. C1 [Wellinghoff, Molly A.; Bunchman, Alison M.; Dean, Jesse C.] Med Univ S Carolina, Div Phys Therapy, Coll Hlth Profess, Charleston, SC 29425 USA. [Dean, Jesse C.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Dean, JC (reprint author), 77 President St,MSC700, Charleston, SC 29425 USA. EM deaje@musc.edu OI Dean, Jesse/0000-0003-2034-4217 FU Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service [1IK2RX000750-01A1]; National Institute of Child Health and Human Development [1R21 HD-064964-01A1] FX This study was partially supported by the Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service through Grant 1IK2RX000750-01A1. This study was also partially supported by the National Institute of Child Health and Human Development through Grant 1R21 HD-064964-01A1. NR 62 TC 1 Z9 1 U1 1 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD MAR PY 2014 VL 111 IS 5 BP 1120 EP 1131 DI 10.1152/jn.00251.2013 PG 12 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA AG8LM UT WOS:000335669900022 PM 24335207 ER PT J AU Pessler, F Ogdie, AR Mayer, CT Kretzschmar, WW Dai, L Elsaman, AM Einhorn, E Krenn, V Schumacher, HR AF Pessler, Frank Ogdie, Alexis R. Mayer, Christian T. Kretzschmar, Warren W. Dai, Lie Elsaman, Ahmed M. Einhorn, Eugene Krenn, Veit Schumacher, H. Ralph TI Amyloid arthropathy associated with multiple myeloma: polyarthritis without synovial infiltration of CD20+or CD38+cells SO AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS LA English DT Article DE Amyloidosis; arthritis; B cells; multiple myeloma; plasma cells; synovitis ID WAR-VETERANS-ILLNESS; JOINT PAIN; DISEASE; ARTHRITIS AB Objectives: To describe histological, immunohistochemical and ultrastructural features of synovial biopsies of amyloid arthropathy associated with multiple myeloma (MM). Methods: Synovial biopsies from affected joints of two patients with MM and amyloid arthropathy were examined with light and electron microscopy, and immunohistochemically for expression of CD3, CD8, CD20, CD38, CD68, Ki-67 and vWF. Results were compared to values from osteoarthritis (OA, n=26), rheumatoid arthritis (RA, n=24) and normal (n=15) synovial membranes. Results: There was no or only mild lining hyperplasia. Vascular density was not elevated, and there were few Ki-67+ proliferating cells in the stroma. The Krenn synovitis score classified one specimen as "low-grade'' and one as "high-grade'' synovitis. CD68+ and CD3+ cells were the predominant mononuclear inflammatory cells, whereas CD20+ and CD38+ cells were absent from both synovial membrane and synovial fluid sediment. Electron microscopy demonstrated amyloid phagocytosis by synovial macrophages. In hierarchical clustering the two amyloid arthropathy specimens were more closely related to OA than to RA or normal synovium. Conclusions: This first detailed immunohistological analysis of MM-associated amyloid arthropathy suggests that it is a chronic synovitis that evolves despite the loss of humoral immunity seen in advanced MM. Instead, amyloid phagocytosis by synovial macrophages likely triggers and perpetuates local disease. C1 [Pessler, Frank; Mayer, Christian T.] TWINCORE Ctr Expt & Clin Infect Res, D-30625 Hannover, Germany. [Pessler, Frank; Elsaman, Ahmed M.] Helmholtz Ctr Infect Res, Braunschweig, Germany. [Ogdie, Alexis R.; Dai, Lie; Schumacher, H. Ralph] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Kretzschmar, Warren W.] Wellcome Trust Ctr Human Genet, Oxford, England. [Dai, Lie] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Rheumatol, Guangzhou 510275, Guangdong, Peoples R China. [Elsaman, Ahmed M.] Sohag Univ, Dept Rheumatol & Rehabil, Sohag, Egypt. [Einhorn, Eugene] Philadelphia VA Med Ctr, Dept Pathol, Philadelphia, PA USA. [Krenn, Veit] Ctr Histol Cytol & Mol Diagnost, Trier, Germany. [Schumacher, H. Ralph] Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA USA. RP Pessler, F (reprint author), TWINCORE Ctr Expt & Clin Infect Res, Feodor Lynen Str 7-9, D-30625 Hannover, Germany. EM frank.pessler@twincore.de OI Kretzschmar, Warren/0000-0002-2575-0807; Ogdie, Alexis/0000-0002-4639-0775 FU American College of Rheumatology/Research; Education Foundation Health Professional Graduate Student Research Preceptorship award; Wellcome Trust [09730/Z/11/Z]; German-Egyptian Scientific Projects (GESP) from the German Academic Exchange Service (DAAD) [51309219]; Ministry of Higher Education and Scientific Research of the Arab Republic of Egypt; Helmholtz Association FX C. T. Mayer was supported by an American College of Rheumatology/Research and Education Foundation Health Professional Graduate Student Research Preceptorship award. WWK is supported by a Wellcome Trust studentship (09730/Z/11/Z). AME was supported by German-Egyptian Scientific Projects (GESP) grant no. 51309219 from the German Academic Exchange Service (DAAD) and the Ministry of Higher Education and Scientific Research of the Arab Republic of Egypt. The study was supported in part by funds from the Helmholtz Association (Programs in Infection and Immunity and in Individualized Medicine, iMed). The study was approved by the Institutional Review Board of the Philadelphia VA Medical Center as part of a larger study of synovial histopathology. The need to obtain informed consent was waived due to the use of anonymized data. NR 21 TC 1 Z9 2 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1350-6129 EI 1744-2818 J9 AMYLOID JI Amyloid-J. Protein Fold. Disord. PD MAR PY 2014 VL 21 IS 1 BP 28 EP 34 DI 10.3109/13506129.2013.862229 PG 7 WC Biochemistry & Molecular Biology; Medicine, General & Internal; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; General & Internal Medicine; Research & Experimental Medicine GA AG9UB UT WOS:000335764200005 PM 24286442 ER PT J AU Belayev, LY Palevsky, PM AF Belayev, Linda Y. Palevsky, Paul M. TI The link between acute kidney injury and chronic kidney disease SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE chronic kidney disease; epidemiology; acute kidney injury ID ACUTE-RENAL-FAILURE; ACUTE TUBULAR-NECROSIS; CHRONIC DIALYSIS; FOLLOW-UP; RISK; PROGRESSION; DEATH; OUTCOMES; INCREASES; FIBROSIS AB Purpose of review It has been argued that the existing epidemiologic data are insufficient to establish a causal link between acute kidney injury (AKI) and subsequent development or progression of chronic kidney disease (CKD), especially given that risk factors for the development of AKI overlap with those for progressive CKD. Recent findings Multiple studies published over the past 5 years have demonstrated a strong epidemiologic association between episodes of AKI and subsequent development or progression of CKD, including evidence that severity of AKI and repeated episodes of AKI are associated with increased risk of CKD. In addition, animal models have provided evidence for a biological basis linking episodes of AKI with CKD. The preponderance of data support a causal link between episodes of AKI and subsequent development or progression of CKD. C1 [Belayev, Linda Y.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Room 7E123 111F U,Univ Dr, Pittsburgh, PA 15240 USA. EM Palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 FU NIDDK NIH HHS [T32 DK061296] NR 35 TC 17 Z9 18 U1 3 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 EI 1473-6543 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD MAR PY 2014 VL 23 IS 2 BP 149 EP 154 DI 10.1097/01.mnh.0000441051.36783.f3 PG 6 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA AG1FF UT WOS:000335159800009 PM 24384553 ER PT J AU Nadeau, KJ Mather, KJ Arslanian, SA Buchanan, TA Caprio, S Edelstein, SL Ehrmann, DA Savage, PJ Kahn, SE Mokhlesi, B Van Cauter, E Montgomery, BK Palmer, J Utzschneider, K Mather, KJ Chisholm, R Hannon, T Nadeau, KJ Zeitler, P Arslanian, SA Caprio, S Buchanan, TA Xiang, A Edelstein, SL Lachin, JM Savage, PJ AF Nadeau, Kristen J. Mather, Kieren J. Arslanian, Silva A. Buchanan, Thomas A. Caprio, Sonia Edelstein, Sharon L. Ehrmann, David A. Savage, Peter J. Kahn, Steven E. Mokhlesi, Babak Van Cauter, Eve Montgomery, Brenda K. Palmer, Jerry Utzschneider, Kristina Mather, Kieren J. Chisholm, Robin Hannon, Tamara Nadeau, Kristen J. Zeitler, Phil Arslanian, Silva A. Caprio, Sonia Buchanan, Thomas A. Xiang, Anny Edelstein, Sharon L. Lachin, John M. Savage, Peter J. CA RISE Consortium TI Restoring Insulin Secretion (RISE): Design of Studies of beta-Cell Preservation in Prediabetes and Early Type 2 Diabetes Across the Life Span SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; STYLE INTERVENTION; GLYCEMIC CONTROL; POSTPRANDIAL HYPERGLYCEMIA; PREVENTION PROGRAM; BARIATRIC SURGERY; CONTROLLED-TRIAL; HISPANIC WOMEN; FOLLOW-UP; METFORMIN AB OBJECTIVEThe Restoring Insulin Secretion (RISE) Consortium is testing interventions designed to preserve or improve -cell function in prediabetes or early type 2 diabetes.RESEARCH DESIGN AND METHODS-Cell function is measured using hyperglycemic clamps and oral glucose tolerance tests (OGTTs). The adult medication protocol randomizes participants to 12 months of placebo, metformin alone, liraglutide plus metformin, or insulin (3 months) followed by metformin (9 months). The pediatric medication protocol randomizes participants to metformin or insulin followed by metformin. The adult surgical protocol randomizes participants to gastric banding or metformin (24 months). Adult medication protocol inclusion criteria include fasting plasma glucose 95-125 mg/dL (5.3-6.9 mmol/L), OGTT 2-h glucose 140 mg/dL (7.8 mmol/L), HbA(1c) 5.8-7.0% (40-53 mmol/mol), and BMI 25-40 kg/m(2). Adult surgical protocol criteria are similar, except for fasting plasma glucose 90 mg/dL (5.0 mmol/L), BMI 30-40 kg/m(2), HbA(1c) <7.0% (<53 mmol/mol), and diabetes duration <12 months. Pediatric inclusion criteria include fasting plasma glucose 90 mg/dL (5.0 mmol/L), 2-h glucose 140 mg/dL (7.8 mmol/L), HbA(1c) 8.0% (64 mmol/mol), BMI >85th percentile and 50 kg/m(2), 10-19 years of age, and diabetes <6 months.RESULTSPrimary outcomes are clamp-derived glucose-stimulated C-peptide secretion and maximal C-peptide response to arginine during hyperglycemia. Measurements are made at baseline, after 12 months on treatment, and 3 months after treatment withdrawal (medication protocols) or 24 months postintervention (surgery protocol). OGTT-derived measures are also obtained at these time points.CONCLUSIONSRISE is determining whether medication or surgical intervention strategies can mitigate progressive -cell dysfunction in adults and youth with prediabetes or early type 2 diabetes. C1 [Nadeau, Kristen J.; Mather, Kieren J.; Chisholm, Robin; Hannon, Tamara] Univ Colorado Denver, Denver, CO 80202 USA. [Nadeau, Kristen J.; Mather, Kieren J.; Chisholm, Robin; Hannon, Tamara] Childrens Hosp Colorado, Colorado Springs, CO USA. [Mather, Kieren J.; Montgomery, Brenda K.; Palmer, Jerry; Utzschneider, Kristina] Indiana Univ, Sch Med, Bloomington, IN 47405 USA. [Arslanian, Silva A.; Nadeau, Kristen J.; Zeitler, Phil] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA 15260 USA. [Buchanan, Thomas A.; Caprio, Sonia] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA. [Caprio, Sonia; Arslanian, Silva A.] Yale Univ, Dept Pediat, New Haven, CT 06520 USA. [Edelstein, Sharon L.; Buchanan, Thomas A.; Xiang, Anny; Edelstein, Sharon L.; Lachin, John M.; Savage, Peter J.] George Washington Univ, Ctr Biostat, Washington, DC 20052 USA. [Ehrmann, David A.] Univ Chicago, Clin Res Ctr, Chicago, IL 60637 USA. [Savage, Peter J.; Kahn, Steven E.; Mokhlesi, Babak; Van Cauter, Eve] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Savage, Peter J.; Kahn, Steven E.; Mokhlesi, Babak; Van Cauter, Eve] Univ Washington, Seattle, WA 98195 USA. [Caprio, Sonia] Kaiser Permanente So Calif, Los Angeles, CA USA. RP Edelstein, SL (reprint author), Univ Colorado Denver, Denver, CO 80202 USA. EM rise@bsc.gwu.edu FU NIDDK [Chicago DK-094431, Denver DK-094467, Indiana DK-094438, Los Angeles DK-094430, Seattle DK-09440]; Department of Veterans Affairs FX RISE is supported by grants from the NIDDK (Chicago DK-094431, Denver DK-094467, Indiana DK-094438, Los Angeles DK-094430, and Seattle DK-09440) and the Department of Veterans Affairs. NR 41 TC 8 Z9 8 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2014 VL 37 IS 3 BP 780 EP 788 DI 10.2337/dc13-1879 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AB3RT UT WOS:000331708600035 ER PT J AU Balentine, CJ Naik, AD Robinson, CN Petersen, NJ Chen, GJ Berger, DH Anaya, DA AF Balentine, Courtney J. Naik, Aanand D. Robinson, Celia N. Petersen, Nancy J. Chen, G. John Berger, David H. Anaya, Daniel A. TI Association of High-Volume Hospitals With Greater Likelihood of Discharge to Home Following Colorectal Surgery SO JAMA SURGERY LA English DT Article ID QUALITY-OF-CARE; INPATIENT SURGERY; UNITED-STATES; MORTALITY; COMPLICATIONS; OUTCOMES; CANCER; IMPACT; COLECTOMY; SURVIVAL AB IMPORTANCE Discharge disposition is a patient-centered quality metric that reflects differences in quality of life and recovery following surgery. The effect of hospital volume on quality of recovery measured by rates of successful discharge to home remains unclear. OBJECTIVE To test the hypothesis that patients having colorectal surgery at high-volume hospitals would more likely be discharged to home rather than discharged to skilled rehabilitation facilities to complete recovery. DESIGN, SETTING, AND PARTICIPANTS Longitudinal analysis of 2008 hospital inpatient data to identify patients undergoing colorectal surgery who survived to discharge. The setting was the Nationwide Inpatient Sample, the largest all-payer inpatient care database, containing data from more than 1000 hospitals. Participants were 280 644 patients (>= 18 years) who underwent colorectal resections for benign or malignant disease and survived to discharge. MAIN OUTCOMES AND MEASURES The primary end point was discharge to home (with or without home health care) vs discharge to skilled facilities (skilled nursing, short-term recovery, or rehabilitation hospitals or other institutions). The secondary end point was discharge to home with home health care rather than to a skilled facility for patients with postdischarge care needs. Multiple logistic regression using robust standard errors was used to compute the odds ratios of each outcome based on hospital volume, while adjusting for other important variables. RESULTS The odds of discharge to home vs discharge to skilled facilities were significantly greater in high-volume hospitals compared with low-volume hospitals (odds ratio, 2.09; 95% CI, 1.70-2.56), with an absolute increase of 9%. For patients with postdischarge care needs, high-volume hospitals were less likely than low-volume hospitals to use skilled facilities rather than home health care (odds ratio, 0.35; 95% CI, 0.27-0.45), with an absolute difference of 10%. CONCLUSIONS AND RELEVANCE Patients having colorectal surgery at high-volume hospitals are significantly more likely to recover and return home after surgery than individuals having operations at low-volume hospitals. This study is the first step in a process of identifying which features of high-volume hospitals contribute toward desirable outcomes. Efforts to identify the reasons for improved recovery at high-volume hospitals can help lower-volume hospitals adopt beneficial practices. C1 [Balentine, Courtney J.; Naik, Aanand D.; Petersen, Nancy J.; Chen, G. John; Berger, David H.; Anaya, Daniel A.] Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Balentine, Courtney J.; Robinson, Celia N.; Berger, David H.; Anaya, Daniel A.] DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Balentine, Courtney J.; Berger, David H.; Anaya, Daniel A.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Naik, Aanand D.; Chen, G. John] Baylor Coll Med, Dept Med, Div Geriatr, Houston, TX 77030 USA. [Naik, Aanand D.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. RP Anaya, DA (reprint author), Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Room 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM danaya@bcm.edu FU National Institute on Aging [K23AG027144]; Doris Duke Charitable Foundation Clinical Scientist Development Award; Baylor College of Medicine Comprehensive Cancer Training Program Grant Cancer Prevention & Research Institute of Texas [101499] FX Dr Naik is supported by grant K23AG027144 from the National Institute on Aging and by a Doris Duke Charitable Foundation Clinical Scientist Development Award. Dr Robinson has received support from Baylor College of Medicine Comprehensive Cancer Training Program Grant Cancer Prevention & Research Institute of Texas, Research Project 101499. No other disclosures were reported. NR 26 TC 16 Z9 16 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD MAR PY 2014 VL 149 IS 3 BP 244 EP 251 DI 10.1001/jamasurg.2013.3838 PG 8 WC Surgery SC Surgery GA AF3JX UT WOS:000334609400007 PM 24430092 ER PT J AU Lehavot, K Stappenbeck, CA Luterek, JA Kaysen, D Simpson, TL AF Lehavot, Keren Stappenbeck, Cynthia A. Luterek, Jane A. Kaysen, Debra Simpson, Tracy L. TI Gender Differences in Relationships Among PTSD Severity, Drinking Motives, and Alcohol Use in a Comorbid Alcohol Dependence and PTSD Sample SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE alcohol dependence; posttraumatic stress disorder; dual diagnosis; drinking motives; gender differences ID POSTTRAUMATIC-STRESS-DISORDER; NATIONALLY REPRESENTATIVE SAMPLE; SEXUAL ASSAULT SURVIVORS; DSM-IV ALCOHOL; PSYCHIATRIC-DISORDERS; UNITED-STATES; SUBSTANCE USE; PSYCHOMETRIC PROPERTIES; VULNERABILITY MODEL; ANXIETY DISORDERS AB Alcohol dependence (AD) and posttraumatic stress disorder (PTSD) are highly prevalent and comorbid conditions associated with a significant level of impairment. Little systematic study has focused on gender differences specific to individuals with both AD and PTSD. The current study examined gender-specific associations between PTSD symptom severity, drinking to cope (i.e., reduce negative affect), drinking for enhancement (i.e., increase positive affect), and average alcohol use in a clinical sample of men (n = 46) and women (n = 46) with comorbid AD and PTSD. Results indicated that PTSD symptoms were highly associated with drinking-to-cope motives for both men and women, but with greater drinking for enhancement motives for men only. Enhancement motives were positively associated with average alcohol quantity for both men and women, but coping motives were significantly associated with average alcohol quantity for women only. These findings suggest that for individuals with comorbid AD and PTSD, interventions that focus on reducing PTSD symptoms are likely to lower coping motives for both genders, and targeting coping motives is likely to result in decreased drinking for women but not for men, whereas targeting enhancement motives is likely to lead to reduced drinking for both genders. C1 [Lehavot, Keren] VA Puget Sound Hlth Care Syst, Adv Fellowship Program Mental Illness Res & Treat, Seattle, WA USA. [Lehavot, Keren; Stappenbeck, Cynthia A.; Luterek, Jane A.; Kaysen, Debra; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Luterek, Jane A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subs Abuse Treatment & Educ, Seattle, WA USA. RP Lehavot, K (reprint author), 1660 S Columbian Way, Seattle, WA 98108 USA. EM klehavot@uw.edu FU NIAAA NIH HHS [R21 AA017130] NR 78 TC 15 Z9 15 U1 5 U2 8 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD MAR PY 2014 VL 28 IS 1 BP 42 EP 52 DI 10.1037/a0032266 PG 11 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA AF4OR UT WOS:000334693600005 PM 23647151 ER PT J AU Kaysen, D Atkins, DC Simpson, TL Stappenbeck, CA Blayney, JA Lee, CM Larimer, ME AF Kaysen, Debra Atkins, David C. Simpson, Tracy L. Stappenbeck, Cynthia A. Blayney, Jessica A. Lee, Christine M. Larimer, Mary E. TI Proximal Relationships Between PTSD Symptoms and Drinking Among Female College Students: Results From a Daily Monitoring Study SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE posttraumatic stress disorder; PTSD; college students; victimization; alcohol use ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-USE DISORDERS; SEXUAL EXPERIENCES SURVEY; SUBSTANCE USE; SELF-MEDICATION; BINGE DRINKING; YOUNG-ADULTS; ATTENDING PEERS; NEGATIVE AFFECT; WITHIN-PERSON AB Self-medication has been theorized to explain comorbidity between posttraumatic stress disorder (PTSD) and drinking, whereupon problem drinking develops in order to modulate negative affect and ameliorate PTSD symptoms. Daily monitoring methodologies may help refine our understanding of proximal relations between PTSD, affect, and alcohol use. One hundred thirty-six female college drinkers with a past history of sexual victimization and 38 female college drinkers with no past trauma history completed electronic monitoring of PTSD symptoms, affect, alcohol use, and alcohol cravings, daily for 4 weeks. A two-part mixed hurdle model was used to examine likelihood of drinking and amount of alcohol consumed on drinking days. We found significant relationships between daily PTSD symptoms, affect, and drinking. On days women experienced more intrusive and behavioral avoidance symptoms of PTSD, they experienced stronger urges to drink and were more likely to drink on that day. On days in which women experienced more negative affect than their average, they experienced stronger urges to drink, whereas on days in which women experienced more of the dysphoric symptoms associated with PTSD than their average, they drank less. On days with higher positive affect, women reported stronger urges to drink and were more likely to drink. Results suggest the need to examine both aspects of affect and specific PTSD symptoms as they may differentially predict drinking behavior. Differences in the ways in which PTSD symptoms and affect influence drinking suggest that interventions more specifically address the function of drinking behaviors in reducing alcohol use among college women. C1 [Kaysen, Debra; Atkins, David C.; Stappenbeck, Cynthia A.; Blayney, Jessica A.; Lee, Christine M.; Larimer, Mary E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Kaysen, Debra; Larimer, Mary E.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Kaysen, Debra] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Kaysen, D (reprint author), Dept Psychiat & Behav Sci, 1100 NE 45th St,Suite 300,UW Box 354944, Seattle, WA 98195 USA. EM dkaysen@u.washington.edu OI Atkins, David/0000-0002-5781-9880 FU NIAAA NIH HHS [R01 AA020252, R01AA020252, R21 AA016211, R21AA016211, T32 AA007455, T32AA007455] NR 89 TC 21 Z9 21 U1 5 U2 12 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD MAR PY 2014 VL 28 IS 1 BP 62 EP 73 DI 10.1037/a0033588 PG 12 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA AF4OR UT WOS:000334693600007 PM 23915369 ER PT J AU Tsai, AG Hosokawa, P Schoen, J Prochazka, AV AF Tsai, Adam G. Hosokawa, Patrick Schoen, Jonathan Prochazka, Allan V. TI Frequency of laboratory testing among gastric bypass patients SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Bariatric surgery; Obesity surgery; Quality of care; Nutrition assessment; Clinical care ID NUTRITIONAL DEFICIENCIES; VITAMIN DEFICIENCY; BARIATRIC SURGERY AB Background: Long-term laboratory monitoring is recommended. after gastric bypass surgery to prevent the development of micronutrient deficiencies. The objective of this study was to characterize patterns of laboratory monitoring after surgery. Methods: We used a large insurance claims database to assess the frequency of laboratory testing after gastric bypass surgery. We assessed the tests recommended by an expert panel on bariatric surgery, including tests recommended routinely as well as second-line tests for specific clinical scenarios (e.g., tests for anemia when iron deficiency is not present). Results: With the exception of testing for diabetes, most gastric bypass patients did not undergo routine laboratory testing in the first year after their surgery, ranging from 54% (electrolytes) to 95% (zinc). However, for first-line tests, significantly more gastric bypass patients underwent testing in the first year,compared with gastric banding patients. Differences in testing frequency between gastric bypass and gastric banding patients were larger for tests of micronutrient deficiency than for common metabolic panels and complete blood counts. For second-line tests, much smaller percentages of both groups of patients underwent testing, either in the first year or after year 1. Conclusion: Patients undergoing gastric bypass do not routinely undergo recommended laboratory tests, although they are undergoing more monitoring than gastric banding patients. Efforts must be made by patients, surgeons, and primary care providers to ensure that routine testing is done to lower the risk of adverse health outcomes. (Surg Obes Relat Dis 2014;10:340-347.) (C) 2014 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved. C1 [Tsai, Adam G.; Prochazka, Allan V.] Univ Colorado, Div Gen Internal Med, Aurora, CO 80045 USA. [Tsai, Adam G.] Univ Colorado, Anschutz Ctr Hlth & Wellness, Aurora, CO 80045 USA. [Hosokawa, Patrick] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO 80045 USA. [Schoen, Jonathan] Univ Colorado, Dept Surg, Aurora, CO 80045 USA. [Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA. RP Tsai, AG (reprint author), Univ Colorado, Sch Med, Anschutz Hlth & Wellness Bldg, Aurora, CO 80045 USA. EM adam.tsai@ucdenver.edu NR 17 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD MAR-APR PY 2014 VL 10 IS 2 BP 340 EP 345 DI 10.1016/j.soard.2013.09.005 PG 6 WC Surgery SC Surgery GA AF3XW UT WOS:000334647000029 PM 24355327 ER PT J AU DeYoung, K Wentzel, JL Schlosser, RJ Nguyen, SA Soler, ZM AF DeYoung, Kristen Wentzel, Jennifer L. Schlosser, Rodney J. Nguyen, Shaun A. Soler, Zachary M. TI Systematic review of immunotherapy for chronic rhinosinusitis SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Review ID ALLERGIC FUNGAL SINUSITIS; GRASS-POLLEN IMMUNOTHERAPY; SUBCUTANEOUS IMMUNOTHERAPY; FOLLOW-UP; RHINITIS; DISEASE; ASTHMA AB Background: Immunotherapy (IT) has been well established as an effective treatment for allergic rhinitis (AR), but little is known about the benefits of IT on clinical outcomes of comorbid chronic rhinosinusitis (CRS). The goal of this publication is to systematically review the literature regarding outcomes of IT in patients with atopic CRS. Methods: A systematic review of the literature was conducted including studies that assessed the efficacy of IT on clinical outcome measures in CRS including without polyp, with polyp, and allergic fungal rhinosinusitis subgroups. Excluded articles were those only reporting outcomes specific to asthma or AR. Results: Seven studies met the inclusion and exclusion criteria for this review, none of which were randomized controlled trials. Generally, symptom scores improved in patients treated with IT when compared with baseline data and control patients. Objective endoscopic exam measures improved with IT treatment in short-term studies. Significant improvements were observed in radiographic assessments, and there was a decreased necessity for revision surgery, interventional office visits, and intranasal and oral steroid use. Conclusion: Conclusions are limited by the paucity of available data on the efficacy of IT for treating CRS-specific outcome measures. There is weak evidence to support the use of IT as an adjunctive treatment in CRS patients, particularly in the postoperative period. C1 [DeYoung, Kristen; Wentzel, Jennifer L.; Schlosser, Rodney J.; Nguyen, Shaun A.; Soler, Zachary M.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Soler, ZM (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM solerz@musc.edu NR 24 TC 9 Z9 10 U1 1 U2 5 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD MAR-APR PY 2014 VL 28 IS 2 BP 145 EP 150 DI 10.2500/ajra.2014.28.4019 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA AE5TL UT WOS:000334052100017 PM 24717953 ER PT J AU Estevez, AO Morgan, KL Szewczyk, NJ Gems, D Estevez, M AF Estevez, Annette O. Morgan, Kathleen L. Szewczyk, Nathaniel J. Gems, David Estevez, Miguel TI The neurodegenerative effects of selenium are inhibited by FOX() and PINK1/PTEN regulation of insulin/insulin-like growth factor signaling in Caenorhabditis elegans SO NEUROTOXICOLOGY LA English DT Article DE Selenium; Neurodegeneration; Insulin/insulin-like signaling; PTEN; PINKI; Amyotrophic lateral sclerosis ID AMYOTROPHIC-LATERAL-SCLEROSIS; COLORECTAL-CANCER CELLS; AGE-1 PI3 KINASE; SUPEROXIDE-DISMUTASE; C-ELEGANS; LIFE-SPAN; OXIDATIVE STRESS; SODIUM SELENITE; TRANSCRIPTION FACTOR; INSULIN-RESISTANCE AB Exposures to high levels of environmental selenium have been associated with motor neuron disease in both animals and humans and high levels of selenite have been identified in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS). We have shown previously that exposures to high levels of sodium selenite in the environment of Caenorhabditis elegans adult animals can induce neurodegeneration and cell loss resulting in motor deficits and death and that this is at least partially caused by a reduction in cholinergic signaling across the neuromuscular junction. Here we provide evidence that reduction in insulin/insulin-like (IIS) signaling alters response to high dose levels of environmental selenium which in turn can regulate the IIS pathway. Most specifically we show that nuclear localization and thus activation of the OAF-16/forkhead box transcription factor occurs in response to selenium exposure although this was not observed in motor neurons of the ventral cord. Yet, tissue specific expression and generalized overexpression of DAF-16 can partially rescue the neurodegenerative and behavioral deficits observed with high dose selenium exposures in not only the cholinergic, but also the GABAergic motor neurons. In addition, two modifiers of IIS signaling, PTEN (phosphatase and tensin homolog, deleted on chromosome 10) and PINK1 (PTEN-induced putative kinase I) are required for the cellular antioxidant reduced glutathione to mitigate the selenium-induced movement deficits. Studies have suggested that environmental exposures can lead to ALS or other neurological diseases and this model of selenium-induced neurodegeneration developed in a genetically tractable organism provides a tool for examining the combined roles of genetics and environment in the neuro-pathologic disease process. (C) 2014 The Authors. Published by Elsevier Inc. All rights reserved. C1 [Estevez, Annette O.; Estevez, Miguel] Univ Arizona, Coll Med, Dept Neurol, Tucson, AZ 85724 USA. [Morgan, Kathleen L.; Estevez, Miguel] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. [Szewczyk, Nathaniel J.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA. [Gems, David] UCL, Inst Hlth Ageing, London WC1E 6BT, England. [Gems, David] UCL, Dept Genet Evolut & Environm, London WC1E 6BT, England. RP Estevez, AO (reprint author), Neurometrica, 1900 Millrace Dr,Suite 113N, Eugene, OR 97403 USA. EM neurometrica@gmail.com; kathleen@immunetrics.com; mbzns3@exmail.nottingham.ac.uk; david.gems@ucl.ac.uk; m_estevez@yahoo.com OI Estevez, Annette/0000-0001-8840-1340 FU Jim Himelic Foundation; Southern Arizona Foundation; Keatings Institute; National Institutes of Environmental Health Sciences [R21-ES012305]; Career Development Award [ME] provided through the Office of Research and Development, Department of Veterans Affairs; NIH National Center for Research Resources (NCRR); International C. elegans Gene Knockout Consortium FX This research was supported by grants from the Jim Himelic Foundation (ME), Southern Arizona Foundation (ME), Keatings Institute (ME), National Institutes of Environmental Health Sciences [R21-ES012305 to AE and ME], and a Career Development Award [ME] provided through the Office of Research and Development, Department of Veterans Affairs. Some nematode strains used in this work were provided by the Caenorhabditis Genetics Center, which is funded by the NIH National Center for Research Resources (NCRR) and the International C. elegans Gene Knockout Consortium. NR 114 TC 8 Z9 8 U1 3 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X EI 1872-9711 J9 NEUROTOXICOLOGY JI Neurotoxicology PD MAR PY 2014 VL 41 BP 28 EP 43 DI 10.1016/j.neuro.2013.12.012 PG 16 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA AE6HW UT WOS:000334092200004 PM 24406377 ER PT J AU Shaikh, H Laghi, F AF Shaikh, Hameeda Laghi, Franco TI Eating on Noninvasive Ventilation SO CRITICAL CARE MEDICINE LA English DT Editorial Material DE chronic obstructive pulmonary disease; noninvasive ventilation; nutrition; respiratory failure; swallowing ID OBSTRUCTIVE PULMONARY-DISEASE; COORDINATION; VOLUME; RESPIRATION; TUBE C1 [Shaikh, Hameeda] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Pulm & Crit Care Sect, Hines, IL 60141 USA. [Laghi, Franco] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. [Laghi, Franco] Loyola Univ, Div Pulm & Crit Care, Dept Med, Maywood, IL 60153 USA. RP Shaikh, H (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Pulm & Crit Care Sect, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 15 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2014 VL 42 IS 3 BP 737 EP 738 DI 10.1097/CCM.0000000000000002 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA AA9AX UT WOS:000331387200062 PM 24534964 ER PT J AU Hansen, L Leo, MC Chang, MF Zucker, BL Sasaki, A AF Hansen, Lissi Leo, Michael C. Chang, Michael F. Zucker, Betsy L. Sasaki, Anna TI Pain and Self-Care Behaviours in Adult Patients with End-Stage Liver Disease: A longitudinal description SO JOURNAL OF PALLIATIVE CARE LA English DT Article DE palliative care; survival time; simple prognostic scores ID QUALITY-OF-LIFE; INTEGRATING PALLIATIVE CARE; CANCER PAIN; PSYCHOLOGICAL DISTRESS; TRANSPLANT CANDIDATES; MODEL; ACUPUNCTURE; MEDICATIONS; CIRRHOSIS; SEVERITY AB This prospective descriptive study investigated pain characteristics in 20 outpatients with end-stage liver disease (ESLD) who were approaching the end of life, described variability in pain between and within patients, and described the pharmacological and nonpharmacological pain management strategies used. The instruments we utilized were the Brief Pain Inventory (BPI) and the self-care behaviour (SCB) log for pain. Data were collected once a month over a six-month period. BPI severity of, and interference from pain mean scores ranged from 5.52 to 6.03 and 5.36 to 6.64, respectively. The top three pain-relieving behaviours reported by patients were "taking pain medication," "taking a nap," and "asking for help." Pain medication intake differed between patients who were pursuing a liver transplant and those who were not eligible for one. If we are to effectively improve care for ESLD patients, it is essential that we understand the ways in which these patients experience pain and the pain management strategies they employ. C1 [Hansen, Lissi] Oregon Hlth & Sci Univ, Sch Nursing, SN ORD, Portland, OR 97239 USA. [Leo, Michael C.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. [Chang, Michael F.; Zucker, Betsy L.; Sasaki, Anna] Portland VA Med Ctr, Portland, OR USA. [Sasaki, Anna] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Hansen, L (reprint author), Oregon Hlth & Sci Univ, Sch Nursing, SN ORD, 3455 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM hansenli@ohsu.edu FU National Institute of Nursing Research, National Institutes of Health (NIH) [R03 NR010614] FX Special thanks go to the patients who participated in the study and to Dr. Christine A. Miaskowski at the University of California, San Francisco, for giving us permission to use the SCB log for pain. This study was supported by research grant R03 NR010614 from the National Institute of Nursing Research, National Institutes of Health (NIH). NR 44 TC 0 Z9 0 U1 0 U2 11 PU CENTRE RECHERCHE INSTITUT UNIV GERIATRIE MONTREAL PI MONTREAL PA 4565 CHEMIN QUEEN MARY, MONTREAL, QUEBEC H3W 1W5, CANADA SN 0825-8597 J9 J PALLIAT CARE JI J. Palliative Care PD SPR PY 2014 VL 30 IS 1 BP 32 EP 40 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AE2HW UT WOS:000333794900005 PM 24826441 ER PT J AU Greene, M Steinman, MA McNicholl, IR Valcour, V AF Greene, Meredith Steinman, Michael A. McNicholl, Ian R. Valcour, Victor TI Polypharmacy, Drug Drug Interactions, and Potentially Inappropriate Medications in Older Adults with Human Immunodeficiency Virus Infection SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE polypharmacy; HIV infection; drug interactions; inappropriate prescribing ID HIV-INFECTION; ANTIRETROVIRAL THERAPY; UNITED-STATES; INDIVIDUALS; COHORT; RISK; MEN; PREVALENCE AB ObjectivesTo describe the frequency of medication-related problems in older adults with human immunodeficiency virus (HIV) infection. DesignRetrospective chart review. SettingCommunity. ParticipantsHIV-positive individuals aged 60 and older and age- and sex-matched HIV-negative individuals. MeasurementsTotal number of medications, potentially inappropriate medications (PIMs) according to the modified Beers Criteria, anticholinergic drug burden according to the Anticholinergic Risk Scale (ARS), and drug-drug interactions using the Lexi-Interact online drug interactions database. ResultsOf 89 HIV-positive participants, most were Caucasian (91%) and male (94%), with a median age of 64 (range 60-82). Common comorbidities included hyperlipidemia, hypertension, and depression. Participants were taking a median of 13 medications (range 2-38), of which only a median of four were antiretrovirals. At least one PIM was prescribed in 46 participants (52%). Sixty-two (70%) participants had at least one Category D (consider therapy modification) drug-drug interaction, and 10 (11%) had a Category X (avoid combination) interaction. One-third of these interactions were between two nonantiretroviral medications. Fifteen participants (17%) had an ARS score of 3 or greater. In contrast, HIV-negative participants were taking a median of six medications, 29% had at least one PIM, and 4% had an ARS score of 3 or greater (P<.05 for each comparison, except P=.07 for anticholinergic burden). ConclusionHIV-positive older adults have a high frequency of medication-related problems, of which a large portion is due to medications used to treat comorbid diseases. These medication issues were substantially higher than HIV-negative participants. Attention to the principles of geriatric prescribing is needed as this population ages in order to minimize complications from multiple medication use. C1 [Greene, Meredith; Steinman, Michael A.; Valcour, Victor] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Greene, Meredith; Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA. [McNicholl, Ian R.] Univ Calif San Francisco, San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA USA. [McNicholl, Ian R.] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. [Valcour, Victor] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. RP Greene, M (reprint author), San Francisco VA Med Ctr, 4150 Clement St,UCSF Box VA-181G, San Francisco, CA 94121 USA. EM meredith.greene@ucsf.edu FU ADRC [K23-AG-032872, P50 AG023501]; UCSF CFAR [P30-AI027763]; UCSF GCRC [UL1 RR024131]; Larry L. Hillblom Foundation; AIDS Research Institute at UCSF; National institutes of Health (NTH) [NIA T32-AG00212]; S.D. Bechtel, Jr. Foundation, Program for the Aging Century; National Institute on Aging; American Federation for Aging Research [1K23-AG030999]; NIH [AG032872]; NIH, University of California at San Francisco-Gladstone Institute of Virology and Immunology Center for AIDS Research [P30-AI027763] FX This work was funded by K23-AG-032872, P50 AG023501 (ADRC, PI: Bruce Miller), P30-AI027763 (UCSF CFAR), UL1 RR024131 (UCSF GCRC), the Larry L. Hillblom Foundation, and the AIDS Research Institute at UCSF. Dr. Greene receives salary support through National institutes of Health (NTH) research training grant NIA T32-AG00212 and has received research funding from the S.D. Bechtel, Jr. Foundation, Program for the Aging Century. Dr. Steinman receives funding from the National Institute on Aging and the American Federation for Aging Research (1K23-AG030999). Dr. Valcour receives research support from NIH, including salary support for work related to HIV and aging (AG032872). Drs. Greene and Valcour receive research funding from the NIH, University of California at San Francisco-Gladstone Institute of Virology and Immunology Center for AIDS Research (P30-AI027763). NR 35 TC 16 Z9 16 U1 5 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 IS 3 BP 447 EP 453 DI 10.1111/jgs.12695 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AC8HJ UT WOS:000332773800005 PM 24576251 ER PT J AU Feng, WG Chumley, P Allon, M George, J Scott, DW Patel, RP Litovsky, S Jaimes, EA AF Feng, Wenguang Chumley, Phillip Allon, Michael George, James Scott, David W. Patel, Rakesh P. Litovsky, Silvio Jaimes, Edgar A. TI The Transcription Factor E26 Transformation-Specific Sequence-1 Mediates Neointima Formation in Arteriovenous Fistula SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID VASCULAR ACCESS; ANGIOTENSIN-II; FACTOR ETS-1; HEMODIALYSIS-PATIENTS; INTIMAL HYPERPLASIA; GENE-EXPRESSION; MESANGIAL CELLS; INCREASED RISK; DNA-BINDING; MORTALITY AB Hemodialysis vascular access dysfunction contributes to increased morbidity and mortality in hemodialysis patients. Arteriovenous fistula (AVF) is the preferred type of vascular access for hemodialysis but has high rates of dysfunction, in part because of excessive neointima formation. The transcription factor E26 transformation-specific sequence-1 (ETS-1) is a mediator of proinflammatory responses in hypertension and endovascular injury. We examined the role of ETS-1 in the formation of neointima in AVF. Right carotid artery to internal jugular vein fistulas were created in C57BL/6 mice and assigned to treatment with an ETS-1-dominant negative peptide (ETS-DN), an inactive mutant peptide (ETS-MU), or vehicle (n=6 per group). After 7 and 21 days, AVFs or contralateral internal jugular veins were processed for PCR, immunofluorescence, immunohistochemistry, and morphometry. In AVFs, ETS-1 mRNA increased 2.5-fold at 7 days and 4-fold at 21 days. By immunofluorescence, we confirmed increased expression of ETS-1 predominantly in the neointima and overlying endothelium. Similarly, ETS-1 expression increased in human AVFs compared with normal veins. In mice, ETS-DN, but not ETS-MU, reduced neointima formation at days 7 and 21 and reduced the expression of nitric oxide synthase 2, NADPH oxidase (NOX) 2, NOX4, E-selectin, and monocyte chemotactic protein-1. Shear stress increased ETS-1 phosphorylation in human umbilical vein cells in a NOX-dependent manner, demonstrating a role for reactive oxygen species in ETS-1 activation. These results unveil the role of ETS-1 as a mediator of neointima formation in AVF and may result in the development of novel strategies for the treatment of AVF dysfunction. C1 [Feng, Wenguang; Chumley, Phillip; Allon, Michael; George, James; Jaimes, Edgar A.] Univ Alabama Birmingham, Div Nephrol, Birmingham, AL 35294 USA. [George, James] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Scott, David W.; Patel, Rakesh P.; Litovsky, Silvio] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Jaimes, Edgar A.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. RP Jaimes, EA (reprint author), Univ Alabama Birmingham, Ziegler Res Bldg,637 1720 2nd Ave South, Birmingham, AL 35294 USA. EM ejaimes@uab.edu OI Patel, Rakesh/0000-0002-1526-4303 FU Veterans Affairs Administration [I01BX001073-03]; National Institutes of Health Research [DK085027-03]; UAB-UCSD O'Brien Core Center for Kidney Research [P30DK079337-05] FX These studies were funded by a Merit Review Award (I01BX001073-03) and a Program Project Award from the Veterans Affairs Administration (IP1BX001595-01A1) to E.A.J., a National Institutes of Health Research Grant (DK085027-03) to M.A., and the UAB-UCSD O'Brien Core Center for Kidney Research Grant (P30DK079337-05). NR 41 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAR PY 2014 VL 25 IS 3 BP 475 EP 487 DI 10.1681/ASN.2013040424 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA AB9YB UT WOS:000332150500009 PM 24203999 ER PT J AU Iaquinto, JM Tsai, R Haynor, DR Fassbind, MJ Sangeorzan, BJ Ledoux, WR AF Iaquinto, Joseph M. Tsai, Richard Haynor, David R. Fassbind, Michael J. Sangeorzan, Bruce J. Ledoux, William R. TI Marker-based validation of a biplane fluoroscopy system for quantifying foot kinematics SO MEDICAL ENGINEERING & PHYSICS LA English DT Article DE Biplane fluoroscopy; X-ray; Foot; Biomechanics ID MODEL AB Introduction: Radiostereometric analysis has demonstrated its capacity to track precise motion of the bones within a subject during motion. Existing devices for imaging the body in two planes are often custom built systems: we present here the design and marker-based validation of a system that has been optimized to image the foot during gait. Methods: Mechanical modifications were made to paired BV Pulsera C-arms (Philips Medical Systems) to allow unfettered gait through the imaging area. Image quality improvements were obtained with high speed cameras and the correction of image distorting artifacts. To assess the system's accuracy, we placed beads at known locations throughout the imaging field, and used post processing software to calculate their apparent locations. Results: Distortion correction reduced overall RMS error from 6.56 mm to 0.17 mm. When tracking beads in static images a translational accuracy of 0.094 +/- 0.081 mm and rotational accuracy of 0.083 +/- 0.068 degrees was determined. In dynamic trials simulating speeds seen during walking, accuracy was 0.126 +/- 0.122 mm. Discussion: The accuracies and precisions found are within the reported ranges from other such systems. With the completion of marker-based validation, we look to model-based validation of the foot during gait. Published by Elsevier Ltd on behalf of IPEM. C1 [Iaquinto, Joseph M.; Tsai, Richard; Fassbind, Michael J.; Sangeorzan, Bruce J.; Ledoux, William R.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA USA. [Iaquinto, Joseph M.; Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Haynor, David R.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Sangeorzan, Bruce J.; Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, Ms 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU Department of Veterans Affairs Rehabilitation Research and Development [A4843C, F7468R]; Magnuson Award FX This research was funded in part by the Department of Veterans Affairs Rehabilitation Research and Development grants A4843C, F7468R and the Magnuson Award. The study sponsor has no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. NR 12 TC 5 Z9 5 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1350-4533 EI 1873-4030 J9 MED ENG PHYS JI Med. Eng. Phys. PD MAR PY 2014 VL 36 IS 3 BP 391 EP 396 DI 10.1016/j.medengphy.2013.08.013 PG 6 WC Engineering, Biomedical SC Engineering GA AE5DT UT WOS:000334008700015 PM 24075068 ER PT J AU Cuijpers, P Turner, EH Mohr, DC Hofmann, SG Andersson, G Berking, M Coyne, J AF Cuijpers, P. Turner, E. H. Mohr, D. C. Hofmann, S. G. Andersson, G. Berking, M. Coyne, J. TI Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis SO PSYCHOLOGICAL MEDICINE LA English DT Review DE placebo; psychotherapy; Depression; meta-analysis ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PATIENTS; COGNITIVE THERAPY; MAJOR DEPRESSION; ANTIDEPRESSANT MEDICATION; PSYCHOLOGICAL TREATMENTS; BEHAVIORAL ACTIVATION; MINOR DEPRESSION; PUBLICATION BIAS; FOLLOW-UP AB Background The effects of antidepressants for treating depressive disorders have been overestimated because of selective publication of positive trials. Reanalyses that include unpublished trials have yielded reduced effect sizes. This in turn has led to claims that antidepressants have clinically insignificant advantages over placebo and that psychotherapy is therefore a better alternative. To test this, we conducted a meta-analysis of studies comparing psychotherapy with pill placebo. Method Ten 10 studies comparing psychotherapies with pill placebo were identified. In total, 1240 patients were included in these studies. For each study, Hedges' g was calculated. Characteristics of the studies were extracted for subgroup and meta-regression analyses. Results The effect of psychotherapy compared to pill placebo at post-test was g=0.25 [95% confidence interval (CI) 0.14-0.36, I (2)=0%, 95% CI 0-58]. This effect size corresponds to a number needed to treat (NNT) of 7.14 (95% CI 5.00-12.82). The psychotherapy conditions scored 2.66 points lower on the Hamilton Depression Rating Scale (HAMD) than the placebo conditions, and 3.20 points lower on the Beck Depression Inventory (BDI). Some indications for publication bias were found (two missing studies). We found no significant differences between subgroups of the studies and in meta-regression analyses we found no significant association between baseline severity and effect size. Conclusions Although there are differences between the role of placebo in psychotherapy and pharmacotherapy research, psychotherapy has an effect size that is comparable to that of antidepressant medications. Whether these effects should be deemed clinically relevant remains open to debate. C1 [Cuijpers, P.] Vrije Univ Amsterdam, Dept Clin Psychol, NL-1081 BT Amsterdam, Netherlands. [Cuijpers, P.] EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. [Turner, E. H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. [Turner, E. H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Turner, E. H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA. [Mohr, D. C.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Hofmann, S. G.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Andersson, G.] Linkoping Univ, Swedish Inst Disabil Res, Dept Behav Sci & Learning, S-58183 Linkoping, Sweden. [Andersson, G.] Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, Stockholm, Sweden. [Berking, M.] Univ Marburg, Dept Clin Psychol, D-35032 Marburg, Germany. [Coyne, J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Hlth Psychol Sect, Groningen, Netherlands. RP Cuijpers, P (reprint author), Vrije Univ Amsterdam, Dept Clin Psychol, Van der Boechorststr 1, NL-1081 BT Amsterdam, Netherlands. EM p.cuijpers@vu.nl RI Andersson, Gerhard/J-8529-2012; Hofmann, Stefan/B-8769-2014 OI Andersson, Gerhard/0000-0003-4753-6745; Hofmann, Stefan/0000-0002-3548-9681; Cuijpers, Pim/0000-0001-5497-2743 NR 46 TC 21 Z9 21 U1 6 U2 32 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD MAR PY 2014 VL 44 IS 4 BP 685 EP 695 DI 10.1017/S0033291713000457 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AD0WJ UT WOS:000332954700003 PM 23552610 ER PT J AU Tartaglione, EV Derleth, M Yu, L Ioannou, GN AF Tartaglione, Erica V. Derleth, Mark Yu, Lei Ioannou, George N. TI Can Computerized Brain Training Games be Used to Identify Early Cognitive Impairment in Cirrhosis? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID MINIMAL HEPATIC-ENCEPHALOPATHY; INHIBITORY CONTROL TEST; LIVER-TRANSPLANTATION; TESTS; DIAGNOSIS; TASK AB OBJECTIVES: We evaluated whether commercially available, computerized "brain-training" games can be used to identify subtle cognitive impairments in patients with cirrhosis. METHODS: We compared patients with cirrhosis who did not have overt encephalopathy (n = 31), patients with pre-cirrhotic chronic liver disease (n = 28), and normal controls without liver disease (n = 16) with respect to their scores on the number connection test-A (NCT-A), the Inhibitory Control Test (ICT), and five, short (similar to 2.5 min), brain-training games that were administered on an Apple iPad and tested different cognitive domains. RESULTS: Patients with cirrhosis had similar scores to patients with pre-cirrhotic liver disease and slightly worse scores than normal controls in the NCT-A and the ICT, although these differences were not statistically significant. In contrast, patients with cirrhosis had significantly worse scores than patients with pre-cirrhotic liver disease and even more so than normal controls in all five of the brain-training games. After adjustment for age and educational attainment, these differences remained significant for two of the tests, "Color Match" which is a version of the Stroop test and measures selective attention, and "Memory Matrix", which measures visuospatial memory. The area under the receiver operating characteristic curve discriminating cirrhosis from pre-cirrhotic liver disease was 0.56 (95% confidence interval (CI) 0.41-0.72) for the ICT and 0.58 (95% CI 0.43-0.73) for the NCT-A, indicating no discrimination, while it was 0.75 (95% CI 0.63-0.87) for "Color Match" and 0.77 (95% CI 0.64-0.90) for "Memory Matrix", indicating good discrimination. CONCLUSIONS: Short, brain-training games administered on an iPad can be used as psychometric tests to detect subtle cognitive impairments in patients with cirrhosis without overt encephalopathy that could not be detected by the NCT-A or the ICT. C1 [Tartaglione, Erica V.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA. [Derleth, Mark; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. [Derleth, Mark; Yu, Lei; Ioannou, George N.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Research Enhancement Award Program (REAP) by the Veterans Affairs Office of Research and Development FX This study was supported by a Research Enhancement Award Program (REAP) by the Veterans Affairs Office of Research and Development (awarded to G.N.I.). NR 31 TC 1 Z9 1 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2014 VL 109 IS 3 BP 316 EP 323 DI 10.1038/ajg.2013.306 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AD4RX UT WOS:000333239300002 PM 24594947 ER PT J AU Brawman-Mintzer, O Durkalski, V Wu, Q Romagnuolo, J Fogel, E Tarnasky, P Aliperti, G Freeman, M Kozarek, R Jamidar, P Wilcox, M Elta, G Orrell, K Wood, A Mauldin, P Serrano, J Drossman, D Robuck, P Cotton, P AF Brawman-Mintzer, Olga Durkalski, Valerie Wu, Qi Romagnuolo, Joseph Fogel, Evan Tarnasky, Paul Aliperti, Giuseppe Freeman, Martin Kozarek, Richard Jamidar, Priya Wilcox, Mel Elta, Grace Orrell, Kyle Wood, April Mauldin, Patrick Serrano, Jose Drossman, Douglas Robuck, Patricia Cotton, Peter TI Psychosocial Characteristics and Pain Burden of Patients With Suspected Sphincter of Oddi Dysfunction in the EPISOD Multicenter Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; IRRITABLE-BOWEL-SYNDROME; FUNCTIONAL GASTROINTESTINAL DISORDERS; NATIONAL-COMORBIDITY-SURVEY; SELF-REPORTED ABUSE; FINDINGS TYPE-I; ABDOMINAL-PAIN; PHYSICAL ABUSE; HEALTH-STATUS; DSM-IV AB OBJECTIVES: Patients with several painful functional gastrointestinal disorders (FGIDs) are reported to have a high prevalence of psychosocial disturbance. These aspects have not been studied extensively in patients with suspected Sphincter of Oddi dysfunction (SOD). METHODS: A total of 214 patients with post-cholecystectomy pain and suspected SOD were enrolled in seven US centers in a multicenter-randomized trial (Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction). Baseline assessments included pain descriptors and burden, structured psychosocial assessments of anxiety/depression, coping, trauma, and health-related quality of life. Patients with high levels of depression, suicidal ideation, or psychosis were excluded. RESULTS: The study population (92% female, mean age 38) reported anxiety (9%), depression (8%), past sexual trauma (18%), and physical abuse (10%). Of the total screened population (n = 1460), 3.9% of the patients were excluded because of the presence of defined severe psychological problems. The mean medical outcomes study short-form-36 (SF-36) physical and mental composite scores were 38.70 (s.d. = 7.89) and 48.74 (s.d. = 9.60), respectively. Most subjects reported symptoms of other FGIDs. There were no correlations between the extent of the pain burden in the 3 months before enrollment and the baseline anxiety scores or victimization history. However, those with greater pain burden were significantly more depressed. There were no meaningful differences in the psychosocial parameters in subjects with or without irritable bowel, and those who had cholecystectomy for stones or functional gallbladder disease. Those declining randomization were comparable to those randomized. CONCLUSIONS: Psychosocial comorbidity in SOD is high. However, it does not appear to differ significantly from that reported in surveys of age-and gender-matched general populations, and may be lower than reported with other FGIDs. C1 [Brawman-Mintzer, Olga; Durkalski, Valerie; Wu, Qi; Romagnuolo, Joseph; Orrell, Kyle; Wood, April; Mauldin, Patrick; Cotton, Peter] Med Univ S Carolina, Ctr Digest Dis, Charleston, SC 29425 USA. [Brawman-Mintzer, Olga] Ralph H Johnson VAMC, Charleston, SC USA. [Fogel, Evan] Indiana Univ, Indianapolis, IN 46204 USA. [Tarnasky, Paul] Methodist Dallas Med Ctr, Dallas, TX USA. [Aliperti, Giuseppe] Midwest Therapeut Endoscopy Consultants, St Louis, MO USA. [Freeman, Martin] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Kozarek, Richard] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Jamidar, Priya] Yale Univ, Newhaven, CT USA. [Wilcox, Mel] Univ Alabama Birmingham, Birmingham, AL USA. [Elta, Grace] Univ Michigan, Ann Arbor, MI 48109 USA. [Serrano, Jose; Robuck, Patricia] NIDDK, Bethesda, MD 20892 USA. [Drossman, Douglas] Univ N Carolina, Chapel Hill, NC USA. [Drossman, Douglas] Drossman Gastroenterol PLLC, Chapel Hill, NC USA. RP Cotton, P (reprint author), Med Univ S Carolina, Ctr Digest Dis, 25 Courtney Dr,ART 7100A,MSC 290, Charleston, SC 29425 USA. EM cottonp@musc.edu FU NIDDK [U01 DK074739] FX This work was funded by NIDDK, study number U01 DK074739. NR 39 TC 10 Z9 10 U1 3 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2014 VL 109 IS 3 BP 436 EP 442 DI 10.1038/ajg.2013.467 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AD4RX UT WOS:000333239300017 PM 24445573 ER PT J AU Gardner, RC Yaffe, K AF Gardner, Raquel C. Yaffe, Kristine TI Traumatic brain injury may increase risk of young onset dementia SO ANNALS OF NEUROLOGY LA English DT Editorial Material ID ALZHEIMERS-DISEASE; HEAD-INJURY; PROPAGATION; POPULATION; CONCUSSION; PROTEINS; FIBRILS; TAU C1 [Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Gardner, Raquel C.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Gardner, RC (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. FU NIA NIH HHS [P01 AG019724, K24 AG031155, R01 AG05401, R01 AG026720, P50 AG023501]; NIDDK NIH HHS [R01 DK069406]; NIMH NIH HHS [R01 MH086498] NR 30 TC 8 Z9 9 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD MAR PY 2014 VL 75 IS 3 BP 339 EP 341 DI 10.1002/ana.24121 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AD8WS UT WOS:000333547000004 PM 24550062 ER PT J AU Shih, YYI Yash, TV Rogers, B Duong, TQ AF Shih, Yen-Yu Ian Yash, Tiwari V. Rogers, Bill Duong, Timothy Q. TI fMRI of Deep Brain Stimulation at the Rat Ventral Posteromedial Thalamus SO BRAIN STIMULATION LA English DT Article DE Striatum; Deep brain stimulation; fMRI; Thalamus; Rat; Isoflurane ID BLOOD-FLOW; RESPONSES; BOLD; ACTIVATION; MRI; PLASTICITY AB Background: Functional magnetic resonance imaging (fMRI) of deep brain stimulation (DBS) has potentials to reveal neuroanatomical connectivity of a specific brain region in vivo. Objective: This study aimed to demonstrate frequency and amplitude tunings of the thalamocortical tract using DBS fMRI at the rat ventral posteromedial thalamus. Methods: Blood oxygenation level dependent (BOLD) fMRI data were acquired in a total of twelve rats at a high-field 11.7 T MRI scanner with modulation of nine stimulus frequencies (1-40 Hz) and seven stimulus amplitudes (0.2-3.6 mA). Results: BOLD response in the barrel cortex peaked at 25 Hz. The response increased with stimulus amplitude and reached a plateau at 1 mA. Cortical spreading depolarization (CSD) was observed occasionally after DBS that carries >10% BOLD waves spanning the entire ipsilateral cortex. Conclusion: fMRI is sensitive to the frequency effect of DBS and has potential to investigate the function of a particular neuroanatomical pathway. (C) 2014 Elsevier Inc. All rights reserved. C1 [Shih, Yen-Yu Ian; Yash, Tiwari V.; Rogers, Bill; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Shih, Yen-Yu Ian] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA. [Shih, Yen-Yu Ian] Univ N Carolina, Biomed Res Imaging Ctr, Chapel Hill, NC 27599 USA. [Shih, Yen-Yu Ian] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA. [Yash, Tiwari V.] Univ Texas San Antonio, Dept Biomed Engn, San Antonio, TX 78249 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Shih, YYI (reprint author), Univ N Carolina, Dept Neurol, Expt Neuroimaging Lab, 130 Mason Farm Rd,CB 7513, Chapel Hill, NC 27599 USA. EM shihy@unc.edu; duongt@uthscsa.edu OI Shih, Yen-Yu Ian/0000-0001-6529-911X FU American Heart Association [10POST4290091]; Clinical Translational Science Awards (CTSA) [UL1RR025767]; San Antonio Area Foundation; NIH/NINDS [R01 NS45879]; VA MERIT FX This work was supported in part by the American Heart Association (10POST4290091), Clinical Translational Science Awards (CTSA, parent grant UL1RR025767), and San Antonio Area Foundation to Dr. Yen-Yu Ian Shih and the NIH/NINDS R01 NS45879 and VA MERIT to Dr. Timothy Q. Duong. NR 19 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAR-APR PY 2014 VL 7 IS 2 BP 190 EP 193 DI 10.1016/j.brs.2013.11.001 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AD7KH UT WOS:000333442200006 PM 24309153 ER PT J AU Jackevicius, CA AF Jackevicius, Cynthia A. TI How Do the 2013 Cholesterol Guidelines Compare With Previous Cholesterol Guideline Reports? SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE guideline; cholesterol; lipids ID TREATMENT PANEL-III C1 [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA 91766 USA. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pharm, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Hlth Network, Dept Pharm, Toronto, ON, Canada. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu NR 5 TC 1 Z9 2 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAR PY 2014 VL 7 IS 2 BP 306 EP 310 DI 10.1161/CIRCOUTCOMES.113.000769 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AD0ZA UT WOS:000332962100015 PM 24594553 ER PT J AU Ma, RS Minsky, N Morshed, SA Davies, TF AF Ma, Risheng Minsky, Noga Morshed, Syed A. Davies, Terry F. TI Stemness in Human Thyroid Cancers and Derived Cell Lines: The Role of Asymmetrically Dividing Cancer Stem Cells Resistant to Chemotherapy SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID TO-MESENCHYMAL TRANSITION; CARCINOMA; DIVISION; MEDULLOBLASTOMA; IDENTIFICATION; EQUILIBRIUM; POPULATION; EXPRESSION; MARKER; STATE AB Context: Cancer stem cells (CSCs) have the ability to self-renew through symmetric and asymmetric cell division. CSCs may arise from mutations within an embryonic stem cell/progenitor cell population or via epithelial-mesenchymal transition (EMT), and recent advances in the study of thyroid stem cells have led to a growing recognition of the likely central importance of CSCs in thyroid tumorigenesis. Objective: The objectives of this study were to establish the presence of a stem cell population in human thyroid tumors and to identify, isolate, and characterize CSCs in thyroid cancer cell lines. Results: 1) Human thyroid cancers (n = 10) and thyroid cancer cell lines (n = 6) contained a stem cell population as evidenced by pluripotent stem cell gene expression. 2) Pulse-chase experiments with thyroid cancer cells identified a label-retaining cell population, a primary characteristic of CSCs, which at mitosis divided their DNA both symmetrically and asymmetrically and included a population of cells expressing the progenitor marker, stage-specific embryonic antigen 1 (SSEA-1). 3) Cells positive for SSEA-1 expressed additional stem cell markers including Oct4, Sox2, and Nanog were confirmed as CSCs by their tumor-initiating properties in vivo, their resistance to chemotherapy, and their multipotent capability. 4) SSEA-1-positive cells showed enhanced vimentin expression and decreased E-cadherin expression, indicating their likely derivation via EMT. Conclusions: Cellular diversity in thyroid cancer occurs through both symmetric and asymmetric cell division, and SSEA-1-positive cells are one form of CSCs that appear to have arisen via EMT and may be the source of malignant thyroid tumor formation. This would suggest that thyroid cancer CSCs were the result of thyroid cancer transformation rather than the source. C1 Icahn Sch Med Mt Sinai, Thyroid Res Unit, New York, NY 10468 USA. James J Peters VA Med Ctr, New York, NY 10468 USA. RP Ma, RS (reprint author), VA Med Ctr, Room 2F-27,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM risheng.ma@mssm.edu FU National Institutes of Health [DK080459, DK069713, DK052464]; VA Merit Review Program; David Owen Segal Endowment Fund FX This work was supported in part by Grants DK080459, DK069713, and DK052464 from the National Institutes of Health, by the VA Merit Review Program, and by the David Owen Segal Endowment Fund. NR 39 TC 13 Z9 14 U1 1 U2 11 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2014 VL 99 IS 3 BP E400 EP E409 DI 10.1210/jc.2013-3545 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD7RD UT WOS:000333461600002 PM 24823711 ER PT J AU Utzschneider, KM Largajolli, A Bertoldo, A Marcovina, S Nelson, JE Yeh, MM Kowdley, KV Kahn, SE AF Utzschneider, Kristina M. Largajolli, Anna Bertoldo, Alessandra Marcovina, Santica Nelson, James E. Yeh, Matthew M. Kowdley, Kris V. Kahn, Steven E. TI Serum ferritin is associated with non-alcoholic fatty liver disease and decreased B-cell function in non-diabetic men and women SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Insulin sensitivity; Ferritin; Insulin secretion in vivo; Fatty liver ID TUMOR-NECROSIS-FACTOR; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; DIABETES-MELLITUS; HEREDITARY HEMOCHROMATOSIS; MAJOR DETERMINANTS; METABOLIC SYNDROME; IRON DEPLETION; HUMAN OBESITY; SENSITIVITY AB Aims: We sought to determine whether NAFLD is associated with poorer beta-cell function and if any beta-cell dysfunction is associated with abnormal markers of iron or inflammation. Methods: This was a cross-sectional study of 15 non-diabetic adults with NAFLD and 15 non-diabetic age and BMI-matched controls. Insulin sensitivity was measured by isotope-labeled hyperinsulinemic-euglycemic clamps and beta-cell function by both oral (OGTT) and intravenous glucose tolerance tests. Liver and abdominal fat composition was evaluated by CT scan. Fasting serum levels of ferritin, transferrin-iron saturation, IL-6, TNF alpha and hsCRP were measured. Results: Compared to controls, subjects with NAFLD had lower hepatic and systemic insulin sensitivity and 12,cell function was decreased as measured by the oral disposition index. Fasting serum ferritin and transferrin-iron saturation were higher in NAFLD and were positively associated with liver fat. Serum ferritin was negatively associated with beta-cell function measured by both oral and intravenous tests, but was not associated with insulin sensitivity. IL-6, TNF alpha and hsCRP did not differ between groups and did not correlate with serum ferritin, liver fat or measures of beta-cell function. Conclusions: These findings support a potential pathophysiological link between iron metabolism, liver fat and diabetes risk. Published by Elsevier Inc. C1 [Utzschneider, Kristina M.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Endocrinol & Metab, Seattle, WA USA. [Utzschneider, Kristina M.; Kahn, Steven E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Largajolli, Anna; Bertoldo, Alessandra] Univ Padua, Padua, Italy. [Nelson, James E.; Kowdley, Kris V.] Virginia Mason Med Ctr, Inst Digest Dis, Seattle, WA 98101 USA. [Nelson, James E.; Kowdley, Kris V.] Benaroya Res Inst, Seattle, WA USA. [Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Kowdley, Kris V.] Univ Washington, Dept Med, Div Gastroenterol Hepatol, Seattle, WA USA. [Marcovina, Santica] Univ Washington, Dept Med, Seattle, WA USA. [Marcovina, Santica] Northwest Lipid Metab & Diabet Res Lab, Seattle, WA USA. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst 151, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU United States Department of Veterans Affairs (Office of Research and Development Medical Research Service); [UL1RR025014]; [P30DK017047]; [P30DK035816]; [T32DK007247] FX This work was supported by the United States Department of Veterans Affairs (Office of Research and Development Medical Research Service) and grant numbers UL1RR025014, P30DK017047, P30DK035816 and T32DK007247. NR 49 TC 5 Z9 6 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAR-APR PY 2014 VL 28 IS 2 BP 177 EP 184 DI 10.1016/j.jdiacomp.2013.11.007 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD8VD UT WOS:000333542900015 PM 24360972 ER PT J AU McMahan, RD Sudore, R AF McMahan, Ryan D. Sudore, Rebecca TI Advance Directives, Advance Care Planning, and Shared Decision Making: Promoting Synergy Over Exclusivity in Contemporary Context Reply SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Letter ID LIFE CARE; TRIAL; END C1 [McMahan, Ryan D.; Sudore, Rebecca] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. RP McMahan, RD (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. EM rebecca.sudore@ucsf.edu NR 9 TC 0 Z9 0 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAR PY 2014 VL 47 IS 3 BP E3 EP E4 DI 10.1016/j.jpainsymman.2013.12.228 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AD4YE UT WOS:000333257000002 PM 24508005 ER PT J AU Hilgeman, MM Mahaney-Price, AF Stanton, MP McNeal, SF Pettey, KM Tabb, KD Litaker, MS Parmelee, P Hamner, K Martin, MY Hawn, MT Kertesz, SG Davis, LL AF Hilgeman, Michelle M. Mahaney-Price, Ann F. Stanton, Marietta P. McNeal, Sandre F. Pettey, Kristin M. Tabb, Kroshona D. Litaker, Mark S. Parmelee, Patricia Hamner, Karl Martin, Michelle Y. Hawn, Mary T. Kertesz, Stefan G. Davis, Lori L. CA Alabama Vet Rural Hlth Initiative TI Alabama Veterans Rural Health Initiative: A Pilot Study of Enhanced Community Outreach in Rural Areas SO JOURNAL OF RURAL HEALTH LA English DT Article DE veterans; motivational interviewing; utilization of health services; access to care; evaluation design and research ID ILLNESS RATING-SCALE; QUALITY-OF-LIFE; OUTPATIENT CLINICS; URBAN VETERANS; VA HOSPITALS; CARE; ACCESS; SERVICES; DISTANCE; AFFAIRS AB Purpose Access, enrollment, and engagement with primary and specialty health care services present significant challenges for rural populations worldwide. The Alabama Veterans Rural Health Initiative evaluated an innovative outreach intervention combining motivational interviewing, patient navigation, and health services education to promote utilization of the United States Veterans Administration Healthcare System (VA) by veterans who live in rural locations. Methods Community outreach workers completed the intervention and assessment, enrolling veterans from 31 counties in a southern state. A total 203 participants were randomized to either an enhanced enrollment and engagement outreach condition (EEE, n = 101) or an administrative outreach (AO, n = 102) condition. Findings EEE participants enrolled and attended VA appointments at higher rates and within fewer days than those who received AO. Eighty-seven percent of EEE veterans attended an appointment within 6 months, compared to 58% of AO veterans (P < .0001). The median time to first appointment was 12 days for the EEE group and 98 days for the AO group (P < .0001). Additionally, a race by outreach group interaction emerged: black and white individuals benefited equally from the EEE intervention; however, black individuals who received AO took significantly longer to attend appointments than their white counterparts. Conclusions Results provide needed empirical support for a specific outreach intervention that speeds enrollment and engagement for rural individuals in VA services. Planned interventions to improve service utilization should ameliorate ambivalence about accessing health care in addition to addressing traditional systems or environmental-level barriers. C1 [Hilgeman, Michelle M.; Mahaney-Price, Ann F.; Davis, Lori L.] Tuscaloosa VA Med Ctr, Res & Dev Serv, Tuscaloosa, AL 35404 USA. [Hilgeman, Michelle M.; Mahaney-Price, Ann F.; Davis, Lori L.] Tuscaloosa Res & Educ Adv Corp, Tuscaloosa, AL USA. [Hilgeman, Michelle M.; Parmelee, Patricia] Univ Alabama, Ctr Mental Hlth & Aging, Tuscaloosa, AL USA. [Stanton, Marietta P.; Hamner, Karl] Univ Alabama, Coll Nursing, Tuscaloosa, AL USA. [McNeal, Sandre F.; Tabb, Kroshona D.; Hawn, Mary T.; Kertesz, Stefan G.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [McNeal, Sandre F.] Univ Alabama Birmingham, Dept Surg, Sect GI Surg, Birmingham, AL 35294 USA. [Pettey, Kristin M.] VA Southeast Vet Integrated Serv Network VISN, Off 7, Dept Vet Affairs, Tuscaloosa, AL USA. [Litaker, Mark S.] Univ Alabama Birmingham, Dept Clin & Community Sci, Div Behav & Populat Sci, Birmingham, AL USA. [Hamner, Karl] Univ Alabama, Sch Social Work, Tuscaloosa, AL USA. [Martin, Michelle Y.; Kertesz, Stefan G.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA. [Davis, Lori L.] Univ Alabama Birmingham, Sch Med, Dept Psychiat & Behav Med, Birmingham, AL USA. RP Hilgeman, MM (reprint author), Tuscaloosa VA Med Ctr, Res & Dev Serv, 3701 Loop Rd, Tuscaloosa, AL 35404 USA. EM Michelle.Hilgeman@va.gov FU VA Office of Rural Health FX Funding: The VA Office of Rural Health funded staff salaries and provided resources for the outreach activities described in this study; however, the sponsor did not have a role in study design, collection, analysis, interpretation of data, preparation of this report, or the decision to submit the paper for publication. NR 48 TC 2 Z9 2 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD SPR PY 2014 VL 30 IS 2 BP 153 EP 163 DI 10.1111/jrh.12054 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AE0YI UT WOS:000333691800005 PM 24330220 ER PT J AU Greenfield, TK Ye, Y Bond, J Kerr, WC Nayak, MB Kaskutas, LA Anton, RF Litten, RZ Kranzler, HR AF Greenfield, Thomas K. Ye, Yu Bond, Jason Kerr, William C. Nayak, Madhabika B. Kaskutas, Lee Ann Anton, Raymond F. Litten, Raye Z. Kranzler, Henry R. TI Risks of Alcohol Use Disorders Related to Drinking Patterns in the US General Population SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID MAXIMUM NUMBER; UNITED-STATES; CONSEQUENCES; CONSUMPTION; GUIDELINES; DEPENDENCE; TRENDS; DRUNK; DRUNKENNESS; QUANTITY AB Objective: The purpose of this study was to examine the relations between drinking (mean quantity and heavy drinking patterns) and alcohol use disorders (AUDs) in the U.S. general population. Method: Data from three telephone National Alcohol Surveys (in 2000, 2005, and 2010) were pooled, with separate analyses for men and women restricted to current drinkers (ns = 5,922 men, 6,270 women). Predictors were 12-month volume (mean drinks per day), rates of heavy drinking (5+14+ drinks in a day for men/women), and very heavy drinking (8+, 12+, and 24+ drinks in a day). Outcomes were negative alcohol-related consequences constituting abuse (1+ of 4 DSM-IV-based domains assessed by 13 items) and alcohol dependence (symptoms in 3+ of 7 DSM-IV based domains), together taken to indicate an AUD. Segmentation analyses were used to model risks of problem outcomes from drinking patterns separately by gender. Results: In the general population, men and women who consumed <= 1 drink/day on average with no heavy drinking days did not incur substantial risks of an AUD (<10%). Men who drank from 1 to 2 drinks/day on average but never 5+ incurred a 16% risk of reporting an AUD (3.5% alcohol dependence). At higher volumes, men and women who indicated higher rates of drinking larger amounts per day and/or involving 8+ and 12+ drinks/day (and even 24+ drinks/day for men) showed much higher risks of experiencing AUDs. Conclusions: The findings provide quantitative guidance for primary care practitioners who wish to make population-based recommendations to patients who might benefit by reducing both overall intake and amounts per occasion in an effort to lower their risks of developing AUDs. C1 [Greenfield, Thomas K.; Ye, Yu; Bond, Jason; Kerr, William C.; Nayak, Madhabika B.; Kaskutas, Lee Ann] Inst Publ Hlth, Alcohol Res Grp, Emeryville, CA USA. [Greenfield, Thomas K.] Univ Calif San Francisco, Dept Psychiat, Clin Serv Res Training Program, San Francisco, CA USA. [Kaskutas, Lee Ann] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Anton, Raymond F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Litten, Raye Z.] NIAAA, Div Treatment & Recovery Res, Bethesda, MD USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Greenfield, TK (reprint author), Alcohol Res Grp, 6475 Christie Ave,Suite 400, Oakland, CA 94608 USA. EM tgreenfield@arg.org OI /0000-0002-3108-4812 FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [P50 AA005595, K24 AA13736]; American Society of Clinical Psychopharmacology; Eli Lilly; Alkermes; Lundbeck; AbbVie FX This research was supported by Center Grant P50 AA005595 (to the Public Health Institute, Alcohol Research Group), including a supplement from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and Grant K24 AA13736 to Dr. Kranzler. Dr. Litten's contribution was supported by NIAAA. Drs. Anton and Kranzler performed this work in conjunction with their affiliation with the Alcohol Clinical Trials Initiative (ACTIVE) sponsored by the American Society of Clinical Psychopharmacology and funded in part by the following pharmaceutical companies: Eli Lilly, Alkermes, Lundbeck, and AbbVie (formerly Abbott Laboratories). In addition, Dr. Anton in the last 12 months was a member of the Scientific Advisory Board for Lundbeck and acted as a consultant for GlaxoSmithKline. In the last 12 months, Dr. Kranzler was a consultant to Alkermes, Lilly, Lundbeck, Pfizer, and Roche. Opinions are those of the authors and not the sponsoring institutions. Pharmaceutical companies listed herein have not reviewed or commented on the research. NR 50 TC 15 Z9 15 U1 3 U2 9 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAR PY 2014 VL 75 IS 2 BP 319 EP 327 PG 9 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA AE0LL UT WOS:000333657700014 PM 24650826 ER PT J AU Falk, DE Litten, RZ Anton, RF Kranzler, HR Johnson, BA AF Falk, Daniel E. Litten, Raye Z. Anton, Raymond F. Kranzler, Henry R. Johnson, Bankole A. CA Active Workgrp TI Cumulative Proportion of Responders Analysis (CPRA) as a Tool to Assess Treatment Outcome in Alcohol Clinical Trials SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PAIN TRIALS; DEPENDENCE; DRINKING; EFFICACY; INTERVENTIONS; NALTREXONE AB Objective: Several definitions of treatment response have been proposed for alcohol clinical trials (e.g., abstinence and no heavy drinking). However, each of these outcomes allows only one definition of successful response. In contrast, the cumulative proportion of responders analysis (CPRA) includes all of the possible drinking response cutoff points, providing a more complete picture of the therapeutic effects of a treatment. CPRA has been used to examine the efficacy of analgesics but not alcohol pharmacotherapy. To demonstrate its potential utility, we conducted CPRA in two large alcohol treatment trials: the COMBINE (Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence) trial (naltrexone) and a multisite topiramate trial. CPRA was used to demonstrate the efficacy of naltrexone and topiramate on continuous measures of in-treatment drinking heavy drinking days and drinks per day and their reductions from pretreatment. Method: All possible cutoff points were portrayed for each measure. We provide graphs to illustrate the effects of the active medications compared with placebo and examined them statistically over a number of salient drinking outcomes to evaluate their efficacy. Results: Treatment group responder curves were not parallel across the entire range of cutoff points; rather, they separated only at lower levels of drinking. In general, effect sizes increased by 0.10-0.15 when going from the lowest drinking level cutoff (i.e., abstinence and no heavy drinking) to the cutoff associated with the maximal treatment effect. Conclusions: CPRA may be useful in designing subsequent trials and helping to illustrate for treatment providers the likelihood of treatment success given various definitions of a positive response. C1 [Falk, Daniel E.; Litten, Raye Z.] NIAAA, Div Treatment & Recovery Res, Rockville, MD 20852 USA. [Anton, Raymond F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network 4, Philadelphia, PA USA. [Johnson, Bankole A.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. RP Falk, DE (reprint author), NIAAA, NIH, 5635 Fishers Lane,Room 2040, Rockville, MD 20852 USA. EM falkde@mail.nih.gov FU NIAAA NIH HHS [K05 AA017435] NR 33 TC 5 Z9 5 U1 0 U2 3 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAR PY 2014 VL 75 IS 2 BP 335 EP 346 PG 12 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA AE0LL UT WOS:000333657700016 PM 24650828 ER PT J AU Zappaterra, M Jim, L Pangarkar, S AF Zappaterra, Mauro Jim, Lysander Pangarkar, Sanjog TI Chronic pain resolution after a lucid dream: A case for neural plasticity? SO MEDICAL HYPOTHESES LA English DT Article ID LOW-BACK-PAIN; SYNAPTIC PLASTICITY; REHABILITATION; KETAMINE; TRIALS AB Chronic pain is often managed using a multidisciplinary, biopsychosocial approach. Interventions targeting the biological, psychological, and social aspects of both the patient and the pain have been demonstrated to provide objective and subjective improvement in chronic pain symptoms. The mechanism by which pain attenuation occurs after these interventions remains to be elucidated. While there is a relatively large body of empirical literature suggesting that functional and structural changes in the peripheral and central nervous systems are key in the development and maintenance of chronic pain states, less is known about changes that take place in the nervous system as a whole after biopsychosocial interventions. Using as a model the unique case of Mr. S, a patient suffering with chronic pain for 22 years who experienced a complete resolution of pain after a lucid dream following 2 years of biopsychosocial treatments, we postulate that central nervous system (CNS) reorganization (i.e., neural plasticity) serves as a possible mechanism for the therapeutic benefit of multidisciplinary treatments, and may set a neural framework for healing, in this case via a lucid dream. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Zappaterra, Mauro; Jim, Lysander; Pangarkar, Sanjog] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90073 USA. RP Zappaterra, M (reprint author), Dept Vet Affairs, Room W117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM maurozappaterra@gmail.com NR 26 TC 0 Z9 0 U1 3 U2 24 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 EI 1532-2777 J9 MED HYPOTHESES JI Med. Hypotheses PD MAR PY 2014 VL 82 IS 3 BP 286 EP 290 DI 10.1016/j.mehy.2013.12.011 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AD8CM UT WOS:000333494100009 PM 24398162 ER PT J AU Rugen, KW Watts, SA Janson, SL Angelo, LA Nash, M Zapatka, SA Brienza, R Gilman, SC Bowen, JL Saxe, JM AF Rugen, Kathryn Wirtz Watts, Sharon A. Janson, Susan L. Angelo, Laura A. Nash, Melanie Zapatka, Susan A. Brienza, Rebecca Gilman, Stuart C. Bowen, Judith L. Saxe, JoAnne M. TI Veteran Affairs Centers of Excellence in Primary Care Education: Transforming nurse practitioner education SO NURSING OUTLOOK LA English DT Article DE Interprofessional education; Nurse practitioner education; Primary care ID CHRONIC DISEASE; COMMUNITY; HOME AB To integrate health care professional learners into patient-centered primary care delivery models, the Department of Veterans Affairs has funded five Centers of Excellence in Primary Care Education (CoEPCEs). The main goal of the CoEPCEs is to develop and test innovative structural and curricular models that foster transformation of health care training from profession-specific "silos" to interprofessional, team-based educational and care delivery models in patient-centered primary care settings. CoEPCE implementation emphasizes four core curricular domains: shared decision making, sustained relationships, interprofessional collaboration, and performance improvement. The structural models allow interprofessional learners to have longitudinal learning experiences and sustained and continuous relationships with patients, faculty mentors, and peer learners. This article presents an overview of the innovative curricular models developed at each site, focusing on nurse practitioner (NP) education. Insights on transforming NP education in the practice setting and its impact on traditional NP educational models are offered. Preliminary outcomes and sustainment examples are also provided. C1 [Rugen, Kathryn Wirtz; Gilman, Stuart C.; Bowen, Judith L.] VA Off Acad Affiliat, Washington, DC USA. [Watts, Sharon A.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Janson, Susan L.; Saxe, JoAnne M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Angelo, Laura A.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Nash, Melanie] Boise VA Med Ctr, Boise, ID USA. [Zapatka, Susan A.; Brienza, Rebecca] VA Connecticut Healthcare Syst, West Haven, CT USA. [Brienza, Rebecca] Yale Univ, Sch Med, New Haven, CT USA. RP Rugen, KW (reprint author), Jesse Brown VA Med Ctr, VA Ctr Excellence Primary Care Educ, Off Acad Affiliat, 820 South Damen, Chicago, IL 60612 USA. EM kathryn.rugen@va.gov FU Office of Academic Affiliations, Veterans Health Administration, US Department of Veterans Affairs FX The Centers of Excellence in Primary Care Education are funded by the Office of Academic Affiliations, Veterans Health Administration, US Department of Veterans Affairs. The authors would like to recognize Office of Academic Affiliations leadership, Malcolm Cox, MD; and site Co-Directors: Rebecca Shunk, MD (San Francisco VA Medical Center); Mamta Singh, MD (Louis Stokes Cleveland VA Medical Center); C. Scott Smith, MD (Boise VA Medical Center) and Joyce Wipf, MD (VA Puget Sound Healthcare System). NR 14 TC 8 Z9 8 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD MAR-APR PY 2014 VL 62 IS 2 BP 78 EP 88 DI 10.1016/j.outlook.2013.11.004 PG 11 WC Nursing SC Nursing GA AD9FZ UT WOS:000333571500005 PM 24630678 ER PT J AU Jorge, RE Arciniegas, DB AF Jorge, Ricardo E. Arciniegas, David B. TI Mood Disorders After TBI SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Traumatic brain injury; Mood disorders; Depressive disorders ID TRAUMATIC BRAIN-INJURY; SEROTONIN TRANSPORTER POLYMORPHISMS; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; RANDOMIZED-TRIAL; AGGRESSIVE-BEHAVIOR; BIPOLAR DISORDER; HEAD-INJURY; AXIS-I; INDIVIDUALS AB In this article, we examine the epidemiology and risk factors for the development of the most common mood disorders observed in the aftermath of TBI: depressive disorders and bipolar spectrum disorders. We describe the classification approach and diagnostic criteria proposed in the fifth edition of the Diagnostic and Statistical Manual for Mental Disorders. We also examine the differential diagnosis of post-TBI mood disorders and describe the mainstay of the evaluation process. Finally, we place a special emphasis on the analysis of the different therapeutic options and provide guidelines for the appropriate management of these conditions. C1 [Jorge, Ricardo E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Mental Hlth Care Line, Houston, TX 77030 USA. [Jorge, Ricardo E.; Arciniegas, David B.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Beth K & Stuart C Yudofsky Div Neuropsychiat, Houston, TX 77030 USA. [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Jorge, RE (reprint author), One Baylor Plaza, Houston, TX 77030 USA. EM jorge@bcm.edu FU NIMH NIH HHS [R01 MH065134, R01 MH65134 01, R01MH53592]; NINDS NIH HHS [R01 NS055827] NR 89 TC 13 Z9 14 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X EI 1558-3147 J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2014 VL 37 IS 1 BP 13 EP + DI 10.1016/j.psc.2013.11.005 PG 18 WC Psychiatry SC Psychiatry GA AD8UM UT WOS:000333541200003 PM 24529421 ER PT J AU Kuriti, M Pearce, EN Braverman, LE He, XM Leung, AM AF Kuriti, Manikya Pearce, Elizabeth N. Braverman, Lewis E. He, Xuemei Leung, Angela M. TI IODINE CONTENT OF US WEIGHT-LOSS FOOD SO ENDOCRINE PRACTICE LA English DT Article ID NATIONAL-HEALTH; UNITED-STATES; BOSTON-AREA; POPULATION AB Objective: The recommended iodine intake is 150 mu g/day in adults, 220 mu g/day during pregnancy, and 290 mu g/day during lactation. Individuals exclusively consuming restricted diets as part of a weight-loss program may be at risk for mild to moderate iodine deficiency. The purpose of this study was to assess the iodine content in meals and snacks from 3 U. S. commercial weight-loss programs, all of which are intended to be the sole source of dietary intake during the desired weight-loss period. Methods: The iodine contents in the products representing 1 week of all meals and snacks from 3 U.S. commercial weight-loss programs were measured by spectrophotometry. The measured total iodine content in 1 week's worth of food from each program is reported as an average level per day. Results: A total of 53 total items were analyzed (29 different items [7 breakfasts, 7 lunches, 7 dinners, 6 snacks, 2 desserts] from Jenny Craig (R), 21 different items [7 breakfasts, 7 lunches, 7 dinners] from Nutrisystem (R), and 3 different items [1 breakfast, 1 lunch, 1 dinner; each to be intended to be eaten daily for 1 week] from Medifast (R)). Daily iodine content (mean +/- SD) of meals and snacks from the weight-loss programs were 34.2 +/- 1.2 (Jenny Craig (R)), 12.2 +/- 0.7 (Nutrisystem (R)), and 70.1 +/- 1.1 (Medifast) mu g/day. Conclusion: These results indicate that the dietary content in the foods from 3 U. S. commercial weight-loss programs is far less than the recommendations for iodine intake of 150 mu g/day in nonpregnant, nonlactating adults. Individuals following each weight-loss program should be advised to take a multivitamin containing 150 mu g of iodine daily. C1 [Kuriti, Manikya] Tufts Univ, Dept Internal Med, St Elizabeth Med Ctr, Boston, MA 02111 USA. [Pearce, Elizabeth N.; Braverman, Lewis E.; He, Xuemei] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol, Los Angeles, CA 90095 USA. RP Leung, AM (reprint author), VA Greater Los Angeles Healthcare Syst, Div Endocrinol, 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM amleung@mednet.ucla.edu OI Leung, Angela M./0000-0001-8935-9332 FU National Institutes of Health [NIH 7K23HD06855204] FX This work was supported by a grant from the National Institutes of Health (NIH 7K23HD06855204) to A.M.L. This work was previously presented at the Endocrine Society annual meeting (June 15-18, 2013, San Francisco, California) as a poster abstract on June 17, 2013. NR 14 TC 1 Z9 1 U1 0 U2 9 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD MAR PY 2014 VL 20 IS 3 BP 232 EP 235 DI 10.4158/EP13310.OR PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD2VP UT WOS:000333094200009 PM 24246349 ER PT J AU Hamilton, AB Oishi, S Yano, EM Gammage, CE Marshall, NJ Scheuner, MT AF Hamilton, Alison B. Oishi, Sabine Yano, Elizabeth M. Gammage, Cynthia E. Marshall, Nell J. Scheuner, Maren T. TI Factors influencing organizational adoption and implementation of clinical genetic services SO GENETICS IN MEDICINE LA English DT Article DE clinical genetic services; diffusion of innovations; implementation ID GENOMIC MEDICINE; HEALTH-CARE; INNOVATIONS; CHALLENGES; DIFFUSION; BARRIERS; TESTS AB Purpose:'We sought to identify characteristics of genetic services that facilitate or hinder adoption. Methods: We conducted semi-structured key informant interviews in five clinical specialties (primary care, medical oncology, neurology, cardiology; pathology/laboratory medicine) within 13 Veterans; Administration facilities. Results: Genetic services (defined as genetic testing and consultation) were not typically characterized by informants (n = 64) as ! advantageous for their facilities or their patients; compatible with organizational florins of low cost and high clinical impact; or applicable to patient populations or norms of clinical care. Furthermore, genetic services had not been systematically adopted in most facilities because of their complexity: knowledge of and expertise on genetic testing was limited, and organizational barriers to utilization of genetic services were formidable. The few facilities that had some success with implementation of genetic services had-knowledgeable clinicians interested in developing services and; organizational-level; facilitators such as at cesable genetic test-ordering processes. Conclusion: Adoption and implementation of genetic services will ! require a multilevel effort that includes education of providers and administrators, opportunities for observing the benefits of genetic; medicine, strategies for reducing the complexity of genomic medicine, expanded strategies for accessing genetics expertise and streamlining utilization, and resources dedicated to assessing the value of; genetic information for the outcomes that matter to health-care-organizations. C1 [Hamilton, Alison B.; Oishi, Sabine; Yano, Elizabeth M.; Gammage, Cynthia E.; Marshall, Nell J.; Scheuner, Maren T.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Excellence Study Healthcare Provider, Los Angeles, CA USA. [Hamilton, Alison B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Yano, Elizabeth M.; Marshall, Nell J.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Hamilton, AB (reprint author), VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Excellence Study Healthcare Provider, Los Angeles, CA USA. EM alison.hamilton@va.gov FU VA Health Services Research & Development (HSRD) Service [IBD 09-101]; HSR&D-funded Health Services Genomics Pilot Program [DNA 08-128]; National Institute of Mental Health [R25 MH080916-01A2]; VA HSRD QUERI; VA HSR&D Senior Research Career Scientist Award [RCS 05-195]; VA Greater Los Angeles HSR&D Center of Excellence [HFP 94-028]; VA HSRD Service FX This study was funded by the VA Health Services Research & Development (HSR&D) Service (IBD 09-101); pilot work conducted through the HSR&D-funded Health Services Genomics Pilot Program (DNA 08-128) also informed this paper. At the time of the study, A.B.H. was an investigator with the Implementation Research Institute (IRI), at the George Warren Brown School of Social Work, Washington University, St. Louis; supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and VA HSR&D QUERI. E.M.Y.'s effort was supported by a VA HSR&D Senior Research Career Scientist Award (RCS 05-195). This work was further supported by the VA Greater Los Angeles HSR&D Center of Excellence (HFP 94-028). A.B.H. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors are employed by the Department of Veterans Affairs. A.B.H., E.M.Y., and M.T.S. receive research funding from the VA HSR&D Service. NR 18 TC 7 Z9 7 U1 1 U2 11 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD MAR PY 2014 VL 16 IS 3 BP 238 EP 245 DI 10.1038/gim.2013.101 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA AC3SP UT WOS:000332441800006 PM 23949572 ER PT J AU Badani, S Na, S AF Badani, Shelby Na, Sopheap TI Chronic Concern Over an Acute-Phase Reactant A Teachable Moment SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID C-REACTIVE PROTEIN; SURGERY C1 [Badani, Shelby] Univ Colorado, Sch Med, Aurora, CO 80045 USA. [Na, Sopheap] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Badani, S (reprint author), Univ Colorado, Sch Med, 2101 N Ursula St,Apt 402, Aurora, CO 80045 USA. EM shelby.badani@ucdenver.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2014 VL 174 IS 3 BP 319 EP 319 DI 10.1001/jamainternmed.2013.12762 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AD2GK UT WOS:000333052100002 PM 24322671 ER PT J AU Thilen, SR Treggiari, MM Lange, JM Lowy, E Weaver, EM Wijeysundera, DN AF Thilen, Stephan R. Treggiari, Miriam M. Lange, Jane M. Lowy, Elliott Weaver, Edward M. Wijeysundera, Duminda N. TI Preoperative Consultations for Medicare Patients Undergoing Cataract Surgery SO JAMA INTERNAL MEDICINE LA English DT Article ID MAJOR NONCARDIAC SURGERY; PERIOPERATIVE MEDICINE; PRACTICE STYLES; ASCRS MEMBERS; UNITED-STATES; PHYSICIANS; HEALTH; PREFERENCES; OUTCOMES; IMPACT AB IMPORTANCE Low-risk elective surgical procedures are common, but there are no clear guidelines for when preoperative consultations are required. Such consultations may therefore represent a substantial discretionary service. OBJECTIVE To assess temporal trends, explanatory factors, and geographic variation for preoperative consultation in Medicare beneficiaries undergoing cataract surgery, a common low-risk elective procedure. DESIGN, SETTING, AND PARTICIPANTS Cohort study using a 5% national random sample of Medicare part B claims data including a cohort of 556 637 patients 66 years or older who underwent cataract surgery from 1995 to 2006. Temporal trends in consultations were evaluated within this entire cohort, whereas explanatory factors and geographic variation were evaluated within the 89 817 individuals who underwent surgery from 2005 to 2006. MAIN OUTCOMES AND MEASURES Separately billed preoperative consultations (performed by family practitioners, general internists, pulmonologists, endocrinologists, cardiologists, nurse practitioners, or anesthesiologists) within 42 days before index surgery. RESULTS The frequency of preoperative consultations increased from 11.3% in 1998 to 18.4% in 2006. Among individuals who underwent surgery in 2005 to 2006, hierarchical logistic regression modeling found several factors to be associated with preoperative consultation, including increased age (75-84 years vs 66-74 years: adjusted odds ratio [AOR], 1.09 [95% CI, 1.04-1.13]), race (African American race vs other: AOR, 0.71 [95% CI, 0.65-0.78]), urban residence (urban residence vs isolated rural town: AOR, 1.64 [95% CI, 1.49-1.81]), facility type (outpatient hospital vs ambulatory surgical facility: AOR, 1.10 [95% CI, 1.05-1.15]), anesthesia provider (anesthesiologist vs non-medically directed nurse anesthetist: AOR, 1.16 [95% CI, 1.10-1.24), and geographic region (Northeast vs South: AOR, 3.09 [95% CI, 2.33-4.10]). The burden of comorbidity was associated with consultation, but the effect size was small (< 10%). Variation in frequency of consultation across hospital referral regions was substantial (median [range], 12% [0-69%]), even after accounting for differences in patient-level, anesthesia provider-level, and facility-level characteristics. CONCLUSIONS AND RELEVANCE Between 1995 and 2006, the frequency of preoperative consultation for cataract surgery increased substantially. Referrals for consultation seem to be primarily driven by nonmedical factors, with substantial geographic variation. C1 [Thilen, Stephan R.; Treggiari, Miriam M.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA. [Treggiari, Miriam M.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Lange, Jane M.] Univ Washington, Dept Biostat, Seattle, WA 98104 USA. [Lowy, Elliott; Weaver, Edward M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Lowy, Elliott] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Weaver, Edward M.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Wijeysundera, Duminda N.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada. [Wijeysundera, Duminda N.] Toronto Gen Hosp, Dept Anesthesia & Pain Management, Toronto, ON, Canada. [Wijeysundera, Duminda N.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada. [Wijeysundera, Duminda N.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Wijeysundera, Duminda N.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. RP Thilen, SR (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, 325 Ninth Ave,POB 359724, Seattle, WA 98104 USA. EM sthilen@uw.edu OI Wijeysundera, Duminda/0000-0002-5897-8605 FU Department of Anesthesiology and Pain Medicine, University of Washington, Seattle; National Institutes of Health [T32GM086270]; Canadian Institutes of Health Research; Department of Anesthesia at the University of Toronto, Toronto, Ontario, Canada; Veterans Affairs Puget Sound Health Care System, Seattle, Washington FX This study was partially supported by funds from the Department of Anesthesiology and Pain Medicine, University of Washington, Seattle. Dr Thilen is supported by grant T32GM086270 from the National Institutes of Health, and by the Department of Anesthesiology and Pain Medicine, University of Washington, Seattle. Dr Wijeysundera is supported by a Clinician Scientist Award from the Canadian Institutes of Health Research and a Merit Award from the Department of Anesthesia at the University of Toronto, Toronto, Ontario, Canada. Drs Weaver and Lowy are partially supported by resources from the Veterans Affairs Puget Sound Health Care System, Seattle, Washington. NR 30 TC 10 Z9 11 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2014 VL 174 IS 3 BP 380 EP 388 DI 10.1001/jamainternmed.2013.13426 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AD2GK UT WOS:000333052100017 PM 24366269 ER PT J AU Patel, MS Reed, DA Loertscher, L McDonald, FS Arora, VM AF Patel, Mitesh S. Reed, Darcy A. Loertscher, Laura McDonald, Furman S. Arora, Vineet M. TI Teaching Residents to Provide Cost-Conscious Care: A National Survey of Residency Program Directors SO JAMA INTERNAL MEDICINE LA English DT Letter ID PHYSICIANS C1 [Patel, Mitesh S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Patel, Mitesh S.] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Reed, Darcy A.] Mayo Clin, Div Primary Care Internal Med, Rochester, MN USA. [Loertscher, Laura] Providence St Vincent Med Ctr, Portland, OR USA. [McDonald, Furman S.] Mayo Clin, Gen & Hosp Internal Med, Rochester, MN USA. [Arora, Vineet M.] Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA. RP Patel, MS (reprint author), Univ Penn, VA Robert Wood Johnson Clin Scholars Program, 423 Guardian Dr,1303B Blockley Hall, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu OI Arora, Vineet/0000-0002-4745-7599 NR 6 TC 14 Z9 14 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2014 VL 174 IS 3 BP 470 EP 472 DI 10.1001/jamainternmed.2013.13222 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA AD2GK UT WOS:000333052100039 PM 24343037 ER PT J AU McConnell, M Downs, JR Good, CB AF McConnell, Mark Downs, John R. Good, Chester B. TI Decrease the Incentives to Order Lipid Panels SO JAMA INTERNAL MEDICINE LA English DT Letter ID TARGETS C1 [McConnell, Mark] Tomah VA Med Ctr, Tomah, WI 54660 USA. [Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Healthcare Syst, San Antonio, TX 78229 USA. [Good, Chester B.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP McConnell, M (reprint author), Tomah VA Med Ctr, 500 E Vet St, Tomah, WI 54660 USA. EM mark.mcconnell@va.gov NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2014 VL 174 IS 3 BP 473 EP 473 DI 10.1001/jamainternmed.2013.12872 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AD2GK UT WOS:000333052100040 PM 24590082 ER PT J AU Liu, J Khan, A Johnson, S Grigorian, C Li, T AF Liu, Joseph Khan, Ambereen Johnson, Samuel Grigorian, Cheryl Li, Tao TI The usefulness of gestational sac and placental sonographic morphology in differentiating between second-trimester tubal and abdominal pregnancy: Case report and a review of literature SO JOURNAL OF CLINICAL ULTRASOUND LA English DT Article DE abdominal pregnancy; crescent-shaped placenta; GS morphology; advanced tubal pregnancy; second-trimester tubal pregnancy ID ADVANCED ECTOPIC PREGNANCY; DIAGNOSIS AB Second-trimester tubal pregnancy is rarely encountered and published cases are limited. There are no established sonographic criteria to differentiate it from abdominal pregnancy; however, differences in their medical management make this distinction important. We report a case of a 14-week 5-day tubal pregnancy that presented near rupture. Sonography demonstrated many overlapping features with abdominal pregnancy. In addition, the extrauterine gestational sac was rounded and well defined and the placenta was crescent-shaped. We propose that these sonographic features represent a second-trimester tubal pregnancy rather than an abdominal pregnancy. (c) 2013 Wiley Periodicals, Inc. J Clin Ultrasound 42:162-168, 2014 C1 [Liu, Joseph; Khan, Ambereen; Johnson, Samuel; Grigorian, Cheryl] Wayne State Univ, Dept Radiol, Detroit Med Ctr, Detroit, MI 48201 USA. [Li, Tao] Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Liu, J (reprint author), Wayne State Univ, Dept Radiol, Detroit Med Ctr, 4201 St Antoine St,DRH 3L-8, Detroit, MI 48201 USA. NR 27 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0091-2751 EI 1097-0096 J9 J CLIN ULTRASOUND JI J. Clin. Ultrasound PD MAR PY 2014 VL 42 IS 3 BP 162 EP 168 DI 10.1002/jcu.22076 PG 7 WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging GA AC2KI UT WOS:000332329300007 PM 23913766 ER PT J AU Munro, MG Nichols, JE Levy, B Vleugels, MPH Veersema, S AF Munro, M. G. Nichols, J. E. Levy, B. Vleugels, M. P. H. Veersema, S. TI Hysteroscopic Sterilization: 10-Year Retrospective Analysis of Worldwide Pregnancy Reports SO JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY LA English DT Article DE Contraception; Essure; Female sterilization; Hysteroscopic sterilization; Permanent birth control ID ESSURE STERILIZATION; TUBAL-STERILIZATION; MICRO-INSERT; FOLLOW-UP; ULTRASOUND; PLACEMENT; CONFIRMATION; MICROINSERTS; TRIAL AB Study Objective: To identify factors that might contribute to pregnancies reported after hysteroscopic sterilization worldwide. Design: Retrospective review of commercial data compiled from the MAUDE database, medical literature, and manufacturer reports received during commercial distribution of hysteroscopic sterilization micro-inserts from 2001 through 2010 (Canadian Taskforce classification ill descriptive study). Measurements and Main Results: From 2001 through 2010, 497 305 hysteroscopic sterilization kits were distributed worldwide, and 748 pregnancies were reported, i.e., 0.15% of the estimated user population based on the number of distributed kits. The data were sufficient to enable analysis of 508 pregnancies for potential contributing factors and showed most to be associated with patient or physician noncompliance (n = 264) or misinterpreted confirmation tests (n = 212). Conceptions deemed to have occurred within 2 weeks of the procedure and therefore too early for detection were identified in 32 cases. Conclusion: Although there are limitations to the dataset and the study design is retrospective, it represents the largest body of cumulative hysterosdopic sterilization data available to date. Of the 748 pregnancies reported, it is apparent that some might have been prevented with greater patient and clinician attention to interim contraceptive use and counseling and with more rigorous evaluation and informed interpretation of the procedure confirmation tests. Although the estimated pregnancy rate based on such a dataset is likely an underestimation, it does suggest that the evaluable field performance of hysteroscopic sterilization micro-inserts is consistent with the labeled age-adjusted effectiveness of 99.74% at 5 years. (c) 2014 AAGL. All rights reserved. C1 [Munro, M. G.] Univ Calif Los Angeles, Dept Obstet & Gynecol, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Munro, M. G.] W Los Angeles Vet Affairs Med Ctr, Kaiser Permanente, Gynecol Serv, Los Angeles, CA 90073 USA. [Nichols, J. E.] Piedmont Reprod Endocrinol Grp, Greenville, SC 29615 USA. [Levy, B.] Amer Congress Obstetricians & Gynecologists, Advocacy Div, Washington, DC USA. [Vleugels, M. P. H.] Rivierenland Hosp, Tiel CASA Clin, Nijmegen, Netherlands. [Veersema, S.] St Antonius Hosp, Utrecht, Netherlands. RP Nichols, JE (reprint author), Piedmont Reprod Endocrinol Grp, 17 Caledon Ct, Greenville, SC 29615 USA. EM j.nichols@yahoo.com NR 17 TC 13 Z9 13 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1553-4650 EI 1553-4669 J9 J MINIM INVAS GYN JI J. Mimim. Invasive Gynecol. PD MAR-APR PY 2014 VL 21 IS 2 BP 245 EP 251 DI 10.1016/j.jmig.2013.09.016 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AD7IN UT WOS:000333437500016 PM 24126261 ER PT J AU Miltner, RS Johnson, KD Deierhoi, R AF Miltner, Rebecca S. Johnson, Kimberly D. Deierhoi, Rhiannon TI Exploring the Frequency of Blood Pressure Documentation in Emergency Departments SO JOURNAL OF NURSING SCHOLARSHIP LA English DT Article DE documentation; Emergency Severity Index (ESI); emergency department; Vital sign monitoring ID VITAL SIGNS; SEVERITY INDEX; CARE; TRIAGE; DETERIORATION; RECORDS; NURSES AB Purpose One of the most commonly performed task in the emergency department (ED) is reported as the monitoring of vital signs, yet there are no published standards of care that provide guidelines for the frequency of obtaining vital signs in the ED. The purpose of this exploratory study was to determine the frequency of documentation of vital signs recorded during ED visits across Veterans Health Administration (VHA) facilities. Methods Deidentified patient level data from the VHA electronic health record (EHR) were abstracted for emergency department visits for 12 randomly selected days in calendar year 2011. The dataset included vital signs data, associated time stamps, facility, length of stay, triage category based on the Emergency Severity Index (ESI), and patient disposition for all patients. Descriptive statistics were used to describe the frequency of the specific vital sign measures, and parametric and nonparametric tests were used to examine study variables by ESI. Findings The sample consisted of over 43,232 unique patient visits to 94 VHA EDs with a median length of stay of 173.3 min (interquartile range [IQR], 96.1-286.9). The mean number of times that blood pressure (BP) was recorded per visit was 1.23 (SD 1.175). For the entire sample, median time between blood pressure measurements was 139.7 min (IQR, 81.6-230.1). There was a significant difference in median length of stay and median time between blood pressure by ESI category. Conclusions In this dataset, median time between documentation of BP in the ED was every 2.3 hr for all patients. While the median time was statistically significant between ESI categories, these times may not be clinically relevant. More important was the inconsistent documentation of vital signs of ED patients in the designated fields in the EHR. Most facilities (84.1%) documented BP for >75% of patient visits. However, eight facilities (9.1%) had BP documented in Clinical Relevance It seems unlikely that vital signs are not monitored in the ED; nurses anecdotally report that vital signs are recorded on a paper chart and later scanned as an image into the EHR. However, lack of consistent process in documentation of vital signs may decrease the care team's ability to note early warning signs of physiological instability or deterioration. C1 [Miltner, Rebecca S.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. [Miltner, Rebecca S.; Deierhoi, Rhiannon] Birmingham VA Med Ctr, Birmingham, AL USA. [Johnson, Kimberly D.] Univ Cincinnati, Coll Nursing, Cincinnati, OH USA. [Deierhoi, Rhiannon] Univ Alabama Birmingham, Dept GI Surg, Birmingham, AL USA. RP Miltner, RS (reprint author), 1449 Haddon Pl, Hoover, AL 35226 USA. EM smiltner@uab.edu OI Miltner, Rebecca/0000-0002-4653-0328 FU Veterans Administration Nursing Academy FX This article was supported in part by the Veterans Administration Nursing Academy, a partnership between the Birmingham Veterans Administration Medical Center and the University of Alabama at Birmingham School of Nursing. The content is solely the responsibility of the authors and does not necessarily represent the views of the Veterans Health Administration. NR 28 TC 4 Z9 6 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6546 EI 1547-5069 J9 J NURS SCHOLARSHIP JI J. Nurs. Scholarsh. PD MAR PY 2014 VL 46 IS 2 BP 98 EP 105 DI 10.1111/jnu.12060 PG 8 WC Nursing SC Nursing GA AC2HT UT WOS:000332321400005 PM 24355058 ER PT J AU Singh, JA Luo, RL Landon, GC Suarez-Almazor, M AF Singh, Jasvinder A. Luo, Ruili Landon, Glenn C. Suarez-Almazor, Maria TI Reliability and Clinically Important Improvement Thresholds for Osteoarthritis Pain and Function Scales: A Multicenter Study SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE RELIABILITY; SENSITIVITY TO CHANGE; KNEE; HIP; ARTHRITIS; PAIN ID OUTCOME SCORE KOOS; PHYSICAL-FUNCTION; HEALTH-STATUS; KNEE INJURY; PORTUGUESE VERSION; HIP DISABILITY; HOOS-PS; RESPONSIVENESS; VALIDITY; REPLACEMENT AB Objective. To assess the reliability and clinically meaningful thresholds of intermittent and constant osteoarthritis pain (ICOAP) score, the Knee injury and Osteoarthritis Outcome Score Physical function Short-form (KOOS-PS), the Hip disability and Osteoarthritis Outcome Score Physical function Short-form (HOOS-PS), and the Quality of life subscales of HOOS/KOOS (HOOS-QOL/KOOS-QOL) in patients with knee or hip arthritis. Methods. One hundred and ninety-five patients (141 knee, 54 hip) seen at 2 orthopedic outpatient clinics with a diagnosis of knee or hip OA completed patient-reported questionnaires (ICOAP pain scale, KOOS-PS, HOOS-PS, KOOS-QOL, HOOS-QOL) at baseline and 2-week followup. Reliability was assessed using intraclass correlation coefficients (ICC). We calculated minimum clinically important difference (MCID) and moderate improvement in the subgroup that reported change in the status of their affected joint. Results. The reliability as assessed by ICC was as follows: ICOAP pain scale, 0.63 (0.48, 0.74) in patients with knee arthritis, and 0.86 (0.73, 0.93) for hip arthritis; KOOS-PS, 0.66 (0.52, 0.77); HOOS-PS, 0.82 (0.66, 0.91); KOOS-QOL, 0.79 (0.69, 0.86); and HOOS-QOL, 0.67 (0.42, 0.83). MCID and moderate improvement estimates in patients with knee arthritis were ICOAP pain scale, 18.5 and 26.7; KOOS-PS, 2.2 and 15.0; and KOOS-QOL, 8.0 and 15.6. A smaller sample in patients with hip arthritis precluded MCID and moderate improvement estimates. Conclusion. We found that ICOAP pain and KOOS-PS/HOOS-PS scales were reasonably reliable in patients with hip OA. Reliability of these scales was much lower in patients with knee arthritis. Thresholds for clinically meaningful change in pain or function on these scales were estimated for patients with knee arthritis. C1 Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Dept Hlth Sci Res, Sch Med, Rochester, MN USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Sch Med, Rochester, MN USA. [Luo, Ruili; Suarez-Almazor, Maria] Univ Texas MD Anderson Canc Ctr, Sect Rheumatol & Clin Immunol, Houston, TX 77030 USA. [Landon, Glenn C.] St Lukes Episopal Hlth Syst, Houston, TX USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU US National Institutes of Health Clinical Translational Science Award [1 KL2 RR024151-01]; Pfizer; Expansciences; Novartis; Negma Lerads; Rottapharm; Fidia; Pierre Fabre Sante laboratories; European League Against Rheumatism; National Institute for Arthritis, Musculoskeletal, and Skin Disorders [AR053593]; Takeda; Savient; Regeneron; Allergan FX Supported by US National Institutes of Health Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research), and the resources and facilities at the Birmingham VA Medical Center, Alabama, USA. The original study was supported by unrestricted grants to scientific societies (Osteoarthritis Research Society International and Outcome Measures in Rheumatology) from pharmaceutical companies: Pfizer, Expansciences, Novartis, Negma Lerads, Rottapharm, Fidia, and Pierre Fabre Sante laboratories, and a research grant from the European League Against Rheumatism. Dr. Suarez-Almazor is the recipient of a K24 award from the National Institute for Arthritis, Musculoskeletal, and Skin Disorders (AR053593). Dr. Singh has received research and travel grants from Takeda and Savient, and consultant fees from Savient, Regeneron, Takeda, and Allergan. NR 31 TC 10 Z9 12 U1 2 U2 6 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2014 VL 41 IS 3 BP 509 EP 515 DI 10.3899/jrheum.130609 PG 7 WC Rheumatology SC Rheumatology GA AD0FX UT WOS:000332911000015 PM 24429183 ER PT J AU Dalbeth, N Zhong, CS Grainger, R Khanna, D Khanna, PP Singh, JA McQueen, FM Taylor, WJ AF Dalbeth, Nicola Zhong, Cathy S. Grainger, Rebecca Khanna, Dinesh Khanna, Puja P. Singh, Jasvinder A. McQueen, Fiona M. Taylor, William J. TI Outcome Measures in Acute Gout: A Systematic Literature Review SO JOURNAL OF RHEUMATOLOGY LA English DT Review DE GOUT; PAIN; MEASUREMENT; OUTCOME ID DOUBLE-BLIND; TRIAMCINOLONE ACETONIDE; CONTROLLED-TRIAL; ACUTE FLARES; ARTHRITIS PATIENTS; CLINICAL-TRIALS; PAIN INTENSITY; INDOMETHACIN; MULTICENTER; CANAKINUMAB AB Objective. Five core domains have been endorsed by Outcome Measures in Rheumatology (OMERACT) for acute gout: pain, joint swelling, joint tenderness, patient global assessment, and activity limitation. We evaluated instruments for these domains according to the OMERACT filter: truth, feasibility, and discrimination. Methods. A systematic search strategy for instruments used to measure the acute gout core domains was formulated. For each method, articles were assessed by 2 reviewers to summarize information according to the specific components of the OMERACT filter. Results. Seventy-seven articles and abstracts met the inclusion criteria. Pain was most frequently reported (76 studies, 20 instruments). The pain instruments used most often were 100 mm visual analog scale (VAS) and 5-point Likert scale. Both methods have high feasibility, face and content validity, and within- and between-group discrimination. Four-point Likert scales assessing index joint swelling and tenderness have been used in numerous acute gout studies; these instruments are feasible, with high face and content validity, and show within- and between-group discrimination. Five-point Patient Global Assessment of Response to Treatment (PGART) scales are feasible and valid, and show within- and between-group discrimination. Measures of activity limitations were infrequently reported, and insufficient data were available to make definite assessments of the instruments for this domain. Conclusion. Many different instruments have been used to assess the acute gout core domains. Pain VAS and 5-point Likert scales, 4-point Liken scales of index joint swelling and tenderness and 5-point PGART instruments meet the criteria for the OMERACT filter. C1 [Dalbeth, Nicola; Zhong, Cathy S.] Univ Auckland, Dept Med, Auckland, New Zealand. [Grainger, Rebecca; Taylor, William J.] Univ Otago, Dept Med, Wellington, New Zealand. [Khanna, Dinesh; Khanna, Puja P.] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. RP Dalbeth, N (reprint author), Univ Auckland, Dept Med, Fac Med & Hlth Sci, 85 Pk Rd, Auckland, New Zealand. EM n.dalbeth@auckland.ac.nz FU University of Auckland; Ardea Biosciences; Metabolex; Novartis; Takeda; Fonterra; Ardea; Savient; Regeneron; Allergan; URL pharmaceuticals FX Supported by a University of Auckland summer studentship (CSZ). Dr. Dalbeth has received consultant fees from Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra; and she is inventor on a patent related to milk products and gout. Dr. D. Khanna has received consultant fees from Ardea,Takeda, Novartis, and Savient, and has served on a speakers bureau for Savient. Dr. P. Khanna serves on the speakers bureau for Takeda. J.A. Singh has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals, and Novartis. J.A. Singh is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. NR 61 TC 6 Z9 6 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2014 VL 41 IS 3 BP 558 EP 568 DI 10.3899/jrheum.131244 PG 11 WC Rheumatology SC Rheumatology GA AD0FX UT WOS:000332911000023 PM 24334652 ER PT J AU Singh, JA Taylor, WJ Dalbeth, N Simon, LS Sundy, J Grainger, R Alten, R March, L Strand, V Wells, G Khanna, D McQueen, F Schlesinger, N Boonen, A Boers, M Saag, KG Schumacher, HR Edwards, NL AF Singh, Jasvinder A. Taylor, William J. Dalbeth, Nicola Simon, Lee S. Sundy, John Grainger, Rebecca Alten, Rieke March, Lyn Strand, Vibeke Wells, George Khanna, Dinesh McQueen, Fiona Schlesinger, Naomi Boonen, Annelies Boers, Maarten Saag, Kenneth G. Schumacher, H. Ralph Edwards, N. Lawrence TI OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE GOUT; OUTCOME MEASURES; PSYCHOMETRICS ID CLINICAL-TRIALS; INDOMETHACIN; ETORICOXIB; PROGRESS; SCALES AB Objective:To determine the extent to which participants at the Outcome Measures in Rheumatology (OMERACT) 11 meeting agree that instruments used in clinical trials to measure OMERACT core outcome domains in acute gout fulfill OMERACT filter requirements of truth, discrimination, and feasibility; and where future research efforts need to be directed. Methods. Results of a systematic literature review and analysis of individual-level data from recent clinical studies of acute gout were presented to OMERACT participants. The information was discussed in breakout groups, and opinion was defined by subsequent voting in a plenary session. Endorsement was defined as at least 70% of participants voting in agreement with the proposition (where the denominator excluded those participants who did not vote or who voted "don't know"). Results. The following measures were endorsed for use in clinical trials of acute gout: (1) 5-point Likert scale and/or visual analog scale (0 to 100 mm) to measure pain; (2) 4-point Likert scale for joint swelling; (3) 4-point Likert scale for joint tenderness; and (4) 5-point Likert scale for patient global assessment of response to treatment. Measures for the activity limitations domain were not endorsed. Conclusion. Measures of pain, joint swelling, joint tenderness, and patient global assessment in acute gout were endorsed at OMERACT 11. These measures should now be used in clinical trials of acute gout. C1 [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.; Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Taylor, William J.; Grainger, Rebecca] Univ Otago, Dept Med, Wellington, New Zealand. [Dalbeth, Nicola] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand. [Simon, Lee S.] SDG LLC, Cambridge, MA USA. [Sundy, John] Duke Univ, Sch Med, Durham, NC USA. [Sundy, John] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore. [Alten, Rieke] Charite, Schlosspk Klin Teaching Hosp, D-13353 Berlin, Germany. [March, Lyn] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2006, Australia. [March, Lyn] Royal N Shore Hosp, Dept Rheumatol, Sydney, NSW, Australia. [Strand, Vibeke] Stanford Univ, Div Rheumatol & Immunol, Portolo Valley, CA USA. [Wells, George] Univ Ottawa, London, ON, Canada. [Khanna, Dinesh] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Schlesinger, Naomi] Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand. [Schlesinger, Naomi] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Boonen, Annelies] Maastricht Univ, Med Ctr, Div Rheumatol, Maastricht, Netherlands. [Boonen, Annelies] Univ Maastricht, Caphri Res Inst, Maastricht, Netherlands. [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. [Schumacher, H. Ralph] Univ Penn, Philadelphia, PA 19104 USA. [Schumacher, H. Ralph] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Edwards, N. Lawrence] Univ Florida, Dept Rheumatol, Gainesville, FL USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Takeda; Savient; Ardea; Regeneron; Allergan; URL pharmaceuticals; Novartis; Fonterra; Savient Pharmaceuticals; Ardea Biosciences; Metabolex; Nuon Therapeutics; Pharmos; Biosciences; BioCryst; Takeda Pharmaceutical; Savient Pharmaceutical; Regeneron Pharmaceuticals; Metabolex Pharmaceuticals; BioCryst Pharmaceuticals FX Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subconmittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees. from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 15 TC 5 Z9 5 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2014 VL 41 IS 3 BP 569 EP 573 DI 10.3899/jrheum.131246 PG 5 WC Rheumatology SC Rheumatology GA AD0FX UT WOS:000332911000024 PM 24334651 ER PT J AU Taylor, WJ Redden, D Dalbeth, N Schumacher, HR Edwards, NL Simon, LS John, MR Essex, MN Watson, DJ Evans, R Rome, K Singh, JA AF Taylor, William J. Redden, David Dalbeth, Nicola Schumacher, H. Ralph Edwards, N. Lawrence Simon, Lee S. John, Markus R. Essex, Margaret N. Watson, Douglas J. Evans, Robert Rome, Keith Singh, Jasvinder A. TI Application of the OMERACT Filter to Measures of Core Outcome Domains in Recent Clinical Studies of Acute Gout SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE GOUT; OUTCOME MEASURES; PSYCHOMETRICS ID HEALTH-STATUS; IMPAIRMENT; ARTHRITIS AB Objective. To determine the extent to which instruments that measure core outcome domains in acute gout fulfill the Outcome Measures in Rheumatology (OMERACT) filter requirements of truth, discrimination, and feasibility. Methods. Patient-level data from 4 randomized controlled trials of agents designed to treat acute gout and 1 observational study of acute gout were analyzed. For each available measure, construct validity, test-retest reliability, within-group change using effect size, between-group change using the Kruskall-Wallis statistic, and repeated measures generalized estimating equations were assessed. Floor and ceiling effects were also assessed and minimal clinically important difference was estimated. These analyses were presented to participants at OMERACT 11 to help inform voting for possible endorsement. Results. There was evidence for construct validity and discriminative ability for 3 measures of pain [0 to 4 Likert, 0 to 10 numeric rating scale (NRS), 0 to 100 mm visual analog scale (VAS)]. Likewise, there appears to be sufficient evidence for a 4-point Likert scale to possess construct validity and discriminative ability for physician assessment of joint swelling and joint tenderness. There was some evidence for construct validity and within-group discriminative ability for the Health Assessment Questionnaire as a measure of activity limitations, but not for discrimination between groups allocated to different treatment. Conclusion.. There is sufficient evidence to support measures of pain (using Likert, NRS, or VAS), joint tenderness, and swelling (using Likert scale) as fulfilling the requirements of the OMERACT filter. Further research on a measure of activity limitations in acute gout clinical trials is required. C1 [Taylor, William J.] Univ Otago, Dept Med, Wellington, New Zealand. [Redden, David] Univ Alabama Birmingham, Dept Biostat, Sch Publ Hlth, Birmingham, AL 35294 USA. [Dalbeth, Nicola] Univ Auckland, Dept Med, Auckland, New Zealand. [Schumacher, H. Ralph] Univ Penn, Philadelphia, PA 19104 USA. Vet Affairs VA Med Ctr, Philadelphia, PA USA. [Edwards, N. Lawrence] Univ Florida, Dept Med, Gainesville, FL USA. [Simon, Lee S.] SDG LLC, Cambridge, MA USA. [John, Markus R.] Novartis Pharma AG, Integrated Hosp Care Franchise, Immunol, Basel, Switzerland. [Essex, Margaret N.] Pfizer Inc, New York, NY USA. [Watson, Douglas J.] Merck Sharp & Dohme Corp, Epidemiol, Whitehouse Stn, NY USA. [Evans, Robert] Regeneron Pharmaceut, Clin Sci, Tarrytown, NJ USA. [Rome, Keith] Auckland Univ Technol, Hlth & Rehabil Res Inst, Auckland, New Zealand. [Rome, Keith] Auckland Univ Technol, Sch Podiatry, Auckland, New Zealand. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. RP Taylor, WJ (reprint author), Univ Otago, Dept Med, POB 7343, Wellington, New Zealand. EM will.taylor@otago.ac.nz FU Ardea Biosciences; Metabolex; Novartis; Takeda; Fonterra; Takeda Pharmaceutical; Savient Pharmaceutical; Regeneron Pharmaceuticals; Metabolex Pharmaceuticals; BioCryst Pharmaceuticals; Ardea; Allergan; URL Pharmaceuticals FX Supported with resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA (J.A.S. and D. Redden). N. Dalbeth has received consulting fees from Ardea Biosciences, Metabolex, Novartis, and Takeda. Her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. H.R. Schumacher has been a consultant for Regeneron, Novartis, Pfizer, Savient, Ardea, Metabolex, and BioCryst, and he has received a grant from Takeda. N.L. Edwards has received consultant fees from Novartis, Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. L.L. Simon has served on the board of directors for Savient Pharmaceuticals, and has consulted for Takeda. M.R. John is employed by Novartis and sometimes owns shares in the company. M.N. Essex is employed by Pfizer and owns shares in the company. DJ. Watson is an employee of and owns stock in Merck & Co. Inc.; the marketing authorization holder for etoricoxib and sponsor of the etorcoxib clinical trials that contributed data for this work. R. Evans is employed by Regeneron and owns shares of stock. J.A. Singh has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL Pharmaceuticals and Novartis. He is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. NR 9 TC 4 Z9 4 U1 1 U2 2 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2014 VL 41 IS 3 BP 574 EP 580 DI 10.3899/jrheum.131245 PG 7 WC Rheumatology SC Rheumatology GA AD0FX UT WOS:000332911000025 PM 24429178 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Research Priorities in Gout: The Patient Perspective SO JOURNAL OF RHEUMATOLOGY LA English DT Letter ID NOMINAL GROUP TECHNIQUE; GENERAL-PRACTICE; POPULATION; MANAGEMENT C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Sch Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU NIA NIH HHS [U01 AG018947]; NIAMS NIH HHS [P50 AR060772] NR 11 TC 4 Z9 4 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2014 VL 41 IS 3 BP 615 EP 616 DI 10.3899/jrheum.131258 PG 2 WC Rheumatology SC Rheumatology GA AD0FX UT WOS:000332911000030 PM 24585526 ER PT J AU Aniemeke, C Jawad, M Thompson, R Lee, S Sanchez-Reilly, S AF Aniemeke, C. Jawad, M. Thompson, R. Lee, S. Sanchez-Reilly, S. TI INTEGRATING AN ADVANCE CARE PLANNING CLINICAL AND EDUCATIONAL INTERVENTION (I-ACP) TO IMPROVE PATIENT-CENTERED CARE AMONG CHRONICALLY ILL OLDER ADULTS SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Aniemeke, C.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Aniemeke, C.; Thompson, R.; Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GRECC GEC, San Antonio, TX USA. [Jawad, M.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S110 EP S110 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500301 ER PT J AU Aspinall, S Zhao, X Schmader, K Pugh, M Semla, T Cunningham, F Hanlon, J AF Aspinall, S. Zhao, X. Schmader, K. Pugh, M. Semla, T. Cunningham, F. Hanlon, J. TI Epidemiology of Drug-Disease Interactions (DDIs) in Older Veteran Nursing Home Residents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Aspinall, S.; Semla, T.; Cunningham, F.] VA Pharm Benefits Management Serv, Hines, IL USA. [Aspinall, S.; Zhao, X.; Hanlon, J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Schmader, K.] Durham VA Med Ctr, Durham, NC USA. [Pugh, M.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S44 EP S45 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500118 ER PT J AU Belland, L Rivera, L Genes, N Thum, F Hwang, U AF Belland, L. Rivera, L. Genes, N. Thum, F. Hwang, U. TI Evaluating the effectiveness of a novel clinical decision support system (CDS) to improve acute abdominal pain for older adults in the Emergency Department (ED) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Belland, L.; Rivera, L.; Genes, N.; Thum, F.; Hwang, U.] Icahn Sch Med Mt Sinai, New York, NY USA. [Hwang, U.] James J Peters VAMC, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S102 EP S102 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500279 ER PT J AU Booth, K Vaughan, C Fix, K Burgio, K Goode, P Redden, D Markland, A AF Booth, K. Vaughan, C. Fix, K. Burgio, K. Goode, P. Redden, D. Markland, A. TI Bladder, Bowel, and Skin Care (BASiC) Toolkit for Home-Based Primary Care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Booth, K.; Fix, K.; Burgio, K.; Goode, P.; Redden, D.; Markland, A.] Univ Alabama Birmingham, Birmingham, AL USA. [Vaughan, C.; Burgio, K.; Goode, P.; Markland, A.] Birmingham Atlanta GRECC, Birmingham, AL USA. [Vaughan, C.] Emory Univ, Decatur, GA USA. [Booth, K.; Fix, K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S7 EP S8 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500019 ER PT J AU Bouldin, EL Littman, AJ Rice, K Reiber, GE AF Bouldin, E. L. Littman, A. J. Rice, K. Reiber, G. E. TI Chronic wound care and outcomes among older veterans using VA and Medicare SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Bouldin, E. L.; Littman, A. J.; Reiber, G. E.] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA. [Bouldin, E. L.; Littman, A. J.; Rice, K.; Reiber, G. E.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S270 EP S270 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500743 ER PT J AU Chiu, C Feuz, MA McMahan, RD Miao, Y Sudore, RL AF Chiu, C. Feuz, M. A. McMahan, R. D. Miao, Y. Sudore, R. L. TI "I Don't Want to Make My Own Decisions": Decision Control Preferences in a Diverse Elderly Population SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Chiu, C.; Feuz, M. A.; McMahan, R. D.; Miao, Y.; Sudore, R. L.] UCSF, Div Geriatr, San Francisco, CA USA. [Feuz, M. A.; McMahan, R. D.; Miao, Y.; Sudore, R. L.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S107 EP S107 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500292 ER PT J AU Eng, JA Allison, TA Kao, H Williams, BA Barnes, DE Ritchie, CS AF Eng, J. A. Allison, T. A. Kao, H. Williams, B. A. Barnes, D. E. Ritchie, C. S. TI Roll-out of GRACE in Two Urban Health Systems: an Early Implementation Science Analysis SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Eng, J. A.; Allison, T. A.; Kao, H.; Williams, B. A.; Ritchie, C. S.] UCSF, Div Geriatr, San Francisco, CA USA. [Eng, J. A.; Allison, T. A.; Williams, B. A.; Ritchie, C. S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Barnes, D. E.] UCSF, Dept Psychiat, San Francisco, CA USA. [Barnes, D. E.] UCSF, Dept Epidemiol & Biostat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S139 EP S140 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500380 ER PT J AU Fung, CH Igodan, U Alessi, C Martin, JL Dzierzewski, JM Josephson, K Kramer, J AF Fung, C. H. Igodan, U. Alessi, C. Martin, J. L. Dzierzewski, J. M. Josephson, K. Kramer, J. TI A qualitative study of human factors barriers to positive airway pressure therapy in older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Fung, C. H.; Igodan, U.; Alessi, C.; Martin, J. L.; Dzierzewski, J. M.; Josephson, K.; Kramer, J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fung, C. H.; Alessi, C.; Martin, J. L.; Dzierzewski, J. M.; Kramer, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Anglees, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S158 EP S158 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500431 ER PT J AU Fung, CH Martin, J Jouldjian, S Dzierzewski, J Rodriguez, J Mitchell, M Josephson, K Alessi, C AF Fung, C. H. Martin, J. Jouldjian, S. Dzierzewski, J. Rodriguez, J. Mitchell, M. Josephson, K. Alessi, C. TI Medical, mental health, and demographic factors associated with a strong belief in using sleeping pills to improve sleep and daytime function SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Fung, C. H.; Martin, J.; Jouldjian, S.; Dzierzewski, J.; Alessi, C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fung, C. H.; Martin, J.; Dzierzewski, J.; Rodriguez, J.; Mitchell, M.; Josephson, K.; Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S116 EP S117 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500318 ER PT J AU Garcia, LE Pastewait, S Rebecca, R Chen-pin, W MacCarthy, D Moris, M Gonzalez, E Conde, A Espinoza, SE AF Garcia, L. E. Pastewait, S. Rebecca, R. Chen-pin, W. MacCarthy, D. Moris, M. Gonzalez, E. Conde, A. Espinoza, S. E. TI A Pharmacy-based Transitional Care Program to Reduce Hospital Readmissions in High Risk Older Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Garcia, L. E.; Pastewait, S.; Rebecca, R.; Chen-pin, W.; MacCarthy, D.; Moris, M.; Gonzalez, E.; Conde, A.; Espinoza, S. E.] UTHSCSA, San Antonio, TX USA. [Garcia, L. E.; Pastewait, S.; Rebecca, R.; Chen-pin, W.; MacCarthy, D.; Moris, M.; Gonzalez, E.; Conde, A.; Espinoza, S. E.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S230 EP S231 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500631 ER PT J AU Greene, M Covinsky, K Deeks, S Miao, Y Madamba, J Mattes, M Lampiris, H Martin, J Valcour, V AF Greene, M. Covinsky, K. Deeks, S. Miao, Y. Madamba, J. Mattes, M. Lampiris, H. Martin, J. Valcour, V. TI Geriatric Syndromes in Older HIV-Infected Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Greene, M.; Covinsky, K.; Deeks, S.; Miao, Y.; Madamba, J.; Lampiris, H.; Martin, J.; Valcour, V.] UCSF, San Francisco, CA USA. [Greene, M.; Covinsky, K.; Miao, Y.; Mattes, M.; Lampiris, H.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S11 EP S11 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500027 ER PT J AU Harris, BM Restrepo, M Bryson, CD Ross, JS Espinoza, SE Sanchez-Reilly, S Villarreal, D AF Harris, B. M. Restrepo, M. Bryson, C. D. Ross, J. S. Espinoza, S. E. Sanchez-Reilly, S. Villarreal, D. TI Changing the Practice of Intensive Care to Improve the Lives of Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Harris, B. M.; Restrepo, M.; Ross, J. S.; Espinoza, S. E.; Sanchez-Reilly, S.; Villarreal, D.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Harris, B. M.; Restrepo, M.; Bryson, C. D.; Ross, J. S.; Espinoza, S. E.; Sanchez-Reilly, S.; Villarreal, D.] South Texas Vet Hlth Care Syst, GRECC GEC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S135 EP S136 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500369 ER PT J AU Harris, BM Washington, F Ross, J Oakes, SL AF Harris, B. M. Washington, F. Ross, J. Oakes, S. L. TI Stopping the Revolving Door: Decreasing Admissions from a Community Nursing Home to Hospital using INTERACT 2 and Palliative Care Interventions SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Harris, B. M.; Ross, J.; Oakes, S. L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Harris, B. M.; Ross, J.; Oakes, S. L.] South Texas Vet Hlth Care Syst, GRECC GECC, San Antonio, TX USA. [Washington, F.] Buena Vida Nursing Home & Rehab, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S136 EP S136 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500370 ER PT J AU Healy, JM Chappell, P Lee, S Villarreal, D Ross, J Sanchez-Reilly, S AF Healy, J. M. Chappell, P. Lee, S. Villarreal, D. Ross, J. Sanchez-Reilly, S. TI The Double Parallel Curriculum in Palliative Care (DP-PC): Using a Double Parallel Education Strategy with Multimedia to Enhance Learners' Knowledge and Skills in End of Life Palliative Care (EOL-PC) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Healy, J. M.; Chappell, P.; Ross, J.; Sanchez-Reilly, S.] UTHSCSA, Geriatr HPM, San Antonio, TX USA. [Healy, J. M.; Lee, S.; Villarreal, D.; Ross, J.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S113 EP S113 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500308 ER PT J AU Higbea, AM Thorpe, C Coley, K McGivney, M Klatt, P Schleiden, L Zaharoff, J Corbo, J Haver, A Cox-Vance, L Balestrino, V Sakely, H AF Higbea, A. M. Thorpe, C. Coley, K. McGivney, M. Klatt, P. Schleiden, L. Zaharoff, J. Corbo, J. Haver, A. Cox-Vance, L. Balestrino, V. Sakely, H. TI Patient perceptions of Pharmacist-led InterVentions on Transitions of Seniors (PIVOTS): A Patient Survey SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Higbea, A. M.; Klatt, P.; Corbo, J.; Haver, A.; Cox-Vance, L.; Balestrino, V.; Sakely, H.] UPMC St Margaret, Pittsburgh, PA USA. [Thorpe, C.; Coley, K.; McGivney, M.; Schleiden, L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Thorpe, C.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Zaharoff, J.] Presbyterian Senior Care, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S276 EP S276 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500760 ER PT J AU Hsu, A Nakagawa, S Walter, L Van den Eeden, S Brown, J Thom, D Lee, S Huang, A AF Hsu, A. Nakagawa, S. Walter, L. Van den Eeden, S. Brown, J. Thom, D. Lee, S. Huang, A. TI Nocturia in women: a consequence of other urinary disorders or a clinical entity in its own right? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Hsu, A.; Walter, L.; Lee, S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Nakagawa, S.; Brown, J.; Thom, D.; Huang, A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Van den Eeden, S.] Kaiser Permanente Div Res, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S104 EP S105 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500286 ER PT J AU Jennings, LA Reuben, D Kim, S Keeler, E Roth, C Zingmond, D Wenger, N Ganz, D AF Jennings, L. A. Reuben, D. Kim, S. Keeler, E. Roth, C. Zingmond, D. Wenger, N. Ganz, D. TI Number of positive responses to a 3-item screen predicts injurious falls among high risk community-dwelling older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Jennings, L. A.; Reuben, D.; Ganz, D.] Univ Calif Los Angeles, Div Geriatr, Los Angeles, CA USA. [Zingmond, D.; Wenger, N.] Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA USA. [Kim, S.; Keeler, E.; Roth, C.] RAND Hlth, Santa Monica, CA USA. [Ganz, D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S119 EP S119 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500324 ER PT J AU Kim, M Shu, Z Shi, Y Kamat, A AF Kim, M. Shu, Z. Shi, Y. Kamat, A. TI Role of Lipin-1 in Beta-Adrenergic Receptor (beta-AR)-Mediated Hepatic Steatosis during Aging SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Kim, M.; Shu, Z.; Shi, Y.; Kamat, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shu, Z.; Shi, Y.; Kamat, A.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S255 EP S255 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500701 ER PT J AU Kinosian, B Edes, T Becker, P Hossain, M AF Kinosian, B. Edes, T. Becker, P. Hossain, M. TI Expanding VA's Home Based Primary Care (HBPC) while Improving Performance: 2006-2012 SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Kinosian, B.] Univ Penn, Philadelphia, PA 19104 USA. [Edes, T.; Becker, P.; Hossain, M.] Dept Vet Affairs, Washington, DC USA. [Kinosian, B.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S136 EP S136 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500371 ER PT J AU Kinosian, B Phibbs, C Dally, S Intrator, O Shay, K AF Kinosian, B. Phibbs, C. Dally, S. Intrator, O. Shay, K. TI Using Cost-Projection Models to evaluate the Department of Veteran Affairs (VA's) T-21 Geriatric Pilots SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Kinosian, B.] Univ Penn, Philadelphia, PA 19104 USA. [Intrator, O.] Univ Rochester, Rochester, NY USA. [Phibbs, C.] Stanford Univ, Palo Alto, CA 94304 USA. [Kinosian, B.; Phibbs, C.; Dally, S.; Intrator, O.; Shay, K.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S18 EP S18 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500045 ER PT J AU Krain, A Olutunmbi, F St Germain, R Gainsley, B Lyons, E Capone-Swearer, D Linkin, D Schwab, E AF Krain, A. Olutunmbi, F. St Germain, R. Gainsley, B. Lyons, E. Capone-Swearer, D. Linkin, D. Schwab, E. TI "Standing Order" Influenza Vaccination Protocol at a Long Term Care Facility SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Krain, A.; Linkin, D.; Schwab, E.] Univ Penn, Philadelphia, PA 19104 USA. [Olutunmbi, F.; St Germain, R.; Gainsley, B.; Lyons, E.; Capone-Swearer, D.; Linkin, D.; Schwab, E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S152 EP S152 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500413 ER PT J AU Marcum, ZA Driessen, J Thorpe, C Donohue, J Gellad, W AF Marcum, Z. A. Driessen, J. Thorpe, C. Donohue, J. Gellad, W. TI Geographic variation in uptake of a novel drug class: the case of incretin mimetics SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Marcum, Z. A.; Driessen, J.; Thorpe, C.; Donohue, J.; Gellad, W.] UPITT, Pittsburgh, PA USA. [Thorpe, C.; Gellad, W.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S132 EP S132 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500360 ER PT J AU Mayans, K Boockvar, K Garrido, MM AF Mayans, K. Boockvar, K. Garrido, M. M. TI Site Differences in Mental Health Care Receipt among Veterans Receiving Palliative Care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Mayans, K.; Boockvar, K.; Garrido, M. M.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY USA. [Boockvar, K.; Garrido, M. M.] James J Peters Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S272 EP S273 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500750 ER PT J AU Mishaw, S Healy, J Sanchez, C Lee, S Sanchez-Reilly, S AF Mishaw, S. Healy, J. Sanchez, C. Lee, S. Sanchez-Reilly, S. TI Cost Analysis of Palliative Care Consults in the Geriatric vs. Non-Geriatric Population SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Mishaw, S.; Healy, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez, C.] Univ Hlth Syst, San Antonio, TX USA. [Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S275 EP S275 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500756 ER PT J AU Mori, T Crandall, CJ Ganz, DA AF Mori, T. Crandall, C. J. Ganz, D. A. TI COST-EFFECTIVENESS OF COMBINED FALL PREVENTION EXERCISE AND ORAL BISPHOSPHONATE THERAPY FOR FRACTURE PREVENTION SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Mori, T.; Ganz, D. A.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. [Mori, T.; Crandall, C. J.; Ganz, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S131 EP S132 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500358 ER PT J AU Nathaniel, J Garrido, MM Chai, E Goldstein, NE AF Nathaniel, J. Garrido, M. M. Chai, E. Goldstein, N. E. TI Cost Analysis of the Palliative Care Unit at Mount Sinai Hospital SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Nathaniel, J.; Garrido, M. M.; Chai, E.; Goldstein, N. E.] Icahn Sch Med, Dept Geriatr & Palliat Med, Mt Sinai, NY USA. [Garrido, M. M.; Goldstein, N. E.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S139 EP S139 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500379 ER PT J AU Patel, C Reilly, SS Karnad, A Lee, S AF Patel, C. Reilly, S. Sanchez Karnad, A. Lee, S. TI To Treat or Not to Treat: An Overview on Cancer Survivorship among Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Patel, C.; Reilly, S. Sanchez; Karnad, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patel, C.; Reilly, S. Sanchez; Karnad, A.; Lee, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S86 EP S86 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500235 ER PT J AU Redding, SE Liu, S Hung, W Boockvar, K AF Redding, S. E. Liu, S. Hung, W. Boockvar, K. TI Opioid Interruptions, Pain, and Withdrawal Symptoms during Acute Illness in Nursing Home Residents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Redding, S. E.; Liu, S.; Hung, W.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Boockvar, K.] Jewish Home Lifecare, Geriatr, New York, NY USA. [Hung, W.; Boockvar, K.] James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S59 EP S59 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500160 ER PT J AU Rodriguez, JC Dzierzewski, J Jouldjian, S Fung, C Martin, J Josephson, K Mitchell, M Alessi, C AF Rodriguez, J. C. Dzierzewski, J. Jouldjian, S. Fung, C. Martin, J. Josephson, K. Mitchell, M. Alessi, C. TI The impact of pain on the efficacy of Cognitive Behavioral Therapy for Insomnia in older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Rodriguez, J. C.; Fung, C.; Martin, J.; Alessi, C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Dzierzewski, J.; Jouldjian, S.; Fung, C.; Martin, J.; Josephson, K.; Mitchell, M.; Alessi, C.] VA Greater Angeles Healthcare Syst, Educ & Clin Ctr, Geriatr Res, Los Angeles, CA USA. [Rodriguez, J. C.] Pontificia Univ Catolica Chile, Santiago, Chile. NR 0 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S146 EP S146 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500398 ER PT J AU Salinas, R AF Salinas, R. TI Late Latent Syphilis: A Red-Herring in a Patient with Spastic Gait, Cognitive Decline, and Upper Motor Findings SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Salinas, R.] VA Puget Sound Hlth Care Syst, Madigan Army Med Ctr, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S175 EP S175 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500477 ER PT J AU Sheffrin, M Miao, Y Steinman, MA AF Sheffrin, M. Miao, Y. Steinman, M. A. TI Weight Loss Associated with Cholinesterase Inhibitors in a National Healthcare System SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 UCSF, Div Geriatr Med, San Francisco, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S12 EP S13 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500031 ER PT J AU Tang, V Stijacic, I Lee, S AF Tang, V. Stijacic, I. Lee, S. TI Lagtime to Benefit after Flexible Sigmoidoscopy Screening for Colorectal Cancer in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Tang, V.; Stijacic, I.; Lee, S.] San Francisco VA Med Ctr, Dept Geriatr, San Francisco, CA USA. [Tang, V.; Stijacic, I.; Lee, S.] UCSF, Dept Geriatr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S132 EP S132 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500359 ER PT J AU Thorpe, CT Obrosky, DS Zhao, X Gellad, W Hanlon, J AF Thorpe, C. T. Obrosky, D. S. Zhao, X. Gellad, W. Hanlon, J. TI Tight Glycemic Control, Use of High-Risk Hypoglycemic Medications, and Associated Factors in Older VA Nursing Home Residents with Diabetes and Comorbid Dementia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 15-17, 2014 CL Orlando, FL SP Amer Geriatr Soc C1 [Thorpe, C. T.; Obrosky, D. S.; Zhao, X.; Gellad, W.; Hanlon, J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Thorpe, C. T.; Gellad, W.; Hanlon, J.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2014 VL 62 SU 1 SI SI BP S127 EP S127 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6XT UT WOS:000333405500347 ER PT J AU Choi, J Choi, KH Reddy, LF Fiszdon, JM AF Choi, Jimmy Choi, Kee-Hong Reddy, L. Felice Fiszdon, Joanna M. TI Measuring motivation in schizophrenia: Is a general state of motivation necessary for task-specific motivation? SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Motivation; Psychosocial rehabilitation; Intrinsic motivation; Quality of life scale; Schizophrenia ID SELF-DETERMINATION THEORY; NEGATIVE SYNDROME SCALE; INTRINSIC MOTIVATION; COMPETENCE; REHABILITATION; NEUROCOGNITION; INDIVIDUALS; INVENTORY; FACTORIAL; COMMUNITY AB Despite the important role of motivation in rehabilitation and functional outcomes in schizophrenia, to date, there has been little emphasis on how motivation is assessed. This is important, since different measures may tap potentially discrete motivational constructs, which in turn may have very different associations to important outcomes. In the current study, we used baseline data from 71 schizophrenia spectrum outpatients enrolled in a rehabilitation program to examine the relationship between task-specific motivation, as measured by the Intrinsic Motivation Inventory (IMI), and a more general state of volition/initiation, as measured by the three item Quality of Life (QLS) motivation index. We also examined the relationship of these motivation measures to demographic, clinical and functional variables relevant to rehabilitation outcomes. The two motivation measures were not correlated, and participants with low general state motivation exhibited a full range of task-specific motivation. Only the QLS motivation index correlated with variables relevant to rehabilitation outcomes. The lack of associations between QLS motivation index and IMI subscales suggests that constructs tapped by these measures may be divergent in schizophrenia, and specifically that task-specific intrinsic motivation is not contingent on a general state of motivation. That is, even in individuals with a general low motivational state (i.e. amotivation), interventions aimed at increasing task-specific motivation may still be effective. Moreover, the pattern of interrelationships between the QLS motivation index and variables relevant to psychosocial rehabilitation supports its use in treatment outcome studies. (C) 2014 Elsevier B. V. All rights reserved. C1 [Choi, Jimmy] Columbia Univ, Med Ctr, New York, NY 10032 USA. [Choi, Kee-Hong] Korea Univ, Dept Psychol, Seoul 136701, South Korea. [Reddy, L. Felice] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC 210A, Los Angeles, CA USA. [Reddy, L. Felice] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Fiszdon, Joanna M.] VA Connecticut Healthcare Syst, Psychol Serv, West Haven, CT 06511 USA. [Fiszdon, Joanna M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA. RP Choi, J (reprint author), Columbia Univ, Med Ctr, 1051 Riverside Dr,Mailbox 100, New York, NY 10032 USA. EM jc3110@columbia.edu; kchoi1@korea.ac.kr; lenafelice@ucla.edu; Joanna.fiszdon@yale.edu FU Department of Veterans Affairs Rehabilitation Research & Development Service [F3195V]; National Institute of Mental Health [K23MH086755] FX This work was supported by the Department of Veterans Affairs Rehabilitation Research & Development Service (J.M.F., F3195V) and the National Institute of Mental Health (J.C., K23MH086755). NR 39 TC 15 Z9 16 U1 3 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR PY 2014 VL 153 IS 1-3 BP 209 EP 213 DI 10.1016/j.schres.2014.01.027 PG 5 WC Psychiatry SC Psychiatry GA AD2GQ UT WOS:000333052800031 PM 24529609 ER PT J AU Peng, HZ Talebzadeh-Farrooji, M Osborne, MJ Prokop, JW McDonald, PC Karar, J Hou, ZY He, M Kebebew, E Orntoft, T Herlyn, M Caton, AJ Fredericks, W Malkowicz, B Paterno, CS Carolin, AS Speicher, DW Skordalakes, E Huang, QH Dedhar, S Borden, KLB Rauscher, FJ AF Peng, Hongzhuang Talebzadeh-Farrooji, Mehdi Osborne, Michael J. Prokop, Jeremy W. McDonald, Paul C. Karar, Jayashree Hou, Zhaoyuan He, Mei Kebebew, Electron Orntoft, Torben Herlyn, Meenhard Caton, Andrew J. Fredericks, William Malkowicz, Bruce Paterno, Christopher S. Carolin, Alexandra S. Speicher, David W. Skordalakes, Emmanuel Huang, Qihong Dedhar, Shoukat Borden, Katherine L. B. Rauscher, Frank J., III TI LIMD2 Is a Small LIM-Only Protein Overexpressed in Metastatic Lesions That Regulates Cell Motility and Tumor Progression by Directly Binding to and Activating the Integrin-Linked Kinase SO CANCER RESEARCH LA English DT Article ID ANKYRIN REPEAT DOMAIN; TRANSCRIPTIONAL REPRESSION; STRUCTURAL BASIS; BACK AGAIN; PINCH; ILK; ADHESION; CANCER; DIFFERENTIATION; COMPLEX AB Proteins that communicate signals from the cytoskeleton to the nucleus are prime targets for effectors of metastasis as they often transduce signals regulating adhesion, motility, and invasiveness. LIM domain proteins shuttle between the cytoplasm and the nucleus, and bind to partners in both compartments, often coupling changes in gene expression to extracellular cues. In this work, we characterize LIMD2, a mechanistically undefined LIM-only protein originally found to be overexpressed in metastatic lesions but absent in the matched primary tumor. LIMD2 levels in fresh and archival tumors positively correlate with cell motility, metastatic potential, and grade, including bladder, melanoma, breast, and thyroid tumors. LIMD2 directly contributes to these cellular phenotypes as shown by overexpression, knockdown, and reconstitution experiments in cell culture models. The solution structure of LIMD2 that was determined using nuclear magnetic resonance revealed a classic LIM-domain structure that was highly related to LIM1 of PINCH1, a core component of the integrin-linked kinase-parvin-pinch complex. Structural and biochemical analyses revealed that LIMD2 bound directly to the kinase domain of integrin-linked kinase (ILK) near the active site and strongly activated ILK kinase activity. Cells that were null for ILK failed to respond to the induction of invasion by LIMD2. This strongly suggests that LIMD2 potentiates its biologic effects through direct interactions with ILK, a signal transduction pathway firmly linked to cell motility and invasion. In summary, LIMD2 is a new component of the signal transduction cascade that links integrin-mediated signaling to cell motility/metastatic behavior and may be a promising target for controlling tumor spread. (c) 2014 AACR. C1 [Peng, Hongzhuang; Karar, Jayashree; Hou, Zhaoyuan; Herlyn, Meenhard; Caton, Andrew J.; Paterno, Christopher S.; Carolin, Alexandra S.; Speicher, David W.; Skordalakes, Emmanuel; Huang, Qihong; Rauscher, Frank J., III] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA. [Fredericks, William; Malkowicz, Bruce] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA. [Fredericks, William; Malkowicz, Bruce] Vet Affairs Med Ctr, Philadelphia, PA USA. [He, Mei; Kebebew, Electron] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Prokop, Jeremy W.] Univ Akron, Akron, OH 44325 USA. [Orntoft, Torben] Aarhus Univ Hosp, Skejby, Denmark. [Talebzadeh-Farrooji, Mehdi; Osborne, Michael J.; Borden, Katherine L. B.] Univ Montreal, Inst Res Immunol & Canc, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada. [McDonald, Paul C.; Dedhar, Shoukat] British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada. RP Borden, KLB (reprint author), Univ Montreal, Inst Res Immunol & Canc, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada. EM katherine.borden@umontreal.ca; rauscher@wistar.org OI Skordalakes, Emmanuel/0000-0002-7600-2833 FU NIH [CA129833, CA010815, CA163761]; DOD-BCRP [W81XWH-11-1-0494] FX Work in the Rauscher laboratory is supported by NIH grants CA129833, CA010815, CA163761, and DOD-BCRP W81XWH-11-1-0494, The Samuel Waxman Cancer Research Foundation, Susan G. Komen for the Cure, and The Noreen O'Neill Foundation for Melanoma Research. K. L. B. Borden holds a Canada Research Chair and is supported by NIH grants NIH RO1-80728 and NIH 98571. NR 40 TC 7 Z9 10 U1 0 U2 12 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAR 1 PY 2014 VL 74 IS 5 BP 1390 EP 1403 DI 10.1158/0008-5472.CAN-13-1275 PG 14 WC Oncology SC Oncology GA AC4FG UT WOS:000332475900013 PM 24590809 ER PT J AU May, CJ Compton, N Falsey, RR Knezevich, S AF May, Caitlin J. Compton, Nicholas Falsey, Ryan R. Knezevich, Stevan TI The best diagnosis is: a. chondroid syringoma b. dermatofibroma c. leiomyosarcoma d. myofibroma e. schwannoma SO CUTIS LA English DT Editorial Material ID FEATURES C1 [May, Caitlin J.; Falsey, Ryan R.] Univ Washington, Div Dermatol, Seattle, WA 98195 USA. [Knezevich, Stevan] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Compton, Nicholas; Knezevich, Stevan] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP May, CJ (reprint author), 660 S Columbian Way, Seattle, WA 98108 USA. NR 5 TC 0 Z9 0 U1 0 U2 2 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 EI 2326-6929 J9 CUTIS JI Cutis PD MAR PY 2014 VL 93 IS 3 BP 129 EP + PG 3 WC Dermatology SC Dermatology GA AD2MW UT WOS:000333070800004 PM 24738101 ER PT J AU Spain, RI Mancini, M Horak, FB Bourdette, D AF Spain, Rebecca I. Mancini, Martina Horak, Fay B. Bourdette, Dennis TI Body-worn sensors capture variability, but not decline, of gait and balance measures in multiple sclerosis over 18 months SO GAIT & POSTURE LA English DT Article DE Multiple sclerosis; Gait; Postural balance; Outcome assessment; Accelerometry ID DISABILITY STATUS SCALE; FUNCTIONAL COMPOSITE; PROGRESSION; IMPAIRMENT; PEOPLE; SCORES; EDSS; MS AB Gait and balance deficits are a frequent complaint in MS but poorly captured by stopwatch-timed tests or rating scales. Body-worn accelerometers and gyroscopes are able to detect gait and balance abnormalities in people with MS who have normal walking speeds. Few longitudinal studies exist using this technology to study the evolution of mobility deficits. The purpose of this study was to determine if body-worn sensors detected any decline in gait and balance measures in people with MS over time. Twenty-seven people with MS (13 mildly disabled, self-rated expanded disability status scale 0-3.5; 14 moderately disabled, SR-EDSS 4.0-5.5) who had normal walking speeds and 18 matched control subjects underwent gait and balance testing using body-worn sensors every 6 months for 18 months. While no parameter worsened over time, the moderately disabled MS cohort performed more poorly than the mildly disabled MS cohort who, in turn, was worse than control subjects for both objective and subjective walking and balance measures. Furthermore, the moderately disabled MS cohort demonstrated greater variation in between-visit performance than did the less disabled MS cohort or controls (Bonferroni-corrected p < 0.05). Variability may be a key indicator of worsening gait and balance disability in MS. Published by Elsevier B. V. C1 [Spain, Rebecca I.; Bourdette, Dennis] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. [Spain, Rebecca I.; Bourdette, Dennis] Portland VA Med Ctr, MS Ctr Excellence West, Portland, OR USA. [Spain, Rebecca I.; Mancini, Martina; Horak, Fay B.; Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. RP Spain, RI (reprint author), Oregon Hlth & Sci Univ, L226,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM spainr@ohsu.edu FU National MS Society [GNEUR0615A]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 RR024140]; NIH Roadmap for Medical Research FX This work was supported by a Pilot Grant from the National MS Society [grant number GNEUR0615A]; and the Oregon Clinical and Translational Research Institute (OCTRI) [grant number UL1 RR024140] from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 24 TC 12 Z9 12 U1 1 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 EI 1879-2219 J9 GAIT POSTURE JI Gait Posture PD MAR PY 2014 VL 39 IS 3 BP 958 EP 964 DI 10.1016/j.gaitpost.2013.12.010 PG 7 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA AD0YM UT WOS:000332960600022 PM 24405749 ER PT J AU Wieczorek, IT Propert, KJ Okawa, J Werth, VP AF Wieczorek, Isabela T. Propert, Kathleen J. Okawa, Joyce Werth, Victoria P. TI Systemic Symptoms in the Progression of Cutaneous to Systemic Lupus Erythematosus SO JAMA DERMATOLOGY LA English DT Article ID DISEASE-ACTIVITY; INDEX; SEVERITY; LESIONS AB IMPORTANCE Patients with cutaneous lupus erythematosus (CLE) who develop systemic lupus erythematosus (SLE) may have few and mild systemic symptoms. OBJECTIVE To characterize the types and severity of systemic symptoms in a longitudinal cohort of patients with CLE. DESIGN, SETTING, AND PARTICIPANTS Prospective, longitudinal cohort study of 77 patients with CLE who presented between January 2007 and April 2011 at a university autoimmune skin disease clinic. MAIN OUTCOMES AND MEASURES Systemic symptoms and severity were determined from data recorded at each study visit and from medical records. RESULTS Of 77 patients with CLE, 13 (17%) went on to meet criteria for SLE, with a mean (SD) time from CLE diagnosis to SLE of 8.03 (6.20) years. Of the 13 patients, 1 (8%) solely met the mucocutaneous American College of Rheumatology (ACR) criteria of malar rash, discoid rash, photosensitivity, and oral ulcers, and 3 (23%) met the mucocutaneous ACR criteria plus positive antinuclear and other antibody titers. After a mean (SD) follow-up time of 2.81 (1.34) years, only 5 of the 13 patients with CLE (38%) who progressed to meet SLE criteria developed moderate to severe additional systemic disease. CONCLUSIONS AND RELEVANCE Patients with CLE who developed SLE during our study did so mostly by meeting the mucocutaneous ACR criteria, and the majority developed none to mild additional systemic disease during the study period. Thus, our study suggests that a small percentage of patients with CLE eventually develop SLE and that even if they do, most patients will have mild systemic disease. C1 [Wieczorek, Isabela T.; Okawa, Joyce; Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Wieczorek, Isabela T.; Okawa, Joyce; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Propert, Kathleen J.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, 3600 Spruce St,2 Rhoads Pavil, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development); National Institutes of Health [NIH K24-AR 02207]; Lupus Foundation of America, Philadelphia Tri-State Chapter FX This study was supported in part by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development) and by the National Institutes of Health (grant NIH K24-AR 02207) (Dr Werth); and The Lupus Foundation of America, Philadelphia Tri-State Chapter (Dr Wieczorek). NR 14 TC 10 Z9 10 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAR PY 2014 VL 150 IS 3 BP 291 EP 296 DI 10.1001/jamadermatol.2013.9026 PG 6 WC Dermatology SC Dermatology GA AD2DQ UT WOS:000333043900013 PM 24477339 ER PT J AU Chirinos, JA Townsend, RR AF Chirinos, Julio A. Townsend, Raymond R. TI Systemic Arterial Hemodynamics and the " Renal Resistive Index:" What is in a Name? SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID TARGET ORGAN DAMAGE; PULSE PRESSURE; BLOOD-PRESSURE; HYPERTENSION; RESISTANCE; DISEASE; VARIABILITY; THERAPY; IMPACT C1 [Chirinos, Julio A.] Univ Penn, Cardiovasc Div, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Townsend, Raymond R.] Univ Penn, Perelman Sch Med, Div Nephrol Hypertens, Philadelphia, PA 19104 USA. RP Chirinos, JA (reprint author), Rm 8B111,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu NR 17 TC 5 Z9 5 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD MAR PY 2014 VL 16 IS 3 BP 170 EP 171 DI 10.1111/jch.12276 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC6HY UT WOS:000332623700005 PM 24548453 ER PT J AU Zeng, Q Ng, YH Singh, T Jiang, K Sheriff, KA Ippolito, R Zahalka, S Li, Q Randhawa, P Hoffman, RA Ramaswami, B Lund, FE Chalasani, G AF Zeng, Qiang Ng, Yue-Harn Singh, Tripti Jiang, Ke Sheriff, Khaleefathullah A. Ippolito, Renee Zahalka, Salwa Li, Qi Randhawa, Parmjeet Hoffman, Rosemary A. Ramaswami, Balathiripurasundari Lund, Frances E. Chalasani, Geetha TI B cells mediate chronic allograft rejection independently of antibody production SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID LONG-TERM; MICE; VASCULOPATHY; DEPLETION; LYMPHOCYTES; EXPRESSION; EFFECTOR; SURVIVAL; IMMUNITY; DISEASE AB Chronic rejection is the primary cause of long-term failure of transplanted organs and is often viewed as an antibody-dependent process. Chronic rejection, however, is also observed in mice and humans with no detectable circulating alloantibodies, suggesting that antibody-independent pathways may also contribute to pathogenesis of transplant rejection. Here, we have provided direct evidence that chronic rejection of vascularized heart allografts occurs in the complete absence of antibodies, but requires the presence of B cells. Mice that were deficient for antibodies but not B cells experienced the same chronic allograft vasculopathy (CAV), which is a pathognomonic feature of chronic rejection, as WT mice; however, mice that were deficient for both B cells and antibodies were protected from CAV. B cells contributed to CAV by supporting splenic lymphoid architecture, T cell cytokine production, and infiltration of T cells into graft vessels. In chimeric mice, in which B cells were present but could not present antigen, both T cell responses and CAV were markedly reduced. These findings establish that chronic rejection can occur in the complete absence of antibodies and that B cells contribute to this process by supporting T cell responses through antigen presentation and maintenance of lymphoid architecture. C1 [Zeng, Qiang; Ng, Yue-Harn; Singh, Tripti; Jiang, Ke; Sheriff, Khaleefathullah A.; Ippolito, Renee; Li, Qi; Randhawa, Parmjeet; Hoffman, Rosemary A.; Ramaswami, Balathiripurasundari; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA. [Zeng, Qiang; Jiang, Ke; Sheriff, Khaleefathullah A.; Ippolito, Renee; Li, Qi; Hoffman, Rosemary A.; Ramaswami, Balathiripurasundari] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Ng, Yue-Harn; Singh, Tripti; Zahalka, Salwa; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Dept Med Renal Electrolyte, Pittsburgh, PA USA. [Ng, Yue-Harn] Natl Univ Singapore Hosp, Dept Med Nephrol, Singapore, Singapore. [Jiang, Ke] Union Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China. [Randhawa, Parmjeet] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. [Hoffman, Rosemary A.; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA. [Lund, Frances E.] Univ Alabama, Dept Microbiol, Birmingham, PA USA. [Chalasani, Geetha] VA Pittsburgh Healthcare Syst, Dept Med Nephrol, Pittsburgh, PA USA. RP Chalasani, G (reprint author), BST W1554,200 Lothrop St, Pittsburgh, PA 15261 USA. EM gec12@pitt.edu FU NIH [A1079 177, AI068056]; ROTRF [978906253]; American Heart Association postdoctoral fellowship; American Society of Transplantation postdoctoral fellowship; Thomas E. Starzl postdoctoral fellowship; University of Pittsburgh Department of Medicine Junior Scholar Award FX This work was supported by grants NIH A1079 177 (to G. Chalasani) and ROTRF 978906253 (to G. Chalasani), an American Heart Association postdoctoral fellowship (to Y-.H. Ng), an American Society of Transplantation postdoctoral fellowship (to K.A. Sheriff), a Thomas E. Starzl postdoctoral fellowship (to K. Jiang), and a University of Pittsburgh Department of Medicine Junior Scholar Award (to G. Chalasani). NIH AI068056 (to F.E. Lund) funds were used to develop, characterize and maintain AIDALS KO mice. We thank Fadi Lakkis and David Rothstein for valuable input and critical comments. NR 28 TC 14 Z9 16 U1 0 U2 4 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2014 VL 124 IS 3 BP 1052 EP 1056 DI 10.1172/JCI70084 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AC2PZ UT WOS:000332347700025 PM 24509079 ER PT J AU Lee, RJ Kofonow, JM Rosen, PL Siebert, AP Chen, B Doghramji, L Xiong, GX Adappa, ND Palmer, JN Kennedy, DW Kreindler, JL Margolskee, RF Cohen, NA AF Lee, Robert J. Kofonow, Jennifer M. Rosen, Philip L. Siebert, Adam P. Chen, Bei Doghramji, Laurel Xiong, Guoxiang Adappa, Nithin D. Palmer, James N. Kennedy, David W. Kreindler, James L. Margolskee, Robert F. Cohen, Noam A. TI Bitter and sweet taste receptors regulate human upper respiratory innate immunity SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID SOLITARY CHEMOSENSORY CELLS; BRONCHIAL EPITHELIAL-CELLS; AIRWAY SURFACE LIQUID; CHRONIC RHINOSINUSITIS; ANTIMICROBIAL PEPTIDES; GLUCOSE-HOMEOSTASIS; CHEMORECEPTOR CELLS; FLUID SECRETION; NASAL CAVITY; SINUS MUCOSA AB Bitter taste receptors (T2Rs) in the human airway detect harmful compounds, including secreted bacterial products. Here, using human primary sinonasal air-liquid interface cultures and tissue explants, we determined that activation of a subset of airway T2Rs expressed in nasal solitary chemosensory cells activates a calcium wave that propagates through gap junctions to the surrounding respiratory epithelial cells. The T2R-dependent calcium wave stimulated robust secretion of antimicrobial peptides into the mucus that was capable of killing a variety of respiratory pathogens. Furthermore, sweet taste receptor (T1R2/3) activation suppressed T2R-mediated antimicrobial peptide secretion, suggesting that T1R2/3-mediated inhibition of T2Rs prevents full antimicrobial peptide release during times of relative health. In contrast, during acute bacterial infection, T1R2/3 is likely deactivated in response to bacterial consumption of airway surface liquid glucose, alleviating T2R inhibition and resulting in antimicrobial peptide secretion. We found that patients with chronic rhinosinusitis have elevated glucose concentrations in their nasal secretions, and other reports have shown that patients with hyperglycemia likewise have elevated nasal glucose levels. These data suggest that increased glucose in respiratory secretions in pathologic states, such as chronic rhinosinusitis or hyperglycemia, promotes tonic activation of T1R2/3 and suppresses T2R-mediated innate defense. Furthermore, targeting T1R2/3-dependent suppression of T2Rs may have therapeutic potential for upper respiratory tract infections. C1 [Lee, Robert J.; Kofonow, Jennifer M.; Rosen, Philip L.; Siebert, Adam P.; Chen, Bei; Doghramji, Laurel; Adappa, Nithin D.; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Xiong, Guoxiang] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA. [Kreindler, James L.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. [Margolskee, Robert F.] Monell Chem Senses Ctr, Philadelphia, PA USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Perelman Sch Med, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM cohenn@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686 FU Flight Attendants Medical Research Institute [082478]; NIH [DC03055]; RLG Foundation Inc. FX We thank D.M. Sabatini, G.K. Beauchamp, and D.R. Reed for helpful discussions and suggestions; W. Meyerhof and D.R. Reed for absinthin; P. Jiang for T2R47-transfected HEK293 cells; and D. LaRosa for Myd88 knockout mice. This work was supported by grant 082478 from Flight Attendants Medical Research Institute (to N:A. Cohen), a philanthropic contribution from the RLG Foundation Inc. (to NA. Cohen), and NIH grant DC03055 (to R.F. Margolskee). NR 75 TC 85 Z9 85 U1 4 U2 35 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2014 VL 124 IS 3 BP 1393 EP 1405 DI 10.1172/JCI72094 PG 13 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AC2PZ UT WOS:000332347700053 PM 24531552 ER PT J AU El-Hage, N Dever, SM Rodriquez, M Masvekaar, RR Shacka, JJ Hauser, KF Gewirtz, DA AF El-Hage, N. Dever, S. M. Rodriquez, M. Masvekaar, R. R. Shacka, J. J. Hauser, K. F. Gewirtz, D. A. TI Opiate and encephalitis mediated dysregulation of autophagy in HIV infected microglia SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY LA English DT Meeting Abstract C1 [El-Hage, N.; Dever, S. M.; Hauser, K. F.; Gewirtz, D. A.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA. [Shacka, J. J.] Univ Alabama Birmingham, Dept Pathol, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Masvekaar, R. R.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA. [Rodriquez, M.] Univ Cent Caribe, Dept Microbiol & Immunol, Bayamon, PR 00970 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1890 EI 1557-1904 J9 J NEUROIMMUNE PHARM JI J. Neuroimmune Pharm. PD MAR PY 2014 VL 9 IS 1 BP 15 EP 16 PG 2 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA AD3ER UT WOS:000333121600034 ER PT J AU Chan, LN Paski, SC AF Chan, Lingtak-Neander Paski, Shirley C. TI Using Plasma Vitamin D Concentration as a Surrogate Marker to Predict Drug Response A New Chapter in the Management of Inflammatory Bowel Disease and Beyond? SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Editorial Material DE nutrition; inflammatory bowel disease; research and diseases; gastroenterology; drug-nutrient interactions; vitamin D ID CROHNS-DISEASE; D-RECEPTOR; TRIAL; MAINTENANCE; ADALIMUMAB; INFLIXIMAB; COLITIS; ALPHA C1 [Chan, Lingtak-Neander] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Chan, Lingtak-Neander] Univ Washington, Grad Program Nutr Sci, Sch Publ Hlth, Seattle, WA 98195 USA. [Paski, Shirley C.] Univ Washington, Div Gastroenterol, Dept Med, Sch Med,VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Chan, LN (reprint author), Univ Washington, Sch Pharm, HSC, Box 357630,1959 NE Pacific St,H-361B, Seattle, WA 98195 USA. EM neander@u.washington.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD MAR PY 2014 VL 38 IS 3 BP 279 EP 280 DI 10.1177/0148607114525470 PG 2 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AC7DV UT WOS:000332688300001 PM 24590306 ER PT J AU Smucny, J Stevens, KE Tregellas, JR AF Smucny, Jason Stevens, Karen E. Tregellas, Jason R. TI Acute administration of Delta(9) tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR LA English DT Article DE Cannabinoid; Clozapine; DBA/2; Gating; P50; Schizophrenia ID NICOTINIC ACETYLCHOLINE-RECEPTORS; SUBSTANCE USE DISORDERS; CANNABIS USE; HIPPOCAMPAL INTERNEURONS; ATYPICAL ANTIPSYCHOTICS; PYRAMIDAL CELLS; SCHIZOPHRENIA; OUTCOMES; ABUSE; RAT AB Despite high rates of marijuana abuse in schizophrenia, the physiological interactions between tetrahydrocannabinol (THC) and antipsychotic medications are poorly understood. A well-characterized feature of schizophrenia is poor gating of the P50 auditory-evoked potential. This feature has been translationally modeled by the DBA/2 mouse, which exhibits poor suppression of the P20-N40 AEP, the rodent analog of the human P50. Previous work has demonstrated that this deficit is reversed by the antipsychotic clozapine. It is unknown, however, if this effect is altered by THC administration. Using a conditioning-testing paradigm with paired auditory stimuli, the effects of clozapine and dronabinol (a pharmaceutical THC formulation) on inhibitory P20-N40 AEP processing were assessed from in vivo hippocampal CA3 recordings in anesthetized DBA/2 mice. The effects of clozapine (0.33 mg/kg) and dronabinol (10 mg/kg) were assessed alone and in combination (033,1 or 1.83 mg/kg clozapine with 10 mg/kg dronabinol). Improved P20-N40 AEP gating was observed after acute administration of 0.33 mg/kg clozapine. Co-injection of 0.33 mg/kg clozapine and 10 mg/kg THC, however, did not improve gating relative to baseline. This effect was overcome by higher doses of clozapine (1 and 1.83 mg/kg), as these doses improved gating relative to baseline in the presence of 10 mg/kg THC. 10 mg/kg THC alone did not affect gating. In conclusion, THC does not prevent improvement of P20-N40 gating by clozapine. (C) 2014 Elsevier Inc. All rights reserved. C1 [Smucny, Jason; Tregellas, Jason R.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA. [Smucny, Jason; Stevens, Karen E.; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Smucny, Jason; Stevens, Karen E.; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. RP Smucny, J (reprint author), Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO 80045 USA. EM Jason.Smucny@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Smucny, Jason/0000-0001-5656-7987 FU Clinical Science Research and Development Service; Brain and Behavior Foundation; Blowitz-Ridgeway Foundation [5P50-MH086383-04]; VA Biomedical Laboratory FX The authors thank Lijun Zheng, B.S. for technical assistance. This work was supported by the VA Biomedical Laboratory and Clinical Science Research and Development Service, the Brain and Behavior Foundation, the Blowitz-Ridgeway Foundation, and 5P50-MH086383-04. NR 48 TC 2 Z9 2 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0091-3057 J9 PHARMACOL BIOCHEM BE JI Pharmacol. Biochem. Behav. PD MAR PY 2014 VL 118 BP 22 EP 29 DI 10.1016/j.pbb.2014.01.001 PG 8 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA AC8ZC UT WOS:000332822600004 PM 24418217 ER PT J AU Fischer, BL Gleason, CE Gangnon, RE Janczewski, J Shea, T Mahoney, JE AF Fischer, Barbara L. Gleason, Carey E. Gangnon, Ronald E. Janczewski, Jodi Shea, Terry Mahoney, Jane E. TI Declining Cognition and Falls: Role of Risky Performance of Everyday Mobility Activities SO PHYSICAL THERAPY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LOWER-EXTREMITY FUNCTION; DWELLING OLDER-ADULTS; EXECUTIVE FUNCTION; ELDERLY PATIENTS; DOUBLE-BLIND; BALANCE; IMPAIRMENT; ATTENTION; ASSOCIATION AB Background. Declining cognition is a risk factor for falls among older adults. The extent to which impaired judgment in performance of daily activities increases fall risk is unclear. Objective. The aim of this study was to determine whether engagement in mobility activities in a risky mariner explains the association between declining cognition and rate of falls. Design. This study was a secondary analysis of baseline and prospective data from older adults enrolled in the intervention arm of a randomized clinical trial. Methods. Two hundred forty-five community-dwelling older adults (79% female; mean age=79 years, SD=8.0) who were at risk for falls received physical, cognitive, and functional evaluations. Cognition was assessed with the Short Portable Mental Status Questionnaire (SPMSQ). Using interview and in-home assessment data, physical therapists determined whether participants were at risk for falls when performing mobility-related activities of daily living (ADL) and instrumental ADL (IADL). Falls were measured prospectively for 1 year using monthly falls diaries. Results. Declining cognition was associated with increased number of mobility activities designated as risky (1.5% of mobility activities performed in a risky manner per SPMSQ point) and with increased rate of falls (rate ratio=1.16 for each unit change in SPMSQ score). Risky performance of mobility activities mediated the relationship between cognition and rate of falls. Limitations. Risk assessment was based on the clinical judgment of experienced physical therapists. Cognition was measured with a relatively insensitive instrument, and only selected mobility activities were evaluated. Conclusions. Engagement in mobility ADL and IADL tasks in a risky manner emerged as a link between declining cognition and increased number of falls, suggesting a mechanism through which the rate of falls may increase. Specifically, declining cognition is associated with performance of mobility activities in an unsafe manner, thereby increasing the risk for falls. C1 [Fischer, Barbara L.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Gleason, Carey E.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI USA. [Gleason, Carey E.; Mahoney, Jane E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Geriatr, Madison, WI USA. [Gangnon, Ronald E.] Univ Wisconsin Madison, Dept Biostat, Madison, WI USA. [Gangnon, Ronald E.] Univ Wisconsin Madison, Dept Med Informat & Populat Hlth Sci, Madison, WI USA. [Janczewski, Jodi; Shea, Terry] Univ Wisconsin Hosp & Clin, Dept Orthoped & Rehabil, Madison, WI 53792 USA. RP Fischer, BL (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terr, Madison, WI 53705 USA. EM barbaralfischer@gmail.com FU Centers for Disease Control and Prevention, National Center for Injury Prevention and Control [02151]; National Institutes of Health, National Institute on Aging [K23 AG024302]; Alzheimer's Disease Research Center [P50 AG033514] FX This work was supported by the Centers for Disease Control and Prevention, National Center for Injury Prevention and Control (grant PA #02151 to Dr Mahoney); the National Institutes of Health, National Institute on Aging (grant #K23 AG024302 to Dr Gleason); and the Alzheimer's Disease Research Center (grant #P50 AG033514 to Dr Gleason). NR 52 TC 7 Z9 9 U1 3 U2 12 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 EI 1538-6724 J9 PHYS THER JI Phys. Ther. PD MAR PY 2014 VL 94 IS 3 BP 355 EP 362 DI 10.2522/ptj.20130195 PG 8 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA AC2RI UT WOS:000332351300009 PM 24231226 ER PT J AU Bush, NE Prins, A Laraway, S O'Brien, K Ruzek, J Ciulla, RP AF Bush, Nigel E. Prins, Annabel Laraway, Sean O'Brien, Karen Ruzek, Josef Ciulla, Robert P. TI A Pilot Evaluation of the AfterDeployment.org Online Posttraumatic Stress Workshop for Military Service Members and Veterans SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE posttraumatic stress; military; online; veterans ID MENTAL-HEALTH PROBLEMS; RANDOMIZED CONTROLLED-TRIAL; NATIONAL-GUARD SOLDIERS; CLINICAL-SIGNIFICANCE; DEPRESSION; DISORDER; CARE; INTERNET; COMBAT; IRAQ AB This pilot study employed a nonconcurrent, multiple-baseline single-case design to examine the impact of an online self-management posttraumatic stress (PTS) workshop on self-reported symptoms of PTS, depression, and functional impairment. Eleven student veterans with PTS first completed between three and five weekly baseline measures. Second, they took part in eight weekly online workshop sessions, each accompanied by symptom assessments. Third, they completed postintervention outcome measures. We found statistically significant reductions in PTS from baseline across workshop sessions for four of 11 participants, and significant overall reductions in PTS between enrollment and postintervention for five participants. One participant also demonstrated significantly reduced depressive symptoms from baseline across the intervention, and two evidenced significant overall reductions from enrollment to postintervention. Three student veterans showed significantly improved general functioning across the sessions and one reported significant overall functional increase. Finally, five of six participants who completed extended measures of educational function showed significant improvements from enrollment to postintervention. Among secondary outcomes, more than 80% of those taking part said they would recommend the online PTS workshop to a colleague or fellow student with PTS issues. These preliminary findings show that our online PTS workshop can be effective in reducing PTS symptoms in some cases, but also suggest that additional research is needed. With increasing numbers of service members and veterans using the Internet and many reluctant or unable to seek in-person care because of stigma or limited access, the time seems right to further examine the utility of networked PTS resources. C1 [Bush, Nigel E.] US Dept Def, Natl Ctr Telehlth & Technol T2, Tacoma, WA USA. [Prins, Annabel; Ruzek, Josef] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Menlo Pk, CA USA. [Prins, Annabel; Laraway, Sean] San Jose State Univ, Dept Psychol, San Jose, CA 95192 USA. [O'Brien, Karen; Ciulla, Robert P.] US Dept Def, Natl Ctr Telehlth & Technol, Tacoma, WA USA. RP Bush, NE (reprint author), Natl Ctr Telehlth & Technol T2, OMAMC, Joint Base Lewis McChord, 9933 West Hayes St, Tacoma, WA 98431 USA. EM nigel.bush@us.army.mil NR 49 TC 2 Z9 2 U1 3 U2 14 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD MAR PY 2014 VL 6 IS 2 BP 109 EP 119 DI 10.1037/a0032179 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AD2VU UT WOS:000333094800002 ER PT J AU Mansoor, D Ganzini, L AF Mansoor, David Ganzini, Linda TI Musical Hallucinations Successfully Treated with Antipsychotic Medications: Three Case Reports SO PSYCHOSOMATICS LA English DT Article ID ACQUIRED DEAFNESS; PHENOMENOLOGY; HALLUCINOSIS C1 [Mansoor, David; Ganzini, Linda] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Dept Psychiat, Portland, OR 97239 USA. RP Mansoor, D (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Dept Psychiat, 3710 SW US Vet Hosp Rd,Mail Code R&D 66, Portland, OR 97239 USA. EM mansoord@ohsu.edu NR 16 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD MAR-APR PY 2014 VL 55 IS 2 BP 191 EP 193 PG 3 WC Psychiatry; Psychology SC Psychiatry; Psychology GA AD2SN UT WOS:000333085600010 PM 23756119 ER PT J AU Warren, SA Huszti, E Bradley, SM Chan, PS Bryson, CL Fitzpatrick, AL Nichol, G AF Warren, Sam A. Huszti, Ella Bradley, Steven M. Chan, Paul S. Bryson, Chris L. Fitzpatrick, Annette L. Nichol, Graham CA Amer Heart Assoc Get TI Adrenaline (epinephrine) dosing period and survival after in-hospital cardiac arrest: A retrospective review of prospectively collected data SO RESUSCITATION LA English DT Article DE Arrhythmia; Cardiopulmonary resuscitation; Heart arrest; Pharmacology ID AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; DOSE EPINEPHRINE; HYPOTHERMIA; OUTCOMES; TRIAL; CARE AB Background and aim: Expert guidelines for treatment of cardiac arrest recommend administration of adrenaline (epinephrine) every three to five minutes. However, the effects of different dosing periods of epinephrine remain unclear. We sought to evaluate the association between epinephrine average dosing period and survival to hospital discharge in adults with an in-hospital cardiac arrest (IHCA). Methods: We performed a retrospective review of prospectively collected data on 20,909 IHCA events from 505 hospitals participating in the Get With The Guidelines-Resuscitation (GWTG-R) quality improvement registry. Epinephrine average dosing period was defined as the time between the first epinephrine dose and the resuscitation endpoint, divided by the total number of epinephrine doses received subsequent to the first epinephrine dose. Associations with survival to hospital discharge were assessed by using generalized estimating equations to construct multivariable logistic regression models. Results: Compared to a referent epinephrine average dosing period of 4 to <5 min per dose, survival to hospital discharge was significantly higher in patients with the following epinephrine average dosing periods: for 6 to <7 min/dose, adjusted odds ratio [OR], 1.41 (95%CI: 1.12, 1.78); for 7 to <8 min/dose, adjusted OR, 1.30 (95%CI: 1.02, 1.65); for 8 to <9 min/dose, adjusted OR, 1.79 (95%CI: 1.38, 2.32); for 9 to <10 min/dose, adjusted OR, 2.17 (95%CI: 1.62, 2.92). This pattern was consistent for both shockable and non-shockable cardiac arrest rhythms. Conclusion: Less frequent average epinephrine dosing than recommended by consensus guidelines was associated with improved survival of in-hospital cardiac arrest. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Warren, Sam A.; Huszti, Ella; Nichol, Graham] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98124 USA. [Warren, Sam A.; Huszti, Ella; Bradley, Steven M.; Bryson, Chris L.; Nichol, Graham] Dept Med, Seattle, WA USA. [Warren, Sam A.; Fitzpatrick, Annette L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Chan, Paul S.] St Lukes Midamer Heart & Vasc Inst, Kansas City, MO USA. [Chan, Paul S.] Univ Missouri, Kansas City, MO 64110 USA. [Bradley, Steven M.; Bryson, Chris L.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. [Fitzpatrick, Annette L.] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98124 USA. [Fitzpatrick, Annette L.] Univ Washington, Dept Global Hlth, Seattle, WA 98124 USA. [Nichol, Graham] Univ Washington, Dept Biostat, Clin Trial Ctr, Seattle, WA 98195 USA. RP Warren, SA (reprint author), Univ Washington, Harborview Med Ctr, Harborview Ctr Prehosp Emergency Care, Dept Med, Box 359702,325 Ninth Ave, Seattle, WA 98124 USA. EM sawarren@u.washington.edu FU Get With The Guidelines-Resuscitation; American Heart Association; Department of Health and Human Services, Public Health Services [HP10002-21-00] FX Data acquisition was funded by Get With The Guidelines-Resuscitation which is supported by the American Heart Association and membership fees paid by participating hospitals. The remainder of the study was funded by a Fellowship training grant from Department of Health and Human Services, Public Health Services, Grant Type 6, Activity T32, ID Serial No. HP10002-21-00, Principal Investigator: Paula Lozano, MD, MPH. NR 24 TC 9 Z9 10 U1 1 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD MAR PY 2014 VL 85 IS 3 BP 350 EP 358 DI 10.1016/j.resuscitation.2013.10.004 PG 9 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA AC8IR UT WOS:000332777200017 PM 24252225 ER PT J AU Lichtman, JH Wang, YF Jones, SB Leifheit-Limson, EC Shaw, LJ Vaccarino, V Rumsfeld, JS Krumholz, HM Curtis, JP AF Lichtman, Judith H. Wang, Yongfei Jones, Sara B. Leifheit-Limson, Erica C. Shaw, Leslee J. Vaccarino, Viola Rumsfeld, John S. Krumholz, Harlan M. Curtis, Jeptha P. TI Age and sex differences in inhospital complication rates and mortality after percutaneous coronary intervention procedures: Evidence from the NCDR (R) SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR CONSORTIUM BMC2; AMERICAN-HEART-ASSOCIATION; INSTITUTE DYNAMIC REGISTRY; IN-HOSPITAL MORTALITY; BODY-SURFACE AREA; CROSS BLUE-SHIELD; GENDER-DIFFERENCES; CLINICAL-OUTCOMES; ACUITY TRIAL AB Background Older women experience higher complication rates and mortality after percutaneous coronary intervention (PCI) than men, but there is limited evidence about sex-based differences in outcomes among younger patients. We compared rates of complications and inhospital mortality by sex for younger and older PCI patients. Methods A total of 1,079,751 hospital admissions for PCI were identified in the CathPCI Registry (R) from 2005 to 2008. Complication rates (general, bleeding, bleeding with transfusion, and vascular) and inhospital mortality after PCI were compared by sex and age (<55 and >= 55 years). Analyses were adjusted for demographic and clinical factors and stratified by PCI type (elective, urgent, or emergency). Results Overall, 6% of patients experienced complications, and 1% died inhospital. Unadjusted complication rates were higher for women compared with men in both age groups. In risk-adjusted analyses, younger women (odds ratio 1.24, 95% CI 1.16-1.33) and older women (1.27, 1.09-1.47) were more likely to experience any complication than similarly aged men. The increased risk persisted across complication categories and PCI type. Within age groups, risk-adjusted mortality was marginally higher for young women (1.19, 1.00-1.41), but not for older women (1.03, 0.97-1.10). In analyses stratified by PCI type, young women had twice the mortality risk after an elective procedure as young men (2.04, 1.15-3.61). Conclusions Women, regardless of age, experience more complications after PCI than men; young women are at increased mortality risk after an elective PCI. Identifying strategies to reduce adverse outcomes, particularly for women younger than 55 years, is important. C1 [Lichtman, Judith H.; Jones, Sara B.; Leifheit-Limson, Erica C.; Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. [Lichtman, Judith H.; Wang, Yongfei; Krumholz, Harlan M.; Curtis, Jeptha P.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Shaw, Leslee J.; Vaccarino, Viola] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Krumholz, Harlan M.; Curtis, Jeptha P.] Yale Univ, Sch Med, New Haven, CT 06520 USA. RP Lichtman, JH (reprint author), Yale Univ, Sch Publ Hlth, POB 208034, New Haven, CT 06520 USA. EM Judith.Lichtman@yale.edu NR 46 TC 21 Z9 25 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAR PY 2014 VL 167 IS 3 BP 376 EP 383 DI 10.1016/j.ahj.2013.11.001 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AC3DT UT WOS:000332395900016 PM 24576523 ER PT J AU Vital, P Castro, P Tsang, S Ittmann, M AF Vital, Paz Castro, Patricia Tsang, Susan Ittmann, Michael TI The Senescence-Associated Secretory Phenotype Promotes Benign Prostatic Hyperplasia SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID EPITHELIAL GROWTH-FACTOR; URINARY-TRACT SYMPTOMS; CELLULAR SENESCENCE; CANCER PROGRESSION; REACTIVE STROMA; CATHEPSIN-D; PARACRINE INDUCER; GENE-EXPRESSION; CELLS; PROLIFERATION AB Benign prostatic hyperplasia (BPH) is characterized by increased tissue mass in the transition zone of the prostate, which leads to obstruction of urine outflow and considerable morbidity in a majority of older men. Senescent cells accumulate in human tissues, including the prostate, with increasing age. Expression of proinflammatory cytokines is increased in these senescent cells, a manifestation of the senescence-associated secretory phenotype. Multiplex analysis revealed that multiple cytokines are increased in BPH, including GM-CSF, IL-1 alpha, and IL-4, and that these are also increased in senescent prostatic epithelial cells in vitro. Tissue levels of these cytokines were correlated with a marker of senescence (cathepsin D), which was also strongly correlated with prostate weight. IHC analysis revealed the multifocal epithelial expression of cathepsin D and coexpression with IL-1a in BPH tissues. In tissue recombination studies in nude mice with immortalized prostatic epithelial cells expressing IL-1 alpha and prostatic stromal cells, both epithelial and stromal cells exhibited increased growth. Expression of IL-1 alpha in prostatic epithelial cells in a transgenic mouse model resulted in increased prostate size and bladder obstruction. In summary, both correlative and functional evidence support the hypothesis that the senescence-associated secretory phenotype can promote the development of BPH, which is the single most common age-related pathology in older men. C1 [Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, One Baylor Plaza, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu FU NIH [R01-DK083244, P20-DK097775, T32-DK007763, T32-AG000183, P30-CA125123] FX Supported by NIH grants R01-DK083244 (Md.), P20-DK097775 (M.I.), T32-DK007763 (DL.), T32-AG000183 (L.D.), and P30-CA125123 (Human Tissue Acquisition and Pathology, Genetically Engineered Mouse, and Proteomics cores) and by use of the facilities of the Michael E. DeBakey Veterans Affairs Medical Center. NR 44 TC 3 Z9 3 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD MAR PY 2014 VL 184 IS 3 BP 721 EP 731 DI 10.1016/j.ajpath.2013.11.015 PG 11 WC Pathology SC Pathology GA AB8QQ UT WOS:000332055500014 PM 24434012 ER PT J AU Zhu, X Cho, ES Sha, Q Peng, JB Oksov, Y Kam, SY Ho, M Walker, RH Leer, S AF Zhu, Xiang Cho, Eun-Sook Sha, Quan Peng, Jianbin Oksov, Yelena Kam, Siok Yuen Ho, Mengfatt Walker, Ruth H. Leer, Soohee TI Giant Axon Formation in Mice Lacking Kell, XK, or Kell and XK Animal Models of McLeod Neuroacanthocytosis Syndrome SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; BLOOD-GROUP PROTEIN; NEUROFILAMENT ACCUMULATION; NERVOUS-SYSTEM; MOUSE KELL; GENE KEL; TRANSPORT; EXPRESSION; COMPLEX; ORGANIZATION AB McLeod neuroacanthocytosis syndrome (MLS) is a rare X-Linked muttisystem disease caused by XK gene mutations and characterized by hematological and neurological abnormalities. XK, a putative membrane transporter, is expressed ubiquitously and is covalently linked to Kell, an endothelin-3-converting enzyme (ECE-3). Absence of XK results in reduction of Kell at sites where both proteins are coexpressed. To elucidate the functional roles of XK, Kell, and the XK-Kell complex associated with pathogenesis in MIS, we studied the pathology of the spinal cord, anterior roots, sciatic nerve, and skeletal muscle from knockout mouse models, using Kel(-/-), Xk(-/-), Kel(-/-)Xk(-/-), and wild-type mice aged 6 to 18 months. A striking finding was that giant axons were frequently associated with paranodaL demyelination. The pathology suggests probable anterograde progression from the spinal cord to the sciatic nerve. The neuropathologicaL abnormalities were found in all three genotypes, but were more marked in the double-knockout Kel(-/-)Xk(-/-) mice than in either Kel(-/-) or Xk/- mice. Skeletal muscles from Xk(-/-) and Kel(-/-)Xk(-/-) mice showed mild abnormalities, but those from Kel(-/-) mice were similar to the wild type. The more marked neuropathological abnormalities in Kel(-/-)Xk(-/-) mice suggest a possible functional association between XK and Kell in nonerythroid tissues. C1 [Zhu, Xiang] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100191, Peoples R China. [Zhu, Xiang; Sha, Quan; Peng, Jianbin; Oksov, Yelena; Leer, Soohee] New York Blood Ctr, New York, NY 10021 USA. [Cho, Eun-Sook] Rutgers State Univ, New Jersey Med Sch, Dept Pathol & Lab Med Neuropathol, Newark, NJ 07102 USA. [Sha, Quan] Immunomedics, Dept Cell Line Dev, Morris Plains, NJ USA. [Kam, Siok Yuen; Ho, Mengfatt] Natl Canc Ctr, Div Med Sci, Singapore, Singapore. [Walker, Ruth H.] James J Peters VAMC, Dept Neurol, Bronx, NY USA. [Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. RP Zhu, X (reprint author), Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100191, Peoples R China. EM zhuxiangbjmu@163.com FU NIH [R01 HL075716] FX Supported by NIH grant R01 HL075716 (S.L.). NR 43 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD MAR PY 2014 VL 184 IS 3 BP 800 EP 807 DI 10.1016/j.ajpath.2013.11.013 PG 8 WC Pathology SC Pathology GA AB8QQ UT WOS:000332055500021 PM 24405768 ER PT J AU Overton, LC Heinrich, MC AF Overton, Lindsay C. Heinrich, Michael C. TI Regorafenib for treatment of advanced gastrointestinal stromal tumors SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE gastrointestinal stromal tumor; kinase inhibitors; KIT; platelet-derived growth factor receptor alpha; sarcoma; vascular endothelial growth factor receptor ID METASTATIC COLORECTAL-CANCER; TYROSINE KINASE INHIBITOR; RENAL-CELL CARCINOMA; PHASE-I; IMATINIB RESISTANCE; ANTITUMOR-ACTIVITY; RANDOMIZED-TRIAL; BAY 73-4506; SUNITINIB; KIT AB Introduction: Gastrointestinal stromal tumors (GISTs) are abdominal sarcomas which are extremely refractory to chemotherapy treatment. The treatment of GISTs has been revolutionized by use of KIT/platelet-derived growth factor receptor-alpha (PDGFRA) kinase inhibitors. Unfortunately, most tumors develop resistance to front-line (imatinib) or second-line (sunitinib) therapy. Regorafenib, a KIT/PDGFRA/vascular endothelial growth factor receptor (VEGFR) oral kinase inhibitor, has been shown to improve progression-free survival in the third- or fourth-line setting. Areas covered: This review covers the preclinical and clinical studies of regorafenib for treatment of GIST. A literature search on regorafenib was carried out using the PubMed database up to October 2013. Expert opinion: Currently, imatinib and sunitinib represent the only proven first- and second-line therapies, respectively, for advanced GISTs. Based on the results of a Phase III study, regorafenib is now established as the only proven third-line therapy. Regorafenib activity in this setting is believed to be due to its activity against oncogenic forms of KIT/PDGFRA. Although side effects are common with this agent, they can be effectively managed with a combination of supportive care, dose interruptions/reductions. The toxicity profile is similar to other oral kinase inhibitors with anti-VEGFR activity. Regorafenib is mainly metabolized by CYP3A4, and concomitant use of strong inducers/inhibitors of this enzyme should be avoided. C1 [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. [Heinrich, Michael C.] OHSU Knight Canc Inst, Portland, OR 97239 USA. RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,Bldg 103 Lab E223,R&D 19, Portland, OR 97239 USA. EM Heinrich@ohsu.edu FU VA Merit Review Grant; GIST Cancer Research Fund; Life Raft Group FX M Heinrich: Consultant - Ariad, Molecular MD, Novartis, Pfizer. Speaker's honorarium - Onyx, Novartis. Equity interest Molecular MD. Intellectual property - patent on treatment of GIST with imatinib - assigned to my institution and licensed to Novartis. L Overton has no conflicts of interest. This paper has been supported by a VA Merit Review Grant, GIST Cancer Research Fund, Life Raft Group. NR 59 TC 6 Z9 6 U1 0 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1465-6566 EI 1744-7666 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD MAR PY 2014 VL 15 IS 4 BP 549 EP 558 DI 10.1517/14656566.2014.877888 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AC5XQ UT WOS:000332594700010 PM 24405315 ER PT J AU Luttrell, LM AF Luttrell, Louis M. TI Minireview: More Than Just a Hammer: Ligand "Bias" and Pharmaceutical Discovery SO MOLECULAR ENDOCRINOLOGY LA English DT Review ID PROTEIN-COUPLED RECEPTOR; BETA(2) ADRENERGIC-RECEPTOR; PARATHYROID-HORMONE PTH; RESONANCE ENERGY-TRANSFER; GROWTH-FACTOR RECEPTOR; KAPPA-OPIOID RECEPTORS; FUNCTIONAL SELECTIVITY; BETA(2)-ADRENERGIC RECEPTOR; ACTIVATED RECEPTOR-2; IN-VIVO AB Conventional orthosteric drug development programs targeting G protein-coupled receptors (GPCRs) have focused on the concepts of agonism and antagonism, in which receptor structure determines the nature of the downstream signal and ligand efficacy determines its intensity. Over the past decade, the emerging paradigms of "pluridimensional efficacy" and "functional selectivity" have revealed that GPCR signaling is not monolithic, and that ligand structure can "bias" signal output by stabilizing active receptor states in different proportions than the native ligand. Biased ligands are novel pharmacologic entities that possess the unique ability to qualitatively change GPCR signaling, in effect creating "new receptors" with distinct efficacy profiles driven by ligand structure. The promise of biased agonism lies in this ability to engender "mixed" effects not attainable using conventional agonists or antagonists, promoting therapeutically beneficial signals while antagonizing deleterious ones. Indeed, arrestin pathway-selective agonists for the type 1 parathyroid hormone and angiotensin AT(1) receptors, and G protein pathway-selective agonists for the GPR109A nicotinic acid and mu-opioid receptors, have demonstrated unique, and potentially therapeutic, efficacy in cell-based assays and preclinical animal models. Conversely, activating GPCRs in "unnatural" ways may lead to downstream biological consequences that cannot be predicted from prior knowledge of the actions of the native ligand, especially in the case of ligands that selectively activate as-yet poorly characterized G protein-independent signaling networks mediated via arrestins. Although much needs to be done to realize the clinical potential of functional selectivity, biased GPCR ligands nonetheless appear to be important new additions to the pharmacologic toolbox. C1 [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,Suite 816 Clin Sci Bldg, Charleston, SC 29425 USA. EM luttrell@musc.edu FU National Institutes of Health [DK055524, R01 GM095497]; Research Service of the Charleston, South Carolina Veterans Affairs Medical Center FX This work was supported by National Institutes of Health Grants DK055524 and R01 GM095497 (to L.M.L.), and the Research Service of the Charleston, South Carolina Veterans Affairs Medical Center. NR 169 TC 42 Z9 44 U1 0 U2 31 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD MAR PY 2014 VL 28 IS 3 BP 281 EP 294 DI 10.1210/me.2013-1314 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AC2ZJ UT WOS:000332384500002 PM 24433041 ER PT J AU Chao, LL Mohlenhoff, BS Weiner, MW Neylan, TC AF Chao, Linda L. Mohlenhoff, Brian S. Weiner, Michael W. Neylan, Thomas C. TI Associations between Subjective Sleep Quality and Brain Volume in Gulf War Veterans SO SLEEP LA English DT Article DE Frontal lobe; structural imaging; Freesurfer; Pittsburgh Sleep Quality Index; Gulf War Veterans ID GRAY-MATTER CONCENTRATION; ADMINISTERED PTSD SCALE; US ARMY VETERANS; PREFRONTAL CORTEX; CYCLOSARIN EXPOSURE; NARCOLEPSY PATIENTS; HIPPOCAMPAL VOLUME; CHILDHOOD TRAUMA; PRIMARY INSOMNIA; OLDER-ADULTS AB Study Objectives: To investigate whether subjective sleep quality is associated with brain volume independent of comorbid psychiatric conditions. Design: Cross-sectional. Setting: Department of Veterans Affairs (VA) Medical Center. Participants: One hundred forty-four Gulf War Veterans (mean age 45 years; range: 31-70 years; 14% female). Interventions: None. Measurements and Results: Total cortical, lobar gray matter, and hippocampal volumes were quantified from 1.5 Tesla magnetic resonance images using Freesurfer version 4.5. Subjective sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI). Multiple linear regressions were used to determine the association of sleep quality with total and regional brain volumes. The global PSQI score was positively correlated with lifetime and current posttraumatic stress disorder (PTSD) and current depressive symptoms (P < 0.001) and was higher in veterans with Gulf War Illness, trauma exposure, and those using psychotropic medication (P <= 0.03). After adjusting for these comorbid variables, age, intracranial volume, and multiple comparisons, global PSQI was inversely associated with total cortical and frontal gray matter volume (adjusted P <= 0.03). Within the frontal lobe, total PSQI was inversely associated with the superior and middle frontal, orbitofrontal, anterior cingulate, and frontal pole volumes (adjusted P <= 0.02). Examination of the 3-factor structure of the PSQI revealed that the associations were driven by perceived sleep quality. Conclusions: Poorer subjective sleep quality was associated with reduced total cortical and regional frontal lobe volumes independent of comorbid psychiatric conditions. Future work will be needed to examine if effective treatment of disturbed sleep leads to improved structural and functional integrity of the frontal lobes. C1 [Chao, Linda L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Chao, Linda L.; Mohlenhoff, Brian S.; Weiner, Michael W.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Chao, Linda L.; Mohlenhoff, Brian S.; Weiner, Michael W.] Dept Vet Affairs Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Neylan, Thomas C.] Dept Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA USA. RP Chao, LL (reprint author), San Francisco VA Med Ctr, 4150 Clement St,114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu FU Department of Defense [DAMD17-01-1-0764]; Department of Defense Gulf War Illnesses Research Program, US Army Medical Research and Materiel Command; Mental Illness Research, Education and Clinical Center at VA VISN 21; Department of Defense and study medication from Glaxo Smith Kline [GSK561679]; Department of Veterans Affairs; Pfizer; Merck; Avid; Departments of Defense and Veterans' Affairs; NIA; Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Anonymous Foundation; AstraZeneca; Bayer Healthcare; BioClinica Inc; Bristol-Meyers Squibb; Cure Alzheimer's Fund < Eisai; Elan; Gene Network Sciences; Genetech; GE Healthcare; GlaxoSmithKline; Innogenetics; Johnson Johnson; Eli Lilly Company; Medpace; Novartis; Pfizer Inc; Roche; Schering Plough; Wyeth; [R25MH060482] FX This was not an industry supported study. This study was supported by Department of Defense Grant DAMD17-01-1-0764, entitled, "Magnetic Resonance and Spectroscopy of the Human Brain in Gulf War Illness," awarded to the Northern California Institute for Research and Education from the Department of Defense Gulf War Illnesses Research Program, US Army Medical Research and Materiel Command. Further support was provided by the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration. Brian S. Mohlenhoff received funding from R25MH060482 and the Mental Illness Research, Education and Clinical Center at VA VISN 21. Resources and the use of facilities were provided by the Veterans Administration Medical Center, San Francisco, California. Dr. Neylan has received study medication (almorexant) from Actelion for a study funded by the Department of Defense and study medication (GSK561679) from Glaxo Smith Kline for a study funded by the Department of Veterans Affairs. Neither is relevant to the content of this report. Dr. Weiner has served on the scientific advisory boards of Pfizer & BOLT international in 2011. He has served as a consultant for Pfizer, Janssen, KLK Associates, Easton Associates, Harvard University, KLJ Associates, in Thought, INC, Research, Inc, University of California (Los Angeles), Alzheimer's Drug Discovery Foundation, Alzheimer's Drug Discovery Foundation, Avid Radio Pharmaceuticals, Eli Lilly, and Sanofi-Aventis. He has received funding for travel from Pfizer, AD PD meeting, Paul Sabatier University, Novartis, Tohoku University, from the MCI Group, France, Travel eDreams, Inc, Neuroscience School of Advanced Studies, Danone Trading, VB, CTAD ANT Congress, ADRC, University of California (Los Angeles), and from AD/PD, ADRC, UCLA. He serves on the editorial advisory boards of Alzheimer's & Dementia and MRI. He has received honoraria from Pfizer, Tohoku University, and from Danone Trading BV. He has received commercial entities research support from Merck and Avid. He has received government entities research support from the Departments of Defense and Veterans' Affairs. He has stock options in Elan. Organizations contributing to the Foundation for NIH and thus to the NIA funded Alzheimer's Disease Neuroimaging Initiative (ADNI) include the following: Abbott, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Anonymous Foundation, AstraZeneca, Bayer Healthcare, BioClinica Inc, Bristol-Meyers Squibb, Cure Alzheimer's Fund < Eisai, Elan, Gene Network Sciences, Genetech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly & Company, Medpace, Merck, Novartis, Pfizer Inc, Roche, Schering Plough, Wyeth. The other authors have indicated not financial conflicts of interest. This study does not include any off-label or investigational use. NR 65 TC 6 Z9 6 U1 3 U2 10 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2014 VL 37 IS 3 BP 445 EP 452 DI 10.5665/sleep.3472 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AC4VY UT WOS:000332520400003 PM 24587566 ER PT J AU Espaldon, R Kirby, KA Fung, KZ Hoffman, RM Powell, AA Freedland, SJ Walter, LC AF Espaldon, Roxanne Kirby, Katharine A. Fung, Kathy Z. Hoffman, Richard M. Powell, Adam A. Freedland, Stephen J. Walter, Louise C. TI Probability of an Abnormal Screening Prostate-specific Antigen Result Based on Age, Race, and Prostate-specific Antigen Threshold SO UROLOGY LA English DT Article ID REFERENCE RANGES; MEN; CANCER; OLDER AB OBJECTIVE To determine the distribution of screening prostate-specific antigen (PSA) values in older men, and how different PSA thresholds affect the proportion of white, black, and Latino men who would have an abnormal screening result across advancing age groups. METHODS We used linked national Veterans Affairs and Medicare data to determine the value of the first screening PSA test (ng/mL) of 327,284 men older than 65 years who underwent PSA screening in the Veterans Affairs health care system in 2003. We calculated the proportion of men with an abnormal PSA result based on age, race, and common PSA thresholds. RESULTS Among men older than 65 years, 8.4% had a PSA >4.0 ng/mL. The percentage of men with a PSA >4.0 ng/mL increased with age and was highest in black men (13.8%) vs white (8.0%) or Latino men (10.0%) (P < .001). Combining age and race, the probability of having a PSA >4.0 ng/mL ranged from 5.1% of Latino men aged 65-69 years to 27.4% of black men older than 85 years. Raising the PSA threshold from >4.0 ng/mL to >10.0 ng/mL reclassified the greatest percentage of black men older than 85 years (18.3% absolute change) and the lowest percentage of Latino men aged 65-69 years (4.8% absolute change) as being under the biopsy threshold (P < .001). CONCLUSION Age, race, and PSA threshold together affect the pretest probability of an abnormal screening PSA result. Based on screening PSA distributions, stopping screening among men whose PSA < 3 ng/mL means more than 80% of white and Latino men older than 70 years would stop further screening, and increasing the biopsy threshold to >10 ng/mL has the greatest effect on reducing the number of older black men who will face biopsy decisions after screening. (C) 2014 Elsevier Inc. C1 Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Univ New Mexico, Dept Med, New Mexico VA Hlth Care Syst, Albuquerque, NM 87131 USA. Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. Durham VA Med Ctr, Durham, NC USA. Duke Univ, Duke Prostate Ctr, Durham, NC USA. RP Walter, LC (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr 181G,4150 Clement St, San Francisco, CA 94121 USA. EM Louise.Walter@ucsf.edu FU National Cancer Institute at the National Institutes of Health [R01 CA134425]; National Institute on Aging at the National Institutes of Health [K24AG041180]; Veterans Affairs Career Development Award Program [CDA 08-024]; New Mexico VA Health Care System FX This work was supported by the National Cancer Institute at the National Institutes of Health (grant number R01 CA134425 to L.W., S.F., A.P., and R.H.); the National Institute on Aging at the National Institutes of Health (grant number K24AG041180 to L.W.); the Veterans Affairs Career Development Award Program (grant number CDA 08-024 to A.P.); and the New Mexico VA Health Care System to R.H. NR 24 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD MAR PY 2014 VL 83 IS 3 BP 599 EP 605 DI 10.1016/j.urology.2013.10.051 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA AC3IR UT WOS:000332411200025 PM 24439009 ER PT J AU Espaldon, R Walter, LC AF Espaldon, Roxanne Walter, Louise C. TI Probability of an Abnormal Screening Prostate-specific Antigen Result Based on Age, Race, and Prostate-specific Antigen Threshold EDITORIAL COMMENT REPLY SO UROLOGY LA English DT Editorial Material C1 [Espaldon, Roxanne; Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Espaldon, R (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD MAR PY 2014 VL 83 IS 3 BP 605 EP 605 DI 10.1016/j.urology.2013.10.056 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AC3IR UT WOS:000332411200027 ER PT J AU Shea, JA Dinges, DF Small, DS Basner, M Zhu, JS Norton, L Ecker, AJ Novak, C Bellini, LM Dine, CJ Mollicone, DJ Volpp, KG AF Shea, Judy A. Dinges, David F. Small, Dylan S. Basner, Mathias Zhu, Jingsan Norton, Laurie Ecker, Adrian J. Novak, Cristina Bellini, Lisa M. Dine, C. Jessica Mollicone, Daniel J. Volpp, Kevin G. TI A Randomized Trial of a Three-Hour Protected Nap Period in a Medicine Training Program: Sleep, Alertness, and Patient Outcomes SO ACADEMIC MEDICINE LA English DT Article ID VIGILANCE TEST PVT; CONTINUOUS OPERATION; PROPHYLACTIC NAPS; DUTY HOURS; PERFORMANCE; INERTIA; SENSITIVITY; WAKEFULNESS; BENEFITS; CAFFEINE AB Purpose Protected sleep periods for internal medicine interns have previously resulted in increased amount slept and improved cognitive alertness but required supplemental personnel. The authors evaluated intern and patient outcomes associated with protected nocturnal nap periods of three hours that are personnel neutral. Method Randomized trial at Philadelphia Veterans Affairs Medical Center (PVAMC) Medical Service and Hospital of the University of Pennsylvania (HUP) Oncology Unit. During 2010-2011, four-week blocks were randomly assigned to a standard intern schedule (extended duty overnight shifts of up to 30 hours), or sequential protected sleep periods (phone sign-out midnight to 3:00 am [early shift] intern 1; 3:00 to 6:00 am [late shift] intern 2). Participants wore wrist Actiwatches, completed sleep diaries, and performed daily assessments of behavioral alertness. Between-group comparisons of means and proportions controlled for within-person correlations. Results HUP interns had significantly longer sleep durations during both early (2.40 hours) and late (2.44 hours) protected periods compared with controls (1.55 hours, P < .0001). At PVAMC sleep duration was longer only for the late shift group (2.40 versus 1.90 hours, P < .036). Interns assigned to either protected period were significantly less likely to have call nights with no sleep and had fewer attentional lapses on the Psychomotor Vigilance Test. Differences in patient outcomes between standard schedule months versus intervention months were not observed. Conclusions Protected sleep periods of three hours resulted in more sleep during call and reductions in periods of prolonged wakefulness, providing a plausible alternative to 16-hour shifts. C1 [Shea, Judy A.; Dinges, David F.; Basner, Mathias; Ecker, Adrian J.; Bellini, Lisa M.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Dinges, David F.] Univ Penn, Dept Psychiat, Div Sleep & Chronobiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Zhu, Jingsan] Univ Penn, LDI Ctr Hlth Incent & Behav Econ, Perelman Sch Med, Philadelphia, PA 19104 USA. [Norton, Laurie; Novak, Cristina] Univ Penn, CHERP, Philadelphia VA Med Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA. [Norton, Laurie; Novak, Cristina] Univ Penn, Perelman Sch Med, CHIBE, Philadelphia, PA 19104 USA. [Bellini, Lisa M.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Dine, C. Jessica] Univ Penn, Perelman Sch Med, Div Pulm & Crit Care, Philadelphia, PA 19104 USA. [Mollicone, Daniel J.] Pulsar Informat Inc, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, CHERP, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Shea, JA (reprint author), 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM sheaja@mail.med.upenn.edu FU grant VA HSRD EDU [08-429] FX This work was funded by grant VA HSR&D EDU 08-429, to Dr. Volpp. NR 27 TC 2 Z9 2 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD MAR PY 2014 VL 89 IS 3 BP 452 EP 459 DI 10.1097/ACM.0000000000000144 PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AB6CC UT WOS:000331874100025 PM 24448046 ER PT J AU Wetherill, RR Jagannathan, K Lohoff, FW Ehrman, R O'Brien, CP Childress, AR Franklin, TR AF Wetherill, Reagan R. Jagannathan, Kanchana Lohoff, Falk W. Ehrman, Ronald O'Brien, Charles P. Childress, Anna Rose Franklin, Teresa R. TI Neural correlates of attentional bias for smoking cues: modulation by variance in the dopamine transporter gene SO ADDICTION BIOLOGY LA English DT Article DE Addiction; attentional bias; dopamine transporter; neuroimaging; smoking cues ID PREFRONTAL CORTEX; INDIVIDUAL-DIFFERENCES; ORBITOFRONTAL CORTEX; BRAIN ACTIVATION; PERFUSION FMRI; DRUG-ADDICTION; HUMAN AMYGDALA; RESPONSES; REWARD; VARENICLINE AB Cigarette-dependent smokers automatically and involuntarily orient attention toward smoking cues (SCs). This attentional bias is clinically significant, as it may contribute to relapse. Thus, identifying neural and genetic correlates of attentional bias is critical for improving interventions. Our previous studies show that the dopamine transporter (DAT) SLC6A3 genotype exerts profound effects on limbic responses to SCs. One potential mechanism underlying these effects is greater attentional bias for SCs. Here, we explored associations between attentional bias for SCs and neural responses to SCs among sated' smokers genotyped for the SLC6A3 polymorphism. Pseudo-continuous arterial spin-labeled perfusion functional magnetic resonance imaging images were acquired during SC exposure in 35 smokers genotyped for the SLC6A3 variable number of tandem repeats polymorphism (n=16, 9-repeats; n=19, 10/10-repeats). Participants completed a visual dot-probe attentional bias task, which contained pictures of smoking and non-smoking pictures, to examine whether genetic variation in DAT influences attentional bias and to investigate relationships between attentional bias and neural responses to SCs. Although attentional bias to smoking pictures was not significantly different between 9-repeats and 10/10-repeats, 9-repeats showed a positive correlation between attentional bias and increased SC-induced brain activity in the amygdala, whereas 10/10-repeats showed an inverse correlation in the medial orbitofrontal cortex (mOFC). In group comparisons, 9-repeats exhibited positive correlations between attentional bias and SCs in the mOFC and amygdala, relative to 10/10-repeats. Findings suggest that genetic variation in the DAT gene influences brain responses associated with attentional bias; thus, providing additional support for a SC-vulnerable endophenotype. C1 [Wetherill, Reagan R.; Jagannathan, Kanchana; Lohoff, Falk W.; O'Brien, Charles P.; Childress, Anna Rose; Franklin, Teresa R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Ehrman, Ronald] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Wetherill, RR (reprint author), Univ Penn, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM rwetherill@mail.med.upenn.edu RI Lohoff, Falk/M-7951-2016 FU National Institutes of Health [5-P60-DA-005186-18, 1R21DA025882-01A1, MH080729, EB015893] FX This work was supported by National Institutes of Health grants 5-P60-DA-005186-18, 1R21DA025882-01A1, MH080729 and EB015893. The authors wish to thank Drs. John Detre and Ze Wang for optimization of the perfusion fMRI technique, and Yin Li for aiding in imaging data preprocessing. We also thank the nursing staff at the Center for the Studies of Addiction for conducting physical evaluations; clinicians Anita Hole, PhD, Jesse Suh, PsyD, and Kathleen Marquez, MA, for conducting the psychological evaluations; Joshua Shin, BS, the lead technician on the study; and the MRI technicians at the Hospital of the University of Pennsylvania for conducting the scanning sessions. NR 65 TC 8 Z9 8 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD MAR PY 2014 VL 19 IS 2 BP 294 EP 304 DI 10.1111/j.1369-1600.2012.00507.x PG 11 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA AB1CO UT WOS:000331529100016 PM 23061530 ER PT J AU Haun, N Hofer, A Greene, MT Borlaug, G Pritchett, J Scallon, T Safdar, N AF Haun, Nicholas Hofer, Adam Greene, M. Todd Borlaug, Gwen Pritchett, Jenny Scallon, Tina Safdar, Nasia TI Prevention of Clostridium difficile infection in rural hospitals SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Health care-associated; Survey; Evidence-based practices ID ACUTE-CARE; NATIONAL-SURVEY; DISEASE; FACILITIES; SURVEILLANCE; EPIDEMIC; DIARRHEA; AMERICA; STRAIN AB Background: Prevention of Clostridium difficile infection (CDI) remains challenging across the spectrum of health care. There are limited data on prevention practices for CDI in the rural health care setting. Methods: An electronic survey was administered to 21 rural facilities in Wisconsin, part of the Rural Wisconsin Health Cooperative. Data were collected on hospital characteristics and practices to prevent endemic CDI. Results: Fifteen facilities responded (71%). Nearly all respondent facilities reported regular use of dedicated patient care items, use of gown and gloves, private patient rooms, hand hygiene, and room cleaning. Facilities in which the infection preventionist thought the support of his/her leadership to be "Very good" or "Excellent" employed significantly more CDI practices (13.3 +/- 2.4 [ standard deviation]) compared with infection preventionists who thought there was less support from leadership (9.8 +/- 3.0, P = .033). Surveillance for CDI was highly variable. The most frequent barriers to implementation of CDI prevention practices included lack of adequate resources, lack of a physician champion, and difficulty keeping up with new recommendations. Conclusion: Although most rural facilities in our survey reported using evidence-based practices for prevention of CDI, surveillance practices were highly variable, and data regarding the impact of these practices on CDI rates were limited. Future efforts that correlate CDI prevention initiatives and CDI incidence will help develop evidence-based practices in these resource-limited settings. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Haun, Nicholas; Hofer, Adam; Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Greene, M. Todd] Univ Michigan, Sch Med, Dept Internal Med, Div Gen Med, Ann Arbor, MI USA. [Greene, M. Todd] Ann Arbor VA Med Ctr, Ann Arbor, MI USA. [Borlaug, Gwen] Wisconsin Div Publ Hlth, Madison, WI USA. [Pritchett, Jenny] Grant Reg Hlth Ctr, Lancaster, WI USA. [Scallon, Tina] Sauk Prairie Mem Hosp, Sauk Prairie, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin Hosp & Clin, MFCB 5221, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu NR 22 TC 0 Z9 0 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR PY 2014 VL 42 IS 3 BP 311 EP 315 DI 10.1016/j.ajic.2013.09.011 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AC2EO UT WOS:000332311500020 PM 24406257 ER PT J AU Watnick, S Crowley, ST AF Watnick, Suzanne Crowley, Susan T. TI ESRD Care Within the US Department of Veterans Affairs: A Forward-Looking Program With an Illuminating Past SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE End-stage renal disease; public policy; US Department of Veterans Affairs ID STAGE RENAL-DISEASE; HOME DIALYSIS; UNITED-STATES; HEMODIALYSIS; VA; SYSTEM; FUTURE AB The first governmental agency to provide maintenance hemodialysis to patients with end-stage renal disease (ESRD) was the Veterans Administration (VA; now the US Department of Veterans Affairs). Many historical VA policies and programs set the stage for the later care of both veteran and civilian patients with ESRD. More recent VA initiatives that target restructuring of care models based on quality management, system-wide payment policies to promote cost-effective dialysis, and innovation grants aim to improve contemporary care. The VA currently supports an expanded and diversified nationwide treatment program for patients with ESRD using an integrated patient-centered care paradigm. This narrative review of ESRD care by the VA explores not only the medical advances, but also the historical, socioeconomic, ethical, and political forces related to the care of veterans with ESRD. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Watnick, Suzanne] Portland VA Med Ctr, Portland, OR 97207 USA. [Watnick, Suzanne] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Crowley, Susan T.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Crowley, Susan T.] Yale Univ, Sch Med, New Haven, CT USA. RP Watnick, S (reprint author), Portland VA Med Ctr, P3NEPH,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM suzanne.watnick@va.gov NR 54 TC 2 Z9 3 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2014 VL 63 IS 3 BP 521 EP 529 DI 10.1053/j.ajkd.2013.10.046 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA AB3ZI UT WOS:000331728300025 PM 24331978 ER PT J AU Quillen, EE Chen, XD Almasy, L Yang, F He, H Li, X Wang, XY Liu, TQ Hao, W Deng, HW Kranzler, HR Gelernter, J AF Quillen, Ellen E. Chen, Xiang-Ding Almasy, Laura Yang, Fang He, Hao Li, Xi Wang, Xu-Yi Liu, Tie-Qiao Hao, Wei Deng, Hong-Wen Kranzler, Henry R. Gelernter, Joel TI ALDH2 Is Associated to Alcohol Dependence and Is the Major Genetic Determinant of "Daily Maximum Drinks" in a GWAS Study of an Isolated Rural Chinese Sample SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE alcohol dependence; maximum drinks; flushing response; genome-wide association; aldehyde dehydrogenase ID GENOME-WIDE ASSOCIATION; LINKAGE ANALYSIS; HAN CHINESE; RISK; RELIABILITY; POPULATION; DISEASES; DEHYDROGENASE; CONSUMPTION; VARIANTS AB Alcohol dependence (AD) is a moderately heritable phenotype with a small number of known risk genes mapped via linkage or candidate gene studies. We considered 313 males from among 595 members of documented, extended pedigrees in which AD segregates collected in Northern Hunan Province, China. A joint analysis of both males and females could not be performed as the difference in alcohol consumption variance was too large. Genome-wide association analyses were performed for approximately 300,000 single nucleotide polymorphisms (SNPs). Significant associations found in the ALDH2 region for AD (minimum P=4.73x10(-8)) and two AD-related phenotypes: flushing response (minimum P=4.75x10(-26)) and maximum drinks in a 24-hr period (minimum P=1.54x10(-16)). Association of previous candidate SNP, rs10774610 in CCDC63, was confirmed but resulted from linkage disequilibrium with ALDH2. ALDH2 is strongly associated with flushing response, AD, and maximum drinks in males, with nonsynonymous SNP rs671 explaining 29.2%, 7.9%, and 22.9% of phenotypic variation, respectively, in this sample. When rs671 was considered as a candidate SNP in females, it explained 23.6% of the variation in flushing response, but alcohol consumption rates were too low among femalesdespite familial enrichment for ADfor an adequate test of association for either AD or maximum drinks. These results support a mediating effect of aldehyde dehydrogenase deficiency on alcohol consumption in males and a secondary, culturally mediated limitation on alcohol consumption by females that should be appropriately modeled in future studies of alcohol consumption in populations where this may be a factor. (c) 2013 Wiley Periodicals, Inc. C1 [Quillen, Ellen E.; Almasy, Laura] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Kranzler, Henry R.] Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA USA. [Chen, Xiang-Ding; Yang, Fang; He, Hao; Li, Xi] Hunan Normal Univ, Hunan Inst Biol, Key Lab Prot Chem & Dev Biol, Minist Educ,Coll Life Sci, Changsha, Hunan, Peoples R China. [Wang, Xu-Yi; Liu, Tie-Qiao; Hao, Wei] Cent S Univ, Xiangya Hosp 2, Mental Hlth Inst, Changsha, Hunan, Peoples R China. [Deng, Hong-Wen] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, West Haven, CT 06516 USA. [Gelernter, Joel] VA CT Healthcare Ctr, Dept Psychiat, West Haven, CT USA. RP Gelernter, J (reprint author), Yale Univ, Sch Med, Dept Psychiat, VA CT Healthcare Ctr S116A2, 950 Campbell Ave, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu OI Deng, Hong-Wen/0000-0002-0387-8818 FU NIAAA [R21 AA015973, P50 AA12870, K24 AA013736]; NIDA [R01 DA12849]; NIMH [MH059490]; SBC Foundation FX Grant sponsor: NIAAA; Grant numbers: R21 AA015973, P50 AA12870, K24 AA013736; Grant sponsor: NIDA; Grant number: R01 DA12849; Grant sponsor: NIMH; Grant number: MH059490; Grant sponsor: SBC Foundation. NR 44 TC 20 Z9 21 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2014 VL 165 IS 2 BP 103 EP 110 DI 10.1002/ajmg.b.32213 PG 8 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA AA8VX UT WOS:000331374200001 PM 24277619 ER PT J AU Jensen, KP Kranzler, HR Stein, MB Gelernter, J AF Jensen, Kevin P. Kranzler, Henry R. Stein, Murray B. Gelernter, Joel TI The Effects of a MAP2K5 MicroRNA Target Site SNP on Risk for Anxiety and Depressive Disorders SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE restless legs syndrome; depression; miR-330; MEK5; GWAS ID RESTLESS LEGS SYNDROME; GENOME-WIDE ASSOCIATION; PARTLY DIFFERENT ENVIRONMENTS; MAJOR DEPRESSION; SEMISTRUCTURED ASSESSMENT; ALCOHOLISM SSADDA; DRUG-DEPENDENCE; COMPLEX TRAITS; HUMAN-DISEASES; VARIANTS AB Functional variants that contribute to genomewide association study (GWAS) signals are difficult to identify. MicroRNAs could contribute to some of these gene-trait relationships. We compiled a set of GWAS trait gene SNPs that were predicted to affect microRNA regulation of mRNA. Trait associations were tested in a sample of 6725 European-American (EA) and African-American (AA) subjects that were interviewed using the polydiagnostic SSADDA to diagnose major psychiatric disorders. A predicted miR-330-3p target site SNP (rs41305272) in mitogen-activated protein kinase kinase 5 (MAP2K5) mRNA was in LD (d=1.0, r(2)=0.02) with a reported GWAS-identified variant for restless legs syndrome (RLS), a disorder frequently comorbid with anxiety and depression, possibly because of a shared pathophysiology. We examined the SNP's association with mood and anxiety-related disorders. Rs41305272 was associated with agoraphobia (Ag) in EAs (odds ratio [OR]=1.95, P=0.007; 195 cases) and AAs (OR=3.2, P=0.03; 148 cases) and major depressive disorder (MDD) in AAs (OR=2.64, P=0.01; 427 cases), but not EAs (465 cases). Rs41305272*T carrier frequency was correlated with the number of anxiety and depressive disorders diagnosed per subject. RLS was not evaluated in our subjects. Predicted miR-330-3p target genes were enriched in pathways relevant to psychiatric disorders. These findings suggest that microRNA target site information may be useful in the analysis of GWAS signals for complex traits. MiR-330-3p and MAP2K5 are potentially important contributors to mood and anxiety-related traits. With support from additional studies, these findings could add to the large number of risk genes identified through association to medical disorders that have primary psychiatric effects. (c) 2014 Wiley Periodicals, Inc. C1 [Jensen, Kevin P.; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, West Haven, CT 06516 USA. [Jensen, Kevin P.; Gelernter, Joel] VA CT Hlth Care Ctr, West Haven, CT USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Ctr Studies Addict, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA. [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, West Haven, CT 06516 USA. RP Gelernter, J (reprint author), Yale Univ, Sch Med, Dept Psychiat, Div Human Genet Psychiat,VA CT Healthcare Ctr 116, 950 Campbell Ave, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu FU NIH [DA12849, DA12690, DA18432, AA017535, DA028909, AA11330, MH64122, T32 MH014276]; VA MERIT Award FX Grant sponsor: NIH; Grant numbers: DA12849, DA12690, DA18432, AA017535, DA028909, AA11330, MH64122, T32 MH014276; Grant sponsor: VA MERIT Award. NR 63 TC 8 Z9 9 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2014 VL 165 IS 2 BP 175 EP 183 DI 10.1002/ajmg.b.32219 PG 9 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA AA8VX UT WOS:000331374200009 PM 24436253 ER PT J AU Coker, J Castiglioni, A Kraemer, RR Massie, FS Morris, JL Rodriguez, M Russell, SW Shaneyfelt, T Willett, LL Estrada, CA AF Coker, Joshua Castiglioni, Analia Kraemer, Ryan R. Massie, F. Stanford Morris, Jason L. Rodriguez, Martin Russell, Stephen W. Shaneyfelt, Terrance Willett, Lisa L. Estrada, Carlos A. TI Evaluation of an Advanced Physical Diagnosis Course Using Consumer Preferences Methods: The Nominal Group Technique SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Internal medicine/education; Clinical clerkship/methods; Physical examination; Curriculum; Program evaluation ID SENIOR MEDICAL-STUDENTS; CURRICULUM; RESIDENTS AB Background: Current evaluation tools of medical school courses are limited by the scope of questions asked and may not fully engage the student to think on areas to improve. The authors sought to explore whether a technique to study consumer preferences would elicit specific and prioritized information for course evaluation from medical students. Methods: Using the nominal group technique (4 sessions), 12 senior medical students prioritized and weighed expectations and topics learned in a 100-hour advanced physical diagnosis course (4-week course; February 2012). Students weighted their top 3 responses (top = 3, middle = 2 and bottom = 1). Results: Before the course, 12 students identified 23 topics they expected to learn; the top 3 were review sensitivity/specificity and high-yield techniques (percentage of total weight, 18.5%), improving diagnosis (13.8%) and reinforce usual and less well-known techniques (13.8%). After the course, students generated 22 topics learned; the top 3 were practice and reinforce advanced maneuvers (25.4%), gaining confidence (22.5%) and learn the evidence (16.9%). The authors observed no differences in the priority of responses before and after the course (P = 0.07). Conclusions: In a physical diagnosis course, medical students elicited specific and prioritized information using the nominal group technique. The course met student expectations regarding education of the evidence-based physical examination, building skills and confidence on the proper techniques and maneuvers and experiential learning. The novel use for curriculum evaluation may be used to evaluate other courses-especially comprehensive and multicomponent courses. C1 [Coker, Joshua] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA. [Castiglioni, Analia] Univ Cent Florida, Dept Med, Orlando, FL 32816 USA. [Kraemer, Ryan R.; Massie, F. Stanford; Morris, Jason L.; Russell, Stephen W.; Shaneyfelt, Terrance; Willett, Lisa L.; Estrada, Carlos A.] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA. [Kraemer, Ryan R.; Morris, Jason L.; Willett, Lisa L.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL 35294 USA. [Rodriguez, Martin] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL 35294 USA. [Rodriguez, Martin] Univ Alabama Birmingham, Tinsley Harrison Med Serv, Birmingham, AL 35294 USA. [Russell, Stephen W.] Univ Alabama Birmingham, Moody Clin, Birmingham, AL 35294 USA. [Russell, Stephen W.] Univ Alabama Birmingham, Div Gen Pediat, Birmingham, AL 35294 USA. [Kraemer, Ryan R.; Morris, Jason L.; Shaneyfelt, Terrance; Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Estrada, Carlos A.] Univ Alabama Birmingham, Vet Affairs Natl Qual Scholars Program, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Estrada, CA (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Div Gen Internal Med, 732 Fac Off Tower,510 20th St South, Birmingham, AL 35294 USA. EM cestrada@uab.edu FU Department of Veterans Affairs Office of Academic Affiliations (OAA) FX The Department of Veterans Affairs National Quality Scholars Fellowship (VAQS) and the Chief Resident in Quality and Safety Program are funded by the Department of Veterans Affairs Office of Academic Affiliations (OAA). The opinions expressed in this article are those of the authors alone and do not reflect the views of the Department of Veterans Affairs. NR 26 TC 1 Z9 1 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAR PY 2014 VL 347 IS 3 BP 199 EP 205 DI 10.1097/MAJ.0b013e3182831798 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AC0YF UT WOS:000332220700007 PM 23552288 ER PT J AU Magulick, JP Frei, CR Ali, SK Mortensen, EM Pugh, MJ Oramasionwu, CU Daniels, KR Mansi, IA AF Magulick, John P. Frei, Christopher R. Ali, Sayed K. Mortensen, Eric M. Pugh, Mary Jo Oramasionwu, Christine U. Daniels, Kelly R. Mansi, Ishak A. TI The Effect of Statin Therapy on the Incidence of Infections: A Retrospective Cohort Analysis SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Fungal; Influenza; Infection; Statin ID COMMUNITY-ACQUIRED PNEUMONIA; COA REDUCTASE INHIBITORS; POPULATION-BASED COHORT; NITRIC-OXIDE; ENDOTHELIAL-CELLS; UNITED-STATES; MORTALITY; OUTCOMES; RISK; SEPSIS AB Background: Statins have been postulated to prevent infection through immunomodulatory effects. Objectives: To compare the incidence of infections in statin users to that in nonusers within the same health care system. Methods: This was a retrospective cohort study of patients enrolled as Tricare Prime or Plus in the San Antonio military multimarket. Statin users were patients who received a statin for at least 3 months between October 1, 2004 and September 30, 2005. Nonusers were patients who did not receive a statin within the study period (October 1, 2003-September 30, 2009). Inpatient and outpatient International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes were used to determine the incidence of infections during the follow-up period (October 1, 2005-September 30, 2009) via multivariable regression analysis and time to infection via Cox regression analysis. Results: Of 45,247 patients who met the study criteria, 12,981 (29%) were statin users and 32,266 were nonusers. After adjustments for age, gender, Charlson Comorbidity Score, tobacco use, alcohol abuse/dependence, health care utilization and use of specific medication classes, statin use was associated with an increased incidence of common infections (odds ratio [OR]: 1.13; 95% confidence interval [CI]: 1.06-1.19) but not influenza or fungal infections (OR: 1.06, 95% CI: 0.80-1.39; OR: 0.97; 95% CI: 0.91-1.04, respectively). Time-to-first infection was similar in statin users and nonusers in all infection categories examined. Conclusions: Statin use was associated with an increased incidence of common infections but not influenza or fungal infections. This study does not support a protective role of statins in infection prevention; however, the influence of potential confounders cannot be excluded. C1 [Magulick, John P.; Ali, Sayed K.] San Antonio Mil Med Ctr, Internal Med Serv, San Antonio, TX 78234 USA. [Frei, Christopher R.; Daniels, Kelly R.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Frei, Christopher R.; Daniels, Kelly R.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, Sch Med, San Antonio, TX 78229 USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, VA North Texas Hlth Care Syst, Dallas, TX 75390 USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Oramasionwu, Christine U.] Univ N Carolina, UNC Eshelman Sch Pharm, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA. [Mansi, Ishak A.] Brooke Army Med Ctr, San Antonio, TX USA. [Mansi, Ishak A.] Uniformed Serv Univ Hlth Sci, San Antonio, TX USA. [Mansi, Ishak A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Mansi, IA (reprint author), San Antonio Mil Med Ctr, Internal Med Serv, 3551 Roger Brooke Dr, San Antonio, TX 78234 USA. EM ishak.mansi@us.army.mil OI Mortensen, Eric/0000-0002-3880-5563 FU U.S. National Institutes of Health (NIH) [RR025766]; AstraZeneca; Bristol Myers Squibb; Elan; Forest; Ortho-McNeil Janssen; Pfizer; VA Health Services Research and Development Service [DHI 09-237] FX C.R. Frei was supported by the U.S. National Institutes of Health (NIH) in the form of an NIH/KL2 career development award (RR025766) during the conduct of this study. C. R. Frei has received research grants and/or served as a scientific consultant/advisor for AstraZeneca, Bristol Myers Squibb, Elan, Forest, Ortho-McNeil Janssen and Pfizer. M.J.P. recieved support from VA Health Services Research and Development Service DHI 09-237. The remaining authors have no financial or other conflicts of interest to disclose. NR 64 TC 5 Z9 5 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAR PY 2014 VL 347 IS 3 BP 211 EP 216 DI 10.1097/MAJ.0b013e31828318e2 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA AC0YF UT WOS:000332220700009 PM 23426088 ER PT J AU Donnelly, JP Baddley, JW Wang, HE AF Donnelly, John P. Baddley, John W. Wang, Henry E. TI Antibiotic Utilization for Acute Respiratory Tract Infections in U.S. Emergency Departments SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID CLOSTRIDIUM-DIFFICILE INFECTION; TIMELY PRIMARY-CARE; UNITED-STATES; PNEUMONIA; COMMUNITY; RISK; FLUOROQUINOLONES; ACCURACY; BARRIERS; VISITS AB Inappropriate use of antibiotics for acute respiratory tract infections (ARTIs) has decreased in many outpatient settings. For patients presenting to U. S. emergency departments (EDs) with ARTIs, antibiotic utilization patterns are unclear. We conducted a retrospective cohort study of ED patients from 2001 to 2010 using data from the National Hospital Ambulatory Medical Care Survey (NHAMCS). We identified patients presenting to U. S. EDs with ARTIs and calculated rates of antibiotic utilization. Diagnoses were classified as antibiotic appropriate (otitis media, sinusitis, pharyngitis, tonsillitis, and nonviral pneumonia) or antibiotic inappropriate (nasopharyngitis, unspecified upper respiratory tract infection, bronchitis or bronchiolitis, viral pneumonia, and influenza). There were 126 million ED visits with a diagnosis of ARTI, and antibiotics were prescribed in 61%. Between 2001 and 2010, antibiotic utilization decreased for patients aged <5 presenting with antibiotic-inappropriate ARTI (rate ratio [RR], 0.94; confidence interval [CI], 0.88 to 1.00). Utilization also decreased significantly for antibiotic-inappropriate ARTI patients aged 5 to 19 years (RR, 0.89; CI, 0.85 to 0.94). Utilization remained stable for antibiotic-inappropriate ARTI among adult patients aged 20 to 64 years (RR, 0.99; CI, 0.97 to 1.01). Among adults, rates of quinolone use for ARTI increased significantly from 83 per 1,000 visits in 2001 to 2002 to 105 per 1,000 in 2009 to 2010 (RR, 1.08; CI, 1.03 to 1.14). Although significant progress has been made toward reduction of antibiotic utilization for pediatric patients with ARTI, the proportion of adult ARTI patients receiving antibiotics in U. S. EDs is inappropriately high. Institution of measures to reduce inappropriate antibiotic use in the ED setting is warranted. C1 [Donnelly, John P.; Wang, Henry E.] Univ Alabama Birmingham, Dept Emergency Med, Birmingham, AL 35294 USA. [Baddley, John W.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. EM jbaddley@uab.edu OI Donnelly, John/0000-0002-0646-9470 FU Agency for Healthcare Research and Quality [T32 HS13852-11]; National Institute of Nursing Research [R01-NR012726] FX J.P.D. is currently supported by the Agency for Healthcare Research and Quality (grant T32 HS13852-11). H.E.W. received grant support from the National Institute of Nursing Research (R01-NR012726). NR 33 TC 16 Z9 16 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2014 VL 58 IS 3 BP 1451 EP 1457 DI 10.1128/AAC.02039-13 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AC0HJ UT WOS:000332175100024 PM 24342652 ER PT J AU Hoang, PD Cameron, MH Gandevia, SC Lord, SR AF Hoang, Phu D. Cameron, Michelle H. Gandevia, Simon C. Lord, Stephen R. TI Neuropsychological, Balance, and Mobility Risk Factors for Falls in People With Multiple Sclerosis: A Prospective Cohort Study SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Accidental falls; Multiple sclerosis; Neuropsychological tests; Postural balance; Rehabilitation; Risk factors ID PREDICTING ACCIDENTAL FALLS; COMMUNITY-DWELLING WOMEN; SENSORIMOTOR FUNCTION; POSTURAL SWAY; OLDER-PEOPLE; DISABILITY; PERFORMANCE; PREVENTION; COMPOSITE; STRENGTH AB Objectives: To determine whether impaired performance in a range of vision, proprioception, neuropsychological, balance, and mobility tests and pain and fatigue are associated with falls in people with multiple sclerosis (PwMS). Design: Prospective cohort study with 6-month follow-up. Setting: A multiple sclerosis (MS) physiotherapy clinic. Participants: Community-dwelling people (N=210; age range, 21-74y) with MS (Disease Steps 0-5). Interventions: Not applicable. Main Outcome Measures: Incidence of falls during 6 months' follow-up. Results: In the 6-month follow-up period, 83 participants (39.7%) experienced no falls, 57 (27.3%) fell once or twice, and 69 (33.0%) fell 3 or more times. Frequent falling (>= 3) was associated with increased postural sway (eyes open and closed), poor leaning balance (as assessed with the coordinated stability task), slow choice stepping reaction time, reduced walking speed, reduced executive functioning (as assessed with the difference between Trail Making Test Part B and Trail Making Test Part A), reduced fine motor control (performance on the 9-Hole Peg Test [9-HPT]), and reported leg pain. Increased sway with the eyes closed, poor coordinated stability, and reduced performance in the 9-HPT were identified as variables that significantly and independently discriminated between frequent fallers and nonfrequent fallers (model x(3)=30.1, P<.001). The area under the receiver operating characteristic curve for this model was.712 (95% confidence interval,.638.785). Conclusions: The study reveals important balance, coordination, and cognitive determinants of falls in PwMS. These should assist the development of effective strategies for prevention of falls in this high-risk group. (C) 2014 by the American Congress of Rehabilitation Medicine C1 [Hoang, Phu D.; Gandevia, Simon C.; Lord, Stephen R.] Univ New S Wales, Neurosci Res Australia, Randwick, NSW, Australia. [Cameron, Michelle H.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Cameron, Michelle H.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. RP Lord, SR (reprint author), Neurosci Res Australia, Barker St, Randwick, NSW 2031, Australia. EM s.lord@neura.edu.au RI Lord, Stephen/C-9612-2011 FU Multiple Sclerosis Research Australia; National Health and Medical Research Council (of Australia); MS International Federation (Du Pre Grant) FX Supported by Multiple Sclerosis Research Australia, the National Health and Medical Research Council (of Australia), and the MS International Federation (Du Pre Grant). NR 35 TC 34 Z9 34 U1 2 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2014 VL 95 IS 3 BP 480 EP 486 DI 10.1016/j.apmr.2013.09.017 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA AB8QR UT WOS:000332055600010 PM 24096187 ER PT J AU Costales, JL Sher, L AF Costales, Jesse L. Sher, Leo TI Do testosterone and brain-derived neurotrophic factor interactions play a role in the pathophysiology of suicidal behavior? SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter C1 [Costales, Jesse L.; Sher, Leo] Mt Sinai Hosp, Dept Psychiat, New York, NY 10029 USA. [Sher, Leo] James J Peters Vet Adm, Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. RP Sher, L (reprint author), James J Peters Vet Adm, Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM leo.sher@mssm.edu NR 3 TC 0 Z9 0 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 EI 1440-1614 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD MAR PY 2014 VL 48 IS 3 BP 290 EP 291 DI 10.1177/0004867413504832 PG 2 WC Psychiatry SC Psychiatry GA AB3KP UT WOS:000331690000015 PM 24042028 ER PT J AU Sher, L AF Sher, Leo TI Testosterone and homicidal behavior SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter ID NEUROTROPHIC FACTOR; SUICIDAL-BEHAVIOR; EXPRESSION; SEX C1 [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY USA. [Sher, Leo] James J Peters Vet Adm, Med Ctr, Bronx, NY 10468 USA. RP Sher, L (reprint author), James J Peters Vet Adm, Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 5 TC 1 Z9 1 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 EI 1440-1614 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD MAR PY 2014 VL 48 IS 3 BP 290 EP 290 DI 10.1177/0004867413504833 PG 1 WC Psychiatry SC Psychiatry GA AB3KP UT WOS:000331690000014 PM 24027080 ER PT J AU Gong, JJ Xie, JP Bedolla, R Rivas, P Chakravarthy, D Freeman, JW Reddick, R Kopetz, S Peterson, A Wang, HM Fischer, SM Kumar, AP AF Gong, Jingjing Xie, Jianping Bedolla, Roble Rivas, Paul Chakravarthy, Divya Freeman, James W. Reddick, Robert Kopetz, Scott Peterson, Amanda Wang, Huamin Fischer, Susan M. Kumar, Addanki P. TI Combined Targeting of STAT3/NF-kappa B/COX-2/EP4 for Effective Management of Pancreatic Cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID NF-KAPPA-B; AMURENSE BARK EXTRACT; MOUSE PROSTATE MODEL; STELLATE CELLS; TRANSGENIC ADENOCARCINOMA; NATURAL-PRODUCTS; GROWTH-FACTOR; EP4 RECEPTOR; STAT3; PATHWAY AB Purpose: Near equal rates of incidence and mortality emphasize the need for novel targeted approaches for better management of patients with pancreatic cancer. Inflammatory molecules NF-kappa B and STAT3 are overexpressed in pancreatic tumors. Inhibition of one protein allows cancer cells to survive using the other. The goal of this study is to determine whether targeting STAB/NE-kappa B crosstalk with a natural product Nexrutine can inhibit inflammatory signaling in pancreatic cancer. Experimental Design: HPNE,HPNE-Ras,BxPC3, Capan-2, MIA PaCa-2, and AsPC-1 cells were tested for growth, apoptosis, cyclooxygenase-2 NF-kappa B, and STAT3 level in response to Nexrutine treatment. Transient expression, gel shift, chromatin immunoprecipitation assay was used to examine transcriptional regulation of COX-2. STAT3 knockdown was used to decipher STAT3/NF-kappa B crosstalk. Histopathologic and immunoblotting evaluation was performed on BK5-COX-2 transgenic mice treated with Nexrutine. In vivo expression of prostaglandin receptor E-prostanoid 4 (EP4) was analyzed in a retrospective cohort of pancreatic tumors using a tissue microarray. Results: Nexrutine treatment inhibited growth of pancreatic cancer cells through induction of apoptosis. Reduced levels and activity of STAT3, NT-kappa B, and their crosstalk led to transcriptional suppression of COX-2 and subsequent decreased levels of prostaglandin E2 (PGE2) and PGF2. STAB knockdown studies suggest. STAT3 as negative regulator of NF-kappa B activation. Nexrutine intervention reduced the levels of NE-kappa B, STAT3, and fibrosis in vivo. Expression of prostaglandin receptor EP4 that is known to play a role in fibrosis was significantly elevated in human pancreatic tumors. Conclusions: Dual inhibition of STAT3-NF-kappa B by Nexrutine may overcome problems associated with inhibition of either pathway. (C) 2014 AACR. C1 [Gong, Jingjing; Xie, Jianping; Bedolla, Roble; Rivas, Paul; Chakravarthy, Divya; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Freeman, James W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Oncol, San Antonio, TX 78229 USA. [Reddick, Robert; Peterson, Amanda] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Kopetz, Scott; Wang, Huamin] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Fischer, Susan M.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX USA. RP Kumar, AP (reprint author), Dept Urol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kumara3@uthscsa.edu FU National Center for Complementary and Alternative Medicine [AT005513-01A1, AT 007448-01]; Veterans Affairs-Merit Award [1 I01 BX 000766-01] FX This work was supported in part by funds from National Center for Complementary and Alternative Medicine AT005513-01A1, AT 007448-01, and Veterans Affairs-Merit Award 1 I01 BX 000766-01(A.P. Kumar). NR 47 TC 13 Z9 16 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAR 1 PY 2014 VL 20 IS 5 BP 1259 EP 1273 DI 10.1158/1078-0432.CCR-13-1664 PG 15 WC Oncology SC Oncology GA AC3GE UT WOS:000332403100022 PM 24520096 ER PT J AU Barnett, CM Heinrich, MC Lim, J Nelson, D Beadling, C Warrick, A Neff, T Higano, CS Garzotto, M Qian, D Corless, CL Thomas, GV Beer, TM AF Barnett, Christine M. Heinrich, Michael C. Lim, Jeong Nelson, Dylan Beadling, Carol Warrick, Andrea Neff, Tanaya Higano, Celestia S. Garzotto, Mark Qian, David Corless, Christopher L. Thomas, George V. Beer, Tomasz M. TI Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID PTEN GENOMIC DELETION; PROTEIN LOSS; EXPRESSION; PATHWAY; PROGRESSION; RECURRENCE; FUSION; PI3K AB Purpose: The characterization of actionable mutations in human tumors is a prerequisite for the development of individualized, targeted therapy. We examined the prevalence of potentially therapeutically actionable mutations in patients with high-risk clinically localized prostate cancer. Experimental Design: Forty-eight samples of formalin-fixed paraffin-embedded prostatectomy tissue from a neoadjuvant chemotherapy trial were analyzed. DNA extracted from microdissected tumor was analyzed for 643 common solid tumor mutations in 53 genes using mass spectroscopy-based sequencing. In addition, PTEN loss and erythroblast transformation-specific-related gene (ERC) translocations were examined using immunohistochemistry (IHC) in associated tissue microarrays. Association with relapse during 5 years of follow-up was examined in exploratory analyses of the potential clinical relevance of the genetic alterations. Results: Of the 40 tumors evaluable for mutations, 10% had point mutations in potentially actionable cancer genes. Of the 47 tumors evaluable for IHC, 36% had PTEN loss and 40% had ERG rearrangement. Individual mutations were not frequent enough to determine associations with relapse. Using Kaplan-Meier analysis with a log-rank test, the 16 patients who had PTEN loss had a significantly shorter median relapse-free survival, 19 versus 106 months (P = 0.01). Conclusions: This study confirms that point mutations in the most common cancer regulatory genes in prostate cancer are rare. However, the PIK3CA/AKT pathway was mutated in 10% of our samples. Although point mutations alone did not have a statistically significant association with relapse, PTEN loss was associated with an increased relapse in high-risk prostate cancer treated with chemotherapy followed by surgery. (C) 2013 AACR. C1 [Barnett, Christine M.; Heinrich, Michael C.; Qian, David; Thomas, George V.; Beer, Tomasz M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA. [Lim, Jeong] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Nelson, Dylan; Beadling, Carol; Warrick, Andrea; Neff, Tanaya; Corless, Christopher L.] Oregon Hlth & Sci Univ, Knight Diagnost Labs, Portland, OR 97239 USA. [Heinrich, Michael C.; Garzotto, Mark] Portland VA Med Ctr, Portland, OR USA. [Higano, Celestia S.] Univ Washington, Puget Sound Oncol Consortium, Seattle Canc Care Alliance, Seattle, WA 98195 USA. RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Knight Canc Inst, 3303 SW Bond Ave, Portland, OR 97239 USA. EM beert@ohsu.edu FU NIH/National Cancer Institute [R01CA119125]; PNW SPORE [P50CA097186]; Immunex; Sanofi FX This work was supported in part by the NIH/National Cancer Institute (R01CA119125) and PNW SPORE grant number P50CA097186. Although this work was not directly funded by the following, the original trial involving acquisition of the specimens used in this study was funded in part by Immunex and Sanofi. NR 36 TC 7 Z9 7 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAR 1 PY 2014 VL 20 IS 5 BP 1306 EP 1312 DI 10.1158/1078-0432.CCR-13-1775 PG 7 WC Oncology SC Oncology GA AC3GE UT WOS:000332403100026 PM 24352642 ER PT J AU Darracq, MA Toy, JM Chen, T Mo, C Cantrell, FL AF Darracq, M. A. Toy, J. M. Chen, T. Mo, C. Cantrell, F. L. TI A retrospective review of isolated gliptin-exposure cases reported to a state poison control system SO CLINICAL TOXICOLOGY LA English DT Article DE Sitagliptin; Saxagliptin; Linagliptin; DPP-4 inhibitors; Poison center; Diabetes mellitus type 2; Overdose ID DIPEPTIDYL PEPTIDASE-4 INHIBITORS; SITAGLIPTIN; TOLERABILITY; OVERDOSE; SAFETY AB Background. The dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin, saxagliptin, and linagliptin are approved by the US Food and Drug Administration in the treatment of type-2 diabetes. Given the limited published information regarding human overdoses to these medications, our goal was to characterize such exposures. Methods. A state poison system database was retrospectively reviewed for all single-agent exposures to sitagliptin, saxagliptin, and linagliptin from 2006 to 2012. Case notes were reviewed and an observational case series was constructed from the data collected including age, weight, gender, circumstances surrounding exposure, symptoms, and outcome. Patients with co-ingestants, confirmed non-exposure, unknown outcomes, or other coding errors were excluded. Results. A total of 197 cases were identified: 135 cases were excluded (123 cases were excluded due to co-ingestants and 12 cases were lost to follow-up); 62 were included for review. No patients experienced hypoglycemia. One of 19 exposed pediatric (0-9 years of age) patients experienced symptoms and was safely managed at home after one episode of emesis. No symptom was experienced following unintentional ingestion by three adolescent (10-18 years of age) patients. Forty single-agent adult exposures to gliptins were included. Thirty-seven involved non-self-harm exposures resulting from double or triple doses; all were safely managed at home without reported symptoms. The majority of these ingestions involved sitagliptin. Three self-harm-adult exposures to gliptins were included for review. All the three were evaluated in a healthcare facility. One patient experienced abdominal discomfort after ingesting 700 mg of sitagliptin and was ultimately discharged from the emergency department. The other two patients experienced no reported symptoms. Conclusion. The majority of gliptin-exposed adult and pediatric/adolescent patients were safely managed at home and when evaluated in a healthcare facility, did not require hospitalization. Intentional self-harm-adult gliptin exposures were managed in a healthcare facility but rarely resulted in hospitalization or serious morbidity at doses up to 18 times the adult therapeutic dose. Additional studies are necessary to determine precise triage guidelines for the management of gliptin overdose. C1 [Darracq, M. A.] UCSF, Fresno Med Educ Program, Dept Emergency Med, Fresno, CA 93701 USA. [Toy, J. M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Chen, T.] Coram Specialty Infus Serv, Hayward, CA USA. [Mo, C.] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. [Cantrell, F. L.] Calif Poison Control Syst, San Diego Div, San Diego, CA USA. RP Darracq, MA (reprint author), UCSF, Fresno Med Educ Program, Dept Emergency Med, 155 N Fresno St, Fresno, CA 93701 USA. EM mike.darracq@gmail.com NR 14 TC 1 Z9 1 U1 0 U2 3 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 EI 1556-9519 J9 CLIN TOXICOL JI Clin. Toxicol. PD MAR PY 2014 VL 52 IS 3 BP 226 EP 230 DI 10.3109/15563650.2014.889302 PG 5 WC Toxicology SC Toxicology GA AC0ER UT WOS:000332168100013 PM 24580063 ER PT J AU Toma, M Ezekowitz, JA Bakal, JA O'Connor, CM Hernandez, AF Sardar, MR Zolty, R Massie, BM Swedberg, K Armstrong, PW Starling, RC AF Toma, Mustafa Ezekowitz, Justin A. Bakal, Jeffrey A. O'Connor, Christopher M. Hernandez, Adrian F. Sardar, Muhammad Rizwan Zolty, Ronald Massie, Barry M. Swedberg, Karl Armstrong, Paul W. Starling, Randall C. TI The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Acute heart failure; Ejection fraction; Clinical trial; Outcomes ID PRESERVED SYSTOLIC FUNCTION; BRAIN NATRIURETIC PEPTIDE; NATIONAL REGISTRY ADHERE; LONG-TERM OUTCOMES; EMERGENCY-DEPARTMENT; ATRIAL-FIBRILLATION; PEP-CHF; DYSFUNCTION; DIAGNOSIS; MANAGEMENT AB Aim Acute decompensated heart failure (ADHF) is associated with significant morbidity and mortality but the relationship between LVEF and outcomes is unclear. We explored the association between LVEF and 30 and 180day mortality in 7007 ADHF patients enrolled in the Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial. Methods and results We explored the association between LVEF and 30 and 180 day mortality in 7007 ADHF patients enrolled in the Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial. LVEF was analysed both as a continuous variable and according to three categories: < 40% (LowEF), 40-50% [intermediate EF (IntEF)], and > 50% [preserved ejection fraction (PresEF)]. Of the patients in the trial, 4474 (78.7%) had LowEF, 674 (11.9%) had IntEF, and 539 (9.5%) had PresEF. The unadjusted 30 and 180 day mortality was similar for LowEF (3.7%, 12.3%), IntEF (3.4%, 13.1%), and PresEF (4.3%, 14.1%), respectively (P > 0.05). After multivariable adjustment, the hazard ratio (HR) for 180 day mortality remained similar for the LowEF [HR 0.96, 95% confidence interval (CI) 0.75-1.24; P = 0.77] and IntEF (0.91, 95% CI 0.66-1.3; P = 0.58) compared to PresEF patients. By contrast, when LVEF was evaluated as a continuous measure, it exhibited a U-shaped pattern with mortality. After matching for age and sex, the mortality risk attributed to LVEF was attenuated, as the LVEF increased as a continuous variable over 35%. However, in patients with EF < 35%, the mortality risk continue to increase as the LVEF declined. Conclusions Among patients with ADHF, the unadjusted mortality rates are similar across LVEF strata. However, after accounting for key patient variables, the mortality risk increases as EF falls below 35%. These data will be useful in planning future studies of ADHF. Clinical Trial Registration identifier: NCT00475852 C1 [Toma, Mustafa] Univ British Columbia, St Pauls Hosp, Div Cardiol, Vancouver, BC V5Z 1M9, Canada. [Ezekowitz, Justin A.] Univ Alberta, Mazankowski Alberta Heart Inst, Div Cardiol, Dept Med, Edmonton, AB T6G 2B7, Canada. [Bakal, Jeffrey A.; Armstrong, Paul W.] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB T6G 2B7, Canada. [O'Connor, Christopher M.; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC USA. [Sardar, Muhammad Rizwan; Zolty, Ronald] Montefiore Med Ctr, Div Cardiol, Bronx, NY 10467 USA. [Massie, Barry M.] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA USA. [Swedberg, Karl] Ostra Goteborg Univ, Sahlgrenska Univ Hosp, Gothenburg, Sweden. [Starling, Randall C.] Cleveland Clin, Inst Heart & Vasc, Kaufman Ctr Heart Failure, Dept Cardiovasc Med, Cleveland, OH 44106 USA. RP Ezekowitz, JA (reprint author), Univ Alberta, Mazankowski Alberta Heart Inst, Div Cardiol, Dept Med, 2C2 WMC-8440-112 St, Edmonton, AB T6G 2B7, Canada. EM jae2@ualberta.ca RI Ezekowitz, Justin/C-4579-2013; Hernandez, Adrian F./A-7818-2016 OI Ezekowitz, Justin/0000-0002-2724-4086; Hernandez, Adrian F./0000-0003-3387-9616 FU Johnson Johnson Inc. FX The ASCEND-HF trial was funded through its sponsor, Johnson & Johnson Inc. The sponsor had no role in this study. NR 32 TC 11 Z9 11 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD MAR PY 2014 VL 16 IS 3 BP 334 EP 341 DI 10.1002/ejhf.19 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AB9FF UT WOS:000332095300012 PM 24464687 ER PT J AU Schlosser, RJ Soler, ZM Schmedes, GW Storck, K Mulligan, JK AF Schlosser, Rodney J. Soler, Zachary M. Schmedes, Gregg W. Storck, Kristina Mulligan, Jennifer K. TI Impact of vitamin D deficiency upon clinical presentation in nasal polyposis SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE polyps; sinusitis; chronic rhinosinusitis; nasal polyposis; vitamin D deficiency; cholecalciferol; vitamin D ID CHRONIC RHINOSINUSITIS AB Background The objective of this work was to determine if specific chronic rhinosinusitis with nasal polyps (CRSwNP) populations are at risk for vitamin D-3 (VD3) deficiency and if VD3 levels correlate with radiographic measures of disease severity or eosinophilia. Methods This study was a retrospective review of an academic rhinology practice. CRSwNP patients who had VD3 levels and CT scan within 6 months of each other were included. CT scans were graded using Lund-Mackay scoring (LMS) and peripheral eosinophil counts were measured. Demographic data including race, gender, age, body mass index, atopic status, and presence of asthma were collected. CRSwNP was subdivided into allergic fungal rhinosinusitis (AFRS), aspirin-exacerbated respiratory disease (AERD), and other CRSwNP. Multivariate analysis was performed to examine correlations and control for confounding factors. Results Insufficient VD3 levels were found in 55% of all CRSwNP patients. VD3 correlated with African American race because nearly 80% of all African Americans had insufficient VD3 levels. Lower VD3 levels also correlated with more severe mucosal disease on CT scans as measured by LMS. There was no correlation between VD3 levels and age, gender, body mass index, atopy, asthma, or CRSwNP subtype. Conclusion VD3 insufficiency/deficiency is common in CRSwNP patients, especially those of African American race. Lower levels of VD3 are associated with worse LMS on CT. The role of VD3 in CRSwNP warrants further investigation. C1 [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. [Schlosser, Rodney J.; Soler, Zachary M.; Schmedes, Gregg W.; Storck, Kristina; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol, Div Rhinol & Sinus Surg, Charleston, SC 29425 USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Div Neonatol, Charleston, SC 29425 USA. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol, Div Rhinol & Sinus Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM schlossr@musc.edu FU Flight Attendant Medical Research Institute; VA Merit grants FX Flight Attendant Medical Research Institute and VA Merit grants (both to R.J.S.). NR 11 TC 14 Z9 14 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD MAR PY 2014 VL 4 IS 3 BP 196 EP 199 DI 10.1002/alr.21274 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA AB9TW UT WOS:000332139600005 PM 24415576 ER PT J AU Kelly, NA Ford, MP Standaert, DG Watts, RL Bickel, CS Moellering, DR Tuggle, SC Williams, JY Lieb, L Windham, ST Bamman, MM AF Kelly, Neil A. Ford, Matthew P. Standaert, David G. Watts, Ray L. Bickel, C. Scott Moellering, Douglas R. Tuggle, S. Craig Williams, Jeri Y. Lieb, Laura Windham, Samuel T. Bamman, Marcas M. TI Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE Parkinson's disease; high-intensity exercise; resistance training; muscle hypertrophy; mitochondria ID PROGRESSIVE RESISTANCE EXERCISE; HUMAN SKELETAL-MUSCLE; QUALITY-OF-LIFE; OLDER-ADULTS; MYOFIBER HYPERTROPHY; PROTEIN EXPRESSION; RESPIRATORY-CHAIN; CITRATE SYNTHASE; CLUSTER-ANALYSIS; WALKING SPEED AB We conducted, in persons with Parkinson's disease (PD), a thorough assessment of neuromotor function and performance in conjunction with phenotypic analyses of skeletal muscle tissue, and further tested the adaptability of PD muscle to high-intensity exercise training. Fifteen participants with PD (Hoehn and Yahr stage 2-3) completed 16 wk of high-intensity exercise training designed to simultaneously challenge strength, power, endurance, balance, and mobility function. Skeletal muscle adaptations (P < 0.05) to exercise training in PD included myofiber hypertrophy (type I: +14%, type II: +36%), shift to less fatigable myofiber type profile, and increased mitochondrial complex activity in both subsarcolemmal and intermyofibrillar fractions (I: +45-56%, IV: +39-54%). These adaptations were accompanied by a host of functional and clinical improvements (P < 0.05): total body strength (+30-56%); leg power (+42%); single leg balance (+34%); sit-to-stand motor unit activation requirement (-30%); 6-min walk (+43 m), Parkinson's Disease Quality of Life Scale (PDQ-39, -7.8pts); Unified Parkinson's Disease Rating Scale (UPDRS) total (-5.7 pts) and motor (-2.7 pts); and fatigue severity (-17%). Additionally, PD subjects in the pretraining state were compared with a group of matched, non-PD controls (CON; did not exercise). A combined assessment of muscle tissue phenotype and neuromuscular function revealed a higher distribution and larger cross-sectional area of type I myofibers and greater type II myofiber size heterogeneity in PD vs. CON (P < 0.05). In conclusion, persons with moderately advanced PD adapt to high-intensity exercise training with favorable changes in skeletal muscle at the cellular and subcellular levels that are associated with improvements in motor function, physical capacity, and fatigue perception. C1 [Kelly, Neil A.; Ford, Matthew P.; Standaert, David G.; Watts, Ray L.; Bickel, C. Scott; Moellering, Douglas R.; Tuggle, S. Craig; Windham, Samuel T.; Bamman, Marcas M.] Univ Alabama Birmingham, UAB Ctr Exercise Med, Birmingham, AL USA. [Kelly, Neil A.; Tuggle, S. Craig; Bamman, Marcas M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [Ford, Matthew P.; Bickel, C. Scott] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL USA. [Standaert, David G.; Watts, Ray L.; Williams, Jeri Y.; Lieb, Laura] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Moellering, Douglas R.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Windham, Samuel T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Tuggle, S. Craig; Bamman, Marcas M.] Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Bamman, MM (reprint author), UAB Ctr Exercise Med, 966 McCallum Bldg,1720 2nd Ave South, Birmingham, AL 35294 USA. EM mbamman@uab.edu OI Standaert, David/0000-0003-2921-8348 FU UAB Department of Neurology; UAB School of Medicine; UAB Center for Exercise Medicine; DRTC Bio-Analytical Redox Biology Core [P30 DK079626]; UAB Center for Clinical and Translational Science [UL1 TR000165]; [1T32 HD071866] FX This work was supported by the UAB Department of Neurology, UAB School of Medicine, UAB Center for Exercise Medicine, 1T32 HD071866 (NAK), P30 DK079626 (DRTC Bio-Analytical Redox Biology Core), and the UAB Center for Clinical and Translational Science (UL1 TR000165). NR 79 TC 9 Z9 9 U1 7 U2 38 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD MAR PY 2014 VL 116 IS 5 BP 582 EP 592 DI 10.1152/japplphysiol.01277.2013 PG 11 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA AC3JR UT WOS:000332414300014 PM 24408997 ER PT J AU Runchey, SS Boyko, EJ Ioannou, GN Utzschneider, KM AF Runchey, Shauna S. Boyko, Edward J. Ioannou, George N. Utzschneider, Kristina M. TI Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE fatty liver; insulin-like growth factor binding protein-3; insulin-like growth factor I; national health and nutrition examination survey ID NUTRITION EXAMINATION SURVEY; PROTEIN-3 IGFBP-3 LEVELS; FACTOR BINDING PROTEIN-3; GH-DEFICIENT ADULTS; 3RD NATIONAL-HEALTH; NONALCOHOLIC STEATOHEPATITIS; IGF-I; HORMONE DEFICIENCY; HEPATIC STEATOSIS; QUALITY-CONTROL AB Background and AimNonalcoholic fatty liver disease (NAFLD), circulating insulin-like growth factor-1 (IGF-1), and IGF-1/IGF-binding protein-3 (IGFBP-3) concentrations are associated with adiposity and insulin resistance. We aimed to determine whether serum IGF-1, IGFBP-3, and IGF-1/IGFBP-3 are associated with presence or severity of NAFLD independent of potential confounding. MethodsWe performed a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey, 1988-1994, a representative sample of the United States adult population. Among participants who had a fasting blood draw and ultrasound examination, we excluded those with missing data, viral hepatitis, iron overload, excessive alcohol intake, pregnancy, or taking glucose-lowering therapy, yielding 4172 adults for this analysis. ResultsIn logistic regression analyses adjusted for age, gender, and race/ethnicity, higher IGF-1 and IGF-1/IGFBP-3 quartiles were associated with lower likelihood of NAFLD and lower grade steatosis. These associations became non-significant when further adjusted for adiposity (body mass index, waist circumference) with the exception of the association between IGF-1/IGFBP-3 and severity of NAFLD which remained significant after adjustment for homeostasis model assessment for insulin resistance (HOMA-IR) (odds ratio [95% CI]: Q3: 0.71 [0.53-0.96], Q4: 0.62 [0.43-0.89]) and adiposity (Q4: 0.67 [0.47-0.96]). Full adjustment (age, gender, race/ethnicity, adiposity, HOMA-IR, A1C%) further attenuated associations between IGF-1 or IGF-1/IGFBP-3 and liver fat such that they were no longer significant. ConclusionsAdiposity explains much of the observed association between IGF-1 or IGF-1/IGFBP-3 and liver fat. These findings do not support a direct role for the growth hormone-IGF-1/IGFBP-3 axis in the pathophysiology of NAFLD. C1 [Runchey, Shauna S.] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Ioannou, George N.] VA Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. [Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA. [Utzschneider, Kristina M.] Univ Washington, Seattle, WA 98108 USA. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Endocrinol, 1660 S Columbian Way 151, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU NIDDK DRC [P30DK017047]; [T32HL007028] FX Grants and fellowships supporting the writing of this paper: T32HL007028, NIDDK DRC grant number P30DK017047. NR 38 TC 8 Z9 8 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0815-9319 EI 1440-1746 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD MAR PY 2014 VL 29 IS 3 BP 589 EP 596 DI 10.1111/jgh.12437 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AB0GH UT WOS:000331469400029 PM 24716226 ER PT J AU Zeliadt, SB Loggers, ET Slatore, CG Au, DH Hebert, PL Klein, GJ Kessler, LG Backhus, LM AF Zeliadt, Steven B. Loggers, Elizabeth T. Slatore, Christopher G. Au, David H. Hebert, Paul L. Klein, Gregory J. Kessler, Larry G. Backhus, Leah M. TI Preoperative PET and the Reduction of Unnecessary Surgery Among Newly Diagnosed Lung Cancer Patients in a Community Setting SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE positron emission tomography; thoracotomy; community practice; non-small cell lung cancer; cancer staging ID POSITRON-EMISSION-TOMOGRAPHY; COMMON OUTCOMES; VETERANS; MANAGEMENT; TRIAL; RISK; PLUS; CT AB The goals of this study were to examine the real-world effectiveness of PET in avoiding unnecessary surgery for newly diagnosed patients with non-small cell lung cancer. Methods: A cohort of 2,977 veterans with non-small cell lung cancer between 1997 and 2009 were assessed for use of PET during staging and treatment planning. The subgroup of 976 patients who underwent resection was assessed for several outcomes, including pathologic evidence of mediastinal lymph node involvement, distant metastasis, and 12-mo mortality. We anticipated that PET may have been performed selectively on the basis of unobserved characteristics (e.g., providers ordered PET when they suspected disseminated disease). Therefore, we conducted an instrumental variable analysis, in addition to conventional multivariate logistic regression, to reduce the influence of this potential bias. This type of analysis attempts to identify an additional variable that is related to receipt of treatment but not causally associated with the outcome of interest, similar to randomized assignment. The instrument here was calendar time. This analysis can be informative when patients do not receive the treatment that the instrument suggests they "should" have received. Results: Overall, 30.3% of patients who went to surgery were found to have evidence of metastasis uncovered during the procedure or within 12 mo, indicating that nearly one third of patients underwent surgery unnecessarily. The use of preoperative PET increased substantially over the study period, from 9% to 91%. In conventional multivariate analyses, PET use was not associated with a decrease in unnecessary surgery (odds ratio, 0.87; 95% confidence interval, 0.66-1.16; P = 0.351). However, a reduction in unnecessary surgery (odds ratio, 0.53; 95% confidence interval, 0.34-0.82; P = 0.004) was identified in the instrumental variable analyses, which attempted to account for potentially unobserved confounding. Conclusion: PET has now become routine in preoperative staging and treatment planning in the community and appears to be beneficial in avoiding unnecessary surgery. Evaluating the effectiveness of PET appears to be influenced by potentially unmeasured adverse selection of patients, especially when PET first began to be disseminated in the community. C1 [Zeliadt, Steven B.; Au, David H.; Hebert, Paul L.] Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA. [Zeliadt, Steven B.; Hebert, Paul L.; Klein, Gregory J.; Kessler, Larry G.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Loggers, Elizabeth T.] Grp Hlth Res Inst, Seattle, WA USA. [Loggers, Elizabeth T.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Slatore, Christopher G.] Portland VA Med Ctr, Pulm & Crit Care Sect, Portland, OR USA. [Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Pulm & Crit Care Serv, Seattle, WA USA. [Au, David H.] Univ Washington, Div Pulm Med, Seattle, WA 98195 USA. [Backhus, Leah M.] VA Puget Sound Hlth Care Syst, Surg Serv, Seattle, WA USA. [Backhus, Leah M.] Univ Washington, Div Cardiothorac Surg, Seattle, WA 98195 USA. RP Zeliadt, SB (reprint author), Dept Vet Affairs Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM steven.zeliadt@va.gov OI Slatore, Christopher/0000-0003-0958-8122 FU National Cancer Institute for the "ADVancing Innovative Comparative Effectiveness research in cancer diagnostics (ADVICE)" [1RC2CA148433-01]; VA Puget Sound Health Care System, Seattle, Washington; Health Services Research and Development Career Development Award from the Department of Veterans Affairs and resources from the Portland VA Medical Center, Portland, Oregon FX The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This material is the result of work supported by a grant from the National Cancer Institute for the "ADVancing Innovative Comparative Effectiveness research in cancer diagnostics (ADVICE)" study, 1RC2CA148433-01; by resources from the VA Puget Sound Health Care System, Seattle, Washington; and in part by a Health Services Research and Development Career Development Award from the Department of Veterans Affairs and resources from the Portland VA Medical Center, Portland, Oregon. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. Government. No other potential conflict of interest relevant to this article was reported. NR 23 TC 4 Z9 4 U1 0 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAR PY 2014 VL 55 IS 3 BP 379 EP 385 DI 10.2967/jnumed.113.124230 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AC2RQ UT WOS:000332352100017 PM 24449594 ER PT J AU Johnson, AL Jung, L Song, Y Brown, KC Weaver, MT Richards, KC AF Johnson, Arlene L. Jung, Lorena Song, Yeonsu Brown, Kathleen C. Weaver, Michael T. Richards, Kathy C. TI Sleep Deprivation and Error in Nurses Who Work the Night Shift: Erratum SO JOURNAL OF NURSING ADMINISTRATION LA English DT Correction C1 [Song, Yeonsu] VA Greater Los Angeles, Los Angeles, CA USA. NR 1 TC 0 Z9 0 U1 3 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 EI 1539-0721 J9 J NURS ADMIN JI J. Nurs. Adm. PD MAR PY 2014 VL 44 IS 3 BP 186 EP 186 DI 10.1097/NNA.0000000000000048 PG 1 WC Nursing SC Nursing GA AC0GS UT WOS:000332173400013 ER PT J AU Artornsombudh, P Pistilli, M Foster, CS Pujari, SS Gangaputra, SS Jabs, DA Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Suhler, EB Thorne, JE Kempen, JH AF Artornsombudh, Pichaporn Pistilli, Maxwell Foster, C. Stephen Pujari, Siddharth S. Gangaputra, Sapna S. Jabs, Douglas A. Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Thorne, Jennifer E. Kempen, John H. TI Factors Predictive of Remission of New-Onset Anterior Uveitis SO OPHTHALMOLOGY LA English DT Article ID JUVENILE IDIOPATHIC ARTHRITIS; INTRAOCULAR INFLAMMATORY DISEASE; INTERMEDIATE UVEITIS; CLINICAL-COURSE; PREVALENCE; EPIDEMIOLOGY; CHILDHOOD; BLINDNESS; FRAGMENT AB Purpose: To identify factors predictive of remission of inflammation in new-onset anterior uveitis cases treated at tertiary uveitis care facilities. Design: Retrospective cohort study. Participants: Patients seeking treatment at participating academic uveitis clinics within 90 days of initial diagnosis of anterior uveitis. Methods: Retrospective cohort study based on standardized chart review. Main Outcome Measures: Factors predictive of remission (no disease activity without corticosteroid or immunosuppressive treatments at all visits during a 90-day period). Results: Nine hundred ninety eyes (687 patients) had a first-ever diagnosis of anterior uveitis within 90 days before initial presentation and had follow-up visits thereafter. The median follow-up time was 160 days. Systemic diagnoses with juvenile idiopathic arthritis (JIA; adjusted hazard ratio [aHR], 0.38; 95% confidence interval [CI], 0.19-0.74) and Behcet's disease (aHR, 0.10; 95% CI, 0.01-0.85) were associated with a lower incidence of uveitis remission. Cases of bilateral uveitis (aHR, 0.68; 95% CI, 0.54-0.87) and those with a history of cataract surgery before presentation (aHR, 0.51; 95% CI, 0.29-0.87) also had a lower incidence of remission. Regarding clinical findings at the initial visit, a high degree of vitreous cells at initial presentation was associated with a lower incidence of remission (for 1+ or more vs. none: aHR, 0.72; 95% CI, 0.55-0.95). An initial visual acuity of 20/200 or worse, with respect to 20/40 or better, also was predictive of a lower incidence of remission (aHR, 0.52; 95% CI, 0.32-0.86). Conclusions: Factors associated with a lower incidence of remission among new-onset anterior uveitis cases included diagnosis with JIA, Behcet's disease, bilateral uveitis, history of cataract surgery, findings of 1+ or more vitreous cells at presentation, and an initial visual acuity of 20/200 or worse. Patients with these risk factors seem to be at higher risk of persistent inflammation; reciprocally, patients lacking these factors would be more likely to experience remission. Patients with risk factors for nonremission of uveitis should be managed taking into account the higher probability of a chronic inflammatory course. (C) 2014 by the American Academy of Ophthalmology. C1 [Artornsombudh, Pichaporn; Foster, C. Stephen; Pujari, Siddharth S.] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Artornsombudh, Pichaporn; Pistilli, Maxwell; Kempen, John H.] Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Pujari, Siddharth S.] Om Eye Care Hosp, Belgaum, Karnataka, India. [Gangaputra, Sapna S.] Duke Univ, Sch Med, Dept Surg, Durham, NC USA. [Gangaputra, Sapna S.] Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Fundus Photograph Reading Ctr, Madison, WI USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA. [Jabs, Douglas A.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA. [Kempen, John H.] Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Pistilli, Maxwell/0000-0002-4266-4150 FU National Eye Institute, National Institutes of Health, Bethesda, Maryland [EY014943]; Research to Prevent Blindness, Inc., New York, New York; Paul and Evanina Mackall Foundation, New York, New York; Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts; Research to Prevent Blindness; National Eye Institute; United States Department of Veterans' Affairs FX Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant no.: EY014943 [J.H.K.]); Research to Prevent Blindness, Inc., New York, New York; the Paul and Evanina Mackall Foundation, New York, New York; and the Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts. During the time of data collection, J.H.K. was an Research to Prevent Blindness James S. Adams Special Scholar Award recipient, J.E.T. was a Research to Prevent Blindness Harrington Special Scholar Award recipient, and D.A.J. and J.T.R. were Research to Prevent Blindness Senior Scientific Investigator Award recipients. G.A.L-C. is an employee of Johnson & Johnson and was previously supported by the National Eye Institute, and R.B.N. continues to be supported by intramural funds of the National Eye Institute. E.B.S. receives support from the United States Department of Veterans' Affairs. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; or in the preparation, review, and approval of this manuscript. NR 31 TC 4 Z9 4 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD MAR PY 2014 VL 121 IS 3 BP 778 EP 784 DI 10.1016/j.ophtha.2013.09.041 PG 7 WC Ophthalmology SC Ophthalmology GA AC3FT UT WOS:000332401800030 PM 24342020 ER PT J AU Li, PY Mao, LL Liu, XR Gan, Y Zheng, J Thomson, AW Gao, YQ Chen, J Hu, XM AF Li, Peiying Mao, Leilei Liu, Xiangrong Gan, Yu Zheng, Jing Thomson, Angus W. Gao, Yanqin Chen, Jun Hu, Xiaoming TI Essential Role of Program Death 1-Ligand 1 in Regulatory T-Cell-Afforded Protection Against Blood-Brain Barrier Damage After Stroke SO STROKE LA English DT Article DE matrix metalloproteinase 9; neutrophils; programmed cell death 1 ligand 1; regulatory T-cells; stroke ID FOCAL CEREBRAL-ISCHEMIA; NEUTROPHIL INFILTRATION; EXPRESSION; MATRIX-METALLOPROTEINASE-9; PD-1; AUTOIMMUNITY; INFLAMMATION; MACROPHAGES; BREAKDOWN; ANTIGEN AB Background and Purpose Our recent research revealed that adoptively transferred regulatory T cells (Tregs) reduced acute ischemic brain injury by inhibiting neutrophil-derived matrix metalloproteinase-9 (MMP-9) and protecting against blood-brain barrier damage. The mechanisms underlying Treg interactions with neutrophils remain elusive. This study evaluates the contribution of program death 1-ligand 1 (PD-L1) to Treg-mediated neutrophil inhibition and neuroprotection after cerebral ischemia. Methods In vitro experiments were performed using a transwell system or a coculture system allowing cell-to-cell contact. Focal cerebral ischemia was induced in mice for 60 minutes. Tregs (2x10(6)) isolated from donor animals (wild-type or PD-L1(-/-)) were intravenously injected into ischemic recipients 2 hours after middle cerebral artery occlusion (MCAO). MMP-9 production, blood-brain barrier permeability, and brain infarct were assessed at 1 or 3 days after MCAO. Results In vitro experiments reveal that Treg-mediated inhibition of neutrophil MMP-9 required direct cell-to-cell contact. The suppression of MMP-9 was abolished when Tregs were pretreated with PD-L1 neutralizing antibodies or when neutrophils were pretreated with PD-1 antibodies. In vivo studies confirmed that intravenous administration of Tregs pretreated with PD-L1 antibodies or Tregs isolated from PD-L1-deficient mice failed to inhibit MMP-9 production by blood neutrophils 1 day after 60 minutes MCAO. Furthermore, the blood-brain barrier damage after MCAO was greatly ameliorated in PD-L1-competent Treg-treated mice but not in PD-L1-compromised Treg-treated mice. Consequently, PD-L1 dysfunction abolished Treg-mediated brain protection and neurological improvements 3 days after MCAO. Conclusions PD-L1 plays an essential role in the neuroprotection afforded by Tregs against cerebral ischemia by mediating the suppressive effect of Tregs on neutrophil-derived MMP-9. C1 [Li, Peiying; Mao, Leilei; Liu, Xiangrong; Gao, Yanqin; Chen, Jun; Hu, Xiaoming] Fudan Univ, Huashan Hosp, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Li, Peiying; Mao, Leilei; Liu, Xiangrong; Gao, Yanqin; Chen, Jun; Hu, Xiaoming] Fudan Univ, Huashan Hosp, Inst Brain Sci, Dept Anesthesiol, Shanghai 200433, Peoples R China. [Li, Peiying; Mao, Leilei; Gan, Yu; Zheng, Jing; Chen, Jun; Hu, Xiaoming] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Surg, Starzl Transplantat Inst, Pittsburgh, PA 15213 USA. [Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Immunol, Starzl Transplantat Inst, Pittsburgh, PA 15213 USA. [Li, Peiying; Hu, Xiaoming] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Liu, Xiangrong] Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing, Peoples R China. RP Hu, XM (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu; hux2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU Veterans Health Administration (GRECC); National Institutes of Health [NS36736, NS43802, NS45048]; American Heart Association [13SDG14570025]; Shanghai Natural Science Foundation [13ZR1452200] FX This work was supported by the Veterans Health Administration (GRECC pilot grant to Dr Chen), the National Institutes of Health Grants (NS36736, NS43802, and NS45048 to Dr Chen), a grant from the American Heart Association (13SDG14570025 to Dr Hu), and Shanghai Natural Science Foundation (13ZR1452200 to Dr Li). NR 32 TC 23 Z9 23 U1 1 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD MAR PY 2014 VL 45 IS 3 BP 857 EP 864 DI 10.1161/STROKEAHA.113.004100 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AB6DC UT WOS:000331876800050 PM 24496394 ER PT J AU Isaac, C Byars-Winston, A McSorley, R Schultz, A Kaatz, A Carnes, ML AF Isaac, Carol Byars-Winston, Angela McSorley, Rebecca Schultz, Alexandra Kaatz, Anna Carnes, Mary L. TI A qualitative study of work-life choices in academic internal medicine SO ADVANCES IN HEALTH SCIENCES EDUCATION LA English DT Article DE Social role theory; Career development; Physicians; Women's issues; Work stress; Retention ID CAREER CHOICE; GENDER; PHYSICIANS; FACULTY; FAMILY; HEALTH; GENERATION AB The high attrition rate of female physicians pursuing an academic medicine research career has not been examined in the context of career development theory. We explored how internal medicine residents and faculty experience their work within the context of their broader life domain in order to identify strategies for facilitating career advancement. Semi-structured interviews were conducted with a purposeful sample of 18 residents and 34 faculty members representing male and female physicians at different career stages. Using thematic analysis, three themes emerged: (1) the love of being a physician ("Raison d'tre"), (2) family obligations ("2nd Shift"), and (3) balancing work demands with non-work life ("Negotiating Academic Medicine"). Female researchers and educators reported more strategies for multiple role planning and management than female practitioners. Interventions aimed at enhancing academic internists' planning and self-efficacy for multiple role management should be investigated as a potential means for increasing participation and facilitate advancement. C1 [Isaac, Carol; Byars-Winston, Angela; McSorley, Rebecca; Schultz, Alexandra; Kaatz, Anna; Carnes, Mary L.] Univ Wisconsin, SMPH, Ctr Womens Hlth Res, Dept Med, Madison, WI 53715 USA. [McSorley, Rebecca; Schultz, Alexandra] Univ Wisconsin, SMPH, Madison, WI 53715 USA. [Kaatz, Anna] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Carnes, Mary L.] Univ Wisconsin, SMPH, Dept Med, Madison, WI 53715 USA. [Carnes, Mary L.] Univ Wisconsin, SMPH, Dept Psychiat, Madison, WI 53715 USA. [Carnes, Mary L.] Univ Wisconsin, Coll Engn, Dept Ind & Syst Engn, Madison, WI 53715 USA. [Carnes, Mary L.] Univ Wisconsin, Coll Engn, Women Sci & Engn Leadership Inst WISELI, Madison, WI 53715 USA. [Carnes, Mary L.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Byars-Winston, A (reprint author), Univ Wisconsin, SMPH, Ctr Womens Hlth Res, Dept Med, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM ambwinst@medicine.wisc.edu FU NIH [T32 AG00265, R25 GM083252, R01 GM094573, R01 GM088477]; Meriter Hospital; Shapiro Research Fellowship for medical students; Jean Manchester Biddick-Bascom Professorship FX NIH T32 AG00265 (Isaac), R25 GM083252 (Kaatz), R01 GM094573 (Byars-Winston), R01 GM088477 (Carnes), Meriter Hospital, the Shapiro Research Fellowship for medical students (McSorley and Schultz), and the Jean Manchester Biddick-Bascom Professorship (Carnes). Dr. Carnes is a part time staff physician at the William S. Middleton Veterans Hospital (GRECC Publication Number XXXX). NR 37 TC 6 Z9 6 U1 2 U2 19 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1382-4996 EI 1573-1677 J9 ADV HEALTH SCI EDUC JI Adv. Health Sci. Educ. PD MAR PY 2014 VL 19 IS 1 BP 29 EP 41 DI 10.1007/s10459-013-9457-5 PG 13 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AB2NU UT WOS:000331630200004 PM 23605099 ER PT J AU Stepanczuk, BC Dicianno, BE Webb, TS AF Stepanczuk, Beth C. Dicianno, Brad E. Webb, Thomas S. TI Young Adults with Spina Bifida May Have Higher Occurrence of Prehypertension and Hypertension SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Prehypertension; Meningomyelocele; Cardiovascular Diseases; Hypertension ID CARDIOVASCULAR-DISEASE RISK; JOINT NATIONAL COMMITTEE; MEDICAL-MANAGEMENT; BLOOD-PRESSURE; CORD-INJURY; PREVALENCE; ADOLESCENTS; ANOMALIES; CARE AB Objective The aims of this study were to determine the occurrence of prehypertension and high blood pressure in adults with spina bifida (SB) and to examine relationships among blood pressure, cardiovascular disease risk factors, and SB-specific factors. Design This is a cross-sectional, retrospective analysis of adults with SB. SB-specific factors and cardiovascular disease risk factors were compared among subjects with high blood pressure, subjects with blood pressure in the prehypertensive range, and normotensive subjects using the chi(2), Kruskal-Wallis, or Fisher's exact tests. Results Of 225 subjects, the occurrence of prehypertension and high blood pressure was 27% (n = 22) and 27% (n = 22) for ages 18-29 yrs, 35% (n = 26) and 41% (n = 30) for ages 30-39 yrs, 18% (n = 8) and 66% (n = 29) for ages 40-49 yrs, and 21% (n = 5) and 67% (n = 16) for 50 yrs or older, respectively. Of the subjects with high blood pressure, 56% were men, 14% had obstructive sleep apnea, 14% had diabetes, 19% had renal dysfunction, 38% used tobacco, 16% had hydronephrosis, and 71% had a shunt. The groups differed significantly with respect to diabetes (P = 0.004), bladder procedures (P = 0.001), and renal dysfunction (P < 0.001), with higher proportions of subjects with high blood pressure having these comorbidities. Conclusions Fewer than half of the subjects were considered normotensive. A greater proportion of young adults with SB appear to have high blood pressure compared with the general United States population. Because elevated blood pressure is an independent, modifiable risk factor of cardiovascular disease, these findings support early screening and intervention for elevated blood pressure in individuals with SB. C1 [Stepanczuk, Beth C.; Dicianno, Brad E.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. [Dicianno, Brad E.] Univ Pittsburgh, Med Ctr, Adult Outpatient Spina Bifida Clin, Pittsburgh, PA 15213 USA. [Dicianno, Brad E.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15213 USA. [Webb, Thomas S.] Huntersville Pediat & Internal Med, Huntersville, NC USA. RP Dicianno, BE (reprint author), Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA. FU Department of Physical Medicine and Rehabilitation, University of Pittsburgh Medical Center FX Supported by funds from the Department of Physical Medicine and Rehabilitation, University of Pittsburgh Medical Center. NR 23 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD MAR PY 2014 VL 93 IS 3 BP 200 EP 206 DI 10.1097/PHM.0b013e3182a92b03 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA AB3RH UT WOS:000331707400002 PM 24088776 ER PT J AU Hilsabeck, RC Hietpas, TL Mccoy, KJM AF Hilsabeck, Robin C. Hietpas, Tammy L. Mccoy, Karin J. M. TI Satisfaction of Referring Providers with Neuropsychological Services within a Veterans Administration Medical Center SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Assessment; Professional issues ID UNITED-STATES AB With the implementation of healthcare reform, it is essential for neuropsychologists to establish themselves as important members of healthcare teams and to work efficiently and effectively. The purpose of this study was to survey the satisfaction of referring providers with neuropsychological services, including turn-around time of reports and their essential elements, within a hospital system that uses electronic medical records. Findings revealed that referral sources are generally satisfied with neuropsychological services and find them valuable. They especially appreciate the neuropsychological report and detailed testing of cognitive and functional abilities and prefer the report within 2 weeks of the patient's appointment. Most find all sections of the report completely essential with the exception of test scores, and most are comfortable with recommendations made by neuropsychologists. With few exceptions, there were no differences among types of referring providers (i.e., physicians, psychologists, and social workers). Future surveys may wish to examine how neuropsychological services affect patient outcomes. C1 [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.; Hietpas, Tammy L.; Mccoy, Karin J. M.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Hietpas, Tammy L.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. RP Hilsabeck, RC (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM hilsabeck@uthscsa.edu NR 8 TC 1 Z9 1 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAR PY 2014 VL 29 IS 2 BP 131 EP 140 DI 10.1093/arclin/act084 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA AB8FY UT WOS:000332026800002 PM 24200634 ER PT J AU Anderson, JP Tchetgen, EJT Lo Re, V Tate, JP Williams, PL Seage, GR Horsburgh, CR Lim, JK Goetz, MB Rimland, D Rodriguez-Barradas, MC Butt, AA Klein, MB Justice, AC AF Anderson, Jeffrey P. Tchetgen, Eric J. Tchetgen Lo Re, Vincent, III Tate, Janet P. Williams, Paige L. Seage, George R., III Horsburgh, C. Robert Lim, Joseph K. Goetz, Matthew Bidwell Rimland, David Rodriguez-Barradas, Maria C. Butt, Adeel A. Klein, Marina B. Justice, Amy C. TI Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus-Coinfected Veterans SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV; hepatitis C; coinfection; hepatic decompensation; marginal structural model ID HUMAN-IMMUNODEFICIENCY-VIRUS; MARGINAL STRUCTURAL MODELS; LIVER FIBROSIS PROGRESSION; INFECTED PATIENTS; PROTECTIVE FACTOR; DISEASE; COHORT; NEVIRAPINE; IMPACT; DEATH AB Background. Human immunodeficiency virus (HIV) coinfection accelerates the rate of liver disease outcomes in individuals chronically infected with hepatitis C virus (HCV). It remains unclear to what degree combination antiretroviral therapy (ART) protects against HCV-associated liver failure. Methods. We evaluated 10 090 HIV/HCV-coinfected males from the Veterans Aging Cohort Study Virtual Cohort, who had not initiated ART at entry, for incident hepatic decompensation between 1996 and 2010. We defined ART initiation as the first pharmacy fill date of a qualifying ART regimen of >= 3 drugs from >= 2 classes. Hepatic decompensation was defined as the first occurrence of 1 hospital discharge diagnosis or 2 outpatient diagnoses for ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage. To account for potential confounding by indication, marginal structural models were used to estimate hazard ratios (HRs) of hepatic decompensation, comparing initiation of ART to noninitiation. Results. We observed 645 hepatic decompensation events in 46 444 person-years of follow-up (incidence rate, 1.4/100 person-years). Coinfected patients who initiated ART had a significantly reduced rate of hepatic decompensation relative to noninitiators (HR = 0.72; 95% confidence interval [CI], .54-.94). When we removed individuals with HIV RNA <= 400 copies/mL at baseline from the analysis (assuming that they may have received undocumented ART at entry), the hazard ratio became more pronounced (HR = 0.59; 95% CI, .43-.82). Conclusions. Initiation of ART significantly reduced the rate of hepatic decompensation by 28%-41% on average. These results suggest that ART should be administered to HIV/HCV-coinfected patients to lower the risk of end-stage liver disease. C1 [Anderson, Jeffrey P.; Tchetgen, Eric J. Tchetgen; Seage, George R., III] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Tchetgen, Eric J. Tchetgen; Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Lo Re, Vincent, III] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Horsburgh, C. Robert] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Horsburgh, C. Robert] Boston Univ, Sch Med, Boston Med Ctr, Infect Dis Sect, Boston, MA 02215 USA. [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Butt, Adeel A.] Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates. [Klein, Marina B.] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada. RP Tate, JP (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. EM janet.tate2@va.gov RI Lo Re, Vincent/N-7817-2015 OI Butt, Adeel/0000-0002-1118-1826; Goetz, Matthew/0000-0003-4542-992X FU National Institutes of Health [T32 AI007358, T32 AI007535]; National Institute on Alcohol Abuse and Alcoholism [U01 AA13566, U24 AA020794, U01 AA020790]; National Heart, Lung and Blood Institute [R01 HL095136, R01 HL090342, RCI HL100347]; National Institute of Allergy and Infectious Diseases [U01 A1069918]; Veterans Health Administration Office of Research and Development [VA REA 08266]; National Institute on Aging; National Institute of Mental Health; Veterans Health Administration FX This work was supported by the National Institutes of Health (grant numbers T32 AI007358 and T32 AI007535 to J. P. A.). The Veterans Aging Cohort Study has been funded by the National Institute on Alcohol Abuse and Alcoholism (grant numbers U01 AA13566, U24 AA020794, U01 AA020790); the National Heart, Lung and Blood Institute (grant numbers R01 HL095136, R01 HL090342, RCI HL100347); the National Institute of Allergy and Infectious Diseases (grant number U01 A1069918); the Veterans Health Administration Office of Research and Development (grant number VA REA 08266); and an interagency agreement between the National Institute on Aging, the National Institute of Mental Health, and the Veterans Health Administration. NR 40 TC 26 Z9 26 U1 2 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2014 VL 58 IS 5 BP 719 EP 727 DI 10.1093/cid/cit779 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AB5RR UT WOS:000331846700023 PM 24285848 ER PT J AU Hussey, SE Lum, H Alvarez, A Cipriani, Y Garduno-Garcia, J Anaya, L Dube, J Musi, N AF Hussey, Sophie E. Lum, Helen Alvarez, Andrea Cipriani, Yolanda Garduno-Garcia, Jesus Anaya, Luis Dube, John Musi, Nicolas TI A sustained increase in plasma NEFA upregulates the Toll-like receptor network in human muscle SO DIABETOLOGIA LA English DT Article DE Acylcarnitine; Ceramide; Diacylglycerol; Inflammation; Insulin resistance ID INDUCED INSULIN-RESISTANCE; FREE FATTY-ACIDS; TYPE-2 DIABETIC SUBJECTS; HUMAN SKELETAL-MUSCLE; PROTEIN-KINASE-C; KAPPA-B; 3-KINASE ACTIVITY; ACTIVATION; EXPRESSION; GLUCOSE AB Insulin-sensitive tissues (muscle, liver) of individuals with obesity and type 2 diabetes mellitus are in a state of low-grade inflammation, characterised by increased Toll-like receptor (TLR) expression and TLR-driven signalling. However, the cause of this mild inflammatory state is unclear. We tested the hypothesis that a prolonged mild increase in plasma NEFA will increase TLR expression and TLR-driven signalling (nuclear factor kappa B [NF kappa B] and mitogen-activated kinase [MAPK]) and impair insulin action in muscle of lean healthy individuals. Twelve lean, normal-glucose-tolerant participants were randomised to receive a 48 h infusion (30 ml/h) of saline or Intralipid followed by a euglycaemic-hyperinsulinaemic clamp. Vastus lateralis muscle biopsies were performed before and during the clamp. Lipid infusion impaired insulin-stimulated IRS-1 tyrosine phosphorylation and reduced peripheral insulin sensitivity (p < 0.01). The elevation in circulating NEFA increased expression of TLR3, TLR4 and TLR5, and several MAPK (MAPK8, MAP4K4, MAP2K3) and inhibitor of kappa B kinase-NF kappa B (CHUK [IKKA], c-REL [REL] and p65 [RELA, NFKB3, p65]) signalling genes (p < 0.05). The lipid infusion also increased extracellular signal-regulated kinase (ERK) phosphorylation (p < 0.05) and tended to reduce the content of inhibitor of kappa B alpha (p = 0.09). The muscle content of most diacylglycerol, ceramide and acylcarnitine species was unaffected. In summary, insulin resistance induced by prolonged low-dose lipid infusion occurs together with increased TLR-driven inflammatory signalling and impaired insulin-stimulated IRS-1 tyrosine phosphorylation. A sustained, mild elevation in plasma NEFA is sufficient to increase TLR expression and TLR-driven signalling (NF kappa B and MAPK) in lean individuals. The activation of this pathway by NEFA may be involved in the pathogenesis of insulin resistance in humans. Trial registration ClinicalTrials.gov NCT01740817. C1 [Hussey, Sophie E.; Lum, Helen; Alvarez, Andrea; Cipriani, Yolanda; Garduno-Garcia, Jesus; Anaya, Luis; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA. [Dube, John] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Ctr Hlth Aging, San Antonio, TX 78229 USA. [Musi, Nicolas] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Musi, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA. EM musi@uthscsa.edu FU National Institutes of Health (NIH) [RO1-DK80157, RO1-DK089229]; American Diabetes Association; University of Texas Health Science Center at San Antonio Clinical and Translational Science Award [TR000149]; NIH National Service Research Award [F32 (1F32DK095565-01A1)]; Lipidomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (MUSC) [P30 CA138313]; Lipidomics Core in the South Carolina Lipidomics and Pathobiology COBRE, Department Biochemistry, MUSC [P20 RR017677]; National Center for Research Resources; Office of the Director of the NIH [C06 RR018823] FX This work was supported by grants from the National Institutes of Health (NIH) (RO1-DK80157 and RO1-DK089229) and the American Diabetes Association to NM. This grant was supported by a University of Texas Health Science Center at San Antonio Clinical and Translational Science Award (TR000149) and an NIH National Service Research Award, Parent F32 (1F32DK095565-01A1) to SH. The research was supported in part by the Lipidomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (MUSC) (P30 CA138313) and the Lipidomics Core in the South Carolina Lipidomics and Pathobiology COBRE, Department Biochemistry, MUSC (P20 RR017677). This project also was supported by the National Center for Research Resources and the Office of the Director of the NIH (C06 RR018823) to MUSC. NR 50 TC 12 Z9 12 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD MAR PY 2014 VL 57 IS 3 BP 582 EP 591 DI 10.1007/s00125-013-3111-x PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AB1NG UT WOS:000331558400018 PM 24337154 ER PT J AU Robertson, J Landham, JB Estrada, CA AF Robertson, Jeffrey Landham, Jonathan B. Estrada, Carlos A. TI Splenic Infarcts Associated with Immune Reconstitution Inflammatory Syndrome SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE splenic infarction; immune reconstitution inflammatory syndrome; HIV infections/drug therapy; HIV infections/complications; inflammation; mycobacterium infections/etiology C1 [Robertson, Jeffrey] Tinsley Harrison Internal Med Residency Training, Birmingham, AL USA. [Robertson, Jeffrey; Landham, Jonathan B.; Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Estrada, CA (reprint author), Univ Alabama Birmingham, 732 FOT,510 20th St South, Birmingham, AL 35294 USA. EM cestrada@uab.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2014 VL 29 IS 3 BP 541 EP 542 DI 10.1007/s11606-013-2599-6 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB7II UT WOS:000331962600028 PM 24002634 ER PT J AU Palaia, JM McConnell, M Achenbach, JE Gustafson, CE Stoermer, KA Nolan, M Guay, LA Leitner, TK Matovu, F Taylor, AW Fowler, MG Janoff, EN AF Palaia, Jana M. McConnell, Michelle Achenbach, Jenna E. Gustafson, Claire E. Stoermer, Kristina A. Nolan, Monica Guay, Laura A. Leitner, Thomas K. Matovu, Flavia Taylor, Allan W. Fowler, Mary Glenn Janoff, Edward N. TI Neutralization of HIV subtypes A and D by breast milk IgG from women with HIV infection in Uganda SO JOURNAL OF INFECTION LA English DT Article DE Breast milk; HIV; Neutralization; IgG,IgA; Uganda; Subtype A; Subtype D; Mucosal immunity ID IMMUNODEFICIENCY-VIRUS TYPE-1; LACTATING RHESUS-MONKEYS; CELL-FREE HIV; MONOCLONAL-ANTIBODIES; ENVELOPE GLYCOPROTEIN; SECRETORY IGA; TRANSMISSION; RESPONSES; INFANT; TRANSCYTOSIS AB Objectives: Among HIV-exposed infants in resource-limited countries, 8e12% are infected postnatally by breastfeeding. However, most of those uninfected at birth remain uninfected over time despite daily exposure to HIV in breast milk. Thus, we assessed the HIVinhibitory activity of breast milk. Methods: We measured cross-clade neutralization in activated PBMC of Ugandan subtype A (92UG031) and D (92UG005) primary HIV by breast milk or purified milk IgG and IgA from 25 HIV-infected Ugandan women. Isotype-specific antigen recognition was resolved by immunoblot. We determined HIV subtype from envelope population sequences in cells from 13 milk samples by PCR. Results: Milk inhibited p24 production by >= 50% (dose-dependent) by subtype A (21/25; 84%) and subtype D (11/25; 44%). IgG consistently reacted with multiple HIV antigens, including gp120/gp41, but IgA primarily recognized p24 alone. Depletion of IgG (n Z 5), not IgA, diminished neutralization (mean 78 +/- 33%) that was largely restored by IgG repletion. Mothers infected with subtype A more effectively neutralized subtype A than D. Conclusions: Breast milk from HIV-infected women showed homotypic and cross-subtype neutralization of HIV by IgG-dependent and -independent mechanisms. These data direct further investigations into mechanisms of resistance against postnatal transmission of HIV to infants from their mothers. (C) 2013 Published by Elsevier Ltd on behalf of The British Infection Association. C1 [Palaia, Jana M.; Achenbach, Jenna E.; Gustafson, Claire E.; Stoermer, Kristina A.; Janoff, Edward N.] Univ Colorado, MAVRC, Aurora, CO 80045 USA. [Palaia, Jana M.; Gustafson, Claire E.; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. [McConnell, Michelle; Nolan, Monica; Taylor, Allan W.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Guay, Laura A.; Matovu, Flavia; Fowler, Mary Glenn] Johns Hopkins Univ, Makerere Univ, Kampala, Uganda. [Leitner, Thomas K.] Los Alamos Natl Lab, Los Alamos, NM 87544 USA. RP Janoff, EN (reprint author), Univ Colorado Denver, MAVRC, Box B-168,12700 E 19th Ave, Aurora, CO 80045 USA. EM Edward.Janoff@ucdenver.edu FU NIH [R01-HD059527, R01-AI41361, R01 AI097265]; United States Centers for Disease Control; Elisabeth Glaser Pediatric AIDS Foundation (EGPAF) [MV00- 9-900-01432-0-00]; University of Colorado Denver's Office of Interdisciplinary Women's Health Research Grant; Mucosal and Vaccine Research Colorado Program (MAVRC); University of Colorado Cancer Center DNA Sequencing and Analysis Core [P30 CA046934] FX This work supported by NIH R01-HD059527, R01-AI41361, R01 AI097265, the United States Centers for Disease Control (CDC; " Pathobiology of Breast Milk among HIV-1 infected Ugandan women receiving intrapartum nevirapine" study), the Elisabeth Glaser Pediatric AIDS Foundation (EGPAF) MV00- 9-900-01432-0-00, University of Colorado Denver's Office of Interdisciplinary Women's Health Research Grant, the Mucosal and Vaccine Research Colorado Program (MAVRC) and the University of Colorado Cancer Center DNA Sequencing and Analysis Core (Grant # P30 CA046934). The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the United States Centers for Disease Control and Prevention. We thank Jacinta Cooper for technical support and advice and the women in Kampala, Uganda for their participation. NR 52 TC 1 Z9 1 U1 1 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 EI 1532-2742 J9 J INFECTION JI J. Infect. PD MAR PY 2014 VL 68 IS 3 BP 264 EP 272 DI 10.1016/j.jinf.2013.11.002 PG 9 WC Infectious Diseases SC Infectious Diseases GA AB3TC UT WOS:000331712100008 PM 24239588 ER PT J AU Sulkowski, MS Kang, M Matining, R Wyles, D Johnson, VA Morse, GD Amorosa, V Bhattacharya, D Coughlin, K Wong-Staal, F Glesby, MJ AF Sulkowski, Mark S. Kang, Minhee Matining, Roy Wyles, David Johnson, Victoria A. Morse, Gene D. Amorosa, Valerianna Bhattacharya, Debika Coughlin, Kristine Wong-Staal, Flossie Glesby, Marshall J. CA AIDS Clinical Trials Grp A5277 TI Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 20th Conference on Retroviruses and Opportunistic Infections (CROI) CY MAR 03-06, 2013 CL Atlanta, GA DE HCV; SRB1; entry inhibitors ID C VIRUS-INFECTION; SCAVENGER RECEPTOR BI; HDL RECEPTOR; ITX 5061; SR-BI; HEPATITIS; IDENTIFICATION; ASSOCIATION AB Background. Hepatitis C virus (HCV) entry involves scavenger receptor B1 (SRB1). In vitro, SRB1 inhibition by ITX5061 impedes HCV replication. Methods. Multicenter study to assess safety/activity of ITX5061 in previously untreated, noncirrhotic, HCV genotype 1 infected adults. Design included sequential cohorts of 10 subjects with ITX5061 (n = 8) or placebo (n = 2) to escalate duration (3 to 14 to 28 days) or deescalate dose (150 to 75 to 25 mg) based on predefined criteria for safety and activity (>= 4 of 8 subjects with HCV RNA decline >= 1 log(10) IU/mL). Results. Thirty subjects enrolled in 3 cohorts: ITX5061 150 mg/day by mouth for 3 (A150), 14 (B150), and 28 (C150) days. Six subjects had grade >= 3 adverse events (one in placebo); none were treatment related. One of the 7 C150 subjects (14.3%, 95% confidence interval [CI], .7%-55.4%) had >= 1 log(10) IU/mL decline in HCV RNA (1.49 log(10) IU/mL), whereas none of the 6 placebo, 8 A150 or 8 B150 subjects showed such decline. Conclusions. Oral ITX5061 150 mg/day for up to 28 days was safe and well tolerated. In the 28-day cohort, 1 of 7 subjects showed antiviral activity; however, predefined criteria for antiviral activity were not met at the doses and durations studied. C1 [Sulkowski, Mark S.] Johns Hopkins Univ, Baltimore, MD USA. [Kang, Minhee; Matining, Roy] Harvard Univ, Boston, MA 02115 USA. [Wyles, David] Univ Calif San Diego, San Diego, CA 92103 USA. [Johnson, Victoria A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Johnson, Victoria A.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Morse, Gene D.] SUNY Buffalo, Buffalo, NY 14260 USA. [Amorosa, Valerianna] Univ Penn, Philadelphia, PA 19104 USA. [Bhattacharya, Debika] Univ Calif Los Angeles, Los Angeles, CA USA. [Coughlin, Kristine] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA. [Wong-Staal, Flossie] iTherxPharma, San Diego, CA USA. [Glesby, Marshall J.] Weill Cornell Med Coll, New York, NY USA. RP Sulkowski, MS (reprint author), 1830 Bldg,Rm 445,600 North Wolfe St, Baltimore, MD 21287 USA. EM msulkowski@jhmi.edu FU NCATS NIH HHS [UL1 TR000042, UL1 TR000124, UL1 TR000165, UL1 TR001079, UL1TR000124, UL1TR00165]; NCRR NIH HHS [NIH UL1RR025005, UL1 RR 025005, UL1 RR024160, UL1 RR025005]; NIAID NIH HHS [UM1 AI106701, 5-P30-AI-045008-15, 5UM1-AI069484-07, 5UM1AI069415-07, 5UO1 AI069502, AI-069467-07, AI-069513, AI69432, AI69465, K24 AI078884, P30 AI027767, P30 AI045008, U01 AI068636, U01 AI069432, U01 AI069452, U01 AI069465, U01 AI069467, U01 AI069502, U01 AI069513, U01AI068636, U01AI069452, UAB CFAR P30AI27767-24, UM1 AI068634, UM1 AI068636, UM1 AI069415, UM1 AI069419, UM1 AI069424, UM1 AI069432, UM1 AI069465, UM1 AI069467, UM1 AI069484, UM1 AI069511, UM1 AI069513, UMI AI069511]; NIDA NIH HHS [K24 DA000432, K24 DA034621, K24DA00432, R01 DA016065]; PHS HHS [NIH/NIAID 7UM1AI068636] NR 23 TC 23 Z9 27 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2014 VL 209 IS 5 BP 658 EP 667 DI 10.1093/infdis/jit503 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AB6BY UT WOS:000331873700006 PM 24041792 ER PT J AU Clark-Cutaia, MN Ren, DX Hoffman, LA Burke, LE Sevick, MA AF Clark-Cutaia, Maya N. Ren, Dianxu Hoffman, Leslie A. Burke, Lora E. Sevick, Mary Ann TI Adherence to Hemodialysis Dietary Sodium Recommendations: Influence of Patient Characteristics, Self-Efficacy, and Perceived Barriers SO JOURNAL OF RENAL NUTRITION LA English DT Article ID STAGE RENAL-DISEASE; PATIENTS RECEIVING HEMODIALYSIS; MEDICATION ADHERENCE; SOCIOECONOMIC-STATUS; PRACTICE PATTERNS; HEALTH BELIEFS; BLOOD-PRESSURE; OLDER-ADULTS; NONADHERENCE; RESTRICTIONS AB Objective: To identify characteristics of hemodialysis patients most likely to experience difficulty adhering to sodium restrictions associated with their dietary regimen. Design: Secondary analysis using baseline data from an ongoing randomized clinical trial examining the effects of a technology-supported behavioral intervention on dietary sodium intake in hemodialysis patients. Setting: Thirteen dialysis centers in southwestern Pennsylvania. Subjects: We included 122 participants (61% women; 48% African American) aged 61 +/- 14 years undergoing maintenance, intermittent hemodialysis for end-stage renal disease. Main Outcome Measures: Normalized dietary sodium intake, adjusted interdialytic weight gain, perceived problems, and self-efficacy for restricting dietary sodium. Results: Younger participants were more likely to report problems managing their hemodialysis diet and low self-efficacy for restricting sodium intake. Consistent with these findings, younger participants had a higher median sodium intake and higher average adjusted interdialytic weight gain. Females reported more problems managing their diet. Race, time on dialysis, and perceived income adequacy did not seem to influence outcome measures. Conclusion: Our findings suggest that patients who are younger and female encounter more difficulty adhering to the hemodialysis regimen. Hence, there may be a need to individualize counseling and interventions for these individuals. Further investigation is needed to understand the independent effects of age and gender on adherence to hemodialysis dietary recommendations and perceived self-fficacy. (C) 2014 by the National Kidney Foundation, Inc. All rights reserved. C1 [Clark-Cutaia, Maya N.] Univ Penn, Ctr Hlth Equity Res, Philadelphia, PA 19104 USA. [Clark-Cutaia, Maya N.] Univ Penn, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Ren, Dianxu; Burke, Lora E.] Univ Pittsburgh, Dept Hlth & Community Syst, Pittsburgh, PA USA. [Hoffman, Leslie A.] Univ Pittsburgh, Pittsburgh, PA USA. [Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sevick, Mary Ann] Univ Pittsburgh, Nursing Ctr Res Hlth Care, Pittsburgh, PA USA. RP Clark-Cutaia, MN (reprint author), Claire M Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA. EM mayan@nursing.upenn.edu FU [NIH-R01-NR010135]; [NIH-K24-NR012226]; [NIH 1F31NR013410] FX Study was supported by grants NIH-R01-NR010135, NIH-K24-NR012226 for MAS, and NIH 1F31NR013410 for MNC. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 42 TC 12 Z9 13 U1 0 U2 16 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 EI 1532-8503 J9 J RENAL NUTR JI J. Renal Nutr. PD MAR PY 2014 VL 24 IS 2 BP 92 EP 99 DI 10.1053/j.jrn.2013.11.007 PG 8 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA AB5FS UT WOS:000331814900007 PM 24462498 ER PT J AU Okon, L Rosenbach, M Krathen, M Rose, M Propert, K Okawa, J Werth, V AF Okon, Lauren Rosenbach, Misha Krathen, Michael Rose, Mathew Propert, Kathleen Okawa, Joyce Werth, Victoria TI Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter ID THERAPY; LESIONS; RISK C1 [Okon, Lauren; Rosenbach, Misha; Krathen, Michael; Rose, Mathew; Okawa, Joyce; Werth, Victoria] Univ Penn, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Okon, Lauren; Rosenbach, Misha; Krathen, Michael; Rose, Mathew; Okawa, Joyce; Werth, Victoria] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Propert, Kathleen] Univ Penn, Perelman Sch Med, Dept Biostat, HUP, Philadelphia, PA 19104 USA. RP Werth, V (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIAMS NIH HHS [K24 AR002207, K24-AR 02207] NR 5 TC 9 Z9 9 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAR PY 2014 VL 70 IS 3 BP 583 EP 584 DI 10.1016/j.jaad.2013.11.007 PG 2 WC Dermatology SC Dermatology GA AB2FA UT WOS:000331607400035 PM 24528907 ER PT J AU Benedek, G Zhu, WB Libal, N Casper, A Yu, XL Meza-Romero, R Vandenbark, A Alkayed, N Offner, H AF Benedek, Gil Zhu, Wenbin Libal, Nicole Casper, Amanda Yu, Xiaolin Meza-Romero, Roberto Vandenbark, Arthur A. Alkayed, Nabil J. Offner, Halina TI A novel HLA-DR alpha 1-MOG-35-55 construct treats experimental stroke SO METABOLIC BRAIN DISEASE LA English DT Article DE Stroke; Inflammation; Immunotherapy; Recombinant T-cell receptor Ligand; MHC class II invariant chain ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MIGRATION INHIBITORY FACTOR; CELL-RECEPTOR LIGANDS; ACUTE ISCHEMIC-STROKE; CLASS-II CONSTRUCTS; CYTOKINE SWITCH; INFARCT VOLUME; T-CELLS; MICE; INFLAMMATION AB Chemoattraction of leukocytes into the brain after induction of middle cerebral artery occlusion (MCAO) increases the lesion size and worsens disease outcome. Our previous studies demonstrated that partial MHC class II constructs can reverse this process. However, the potential application of pMHC to human stroke is limited by the need to rapidly match recipient MHC class II with the beta 1 domain of the pMHC construct. We designed a novel recombinant protein comprised of the HLA-DR alpha 1 domain linked to MOG-35-55 peptide but lacking the beta 1 domain found in pMHC and treated MCAO after 4 h reperfusion in humanized DR2 mice. Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of CD74 and other cell surface, cytokine and pathway markers. This study demonstrates that four daily treatments with DR alpha 1-MOG-35-55 reduced infarct size by 40 % in the cortex, striatum and hemisphere, inhibited the migration of activated CD11b(+)CD45(high) cells from the periphery to the brain and reversed splenic atrophy. Furthermore, DR alpha 1-MOG-35-55 bound to CD74 on monocytes and blocked both binding and downstream signaling of macrophage migration inhibition factor (MIF) that may play a key role in infarct development. The novel DR alpha 1-MOG-35-55 construct is highly therapeutic in experimental stroke and could be given to all patients at least 4 h after stroke onset without the need for tissue typing due to universal expression of DR alpha 1 in humans. C1 [Benedek, Gil; Yu, Xiaolin; Meza-Romero, Roberto; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Portland, OR 97239 USA. [Zhu, Wenbin; Libal, Nicole; Casper, Amanda; Alkayed, Nabil J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Benedek, Gil; Yu, Xiaolin; Meza-Romero, Roberto; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH [NS076013, NS047661]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Melissa S. Barber for assistance with manuscript submission. This work was supported by NIH Grants #NS076013 (STTR), and NS047661 and by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 29 TC 11 Z9 11 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 EI 1573-7365 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD MAR PY 2014 VL 29 IS 1 BP 37 EP 45 DI 10.1007/s11011-013-9440-0 PG 9 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA AB7JM UT WOS:000331965900004 PM 24122483 ER PT J AU Bodhankar, S Chen, YX Vandenbark, AA Murphy, SJ Offner, H AF Bodhankar, Sheetal Chen, Yingxin Vandenbark, Arthur A. Murphy, Stephanie J. Offner, Halina TI Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice SO METABOLIC BRAIN DISEASE LA English DT Article DE MCAO; Inflammatorycells; RegulatoryB-cells; IL-10 ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL CEREBRAL-ISCHEMIA; DEFICIENT MICE; IMMUNE-SYSTEM; BRAIN; MECHANISMS; IL-10; ROLES; IMMUNOSUPPRESSION AB Clinical stroke induces inflammatory processes leading to cerebral and splenic injury and profound peripheral immunosuppression. IL-10 expression is elevated during major CNS diseases and limits inflammation in the brain. Recent evidence demonstrated that absence of B-cells led to larger infarct volumes and CNS damage after middle cerebral artery occlusion (MCAO) that could be prevented by transfer of IL-10(+) B-cells. The purpose of this study was to determine if the beneficial immunoregulatory effects on MCAO of the IL-10(+) B-cell subpopulation also extends to B-cell-sufficient mice that would better represent stroke subjects. CNS inflammation and infarct volumes were evaluated in male C57BL/6J (WT) mice that received either RPMI or IL-10(+) B-cells and underwent 60 min of middle cerebral artery occlusion (MCAO) followed by 96 h of reperfusion. Transfer of IL-10(+) B-cells markedly reduced infarct volume in WT recipient mice when given 24 h prior to or 4 h after MCAO. B-cell protected (24 h pre-MCAO) mice had increased regulatory subpopulations in the periphery, reduced numbers of activated, inflammatory T-cells, decreased infiltration of T-cells and a less inflammatory milieu in the ischemic hemispheres of the IL-10(+) B-cell-treated group. Moreover, transfer of IL-10(+) B-cells 24 h before MCAO led to a significant preservation of regulatory immune subsets in the IL-10(+) B-cell protected group presumably indicating their role in immunomodulatory mechanisms, post-stroke. Our studies are the first to demonstrate a major immunoregulatory role for IL-10(+) regulatory B-cells in preventing and treating MCAO in WT mice and also implicating their potential role in attenuating complications due to post-stroke immunosuppression. C1 [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] VA Med Ctr, Portland, OR USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Chen, Yingxin; Murphy, Stephanie J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Murphy, Stephanie J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Offner, Halina] Portland VA Med Ctr, R&D 31, Portland, OR 97239 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH/NINDS [1RO1 NS075887]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Andrew Lapato for technical assistance and Melissa S. Barber for assistance with manuscript submission. This work was supported by NIH/NINDS 1RO1 NS075887. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 47 TC 20 Z9 20 U1 0 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 EI 1573-7365 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD MAR PY 2014 VL 29 IS 1 BP 59 EP 73 DI 10.1007/s11011-013-9474-3 PG 15 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA AB7JM UT WOS:000331965900006 PM 24374817 ER PT J AU Janoff, EN Rubins, JB Fasching, C Charboneau, D Rahkola, JT Plaut, AG Weiser, JN AF Janoff, E. N. Rubins, J. B. Fasching, C. Charboneau, D. Rahkola, J. T. Plaut, A. G. Weiser, J. N. TI Pneumococcal IgA1 protease subverts specific protection by human IgA1 SO MUCOSAL IMMUNOLOGY LA English DT Article ID FC-ALPHA-RECEPTOR; STREPTOCOCCUS-PNEUMONIAE; IMMUNOGLOBULIN-A1 PROTEASE; CAPSULAR POLYSACCHARIDES; HAEMOPHILUS-INFLUENZAE; NEISSERIA-GONORRHOEAE; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODY; IMMUNE-RESPONSE; SECRETORY IGA AB Bacterial immunoglobulin A1 (IgA1) proteases may sabotage the protective effects of IgA. In vitro, both exogenous and endogenously produced IgA1 protease inhibited phagocytic killing of Streptococcus pneumoniae by capsule-specific IgA1 human monoclonal antibodies (hMAbs) but not IgA2. These IgA1 proteases cleaved and reduced binding of the the effector Fc alpha 1 heavy chain but not the antigen-binding F(ab)/light chain to pneumococcal surfaces. In vivo, IgA1 protease-resistant IgA2, but not IgA1 protease-sensitive IgA1, supported 60% survival in mice infected with wild-type S. pneumoniae. IgA1 hMAbs protected mice against IgA1 protease-deficient but not -producing pneumococci. Parallel mouse sera with human IgA2 showed more efficient complement-mediated reductions in pneumococci with neutrophils than did IgA1, particularly with protease-producing organisms. After natural human pneumococcal bacteremia, purified serum IgG inhibited IgA1 protease activity in 7 of 11 patients (64%). These observations provide the first evidence in vivo that IgA1 protease can circumvent killing of S. pneumoniae by human IgA. Acquisition of IgA1 protease-neutralizing IgG after infection directs attention to IgA1 protease both as a determinant of successful colonization and infection and as a potential vaccine candidate. C1 [Janoff, E. N.; Rahkola, J. T.] Univ Colorado Denver, Div Infect Dis, Mucosal & Vaccine Res Colorado MAVRC, Aurora, CO 80045 USA. [Rubins, J. B.; Charboneau, D.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Fasching, C.] Denver Vet Affairs Med Ctr, Vet Affairs Med Ctr, Denver, CO USA. [Plaut, A. G.] Tufts Univ New England Med Ctr, Dept Med, Boston, MA USA. [Plaut, A. G.] Tufts Univ New England Med Ctr, Div Gastroenterol, Boston, MA USA. [Weiser, J. N.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA. [Weiser, J. N.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA. RP Janoff, EN (reprint author), Univ Colorado Denver, Div Infect Dis, Mucosal & Vaccine Res Colorado MAVRC, Aurora, CO 80045 USA. EM Edward.Janoff@ucdenver.edu FU National Institutes of Health [AI-092468, AI-48796, AI-42240, HD-41361, AI092468, AI-38446, DE15844]; Tufts Digestive Disease Research Center [P30 DK34928]; Mucosal and Vaccine Research Center at the University of Colorado School of Medicine; Department of Veterans Affairs Research Service FX All human and mouse studies were approved by the Human and Animal Subjects Subcommittees, and written informed consent was obtained from patients. We thank Ann Emery for secretarial support. This work was supported by the National Institutes of Health Grants AI-092468, AI-48796, AI-42240, HD-41361, AI092468 (ENJ), AI-38446 (JNW), DE15844, the Tufts Digestive Disease Research Center P30 DK34928 (AGP), the Mucosal and Vaccine Research Center at the University of Colorado School of Medicine, and the Department of Veterans Affairs Research Service. NR 53 TC 10 Z9 10 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1933-0219 EI 1935-3456 J9 MUCOSAL IMMUNOL JI Mucosal Immunol. PD MAR PY 2014 VL 7 IS 2 BP 249 EP 256 DI 10.1038/mi.2013.41 PG 8 WC Immunology SC Immunology GA AB7DA UT WOS:000331948300006 PM 23820749 ER PT J AU Leung, AM Braverman, LE AF Leung, Angela M. Braverman, Lewis E. TI Consequences of excess iodine SO NATURE REVIEWS ENDOCRINOLOGY LA English DT Review ID AMIODARONE-INDUCED THYROTOXICOSIS; THYROID-FUNCTION; URINARY IODINE; CONTRAST-MEDIA; SUBCLINICAL HYPOTHYROIDISM; DIETARY IODINE; POLYVINYLPYRROLIDONE-IODINE; CONGENITAL HYPOTHYROIDISM; EUTHYROID PATIENTS; SUFFICIENT AREA AB Iodine is a micronutrient that is essential for the production of thyroid hormones. The primary source of iodine is the diet via consumption of foods that have been fortified with iodine, including salt, dairy products and bread, or that are naturally abundant in the micronutrient, such as seafood. Recommended daily iodine intake is 150 mu g in adults who are not pregnant or lactating. Ingestion of iodine or exposure above this threshold is generally well-tolerated. However, in certain susceptible individuals, including those with pre-existing thyroid disease, the elderly, fetuses and neonates, or patients with other risk factors, the risk of developing iodine-induced thyroid dysfunction might be increased. Hypothyroidism or hyperthyroidism as a result of supraphysiologic iodine exposure might be either subclinical or overt, and the source of the excess iodine might not be readily apparent. C1 [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol,VA Greater Los Angeles Healthcare, Los Angeles, CA 90073 USA. [Braverman, Lewis E.] Boston Univ, Sch Med, Dept Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA. RP Braverman, LE (reprint author), Boston Univ, Sch Med, Dept Med, Sect Endocrinol Diabet & Nutr, 88 East Newton St, Boston, MA 02118 USA. EM lewis.braverman@bmc.org OI Leung, Angela M./0000-0001-8935-9332 FU NIH [7K23HD06855204] FX A. M. Leung would like to acknowledge the support of NIH grant 7K23HD06855204. NR 80 TC 46 Z9 49 U1 6 U2 22 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5029 EI 1759-5037 J9 NAT REV ENDOCRINOL JI Nat. Rev. Endocrinol. PD MAR PY 2014 VL 10 IS 3 BP 136 EP 142 DI 10.1038/nrendo.2013.251 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AB6HS UT WOS:000331888800005 PM 24342882 ER PT J AU Eshleman, AJ Forster, MJ Wolfrum, KM Johnson, RA Janowsky, A Gatch, MB AF Eshleman, Amy J. Forster, Michael J. Wolfrum, Katherine M. Johnson, Robert A. Janowsky, Aaron Gatch, Michael B. TI Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function SO PSYCHOPHARMACOLOGY LA English DT Article DE Substituted phenethylamines; Drug discrimination; Serotonin receptor; Locomotor activity; Lysergic acid diethylamide (LSD); (-)-2,5-dimethoxy-4-methylamphetamine; Drug abuse ID LYSERGIC-ACID DIETHYLAMIDE; 5-HT2C RECEPTORS; PHOSPHOLIPASE-C; HALLUCINOGENIC PHENETHYLAMINE; PHOSPHOINOSITIDE HYDROLYSIS; SEROTONIN 5-HT2A; STIMULUS; AGONIST; MDMA; LSD AB Psychoactive-substituted phenethylamines 2,5-dimethoxy-4-chlorophenethylamine (2C-C); 2,5-dimethoxy-4-methylphenethylamine (2C-D); 2,5-dimethoxy-4-ethylphenethylamine (2C-E); 2,5-dimethoxy-4-iodophenethylamine (2C-I); 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2); and 2,5-dimethoxy-4-chloroamphetamine (DOC) are used recreationally and may have deleterious side effects. This study compares the behavioral effects and the mechanisms of action of these substituted phenethylamines with those of hallucinogens and a stimulant. The effects of these compounds on mouse locomotor activity and in rats trained to discriminate dimethyltryptamine, (-)-DOM, (+)-LSD, (+/-)-MDMA, and S(+)-methamphetamine were assessed. Binding and functional activity of the phenethylamines at 5-HT1A, 5-HT2A, 5-HT2C receptors and monoamine transporters were assessed using cells heterologously expressing these proteins. The phenethylamines depressed mouse locomotor activity, although 2C-D and 2C-E stimulated activity at low doses. The phenethylamines except 2C-T-2 fully substituted for at least one hallucinogenic training compound, but none fully substituted for (+)-methamphetamine. At 5-HT1A receptors, only 2C-T-2 and 2C-I were partial-to-full very low potency agonists. In 5-HT2A arachidonic acid release assays, the phenethylamines were partial to full agonists except 2C-I which was an antagonist. All compounds were full agonists at 5-HT2A and 5-HT2C receptor inositol phosphate assays. Only 2C-I had moderate affinity for, and very low potency at, the serotonin transporter. The discriminative stimulus effects of 2C-C, 2C-D, 2C-E, 2C-I, and DOC were similar to those of several hallucinogens, but not methamphetamine. Additionally, the substituted phenethylamines were full agonists at 5-HT2A and 5-HT2C receptors, but for 2C-T-2, this was not sufficient to produce hallucinogen-like discriminative stimulus effects. Additionally, the 5-HT2A inositol phosphate pathway may be important in 2C-I's psychoactive properties. C1 [Eshleman, Amy J.; Wolfrum, Katherine M.; Johnson, Robert A.; Janowsky, Aaron] Portland VA Med Ctr, Res Serv, Portland, OR USA. [Eshleman, Amy J.; Janowsky, Aaron] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Eshleman, Amy J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Forster, Michael J.; Gatch, Michael B.] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA. [Janowsky, Aaron] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA. RP Eshleman, AJ (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. EM eshleman@ohsu.edu FU National Institutes of Health National Institute on Drug Abuse/Veterans Affairs Interagency agreements [Y1 DA 5007-05, Y1-DA-0101-01]; Methamphetamine Abuse Research Center [P50 DA018165]; Veterans Affairs Research Career program; Veterans Affairs Merit Review program; National Institute on Drug Abuse [N01DA2-8822, N01DA-7-8872] FX Funding for this study was provided by National Institutes of Health National Institute on Drug Abuse/Veterans Affairs Interagency agreements (Y1 DA 5007-05, Y1-DA-0101-01), The Methamphetamine Abuse Research Center (P50 DA018165), the Veterans Affairs Research Career and Merit Review programs, and by the National Institute on Drug Abuse contracts (N01DA2-8822 and N01DA-7-8872). The NIDA project officers contributed to study design and had no further role in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. NR 50 TC 8 Z9 8 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD MAR PY 2014 VL 231 IS 5 BP 875 EP 888 DI 10.1007/s00213-013-3303-6 PG 14 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AB3VU UT WOS:000331719100007 PM 24142203 ER PT J AU Lombardero, A Campbell, DG Harris, KJ Chaney, EF Lanto, AB Rubenstein, LV AF Lombardero, Anayansi Campbell, Duncan G. Harris, Kari J. Chaney, Edmund F. Lanto, Andrew B. Rubenstein, Lisa V. TI Prevalence and correlates of smoking status among Veterans Affairs primary care patients with probable Major Depressive Disorder SO ADDICTIVE BEHAVIORS LA English DT Article DE Smoking; Depression; PTSD; Veterans; Primary care; Alcohol misuse ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; SOCIAL SUPPORT SURVEY; CIGARETTE-SMOKING; SUICIDAL IDEATION; MENTAL-HEALTH; PSYCHIATRIC-DISORDERS; ALCOHOL-CONSUMPTION; SUBSEQUENT RISK; FOLLOW-UP AB In an attempt to guide planning and optimize outcomes for population-specific smoking cessation efforts, the present study examined smoking prevalence and the demographic, clinical and psychosocial characteristics associated with smoking among a sample of Veterans Affairs primary care patients with probable major depression. Survey data were collected between 2003 and 2004 from 761 patients with probable major depression who attended one of 10 geographically dispersed VA primary care clinics. Current smoking prevalence was 39.8%. Relative to nonsmokers with probable major depression, bivariate comparisons revealed that current smokers had higher depression severity, drank more heavily, and were more likely to have comorbid PTSD. Smokers with probable major depression were also more likely than nonsmokers with probable major depression to have missed a health care appointment and to have missed medication doses in the previous 5 months. Smokers were more amenable than non-smokers to depression treatment and diagnosis, and they reported more frequent visits to a mental health specialist and less social support Alcohol abuse and low levels of social support were significant concurrent predictors of smoking status in controlled multivariable logistic regression. In conclusion, smoking prevalence was high among primary care patients with probable major depression, and these smokers reported a range of psychiatric and psychosocial characteristics with potential to complicate systems-level smoking cessation interventions. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Lombardero, Anayansi; Campbell, Duncan G.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. [Harris, Kari J.] Univ Montana, Sch Publ & Community Hlth Sci, Missoula, MT 59812 USA. [Chaney, Edmund F.] VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. [Chaney, Edmund F.] Univ Washington, Sch Med, Warren G Magnuson Hlth Sci Ctr, Seattle, WA 98195 USA. [Lanto, Andrew B.; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Rubenstein, Lisa V.] RAND Hlth Program, Santa Monica, CA 90407 USA. RP Lombardero, A (reprint author), Univ Montana, Dept Psychol, 32 Campus Dr, Missoula, MT 59812 USA. EM anayansilombardero@gmail.com FU VA Health Services Research & Development service; VA Mental Health Quality Enhancement Research Initiative [MHI-99-375, MNT 01-027, MHQ 10-06] FX This work was funded by the VA Health Services Research & Development service and the VA Mental Health Quality Enhancement Research Initiative (MHI-99-375, MNT 01-027, and MHQ 10-06). NR 87 TC 5 Z9 5 U1 6 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD MAR PY 2014 VL 39 IS 3 BP 538 EP 545 DI 10.1016/j.addbeh.2013.10.030 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA AA5SU UT WOS:000331160700007 PM 24290879 ER PT J AU Gilmore, AK Koo, KH Nguyen, HV Granato, HF Hughes, TL Kaysen, D AF Gilmore, Amanda K. Koo, Kelly H. Nguyen, Hong V. Granato, Holline F. Hughes, Tonda L. Kaysen, Debra TI Sexual assault, drinking norms, and drinking behavior among a national sample of lesbian and bisexual women SO ADDICTIVE BEHAVIORS LA English DT Article DE Alcohol use; Sexual assault; Lesbian and bisexual women; Drinking norms ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE-USE; ALCOHOL-CONSUMPTION; COLLEGE-STUDENTS; SOCIAL NORMS; NORMATIVE MISPERCEPTIONS; RISK BEHAVIORS; BINGE DRINKING; MENTAL-HEALTH; VICTIMIZATION AB Childhood sexual abuse (CSA) and adolescent/adult sexual assault (ASA) are strongly associated with women's alcohol use and the rates of both alcohol use and sexual assault history are higher among lesbian and bisexual women than heterosexual women. Although descriptive drinking norms are one of the highest predictors of alcohol use in emerging adults, this is the first study to examine the relationship between sexual assault history, drinking norms, and alcohol use in lesbian and bisexual women. We found that CSA severity was associated with a higher likelihood of experiencing more severe alcohol-involved ASA, more severe physically forced ASA, and was indirectly associated with more drinking behavior and higher drinking norms. Additionally, more severe alcohol-involved ASA was associated with higher drinking norms and more drinking behavior, but physically forced ASA was not. These findings help explain previous contradictory findings and provide information for interventions. Published by Elsevier Ltd. C1 [Gilmore, Amanda K.; Nguyen, Hong V.; Granato, Holline F.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Koo, Kelly H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Koo, Kelly H.] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA 94121 USA. [Hughes, Tonda L.] Univ Illinois, Coll Nursing, Chicago, IL 60612 USA. [Kaysen, Debra] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. RP Gilmore, AK (reprint author), Univ Washington, Dept Psychol, Box 351525, Seattle, WA 98195 USA. EM amandakg@uw.edu FU NIAAA [R01-AA018292]; NIAAA Grants [R01-AA018292, F31-AA020134, T32-AA007455, F31-AA018237]; Substance Abuse and Mental Health Services Administration (SAMHSA) Grant [1T06SM60563-38] FX Funding for data collection of this study was provided by NIAAA Grant R01-AA018292. Funding for analysis and interpretation of the data and writing the manuscript was provided by NIAAA Grants R01-AA018292, F31-AA020134, T32-AA007455, and F31-AA018237 and Substance Abuse and Mental Health Services Administration (SAMHSA) Grant 1T06SM60563-38. NIAAA and SAMHSA had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication. NR 72 TC 5 Z9 5 U1 9 U2 19 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD MAR PY 2014 VL 39 IS 3 BP 630 EP 636 DI 10.1016/j.addbeh.2013.11.015 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA AA5SU UT WOS:000331160700020 PM 24360780 ER PT J AU Shahim, P Rejdak, R Ksiazek, P Blennow, K Zetterberg, H Mattsson, N Rejdak, K AF Shahim, P. Rejdak, R. Ksiazek, P. Blennow, K. Zetterberg, H. Mattsson, N. Rejdak, K. TI Cerebrospinal fluid biomarkers of beta-amyloid metabolism and neuronal damage in epileptic seizures SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE amyloid; heart-type fatty acid binding protein; neuronal injury; seizures; amyloid precursor protein; tau ID ACID-BINDING PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; TAU; MODELS; BRAIN; HYPEREXCITABILITY; PATHOLOGY; RELEASE; NETWORK AB Background and purposeThe main objectives of this study were to investigate if epileptic seizures have effects on brain metabolism of -amyloid (A), as reflected by cerebrospinal fluid (CSF) levels of different isoforms of A peptides and soluble amyloid precursor protein (APP), and neuronal degeneration, as reflected by CSF biomarker signs of acute neuronal injury. MethodsForty-five patients were included, 21 of whom had single generalized tonic-clonic seizures sGTCS), 11 had repetitive GTCS, 7 had repetitive partial seizures (rPS), 6 had single partial seizure (sPS) and 4 fulfilled the criterion for non-convulsive status epilepticus (nSE). CSF was analyzed for Ax-38, Ax-40, Ax-42, A1-42, soluble APP fragments (sAPP-/), total-tau (T-tau) and phosphorylated tau (P-tau), as well as heart-type fatty acid binding protein (H-FABP). ResultsPatients with seizures had decreased levels of T-tau (P=0.0016) and P-tau (P=0.0028) compared with controls, but no differences in H-FABP (P=0.67). There were no overall differences in A or sAPP peptides between seizure patients and controls. In patients with rPS, the levels of Ax-38 and Ax-40 were elevated compared with nSE (P<0.01), sPS (P<0.05) and controls (P<0.05), and Ax-42 was elevated in rPS relative to nSE (P<0.05). ConclusionsThe findings of this study argue against acute neuronal injury following medically treated seizures but suggest that seizures may reduce CSF levels of tau. Although seizures generally did not affect CSF levels of A or sAPP peptides, our findings suggest that different types of seizures may have different effects on APP metabolism. C1 [Shahim, P.; Blennow, K.; Zetterberg, H.; Mattsson, N.] Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Clin Neurochem Lab, Molndal, Sweden. [Rejdak, R.] Med Univ Lublin, Dept Gen Ophthalmol, Lublin, Poland. [Rejdak, R.; Rejdak, K.] Polish Acad Sci, Med Res Ctr, Warsaw, Poland. [Ksiazek, P.] Med Univ Lublin, Dept Publ Hlth, Lublin, Poland. [Zetterberg, H.] UCL Inst Neurol, Dept Mol Neurosci, London, England. [Zetterberg, H.] UCL Inst Neurol, Reta Lilla Weston Labs, London, England. [Mattsson, N.] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94143 USA. [Rejdak, K.] Med Univ Lublin, Dept Neurol, Lublin, Poland. RP Shahim, P (reprint author), Sahlgrenska Univ Hosp Molndal, Clin Neurochem Lab, S-43180 Molndal, Sweden. EM pashtun.shahim@neuro.gu.se NR 27 TC 4 Z9 4 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 EI 1468-1331 J9 EUR J NEUROL JI Eur. J. Neurol. PD MAR PY 2014 VL 21 IS 3 BP 486 EP 491 DI 10.1111/ene.12336 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA3ER UT WOS:000330976200020 PM 24372994 ER PT J AU Baldwin, ML Marcus, SC AF Baldwin, Marjorie L. Marcus, Steven C. TI THE IMPACT OF MENTAL AND SUBSTANCE-USE DISORDERS ON EMPLOYMENT TRANSITIONS SO HEALTH ECONOMICS LA English DT Article ID LABOR-MARKET OUTCOMES; PROBLEM DRINKING; JOB LOSS; ATTITUDES; DISABILITIES; ILLNESS; HEALTH; WORK C1 [Baldwin, Marjorie L.] Arizona State Univ, WP Carey Sch Business, Dept Econ, Tempe, AZ 85287 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Baldwin, ML (reprint author), Arizona State Univ, WP Carey Sch Business, Dept Econ, POB 879801, Tempe, AZ 85287 USA. EM marjorie.baldwin@asu.edu FU National Institute on Drug and Alcohol Abuse [R03 DA019860-01A2] FX This research was supported by the National Institute on Drug and Alcohol Abuse (grant no. R03 DA019860-01A2). NR 24 TC 5 Z9 5 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9230 EI 1099-1050 J9 HEALTH ECON JI Health Econ. PD MAR PY 2014 VL 23 IS 3 BP 332 EP 344 PG 13 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA AA8OH UT WOS:000331354300006 PM 23784938 ER PT J AU Motraghi, TE Seim, RW Meyer, EC Morissette, SB AF Motraghi, Terri E. Seim, Richard W. Meyer, Eric C. Morissette, Sandra B. TI Virtual Reality Exposure Therapy for the Treatment of Posttraumatic Stress Disorder: A Methodological Review Using CONSORT Guidelines SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED-TRIALS; PTSD; ANXIETY; STATEMENT; VETERANS; QUALITY; FEAR C1 [Seim, Richard W.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Morissette, Sandra B.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Morissette, SB (reprint author), 4800 Mem Dr 51C, Waco, TX 76711 USA. EM sandra.morissette@va.gov NR 36 TC 16 Z9 17 U1 2 U2 37 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 EI 1097-4679 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD MAR PY 2014 VL 70 IS 3 BP 197 EP 208 PG 12 WC Psychology, Clinical SC Psychology GA AA5HD UT WOS:000331125800001 PM 24108479 ER PT J AU deCamp, A Hraber, P Bailer, RT Seaman, MS Ochsenbauer, C Kappes, J Gottardo, R Edlefsen, P Self, S Tang, HL Greene, K Gao, HM Daniell, X Sarzotti-Kelsoe, M Gorny, MK Zolla-Pazner, S LaBranche, CC Mascola, JR Korber, BT Montefiori, DC AF deCamp, Allan Hraber, Peter Bailer, Robert T. Seaman, Michael S. Ochsenbauer, Christina Kappes, John Gottardo, Raphael Edlefsen, Paul Self, Steve Tang, Haili Greene, Kelli Gao, Hongmei Daniell, Xiaoju Sarzotti-Kelsoe, Marcella Gorny, Miroslaw K. Zolla-Pazner, Susan LaBranche, Celia C. Mascola, John R. Korber, Bette T. Montefiori, David C. TI Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; HIV-1-INFECTED INDIVIDUALS; POTENT NEUTRALIZATION; BROAD NEUTRALIZATION; CROSS-REACTIVITY; CD4-BINDING SITE; STRUCTURAL BASIS; RATIONAL DESIGN; V3 DOMAIN AB Standardized assessments of HIV-1 vaccine-elicited neutralizing antibody responses are complicated by the genetic and antigenic variability of the viral envelope glycoproteins (Envs). To address these issues, suitable reference strains are needed that are representative of the global epidemic. Several panels have been recommended previously, but no clear answers have been available on how many and which strains are best suited for this purpose. We used a statistical model selection method to identify a global panel of reference Env clones from among 219 Env-pseudotyped viruses assayed in TZM-bl cells with sera from 205 HIV-1-infected individuals. The Envs and sera were sampled globally from diverse geographic locations and represented all major genetic subtypes and circulating recombinant forms of the virus. Assays with a panel size of only nine viruses adequately represented the spectrum of HIV-1 serum neutralizing activity seen with the larger panel of 219 viruses. An optimal panel of nine viruses was selected and augmented with three additional viruses for greater genetic and antigenic coverage. The spectrum of HIV-1 serum neutralizing activity seen with the final 12-virus panel closely approximated the activity seen with subtype-matched viruses. Moreover, the final panel was highly sensitive for detection of many of the known broadly neutralizing antibodies. For broader assay applications, all 12 Env clones were converted to infectious molecular clones using a proviral backbone carrying a Renilla luciferase reporter gene (Env. IMC. LucR viruses). This global panel should facilitate highly standardized assessments of vaccine-elicited neutralizing antibodies across multiple HIV-1 vaccine platforms in different parts of the world. IMPORTANCE An effective HIV-1 vaccine will need to overcome the extraordinary genetic variability of the virus, where most variation occurs in the viral envelope glycoproteins that are the sole targets for neutralizing antibodies. Efforts to elicit broadly cross-reactive neutralizing antibodies that will protect against infection by most circulating strains of the virus are guided in part by in vitro assays that determine the ability of vaccine-elicited antibodies to neutralize genetically diverse HIV-1 variants. Until now, little information was available on how many and which strains of the virus are best suited for this purpose. We applied robust statistical methods to evaluate a large neutralization data set and identified a small panel of viruses that are a good representation of the global epidemic. The neutralization properties of this new panel of reference strains should facilitate the development of an effective HIV-1 vaccine. C1 [deCamp, Allan; Gottardo, Raphael; Edlefsen, Paul; Self, Steve] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Hraber, Peter; Korber, Bette T.] Los Alamos Natl Lab, Los Alamos, NM USA. [Bailer, Robert T.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Seaman, Michael S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Virol & Vaccine Res, Boston, MA 02215 USA. [Ochsenbauer, Christina; Kappes, John] Univ Alabama Birmingham, Birmingham, AL USA. [Kappes, John] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. [Tang, Haili; Greene, Kelli; Gao, Hongmei; Daniell, Xiaoju; Sarzotti-Kelsoe, Marcella; LaBranche, Celia C.; Montefiori, David C.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA. [Sarzotti-Kelsoe, Marcella] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA. [Gorny, Miroslaw K.; Zolla-Pazner, Susan] NYU, Dept Pathol, Langone Sch Med, New York, NY 10016 USA. [Zolla-Pazner, Susan] Vet Affairs Med Ctr, Res Ctr AIDS & HIV Infect, New York, NY USA. RP Montefiori, DC (reprint author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA. EM monte@duke.edu OI Korber, Bette/0000-0002-2026-5757; Hraber, Peter/0000-0002-2920-4897; Gorny, Miroslaw/0000-0002-2714-8780 FU Bill & Melinda Gates Foundation [38619, 1032144]; Intramural Research Program of the Vaccine Research Center, NIAID, NIH; Virology Core of the Birmingham Center for AIDS Research (CFAR) [AI27767] FX This work was funded by grants from the Bill & Melinda Gates Foundation (Collaboration for AIDS Vaccine Discovery no. 38619 and 1032144) and by the Intramural Research Program of the Vaccine Research Center, NIAID, NIH. This work was further supported by the Virology Core of the Birmingham Center for AIDS Research (CFAR, AI27767). NR 85 TC 39 Z9 39 U1 1 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD MAR PY 2014 VL 88 IS 5 BP 2489 EP 2507 DI 10.1128/JVI.02853-13 PG 19 WC Virology SC Virology GA AA5JK UT WOS:000331131700012 PM 24352443 ER PT J AU Guerrero-Berroa, E Ravona-Springer, R Schmeidler, J Silverman, JM Sano, M Koifmann, K Preiss, R Hoffman, H Heymann, A Beeri, MS AF Guerrero-Berroa, Elizabeth Ravona-Springer, Ramit Schmeidler, James Silverman, Jeremy M. Sano, Mary Koifmann, Keren Preiss, Rachel Hoffman, Hadas Heymann, Anthony Beeri, Michal Schnaider TI Age, gender, and education are associated with cognitive performance in an older Israeli sample with type 2 diabetes SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE neuropsychology; CERAD; cognitive functioning; diabetes; demographics; older adults ID NEUROPSYCHOLOGICAL TEST-PERFORMANCE; ALZHEIMERS-DISEASE CERAD; MINI-MENTAL-STATE; NORMATIVE DATA; SPANISH-SPEAKING; AFRICAN-AMERICAN; LACUNAR INFARCTIONS; SEMANTIC FLUENCY; ENGLISH-SPEAKING; WAIS-R AB ObjectiveTo evaluate the relationships of age, education, and gender with performance on neuropsychological tests in a cognitively intact, older Israeli sample with type 2 diabetes (T2D). MethodsWe examined 862 participants, 65-84years old, enrolled in the Israel Diabetes and Cognitive Decline study. Multiple regression assessed associations of performance on 17 neuropsychological tests, including the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery, with age, education, and gender. ResultsHigher education and younger age were consistently associated with better performance. Women outperformed men on all memory tasks; men outperformed women on two non-verbal measures. These patterns of demographic associations with cognitive performance were very similar to those of US cohorts. ConclusionsIn a cognitively intact, older Israeli sample with T2D, better test performance is associated primarily with higher education, followed by younger age and gender differences. Although T2D is associated with cognitive deficits, it recapitulates the patterns of relationships between cognitive performance and demographic characteristics seen in non-T2D diabetic samples. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Guerrero-Berroa, Elizabeth; Schmeidler, James; Silverman, Jeremy M.; Sano, Mary; Beeri, Michal Schnaider] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Ravona-Springer, Ramit; Koifmann, Keren; Beeri, Michal Schnaider] Joseph Sagol Neurosci Ctr, Sheba Med Ctr, Ramat Gan, Israel. [Guerrero-Berroa, Elizabeth; Silverman, Jeremy M.; Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Preiss, Rachel; Hoffman, Hadas; Heymann, Anthony] Maccabi Healthcare Serv, Tel Aviv, Israel. RP Guerrero-Berroa, E (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM elizabeth.guerrero-berroa@mssm.edu FU NIA [R01 AG034087, P50 AG05138]; Helen Bader Foundation; Irma T. Hirschl Scholar award; American Federation for Aging Research (AFAR) Young Investigator award; Alzheimer's Association [NIRG-11-205083] FX This study was supported by NIA grants R01 AG034087 to Dr. Beeri and P50 AG05138 to Dr. Sano, the Helen Bader Foundation and the Irma T. Hirschl Scholar award to Dr. Beeri, the American Federation for Aging Research (AFAR) Young Investigator award, and the Alzheimer's Association grant NIRG-11-205083 to Dr. Ravona-Springer. NR 46 TC 8 Z9 8 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD MAR PY 2014 VL 29 IS 3 BP 299 EP 309 DI 10.1002/gps.4008 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AA2EJ UT WOS:000330907600010 PM 23925856 ER PT J AU Armstrong, A Mattsson, N Appelqvist, H Janefjord, C Sandin, L Agholme, L Olsson, B Svensson, S Blennow, K Zetterberg, H Kagedal, K AF Armstrong, Andrea Mattsson, Niklas Appelqvist, Hanna Janefjord, Camilla Sandin, Linnea Agholme, Lotta Olsson, Bob Svensson, Samuel Blennow, Kaj Zetterberg, Henrik Kagedal, Katarina TI Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer's Disease SO NEUROMOLECULAR MEDICINE LA English DT Article DE PICALM; DRAM; TFEB; Cathepsins; Proteasome; hsc70 ID UBIQUITIN PROTEASOME SYSTEM; MILD COGNITIVE IMPAIRMENT; HUMAN CEREBROSPINAL-FLUID; NEURODEGENERATIVE DISEASES; EARLY ENDOSOMES; DOWN-SYNDROME; AUTOPHAGY; DEMENTIA; PLASMA; STANDARDIZATION AB The success of future intervention strategies for Alzheimer's disease (AD) will likely rely on the development of treatments starting early in the disease course, before irreversible brain damage occurs. The pre-symptomatic stage of AD occurs at least one decade before the clinical onset, highlighting the need for validated biomarkers that reflect this early period. Reliable biomarkers for AD are also needed in research and clinics for diagnosis, patient stratification, clinical trials, monitoring of disease progression and the development of new treatments. Changes in the lysosomal network, i.e., the endosomal, lysosomal and autophagy systems, are among the first alterations observed in an AD brain. In this study, we performed a targeted search for lysosomal network proteins in human cerebrospinal fluid (CSF). Thirty-four proteins were investigated, and six of them, early endosomal antigen 1 (EEA1), lysosomal-associated membrane proteins 1 and 2 (LAMP-1, LAMP-2), microtubule-associated protein 1 light chain 3 (LC3), Rab3 and Rab7, were significantly increased in the CSF from AD patients compared with neurological controls. These results were confirmed in a validation cohort of CSF samples, and patients with no neurochemical evidence of AD, apart from increased total-tau, were found to have EEA1 levels corresponding to the increased total-tau levels. These findings indicate that increased levels of LAMP-1, LAMP-2, LC3, Rab3 and Rab7 in the CSF might be specific for AD, and increased EEA1 levels may be a sign of general neurodegeneration. These six lysosomal network proteins are potential AD biomarkers and may be used to investigate lysosomal involvement in AD pathogenesis. C1 [Armstrong, Andrea; Appelqvist, Hanna; Janefjord, Camilla; Sandin, Linnea; Agholme, Lotta; Kagedal, Katarina] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, S-58185 Linkoping, Sweden. [Armstrong, Andrea; Svensson, Samuel] AlzeCure Fdn, Stockholm, Sweden. [Mattsson, Niklas; Olsson, Bob; Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Dept Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden. [Mattsson, Niklas] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Svensson, Samuel] Linkoping Univ, Dept Clin & Expt Med, S-58185 Linkoping, Sweden. [Zetterberg, Henrik] UCL Inst Neurol, London WC1N 3BG, England. RP Armstrong, A (reprint author), Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, S-58185 Linkoping, Sweden. EM andrea.armstrong@liu.se OI Olsson, Bob/0000-0002-6368-6172 NR 43 TC 21 Z9 22 U1 1 U2 13 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1535-1084 EI 1559-1174 J9 NEUROMOL MED JI Neuromol. Med. PD MAR PY 2014 VL 16 IS 1 BP 150 EP 160 DI 10.1007/s12017-013-8269-3 PG 11 WC Neurosciences SC Neurosciences & Neurology GA AA4YF UT WOS:000331101900015 PM 24101586 ER PT J AU Antai-Otong, D AF Antai-Otong, Deborah TI Vitamin D: An Anti-Inflammatory Treatment Option for Depression? SO ISSUES IN MENTAL HEALTH NURSING LA English DT Editorial Material ID D DEFICIENCY ALTERS; C-REACTIVE PROTEIN; MAJOR DEPRESSION; 1,25-DIHYDROXYVITAMIN D-3; COGNITIVE THERAPY; ADULT-RAT; BRAIN; INFLAMMATION; METAANALYSIS; CYTOKINES C1 US Dept Vet Affairs, Med Ctr, Dallas, TX 75216 USA. RP Antai-Otong, D (reprint author), US Dept Vet Affairs, Med Ctr, Dallas, TX 75216 USA. EM Deborah.Antai-Otong@va.gov NR 74 TC 1 Z9 1 U1 1 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0161-2840 EI 1096-4673 J9 ISSUES MENT HEALTH N JI Issues Ment. Health Nurs. PD MAR PY 2014 VL 35 IS 3 BP 227 EP 234 DI 10.3109/01612840.2013.875086 PG 8 WC Nursing; Psychiatry SC Nursing; Psychiatry GA CG3XL UT WOS:000353212800012 PM 24597590 ER PT J AU Matthews, DD Blosnich, JR Farmer, GW Adams, BJ AF Matthews, Derrick D. Blosnich, John R. Farmer, Grant W. Adams, Brian J. TI Operational Definitions of Sexual Orientation and Estimates of Adolescent Health Risk Behaviors SO LGBT HEALTH LA English DT Article DE adolescents; data analysis; health behavior; measurement; sexual orientation ID UNITED-STATES; SUBSTANCE USE; COLLEGE-STUDENTS; MINORITY; IDENTITY; GAY; SURVEILLANCE; YOUTH; MEN AB Purpose: Increasing attention to the health of lesbian, gay, and bisexual (LGB) populations comes with requisite circumspection about measuring sexual orientation in surveys. However, operationalizing these variables also requires considerable thought. This research sought to document the consequences of different operational definitions of sexual orientation by examining variation in health risk behaviors. Methods: Using Massachusetts Youth Risk Behavior Survey data, we examined how operational definitions of sexual behavior and sexual identity influenced differences among three health behaviors known to disparately affect LGB populations: smoking, suicide risk, and methamphetamine use. Sexual behavior and sexual identity were also examined together to explore if they captured unique sources of variability in behavior. Results: Estimates of health disparities changed as a result of using either sexual behavior or sexual identity. Youth who reported their sexual identity as "not sure'' also had increased odds of health risk behavior. Disaggregating bisexual identity and behavior from same-sex identity and behavior frequently resulted in the attenuation or elimination of health disparities that would have otherwise been attributable to exclusively same-sex sexual minorities. Finally, sexual behavior and sexual identity explained unique and significant sources of variability in all three health behaviors. Conclusion: Researchers using different operational definitions of sexual orientation could draw different conclusions, even when analyzing the same data, depending upon how they chose to represent sexual orientation in analyses. We discuss implications that these manipulations have on data interpretation and provide specific recommendations for best-practices when analyzing sexual orientation data collected from adolescent populations. C1 [Matthews, Derrick D.; Adams, Brian J.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC 27599 USA. [Blosnich, John R.] Univ Rochester, Rochester, NY USA. [Blosnich, John R.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA. [Farmer, Grant W.] St Louis Univ, Dept Epidemiol, Coll Publ Hlth & Social Justice, St Louis, MO 63103 USA. RP Matthews, DD (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Campus Box 7440, Chapel Hill, NC 27599 USA. EM derrick.matthews@unc.edu FU Summer Institute in LGBT Population Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [R25HD064426]; National Institute of Mental Health [5T32MH020061] FX This research project was partially supported by a training fellowship from the Summer Institute in LGBT Population Health to D.D.M., J.R.B., and G.W.F. under award number R25HD064426 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The project was also supported by a post-doctoral fellowship to J.R.B. in an Institutional National Research Service Award from the National Institute of Mental Health (5T32MH020061). NR 37 TC 19 Z9 19 U1 5 U2 15 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2325-8292 EI 2325-8306 J9 LGBT HEALTH JI LGBT Health PD MAR PY 2014 VL 1 IS 1 BP 42 EP 49 DI 10.1089/lgbt.2013.0002 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR9PQ UT WOS:000361689300009 PM 25110718 ER PT J AU Pedersen, ER Kaysen, DL Lindgren, KP Blayney, J Simpson, TL AF Pedersen, Eric R. Kaysen, Debra L. Lindgren, Kristen P. Blayney, Jessica Simpson, Tracy L. TI Impact of Daily Assessments on Distress and PTSD Symptoms in Trauma-Exposed Women SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE daily assessments; PTSD; women; distress ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE; SEXUAL EXPERIENCES; VICTIMS; COLLEGE; PARTICIPATION; THERAPY; ASSAULT; RAPE; VICTIMIZATION AB As more advanced methodologies are developed for symptom assessment in traumatic stress studies, it is important to examine how these methodologies can exacerbate distress or contribute to symptoms among study participants. Using a sample of 202 female college students, we examined the changes in posttraumatic stress disorder (PTSD) symptoms and general psychological symptomatology among groups of trauma-exposed and non-trauma-exposed women randomly assigned to complete 30 days of daily monitoring of traumatic symptoms and substance use behaviors using personal digital assistants (PDAs). These two groups were compared with a trauma-exposed sample of women who did not complete daily monitoring assessments and only completed pre- and post-monitoring online assessments. While trauma-exposed participants in the monitoring group reported more distress from the daily assessments than those in the monitoring group with no history of trauma, this distress level was relatively low. Online surveys delivered pre- and post-monitoring showed a similar pattern. Trauma-exposed participants in monitoring and no-monitoring groups reported a decrease in general psychological symptoms over the 30 days; however, monitoring participants reported increased levels of PTSD severity over time. Closer examination revealed the observed changes were relatively moderate. Participants expressed benefits and risks regarding study participation supporting the findings that repeated assessments of traumatic symptoms using personal handheld devices may lead to small increases in distress and PTSD symptoms, but that these approaches may be generally well tolerated. C1 [Pedersen, Eric R.] RAND Corp, Santa Monica, CA 90407 USA. [Kaysen, Debra L.; Lindgren, Kristen P.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Kaysen, Debra L.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Kaysen, Debra L.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Blayney, Jessica] Univ Washington, Ctr Hlth & Risk Behav, Seattle, WA 98195 USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Pedersen, ER (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA. EM ericp@rand.org FU NIAAA NIH HHS [F31 AA018591, F31AA018591, R21 AA016211, R21AA016211] NR 37 TC 5 Z9 5 U1 2 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 EI 1552-6518 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD MAR PY 2014 VL 29 IS 5 BP 824 EP 845 DI 10.1177/0886260513505705 PG 22 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA 294CK UT WOS:000330019800003 PM 24257591 ER PT J AU Rubio, DM Day, NL Conigliaro, J Hanusa, BH Larkby, C McNeil, M Cohen, E Jones, B Watt-Morse, M Gilmour, C Lancet, M Kraemer, KL AF Rubio, Doris McGartland Day, Nancy L. Conigliaro, Joseph Hanusa, Barbara H. Larkby, Cynthia McNeil, Melissa Cohen, Elan Jones, Bobby Watt-Morse, Margaret Gilmour, Carol Lancet, Michelle Kraemer, Kevin L. TI Brief motivational enhancement intervention to prevent or reduce postpartum alcohol use: A single-blinded, randomized controlled effectiveness trial SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Brief motivational enhancement; Postpartum alcohol use; Comparative effectiveness; Randomized trial ID POSTNATAL-DEPRESSION-SCALE; PREGNANT-WOMEN; PRIMARY-CARE; CONSUMPTION; DRINKING; DRINKERS; EXPOSURE AB Aims: The aim of this study is to assess the effect of brief motivational enhancement intervention postpartum alcohol use. Design: This study is a single-blinded, randomized controlled effectiveness trial in which pregnant women were assigned to receive usual care or up to 5 face-to-face brief motivational enhancement sessions lasting 10-30 minutes each and occurring at study enrollment, 4 and 8 weeks after enrollment, 32 weeks of gestation, and 6 weeks postpartum. Setting: The setting is in a large, urban, obstetrics clinic. Participants: Participants were women who were years old, <20 weeks of gestation, and consumed alcohol during pregnancy. Of 3438 women screened, 330 eligible women were assigned to usual care (n = 165) or intervention (n = 165). Due to missing data, we analyzed 125 in the intervention group and 126 in the usual care group. Measurements: The measurements were the proportion of women with any alcohol use and the number of drinks per day, reported via follow-up telephone interviews at 4 and 8 weeks after enrollment, 32 weeks of gestation, and 6 weeks, 6 months, and 12 months postpartum. Findings: In random effects models adjusted for confounders, the intervention group was less likely to use any alcohol (odds ratio 0.50; 95% confidence interval ICI], 0.23-1.09; P = 0.08) and consumed fewer drinks per day (coefficient 0.11; 95% Cl 0.23-0.01; P. = 0.07) than, the usual care group in the postpartum period but these differences were non-significant. Missing data during the prenatal period prevented us from modeling prenatal alcohol use. Conclusions: Brief motivational enhancement intervention delivered in an obstetrical outpatient setting did not conclusively decrease alcohol use during the postpartum period. (C) 2014 Elsevier Inc. All rights reserved. C1 [Rubio, Doris McGartland; McNeil, Melissa; Lancet, Michelle; Kraemer, Kevin L.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Rubio, Doris McGartland; Cohen, Elan] Univ Pittsburgh, Sch Med, Ctr Data, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Day, Nancy L.; Larkby, Cynthia; Jones, Bobby] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Conigliaro, Joseph] NYU, Dept Med, New York, NY 10016 USA. [Hanusa, Barbara H.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Watt-Morse, Margaret] Magee Womens Hosp, Dept Obstet & Gynecol, Pittsburgh, PA USA. [Gilmour, Carol] UPMC, Hamot Womens Hosp, Erie, PA USA. RP Rubio, DM (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Ctr Res Hlth Care,Div Gen Internal Med, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM rubiodm@upmc.edu RI Day, Nancy/H-3171-2016 FU NCATS NIH HHS [UL1 TR000005]; NIAAA NIH HHS [R01 AA012485] NR 33 TC 3 Z9 4 U1 3 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD MAR PY 2014 VL 46 IS 3 BP 382 EP 389 DI 10.1016/j.jsat.2013.10.009 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 294XX UT WOS:000330082300014 PM 24315218 ER PT J AU Sahni, H Kirkwood, K Kyriakides, TC Stapleton, J Brown, ST Holodniy, M AF Sahni, Harleen Kirkwood, Katherine Kyriakides, Tassos C. Stapleton, Jack Brown, Sheldon T. Holodniy, Mark CA OPTIMA Study Team TI GBV-C Viremia and Clinical Events in Advanced HIV Infection SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE HIV; GBV-C; Veterans; antiretroviral therapy; clinical trial ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; COINFECTION; PREVALENCE; INDIVIDUALS; PROGRESSION; ACTIVATION; MORTALITY; SURVIVAL; DISEASE AB GB Virus C (GBV-C) is a non-pathogenic flavivirus, commonly found in HIV infected patients. Studies suggest a survival benefit of GBV-C viremia in HIV infection. Impact of GBV-C viremia was evaluated on clinical outcome in multidrug-resistant HIV. The OPTIMA study enrolled advanced multidrug-resistant HIV patients with a CD4 count 300cells/mm(3). This study included a subset of OPTIMA patients. Primary endpoints included AIDS events or death. GBV-C status was assessed at baseline and last time point on study by real-time PCR. Cox proportional hazards models were used to determine if CD4 count (100/mm(3)), treatment assignment, presence or disappearance of GBV-C viremia, GBV-C viral load level and Hepatitis C virus antibody status were associated with outcome. Of 288 patients (98% male, baseline mean age 48 years, HIV viral load 4.67log(10)/ml, and CD4 127cells/mm(3)), 62 (21.5%) had detectable GBV-C viremia. The mortality rate for GBV-C infected subjects was lower, 19/62 (30.7%) versus 87/226 (38.5%), and time to death shorter (HR 0.67, 95% CI 0.41-1.11), but the results were not significantly different. The time to development of AIDS events was not different (HR 0.90, 95% CI 0.52-1.53). Among covariates, only CD4 count (HR 0.28, CI 0.19-0.42) had a significant survival effect. A trend in decreased mortality was seen in GBV-C+ patients with CD4 <100/mm(3) in multivariate analyses. GBV-C co-infection in multidrug-resistant HIV infected patients was associated with a trend in improved survival but not decreased AIDS events. Analysis was limited by cohort size. J. Med. Virol. 86:426-432, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Sahni, Harleen; Holodniy, Mark] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Kirkwood, Katherine; Kyriakides, Tassos C.] West Haven VA CSPCC, West Haven, CT USA. [Stapleton, Jack] Iowa City VAMC, Iowa City, IA USA. [Brown, Sheldon T.] James J Peters VAMC, Bronx, NY USA. RP Sahni, H (reprint author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave 132, Palo Alto, CA 94304 USA. EM harleen.sahni@gmail.com FU Office of Research and Development (Cooperative Studies Program), US Department of Veterans Affairs FX We thank Donna Klinzman at the Iowa city VA for technical assistance in conducting the assays. This work was supported by the Office of Research and Development (Cooperative Studies Program), US Department of Veterans Affairs. NR 20 TC 4 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD MAR PY 2014 VL 86 IS 3 BP 426 EP 432 DI 10.1002/jmv.23845 PG 7 WC Virology SC Virology GA 286IJ UT WOS:000329461000008 PM 24249700 ER PT J AU Trask, DJ Ledoux, WR Whittaker, EC Roush, GC Sangeorzan, BJ AF Trask, Darrin J. Ledoux, William R. Whittaker, Eric C. Roush, Grant C. Sangeorzan, Bruce J. TI Second Metatarsal Osteotomies for Metatarsalgia: A Robotic Cadaveric Study of the Effect of Osteotomy Plane and Metatarsal Shortening on Plantar Pressure SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE second metatarsal; plantar pressure; metatarsalgia; lesser metatarsal osteotomies; gait simulation ID LESSER METATARSOPHALANGEAL JOINTS; WEIL OSTEOTOMY; FOLLOW-UP; GAIT; SIMULATION; FORCE; FEET; TOE AB Symptom relief of recalcitrant metatarsalgia can be achieved through surgical shortening of the affected metatarsal, thus decreasing plantar pressure. Theoretically an oblique metatarsal osteotomy can be oriented distal to proximal (DP) or proximal to distal (PD). We characterized the relationship between the amount of second metatarsal shortening, osteotomy plane, and plantar pressure. We hypothesized that the PD osteotomy is more effective in reducing metatarsal peak pressure and pressure time integral. We performed eight DP and eight PD second metatarsal osteotomies on eight pairs of cadaveric feet. A custom designed robotic gait simulator (RGS) generated dynamic in vitro simulations of gait. Second metatarsals were incrementally shortened, with three trials for each length. We calculated regression lines for peak pressure and pressure time integral vs. metatarsal shortening. Shortening the second metatarsal using either osteotomy significantly affected the metatarsal peak pressure and pressure time integral (first and third metatarsal increased, p<0.01 and <0.05; second metatarsal decreased, p<0.01). Changes in peak pressure (p=0.0019) and pressure time integral (p=0.0046) were more sensitive to second metatarsal shortening with the PD osteotomy than the DP osteotomy. The PD osteotomy plane reduces plantar pressure more effectively than the DP osteotomy plane. Published 2013 by Wiley Periodicals, Inc. on behalf of the Orthopaedic Research Society. J Orthop Res 32:385-393, 2014. C1 [Trask, Darrin J.; Ledoux, William R.; Whittaker, Eric C.; Roush, Grant C.; Sangeorzan, Bruce J.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA 98108 USA. [Trask, Darrin J.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Ledoux, William R.; Sangeorzan, Bruce J.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Ledoux, William R.; Roush, Grant C.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA 98108 USA. EM wrledoux@uw.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU Department of Veterans Affairs Rehabilitation Research and Development Service [A4843C]; University of Washington Medical Student Research Training Program FX Department of Veterans Affairs Rehabilitation Research and Development Service A4843C; Grant sponsor: University of Washington Medical Student Research Training Program. NR 33 TC 2 Z9 2 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD MAR PY 2014 VL 32 IS 3 BP 385 EP 393 DI 10.1002/jor.22524 PG 9 WC Orthopedics SC Orthopedics GA 285UW UT WOS:000329421500005 PM 24243763 ER PT J AU Salem, BE Nyamathi, A Brecht, ML Phillips, LR Mentes, JC Sarkisian, C Stein, JA AF Salem, Benissa E. Nyamathi, Adeline Brecht, Mary-Lynn Phillips, Linda R. Mentes, Janet C. Sarkisian, Catherine Stein, Judith A. TI Constructing and identifying predictors of frailty among homeless adults-A latent variable structural equations model approach SO ARCHIVES OF GERONTOLOGY AND GERIATRICS LA English DT Article DE Frailty; Homeless; SEM; Health disparities and vulnerable populations ID YOUNG-ADULTS; GERIATRIC SYNDROMES; SAN-FRANCISCO; OLDER-ADULTS; HEALTH-CARE; ORAL-HEALTH; PREVALENCE; POPULATION; INDIVIDUALS; TORONTO AB Homeless urbanites are a heterogeneous population with unique health and social service needs. The study examined situational, behavioral, health-related and resource indicators in terms of their direct impact on frailty, hypothesized as a latent variable. Using structural equation modeling (SEM), a model was tested with 150 homeless men and women, ages 40-73, from three homeless day center drop-in sites on Skid Row and one residential drug treatment (RDT) facility that works with homeless parolees and probationers. In bivariate analyses with the latent construct frailty, months homeless (p < 0.01), female gender (p < 0.05), education (p < 0.05), comorbid conditions (p < 0.001), nutrition (p < 0.001), resilience (p < 0.001), health care utilization (p < 0.01), and falls (p < 0.001) were significantly associated with frailty. In the final path model, significant predictors of frailty included educational attainment (p < 0.01), comorbid conditions (p < 0.001), nutrition (p < 0.001), resilience (p < 0.001), and falls (p < 0.01). These findings will serve as a foundation for future nurse-led, community-based initiatives that focus on key predictors of frailty among the homeless and the development of interventions. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Salem, Benissa E.; Nyamathi, Adeline; Brecht, Mary-Lynn; Phillips, Linda R.; Mentes, Janet C.; Stein, Judith A.] UCLA Sch Nursing, Los Angeles, CA 90007 USA. [Sarkisian, Catherine] UCLA, Div Geriatr, VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA 90073 USA. RP Salem, BE (reprint author), UCLA Sch Nursing, 700 Tiverton Ave, Los Angeles, CA 90007 USA. EM bsalem@sonnet.ucla.edu FU National Institute of Health (NIH)/Nursing Research (NINR) [T32 NR007077]; University of California Los Angeles (UCLA) Dissertation Year Fellowship Award; University of California, Los Angeles Community Academic Partnership for Research in Aging (L.A. CAPRA) Center NIH [1RC4AG038182-01] FX This work was supported by the National Institute of Health (NIH)/Nursing Research (NINR) T32 NR007077, University of California Los Angeles (UCLA) Dissertation Year Fellowship Award, and the University of California, Los Angeles Community Academic Partnership for Research in Aging (L.A. CAPRA) Center NIH Grant 1RC4AG038182-01. We acknowledge the support of Judith Stein, PhD in providing guidance with the analysis. We similarly thank the Los Angeles-based Skid Row homeless participants for their willingness to share of their time and experiences. NR 71 TC 0 Z9 0 U1 3 U2 24 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-4943 EI 1872-6976 J9 ARCH GERONTOL GERIAT JI Arch. Gerontol. Geriatr. PD MAR-APR PY 2014 VL 58 IS 2 BP 248 EP 256 DI 10.1016/j.archger.2013.09.005 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 280WR UT WOS:000329062000011 PM 24505611 ER PT J AU Friedberg, MW Schneider, EC Rosenthal, MB Volpp, KG Werner, RM AF Friedberg, Mark W. Schneider, Eric C. Rosenthal, Meredith B. Volpp, Kevin G. Werner, Rachel M. TI Association Between Participation in a Multipayer Medical Home Intervention and Changes in Quality, Utilization, and Costs of Care SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID LONGITUDINAL DATA-ANALYSIS; STRUCTURAL CAPABILITIES; TRANSFORMATION; EFFICIENCY; MODELS; TRIAL; WILL AB IMPORTANCE Interventions to transform primary care practices into medical homes are increasingly common, but their effectiveness in improving quality and containing costs is unclear. OBJECTIVE To measure associations between participation in the Southeastern Pennsylvania Chronic Care Initiative, one of the earliest and largest multipayer medical home pilots conducted in the United States, and changes in the quality, utilization, and costs of care. DESIGN, SETTING, AND PARTICIPANTS Thirty-two volunteering primary care practices participated in the pilot (conducted from June 1, 2008, to May 31, 2011). We surveyed pilot practices to compare their structural capabilities at the pilot's beginning and end. Using claims data from 4 participating health plans, we compared changes (in each year, relative to before the intervention) in the quality, utilization, and costs of care delivered to 64 243 patients who were attributed to pilot practices and 55 959 patients attributed to 29 comparison practices (selected for size, specialty, and location similar to pilot practices) using a difference-in-differences design. EXPOSURES Pilot practices received disease registries and technical assistance and could earn bonus payments for achieving patient-centered medical home recognition by the National Committee for Quality Assurance (NCQA). MAIN OUTCOMES AND MEASURES Practice structural capabilities; performance on 11 quality measures for diabetes, asthma, and preventive care; utilization of hospital, emergency department, and ambulatory care; standardized costs of care. RESULTS Pilot practices successfully achieved NCQA recognition and adopted new structural capabilities such as registries to identify patients overdue for chronic disease services. Pilot participation was associated with statistically significantly greater performance improvement, relative to comparison practices, on 1 of 11 investigated quality measures: nephropathy screening in diabetes (adjusted performance of 82.7% vs 71.7% by year 3, P<.001). Pilot participation was not associated with statistically significant changes in utilization or costs of care. Pilot practices accumulated average bonuses of $92 000 per primary care physician during the 3-year intervention. CONCLUSIONS AND RELEVANCE A multipayer medical home pilot, in which participating practices adopted new structural capabilities and received NCQA certification, was associated with limited improvements in quality and was not associated with reductions in utilization of hospital, emergency department, or ambulatory care services or total costs over 3 years. These findings suggest that medical home interventions may need further refinement. C1 [Friedberg, Mark W.; Schneider, Eric C.] RAND Corp, Boston, MA USA. [Friedberg, Mark W.; Schneider, Eric C.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. [Friedberg, Mark W.; Schneider, Eric C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Schneider, Eric C.; Rosenthal, Meredith B.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Volpp, Kevin G.; Werner, Rachel M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Wharton Business Sch, Dept Hlth Care Management, Philadelphia, PA USA. [Volpp, Kevin G.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA. RP Friedberg, MW (reprint author), 20 Pk Plaza,Ste 920, Boston, MA 02116 USA. EM mfriedbe@rand.org OI Rosenthal, Meredith/0000-0003-3410-0184; Schneider, Eric/0000-0002-1132-5084 FU Commonwealth Fund; Aetna FX This study was sponsored by the Commonwealth Fund and Aetna. NR 42 TC 142 Z9 142 U1 6 U2 35 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 26 PY 2014 VL 311 IS 8 BP 815 EP 825 DI 10.1001/jama.2014.353 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA AB4XQ UT WOS:000331793700021 PM 24570245 ER PT J AU Anderson, RI Becker, HC Adams, BL Jesudason, CD Rorick-Kehn, LM AF Anderson, Rachel I. Becker, Howard C. Adams, Benjamin L. Jesudason, Cynthia D. Rorick-Kehn, Linda M. TI Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models SO FRONTIERS IN NEUROSCIENCE LA English DT Article DE hypocretins/orexins; ethanol consumption; operant progressive ratio; P rat; C57BL/6J mouse ID PREFERRING P RATS; ALCOHOL-SEEKING; OREXIN/HYPOCRETIN; ADDICTION; INVOLVEMENT; ACTIVATION; AROUSAL; NEURONS; SYSTEM; REWARD AB To examine the role of orexin-1 and orexin-2 receptor activity on ethanol self-administration, compounds that differentially target orexin (OX) receptor subtypes were assessed in various self-administration paradigms using high-drinking rodent models. Effects of the OX1 antagonist SB334867, the OX2 antagonist LSN2424100, and the mixed OX1/2 antagonist almorexant (ACT-078573) on home cage ethanol consumption were tested in ethanol-preferring (P) rats using a 2-bottle choice procedure. In separate experiments, effects of SB334867, LSN2424100, and almorexant on operant ethanol self-administration were assessed in P rats maintained on a progressive ratio operant schedule of reinforcement. In a third series of experiments, SB334867 LSN2424100, and almorexant were administered to ethanol-preferring C57BL/6J mice to examine effects of OX receptor blockade on ethanol intake in a binge-like drinking (drinking-in-the-dark) model. In P rats with chronic home cage free-choice ethanol access, SB334867 and almorexant significantly reduced ethanol intake, but almorexant also reduced water intake, suggesting non-specific effects on consummatory behavior. In the progressive ratio operant experiments, LSN2424100 and almorexant reduced breakpoints and ethanol consumption in P rats, whereas the almorexant inactive enantiomer and SB334867 did not significantly affect the motivation to consume ethanol. As expected, vehicle-injected mice exhibited binge-like drinking patterns in the drinking-in-the-dark model. All three OX antagonists reduced both ethanol intake and resulting blood ethanol concentrations relative to vehicle-injected controls, but SB334867 and LSN2424100 also reduced sucrose consumption in a different cohort of mice, suggesting non-specific effects. Collectively, these results contribute to a growing body of evidence indicating that OX1 and OX2 receptor activity influences ethanol self-administration, although the effects may not be selective for ethanol consumption. C1 [Anderson, Rachel I.; Becker, Howard C.] Med Univ S Carolina, Charleston, SC 29425 USA. [Anderson, Rachel I.; Becker, Howard C.] Charleston Alcohol Res Ctr, Charleston, SC USA. [Becker, Howard C.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Adams, Benjamin L.; Jesudason, Cynthia D.; Rorick-Kehn, Linda M.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. RP Rorick-Kehn, LM (reprint author), Lilly Corp Ctr, Lilly Res Labs, Neurosci Discovery Res, DC0510, Indianapolis, IN 46285 USA. EM rorickkehnlm@lilly.com OI Anderson, Rachel/0000-0002-6671-4810 FU Eli Lilly and Company; NIH/NIAAA [P50 AA010761, U01 AA014095, U01 AA020929, T32 AA007474]; Department of Veterans Affairs FX Financial support for P-rat studies was provided by Eli Lilly and Company. Mouse studies were supported by NIH/NIAAA grants to Howard C. Becker (P50 AA010761, U01 AA014095, and U01 AA020929) and the Department of Veterans Affairs. Rachel I. Anderson is supported by NIH/NIAAA grant T32 AA007474. NR 31 TC 16 Z9 16 U1 0 U2 4 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-453X J9 FRONT NEUROSCI-SWITZ JI Front. Neurosci. PD FEB 25 PY 2014 VL 8 AR 33 DI 10.3389/fnins.2014.00033 PG 9 WC Neurosciences SC Neurosciences & Neurology GA AW7ED UT WOS:000346426500002 PM 24616657 ER PT J AU Nallamothu, BK Tommaso, CL Anderson, HV Anderson, JL Cleveland, JC Dudley, RA Duffy, PL Faxon, DP Gurm, HS Hamilton, LA Jensen, NC Josephson, RA Malenka, DJ Maniu, CV McCabe, KW Mortimer, JD Patel, MR Persell, SD Rumsfeld, JS Shunk, KA Smith, SC Stanko, SJ Watts, B AF Nallamothu, Brahmajee K. Tommaso, Carl L. Anderson, H. Vernon Anderson, Jeffrey L. Cleveland, Joseph C., Jr. Dudley, R. Adams Duffy, Peter Louis Faxon, David P. Gurm, Hitinder S. Hamilton, Lawrence A. Jensen, Neil C. Josephson, Richard A. Malenka, David J. Maniu, Calin V. McCabe, Kevin W. Mortimer, James D. Patel, Manesh R. Persell, Stephen D. Rumsfeld, John S. Shunk, Kendrick A. Smith, Sidney C., Jr. Stanko, Stephen J. Watts, Brook CA Amer Assoc Cardiovasc Pulm TI ACC/AHA/SCAI/AMA-Convened PCPI/NCQA 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance SO CIRCULATION LA English DT Article DE AHA Scientific Statements; health policy and outcome research; quality indicators; ambulatory-level quality; hospital quality; percutaneous coronary intervention ID ELEVATION MYOCARDIAL-INFARCTION; CONTRAST-INDUCED NEPHROPATHY; APPROPRIATE USE CRITERIA; ACCF/AHA FOCUSED UPDATE; CARDIAC REHABILITATION; PRACTICE GUIDELINES; ARTERY-DISEASE; SECONDARY PREVENTION; THORACIC-SURGEONS; COMPUTED-TOMOGRAPHY C1 [Nallamothu, Brahmajee K.] Univ Michigan, Ann Arbor VAMC Ctr Clin Management Res, Ann Arbor, MI 48109 USA. [Nallamothu, Brahmajee K.] NorthShore Univ HealthSyst, Evanston, IL USA. [Tommaso, Carl L.] Univ Texas Hlth Sci Ctr Houston, Dept Med, Houston, TX 77030 USA. [Anderson, H. Vernon] Intermt Med Ctr, Murray, UT USA. [Cleveland, Joseph C., Jr.] Univ Colorado, Denver, CO 80202 USA. [Faxon, David P.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Gurm, Hitinder S.] Univ Michigan, Cardiovasc Ctr, Ann Arbor, MI 48109 USA. [Hamilton, Lawrence A.] Kaiser Permanente No Calif, Cardiac & Renal Serv, Oakland, CA USA. [Josephson, Richard A.] Univ Hosp Cleveland Med Grp, Cleveland, OH USA. [Josephson, Richard A.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. [Malenka, David J.] Dartmouth Hitchcock Med Ctr, Div Cardiol, Dartmouth, NS, Canada. [Maniu, Calin V.] Bon Secours Hlth Syst, Suffolk, VA USA. [Patel, Manesh R.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Persell, Stephen D.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA. [Rumsfeld, John S.] US Vet Hlth Adm, Oakland, CA USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Smith, Sidney C., Jr.] Univ N Carolina, Chapel Hill, NC USA. [Stanko, Stephen J.] Mended Hearts Inc, Dallas, TX USA. [Watts, Brook] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Watts, Brook] Case Western Reserve Univ, Cleveland, OH 44106 USA. RP Nallamothu, BK (reprint author), Univ Michigan, Ann Arbor VAMC Ctr Clin Management Res, Ann Arbor, MI 48109 USA. FU Aastrom Biosciences; Abbott; Abiomed; Acom Cardiovascular; Adolor Corp.; Advanced Cardiovascular Systems; Advanced Stent Technologies; Adynnx; Aijnomoto; Allergan; Amgen; Alnylam Pharma; Alpharma; Amylin Pharmaceuticals; Anadys; Anesiva; Angel Medical Systems; ANGES MG; Angiomedtrix; APT Nidus Center; ASCA Biopharma; Astellas Pharma; Asklepios; AstraZeneca; Atritech; Attention Therapeutics; Aventis; Baxter; Bayer; Berlex; BG Medicine; Biogen; Biolex Therapeutics; Biomarker Factory; Biosite; Boehringer Ingelheim Biogen; Boston Scientific; Bristol-Myers Squibb; BMS Pfizer; Carbomed; CardioDx; CardioKinetix; Cardiovascular Systems; Cardiovax; Celsion Corp.; Centocor; Cerexa; Chase Medical; Conatus Pharmaceuticals; Conor Medsystems; Cortex; Corgentech; CSL Behring; CV Therapeutics; Daiichi Pharmaceuticals; Daiichi Sankyo; Daiichi Sankyo Lilly; Ev3; F2G; General Electric Medical Systems; Genzyme Corp.; Genome Canada; KAI Pharmaceuticals; Nabriva; Novartis AG Group; Roche Molecular Systems; Roche Group; Roche Diagnostic; Salix Pharmaceuticals; Sanofi-Pasteur, Inc; Sanofi-aventis; Santaris Pharmaceuticals; TherOx; Tethys Bioscience; Theregen; Three Rivers Pharmaceuticals; EMMES Corporation; UCB; Valentis; Valleylab; Vertex; Viacor; Wyeth FX DCRI has numerous grants and contracts sponsored by industry. These include the following: Aastrom Biosciences; Abbott; Abiomed; Acom Cardiovascular; Adolor Corp.; Advanced Cardiovascular Systems; Advanced Stent Technologies; Adynnx; Aijnomoto; Allergan; Amgen; Alnylam Pharma; Alpharma; Amylin Pharmaceuticals; Anadys; Anesiva; Angel Medical Systems; ANGES MG; Angiomedtrix; APT Nidus Center; ASCA Biopharma; Astellas Pharma; Asklepios; AstraZeneca; Atritech; Attention Therapeutics; Aventis; Baxter; Bayer; Berlex BG Medicine; Biogen; Biolex Therapeutics; Biomarker Factory; Biosite; Boehringer Ingelheim Biogen; Boston Scientific; Bristol-Myers Squibb; BMS Pfizer; Carbomed; CardioDx; CardioKinetix; Cardiovascular Systems; Cardiovax; Celsion Corp; Centocor; Cerexa; Chase Medical; Conatus Pharmaceuticals; Conor Medsystems; Cortex; Corgentech; CSL Behring; CV Therapeutics; Daiichi Pharmaceuticals; Daiichi Sankyo; Daiichi Sankyo Lilly; Datascope; Dendreon; Dainippon; Dr. Reddy's Laboratories; Eclipse Surgical Technologies; Edwards Lifesciences; Eisai; Endicor; EnteroMedics; Enzon Pharmaceuticals; Eli Lilly; Ethicon; Ev3; Evalve; F2G; Flow Cardia; Fox Hollow Pharmaceuticals; Fujisawa; Genetech; General Electric; General Electric Co.; General Electric Healthcare; General Electric Medical Systems; Genzyme Corp.; Genome Canada; Gilead Sciences; GlaxoSmithKline; Guidant Corp.; Heartscape Technologies; Hoffman-LaRoche; Hospira; Idera Pharmaceuticals; Ikaria; Imcor Pharmaceuticals; Immunex; INFORMD; Inimex; Inspire Pharmaceuticals; Ischemix; Janssen; Johnson and Johnson; Jomed; Juventus Therapeutics; KAI Pharmaceuticals; King Pharmaceuticals; Kyowa Pharma; Luitpold; Mardil; MedImmune; Medscape; Medtronic Diabetes; Medtronic; Medtronic Vascular; Merck Group; MicroMed Technology; Millennium Pharmaceuticals; Mitsubishi Tanabe Momenta; Nabriva; Neuron Pharmaceuticals; NitroMed; NovaCardia Inc; Novartis AG Group; Novartis Pharmaceuticals; Oncura; Orexigen; Ortho-McNeil-Janssen; OSI Eyetech; OSI Pharmaceuticals; Pfizer; Pharmacyclics; Pharmasset; Pharmos; Phyxius Pharmaceuticals; Pharsight; Pluristen Therapeutics; Portola Pharmaceuticals; Proventys; Radiant; Regado Biosciences; Rengeneron Pharmaceuticals; Roche Molecular Systems; Roche Group; Roche Diagnostic; Salix Pharmaceuticals; Sanofi-Pasteur, Inc; Sanofi-aventis; Santaris Pharmaceuticals; Schering-Plough; Scios; Siemens; Southwest Oncology Group; Spectranetics; Summit; Sunovion Pharmaceuticals; TAP Pharmaceutical Products; Tengion; The Medicines Company; Theravance; TherOx; Tethys Bioscience; Theregen; Three Rivers Pharmaceuticals; The EMMES Corporation; UCB; Valentis; Valleylab Vertex; Viacor; and Wyeth . NR 50 TC 8 Z9 8 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD FEB 25 PY 2014 VL 129 IS 8 BP 926 EP 949 DI 10.1161/01.cir.0000441966.31451.3f PG 24 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AB4RF UT WOS:000331776900019 PM 24357402 ER PT J AU Nallamothu, BK Tommaso, CL Anderson, HV Anderson, JL Cleveland, JC Dudley, RA Duffy, PL Faxon, DP Gurm, HS Hamilton, LA Jensen, NC Josephson, RA Malenka, DJ Maniu, CV McCabe, KW Mortimer, JD Patel, MR Persell, SD Rumsfeld, JS Shunk, KA Smith, SC Stanko, SJ Watts, B AF Nallamothu, Brahmajee K. Tommaso, Carl L. Anderson, H. Vernon Anderson, Jeffrey L. Cleveland, Joseph C., Jr. Dudley, R. Adams Duffy, Peter Louis Faxon, David P. Gurm, Hitinder S. Hamilton, Lawrence A. Jensen, Neil C. Josephson, Richard A. Malenka, David J. Maniu, Calin V. McCabe, Kevin W. Mortimer, James D. Patel, Manesh R. Persell, Stephen D. Rumsfeld, John S. Shunk, Kendrick A. Smith, Sidney C., Jr. Stanko, Stephen J. Watts, Brook TI ACC/AHA/SCAI/AMA-Convened PCPI/NCQA 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE ACC/AHA/SCAI/AMA-PCPI/NCQA Performance Measures; health policy and outcome research; quality indicators; ambulatory-level quality; hospital quality; percutaneous coronary intervention ID ELEVATION MYOCARDIAL-INFARCTION; CONTRAST-INDUCED NEPHROPATHY; APPROPRIATE USE CRITERIA; ACCF/AHA FOCUSED UPDATE; OF-CARDIOLOGY; CARDIAC REHABILITATION; PRACTICE GUIDELINES; ARTERY-DISEASE; SECONDARY PREVENTION; 30-DAY READMISSION C1 [Nallamothu, Brahmajee K.] Univ Michigan, Ann Arbor VAMC Ctr Clin Management Res, Ann Arbor, MI 48109 USA. [Tommaso, Carl L.] NorthShore Univ HealthSyst, Rush Med Coll Phys, Evanston, IL USA. [Anderson, H. Vernon] Univ Texas Hlth Sci Ctr Houston, Dept Med, Houston, TX 77030 USA. [Anderson, Jeffrey L.] Intermt Med Ctr, Murray, UT USA. [Cleveland, Joseph C., Jr.] Univ Colorado, Denver, CO 80202 USA. [Cleveland, Joseph C., Jr.] Cardiac Transplant & MCS, Chicago, IL USA. [Dudley, R. Adams] Inst Hlth Policy Studies, San Francisco, CA USA. [Duffy, Peter Louis] FirstHlth Carolinas, Pinehurst, NC USA. [Duffy, Peter Louis] Reid Heart Ctr Intervent Cardiol, Cardiovasc Serv Line, Ottawa, ON, Canada. [Faxon, David P.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Gurm, Hitinder S.] Univ Michigan, Cardiovasc Ctr, Ann Arbor, MI 48109 USA. [Hamilton, Lawrence A.] Kaiser Permanente, Columbia, SC USA. [Jensen, Neil C.] United Healthcare, Minnetonka, MN USA. [Josephson, Richard A.] Case Western Reserve Univ, Sch Med, Univ Hosp Cleveland Med Grp, Cleveland, OH 44106 USA. [Malenka, David J.] Dartmouth Hitchcock Med Ctr, Div Cardiol, Lebanon, NH USA. [Maniu, Calin V.] Bon Secours Hlth Syst, Suffolk, VA USA. [McCabe, Kevin W.] SC Johnson & Son Inc, Racine, WI USA. [Mortimer, James D.] Jim Mortimer Consulting, Chicago, IL USA. [Patel, Manesh R.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Persell, Stephen D.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA. [Rumsfeld, John S.] US Vet Hlth Adm, Oakland, CA USA. [Rumsfeld, John S.] Natl Cardiovasc Data Registry, Washington, DC USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Smith, Sidney C., Jr.] Univ N Carolina, Chapel Hill, NC USA. [Stanko, Stephen J.] Mended Hearts Inc, Dallas, TX USA. [Watts, Brook] Case Western Reserve Univ, Louis Stokes Cleveland VA Med Ctr, Cleveland, OH 44106 USA. RP Nallamothu, BK (reprint author), Univ Michigan, Ann Arbor VAMC Ctr Clin Management Res, Ann Arbor, MI 48109 USA. NR 50 TC 16 Z9 16 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 25 PY 2014 VL 63 IS 7 BP 722 EP 745 DI 10.1016/j.jacc.2013.12.003 PG 24 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AB3WB UT WOS:000331719800018 PM 24361978 ER PT J AU Yan, HQ Shin, SS Ma, XC Li, YM Dixon, CE AF Yan, Hong Q. Shin, Samuel S. Ma, Xiecheng Li, Youming Dixon, C. Edward TI Differential effect of traumatic brain injury on the nuclear factor of activated T Cells C3 and C4 isoforms in the rat hippocampus SO BRAIN RESEARCH LA English DT Article DE Nuclear factor of activated T cells (NFAT); Immunohistochemistry; Rat; Traumatic brain injury (TBI); Calcineurin ID FLUID PERCUSSION INJURY; DELAYED NEURONAL DEATH; GENE-EXPRESSION; TRANSCRIPTION FACTORS; TYROSINE-HYDROXYLASE; CALCINEURIN SUBUNIT; REACTIVE ASTROCYTES; FRONTAL-CORTEX; NFAT; APOPTOSIS AB The interaction between the phosphatase calcineurin and transcription factor nuclear factor of activated T cells (NFAT) plays an important role numerous signaling and the regulatory events. Although NFAT is mostly known for its transcription function in the immune system, NFAT also has essential functions even in the central nervous system (CNS). The effects of traumatic brain injury (TBI) on NFAT are currently unknown. To determine if there is an alteration in NFAT after TBI, we examined NFATc3 and c4 levels at 6 h, 1 day, 1 week, 2 weeks and 4 weeks post injury. Rats were anesthetized and surgically prepared for controlled cortical impact (CCI) injury or sham surgery. Semi-quantitative measurements of NFATc3 and c4 in the hippocampal homogenates from injured and sham rats sacrificed at the appropriate time after injury were assessed using Western blot analysis. After TBI insult, in the hippocampus ipsilateral to the injury, NFATc3 expression levels were decreased both in the cytoplasmic and nuclear fractions. However, NFATc4 expression levels were increased in the cytoplasmic fraction but decreased in the nuclear fraction. Double labeling (with NeuN and GFAP) immunohistochemistry revealed that NFATc3 was expressed in subset of astrocytes and NFATc4 was expressed primarily in neurons. These differential responses in NFATc3 and c4 expression after TBI insult may indicate long-term changes in hippocampal excitability and may contribute to behavioral deficits. Further study is warranted to illustrate the role of NFATc3 and c4 in the setting of TBI. Published by Elsevier B.V. C1 [Yan, Hong Q.; Shin, Samuel S.; Ma, Xiecheng; Li, Youming; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Dixon, CE (reprint author), Univ Pittsburgh, Dept Neurol Surg, Safar Ctr, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA. EM dixonec@upmc.edu FU NIH/NINDS [NS33150, NS060672, NS079061]; Veterans Affairs grant [B6761R] FX This work was supported by NIH/NINDS grants NS33150, NS060672 and NS079061; and the Veterans Affairs grant B6761R. NR 50 TC 6 Z9 7 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD FEB 22 PY 2014 VL 1548 BP 63 EP 72 DI 10.1016/j.brainres.2013.12.028 PG 10 WC Neurosciences SC Neurosciences & Neurology GA AB6UM UT WOS:000331925000006 PM 24389074 ER PT J AU Vazquez, J Reboli, AC Pappas, PG Patterson, TF Reinhardt, J Chin-Hong, P Tobin, E Kett, DH Biswas, P Swanson, R AF Vazquez, Jose Reboli, Annette C. Pappas, Peter G. Patterson, Thomas F. Reinhardt, John Chin-Hong, Peter Tobin, Ellis Kett, Daniel H. Biswas, Pinaki Swanson, Robert TI Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial SO BMC INFECTIOUS DISEASES LA English DT Article DE Anidulafungin; Azole; Candidemia; Step-down strategy ID GUIDELINES; ANTIBIOTICS; FLUCONAZOLE; MANAGEMENT; CASPOFUNGIN; INFECTIONS; MORTALITY; EFFICACY; OUTCOMES; PHASE-2 AB Background: Hospitalized patients are at increased risk for candidemia and invasive candidiasis (C/ IC). Improved therapeutic regimens with enhanced clinical and pharmacoeconomic outcomes utilizing existing antifungal agents are still needed. Methods: An open-label, non-comparative study evaluated an intravenous (IV) to oral step-down strategy. Patients with C/ IC were treated with IV anidulafungin and after 5 days of IV therapy had the option to step-down to oral azole therapy (fluconazole or voriconazole) if they met prespecified criteria. The primary endpoint was the global response rate (clinical + microbiological) at end of treatment (EOT) in the modified intent-to-treat (MITT) population (at least one dose of anidulafungin plus positive Candida within 96 hours of study entry). Secondary endpoints included efficacy at other time points and in predefined patient subpopulations. Patients who stepped down early (<= 7 days' anidulafungin) were identified as the " early switch" subpopulation. Results: In total, 282 patients were enrolled, of whom 250 were included in the MITT population. The MITT global response rate at EOT was 83.7% (95% confidence interval, 78.7-88.8). Global response rates at all time points were generally similar in the early switch subpopulation compared with the MITT population. Global response rates were also similar across multiple Candida species, including C. albicans, C. glabrata, and C. parapsilosis. The most common treatment-related adverse events were nausea and vomiting (four patients each). Conclusions: A short course of IV anidulafungin, followed by early step-down to oral azole therapy, is an effective and well-tolerated approach for the treatment of C/IC. C1 [Vazquez, Jose] Georgia Regents Univ, Augusta, GA USA. [Reboli, Annette C.] Rowan Univ, Cooper Med Sch, Camden, NJ USA. [Pappas, Peter G.] Univ Alabama Birmingham, Birmingham, AL USA. [Patterson, Thomas F.] Univ Texas San Antonio, San Antonio, TX USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Reinhardt, John] Christiana Care Hlth Syst, Newark, DE USA. [Chin-Hong, Peter] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tobin, Ellis] Albany Med Ctr, Albany, NY USA. [Kett, Daniel H.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Kett, Daniel H.] Jackson Mem Hosp, Miami, FL 33136 USA. [Biswas, Pinaki; Swanson, Robert] Pfizer Inc, New York, NY USA. RP Swanson, R (reprint author), Pfizer Inc, New York, NY USA. EM swansr1@pfizer.com FU Pfizer Inc. FX The authors would like to thank the A8851011 investigators and study team. Editorial support was provided by Anne Marie Reid, PhD, and Philip Matthews, PhD, at Complete Medical Communications and was funded by Pfizer Inc. This study was sponsored by Pfizer Inc. NR 21 TC 18 Z9 18 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD FEB 21 PY 2014 VL 14 AR 14:97 DI 10.1186/1471-2334-14-97 PG 10 WC Infectious Diseases SC Infectious Diseases GA AC6IW UT WOS:000332626500002 PM 24559321 ER PT J AU Fried, LF Emanuele, N Zhang, JH AF Fried, Linda F. Emanuele, Nicholas Zhang, Jane H. TI Combined Angiotensin Inhibition in Diabetic Nephropathy REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Emanuele, Nicholas] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Zhang, Jane H.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. RP Fried, LF (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. EM linda.fried@va.gov NR 4 TC 2 Z9 2 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 20 PY 2014 VL 370 IS 8 BP 779 EP 779 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AB1DO UT WOS:000331531900020 PM 24552328 ER PT J AU Parikh, RV Scherzer, R Nitta, EM Leone, A Hur, S Mistry, V Macgregor, JS Martin, JN Deeks, SG Ganz, P Hsue, PY AF Parikh, Rushi V. Scherzer, Rebecca Nitta, Elaine M. Leone, Anna Hur, Sophia Mistry, Vanita Macgregor, John S. Martin, Jeffrey N. Deeks, Steven G. Ganz, Peter Hsue, Priscilla Y. TI Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection SO AIDS LA English DT Article DE HIV; endothelial dysfunction; nitric oxide; asymmetric dimethylarginine; pulmonary arterial hypertension ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; ENDOTHELIAL DYSFUNCTION; PROGNOSTIC-FACTORS; SURVIVAL; ERA; INFLAMMATION; PRESSURE; REGISTRY; ADMA AB Objective: To examine the relationship between asymmetric dimethylarginine (ADMA) and HIV-associated pulmonary arterial hypertension (PAH). Design: HIV infection is an independent risk factor for PAH, but the underlying pathogenesis remains unclear. Chronic inflammation resulting in nitric oxide-mediated endothelial dysfunction is a key mechanism underlying other types of PAH. ADMA is an endogenous inhibitor of endothelial nitric oxide synthase. Among uninfected individuals, ADMA is associated with PAH and predicts disease-related mortality. Methods: We measured ADMA, high sensitivity C-reactive protein, interleukin-6 (IL-6), D-dimer, and pulmonary artery systolic pressure (PASP) using echocardiography in HIV-infected individuals. Right heart catheterization (RHC) was performed in individuals with a PASP at least 30 mmHg. We performed multivariable analysis to identify factors associated with high PASP by echocardiogram and PAH by RHC. Results: Among 214 HIV-infected individuals, the median age was 50 years, 82% were men, 71% were on antiretroviral therapy, and 4.2% carried a prior diagnosis of PAH. ADMA and IL-6 were associated with increased values of PASP following multivariable adjustment (7.2% per 0.1 mu mol/l, P = 0.0049 and 3.9% per doubling, P = 0.027, respectively). In adjusted analysis among the 85 participants who underwent RHC, ADMA and IL-6 were associated with higher values of mean PAP (14.2% per 0.1 mu mol/l, P = 0.0014 and 5.8% per doubling, P = 0.038, respectively). However, only ADMA was associated with PAH (prevalence ratio = 1.74, P = 0.029). Conclusion: Elevated levels of ADMA are independently associated with PAH among HIV-infected individuals. Our findings suggest that chronic HIV-associated inflammation leading to an accumulation of ADMA and subsequent nitric oxide-mediated endothelial dysfunction may represent a novel mechanism for HIV-associated PAH. C1 [Parikh, Rushi V.; Scherzer, Rebecca] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Scherzer, Rebecca] San Francisco VA Med Ctr, Div Endocrinol & Metab, San Francisco, CA USA. [Nitta, Elaine M.; Hur, Sophia; Mistry, Vanita; Macgregor, John S.; Ganz, Peter; Hsue, Priscilla Y.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Cardiol, San Francisco, CA USA. [Leone, Anna] Oxonon BioAnal, Emeryville, CA USA. [Martin, Jeffrey N.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA USA. RP Hsue, PY (reprint author), Room 5G1 Cardiol SFGH,1001 Potrero Ave, San Francisco, CA 94110 USA. EM phsue@medsfgh.ucsf.edu FU SCOPE* [R01HL095130, R01HL095126]; NIAID [RO1 AI087145, K24AI069994]; UCSF/Gladstone Institute of Virology & Immunology CFAR [P30 AI027763]; UCSF Clinical and Translational Research Institute Clinical Research Center [UL1 RR024131]; CFAR Network of Integrated Systems [R24 AI067039] FX The study received grant support from R01HL095130 (P.Y.H.), R01HL095126 (P.Y.H.), SCOPE*.; SCOPE cohort supported by NIAID (RO1 AI087145, K24AI069994), UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763), UCSF Clinical and Translational Research Institute Clinical Research Center (UL1 RR024131), and CFAR Network of Integrated Systems (R24 AI067039). NR 35 TC 20 Z9 21 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD FEB 20 PY 2014 VL 28 IS 4 BP 511 EP 519 DI 10.1097/QAD.0000000000000124 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AC3AI UT WOS:000332387000007 PM 24469026 ER PT J AU Yanai, M Rocha, MA Matolek, AZ Chintalacharuvu, A Taira, Y Chintalacharuvu, K Beenhouwer, DO AF Yanai, Machi Rocha, Miguel A. Matolek, Anthony Z. Chintalacharuvu, Archana Taira, Yasuhiko Chintalacharuvu, Koteswara Beenhouwer, David O. TI Separately or Combined, LukG/LukH Is Functionally Unique Compared to Other Staphylococcal Bicomponent Leukotoxins SO PLOS ONE LA English DT Article ID PANTON-VALENTINE LEUKOCIDIN; NF-KAPPA-B; INTERLEUKIN-8 GENE-EXPRESSION; HUMAN NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; SUBSEQUENT ACTIVATION; GAMMA-HEMOLYSIN; IL-8 PRODUCTION; PORE FORMATION; 2 COMPONENTS AB Staphylococcus aureus is a major human pathogen that elaborates several exotoxins. Among these are the bicomponent leukotoxins (BCLs), which include gamma-hemolysin, Panton-Valentine leukocidin (PVL), and LukDE. The toxin components are classified as either F or S proteins, which are secreted individually and assemble on cell surfaces to form hetero-oligomeric pores resulting in lysis of PMNs and/or erythrocytes. F and S proteins of gamma-hemolysin, PVL and LukDE have similar to 70% sequence homology within the same class and several heterologous combinations of F and S members from these three bicomponent toxin groups are functional. Recently, an additional BCL pair, LukGH (also called LukAB) that has only 30% homology to gamma-hemolysin, PVL and LukDE, has been characterized from S. aureus. Our results showed that LukGH was more cytotoxic to human PMNs than PVL. However, LukGH-induced calcium ion influx in PMNs was markedly attenuated and slower than that induced by PVL and other staphylococcal BCLs. In contrast to other heterologous BCL combinations, LukG in combination with heterologous S components, and LukH in combination with heterologous F components did not induce calcium ion entry or cell lysis in human PMNs or rabbit erythrocytes. Like PVL, LukGH induced IL-8 production by PMNs. While individual components LukG and LukH had no cytolytic or calcium influx activity, they each induced high levels of IL-8 transcription and secretion. IL-8 production induced by LukG or LukH was dependent on NF-kappa B. Therefore, our results indicate LukGH differs functionally from other staphylococcal BCLs. C1 [Yanai, Machi; Rocha, Miguel A.; Matolek, Anthony Z.; Chintalacharuvu, Archana; Chintalacharuvu, Koteswara; Beenhouwer, David O.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. [Yanai, Machi; Taira, Yasuhiko] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan. [Beenhouwer, David O.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP Beenhouwer, DO (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. EM dbeenhou@ucla.edu FU NIH [AI071025]; Veterans Affairs (Merit Award) FX This work was supported by grants from NIH (AI071025, DOB) and the Veterans Affairs (Merit Award, DOB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 3 Z9 3 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 20 PY 2014 VL 9 IS 2 AR e89308 DI 10.1371/journal.pone.0089308 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AB3UC UT WOS:000331714700098 PM 24586678 ER PT J AU Zhang, B Zhang, B Chen, X Bae, S Singh, K Washington, MK Datta, PK AF Zhang, B. Zhang, B. Chen, X. Bae, S. Singh, K. Washington, M. K. Datta, P. K. TI Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway SO BRITISH JOURNAL OF CANCER LA English DT Article DE Smad4; colorectal cancer; 5-fluorouracil; Akt; mouse model; tissue microarray; angiogenesis; Bcl-2; TGF-beta ID MULTICENTER RANDOMIZED-TRIAL; COLON-CANCER; TGF-BETA; 1ST-LINE TREATMENT; SIGNALING PATHWAY; LIVER METASTASIS; CARCINOMA-CELLS; DOWN-REGULATION; EXPRESSION; CHEMORESISTANCE AB Background: Higher frequency of Smad4 inactivation or loss of expression is observed in metastasis of colorectal cancer (CRC) leading to unfavourable survival and contributes to chemoresistance. However, the molecular mechanism of how Smad4 regulates chemosensitivity of CRC is unknown. Methods: We evaluated how the loss of Smad4 in CRC enhanced chemoresistance to 5-fluorouracil (5-FU) using two CRC cell lines in vitro and in vivo. Immunoblotting with cell and tumour lysates and immunohistochemical analyses with tissue microarray were performed. Results: Knockdown or loss of Smad4 induced tumorigenicity, migration, invasion, angiogenesis, metastasis, and 5-FU resistance. Smad4 expression in mouse tumours regulated cell-cycle regulatory proteins leading to Rb phosphorylation. Loss of Smad4 activated Akt pathway that resulted in upregulation of anti-apoptotic proteins, Bcl-2 and Bcl-w, and Survivin. Suppression of phosphatidylinositol-3-kinase (PI3K)/Akt pathway by LY294002 restored chemosensitivity of Smad4-deficient cells to 5-FU. Vascular endothelial growth factor-induced angiogenesis in Smad4-deficient cells might also lead to chemoresistance. Low levels of Smad4 expression in CRC tissues correlated with higher levels of Bcl-2 and Bcl-w and with poor overall survival as observed in immunohistochemical staining of tissue microarrays. Conclusion: Loss of Smad4 in CRC patients induces resistance to 5-FU-based therapy through activation of Akt pathway and inhibitors of this pathway may sensitise these patients to 5-FU. C1 [Zhang, B.; Datta, P. K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Zhang, B.; Bae, S.; Singh, K.; Datta, P. K.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Zhang, B.; Zhang, B.; Datta, P. K.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Surg, Nashville, TN 37212 USA. [Chen, X.] Huazhong Univ Sci & Technol, Tongji Med Coll, Hepat Surg Ctr, Dept Surg,Tongji Hosp, Wuhan 430030, Peoples R China. [Washington, M. K.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA. RP Chen, X (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Hepat Surg Ctr, Dept Surg,Tongji Hosp, 1095 Jiefang Ave, Wuhan 430030, Peoples R China. EM chenxp@medmail.com.cn; prandatta@uabmc.edu FU NCI SPORE grant in lung cancer [5P50CA90949]; Veterans Affairs Merit Review Award; VDDRC [NIH P30DK058404]; [R01 CA95195] FX This study was supported by R01 CA95195, NCI SPORE grant in lung cancer (5P50CA90949, project#4), and Veterans Affairs Merit Review Award (to PK Datta). We thank VDDRC for supporting core services (NIH P30DK058404). We also thank Dr Frank Revetta for immunohistochemical analyses. NR 40 TC 28 Z9 30 U1 1 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 EI 1532-1827 J9 BRIT J CANCER JI Br. J. Cancer PD FEB 18 PY 2014 VL 110 IS 4 BP 946 EP 957 DI 10.1038/bjc.2013.789 PG 12 WC Oncology SC Oncology GA AB9FR UT WOS:000332096600016 PM 24384683 ER PT J AU Nihal, M Ahmad, N Wood, GS AF Nihal, Minakshi Ahmad, Nihal Wood, Gary S. TI SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis SO CELL CYCLE LA English DT Article DE CTCL; SIRT1; HDACI; p53; apoptosis ID HISTONE DEACETYLASE INHIBITOR; TUMOR-SUPPRESSOR; ROMIDEPSIN; EXPRESSION; P53; VORINOSTAT; MECHANISM; CANCER; SAHA; LOCALIZATION AB Silent information regulator type-1 (SIRT1) is the best-studied member of the Sirtuin (Sir2) family of nicotinamide dinucleotide (NAD)-dependent class III histone deacetylases (HDACs), but has not yet been explored in cutaneous T-cell lymphoma (CTCL). We analyzed five CTCL cell lines and lesional tissues using flow cytometry, immunostaining, immunoblotting, cell death, viability, and apoptosis assays, small-molecule inhibitors, and shRNA knockdown. We found strong SIRT1 expression among CTCL lines relative to normal lymphocytes. CTCL cells in lesional tissues also expressed SIRT1 strongly. SIRT1 knockdown resulted in reduced cellular metabolism and proliferation, increased apoptosis, and PARP cleavage products. Tenovin-1, which reversibly inhibits class III HDACs (SIRT1 and SIRT2), reduced SIRT enzymatic activity and SIRT1 expression and led to increased apoptosis. These alterations were accompanied by increased forkhead box O3 (FoxO3) in several cell lines and increased nuclear p53, as well as acetylated p53 in wtp53 MyLa CTCL line. A combination of class I/II and class III HDACIs (vorinostat and tenovin-1) produced significantly greater growth inhibition, cell death via apoptosis, as well as superior p53 promoter upregulation in wtp53 MyLa cells as compared with either agent alone. This occurred in a partially p53-dependent manner, as these effects were blunted by p53 knockdown. Our results indicate that SIRT1 is strongly expressed in CTCL. Its inhibition results in reduced growth and increased apoptosis of CTCL cells. Furthermore, our findings suggest that some CTCL patients, such as those with wtp53, might benefit more from treatment with a combination of different classes of HDACIs than with a single agent. C1 [Nihal, Minakshi; Ahmad, Nihal; Wood, Gary S.] Univ Wisconsin, Dept Dermatol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Nihal, Minakshi; Ahmad, Nihal; Wood, Gary S.] Univ Wisconsin, Sch Med & Publ Hlth, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA. [Ahmad, Nihal; Wood, Gary S.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Wood, GS (reprint author), Univ Wisconsin, Dept Dermatol, Sch Med & Publ Hlth, Madison, WI 53706 USA. EM gwood@dermatology.wisc.edu FU Department of Veterans Affairs; NCI [P30CA014520, CA164417] FX Supported by Merit Review funding from the Department of Veterans Affairs (GSW and NA) and NCI (P30CA014520 and CA164417). NR 50 TC 15 Z9 18 U1 0 U2 5 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PD FEB 15 PY 2014 VL 13 IS 4 BP 632 EP 640 DI 10.4161/cc.27523 PG 9 WC Cell Biology SC Cell Biology GA AF0RY UT WOS:000334422900021 PM 24343700 ER PT J AU Zhao, X Chen, F Feng, ZJ Li, XS Zhou, XH AF Zhao, Xing Chen, Fei Feng, Zijian Li, Xiaosong Zhou, Xiao-Hua TI The temporal lagged association between meteorological factors and malaria in 30 counties in south-west China: a multilevel distributed lag non-linear analysis SO MALARIA JOURNAL LA English DT Article ID EAST-AFRICAN HIGHLANDS; CLIMATE-CHANGE; YUNNAN PROVINCE; SPATIOTEMPORAL DISTRIBUTION; INFECTIOUS-DISEASES; FALCIPARUM-MALARIA; BORNE DISEASES; MODELS; EPIDEMIC; TRANSMISSION AB Background: The association between malaria and meteorological factors is complex due to the lagged and non-linear pattern. Without fully considering these characteristics, existing studies usually concluded inconsistent findings. Investigating the lagged correlation pattern between malaria and climatic variables may improve the understanding of the association and generate possible better prediction models. This is especially beneficial to the south-west China, which is a high-incidence area in China. Methods: Thirty counties in south-west China were selected, and corresponding weekly malaria cases and four weekly meteorological variables were collected from 2004 to 2009. The Multilevel Distributed Lag Non-linear Model (MDLNM) was used to study the temporal lagged correlation between weekly malaria and weekly meteorological factors. The counties were divided into two groups, hot and cold weathers, in order to compare the difference under different climatic conditions and improve reliability and generalizability within similar climatic conditions. Results: Rainfall was associated with malaria cases in both hot and cold weather counties with a lagged correlation, and the lag range was relatively longer than those of other meteorological factors. Besides, the lag range was longer in hot weather counties compared to cold weather counties. Relative humidity was correlated with malaria cases at early and late lags in hot weather counties. Minimum temperature had a longer lag range and larger correlation coefficients for hot weather counties compared to cold weather counties. Maximum temperature was only associated with malaria cases at early lags. Conclusion: Using weekly malaria cases and meteorological information, this work studied the temporal lagged association pattern between malaria cases and meteorological information in south-west China. The results suggest that different meteorological factors show distinct patterns and magnitudes for the lagged correlation, and the patterns will depend on the climatic condition. Existing inconsistent findings for climatic factors' lags could be due to either the invalid assumption of a single fixed lag or the distinct temperature conditions from different study sites. The lag pattern for meteorological factors should be considered in the development of malaria early warning system. C1 [Zhao, Xing; Chen, Fei; Li, Xiaosong] Sichuan Univ, West China Sch Publ Hlth, Chengdu 610041, Peoples R China. [Zhao, Xing; Zhou, Xiao-Hua] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Feng, Zijian] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing 102206, Peoples R China. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. RP Li, XS (reprint author), Sichuan Univ, West China Sch Publ Hlth, 17 Sect 3,South Renmin Rd, Chengdu 610041, Peoples R China. EM lixiaosong1101@126.com; azhou@u.washington.edu FU Natural Science Foundation of China [30571618]; Ministry of Health, China [200802133]; China Scholarship Council FX The reviewer's comments has greatly improved the explanation and discussion of Figure 5. This study was supported by the Natural Science Foundation of China (No.30571618), Grants of the Ministry of Health, China (No.200802133), China Scholarship Council (http://en.csc.edu.cn/). NR 57 TC 11 Z9 12 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD FEB 15 PY 2014 VL 13 AR 57 DI 10.1186/1475-2875-13-57 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AC8HN UT WOS:000332774200002 PM 24528891 ER PT J AU Musher, DM Bebko, SP Roig, IL AF Musher, Daniel M. Bebko, Serge P. Roig, Ingrid L. TI Serum Procalcitonin Level, Viral Polymerase Chain Reaction Analysis, and Lower Respiratory Tract Infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA; ANTIBIOTIC-THERAPY; ACUTE EXACERBATIONS C1 [Musher, Daniel M.; Bebko, Serge P.; Roig, Ingrid L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Musher, Daniel M.; Bebko, Serge P.; Roig, Ingrid L.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd,Rm 4B-370, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 9 TC 6 Z9 6 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2014 VL 209 IS 4 BP 631 EP U155 DI 10.1093/infdis/jit579 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AA2BD UT WOS:000330899200023 PM 24218499 ER PT J AU Wu, RR Himmel, TL Buchanan, AH Powell, KP Hauser, ER Ginsburg, GS Henrich, VC Orlando, LA AF Wu, R. Ryanne Himmel, Tiffany L. Buchanan, Adam H. Powell, Karen P. Hauser, Elizabeth R. Ginsburg, Geoffrey S. Henrich, Vincent C. Orlando, Lori A. TI Quality of family history collection with use of a patient facing family history assessment tool SO BMC FAMILY PRACTICE LA English DT Article DE Family history; Data quality; Patient-centered ID GENETICALLY COMPLEX TRAITS; AMERICAN-CANCER-SOCIETY; AFFECTED RELATIVE PAIRS; PRIMARY-CARE PHYSICIANS; RISK-ASSESSMENT; LINKAGE STRATEGIES; COMMON DISEASES; HEALTH HISTORY; HEART-ASSOCIATION; COLORECTAL-CANCER AB Background: Studies have shown that the quality of family health history (FHH) collection in primary care is inadequate to assess disease risk. To use FHH for risk assessment, collected data must have adequate detail. To address this issue, we developed a patient facing FHH assessment tool, MeTree. In this paper we report the content and quality of the FHH collected using MeTree. Methods: Design: A hybrid implementation-effectiveness study. Patients were recruited from 2009 to 2012. Setting: Two community primary care clinics in Greensboro, NC. Participants: All non-adopted adult English speaking patients with upcoming appointments were invited to participate. Intervention: Education about and collection of FHH with entry into MeTree. Measures: We report the proportion of pedigrees that were high-quality. High-quality pedigrees are defined as having all the following criteria: (1) three generations of relatives, (2) relatives' lineage, (3) relatives' gender, (4) an up-to-date FHH, (5) pertinent negatives noted, (6) age of disease onset in affected relatives, and for deceased relatives, (7) the age and (8) cause of death (Prim Care 31:479-495, 2004.). Results: Enrollment: 1,184. Participant demographics: age range 18-92 (mean 58.8, SD 11.79), 56% male, and 75% white. The median pedigree size was 21 (range 8-71) and the FHH entered into MeTree resulted in a database of 27,406 individuals. FHHs collected by MeTree were found to be high quality in 99.8% (N = 1,182/1,184) as compared to <4% at baseline. An average of 1.9 relatives per pedigree (range 0-50, SD 4.14) had no data reported. For pedigrees where at least one relative has no data (N = 497/1,184), 4.97 relatives per pedigree (range 1-50, SD 5.44) had no data. Talking with family members before using MeTree significantly decreased the proportion of relatives with no data reported (4.98% if you talked to your relative vs. 10.85% if you did not, p-value < 0.001.). Conclusion: Using MeTree improves the quantity and quality of the FHH data that is collected and talking with relatives prior to the collection of FHH significantly improves the quantity and quality of the data provided. This allows more patients to be accurately risk stratified and offered appropriate preventive care guided by their risk level. C1 [Wu, R. Ryanne] US Dept Vet Affairs, Med Ctr, Hlth Serv Res & Dev, Durham, NC 27701 USA. [Wu, R. Ryanne; Himmel, Tiffany L.; Ginsburg, Geoffrey S.; Orlando, Lori A.] Duke Univ, Inst Genome Sci & Policy, Duke Ctr Personalized & Precis Med, Durham, NC 27708 USA. [Wu, R. Ryanne; Orlando, Lori A.] Duke Univ Hlth Syst, Duke Dept Internal Med, Durham, NC USA. [Buchanan, Adam H.] Duke Univ Hlth Syst, Duke Canc Inst, Durham, NC 27710 USA. [Powell, Karen P.; Henrich, Vincent C.] UNC Greensboro, Ctr Biotechnol Genom & Hlth Res, Greensboro, NC 27412 USA. [Hauser, Elizabeth R.] US Dept Vet Affairs, Med Ctr, CSP Epidemiol Ctr, Durham, NC 27701 USA. [Hauser, Elizabeth R.] Duke Univ, Ctr Human Genet, DUMC, Durham, NC 27710 USA. RP Wu, RR (reprint author), US Dept Vet Affairs, Med Ctr, Hlth Serv Res & Dev, 411 W Chapel Hill St,Ste 600, Durham, NC 27701 USA. EM ryanne.wu@duke.edu FU DoD FX This study is funded by the DoD. All authors are funded by the study as was time for manuscript preparation. The funding body provided IRB approval and ethical oversight of the study but did not have a role in the study design, data collection, analysis, interpretation, or in the writing of this manuscript. This material is also the result of work supported with resources and the use of facilities at the Durham, NC VA medical center by RW. NR 40 TC 8 Z9 8 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2296 J9 BMC FAM PRACT JI BMC Fam. Pract. PD FEB 13 PY 2014 VL 15 AR 31 DI 10.1186/1471-2296-15-31 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA AB8YT UT WOS:000332076800001 PM 24520818 ER PT J AU Rosenbaum, L AF Rosenbaum, Lisa TI "Misfearing" - Culture, Identity, and Our Perceptions of Health Risks SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Rosenbaum, Lisa] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Rosenbaum, Lisa] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. RP Rosenbaum, L (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 5 TC 7 Z9 7 U1 0 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 13 PY 2014 VL 370 IS 7 BP 595 EP 597 DI 10.1056/NEJMp1314638 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AA6CX UT WOS:000331187500005 PM 24521105 ER PT J AU Woolley, JD Khan, BK Natesan, A Karydas, A Dallman, M Havel, P Miller, BL Rankin, KP AF Woolley, Josh D. Khan, Baber K. Natesan, Alamelu Karydas, Anna Dallman, Mary Havel, Peter Miller, Bruce L. Rankin, Katherine P. TI Satiety-related hormonal dysregulation in behavioral variant frontotemporal dementia SO NEUROLOGY LA English DT Article ID BINGE-EATING DISORDER; PLASMA GHRELIN; ALZHEIMERS-DISEASE; INSULIN-SECRETION; FOOD REWARD; BRAIN; LEPTIN; STRESS; HUMANS; WOMEN AB Objective:To investigate whether patients with behavioral variant frontotemporal dementia (bvFTD) have dysregulation in satiety-related hormonal signaling using a laboratory-based case-control study.Methods:Fifty-four participants (19 patients with bvFTD, 17 patients with Alzheimer disease dementia, and 18 healthy normal controls [NCs]) were recruited from a tertiary-care dementia clinic. During a standardized breakfast, blood was drawn before, during, and after the breakfast protocol to quantify levels of peripheral satiety-related hormones (ghrelin, cortisol, insulin, leptin, and peptide YY) and glucose. To further explore the role of patients' feeding abnormalities on hormone levels, patients were classified into overeating and nonovereating subgroups based on feeding behavior during separate laboratory-based standardized lunch feeding sessions.Results:Irrespective of their feeding behavior in the laboratory, patients with bvFTD, but not patients with Alzheimer disease dementia, have significantly lower levels of ghrelin and cortisol and higher levels of insulin compared with NCs. Furthermore, while laboratory feeding behavior did not predict alterations in levels of ghrelin, cortisol, and insulin, only patients with bvFTD who significantly overate in the laboratory demonstrated significantly higher levels of leptin compared with NCs, suggesting that leptin may be sensitive to particularly severe feeding abnormalities in bvFTD.Conclusions:Despite a tendency to overeat, patients with bvFTD have a hormonal profile that should decrease food intake. Aberrant hormone levels may represent a compensatory response to the behavioral or neuroanatomical abnormalities of bvFTD. C1 [Woolley, Josh D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Dallman, Mary] Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA. [Dallman, Mary] Univ Calif San Francisco, Dept Neurosci, San Francisco, CA USA. [Khan, Baber K.; Natesan, Alamelu; Karydas, Anna; Miller, Bruce L.; Rankin, Katherine P.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. [Woolley, Josh D.] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA. [Havel, Peter] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA. [Havel, Peter] Univ Calif Davis, Sch Vet Med, Dept Nutr, Davis, CA 95616 USA. RP Woolley, JD (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM josh.woolley@ucsf.edu FU National Institute on Aging (NIA) [5-P01 AG19724, P50 AG023501]; state of California, Alzheimer's Disease Research Center of California [03-7527]; NIH [R01AG038791, R01AG031278]; National Center for Research Resources; National Center for Advancing Translational Sciences, NIH, through UCSF-CTSI [UL1 RR024131] FX National Institute on Aging (NIA) grants 5-P01 AG19724 and P50 AG023501; state of California, Alzheimer's Disease Research Center of California grant 03-7527; NIH grants R01AG038791 and R01AG031278; 2004 UCSF REAC grant (Rankin). This publication was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, through UCSF-CTSI grant UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 39 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 11 PY 2014 VL 82 IS 6 BP 512 EP 520 DI 10.1212/WNL.0000000000000106 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA AH9VW UT WOS:000336493900012 PM 24415571 ER PT J AU Tsuang, D Esterberg, M Braff, D Calkins, M Cadenhead, K Dobie, D Freedman, R Green, MF Greenwood, T Gur, R Gur, R Horan, W Lazzeroni, LC Light, GA Millard, SP Olincy, A Nuechterlein, K Seidman, L Siever, L Silverman, J Stone, W Sprock, J Sugar, C Swerdlow, N Tsuang, M Turetsky, B Radant, A AF Tsuang, Debby Esterberg, Michelle Braff, David Calkins, Monica Cadenhead, Kristin Dobie, Dorcas Freedman, Robert Green, Michael F. Greenwood, Tiffany Gur, Raquel Gur, Ruben Horan, William Lazzeroni, Laura C. Light, Gregory A. Millard, Steven P. Olincy, Ann Nuechterlein, Keith Seidman, Larry Siever, Larry Silverman, Jeremy Stone, William Sprock, Joyce Sugar, Catherine Swerdlow, Neal Tsuang, Ming Turetsky, Bruce Radant, Allen TI Is There an Association between Advanced Paternal Age and Endophenotype Deficit Levels in Schizophrenia? SO PLOS ONE LA English DT Article ID PARENTAL AGE; NEUROCOGNITIVE ENDOPHENOTYPES; ANTISACCADE PERFORMANCE; RISK; CONSORTIUM; GENETICS; DISORDER; AUTISM; MULTISITE; RELATIVES AB The children of older fathers have increased risks of developing schizophrenia spectrum disorders, and among those who develop these disorders, those with older fathers present with more severe clinical symptoms. However, the influence of advanced paternal age on other important domains related to schizophrenia, such as quantitative endophenotype deficit levels, remains unknown. This study investigated the associations between paternal age and level of endophenotypic impairment in a well-characterized family-based sample from the Consortium on the Genetics of Schizophrenia (COGS). All families included at least one affected subject and one unaffected sibling. Subjects met criteria for schizophrenia (probands; n = 293) or were unaffected first-degree siblings of those probands (n = 382). Paternal age at the time of subjects' birth was documented. Subjects completed a comprehensive clinical assessment and a battery of tests that measured 16 endophenotypes. After controlling for covariates, potential paternal age-endophenotype associations were analyzed using one model that included probands alone and a second model that included both probands and unaffected siblings. Endophenotype deficits in the Identical Pairs version of the 4-digit Continuous Performance Test and in the Penn Computerized Neurocognitive Battery verbal memory test showed significant associations with paternal age. However, after correcting for multiple comparisons, no endophenotype was significantly associated with paternal age. These findings suggest that factors other than advanced paternal age at birth may account for endophenotypic deficit levels in schizophrenia. C1 [Tsuang, Debby] VA Puget Sound Hlth Care Syst, VISN Geriatr Res Educ & Clin Ctr 20, Seattle, WA 98108 USA. [Tsuang, Debby; Esterberg, Michelle; Dobie, Dorcas; Radant, Allen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Braff, David; Light, Gregory A.] VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 22, San Diego, CA USA. [Braff, David; Cadenhead, Kristin; Greenwood, Tiffany; Light, Gregory A.; Sprock, Joyce; Swerdlow, Neal; Tsuang, Ming] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Calkins, Monica; Gur, Raquel; Gur, Ruben; Turetsky, Bruce] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Dobie, Dorcas; Millard, Steven P.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Green, Michael F.; Horan, William; Nuechterlein, Keith; Sugar, Catherine] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA. [Green, Michael F.; Horan, William; Sugar, Catherine] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Seidman, Larry; Stone, William] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr Publ, Psychiat Div,Med Sch,Dept Psychiat, Boston, MA 02215 USA. [Siever, Larry; Silverman, Jeremy] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry; Silverman, Jeremy] James J Peters VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 3, New York, NY USA. RP Tsuang, D (reprint author), VA Puget Sound Hlth Care Syst, VISN Geriatr Res Educ & Clin Ctr 20, Seattle, WA 98108 USA. EM dwt1@uw.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Lazzeroni, Laura/0000-0002-1846-6920; Greenwood, Tiffany/0000-0002-6080-6503 FU Office of Research and Development Medical Research Service, Department of Veterans Affairs; NIMH [R01 MH65571, R01 MH042228, R01 MH65588, R01 MH65562, R01 MH65707, R01 MH65554, R01 MH65578, R01 MH086135, R01 MH65558] FX This material is based upon work supported (or supported in part) by the Office of Research and Development Medical Research Service, Department of Veterans Affairs. This study was supported by NIMH grants R01 MH65571, R01 MH042228, R01 MH65588, R01 MH65562, R01 MH65707, R01 MH65554, R01 MH65578, R01 MH086135, and R01 MH65558. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 3 Z9 3 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 11 PY 2014 VL 9 IS 2 AR e88379 DI 10.1371/journal.pone.0088379 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AA7DT UT WOS:000331258100037 PM 24523888 ER PT J AU Hill-Burns, EM Wissemann, WT Hamza, TH Factor, SA Zabetian, CP Payami, H AF Hill-Burns, Erin M. Wissemann, William T. Hamza, Taye H. Factor, Stewart A. Zabetian, Cyrus P. Payami, Haydeh TI Identification of a novel Parkinson's disease locus via stratified genome-wide association study SO BMC GENOMICS LA English DT Article DE GWAS; Parkinson's disease; SNCA; MAPT; HLA; Genetic heterogeneity; Secondary GWAS; Stratified GWAS; Chromosome 1p ID HUMAN PREFRONTAL CORTEX; GENE-EXPRESSION; HLA REGION; MUTATIONS; ZINC; VISUALIZATION; DIAGNOSIS; VARIANTS; RISK; IRON AB Background: Parkinson's disease (PD) is complex and heterogeneous. The numerous susceptibility loci that have been identified reaffirm the complexity of PD but do not fully explain it; e. g., it is not known if any given PD susceptibility gene is associated with all PD or a disease subtype. We also suspect that important disease genes may have escaped detection because of this heterogeneity. We used presence/ absence of family history to subdivide the cases and performed genome-wide association studies (GWAS) in Sporadic-PD and Familial-PD separately. The aim was to uncover new genes and gain insight into the genetic architecture of PD. Results: Employing GWAS on the NeuroGenetics Research Consortium (NGRC) dataset stratified by family history (1565 Sporadic-PD, 435 Familial-PD, 1986 controls), we identified a novel locus on chromosome 1p21 in Sporadic-PD (PNGRC= 4x10(-8)) and replicated the finding (PReplication = 6x10(-3); PPooled= 4x10(-10)) in 1528 Sporadic-PD and 796 controls from the National Institutes of Neurologic Disease and Stroke (NINDS) Repository. This is the fifth PD locus to be mapped to the short arm of chromosome 1. It is flanked by S1PR1 and OLFM3 genes, and is 200 kb from a multiple sclerosis susceptibility gene. The second aim of the study was to extend the stratified GWAS to the well-established PD genes. SNCA_ rs356220 was associated with both Sporadic-PD (OR = 1.37, P = 1x10(-9)) and Familial-PD (OR = 1.40, P = 2x10(-5)). HLA_ rs3129882 was more strongly associated with Sporadic-PD (OR = 1.38, P = 5x10(-10)) than Familial-PD (OR = 1.12, P = 0.15). In the MAPT region, virtually every single nucleotide polymorphism (SNP) had a stronger effect-size and lower P-value in Familial-PD (peak P = 8x10(-7)) than in Sporadic-PD (peak P = 2x10(-5)). Conclusions: We discovered and replicated a new locus for Sporadic-PD which had escaped detection in un-stratified GWAS. This demonstrates that by stratifying on a key variable the power gained due to diminished heterogeneity can sometimes outweigh the power lost to reduced sample size. We also detected distinct patterns of disease associations for previously established PD susceptibility genes, which gives an insight to the genetic architecture of the disease and could aid in the selection of appropriate study population for future studies. C1 [Hill-Burns, Erin M.; Wissemann, William T.; Hamza, Taye H.; Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Div Genet, Albany, NY USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Zabetian, Cyrus P.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Payami, Haydeh] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Div Genet, Albany, NY USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306 FU National Institute of Neurological Disorders And Stroke [R01NS36960]; Global Genetic Consortium Grant from the Michael J Fox Foundation for Parkinson's Disease Research; Department of Veterans Affairs [1I01BX000531]; National Institutes of Aging [P30AG08017]; Office of Research & Development, Clinical Sciences Research & Development Service, Department of Veteran Affairs; NIH at National Library of Medicine; Close to the Cure Foundation. Genotyping services; Center for Inherited Disease Research (CIDR),; National Institutes of Health to The Johns Hopkins University [HHSN268200782096C]; NINDS Human Genetics Resource Center DNA and Cell Line Repository FX We would like to acknowledge the persons with PD, their families and healthy volunteers who participated in this study. The project was supported by Award Number R01NS36960 from the National Institute of Neurological Disorders And Stroke. Additional support was provided by a Global Genetic Consortium Grant from the Michael J Fox Foundation for Parkinson's Disease Research, Merit Review Award from the Department of Veterans Affairs (1I01BX000531), National Institutes of Aging (P30AG08017), Office of Research & Development, Clinical Sciences Research & Development Service, Department of Veteran Affairs, The Intramural Research Program of the NIH at National Library of Medicine, and the Close to the Cure Foundation. Genotyping services were provided by the Center for Inherited Disease Research (CIDR), which is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This study used samples from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (http:// ccr. coriell. org/ ninds), as well as clinical data. Funding for NINDS- Genome-Wide Genotyping in Parkinson's Disease which generated the GWAS used for replication was provided by NINDS, and the GWAS data were obtained from the NINDS database at (http:// www. ncbi. nlm. nih. gov/ gap) accession number phs000089. v3. p2. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. NR 49 TC 18 Z9 19 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2164 J9 BMC GENOMICS JI BMC Genomics PD FEB 10 PY 2014 VL 15 AR 15:118 DI 10.1186/1471-2164-15-118 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA AC5ZD UT WOS:000332598600003 PM 24511991 ER PT J AU Pava, MJ den Hartog, CR Blanco-Centurion, C Shiromani, PJ Woodward, JJ AF Pava, Matthew J. den Hartog, Carolina R. Blanco-Centurion, Carlos Shiromani, Priyattam J. Woodward, John J. TI Endocannabinoid Modulation of Cortical Up-States and NREM Sleep SO PLOS ONE LA English DT Article ID CB1 CANNABINOID RECEPTOR; VENTRAL TEGMENTAL AREA; LONG-TERM DEPRESSION; PREFRONTAL CORTEX; PYRAMIDAL NEURONS; ENDOGENOUS CANNABINOIDS; IN-VIVO; NEOCORTICAL INTERNEURONS; GLUTAMATERGIC NEURONS; VANILLOID RECEPTORS AB Up-/down-state transitions are a form of network activity observed when sensory input into the cortex is diminished such as during non-REM sleep. Up-states emerge from coordinated signaling between glutamatergic and GABAergic synapses and are modulated by systems that affect the balance between inhibition and excitation. We hypothesized that the endocannabinoid (EC) system, a neuromodulatory system intrinsic to the cortical microcircuitry, is an important regulator of up-states and sleep. To test this hypothesis, up-states were recorded from layer V/VI pyramidal neurons in organotypic cultures of wild-type or CB1R knockout (KO) mouse prefrontal cortex. Activation of the cannabinoid 1 receptor (CB1) with exogenous agonists or by blocking metabolism of endocannabinoids, anandamide or 2-arachidonoyl glycerol, increased up-state amplitude and facilitated action potential discharge during up-states. The CB1 agonist also produced a layer II/IIIselective reduction in synaptic GABAergic signaling that may underlie its effects on up-state amplitude and spiking. Application of CB1 antagonists revealed that an endogenous EC tone regulates up-state duration. Paradoxically, the duration of up-states in CB1 KO cultures was increased suggesting that chronic absence of EC signaling alters cortical activity. Consistent with increased cortical excitability, CB1 KO mice exhibited increased wakefulness as a result of reduced NREM sleep and NREM bout duration. Under baseline conditions, NREM delta (0.5-4 Hz) power was not different in CB1 KO mice, but during recovery from forced sleep deprivation, KO mice had reduced NREM delta power and increased sleep fragmentation. Overall, these findings demonstrate that the EC system actively regulates cortical up-states and important features of NREM sleep such as its duration and low frequency cortical oscillations. C1 [Pava, Matthew J.; den Hartog, Carolina R.; Woodward, John J.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Pava, Matthew J.; den Hartog, Carolina R.; Woodward, John J.] Med Univ S Carolina, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA. [Blanco-Centurion, Carlos; Shiromani, Priyattam J.; Woodward, John J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Blanco-Centurion, Carlos; Shiromani, Priyattam J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Woodward, JJ (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. EM woodward@musc.edu OI Pava, Matthew/0000-0002-9867-4577 FU National Institutes of Health [P50 AA010761, F31 AA018908, MH055772, NS052287, NS079940]; Medical Research Service of the Department of Veterans Affairs FX This work was supported by National Institutes of Health grants P50 AA010761 (RC3; Charleston Alcohol Research Center; JJW), F31 AA018908 (MJP), MH055772 (PJM), NS052287 (PJM), NS079940 (PJM), and Medical Research Service of the Department of Veterans Affairs (PJM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 70 TC 7 Z9 7 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 10 PY 2014 VL 9 IS 2 AR e88672 DI 10.1371/journal.pone.0088672 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AA7CL UT WOS:000331254600102 PM 24520411 ER PT J AU Seliger, SL Fried, LF AF Seliger, Stephen L. Fried, Linda F. TI Serum Potassium in Dual Renin-Angiotensin-Aldosterone System Blockade SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID DIABETIC-NEPHROPATHY; HEART-FAILURE; HYPERKALEMIA; RISK; OUTCOMES; TRIAL; TELMISARTAN; INHIBITION; ALISKIREN; LOSARTAN C1 [Seliger, Stephen L.] Vet Affairs Maryland Healthcare Syst, Baltimore, MD USA. [Seliger, Stephen L.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Fried, LF (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr C,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM Linda.Fried@va.gov NR 23 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD FEB 7 PY 2014 VL 9 IS 2 BP 219 EP 221 DI 10.2215/CJN.12411213 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA AI9FY UT WOS:000337238400001 PM 24408119 ER EF